METS? NO METS? START XTANDI.

Regardless of metastatic status, XTANDI offers your patients with castration-resistant prostate cancer (CRPC) the confidence of proven efficacy when PSA is rising* during LHRH therapy.†1

*PSA level ≥ 2 ng/mL with at least 2 consecutive rises despite castrate testosterone levels (≤ 50 ng/dL).2-4

**INDICATION AND IMPORTANT SAFETY INFORMATION**

**Indication**

XTANDI (enzalutamide) is indicated for the treatment of patients with castration-resistant prostate cancer (CRPC).

**Important Safety Information**

**Warnings and Precautions**

**Seizure** occurred in 0.4% of patients receiving XTANDI in clinical studies. In a study of patients with predisposing factors for seizure, 2.2% of XTANDI-treated patients experienced a seizure. Patients in the study had one or more of the following pre-disposing factors: use of medications that may lower the seizure threshold; history of traumatic brain or head injury, cerebrovascular accident or transient ischemic attack, Alzheimer’s disease, meningioma, or leptomeningeal disease from prostate cancer, unexplained loss of consciousness within the last 12 months; history of seizure, presence of a space occupying lesion of the brain, history of arteriovenous malformation, or history of brain infection. It is unknown whether anti-epileptic medications will prevent seizures with XTANDI. Advise patients of the risk of developing a seizure while taking XTANDI and of engaging in any activity where sudden loss of consciousness could cause serious harm to themselves or others. Permanently discontinue XTANDI in patients who develop a seizure during treatment.

**Posterior Reversible Encephalopathy Syndrome (PRES)**

In post approval use, there have been reports of PRES in patients receiving XTANDI. PRES is a neurological disorder which can present with rapidly evolving symptoms including seizure, headache, lethargy, confusion, blindness, and other visual and neurological disturbances, with or without associated hypertension. A diagnosis of PRES requires confirmation by brain imaging, preferably MRI. Discontinue XTANDI in patients who develop PRES.

**Hypersensitivity** reactions, including edema of the face (0.5%), tongue (0.1%), or lip (0.1%) have been observed with XTANDI in clinical trials. Pharyngeal edema has been reported in post-marketing cases. Advise patients who experience any symptoms of hypersensitivity to temporarily discontinue XTANDI and promptly seek medical care. Permanently discontinue XTANDI for serious hypersensitivity reactions.

**Ischemic Heart Disease** In the placebo-controlled clinical studies, ischemic heart disease occurred more commonly in patients on the XTANDI arm compared to patients on the placebo arm (2.7% vs 1.2%). Grade 3-4 ischemic events occurred in 1.2% of patients on XTANDI versus 0.5% on placebo. Ischemic events led to death in 0.4% of patients on XTANDI compared to 0.1% on placebo. Monitor for signs and symptoms of ischemic heart disease. Optimize management of cardiovascular risk factors, such as hypertension, diabetes, or dyslipidemia. Discontinue XTANDI for Grade 3-4 ischemic heart disease.

**Falls and Fractures** In the placebo-controlled clinical studies, falls occurred in 10% of patients treated with XTANDI compared to 4% of patients treated with placebo. Fractures occurred in 8% of patients treated with XTANDI and in 3% of patients treated with placebo. Evaluate patients for fracture and fall risk. Monitor and manage patients at risk for fractures according to established treatment guidelines and consider use of bone-targeted agents.

**Embryo-Fetal Toxicity** Safety and efficacy of XTANDI have not been established in females. XTANDI can cause fetal harm and loss of pregnancy when administered to a pregnant female. Advise males with female partners of reproductive potential to use effective contraception during treatment with XTANDI and for 3 months after the last dose of XTANDI. XTANDI should not be handled by females who are or may become pregnant.

**Adverse Reactions**

The most common adverse reactions (≥ 10%) that occurred more frequently (≥ 2% over placebo) in the XTANDI patients from the randomized placebo-controlled trials were asthenia/fatigue, decreased appetite, hot flush, arthralgia, dizziness/vertigo, hypertension, headache and weight decreased. In the bicalutamide-controlled study, the most common adverse reactions (≥ 10%) reported in XTANDI patients...
XTANDI significantly prolonged metastasis-free survival in patients with nonmetastatic CRPC and significantly extended overall survival and radiographic progression-free survival in patients with metastatic CRPC.

Nonmetastatic CRPC: Median metastasis-free survival was 3 years (36.6 months [95% CI, 33.1-NR]) with XTANDI + LHRH therapy vs 14.7 months (95% CI, 14.2-15.0) with placebo + LHRH therapy (HR = 0.29 [95% CI, 0.24-0.35]; P < 0.0001).

Metastatic CRPC: 23% reduction in the risk of death with XTANDI + LHRH therapy vs placebo + LHRH therapy (HR = 0.77 [95% CI, 0.67-0.88]) and 83% reduction in the risk of radiographic progression or death vs placebo + LHRH therapy (HR = 0.17 [95% CI, 0.14-0.21]; P < 0.0001).

Castration-resistant prostate cancer is defined as disease progression on androgen deprivation therapy (LHRH therapy or prior bilateral orchiectomy).

Drug Interactions

Effect of Other Drugs on XTANDI Avoid strong CYP2C8 inhibitors, as they can increase the plasma exposure to XTANDI. If co-administration is necessary, reduce the dose of XTANDI.
Avoid strong CYP3A4 inducers as they can decrease the plasma exposure to XTANDI. If co-administration is necessary, increase the dose of XTANDI.

Effect of XTANDI on Other Drugs Avoid CYP3A4, CYP2C9, and CYP2C19 substrates with a narrow therapeutic index, as XTANDI may decrease the plasma exposures of these drugs. If XTANDI is co-administered with warfarin (CYP2C9 substrate), conduct additional INR monitoring.

References:

Visit XtandiHCP.com for clinical trial results
XTANDI® (enzalutamide) capsules for oral use
Initial U.S. Approval: 2012

BRIEF SUMMARY OF PRESCRIBING INFORMATION
The following is a brief summary. Please see the package insert for full prescribing information.

INDICATIONS AND USAGE
XTANDI is an androgen receptor inhibitor indicated for the treatment of patients with castration-resistant prostate cancer.

CONTRAINDICATIONS
None.

WARNINGS AND PRECAUTIONS
Seizure
Seizure occurred in 0.4% of patients receiving XTANDI in clinical studies. In 4% of these patients, patients with predisposing factors for seizure were generally excluded. Seizure occurred from 13 to 604 days after initiation of XTANDI. Patients experiencing seizure were permanently discontinued from therapy and all seizure events resolved.

In a single-arm trial designed to assess the risk of seizures in patients with pre-disposing factors for seizure, 8 of 366 (2.2%) XTANDI-treated patients experienced a seizure. Three of the 8 patients had a second seizure during continued treatment with XTANDI after their first seizure resolved. It is unknown whether anti-epileptic medications will prevent seizures with XTANDI. Patients in the study had one or more of the following pre-disposing factors: the use of medications that may lower the seizure threshold (~54%), history of traumatic brain or head injury (~24%), history of cerebrovascular accident or transient ischemic attack (~24%), and Alzheimer's disease, meningoima, or leptomeningeal disease; prostate cancer; unexplained loss of consciousness within the last 12 months; past history of seizure; presence of a space occupying lesion of the brain, history of arteriovenous malformation, or history of brain infection (all <5%). Approximately 17% of patients had more than one risk factor.

Advise patients of the risk of developing a seizure while receiving XTANDI and of engaging in any activity where loss of consciousness could cause serious harm to themselves or others. Permanently discontinue XTANDI in patients who develop a seizure during therapy.

Posterior Reversible Encephalopathy Syndrome (PRES)
There have been reports of posterior reversible encephalopathy syndrome (PRES) in patients receiving XTANDI. PRES is a neurological disorder which can present with rapidly evolving symptoms including seizure, headache, lethargy, confusion, blindness, and other visual and neurological disturbances, with or without associated hypertension. A diagnosis of PRES requires correlation by brain imaging, preferably magnetic resonance imaging (MRI). Discontinue XTANDI in patients who develop PRES.

Hypersensitivity
Hypersensitivity reactions, including edema of the face (0.5%), tongue (0.1%), or lip (0.1%) have been observed with enzalutamide in four randomized clinical trials. Pharyngeal edema has been reported in post-marketing cases. Advise patients to contact a healthcare provider if any symptoms of hypersensitivity to temporarily discontinue XTANDI and promptly seek medical care. Permanently discontinue XTANDI for serious hypersensitivity reactions.

Ischemic Heart Disease
In the combined data of three randomized, placebo-controlled clinical studies, ischemic heart disease occurred more commonly in patients on the XTANDI arm compared to patients on the placebo arm (2.7% vs 1.2%). Grade 3-4 ischemic events occurred in 1.2% of patients in the XTANDI arm compared to 0.5% in the placebo arm. Ischemic events led to death in 0.4% of patients in the XTANDI arm compared to 0.1% in the placebo arm.

Monitor for signs and symptoms of ischemic heart disease. Optimize risk factors such as hypertension, diabetes, or dyslipidemia. Discontinue XTANDI for Grade 3-4 ischemic heart disease.

Falls and Fractures
Falls and fractures occurred in patients receiving XTANDI. Evaluate patients for fracture and fall risk. Monitor and manage patients at risk for fractures according to established treatment guidelines and consider use of bone-targeted agents.

In the combined data of three randomized, placebo-controlled clinical studies, falls occurred in 10% of patients treated with XTANDI compared to 4% of patients treated with placebo. Falls were not associated with loss of consciousness or seizure. Fractures occurred in 8% of patients treated with XTANDI and in 3% of patients treated with placebo. Grade 3-4 fractures occurred in 2% of patients treated with XTANDI and in <1% of patients treated with placebo. The median time to onset of fracture was 337 days (range: 2 to 996 days) for patients treated with XTANDI. Routine bone density assessment and treatment of osteoporosis with bone-targeted agents were not performed in the studies.

Endo-Gastrointestinal Toxicity
The safety and efficacy of XTANDI have not been established in females. Based on animal reproductive studies and mechanism of action, XTANDI can cause fetal harm and loss of pregnancy when administered to a pregnant female. Advise males with female partners of reproductive potential to use effective contraceptive during treatment with XTANDI and for 3 months after the last dose of XTANDI. XTANDI should not be handled by females who are or may become pregnant.

ADVERSE REACTIONS

Clinical Trial Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Four randomized controlled clinical trials enrolled patients with CRPC that had progressed on androgen deprivation therapy (GnRH therapy or prior bilateral orchiectomy). One of the trials was placebo-controlled and one trial was bicalutamide-controlled. Patients received XTANDI 160 mg (2784 patients) or placebo orally once daily (3708 patients) or bicalutamide 50 mg orally once daily (189 patients). All patients continued androgen deprivation therapy (ADT).

The most common adverse reactions (≥10%) that occurred more frequently (≥2% over placebo) in the XTANDI-treated patients from the randomized placebo-controlled clinical trials were asthenia (24%), decreased appetite, hot flush, arthralgia, dizziness/vertigo, headache, and weight decreased.

AFFIRM (NCT00974311): XTANDI versus Placebo in Metastatic CRPC Following ChemoTherapy
AFFIRM enrolled 1199 patients with metastatic CRPC who had previously received docetaxel.

The median duration of treatment was 8.3 months with XTANDI and 3.0 months with placebo. During the trial, 48% of patients on the XTANDI arm and 46% of patients on the placebo arm received glucocorticoids.

Grade 3 and higher adverse reactions were reported for 47% of XTANDI-treated patients and 53% of placebo-treated patients. Discontinuations due to adverse events were reported for 16% of XTANDI-treated patients and 18% of placebo-treated patients. The most common adverse reaction leading to treatment discontinuation was seizure, which occurred in 2% of the XTANDI-treated patients compared to none (0%) of the placebo-treated patients.

Table 1. Adverse Reactions in AFFIRM

<table>
<thead>
<tr>
<th></th>
<th>XTANDI</th>
<th>Grade 1-3</th>
<th>Grade 3-4</th>
<th>Placebo</th>
<th>Grade 1-3</th>
<th>Grade 3-4</th>
</tr>
</thead>
<tbody>
<tr>
<td>General Disorders</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Asthenic Conditions</td>
<td>5.1</td>
<td>9.0</td>
<td></td>
<td>44.9</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Edema</td>
<td>15.0</td>
<td>1.0</td>
<td></td>
<td>13.8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Musculoskeletal and Connective Tissue Disorders</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Back Pain</td>
<td>26.5</td>
<td>5.3</td>
<td></td>
<td>24.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arthralgia</td>
<td>21.2</td>
<td>2.5</td>
<td></td>
<td>17.8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Musculoskeletal Pain</td>
<td>15.1</td>
<td>1.3</td>
<td></td>
<td>12.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Muscular Weakness</td>
<td>9.8</td>
<td>1.5</td>
<td></td>
<td>6.8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Musculoskeletal Stiffness</td>
<td>2.6</td>
<td>0.3</td>
<td></td>
<td>0.3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gastrointestinal Disorders</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diarrhea</td>
<td>22.1</td>
<td>1.1</td>
<td></td>
<td>18.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urinary Tract Disorders</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hot Flush</td>
<td>20.0</td>
<td>0.0</td>
<td></td>
<td>10.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypertension</td>
<td>6.4</td>
<td>2.1</td>
<td></td>
<td>2.8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nervous System Disorders</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Headache</td>
<td>12.0</td>
<td>0.9</td>
<td></td>
<td>5.5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dizziness</td>
<td>9.5</td>
<td>0.5</td>
<td></td>
<td>7.5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Spinal Cord Compression and Nerve Equina Syndrome</td>
<td>7.4</td>
<td>6.6</td>
<td>4.5</td>
<td>3.8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Paresthesia</td>
<td>6.6</td>
<td>0.0</td>
<td></td>
<td>4.5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mental Impairment Disorders</td>
<td>4.3</td>
<td>0.3</td>
<td></td>
<td>1.8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypoesthesia</td>
<td>4.0</td>
<td>0.3</td>
<td></td>
<td>1.8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Infections and Infestations</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Upper Respiratory Tract Infection</td>
<td>11.0</td>
<td>0.0</td>
<td>6.5</td>
<td>0.3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lower Respiratory Tract and Lung Infection</td>
<td>8.5</td>
<td>2.4</td>
<td>4.8</td>
<td>1.3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Psychiatric Disorders</td>
<td>8.8</td>
<td>0.0</td>
<td>6.0</td>
<td>0.5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Insomnia</td>
<td>6.5</td>
<td>0.3</td>
<td></td>
<td>4.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anxiety</td>
<td>6.5</td>
<td>0.3</td>
<td></td>
<td>4.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Renal and Urinary Disorders</td>
<td>6.9</td>
<td>1.4</td>
<td>8.5</td>
<td>1.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hematuria</td>
<td>4.8</td>
<td>0.0</td>
<td></td>
<td>2.5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Infection, Poisoning and Procedural Complications</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fall</td>
<td>4.6</td>
<td>0.3</td>
<td></td>
<td>1.3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-pathologic Fracture</td>
<td>4.0</td>
<td>1.4</td>
<td></td>
<td>0.8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Skin and Subcutaneous Tissue Disorders</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pruritus</td>
<td>3.8</td>
<td>0.0</td>
<td></td>
<td>1.3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dry Skin</td>
<td>3.5</td>
<td>0.0</td>
<td></td>
<td>1.3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Respiratory Disorders</td>
<td>3.3</td>
<td>0.1</td>
<td></td>
<td>1.3</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

1. CTCAE v4
2. Includes asthenia and fatigue.
3. Includes dizziness and vertigo.
4. Includes amyotrophy, memory impairment, cognitive disorder, and disturbance in attention.
5. Includes nausea, vomiting, anorexia, and pyrexia.
6. Includes rhinitis, pharyngitis, and laryngitis.
PREVAIL (NCT01212991): XTANDI versus Placebo in Chemotherapy-naive Metastatic CRPC

PREVAIL enrolled 1717 patients with metastatic CRPC who had not received prior cytotoxic chemotherapy, of whom 1715 received at least one dose of study drug. The median duration of treatment was 17.5 months with XTANDI and 4.6 months with placebo. Grade 3-4 adverse reactions were reported in 44% of XTANDI-treated patients and 37% of placebo-treated patients. Discontinuations due to adverse events were reported for 6% of XTANDI-treated patients and 6% of placebo-treated patients. The most common adverse reaction leading to treatment discontinuation was fatigue/asthenia, which occurred in 1% of patients on each treatment arm. Table 2 includes adverse reactions reported in PREVAIL that occurred at ≥ 2% higher frequency in the XTANDI arm compared to the placebo arm.

Table 2. Adverse Reactions in PREVAIL

<table>
<thead>
<tr>
<th></th>
<th>XTANDI (N = 871)</th>
<th>Placebo (N = 844)</th>
</tr>
</thead>
<tbody>
<tr>
<td>General Disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Asthenic Conditions</td>
<td>47 (3.4)</td>
<td>33 (2.8)</td>
</tr>
<tr>
<td>Polyserosal Edema</td>
<td>12 (0.2)</td>
<td>8.2 (0.4)</td>
</tr>
<tr>
<td>Musculoskeletal and Connective Tissue Disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Back Pain</td>
<td>29 (2.5)</td>
<td>22 (3.0)</td>
</tr>
<tr>
<td>Arthralgia</td>
<td>21 (1.6)</td>
<td>16 (1.1)</td>
</tr>
<tr>
<td>Gastrointestinal Disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Constipation</td>
<td>23 (0.7)</td>
<td>17 (0.4)</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>17 (0.3)</td>
<td>14 (0.4)</td>
</tr>
<tr>
<td>Vascular Disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hot Flush</td>
<td>18 (0.1)</td>
<td>7.8 (0.0)</td>
</tr>
<tr>
<td>Hypertension</td>
<td>14 (7.2)</td>
<td>4.1 (2.3)</td>
</tr>
<tr>
<td>Nervous System Disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dizziness</td>
<td>11 (0.3)</td>
<td>7.1 (0.0)</td>
</tr>
<tr>
<td>Headache</td>
<td>11 (0.2)</td>
<td>7.0 (0.0)</td>
</tr>
<tr>
<td>Dysgeusia</td>
<td>7.6 (0.1)</td>
<td>3.7 (0.0)</td>
</tr>
<tr>
<td>Mental Impairment Disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5.0 (0.7)</td>
<td>1.3 (0.1)</td>
<td></td>
</tr>
<tr>
<td>Restless Legs Syndrome</td>
<td>2.1 (0)</td>
<td>0.4 (0.0)</td>
</tr>
<tr>
<td>Respiratory Disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dyspnea</td>
<td>11 (0.6)</td>
<td>8.5 (0.6)</td>
</tr>
<tr>
<td>Infections and infestations</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Upper Respiratory Tract Infection</td>
<td>16 (0.0)</td>
<td>11 (0.0)</td>
</tr>
<tr>
<td>Lower Respiratory Tract and Lung Infection</td>
<td>7.9 (1.5)</td>
<td>4.7 (1.1)</td>
</tr>
<tr>
<td>Psychiatric Disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Insomnia</td>
<td>8.2 (0.2)</td>
<td>5.7 (0.0)</td>
</tr>
<tr>
<td>Renal and Urinary Disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hematuria</td>
<td>8.8 (1.3)</td>
<td>5.8 (1.3)</td>
</tr>
<tr>
<td>Injury, Poisoning and Procedural Complications</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fall</td>
<td>13 (1.6)</td>
<td>5.3 (0.7)</td>
</tr>
<tr>
<td>Non-Pathological Fracture</td>
<td>8.8 (2.1)</td>
<td>3.0 (1.1)</td>
</tr>
<tr>
<td>Metabolism and Nutrition Disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Decreased Appetite</td>
<td>19 (0.3)</td>
<td>16 (0.7)</td>
</tr>
<tr>
<td>Investigations</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Weight Decreased</td>
<td>12 (0.8)</td>
<td>8.5 (0.2)</td>
</tr>
<tr>
<td>Reproductive System and Breast Disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gynecomastia</td>
<td>3.4 (0.0)</td>
<td>1.4 (0.0)</td>
</tr>
</tbody>
</table>

Table 3. Adverse Reactions in TERRAIN

<table>
<thead>
<tr>
<th></th>
<th>XTANDI (N = 183)</th>
<th>Bicalutamide (N = 189)</th>
</tr>
</thead>
<tbody>
<tr>
<td>General Disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Asthenic Conditions</td>
<td>32 (1.6)</td>
<td>23 (1.1)</td>
</tr>
<tr>
<td>Musculoskeletal and Connective Tissue Disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Back Pain</td>
<td>19 (2.7)</td>
<td>18 (1.6)</td>
</tr>
<tr>
<td>Musculoskeletal Pain</td>
<td>16 (1.1)</td>
<td>14 (0.5)</td>
</tr>
<tr>
<td>Vascular Disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hot Flush</td>
<td>15 (0)</td>
<td>11 (0)</td>
</tr>
<tr>
<td>Hypertension</td>
<td>14 (7.1)</td>
<td>7.4 (4.2)</td>
</tr>
<tr>
<td>Gastrointestinal Disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nausea</td>
<td>14 (0)</td>
<td>18 (0)</td>
</tr>
<tr>
<td>Constipation</td>
<td>13 (1.1)</td>
<td>13 (0.5)</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>12 (0.0)</td>
<td>9.0 (1.1)</td>
</tr>
<tr>
<td>Infections and infestations</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Upper Respiratory Tract Infection</td>
<td>12 (0)</td>
<td>6.3 (0.5)</td>
</tr>
<tr>
<td>Lower Respiratory Tract and Lung Infection</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Psychiatric Disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Insomnia</td>
<td>8.2 (0.2)</td>
<td>5.7 (0.0)</td>
</tr>
</tbody>
</table>

Table 4. Laboratory Abnormalities in PROSPER

<table>
<thead>
<tr>
<th></th>
<th>XTANDI (N = 930)</th>
<th>Placebo (N = 465)</th>
</tr>
</thead>
<tbody>
<tr>
<td>General Disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Asthenic Conditions</td>
<td>40 (4.0)</td>
<td>20 (0.9)</td>
</tr>
<tr>
<td>Vascular Disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Weight Decreased</td>
<td>5.9 (0.2)</td>
<td>1.5 (0.0)</td>
</tr>
<tr>
<td>Gastrointestinal Disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nausea</td>
<td>11 (0.3)</td>
<td>8.6 (0.0)</td>
</tr>
<tr>
<td>Constipation</td>
<td>9.1 (0.2)</td>
<td>6.9 (0.4)</td>
</tr>
<tr>
<td>General Disorders and Administration Site Conditions</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Asthenic Conditions</td>
<td>4.0 (0)</td>
<td>4.0 (0)</td>
</tr>
<tr>
<td>Investigations</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Weight Decreased</td>
<td>5.9 (0.2)</td>
<td>1.5 (0.0)</td>
</tr>
<tr>
<td>Injury, Poisoning and Procedural Complications</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fractures</td>
<td>9.8 (2.0)</td>
<td>4.9 (1.7)</td>
</tr>
<tr>
<td>Fall</td>
<td>11 (1.3)</td>
<td>4.1 (0.6)</td>
</tr>
</tbody>
</table>

Table 4. Adverse Reactions in PROSPER

<table>
<thead>
<tr>
<th></th>
<th>XTANDI (N = 930)</th>
<th>Placebo (N = 465)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Metabolism and Nutrition Disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Decreased Appetite</td>
<td>9.6 (0.2)</td>
<td>3.9 (0.2)</td>
</tr>
<tr>
<td>Nervous System Disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dizziness</td>
<td>12 (0.5)</td>
<td>5.2 (0.0)</td>
</tr>
<tr>
<td>Headache</td>
<td>9.1 (0.2)</td>
<td>4.5 (0.0)</td>
</tr>
<tr>
<td>Vascular Disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hot Flush</td>
<td>13 (0.1)</td>
<td>7.7 (0.0)</td>
</tr>
<tr>
<td>Hypertension</td>
<td>12 (4.6)</td>
<td>5.2 (2.2)</td>
</tr>
<tr>
<td>Gastrointestinal Disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nausea</td>
<td>11 (0.3)</td>
<td>8.6 (0.0)</td>
</tr>
<tr>
<td>Constipation</td>
<td>9.1 (0.2)</td>
<td>6.9 (0.4)</td>
</tr>
<tr>
<td>General Disorders and Administration Site Conditions</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Asthenic Conditions</td>
<td>40 (4.0)</td>
<td>20 (0.9)</td>
</tr>
<tr>
<td>Investigations</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Weight Decreased</td>
<td>5.9 (0.2)</td>
<td>1.5 (0.0)</td>
</tr>
<tr>
<td>Injury, Poisoning and Procedural Complications</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fractures</td>
<td>9.8 (2.0)</td>
<td>4.9 (1.7)</td>
</tr>
<tr>
<td>Fall</td>
<td>11 (1.3)</td>
<td>4.1 (0.6)</td>
</tr>
</tbody>
</table>

Laboratory Abnormalities in the AFFIRM and PREVAIL studies in metastatic CRPC. Grade 1-4 neutropenia occurred in 15% of patients receiving XTANDI (1% Grade 3-4) and in 6% of patients receiving placebo (0.5% Grade 3-4). Table 5 shows laboratory abnormalities that occurred in ≥ 5% of patients and more frequently (> 2%) in the XTANDI arm compared to placebo in the PROSPER study.

Table 5. Laboratory Abnormalities in PROSPER

<table>
<thead>
<tr>
<th></th>
<th>XTANDI (N = 930)</th>
<th>Placebo (N = 465)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hematology</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neutropenia</td>
<td>8.2 (0.5)</td>
<td>5.4 (0.2)</td>
</tr>
<tr>
<td>Hypotension</td>
<td>16 (1.3)</td>
<td>8.8 (1.5)</td>
</tr>
<tr>
<td>Hypoglycemia</td>
<td>78 (2.9)</td>
<td>73 (1.3)</td>
</tr>
<tr>
<td>Hyper-magnesemia</td>
<td>26 (0.0)</td>
<td>21 (0.0)</td>
</tr>
</tbody>
</table>
Hypertension
In the AFFIRM and PREVAIL studies in metastatic CRPC, hypertension was reported in 11% of patients receiving XTANDI and 4% of patients receiving placebo. Medical history of hypertension was balanced between arms. Hypertension led to study discontinuation in <1% of patients in the AFFIRM study. In the PROSPER study in metastatic CRPC, hypertension was reported in 12% of patients receiving XTANDI and 5% of patients receiving placebo.

Post-Marketing Experience
The following additional adverse reactions have been identified during post-approval use of XTANDI. Because these reactions were reported voluntarily from a population of uncertain size, it is not possible to reliably estimate the frequency or establish a causal relationship to drug exposure.

Body as a Whole: hypersensitivity (edema of the face, tongue, lip, or pharynx)

Gastrointestinal Disorders: vomiting

Neurological Disorders: posterior reversible encephalopathy syndrome (PRES)

Drug Interactions
Drugs that Inhibit CYP2C8
Co-administration of a strong CYP2C8 inhibitor (gemfibrozil) increased the plasma exposure of enzalutamide plus N-desmethyl enzalutamide by 2.2-fold. Co-administration of XTANDI with strong CYP2C8 inhibitors should be avoided if possible. If co-administration of XTANDI with a strong CYP2C8 inhibitor cannot be avoided, reduce the dose of XTANDI.

Drugs that Induce CYP3A4
Co-administration of rifampin (strong CYP3A4 inducer and moderate CYP2C8 inducer) decreased the composite AUC of enzalutamide plus N-desmethyl enzalutamide by 37%. Co-administration of strong CYP3A4 inducers (e.g., carbamazepine, phenobarbital, phenytoin, rifabutin, rifampin, rifapentine) with XTANDI should be avoided if possible. St John’s wort may decrease enzalutamide exposure and should be avoided. If co-administration of a strong CYP3A4 inducer with XTANDI cannot be avoided, increase the dose of XTANDI.

Effect of XTANDI on Drug Metabolizing Enzymes
Enzalutamide is a strong CYP3A4 inducer and a moderate CYP2C9 and CYP2C19 inducer in humans. At steady-state, XTANDI did not increase the plasma exposure to midazolam (CYP3A4 substrate), warfarin (CYP2C9 substrate), and omeprazole (CYP2C19 substrate). Concomitant use of XTANDI with narrow therapeutic index drugs that are metabolized by CYP3A4 (e.g., alfentanil, cyclosporine, diltiazem, ergotamine, fentanyl, pimozone, quinidine, sirolimus and tacrolimus), CYP2C9 (e.g., phenytoin, warfarin) and CYP2C19 (e.g., S-mephenytoin, clopidogrel) should be avoided, as enzalutamide may decrease their exposure. If co-administration with warfarin cannot be avoided, conduct additional INR monitoring.

Use in Specific Populations

Pregnancy

Risk Summary
The safety and efficacy of XTANDI have not been established in females. Based on animal reproductive studies, XTANDI may impair fertility in males of reproductive potential.

Pediatric Use

Safety and effectiveness of XTANDI in pediatric patients have not been established.

Geriatric Use

Of 2784 patients who received XTANDI in four randomized controlled clinical trials, 79% were 65 and over, while 36% were 75 and over. No overall differences in safety or effectiveness were observed between these patients and younger patients. Other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

Patients with Renal Impairment

A dedicated renal impairment trial for XTANDI has not been conducted. Based on the population pharmacokinetic analysis using data from clinical trials in patients with metastatic CRPC and healthy volunteers, no significant difference in enzalutamide clearance was observed in patients with pre-existing mild to moderate renal impairment (30 mL/min ≤ creatinine clearance [CrCL] ≤ 60 mL/min) compared to patients with baseline normal renal function (CrCL ≥ 90 mL/min). No initial dosage adjustment is necessary for patients with mild to moderate renal impairment. Severe renal impairment (CrCl < 30 mL/min) and end-stage renal disease have not been assessed.

Patients with Hepatic Impairment

Dedicated hepatic impairment trials compared the composite systemic exposure of enzalutamide plus N-desmethyl enzalutamide in volunteers with baseline mild, moderate, or severe hepatic impairment (Child-Pugh Class A, B, or C, respectively) versus healthy controls with normal hepatic function. The composite AUC of enzalutamide plus N-desmethyl enzalutamide was similar in volunteers with mild, moderate, or severe baseline hepatic impairment compared to volunteers with normal hepatic function. No initial dosage adjustment is necessary for patients with baseline mild, moderate, or severe hepatic impairment.

OVERDOSAGE
In the event of an overdose, stop treatment with XTANDI and initiate general supportive measures taking into consideration the half-life of 5.8 days. In a dose escalation study, no seizures were reported at ≤ 240 mg daily, whereas 3 seizures were reported, 1 each at 360 mg, 480 mg, and 600 mg daily. Patients may be at increased risk of seizure following an overdose.

Nonclinical Toxicology

Carcinogenesis, Mutagenesis, Impairment of Fertility

Administration of enzalutamide to male and female rats on gestation days 6-15 (approximately 0.4 times the exposure in patients based on AUC). In a pharmacokinetic study in pregnant rats with a single oral 30 mg/kg enzalutamide administration on gestation day 14, enzalutamide and/or its metabolites were present in milk of lactating rats (see Data). Following a single oral administration in lactating rats on postnatal day 14, enzalutamide and/or its metabolites were present in milk at a Cmax that was approximately 0.3 times the concentration found in maternal plasma and occurred 4 hours after administration.

Lactation

Risk Summary
The safety and efficacy of XTANDI have not been established in females. There is no information available on the presence of XTANDI in human milk, the effects of the drug on the breastfeeding infant, or the effects of the drug on milk production. Enzalutamide and/or its metabolites were present in milk of lactating rats (see Data).

Data
Following a single oral administration in lactating rats on postnatal day 14, enzalutamide and/or its metabolites were present in milk at a Cmax that was 4 times higher than concentrations in the plasma and occurred 4 hours after administration.

Females and Males of Reproductive Potential

Contraception

Males
Based on findings in animal reproduction studies, advise male patients with female partners of reproductive potential to use effective contraception during treatment and for 3 months after the last dose of XTANDI.

Infertility

Males
Based on animal studies, XTANDI may impair fertility in males of reproductive potential.

Manufactured for and Distributed by: Astellas Pharma US, Inc., Northbrook, IL 60062
Marketed by: Astellas Pharma US, Inc., Northbrook, IL 60062
Pfizer Inc., New York, NY 10017

Revised: July 2018

Rx Only © 2018 Astellas Pharma US, Inc.
XTANDI® is a registered trademark of Astellas Pharma Inc.

076-3717-PM
• Join the AUA – special on-site membership rates, gifts and prices will be available
• Sign up for Automatic Dues Renewal and claim your $5 virtual Visa card – set it and forget it!
• Pay your dues
• Learn about the latest AUA member benefits
• Meet AUA Member Services Staff
Where will your patients go with Myrbetriq?

Find out at Booth #4001
Where will your patients go with Myrbetriq?

Myrbetriq is a registered trademark of Astellas Pharma Inc.

©2019 Astellas Pharma US, Inc. All rights reserved. Printed in USA 057-3092-PM March 2019

Find out at Booth #4001
ENGAGE. EXPLORE.
RELAX. REFUEL.

SQUARE

LEVEL 3
Member Central
AUAAUniversity Store
Urology Care Foundation
AUA Research
AUA Quality Registry (AQUA)
International Programs
Take the Census
Twitter Training
Silent Auction
### Table of Contents

<table>
<thead>
<tr>
<th>Board of Directors</th>
<th>Committees</th>
<th>CME Information</th>
<th>Specialty Programs</th>
<th>Office of Education Courses</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Thursday</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Society of Academic Urologists</td>
<td>17</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Evolving Role of the Urologist in Metastatic and Castration-Resistant Prostate Cancer (CRPC): A Guidelines and Case-Based Discussion</td>
<td>18</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Friday</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Plenary: Prime Time, Morning Session</td>
<td>21</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Plenary: Prime Time, Afternoon Session</td>
<td>21</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Poster, Podium and Video Sessions (MP1-6, PD1-5, V1)</td>
<td>22</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urologic Oncology Research Symposium: Metabolism and Cancer</td>
<td>38</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Society for Pediatric Urology</td>
<td>39</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Indian American Urological Association</td>
<td>42</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>World Chinese Urological Society</td>
<td>43</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Confederación Americana de Urología</td>
<td>45</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sexual Medicine Society of North America</td>
<td>46</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Poster, Podium and Video Sessions (MP7-11, PD6-10, V2)</td>
<td>47</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Society of Genitourinary Reconstructive Surgeons/Society of Urologic Prosthetic Surgeons</td>
<td>62</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction</td>
<td>62</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Poster and Podium Sessions (MP12-16, PD11-15)</td>
<td>63</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>History of Urology Forum</td>
<td>77</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Poster and Podium Sessions (MP17-21, PD16-18)</td>
<td>79</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Saturday</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Plenary: Prime Time, Morning Session</td>
<td>93</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Plenary: Next Frontier, Afternoon Session</td>
<td>93</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Plenary: Prime Time, Afternoon Session</td>
<td>94</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Poster, Podium and Video Sessions (MP22-27, PD19-23, V3)</td>
<td>95</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Challenges for Urologic Research</td>
<td>113</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Society for Pediatric Urology</td>
<td>113</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Society for Basic Urologic Research/Society of Urologic Oncology</td>
<td>116</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>American College of Osteopathic Surgeons</td>
<td>117</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urologic Care for the Advanced Practice Provider I</td>
<td>117</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Poster, Podium and Video Sessions (MP28-33, PD24-28, V4)</td>
<td>118</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Young Urologists Forum</td>
<td>136</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Society of Urologic Oncology</td>
<td>137</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Poster, Podium and Video Sessions (MP34-39, PD29-33, V5)</td>
<td>138</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Asociación Española de Urología</td>
<td>157</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Society for Basic Urologic Research</td>
<td>157</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AUA/Brazilian Portuguese Urology Program</td>
<td>157</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Korean World Urologic Congress</td>
<td>158</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hibernian Urological Society</td>
<td>158</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical Controversies in Men’s Health</td>
<td>159</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Polish Urological Association/Hungarian Urological Association</td>
<td>159</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Poster, Podium and Video Sessions (MP40-45, PD34-38, V6)</td>
<td>159</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**INDEX EXHIBITORS**

**TUESDAY**

**MONDAY**

**SATURDAY**

**SUNDAY**

**FRIDAY**

**THURSDAY**

**EXHIBITORS**

**INDEX**
Sunday
Plenary: Next Frontier, Morning Session ............................................................... 181
Plenary: Prime Time, Morning Session ............................................................... 181
Plenary: Next Frontier, Afternoon Session ......................................................... 182
Plenary: Prime Time, Afternoon Session ............................................................. 184
Society of Women in Urology .................................................................. 185
Poster, Podium and Video Sessions (MP46-51, PD39-43, V7) ......................... 185
Residents Forum ......................................................................................... 202
Basic Sciences Symposium: Social (and Antisocial) Cell Signaling Network in the Urinary Tract ..................................................................................... 203
Engineering & Urology Section of the Endourological Society .................... 203
Urologic Care for the Advanced Practice Provider II ....................................... 204
Poster, Podium and Video Sessions (MP52-57, PD44-48, V8) ......................... 206
18th International Prostate Forum ..................................................................... 222
Poster, Podium and Video Sessions (MP58-63, PD49-53, V9) ......................... 223
Research Forum I: Funding Opportunities and Grant Writing Guidance for Early-Career Investigators ................................................................. 240
Society for Infection and Inflammation in Urology ......................................... 241
Geriatric Urological Society ........................................................................... 241
R. Frank Jones Urological Society ................................................................. 242
Society for the Study of Male Reproduction .................................................... 242
Urological Society for American Veterans ....................................................... 243
Society for Urologic Robotic Surgery .............................................................. 243
Japanese Urological Association ................................................................... 244
British Association of Urological Surgeons – Urological Society of Australia and New Zealand ................................................................. 245
Sociedad Argentina de Urología ...................................................................... 245
Società Italiana di Urologia ............................................................................ 246
Research Forum II: Early-Career Investigators Showcase ............................... 247
Association Française d’Urologie .................................................................... 247
Poster, Podium and Video Sessions (MP64-69, PD54-58, V10) ......................... 248

Monday
Plenary: Prime Time I and II, Morning Sessions .............................................. 265
Plenary: Prime Time, Take Home Messages .................................................... 266
Poster, Podium and Video Sessions (MP70-75, PD59-63, V11) ......................... 267
American Society for Men’s Health ................................................................ 284
American Board of Urology Town Hall .......................................................... 284
Poster, Podium and Video Sessions (MP76-81, PD64-67, V12) ......................... 284
Research on Calculus Kinetics Society ........................................................... 300
Urologic Society for Transplantation & Renal Surgery ..................................... 301
Pan African Urological Surgeons Association/Caribbean Urological Surgeons Association ................................................................. 301
Philippine Urological Association ................................................................ 302
Exhibitor Listing ......................................................................................... 303
Author Index ............................................................................................. 305
2018-2019 Board of Directors

Officers of the Board of Directors

President.......................................................................................................................................Robert C. Flanigan
President-Elect .....................................................................................................................................John H. Lynch
Immediate Past President .........................................................................................................J. Brantley Thrasher
Secretary..............................................................................................................................................Manoj Monga
Treasurer .............................................................................................................................................David F. Green

Section Representatives to the Board of Directors

Mid-Atlantic.......................................................................................................................................Roger E. Schultz
New England .......................................................................................................................................E. Ann Gormley
New York ...........................................................................................................................................Frederick A. Gulmi
North Central ......................................................................................................................................Chandru P. Sundaram
Northeastern ......................................................................................................................................Barry A. Kogan
South Central ......................................................................................................................................Anthony Y. Smith
Southeastern .......................................................................................................................................Thomas F. Stringer
Western ...............................................................................................................................................Scott K. Swanson

AUA Headquarters
American Urological Association, Inc.
1000 Corporate Boulevard
Linthicum, Maryland 21090
Telephone: 410-689-3700
FAX: 410-689-3800
E-mail: aua@auanet.org
Website: www.auanet.org

Annual Business Meeting
Monday, May 6, 2019 @ 12:00 pm
W181C McCormick Place
2019 Committees

Program Planning Committee

Rosalyn Adam
Joseph Alukal
Dean Assimos
John Barry
David Bushinsky
Christopher Coogan
Michael Cookson
John Denstedt
Ananias Diokno
Yang Dong
Michael Eisenberg
Khurshid Ghani
David Ginsberg
Leonard Gornella
Christopher Gonzalez
Tomas Griebling
CD Anthony Henndon
David Jarrard
Travis Jerde
Anil Kapoor
Louis Kavoussi
Mohit Khera
Ziya Kirikai
Kathleen Kobashi
Badrinath Konety
Dolores Lamb
Thomas Lendvay

Brian Mattaga
Kurt McCammon
Linda McIntyre
Manoj Monga
Jeremy Myers
Craig Niederberger
Victor Nitti
Aria F. Olumi
Lane Palmer
Margaret Pearle
Kristina Penniston
Michel Pontari
Robert Reiter
Andrew Rule
Hossein Sadeghi-Nejad
Edward Schaeffer
Alp Sener
Arieh Shalhav
David Shin
Daniel Shoskes
Sandip Vasavada
Bryan Voelzke
Run Wang
Daniel Williams
Hadley Wood
Claire Yang

Urologic Video Education Committee

Sero Andonian
Clinton Bahler
Daniel Canter
Maude Carmel
Thomas Chi
Leslie Deane
Daniel Dugi
Obi Ekwenna
Sherb Figenshau
Patricio Gargollo
Reza Ghavamian
Mohan Gundeti
Shubham Gupta
Judith Hagedorn
Lindsay Hampson
Jon Harper
Jim Hu
Isaac Kim
Jason Kim
Tracey Krupski
Costas Lallas
Susan MacDonald
Ravi Munver
Robert Nadler
Neem Navai
Dmitriy Nikolovsky
Brock O’Neil
Charles Osferber
Will Parker
Nishant Patel
Stephen Pautler
James Porter
Jay Raman
Lee Richstone
Chad Ritch
Neal Rowe
Kristen Scarpato
George Schade
Casey Seideman
John Seiph
Ajay Singla
Arianna Smith
Mark Tyson
Ramakrishnan Venkatesh
Ramon Virasora
Eric Wallen
Daniel Williams
Steve Wilson
Hadley Wyre
Jennifer Yang

Program Abstract Review Committee

Philip Abbosh
Rosalyn M. Adam
Jennifer Ahn
Peter C. Albertsen
Mohammad Alifaf
Zaki Almallah
Seth Alpert
Joseph P. Alukal
Kari-Erik Andersson
Jennifer T. Angermeier
Jodi Antonell
Monish Aron
William J. Aronson
Kenneth Aston
Anthony Atala
Christopher Austin
Paul Austin
Riccardo Autorino
Timothy D. Averch
Ketan Badani
Michael Bailey
Linda Baker
K. C. Balaji
D. Duane Baldwin
Chris Bangma
Ahmad Bani-Hani
Christopher Barbieri
Daniel A. Barocas
Aaronz Bayne
Arie S. Belledestre
Carol J. Bennett
Nelson Bennett
Mitchell C. Benson
Ryan K. Berglund
Sara Best
Lori Birder
Jay T. Bishoff
Trinity Bivalacqua
Dale E. Bjorling
Peter C. Black
Jerry G. Blaivas
Michael L. Blute
Stephen A. Boorjian
Joseph Borer
James F. Borin
Mike S. Borofsky
Luis Braga
Robert Brannigan
Peter N. Brelan
Ben Breyer
Alberto Briganti
Gerald Brock
Gregory A. Broderick
Joshua Broghammer
James D. Brooks
Benjamin Brucker
Fiona Burkhard
Frank N. Burks
Arthur L. Burnett
Wade Bushman
Ralph Buttyan
Jeffrey A. Cadeddu
Brian Caldwell
Anne P. Cameron
Steven C. Campbell
Benjamin K. Canales
Glenn Cannon
Stephen Cannon
Douglas Carrell
Serge Carrier
Rafael Carrion
Statement of Need

Urologists need a thorough knowledge of the most recent developments and techniques as well as established guidelines in urology to ensure the highest standards of patient care and safety.

Learning Objectives

At the conclusion of the 2018 Annual Meeting, participants should be able to:
● describe recent developments in the medical and surgical management of urology patients
● identify new technologies for the treatment of urologic conditions
● integrate the latest guidelines on the management of urological diseases into their practice
● incorporate evidence based research and literature into the shared decisions making process

Accreditation Statement

The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

The American Urological Association designates this live activity for a maximum of 46.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Other Learners

The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.

Evidence-Based Content

It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous and free of commercial bias.

AUA Disclosure Policy

All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners with information so they can make their own judgments.

Resolution of Conflict of Interest

All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:
● Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director and/or Education Conflict of Interest Review Committee or its sub-group
● Limit content to evidence with no recommendations
● Introduction of a debate format with an unbiased moderator (point-counterpoint)
● Inclusion of moderated panel discussion
● Publication of a parallel or rebuttal article for an article that is felt to be biased
● Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
● Divestiture of the relationship by faculty

Off-label or Unapproved Use of Drugs or Devices

The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

AUA ATTENDEE INFORMATION & POLICIES

Disclaimer

The opinions and recommendations expressed by faculty, authors, and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.

Consent to Use of Photographic Images

Attendance at or participation in AUA meetings and other activities constitutes an agreement by the registrant to AUA’s use and distribution (both now and in the future) of the registrant’s name, medical specialty, medical specialty, and other personal information for publication of photographs, videos or other media for educational and/ or promotional purposes.
future) of the attendee’s image or voice in photographs and electronic reproductions of such events and activities.

Audio, Video and Photographic Equipment

The use of audio, video and other photographic recording equipment by attendees is prohibited inside AUA meeting rooms.

Reproduction Permission

Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.

Special Assistance

The American Urological Association (AUA), an organization accredited for continuing medical education (CME), complies with the Americans with Disabilities Act §12112(a). If any participant is in need of special assistance or has any dietary restrictions, a written request should be submitted at least one month in advance. For additional assistance with your request, please call 1-800-908-9414.

Getting Your CME Credits or Certificate of Attendance

You can claim your CME/Certificate of Attendance several ways:
- Onsite: AUA Store
  Sunday, 6:30 a.m.–4 p.m.
  Monday, 6:30 a.m.–4 p.m.
- Online: AUA2019.org/CME
- Mobile App (iPhone, iPad, Android phones and tablets)

To claim credits/participation hours:
1. Scan your badge upon entrance into accredited courses and sessions (except for Plenary).
2. Login to the CME Credit Claim.
3. For scanned sessions, adjust the credit hours to reflect the time spent in the session.
4. Manually add Plenary credit/hours.
5. Submit evaluation to have credits added to your transcript.

Note: All 2019 Annual Meeting CME credits/participation must be claimed by December 31, 2019. Credits/participation for the 2019 Annual Meeting cannot be claimed after this date. Credits will be awarded only to the person whose name is associated with the badge.

Questions? Email education@AUAnet.org.
<table>
<thead>
<tr>
<th>Association</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>American College of Osteopathic Surgeons</td>
<td>117</td>
</tr>
<tr>
<td>American Society for Men’s Health</td>
<td>284</td>
</tr>
<tr>
<td>Asociación Española de Urología</td>
<td>157</td>
</tr>
<tr>
<td>Association Française d’Urologie</td>
<td>247</td>
</tr>
<tr>
<td>AUA/Brazilian Portuguese Urology Program</td>
<td>157</td>
</tr>
<tr>
<td>AUA/Confederación Americana de Urología</td>
<td>45</td>
</tr>
<tr>
<td>British Association of Urological Surgeons – Urological Society of Australia and New Zealand</td>
<td>245</td>
</tr>
<tr>
<td>Engineering and Urology Section of the Endourological Society</td>
<td>203</td>
</tr>
<tr>
<td>Geriatric Urological Society</td>
<td>241</td>
</tr>
<tr>
<td>Hibernian Urological Society</td>
<td>158</td>
</tr>
<tr>
<td>Indian American Urological Association</td>
<td>42</td>
</tr>
<tr>
<td>Japanese Urological Association</td>
<td>244</td>
</tr>
<tr>
<td>Korean World Urologic Congress</td>
<td>158</td>
</tr>
<tr>
<td>Pan African Urological Surgeans Association/Caribbean Urological Surgeons Association</td>
<td>301</td>
</tr>
<tr>
<td>Philippine Urological Association</td>
<td>302</td>
</tr>
<tr>
<td>Polish Urological Association and Hungarian Urological Association</td>
<td>159</td>
</tr>
<tr>
<td>R. Frank Jones Urological Society</td>
<td>242</td>
</tr>
<tr>
<td>Research on Calculus Kinetics Society</td>
<td>300</td>
</tr>
<tr>
<td>Sexual Medicine Society of North America</td>
<td>46</td>
</tr>
<tr>
<td>Sociedad Argentina de Urología</td>
<td>245</td>
</tr>
<tr>
<td>Società Italiana di Urologia</td>
<td>246</td>
</tr>
<tr>
<td>Society for Pediatric Urology</td>
<td>39</td>
</tr>
<tr>
<td>Society for Basic Urologic Research</td>
<td>157</td>
</tr>
<tr>
<td>Society for Basic Urologic Research and Society of Urologic Oncology</td>
<td>116</td>
</tr>
<tr>
<td>Society for Infection and Inflammation in Urology</td>
<td>241</td>
</tr>
<tr>
<td>Society for the Study of Male Reproduction</td>
<td>242</td>
</tr>
<tr>
<td>Society of Academic Urologists</td>
<td>17</td>
</tr>
<tr>
<td>Society of Genitourinary Reconstructive Surgeons/Society of Urologic Prosthetic Surgeons</td>
<td>62</td>
</tr>
<tr>
<td>Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction</td>
<td>62</td>
</tr>
<tr>
<td>Society of Urologic Oncology</td>
<td>137</td>
</tr>
<tr>
<td>Society of Urologic Robotic Surgery</td>
<td>243</td>
</tr>
<tr>
<td>Society of Women in Urology</td>
<td>185</td>
</tr>
<tr>
<td>Urologic Society for Transplantation &amp; Renal Surgery</td>
<td>301</td>
</tr>
<tr>
<td>Urological Society for American Veterans</td>
<td>243</td>
</tr>
<tr>
<td>World Chinese Urological Society</td>
<td>43</td>
</tr>
</tbody>
</table>
Thursday, May 2, 2019

7:30 am - 5:00 pm

101HO  HANDS-ON UROLOGIC ULTRASOUND
Pat Fulgham, Course Director
Craig Smith, Christopher Porter, Stephen Savage,
Phillip Wise, Eric Singer, Lewis Chan, Majid Eshghi,
Mohammad Bhatti, Tillmann Loch, Edouard Trabulsi

Friday, May 3, 2019

7:30 am - 9:30 am

001IC  ACTIVE SURVEILLANCE FOR PROSTATE CANCER: 2019 UPDATE
Laurence Klotz, Course Director
Mark Emberton, Ian Thompson
Room W183b

002IC  ROBOTIC UPPER URINARY TRACT RECONSTRUCTION: A TOP TO BOTTOM APPROACH
Lee Zhao, Course Director
Michael Stifelman, Daniel Eun, Raju Thomas
Room W183c

003IC  VASECTOMY: A VERY PRACTICAL CASE-BASED COURSE ON PREOPERATIVE, INTRAOPERATIVE & POSTOPERATIVE MANAGEMENT
Ira Sharlip, Course Director
Jay Sandlow, Stanton Honig, Joel Mamar
Room W184bc

004IC  UPDATES IN THE MANAGEMENT OF PENILE CANCER: A CASE-BASED APPROACH
Philippe Spiess, Course Director
Viraj Master, Timothy Masterson, Andrea Necchi, Chris Protzel
Room W187a

005IC  UROLITHIASIS: METABOLIC EVALUATION & MEDICAL TREATMENT
Michael Lipkin, Course Director
Sara Best, Jodi Antonelli, Brian Eisner
Room W186abc

006IC  THE PRACTICAL MANAGEMENT OF OVERACTIVE BLADDER: INTEGRATING THE SUFU OVERACTIVE BLADDER CLINICAL CARE PATHWAY INTO YOUR PRACTICE
Benjamin Brucker, Course Director
Stephan Kraus, Diane Newman
Room W185bc

9:00 am - 12:00 pm

102HO  PROSTATE MR IMAGING: WHAT A UROLOGIST SHOULD KNOW
Art Rastinehad, Rajan Gupta, Co- Course Directors,
Jelle Barentsz, Ismail Turkbey, Arvin George, Sara Lewis,
Srinivas Vourganti

10:00 am - 12:00 pm

007IC  WINNING THE BATTLE AGAINST BURNOUT: THE SECRETS TO RESILIENCE & THE WORK-LIFE BALANCE
Amanda North, Course Director
Paul Maroni, Ryan Terlecki
Room W183b
CAN IT BE FIXED ROBOTICALLY? SURGICAL SOLUTIONS FOR CHALLENGING SCENARIOS
Mihir Desai, Course Director
Andre Berger, Alvin Goh, Lee Zhao
Room W185bc

HOW TO PICK THE RIGHT PRACTICE AND BE SUCCESSFUL
Mike Kozminski, Course Director
Sapan Ambani, Thomas Stringer, Parth Shah
Room W187a

CONTROVERSIES IN SURGICAL STONE MANAGEMENT: A CASE-BASED INSTRUCTIONAL COURSE
Stephen Nakada, Margaret Pearle
Room W186abc

INTRODUCTION TO MR ULTRASOUND FUSION GUIDED PROSTATE BIOPSIES
Art Rastinehad, Peter Pinto, Co-Course Directors, Thomas Polascik, Ismail Turkbey, Osamu Ukimura, Srinivas Vourganti, James Wysock, Preston Spenkle, Marc Bjurlin, Leonard Marks, Raymond Lance, Jonathan Coleman, Winston Barzell, Sara Lewis, Jelle Barentsz, Arvin George
Room W184abc

NEW TECHNOLOGY IN THE MANAGEMENT OF STONE DISEASE: WHAT'S NEW, WHAT WORKS, & WHAT TO BUY
Ben Chew, Mitchell Humphreys
Room W183b

TÉCNICAS DE AVANZADA EN CIRUGÍA RECONSTRUCTIVA URETRAL: ANÁLISIS DE NUESTROS ERRORES (CURSO EN ESPAÑOL)
Ramon Virasoro, Course Director
Room W187a

SURGICAL APPROACH TO THE MANAGEMENT OF POST PROSTATECTOMY INCONTINENCE - INITIAL & REVISION PROCEDURES
Ajay Singla, Gregory Bales
Room W186abc

URETERAL STRICTURE DISEASE
Sammy Elsamra, Course Director
Louis Kavoussi, Richard Link, Thomas Jarrett
Room W183c

TESTIS CANCER: CURRENT CONCEPTS & CONTROVERSIES
Joel Sheinfeld, Course Director
Brett Carver, Darren Feldman
Room W186abc

CONTROVERSIES IN PROSTATE BIOPSY
Jeffrey Tomaszewski, Allen Selfel, Alexander Kutikov
Room W178a

CHEMOTHERAPY & IMMUNOTHERAPY OPTIONS FOR GENITOURINARY MALIGNANCIES: A PRIMER FOR UROLOGISTS & ADVANCED PRACTICE PROVIDERS
Costas Lallas
Room W184abc

PROSTATE CANCER DIAGNOSTICS: BIOMARKERS, MRI, & BIOPSY TECHNIQUES
Daniel Barocas, John Wei, Scott Eggener
Room W185bc

Saturday, May 4, 2019

MANAGEMENT OF UROLOGIC COMPLICATIONS AFTER GENDER AFFIRMING SURGERY FOR TRANSGENDER PERSONS
Polina Reyblat, Lee Zhao, Miroslav Djordjevic, Dmitry Nikolavsky, Karl Luber
Room W183b

DUST OR BUST: A BEGINNER’S GUIDE TO MODERN DAY LASER LITHOTRIPSY STRATEGIES FOR URETEROSCOPY
Khurshid Ghani, Oliver Wiseman, Joel Teichman, William Roberts
Room W183c

AUA CASTRATION RESISTANT PROSTATE CANCER (CRPC) GUIDELINES AND THERAPEUTIC ADVANCES IN METASTATIC PROSTATE CANCER
Michael Cookson, David Jarrard, Adam Kibel, William Lowrance
Room W184bc
OFFICE OF EDUCATION COURSES
ALL COURSES ARE APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

9:00 am - 12:00 pm
104HO  INTRODUCTION TO OFFICE-BASED TRANSPERINEAL PROSTATE INTERVENTIONS: SYSTEMATIC BIOPSY, RECTAL HYDROGEL SPACER, AND MR/US FUSION
John Wei, Arvin George, Co-Course Directors, James Wysock, Valal George, Bradford Wood, Matthew Allaway, John Dibianco, Chandy Ellimoottil, Lindsey Herrel, Richard Popert, Art Rastinehad, Osamu Ukimura, Peter Pinto

10:00 am - 12:00 pm
031IC  SURGICAL & MEDICAL STONE GUIDELINES UPDATE: A CASE-BASED APPROACH
Ojas Shah, Course Director
Dean Assimos, John Lieske, Brian Matlaga
Room W183b

032IC  MANAGEMENT OF COMPLICATED URINARY DYSFUNCTION AFTER PROSTATE CANCER TREATMENT
Jaspreet Sandhu, Course Director
Kurt McCammon, Ouida Westney
Room W183c

033IC  WHAT GENERAL UROLOGISTS CAN DO TO COMPREHENSIVELY EVALUATE & SUCCESSFULLY TREAT MALE INFERTILITY
Marc Goldstein, Course Director
Mark Sigman, Peter Chan
Room W186abc

034IC  ROBOTIC SINGLE-PORT SURGERY: APPROPRIATE ADOPTION INTO YOUR PRACTICE
Jihad Kaouk, Course Director
Jean Joseph, Matthew Gettman, Michael Stifelman, Ronney Abaza
Room W187a

035IC  CONTEMPORARY PHARMACOTHERAPY FOR OAB 2019: MONOTHERAPY & COMBINED PHARMACOTHERAPY TO OPTIMIZE TREATMENT
Eric Rovner, Course Director
Alan Wein, Christopher Chapple
Room W184abc

036IC  WHAT THE UROLOGIST NEEDS TO KNOW TO MANAGE FEMALE SEXUAL DYSFUNCTION
Irwin Goldstein, Course Director
Eric Biewenga, Noel Kim, Rachel Rubin
Room W185bc

1:30 pm - 3:30 pm
037IC  USING SHARED DECISION MAKING TO HELP PATIENTS DECIDE ON PROSTATE CANCER SCREENING & TREATMENT
Danil Makarov, Course Director
Michael Barry, Angela Fagerlin
Room W183b

4:00 pm - 6:00 pm
038IC  CASE-BASED DISCUSSION OF AUA NON-MUSCLE INVASIVE BLADDER CANCER GUIDELINES
Sam Chang, Course Director
James McKiernan, Chad Ritch
Room W183c

039IC  INTERSTITIAL CYSTITIS/BLADDER PAIN SYNDROME: CURRENT DIAGNOSIS & MANAGEMENT - FUTURE TRENDS
Philip Hanno, Course Director
Quentin Clemens, Sander Lovasz
Room W184abc

040IC  VAGINAL SURGERY FOR THE UROLOGIST
Victor Nitti, Course Director
Benjamin Brucker
Room W186abc

041IC  PARADIGM CHANGES IN A 40-YEAR-OLD OPERATION: INFLATABLE PENILE IMPLANT (IPP)
Steven Wilson, Tobias Köhler, Course Directors
Paul Perito
Room W187a

042IC  DERMATOLOGY FOR THE PRACTICING UROLOGIST: A SYSTEMATIC APPROACH
Richard Link, Course Director
Kathryn Martires, Nikki Tang, Elise Ng
Room W183b

043IC  HOW TO START, BUILD & RUN A SUCCESSFUL ANDROLOGY/MEN’S HEALTH PRACTICE
Ranjith Ramasamy, Course Director
Ryan Smith, Jason Kovac
Room W183c

044IC  AUA BPH GUIDELINES: HOW TO BEST DIAGNOSE & HOW TO MOST EFFECTIVELY & SAFELY TREAT
Steven Kaplan, Course Director
Claus Roehrborn, Alexis Te
Room W184abc

045IC  WOMEN’S HEALTH UPDATE & GYNECOLOGIC CONSIDERATIONS FOR THE UROLOGIST
Ariana Smith, Course Director
Una Lee, Nirit Rosenblum
Room W185bc

046IC  EVIDENCE BASED NUTRITION COUNSELING FOR KIDNEY STONE PREVENTION
Patrick Lowry, Course Director
Kristina Penniston, Sutchin Patel
Room W186abc

047IC  UROLOGICAL TRAUMA & RECONSTRUCTION
Steven Hudak, Course Director
Noel Armenakas, Michael Coburn, Allen Morey
Room W187a
OFFICE OF EDUCATION COURSES
ALL COURSES ARE APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Sunday, May 5, 2019 7:30 am - 6:00 pm

7:30 am - 9:30 am
048IC NOVEL AGENTS & CONCEPTS IN THE MANAGEMENT OF HORMONE NAÏVE & CASTRATE RESISTANT PROSTATE CANCER
Judd Moul, Course Director
Lawrence Karsh, Christopher Sweeney
Room W183b

049IC INFERTILITY UPDATE 2019: A COMPREHENSIVE APPROACH TO UNDERSTANDING & TREATING MALE INFERTILITY IN THE ERA OF IVF
Larry Lipshultz, Course Director
Robert Brannigan, Michael Eisenberg, Mary Samplaski
Room W183c

050IC ADVANCED ROBOTIC UROLOGIC ONCOLOGY: EXTREME UNFORGETTABLE CASES & THEIR MANAGEMENT
Vipul Patel, Course Director
Alexandre Mottie, Sam Bhayani, Bernardo Rocco, Rafael Coelho, David Albala
Room W185bc

051IC OPIOID-SPARING ANALGESIA FOR ENHANCED RECOVERY AFTER UROLOGICAL SURGERY
T. Anthony Anderson, Course Director
Francis McGovern
Room W185b

052IC COMPLEX PELVIC RECONSTRUCTION: USE OF FLAPS
Ja-Hong Kim, Course Director
Christian Twiss, Zachery Baxter, Victor Nitti
Room W187a

053IC GERIATRIC UROLOGY: BEYOND THE BASICS
Tomas Griebling, Course Director
Jonathan Bergman, E. Camille Vaughan
Room W184bc

7:30 am - 11:00 am
054IC THE INDICATIONS FOR VAGINAL THERMOTHERAPY: WHAT IS (AND IS THERE) A ROLE FOR LASER TREATMENT
Roger Dmochowski, Course Director
Mickey Karram
Room W183b

055IC DIFFICULT CASES IN HIGH-RISK BLADDER CANCER: AN EVIDENCE-BASED APPROACH
Michael Cookson, Course Director
Jeffrey Holzbieierlein, Timothy Masterson, Sanjay Patel
Room W183c

056IC A GUIDELINES-BASED REVIEW OF CHALLENGING KIDNEY CANCER CASES: VIDEOS & DISCUSSIONS
Steven Campbell, Course Director
Brian Lane, Philip Pierorazio, Robert Uzzo
Room W185bc

057IC GLOBAL PERSPECTIVES IN URETHRAL RECONSTRUCTION
Hunter Wassells, Course Director
Sanjay Kulkarni, Guido Barbagli
Room W187a

058IC MANAGEMENT OF PROSTATE CANCER: A CASE-ORIENTED APPROACH
Eric Klein, Course Director
Room W184bc

1:30 pm - 3:30 pm
059IC AUA GUIDELINE 2019: RECURRENT URINARY TRACT INFECTION
Jennifer Anger, Course Director
Toby Chai, Una Lee
Room W186abc

2:00 pm - 5:00 pm
060IC UNDERSTANDING THE EVIDENCE: NEW TECHNOLOGIES FOR TREATING BPH & LUTS
Peter Gilling, Course Director
Dean Elterman, Henry Woo
Room W183b

061IC PEYRONIE'S DISEASE, CONGENITAL CURVATURE, & ADULT BURIED PENIS
Laurence Levine, Course Director
David Ralph
Room W183c

062IC PRACTICAL & EVIDENCE-BASED MINIMALLY INVASIVE & ROBOTIC-ASSISTED SURGERY IN PEDIATRIC UROLOGY
Patricio Gargollo, Course Director
Michael Ost, Aseem Shukla
Room W187a

063IC HOW TO MANAGE COMMON DILEMMAS IN PROSTATE CANCER DIAGNOSIS & TREATMENT
Gerald Andriole, Course Director
Anthony D’Amico, Adam Kibel, A. Oliver Sartor
Room W186abc

064IC URODYNAMICS – INDICATIONS & INTERPRETATION: A CASE-BASED APPROACH
Craig Comiter, Course Director
Sandip Vasavada
Room W184bc

10:00 am - 12:00 pm
065IC FLEXIBLE URETEROSCOPY
Olivier Traxer, Course Director
Vincent De Coninck, Steve Doizi, Silvia Proietti, Luca Villa, Michele Talso, Laurian Dragos, Esteban Emilianii, Etienne Xavier Keller

066IC PRACTICAL PCNL: FROM ACCESS TO EXIT
Robert Sweet, Course Director
Mathew Sorensen, Zhamshid Okhunov, David Hoenig, Patrick Samson, Art Rastinehad, Jaime Landman, Thomas Chi, Zeph Okeke, David Leavitt, Michael Borofsky, Helena Chang, Sammy Elsamra
Room W186abc
4:00 pm - 6:00 pm

065IC PROSTATE CANCER UPDATE
William Catalona, Course Director
Stacy Loeb, Robert Nadler, Douglas Dahl, Russell Szmulewitz, Stanley Liauw
Room W183c

066IC MERGERS, ACQUISITIONS & PRIVATE EQUITY: CHOOSING A PRACTICE MODEL THAT WORKS FOR YOU IN A CONSTANTLY CHANGING ENVIRONMENT
Randall Meacham, Course Director
Henry Rosevear, David Sobel
Room W183b

067IC PRACTICAL MEDICAL MANAGEMENT OF NEPHROLITHIASIS - A GUIDELINES & CASE-BASED APPROACH
Glenn Preminger, Course Director
Roger Sur, George Halebian
Room W184bc

OFFICE OF EDUCATION COURSES
ALL COURSES ARE APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Monday, May 6, 2019
7:30 am - 3:30 pm

7:30 am - 9:30 am
071IC PESADILLAS EN ENDOUROLOGÍA - NIGHTMARES IN ENDOUROLOGY (CURSO EN ESPAÑOL)
Daniel Olvera-Posada, Course Director
Brian Eisner, Carlos Mendez Probst
Room W183b

072IC MANAGEMENT OF NMIBC: PRACTICAL SOLUTIONS FOR COMMON PROBLEMS
Kamal Pohar, Course Director
Cheryl Lee, Ashish Kamat, J. Witjes
Room W184bc

073IC COMMON PROBLEMS IN PEDIATRIC UROLOGY: WHAT EVERY UROLOGIST SHOULD KNOW
Richard Rink, Course Director
Mark Cain
Room W187a

10:00 am - 12:00 pm
074IC AUA GUIDELINE 2019: TESTICULAR CANCER
Andrew Stephenson, Course Director
Scott Eggener
Room W185bc

075IC AVOIDING MEDICAL MALPRACTICE IN THE AGE OF EMR
Mitchell Benson, Course Director
Ben Rubinowitz
Room W183c

076IC ADVANCED OVERACTIVE BLADDER THERAPIES: WHAT TO DO WHEN 1ST & 2ND LINE THERAPIES DON'T WORK
Kathleen Kobashi, Course Director
Sandip Vasavada, David Ginsberg
Room W184bc

077IC INTEGRATING CARE FOR ONCOLOGY PATIENTS: ESTABLISHING A MULTIDISCIPLINARY ONCOLOGY CLINIC WITH ADVANCED THERAPEUTICS
Kelly Stratton, Course Director
Brian Shuch, Kelvin Moses, Alicia Morgans
Room W183b

078IC CATASTROPHES, COMPLICATIONS & CORRECTIONS OF PERCUTANEOUS STONE PROCEDURES
Arthur Smith, Course Director
Ralph Clayman, Mahesh Desai, Zeph Okeke
Room W187a

079IC EVALUATION & MANAGEMENT OF URINARY TRACT BLEEDING: FROM ASYMPTOMATIC MICROHEMATURIA TO INTRACTABLE HEMORRHAGIC CYSTITIS
Stephen Boorjian, Course Director
Daniel Barocas, Jay Raman
Room W186abc

1:30 pm - 3:30 pm
080IC APP INTEGRATION: FINDING THE BEST APPLICANT & RECREATING AN APP UROLOGY FELLOWSHIP IN A PRIVATE PRACTICE SETTING
Gwendolyn Zilinskas, Course Director
Anne Calvaresi, Brad Hornberger, Claus Roehrborn, Benjamin Dillon
Room W183b

081IC TESTOSTERONE THERAPY FOR THE ADVANCED CLINICIAN
Abraham Morgentaler, Course Director
Abdul Traish
Room W183c

082IC ROBOTIC PARTIAL NEPHRECTOMY: INDICATIONS & ADVANCED TECHNIQUES
Chandru Sundaram, Course Director
Arleth Shalhav, Jihad Kaouk, Mihir Desai
Room W184bc
OFFICE OF EDUCATION COURSES
ALL COURSES ARE APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

083IC AUA GUIDELINE 2019: INCONTINENCE AFTER PROSTATE TREATMENT
Jaspreet Sandhu, Course Director
Kurt McCammon
Room W185bc

084IC COMPLICATIONS OF VAGINAL MESH: MANAGEMENT & CONTROVERSIES
Kamran Sajadi, Course Director
Farzeen Firoozi, Christopher Tenggardjaja
Room W186abc

085IC UPPER TRACT UROTHELIAL CARCINOMA TUMOR BOARD: A CASE-BASED APPROACH TO MANAGEMENT
Surena Matin, Course Director
Shahrokh Shariat, Vitaly Margulis
Room W187a
8:00  WELCOME AND INTRODUCTION
Program Chairs: Kurt McCammon, Martha Terris

8:05  RRC UPDATE
Chad Ritenour

8:15  ABU UPDATE
David Joseph

8:25  AUA OFFICE OF RESEARCH UPDATE
Aria Olumi

8:35  AAMC UPDATE
Mark Jordan

8:45  SAU UPDATE
Badrinath Konety

8:55  DISCUSSION/Q & A

9:05  HOW DO WE MANAGE THE INTERNS NOW THAT THEY ARE NOT IN GENERAL SURGERY?
RRC’S THOUGHTS
Chad Ritenour

ABU RULES AND THOUGHTS
Eila Skinner

WHAT DO WE NEED TO TEACH THE INTERNS?
Martha Terris

LESSONS LEARNED FROM OTOLARYNGOLOGY AS THEY INCORPORATED THEIR INTERNS
Fuad Baroody

CAN THE ACS HELP?
Ajit Sachdeva

DISCUSSION/Q & A

10:35  BREAK

10:55  MENTORSHIP AND FACULTY DEVELOPMENT: WORKING ON FACULTY
WHAT WE NEED TO DO TO MENTOR RESIDENTS
Christopher Gonzalez

MENTORING OF JUNIOR FACULTY
David Penson

HOW DO WE ENGAGE AND MENTOR STUDENTS?
Jessica Kreshover

DISCUSSION/Q & A

12:00  LUNCH & ANNUAL BUSINESS MEETING

1:00  GRANT RECIPIENT REPORTS

AUTOMATION OF RESIDENT AND FELLOW ACGME SURGICAL CASE LOGS
Kyle Rove

**Presenting author**
7:30 REGISTRATION & CONTINENTAL BREAKFAST

8:20 WELCOME
AUA Chair of Education: Victor Nitti
Course Co-Directors: Michael S. Cookson, David F. Jarrard

8:25 PRE-TEST
Michael S. Cookson, David F. Jarrard

8:35 SESSION I
IDENTIFICATION OF HIGH RISK DISEASE AND INITIAL MANAGEMENT OF BIOCHEMICAL RECURRENCE
Stephen Boorjian

CASE-BASED PANEL DISCUSSION: CHEMOTHERAPY FOR METASTATIC HORMONE SENSITIVE PROSTATE CANCER
Moderators: David F. Jarrard, Joshua Lang
Panelists: All Faculty
CASE 1: BCR AFTER RRP WITH RAPID DOUBLING TIME
CASE 2: HIGH VOLUME M1HSPC
IMAGING OF ADVANCED PROSTATE CANCER
Leonard Gomella

M0 CRPC: EMERGING TREATMENT OPTIONS
Michael S. Cookson

9:50 BREAK

9:50 GENETIC TESTING IN ADVANCED PROSTATE CANCER
Leonard Gomella

SETTING UP AND MANAGING ADVANCED PROSTATE CANCER IN THE COMMUNITY SETTING: UNIQUE CHALLENGES
Benjamin Lowentritt

CASE-BASED ROUNDTABLE DISCUSSIONS
Moderators: Michael S. Cookson, Joshua Lang
Panelists: All Faculty
OLIGOMETASTATIC M1 HSPC
HIGH RISK PATIENT (GENETIC TESTING)
M0 CRPC – INDEX PATIENT 1 (SLOW PSADT)

11:45 NON-CME LUNCH SYMPOSIUM SUPPORTED BY ASTELLAS PHARMA US, INC.

1:00 SESSION II
MANIPULATING THE ANDROGEN AXIS: ANDROGEN BIOSYNTHESIS INHIBITORS AND ANDROGEN RECEPTOR SIGNALING AGENTS
David F. Jarrard

RADIONUCLIDE THERAPY AND BONE HEALTH
Stephen Boorjian

CASE-BASED ROUNDTABLE DISCUSSIONS
Moderators: Stephen Boorjian, Evan Yu
Panelists: All Faculty
M1 CRPC – CRPC INDEX PATIENT 2
M1 HSPC THEN PROGRESSES TO M1 CRPC – CRPC INDEX PATIENT 3

2:10 BREAK

2:30 SESSION III
ROLE OF CHEMOTHERAPY, TREATMENT SEQUENCING AND FUTURE APPROACHES
Evan Yu

CASE BASED ROUNDTABLE DISCUSSIONS
Moderators: Joshua Lang, Evan Yu
Panelists: All Faculty
MCRPC INDEX PATIENT 5
MCRPC INDEX PATIENT 3
MCRPC (INDEX) IMMUNOTHERAPY
MCRPC (ARV7 VARIANT) FUTURE DIRECTIONS PARP INH
APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
**Plenary: Prime Time, Friday, Morning Session**

**Friday, May 3, 2019**

**7:30**
**SURVIVOR DEBATE: 3.5 CM RENAL MASS IN A 71 YEAR OLD HEALTHY MAN**
- **Moderator:** Michael Blute, Sr.
- **Debaters:**
  - Steven Campbell, David Curry, Robert Figenshau, Louis Kavoussi, Lee Ponsky, Sarah Psutka, Jay Raman

**8:20**
**CROSSFIRE: CONTROVERSIES IN UROLOGY: RADICAL NEPHRECTOMY FOR T1B/T2 RENAL CANCER**
- **Moderator:** Matthew Gettman
- **Debaters - Con:** R. Houston Thompson, Christopher Porter
- **Debaters - Pro:** Ketan Badani, Lindsey Herrel

**8:50**
**SURGICAL TECHNIQUES: TIPS & TRICKS: ROBOTIC PARTIAL NEPHRECTOMY**
- **Moderator:** Chandru Sundaram
- **Surgeons:** Mohamad Allaf, Inderbir Gill, Craig Rogers

**9:20**
**TUMOR BOARD: KIDNEY CANCER**
- **Moderator:** W. Marston Linehan
- **Panelists:** Suzanne Merrill, Andrew Wagner, Ithaar Derweesh, Guliz Barkan, Rana McKay

**9:50**
**CROWDSOURCING: TRANSURETHRAL RESECTION OF BLADDER TUMOR**
- **Moderator:** Khurshid Ghani
- **Panelists:** Cheryl Lee, Martha Terris, Mark Soloway

**10:20**
**TUMOR BOARD: BLADDER CANCER**
- **Moderator:** A. Karim Kader
- **Panelists:** Abhishek Solanki, Gladell Paner, Eila Skinner, Kelly Stratton, Tracy Downs, Elizabeth Henry

**10:50**
**SECOND OPINION CASES (ASK THE GUIDELINES!): CASTRATION RESISTANT PROSTATE CANCER**
- **Moderator:** David Jarrard
- **Panelists:** William Lowrance, Michael Cookson, William Oh

**APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

**Plenary: Prime Time, Friday, Afternoon Session**

**Friday, May 3, 2019**

**1:00**
**SURGICAL TECHNIQUES: TIPS & TRICKS: MINIMALLY INVASIVE THERAPIES FOR LUTS**
- **Moderator:** John Wei
- **Surgeons:** Mitchell Humphreys, Claus Roehrborn, Steve Kaplan, Neal Shore, Michael Borofsky

**2:15**
**COURT IS IN SESSION: CLINICAL LESSONS THROUGH A LEGAL LENS: CASE PRESENTATION – THE RETAINED URETERAL STENT**
- **Attorney:** Sarah Ferrill
- **Moderator:** Jodi Antonelli
- **Defendant:** Glenn Preminger
- **Expert Witness (Defense):** Ben Chew
- **Expert Witness (Plaintiff):** Brian Matlaga

**3:15**
**CROWDSOURCING: RENAL HILAR DISSECTION**
- **Moderator:** Khurshid Ghani
- **Panelists:** Benjamin Lee, James Porter, Tim O’Brien

**3:45**
**SETBACKS AND OPERATIVE SOLUTIONS (SOS): ROBOTIC RADICAL PROSTATECTOMY**
- **Moderator:** John Davis
- **Panelists:** Ashok Hemal, Ashutosh Tewari, Arieh Shalhav, Jennifer Taylor

**4:15**
**TUMOR BOARD: PROSTATE CANCER**
- **Moderator:** Ian Thompson
- **Panelists:** Rodney Davis, Laurence Klotz, Armine Smith, Scott Lucia, Stanley Liauw, Aytekin Oto, Timothy Kuzel

**4:45**
**SURGICAL TECHNIQUES: TIPS & TRICKS: ONCOLOGY**
- **Moderator:** Prokar Dasgupta
- **Surgeons:** Yair Lotan, Karim Chamie, Preston Spremkle, Jihad Kaouk

**APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

*Presenting author*
<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
</table>
| MP01-01         | WATER VS WATER II: AQUABLATION THERAPY FOR BENIGN PROSTATIC HYPERPLASIA  
David-Dan Nguyen*, Naeem Bhojani,  
Montreal, Canada |
| MP01-02         | WHAT MINIMAL IMPORTANT DIFFERENCE IN URINARY SYMPTOM RELIEF BENEFITS PATIENT QUALITY OF LIFE? – ASSOCIATED WITH REZUM WATER VAPOR THERMAL THERAPY 4 YEAR OUTCOMES  
Kevin McVary*, Maywood, IL, Tyson Rogers,  
Minneapolis, MN, Christopher Cantrill, San Antonio, TX, Claus Roehrborn, Dallas, TX |
| MP01-03         | REZUM WATER VAPOUR ABLATION THERAPY FOR BENIGN PROSTATIC HYPERPLASIA: INITIAL RESULTS FROM THE UNITED KINGDOM  
Maximilian Johnston*, Basingstoke, United Kingdom, Taimur Shah, London, United Kingdom, Amr Emara, Tina Gehring, Thomas Farmer, Tim Nedas, Raj Kumar, Basingstoke, United Kingdom, Ashley Mcfarlane, Mathias Winkler, Tamer El-Husseiny, Hashim Ahmed, London, United Kingdom, Richard Hindley, Basingstoke, United Kingdom |
| MP01-04         | LARGE RETROSPECTIVELY MANAGED SINGLE SURGEON EXPERIENCE WITH PROSTATIC URETERAL LIFT  
Gregory C. McMahon*, Sravan Panuganti,  
Michael Wilson, Kiran Thalody, Stratford, NJ, Thomas J. Mueller, Voorhees, NJ |
| MP01-05         | THE RESULTS OF ONE ARM MULTICENTER PROSPECTIVE STUDY ON AN INNOVATIVE MINIMALLY INVASIVE SURGICAL TECHNIQUE FOR LUTS MANAGEMENT: THE SECOND GENERATION TEMPORARY IMPLANTABLE NITINOL DEVICE (I-TIND) MEDITATE®  
Francesco Porpiglia*, Cristian Fiori, Daniele Amparore, Gabriele Volpi, Orbassano, Italy, Gregor Kadner, Frauenfeld, Switzerland, Arya Manit, London, United Kingdom, Massimo Valerio, Lausanne, Switzerland, Lumen Nicolaas, Gent, Belgium, Brian SH Ho, Hong Kong, Hong Kong, Sergio Alonso, Madrid, Spain, Claude Schulman, Brussels, Belgium, Neil Barber, London, United Kingdom |
| MP01-06         | EFFECTS OF POLOXAMER-BASED THERMO-SENSITIVE SOL-GEL ON URETHRAL STRICURE AFTER TRANSURETHRAL RESECTIONS OF THE PROSTATE FOR BENIGN PROSTATIC HYPERPLASIA: A MULTICENTER, SINGLE BLINDED, RANDOMIZED CONTROLLED STUDY  
Kyu Shik Kim*, Jae Hoon Chung, Seoul, Korea, Republic of, Tae Hyo Kim, Ki Soo Lee, Busan, Korea, Republic of, Cheol Young Oh, Seoul, Korea, Republic of, Joon Hwa Noh, Jun Seok Kim, Gwangju, Korea, Republic of, Won Tae Kim, Cheongju, Korea, Republic of, Seung Hwan Lee, Jae Heon Kim, Seoul, Korea, Republic of, Tae Nam Kim, Busan, Korea, Republic of, Wan Huh, Seung Wook Lee, Seoul, Korea, Republic of |
| MP01-07         | PROSTACARE: WATER ELECTROLYSIS SYSTEM FOR THE TREATMENT OF BENIGN PROSTATE HYPERPLASIA  
Yong Wei Lim*, Ho Yee Tiong, Wei Jin Chua, Soon Phang Allen Sim, Sun Sien Henry Ho, Singapore, Singapore |
| MP01-08         | A PROSPECTIVE-RANDOMIZED TRIAL COMPARING THULIUM VAPOENUCLEATION OF THE PROSTATE VERSUS HOLMIUM LASER ENUCLEATION OF THE PROSTATE: RESULTS AT 24-MONTH FOLLOW-UP  
Christopher Netsch*, Benedikt Becker, Andreas J. Gross, Hamburg, Germany |
| MP01-09         | HOLMIUM LASER ENUCLEATION OF THE PROSTATE (HOLEP) FOR OBSTRUCTIVE BENIGN PROSTATE HYPERPLASIA - A SINGLE CENTRE EXPERIENCE OF MORE THAN 2,000 CONSECUTIVE CASES  
Philipp Gild*, Raisa Pompe, Malte W. Vetterlein, Valentin Maurer, Tim A. Ludwig, Philipp Marks, Tabea Ernst, Ihab Daoud, Lukas Lenke, Roland Dahlem, Margit Fisch, Philip Reiss, Michael Rink, Christian P. Meyer, Hamburg, Germany, Andreas Becker, Frankfurt, Germany |
**MP01-10** COMPARISON BETWEEN OPEN, LAPAROSCOPIC VS ROBOTIC SIMPLE PROSTATECTOMY IN A REAL-LIFE SETTINGS: ANALYSIS OF TRIFECTA OUTCOMES

Cosimo De Nunzio*, Rome, Italy, Anton Zarraonandia, Pontevedra, Spain, Giuseppe Simone, Rome, Italy, Simone Albisinni, Bruxelles, Belgium, Riccardo Lombardo, Rome, Italy, Mathieu Coscarella, Bruxelles, Belgium, Salvatore Guaglione, Rocco Simone Flammia, Rome, Italy, Ayhan Bakar, Bruxelles, Belgium, Almudena Carrion Valencia, Pontevedra, Spain, Michele Gallucci, Rome, Italy, Manuel Ruibal Moldes, Pontevedra, Spain, Andrea Tubaro, Rome, Italy

**MP01-11** LONG-TERM REOPERATION RATES FOLLOWING SURGERY FOR BPH: VARIATION BASED ON SURGICAL MODALITY

Abhinav Khanna*, Navin Sabharwal, Khaled Fareed, James Ulchaker, Kyle Ericson, Bradley Gill, Cleveland, OH

**MP01-12** A SYSTEMATIC REVIEW AND META-ANALYSIS EVALUATING THE SAFETY AND EFFICACY OF THE ENDOSCOPIC TREATMENT OPTIONS FOR BENIGN PROSTATIC ENLARGEMENT.

Saulo Teles*, Breno Amaral, Arié Carneiro, Paulo Kayano, Jonathan Cha, Wladimir Aller Jr., Jose Monteiro Jr., Antonio Gil, Alan Barbosa, Alexandre Partezani, Danilo Lourenço, Gustavo Lemos, Marcelo Wroclawski, Sao Paulo, Brazil

**MP01-13** A HIGH PREOPERATIVE PSA LEVEL IS NOT ACCURATE TO PREDICT INCIDENTAL PROSTATE CANCER DETECTION IN PATIENT UNDERWENT ENDOSCOPIC ENUCLEATION OF THE PROSTATE FOR LARGE GLANDS.

Vincent Misrai*, Toulouse, France, Benoit Peyronnet, Rennes, France, Benjamin Pradere, Tours, France, Benoit Bordier, Julien Guillotreau, Alexandre Grym, Toulouse, France, Kevin C. Zorn, Montreal, Canada

**MP01-14** THE SURGICAL LEARNING CURVE FOR GREEN LIGHT ENDOSCOPIC ENUCLEATION OF THE PROSTATE: IMPACT OF SURGICAL EXPERIENCE ON PERIOPERATIVE OUTCOMES

Zine-Eddine Khene*, Benoit Peyronnet, Sébastien Vincendeau, Romain Huet, Romain Mathieu, Rennes, France, Enrique Enrique, Barcelona, Spain, Fernando Gomez-Sancha, Madrid, Spain, Vincent Misrai, Toulouse, France

**MP01-15** ANTICOAGULANTS CONTINUED DURING PVP DOES NOT IMPACT THE RISK OF POSTOPERATIVE HEMORRHAGIC COMPLICATIONS: A MULTICENTRIC PROSPECTIVE STUDY

Benjamin Pradere*, Tours, France, Richard Naspro, Bergamo, Italy, Benoit Peyronnet, Rennes, France, Julien Guillotreau, Benoit Bordier, Toulouse, France, Kevin Zorn, Montreal, Canada, Vincent Misrai, Toulouse, France

**MP01-16** IMPACT OF ENERGY DENSITY ON FUNCTIONAL OUTCOMES AFTER PHOTOVAPORIZATION OF THE PROSTATE WITH GREENLIGHT™ 180W XPS LASER: ¡DOES IT MATTER?

Laura Zuluaga*, Mauricio Plata, Carlos Gustavo Trujillo, Catalonia Barco-Castillo, Jessica Santander, Daniela Robledo,Juan Ignacio Caicedo, Julian Azuero, Martin Rondon, Bogotá DC, Colombia

**MP01-17** HOW TO MAKE SURGEON EDUCATIONAL SYSTEM FOR TRANSURETHRAL SURGERY FOR BENIGN PROSTATE HYPERPLASIA?

Katsumi Shigemura*, Koji Chiba, Keisuke Okada, Masato Fujisawa, Kobe, Japan

**MP01-18** ECONOMIC IMPACT OF THE INTRODUCTION OF LASER SURGERY IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA.

Serena Maruccia*, Ella Kinzikeeva, Paolo Spiga, Gianluca Cacace, Stefano Casellato, Monza, Italy

**MP01-19** EFFECT OF INDEX SURGICAL CARE SETTING ON 30-DAY REVISIT RATES AND ASSOCIATED COSTS FOLLOWING OUTLET PROCEDURE FOR SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA

David F. Friedlander*, Brighton, MA, Marike J. Krimphove, Alexander P. Cole, Gezzer Ortega, Quoc-Dien Trinh, Boston, MA

**MP01-20** AN IN-VITRO STUDY OF HYBRID LASER FOR PROSTATE SURGERY

Mark Taratkin*, Dmitry Enikeev, Petr Glybochko, Leonid Rapoport, Moscow, Russian Federation, Christopher Netsch, Benedikt Becker, Andreas J. Gross, Hamburg, Germany

*Presenting author

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
ABSTRACT NUMBER TITLE
MP02-01 DOES A RISK CALCULATOR CORRECTLY PREDICT DE NOVO POSTOPERATIVE STRESS URINARY INCONTINENCE AFTER SURGERY FOR PELVIC ORGAN PROLAPSE IN A RACIALLY/ETHNICALLY DIVERSE POPULATION?
Sophie Sohval, Shirly Solouki, Nitya Abraham*, Bronx, NY

MP02-02 IS PRIMARY ELECTIVE CESAREAN DELIVERY PROTECTIVE AGAINST PELVIC FLOOR DISORDERS?
Colby Souders*, Farnoosh Nik-Ahd, Ashley Caron, Karyn Eilber, Jennifer Anger, Los Angeles, CA

MP02-03 REPRESENTATION OF MINORITY GROUPS IN PELVIC FLOOR DISORDER TRIALS
Elishia McKay*, Jonathan Davila, Nitya Abraham, Bronx, NY

MP02-04 FACTORS CONTRIBUTING TO HEALTH DISPARITIES IN SPANISH-SPEAKING LATINA WOMEN WITH PELVIC FLOOR DISORDERS
Claudia Sevilla*, Christine Horton, Katherine Volpe, Jennifer Unger, Mariana Stern, Larissa Rodriguez, Los Angeles, CA

MP02-05 USING DIGITAL ETHNOGRAPHY TO UNDERSTAND THE BIOPSYCHOSOCIAL ILLNESS EXPERIENCE OF WOMEN SUFFERING FROM PELVIC ORGAN PROLAPSE
Gabriela Gonzalez*, Yuliya Zekster, Los Angeles, CA, Carine Khalil, Kristina Vaculk, Corey Arnold, Christopher V Almario, Brennan M.R. Spiegel, Los Angeles, CA, Jennifer T. Anger, Los Angeles, CA

MP02-06 READABILITY OF PATIENT EDUCATION MATERIALS ON PELVIC ORGAN PROLAPSE, OVERACTIVE BLADDER, AND STRESS URINARY INCONTINENCE
Chris Du*, Stony Brook, NY, Wai Lee, Alvaro Lucioni, Kathleen Kobashi, Una Lee, Seattle, WA

MP02-07 PROSPECTIVE COMPARATIVE INVESTIGATION OF TELEPHONE FOLLOW-UP IN FEMALE UROLOGY
Matteo Balzarro*, Emanuele Rublotta, Silvia Bassi, Nicolò Trabacchin, Verona, Italy, Vito Mancini, Foggia, Italy, Ester Ililiao, Elisabetta Costantini, Temi, Italy, Walter Artibani, Verona, Italy

MP02-08 REVIEW OF ENHANCED RECOVERY AFTER SURGERY PATHWAY FOR THE PERIOPERATIVE MANAGEMENT OF ABDOMINAL SACROCOLPOPEXY
Amy Nemirovsky*, Rena D Malik, Baltimore, MD

MP02-09 ASSESSING THE IMPACT OF PROCEDURE-SPECIFIC OPIOID PRESCRIBING RECOMMENDATIONS ON OPIOID STEWARDSHIP FOLLOWING PELVIC ORGAN PROLAPSE SURGERY
Brian Linder*, John Occhino, Christopher Klingele, Emanuel Trabuco, John Gebhart, Rochester, MN

MP02-10 TRANSVAGINAL REPAIR OF ANTERIOR AND APICAL PROLAPSE USING OPUR 6-STRAP MESH: FIVE YEARS OF EXPERIENCE.
Olesya Snurnitsyna*, Petr Glybochko, Leonid Raportov, Mikhail Enikeev, Aleksandr Nikitin, Mikhail Enikeev, Abdusalam Abdusalamov, Moscow, Russian Federation

MP02-11 TOTAL AUTOLOGOUS FASCIA LATA ANTERIOR AND APICAL PELVIC ORGAN PROLAPSE REPAIR: EXPERIENCE IN THIRTY-THREE PATIENTS
Fahad Chaus*, Jayce Pangilinan, Joel Funk, Christian Twiss, Tucson, AZ

MP02-12 A MULTICENTER RANDOMIZED TRIAL COMPARING ROBOT-ASSISTED VERSUS PURE LAPAROSCOPIC SACROCOLPOPEXY FOR PELVIC ORGAN PROLAPSE.

MP02-13 TRENDS AND SAFETY OF CONCURRENT SACROCOLPOPEXY AND RECTOPEXY
Claire S. Burton*, Catherine Bresee, Colby P. Souders, Los Angeles, CA, Alex Hannemann, Vermillion, SD, Karyn S. Eilber, Jennifer T. Anger, Los Angeles, CA
MP02-14 DE NOVO DEFECATORY SYMPTOMS AND POSTERIOR COMPARTMENT PROLAPSE AS A COMPLICATION OF SACROCOLPOPEXY
Hanson Zhao, Carrie A. Stewart, Colby P. Souders*, Gabriela Gonzalez, Christopher Gonzales-Alabastro, A. Lenore Ackerman, Karyn Eliber, Jennifer T. Anger, Los Angeles, CA

MP02-15 THE MANAGEMENT AND EFFICACY OF SURGICAL OUTCOMES USED FOR EROSI VE MESH IN THE URETHRA AND BLADDER
Dominique Thomas, Mitali Kini*, Tirsit Asfaw, Bilal Chughtai, New York, NY

MP02-16 UROLOGIC INJURY AND FISTULA FOLLOWING HYSTERECTOMY FOR BENIGN INDICATIONS
Kai Dallas*, Lisa Rogo-Gupta, Christopher Elliott, Stanford, CA

MP02-17 LONG-TERM REOPERATION RATES ARE EQUIVALENT FOR PELVIC ORGAN PROLAPSE REPAIRS WITH BIOLOGIC AND SYNTHETIC GRAFTS IN A LARGE POPULATION BASED COHORT
Ericka Sohlberg*, Kai Dallas, Christopher Elliott, Lisa Rogo-Gupta, Stanford, CA

MP02-18 RISK OF PROLAPSE AND URINARY COMPLICATIONS IN ADULT SPINA BIFIDA PATIENTS WITH NEUROGENIC ACONTRACTILE DETRUSOR USING CLEAN INTERMITTENT CATHETERIZATION VERSUS VALSALVA VOIDING

MP02-19 OPTIMIZING THE NANOPARTICLE ENHANCED ADHESION OF MUSSEL INSPIRED HYDROGELS FOR TISSUE INTERFACING
Nikhil Pandey*, Andres Urias, Valinda Jones, Serkan Yaman, Amirhossein Hakamivala, Boris Rodionov, Jun Liao, Arlington, TX, Philippe Zimmern, Dallas, TX, Kytai Nguyen, Yi Hong, Arlington, TX

MP02-20 INVESTIGATION OF PO AGENTS FOR CYSTOSCOPIC EVALUATION OF URETERAL JETS
Russell Stanley*, Cornelia DeRiese, Lubbock, TX

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
MP03-06 OXALATE DECARBOXYLASE ENZYME REDUCES HYPEROXALURIA IN AN ANIMAL MODEL THAT MIMICS PRIMARY HYPEROXALURIA
Matthew Lindeblad, Chicago, IL, Victoria Bird*, Meekah Chardeton, Ming Yang, Qing-Shan Li, Gainesville, FL, Haifeng Liu, Kangfude, China, People's Republic of, Aaron Cowley, Gainesville, FL

MP03-07 LIVE IMAGING OF A DROSOPHILA MELANOGASTER MODEL OF NEPHROLITHIASIS WITH PROBIOTIC SUPPLEMENTATION USING CO2 ANESTHESIA AND MICRO-CT
Kait Al*, Danny Poinapen, Joanna Konopka, Chris Norley, Jaques Milner, David Holdsworth, Hassan Razvi, Jeremy Burton, London, Canada

MP03-08 SPECIFIC GUT BACTERIA ARE RESPONSIBLE FOR ABSORPTIVE HYPERCALCIURIA IN A NEW ANTIBIOTIC RODENT MODEL
Paul Dominguez Gutierrez*, Pedro Espino-Grosso, Raghav Pai, William Donelan, Benjamin Canales, Gainesville, FL

MP03-09 THE EFFECT OF AN ESCHERICHIA COLI BACTERIAL URINARY INFECTION ISOLATE AND CIPROFLOXACIN ON CALCICUM UROLITHIASIS IN A DROSOPHILA MELANOGASTER MODEL
Jennifer Bjaazevic*, Kaitlin F. Al, Jaswanth Gorla, Hassan Razvi, Jeremy P. Burton, LONDON, Canada

MP03-10 EFFECT OF A BACTERIAL URINARY INFECTION ISOLATE ON CALCICUM OXALATE CRYSTAL ADHERENCE TO RENAL EPITHELIAL CELLS
Jennifer Bjaazevic*, Kaitlin F. Al, Jaswanth Gorla, Hassan Razvi, Jeremy P. Burton, LONDON, Canada

MP03-11 GUT MICROBIOME AND SHORT CHAIN FATTY ACIDS IN RENAL CALCIUM OXALATE STONES FORMATION
Kunjie Wang*, Yu Liu, Liang Zhou, Yi Li, Qun Sun, Zude Chen, Qingyao Jiang, Liang Cheng, Lei Tian, Hong Li, Chengdu, China, People's Republic of

MP03-12 WIELDING A STONE ANALYSIS TO ITS FULL POTENTIAL: CAN PATIENTS WITH CAOX STONE DISEASE BE TREATED BASED ON COM VS COD?
Ethan Brinkman*, Tim Large, James Williams, Amy Krambeck, Indianapolis, IN

MP03-13 RANDALL'S (INTERSTITIAL) PLAQUE SHOWS DISTINCTIVE AUTOFLUORESCENCE IN HUMAN KIDNEY STONES COLLECTED DURING ENDOSCOPIC PROCEDURES
Seth Winfree*, Tarek El-Achkar, Indianapolis, IN, Andre Sommer, Oxford, OH, James Lingeman, James Williams, Indianapolis, IN

MP03-14 RELATIONSHIP OF ENDOSCOPIC LESIONS OF THE RENAL PAPILLA WITH TYPE OF RENAL STONE AND 24 H URINE CHEMISTRY
Xavier Arnaub Sabate Arroyo*, Sant Iscle de Vallalta, Spain, Enrique Piersas Ayala, Felix Grases Freixedas, Jose Luis Bauza Quetglas, Jorge Guimerà García, Pedro Piza Reus, Palma de Mallorca, Spain

MP03-15 MUTATIONAL ANALYSIS OF HOGA1 IN CHINESE PEDIATRIC PATIENTS WITH PRIMARY HYPEROXALURIA TYPE 3
wenying wang*, Jun Li, beijing, China, People's Republic of

MP03-16 SEVERE AND EARLY BEGINNING OF UROLITHIASIS RELATED TO THE INHERITANCE OF SLC7A9 MUTATIONS
Sabrina Reis*, Ruan Pimenta, Giovanni Marchini, Katia Leite, Nayara Viana, William Simoes, Fabio Torricelli, Fabio Vicentini, Alexandre Danilovic, William Nahas, Miguel Srougi, Eduardo Mazzuchelli, Sao Paulo, Brazil

MP03-17 RAMAN SPECTROSCOPY ANALYSIS OF SOLID STONE COMPOSITION IN BIOLOGICAL ENVIRONMENTS: FEASIBILITY STUDY AND PRELIMINARY RESULTS
Benjamin PRADERE*, Tours, France, Ivan Lucas, Steeve Doizy, Darine Abi Haidar, Michel Daudon, Olivier Traxer, Paris, France

MP03-18 POLYMER-MINERAL COMPOSITES MIMIC HUMAN KIDNEY STONES IN LASER LITHOTRIPSY EXPERIMENTS
Derek Frank*, Ali Aldoukhi, William Roberts, Khurshid Ghani, William Le, Milan Shah, D. Duane Baldwin, Loma Linda, CA

MP03-19 BENCHTOP COMPARISON OF 13 DIFFERENT GUIDEWIRES IN 3 DIFFERENT IMPACTED STONE MODELS
Akio S. Amsiyail*, Mohammad Hajiba, Jason Groegler, Muhammad Alsyfouh, Phillip Stokes, Williamson Le, Milan Shah, D. Duane Baldwin, Loma Linda, CA

MP03-20 DUSTING EFFICIENCY COMPARISON BETWEEN MOSES TECHNOLOGY OF HO: YAG LASER AND SUPERPULSE THULIUM FIBER LASER
Vincent De Coninck*, Brasschaat, Belgium, Etienne Xavier Keller, Paris, France, Anastasiya Kovalenko, Viktoriya Vinnichenko, Moscow, Russian Federation, Olivier Traxer, Paris, France

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
Friday, May 3, 2019 7:00 am - 9:00 am

Moderated Poster Session 4

TRAUMA/RECONSTRUCTION/DIVERSION: EXTERNAL GENITALIA RECONSTRUCTION AND UROTRAUMA (INCLUDING TRANSGENDER SURGERY)

Room W179a @ McCormick Place

Moderators: Richard Santucci, Steven Brandes & Matthew Gretzer

ABSTRACT NUMBER TITLE

MP04-01 OPTIMAL CUT-OFF POINTS FOR LACERATION SIZE AND PERI-RENAL HEMATOMA RIM DISTANCE TO PREDICT BLEEDING INTERVENTIONS AFTER HIGH-GRADE RENAL TRAUMA

Sorena Keihani*, Douglas Rogers, Bryn Putbrese, Rachel Moses, Chong Zhang, Salt Lake City, UT, Kaushik Mukherjee, Loma Linda, CA, Sarah Majercik, Murray, UT, Joshua Piotrowski, Christopher Dodgion, Milwaukee, WI, Brenton Sherwood, Bradley Erickson, Iowa City, IA, Ian Schwartz, Sean Elliott, Minneapolis, MN, Erik DeSoucy, Scott Zakaluzny, Sacramento, CA, Nima Baradaran, Benjamin Breyer, San Francisco, CA, Brian Smith, Philadelphia, PA, Brandi Miller, Richard Santucci, Detroit, MI, Matthew Carrick, Plano, TX, Jurek Kocik, Tyler, TX, Timothy Hewitt, Frank Burks, Royal Oak, MI, Angela Presson, Salt Lake City, UT, Marta Heilbrun, Atlanta, GA, Raminder Nirula, James Hotaling, Jeremy Myers, Salt Lake City, UT

MP04-02 RELIABILITY OF THE AMERICAN ASSOCIATION FOR THE SURGERY OF TRAUMA (AAST) RENAL INJURY GRADING FOR HIGH-GRADE RENAL INJURIES

Sorena Keihani*, Bryn Putbrese, Douglas Rogers, Gregory Stoddard, Salt Lake City, UT, Kaushik Mukherjee, Loma Linda, CA, Sarah Majercik, Murray, UT, Joshua Piotrowski, Christopher Dodgion, Milwaukee, WI, Brenton Sherwood, Bradley Erickson, Iowa City, IA, Ian Schwartz, Sean Elliott, Minneapolis, MN, Erik DeSoucy, Scott Zakaluzny, Sacramento, CA, Nima Baradaran, Benjamin Breyer, San Francisco, CA, Brian Smith, Philadelphia, PA, Brandi Miller, Richard Santucci, Detroit, MI, Matthew Carrick, Plano, TX, Jurek Kocik, Tyler, TX, Timothy Hewitt, Frank Burks, Royal Oak, MI, Angela Presson, Salt Lake City, UT, Marta Heilbrun, Atlanta, GA, Raminder Nirula, James Hotaling, Jeremy Myers, Salt Lake City, UT

MP04-03 TREATMENT COMPLICATIONS ASSOCIATED WITH EXTRAPERITONEAL BLADDER INJURIES: RESULTS FROM THE MULTI-INSTITUTIONAL AAST STUDY OF BLADDER TRAUMA


MP04-04 PROACTIVE REPEAT IMAGING FOR BLUNT HIGH-GRADE RENAL TRAUMA WITH URINARY EXTRAVASATION DOES NOT IMPROVE OUTCOMES

Christopher Loftus*, Niels Johnsen, Seattle, WA

MP04-05 SCROTAL ULTRASOUND REDUCES UNNECESSARY SCROTAL EXPLORATION IN BLUNT SCROTAL TRAUMA

Emily Yura*, Lauren Golgosa Cooley, Jason Cohen, Matthias Hofer, Chicago, IL

MP04-06 DETERMINING THE VALUE OF GENITOURINARY TRAUMA RESIDENCY EDUCATION: A NEEDS-ASSESSMENT SURVEY OF CURRENT AUA RESIDENTS

Christopher Loftus*, Niels Johnsen, Seattle, WA

MP04-07 PENILE SKIN PRESERVATION TECHNIQUE FOR PENILE PARAFFINOMA

Yu Seob Shin*, Jae Hyung You, Myung Ki Kim, Young Beom Jeong, Jong Kwan Park, J eonju, Korea, Republic of

MP04-08 MANAGING DIFFICULT CATHETER PLACEMENT IN COMPLEX URETHROPLASTY AND LOWER URINARY TRACT RECONSTRUCTION WITH A NEW URETHRAL CATHETERISATION DEVICE

Anastasia Frost*, Simon Bugeja, Nikki Jeffery, Mohammad Alkandari, Angelica Lomileng, Mariva Dragova, Anthony Mundy, London, United Kingdom

*Presenting author
MP04-09 PREDICTORS OF SURGICAL COMPLICATIONS AND EVALUATION OF OUTCOMES AFTER SURGICAL CORRECTION OF ADULT ACQUIRED BURIED PENIS
Melanie Aube-Peterkin, Montreal, Canada, Michael Chua*, Jessica DeLong, Jeremy Tonkin, David Gilbert, Kurt McCammon, Ramon Virasoro, Norfolk, VA

MP04-10 OUTCOMES OF PATIENTS UNDERGOING FULL THICKNESS GRAFT PHALLOPLASTY DURING BURIED PENIS REPAIR
M Francesca Monn*, Juan Socas, Matthew J Mellon, Indianapolis, IN

MP04-11 POSTOPERATIVE PAIN MANAGEMENT AFTER URETHROPLASTY AND INFLATABLE PENILE PROSTHESIS
Seth Teplitsky*, Philadelphia, PA, Patrick Pfizenmayer, Ronak Gor, Camden, NJ, Paul Chung, Philadelphia, PA

MP04-12 PATIENT REPORTED OUTCOMES FROM A 6 YEAR PROSPECTIVE STUDY ON SATISFACTION FOLLOWING PENILE CURVATURE SURGERY
Deji Akiboye*, London, United Kingdom, Pareeta Patel, Angus Campbell, Professor Nick Watkin, Surrey, United Kingdom

MP04-13 SPERMATOGENESIS IN THE TRANSGENDER TESTIS
Tristan M. Nicholson*, Ivor Clinton, John K. Amory, Nicholas Reder, Thomas J. Walsh, Ashleigh B. Theberge, Seattle, WA

MP04-14 TOTAL PHALLIC RECONSTRUCTION IN THE GENETIC MALE: A SINGLE CENTRE ANALYSIS
David J Ralph*, London, United Kingdom, Marco Falcone, Mattia Anfosso, Paolo Gontero, Turin, Italy, Andrew Nim Christopher, Oliver Ralph, London, United Kingdom

MP04-15 PHALLOPLASTY FOLLOWED BY PENILE PROSTHESIS INSERTION IN FEMALE TO MALE TRANSEXUALS
Borko Stojanovic, Marta Bizic, Vladimir Kojovic, Slavica Pusica, Marko Bencic, Miroslav Djordjevic*, Belgrade, Serbia

MP04-16 REVISION VAGINOPLASTY USING ROBOTIC PERITONEAL FLAPS FOR VAGINAL STENOSIS IN TRANSWOMEN
Geolani W. Dy*, Ian Nolan, Matthew Katz, Adam Jacoby, Rachel Bluebond-Langner, Lee Zhao, New York, NY

MP04-17 GENDER-AFFIRMING VAGINECTOMY AND COLPOCLEISIS
Helen Hougen*, Dan Dugi, Kamran Sajadi, Portland, OR

MP04-18 CONTEMPORARY PRACTICE PATTERNS AND ATTITUDES TOWARDS GENDER AFFIRMING SURGERY IN TRANSGENDER PATIENTS: RESULTS FROM THE SOCIETY OF GENITOURINARY RECONSTRUCTIVE SURGEONS SURVEY
Shyam Sukumar*, Debduh Pijush, Stanley Desire, Steven Brandes, New York, NY

MP04-19 IMPLEMENTATION OF A PELVIC FLOOR PHYSICAL THERAPY PROGRAM FOR TRANSGENDER WOMEN UNDERGOING GENDER-AFFIRMING VAGINOPLASTY
Da David Jiang*, Sandra Gallagher, Laura Burchill, Jens Berli, Daniel Dugi, Portland, OR

MP04-20 SEGMENTAL VASCULAR INJURIES FOLLOWING BLUNT HIGH GRADE RENAL TRAUMA DO NOT REQUIRE REPEAT IMAGING
Christopher Loftus*, Niels Johnsen, Seattle, WA

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
MP05-03 EXTERNAL VALIDATION OF RISK MODELS PREDICTING OUTCOMES IN NON-MUSCLE INVASIVE BLADDER UROTHELIAL CARCINOMA PATIENT AFTER TRANSURETHRAL TUMOR RESECTION: A SINGLE-INSTITUTE EXPERIENCE IN TAIWAN.
Yu-Kuang Chen*, Tzu-Ping Lin, Taipei City, Taiwan, Shih-Yen Lu, Taoyuan City, Taiwan, Yen-Hwa Chang, Junne Yih Kuo, Hsiao-Jen Chung, Howard H.H. Wu, Shing-Hwa Lu, Eric Yi-Hsiu Huang, Chi-Cheh Lin, Yu-Hua Fan, I-shen Huang, William J. Huang, Alex T.L. Lin, Kuang-Kuo Chen, Taipei City, Taiwan

MP05-04 PREOPERATIVE THROMBOCYTOSIS IN PATIENTS UNDERGOING RADICAL CYSTECTOMY FOR UROTHELIAL CANCER OF THE BLADDER- AN INDEPENDENT PROGNOSTIC PARAMETER FOR AN IMPAIRED ONCOLOGICAL OUTCOME
Friedrich Jokisch*, Munich, Germany, Tobias Grimm, Munich, Germany, Alexander Buchner, Gerald Schulz, Alexander Kretzschmer, Munich, Germany, Alexander Karl, Christian Stief, Munich, Germany

MP05-05 PERIVESICAL STRANDING ON PREOPERATIVE AXIAL IMAGING DOES NOT PREDICT T3 BLADDER CANCER ON FINAL PATHOLOGY
Jay Fuletra*, Matthew Kaag, Andrew Watts, Erik Lehman, Jay Raman, Suzanne Merrill, Hershey, PA

MP05-06 MIX METHODS APPROACH TO EXPLORE PATIENTS’ PERSPECTIVES ON THE ACCEPTABILITY OF A URINARY BIOMARKER TEST IN REPLACEMENT OF CYSTOSCOPY FOR BLADDER CANCER SURVEILLANCE
Wei Shen Tan*, London, United Kingdom, Chinh Hai Teo, Delcos Chan, Malgorzata Heinrich, Kuala Lumpur, Malaysia, Andrew Feber, Rachael Sarporg, Jennifer Allan, Norman Williams, Chris Brew-Graves, London, United Kingdom, Chirk Jenn Ng, Kuala Lumpur, Malaysia, John Kelly, London, United Kingdom

MP05-07 PROSPECTIVE IMPLEMENTATION OF A NON-OPIOID (NOP) PROTOCOL FOR PATIENTS UNDERGOING ROBOT-ASSISTED RADICAL CYSTECTOMY
Kyrollis Attalla*, Francois Audenet, Morgane Giordano, John Pfail, Marc Lubin, Nikhil Wasingankar, Daniel Ginsburg, Ketan Badani, Alan Sim, John Stakiacos, New York, NY

MP05-08 RADICAL CYSTECTOMY ACCESSIBILITY CHALLENGES ASSOCIATED WITH HOSPITAL VOLUME
Olamide Omidele*, New York, NY, Mark Finkelstein, Khawaja Bilal, Michael Palese, New York, NY

MP05-09 TRENDS IN EXTENDED-DURATION POSTOPERATIVE VENOUS THROMBOEMBOLISM PROPHYLAXIS FOLLOWING RADICAL CYSTECTOMY AMONG COMMERCIALLY INSURED PATIENTS IN THE UNITED STATES
Timothy Lyon*, Nilay Shah, Paras Shah, Lindsey Sangaralingham, Dennis Asante, R. Houston Thompson, Matthew Tolleson, R. Jeffrey Karnes, Igor Frank, Stephen Boorjian, Rochester, MN

MP05-10 DISPARATE ESTIMATES OF BENEFIT FROM POST-DISCHARGE ANTICOAGULATION AFTER CYSTECTOMY IN THE LITERATURE: IMPLICATIONS FOR COST EFFECTIVENESS?
Kristian Stensland*, Burlington, MA, Brendan Waldoch, Mark Broadwin, Navneet Ramesh, Boston, MA, Alireza Moinzadeh, Harras Zaid, David Canes, Burlington, MA

MP05-11 RECOVERY OF PATIENT-REPORTED FUNCTION, BODY IMAGE AND GENERAL HEALTH AFTER CYSTECTOMY AND URINARY DIVERSION
Charles Peyton*, Richard Reich, Tampa, FL, Carl Henrikson, Gainesville, FL, Mounissi Azizi, Wade Sexton, Michael Poch, Philippe Spiess, Tampa, FL, Paul Crispin, Gainesville, FL, Scott Gilbert, Tampa, FL

MP05-12 RE-EXAMINING AN OLD TREND: THE ASSOCIATION OF HUMAN PAPILLOMAVIRUS AND BLADDER CANCER
Lael Reinstatler*, Kevin Shee, Lebanon, NH, Kristian Stensland, Burlington, MA, Lawrence Dagrosa, John Seigne, Einar Sverrison, Lebanon, NH

MP05-13 HEPATITIS B SEROLOGY IS A NOVEL RISK FACTOR FOR BLADDER CANCER
Kevin Shee*, Lael Reinstatler, Lebanon, NH, Kristian Stensland, Burlington, MA, John D. Seigne, Einar F. Sverrison, Lebanon, NH

MP05-14 NATIONWIDE MORTALITY TRENDS IN BLADDER VS LUNG CANCER: DATA FROM THE CAUSES OF UROLOGIC DEATH IN AMERICA (CUDA) STUDY
Jyoti Chouhan*, Ethan Matz, Marc Colaco, Amy Pearlman, James Lovato, Ryan Terlecki, Winston-Salem, NC

MP05-15 MALIGNANCY AFTER AUGMENTATION ENTEROCYSTOPLASTY: A NATIONWIDE STUDY AND MOLECULAR ANALYSIS OF CANCER GENE PANEL.

*Presenting author
MP05-16 TSC1 EXPRESSION AS A PREDICTIVE BIOMARKER OF BLADDER CANCER RESPONSE TO HSP90 INHIBITORS
Michael Hughes*, Mark Woodford, Mahmoud Chehab, Oleg Shapiro, Gennady Bratslavsky, Dimitra Bourboulia, Mehdi Mollapour, Syracuse, NY

MP05-17 NEW PSYCHIATRIC DIAGNOSIS IS A POOR PROGNOSTIC FACTOR FOR PATIENTS WITH MUSCLE INVASIVE BLADDER CANCER
Omar Ayyash*, Jonathan Yabes, Lee Hugar, Avinash Maganty, Pittsburgh, PA, Stephen Williams, Galveston, TX, Benjamin Davies, Bruce Jacobs, Pittsburgh, PA

MP05-18 DISPARITIES IN BLADDER CANCER TREATMENT AND SURVIVAL AMONGST ELDERLY PATIENTS WITH A PRE-EXISTING MENTAL ILLNESS
Niranjan Sathianathen*, Yunhua Fan, Stephanie Jarosek, Isha Konety, Christopher Weight, Sophia Vinogradov, Badrinath Konety, Minneapolis, MN

Friday, May 3, 2019
7:00 am - 9:00 am

Moderated Poster Session 6

BENIGN PROSTATIC HYPERPLASIA: BASIC RESEARCH & PATHOPHYSIOLOGY
Room W175ab @ McCormick Place
Moderators: Gail Prins, Petra Popovics & Wade Bushman

ABSTRACT NUMBER TITLE
MP06-01 OBESITY-ASSOCIATED INFLAMMATION INDUCES ANDROGENIC TO ESTROGENIC SWITCH IN THE PROSTATE GLAND
Bichen Xue*, Shulin Wu, Libing Hu, Shahin Tabatabaei, Chin-Lee Wu, Boston, MA, Zhiyong Cheng, Blacksburg, VA, Douglas Strand, Dallas, TX, Aria Olumi, Zongwei Wang, Boston, MA

MP06-02 SELECTIVE ESTROGEN RECEPTOR MODULATOR CAN IMPROVE BENIGN PROSTATIC HYPERPLASIA IN HIGH FAT INDUCED OBESITY RAT MODEL
Naoyuki Yamanaka*, Kenichi Mori, Shinsuke Mizoguchi, Toshtaka Shin, Hiromitsu Mimata, Oita, Japan

MP06-03 EFFECTS OF COX2 INHIBITION ON BLADDER OVERACTIVITY IN RAT MODEL OF CHEMICALLY INDUCED PROSTATIC INFLAMMATION
Shinsuke Mizoguchi*, Pittsburgh, PA, Kenichi Mori, Hiromitsu Mimata, Oita, Japan, Jianshu Ni, Masahiro Kurobe, Tetsuchii Saito, Donald B. DeFranco, Zhou Wang, Naoki Yoshimura, Pittsburgh, PA

MP06-04 INDUCIBLE PROSTATE LUMINAL EPITHELIAL CELL-SPECIFIC DELETION OF CDH1 INDUCES MURINE PROSTATIC HYPERPLASIA, INFLAMMATION, AND STROMAL FIBROSIS

MP06-05 UPREGULATED INTERLEUKIN 21 RECEPTOR ENHANCES PROLIFERATION AND EPITHELIAL-MESENCHYMAL TRANSITION PROCESS IN BENIGN PROSTATIC HYPERPLASIA
Deqiang Xu, He Xia, Ping Chen, Weixiang He, Daquan Liu, Jianmin Liu, Wuhan, China, People's Republic of, Michael DiSanto, Camden, NJ, Xinhu Zhang*, Wuhan, China, People's Republic of

MP06-06 POSTOPERATIVE CLINICAL PARAMETERS OF PATIENTS WITH STRONG CHRONIC PROSTATIC INFLAMMATION IN TRANSURETHRAL BPH SURGERY IMPROVED MORE THAN THOSE WITHOUT SUCH INFLAMMATION
So Inamura*, Hisato Kobayashi, Makoto Tanio, Manami Tsutsumiuchi, Minekatsu Taga, Katsuki Tsuchiyama, Yosuke Matsuta, Yoshitaka Aoki, Hideaki Ito, Osamu Yokoyama, Fukui, Japan
MP06-07 A PROSPECTIVE STUDY TO EXAMINE THE ASSOCIATION OF THE URINARY AND FECAL MICROBIOTA WITH LOWER URINARY TRACT SYMPTOMS USING 16S RNA GENE ANALYSIS

Shaheen Alanee*, Detroit, MI, Bradley Holland, Kristin Delfino, Danuta Dynda, Ahmed El-Zawahry, Andrea Braundmeier, Springfield, IL, kevin MCVary, kevin MCVary, Maywood, IL

MP06-08 THE METABOLIC HORMONE LEPTIN PROMOTES PROSTATE SMOOTH MUSCLE CONTRACTION AND INDUCES PROLIFERATION OF PROSTATE STROMAL CELLS

Xiaolong Wang*, Yiming Wang, Christian Gratzke, Anna Ciotkowska, Qingfeng Yu, Ruixao Wang, Bingsheng Li, Frank Strittmatter, Christian G. Stief, Martin Hennenberg, Munich, Germany

MP06-09 SENESCENT PROSTATE EPITHELIAL CELLS INDUCE PROLIFERATION OF PROSTATE FIBROBLAST DURING THE PROGRESSION OF BENIGN PROSTATIC HYPERPLASIA

Muqiu Zhang*, Zhenjie Zhu, Jindong Sheng, Jin Song, Peng Xiang, Hualin Song, Shuai Hu, Jie Jin, Beijing, China, People’s Republic of

MP06-10 INHIBITION OF PROSTATE SMOOTH MUSCLE CONTRACTION BY NAV2729 SUGGESTS PROMOTION OF PROSTATE SMOOTH MUSCLE CONTRACTION BY ADP RIBOSYLATION FACTOR 6

Qingfeng Yu*, Christian Gratzke, Paul Kuppermann, Annika Herlemann, Alexander Tamalunas, Yiming Wang, Beata Rutz, Anna Ciotkowska, Raphaele Waidelich, Christian G. Stief, Martin Hennenberg, Munich, Germany

MP06-11 AUTOPHAGY-MEDIATED MYOFIBROBLAST PHENOTYPE AND PROLIFERATION DURING THE PROGRESSION OF BENIGN PROSTATIC HYPERPLASIA

Jin Song*, Xiang Peng, Sheng Jindong, Yang Yang, Hu Shuai, Jin Jie, Beijing, China, People’s Republic of

MP06-12 GHRELIN-MEDIATED PROMOTION OF PROSTATE GROWTH AND PROSTATE SMOOTH MUSCLE CONTRACTION: EVIDENCE FROM FUNCTIONAL, IN VIVO, AND GENOMIC APPROACHES

Xiaolong Wang*, Yiming Wang, Christian Gratzke, Bingsheng Li, Qingfeng Yu, Frank Strittmatter, Christian G. Stief, Munich, Germany, Chunxiao Liu, Guangzhou, China, People’s Republic of, Martin Hennenberg, Munich, Germany

MP06-13 INHIBITION OF HUMAN PROSTATE STROMAL CELL GROWTH AND MODULATION OF CYTOSKELETAL ORGANIZATION BY LENALIDOMIDE: A NEW TREATMENT OPTION IN MALE LUTS?

Alexander Tamalunas*, Cora Sauckel, Anna Ciotkowska, Beata Rutz, Christian G. Stief, Christian Gratzke, Martin Hennenberg, Munich, Germany

MP06-14 CHARACTERIZING THE CELLULAR PATHOGENESIS OF BPH THROUGH SINGLE CELL RNA SEQUENCING OF NORMAL AND HYPERPLASTIC HUMAN PROSTATE

Gervaise Henry, Alicia Malewska, Dallas, TX, Diya Joseph, Madison, WI, Venkat Malladi, Ryan Mauck, Jeffrey Gahan, Ganesh Raj, Claus Roehrbom, Jeffrey Hutchinson, Dallas, TX, Chad Vezina, Madison, WI, Douglas Strand*, Dallas, TX

MP06-15 DIVERGENT EFFECTS OF THE P21-ACTIVATED KINASE (PAK) INHIBITORS FRAX486 AND IPA3 REFLECT DIFFERENT, ISOFORM-SPECIFIC PAK REGULATION OF THROMBOXANE A2- AND ENDOTHELIN-1-INDUCED PROSTATE SMOOTH MUSCLE CONTRACTIONS

Qingfeng Yu*, Bingsheng Li, Christian Gratzke, Alexander Tamalunas, Yiming Wang, Frank Strittmatter, Christian G. Stief, Martin Hennenberg, Munich, Germany

MP06-16 THE FUNCTIONAL ROLE OF ADENOSINE A2B RECEPTOR SUBTYPES IN THE BLADDER OF MALE RATS WITH BLADDER OUTLET OBSTRUCTION

Masahiro Kurobe*, Pittsburgh, PA, Ei-ichiro Takaoka, Narita, J apan, Takahisa Suzuki, Hamamatsu, J apan, Shin-suke Mizoguchi, Tetsuichi Saito, Pittsburgh, PA, Jun Miyazaki, Narita, J apan, Hiroyuki Nishiyama, Tsukuba, J apan, Edwin K. Jackson, Lori A. Birder, Naoki Yoshimura, Pittsburgh, PA

MP06-17 URINARY NGF AND MMP-1 LEVELS ARE ASSOCIATED WITH PERSISTENCE OF DETRUSOR HYPERACTIVITY IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA AFTER SURGERY

Paulo Sajovic de Conti, São Paulo, Brazil, João A B A Barbosa*, Sabrina Reis, Naya Viana, Marco Nunes, William Nahas, Miguel Srougi, Alberto Antunes, Sao Paulo, Brazil

MP06-18 PHOSPHODIESTERASE TYPE 5 INHIBITOR ATTENUATES CHRONIC ISCHEMIA-INDUCED PROSTATIC HYPERPLASIA IN A RAT MODEL

Shinji Fuji*, Shinichi Yamashita, Natsuho Hayashi, Goto Takuro, Juntaro Koyama, Takuma Sató, Shuchi Shimada, Yoshihide Kawasaki, Hideaki Izumi, Naoki Kawamori, Koji Mitsuzuka, Akhiro Ito, Yoichi Arai, Sendai, Miyagi, J apan
### Podium Session 1

**STONE DISEASE: SURGICAL THERAPY I**  
Room W181c @ McCormick Place  
**Moderators:** Nishant Patel, Alfredo Domenech & Olivier Traxer

<table>
<thead>
<tr>
<th>Time</th>
<th>Number</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00</td>
<td>PD01-01</td>
<td>EFFECT OF PAYER STATUS ON PERIOPERATIVE OUTCOMES AND COSTS ASSOCIATED WITH ELECTIVE THERAPY FOR NEPHROURETEROLITHIASIS</td>
<td>David F. Friedlander*, Brighton, MA, Marieke J. Krimphove, Alexander P. Cole, Maya Marchese, Gezzer Ortega, George E. Halebian, Quoc-Dien Trinh, Boston, MA</td>
</tr>
<tr>
<td>7:10</td>
<td>PD01-02</td>
<td>ECONOMIC EVALUATION OF STENTLESS VS. STENTED URETEROSCOPY AND LASER LITHOTRIPSY</td>
<td>Tammer Yamany*, Michal Ursiny, Brian Eisner, Boston, MA</td>
</tr>
<tr>
<td>7:20</td>
<td>PD01-03</td>
<td>TIME TO DECOMPRESSION OF STONE RELATED OBSTRUCTIVE PYELONEPHRITIS IS ASSOCIATED WITH INCREASED ODDS OF DEATH IN THE NATIONAL INPATIENT SAMPLE</td>
<td>Christopher R Haas*, Gen Li, Marl Wardenburg, Kelly A Healy, Elias S Hyams, Ojas Shah, New York, NY</td>
</tr>
<tr>
<td>7:30</td>
<td>PD01-04</td>
<td>APPLICATION OF PERCUTANEOUS NEPHROLITHOTOMY WITH CLEARPETRA NEGATIVE PRESSURE SHEATH IN THE TREATMENT OF OBSTRUCTIVE CALCULOUS PYONEPHROSIS</td>
<td>Dehui Lai*, Melling Chen, Xin Li, Yongzhong He, Ming Sheng, Guangzhou, China, People's Republic of</td>
</tr>
<tr>
<td>7:40</td>
<td>PD01-05</td>
<td>HIGH POWER HOLMIM MOSES TECHNOLOGY VERSUS SUPER-PULSE THULIUM FIBRE LASER. WHICH IS MORE EFFICIENT ON STONES?</td>
<td>Laurian Dragas*, Ghirda, Romania, Bhaskar K. Somani, Southampton, United Kingdom, Keller Etienne X., De Coninck Vincent M.J., Doizi Steeve, Paris, France, Cumpansan Alin A., Martis Sandra M., Livius C. Daminescu, Timisoara, Romania, Wiseman Oliver J., Cambridge, United Kingdom, Traxer Olivier, Paris, France</td>
</tr>
<tr>
<td>7:50</td>
<td>PD01-06</td>
<td>PROSPECTIVE CLINICAL STUDY ON SUPERPULSE THULIUM FIBER LASER: INITIAL ANALYSIS OF OPTIMAL LASER SETTINGS</td>
<td>Alim Dymov*, Leonid Rapoport, Dmitry Tsarichenko, Dmitry Enikeev, Nikolay Sorokin, Gagik Akopyan, Alexandra Proskura, Stanislav Ali, Roman Klimov, Vladimir Lekarev, Dmitry Korolev, Moscow, Russian Federation</td>
</tr>
<tr>
<td>8:00</td>
<td>PD01-07</td>
<td>HIGH FREQUENCY FOR DUSTING DURING HOLMIUM LASER LITHOTRIPSY: DOES IT MATTER?</td>
<td>Ali H Aldoukhi*, Kristian M Black, Timothy L Hall, William W Roberts, Khurshid R Ghani, Ann Arbor, MI</td>
</tr>
<tr>
<td>8:10</td>
<td>PD01-08</td>
<td>PREDICTING NEED FOR REPEAT SURGERY FOLLOWING PERCUTANEOUS NEPHROLITHOTOMY: A SINGLE INSTITUTIONAL LONGITUDINAL ANALYSIS OF RESIDUAL FRAGMENT SIZE</td>
<td>Ravin J. Bastiampillai*, Shuang Li, Kristina L. Penniston, Sara L. Best, Sean P. Hedican, Stephen Y. Nakada, Madison, WI</td>
</tr>
<tr>
<td>8:20</td>
<td>PD01-09</td>
<td>PATIENT CRITERIA ON EMERGENCY PHYSICIAN ASSESSMENT TO REDUCE CT UTILIZATION: AN E-QUAL STUDY</td>
<td>John Fisher*, Matthew Sorensen, KNOXVILLE, TN, Michael Jennings, 37919, TN, Jerry Edwards, James Bienvenu, Knoxville, TN</td>
</tr>
<tr>
<td>8:30</td>
<td>PD01-10</td>
<td>EFFECTIVENESS OF LEAD APRONS IN SHIELDING THE SURGEON DURING PERCUTANEOUS NEPHROLITHOTOMY</td>
<td>John Smith, Loma Linda, CA, Mohammad Hajiha*, Akin Amasyali, Loma Linda, CA, Zahabiya Campwala, Loma Linda, CA, Hyelin You, Muhammad Alsyouf, Loma Linda, CA, Jon Ewald, Andrew Krause, Daniel Baldwin, Reihaneh Moghisi, D.Duane Baldwin, Loma Linda, CA</td>
</tr>
</tbody>
</table>
8:40 PD01-11 DEFINING A NATIONAL REFERENCE LEVEL FOR INTRA-OPERATIVE RADIATION EXPOSURE IN UROLOGICAL PROCEDURES: FLASH; A RETROSPECTIVE MULTI-CENTRE STUDY
Nick Simson*, Thomas Stonier, London, United Kingdom, Narin Suleyman, Luton, United Kingdom, Julian Peacock, Worthing, United Kingdom, Miriam Saltib, Oliver Bottrell, Martin Connor, London, United Kingdom, Jane Hendry, Glasgow, United Kingdom, Oliver Jones, James Schuster-Bruce, Stevenage, United Kingdom, Charles Horn, Derriford, United Kingdom, Louise English, Worthing, United Kingdom, Neba Hamami, Catherine Lovegrove, London, United Kingdom, Abdurahman Bareh, Dominic Jaikaransingh, Nusrat Mohamed, London, United Kingdom, Uchenna Ukwu, Cambridge, United Kingdom, Nimlan Shanmugathas, London, United Kingdom, John Bycroft, Stevenage, United Kingdom, Oliver Wiseman, Cambridge, United Kingdom, Ahmed Qteishat, Harlow, United Kingdom, Marco Bolgeri, London, United Kingdom, Omar Aboumarzouk, Glasgow, United Kingdom

8:50 PD01-12 EFFECT OF PAYER STATUS AND INDEX CARE SETTING ON 30-DAY REVISIT FOLLOWING ELECTIVE SURGERY FOR NEPHROURETEROLITHIASIS
David F. Friedlander*, Brighton, MA, Marieke J. Krimphove, Alexander P. Cole, Maya Marchese, Gezzer Ortega, George E. Halebian, Quoc-Dien Trinh, Boston, MA

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
8:00 PD02-07 PROPHYLACTIC MIDURETHRAL SLINGS AT THE TIME OF PELVIC ORGAN PROLAPSE REPAIR SURGERY TO PREVENT DE-NOVO STRESS URINARY INCONTINENCE: A NEED TO REAPPRAISE? Kai Dallas*, Lisa Rogo-Gupta, Raveen Syan, Ekene Enemchukwu, Christopher Elliott, Stanford, CA

8:10 PD02-08 TENSION-FREE VAGINAL TAPE VERSUS POLYACRYLAMIDE HYDROGEL-INJECTION FOR PRIMARY STRESS URINARY INCONTINENCE: A RANDOMIZED CLINICAL TRIAL Anna-Maija Freitas, Maarit Mentula, Päivi Rahkola-Soisalo, Sari Tulokas, Tomi Mikkola*, Helsinki, Finland

8:20 PD02-09 OUTCOMES OF MACROPLASTIQUE INJECTIONS FOR STRESS URINARY INCONTINENCE AFTER SUB-URETHRAL SLING REMOVAL Dayron Rodriguez*, Deborah Hess, Feras Alhalabi, Timothy Carroll, Maude Carmel, Philippe Zimmern, Dallas, TX

8:30 PD02-10 EFFECTS OF THE REMEEX SYSTEM® IN FEMALE PATIENTS WITH INTRINSIC SPHINCTERIC DEFICIENCY AND RECURRENT URINARY INCONTINENCE: 10-YEAR OUTCOMES Phil Hyun Song*, Daegu, Korea, Republic of, Gyeong Eun Min, Seoul, Korea, Republic of, Yeong Uk Kim, Jae Young Choi, Young Hwi Ko, Ki Hak Moon, Hee Chang Jung, Daegu, Korea, Republic of

8:40 PD02-11 LONG-TERM SAFETY AND EFFICACY OF POLYDIMETHYLSILOXANE (MACROPLASTIQUE®) IN PATIENTS WITH STRESS URINARY INCONTINENCE: ANALYSIS OF PATIENTS WHO COMPLETED 3-YEARS OF TREATMENT Gamal Ghoniem MD, FACS, ABD/FPMRS*, Bilal Farhan MD, Masrin Chowdhury DO, Orange, CA, Yanjun Chen MS, Irvine, CA

8:50 PD02-12 REDUCED EXPRESSION OF UROPLAKIN-3A FOLLOWING CYSTOSCOPY WITH FULGURATION OF TRIGONITIS IN WOMEN WITH RECURRENT UTI Amy Kuprasertkul*, Luming Chen, Kim Orth, Dallas, TX, Nicole J. DeNisco, Richardson, TX, Philippe Zimmern, Dallas, TX

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Friday, May 3, 2019

Podium Session 3

KIDNEY CANCER: ADVANCED (INCLUDING DRUG THERAPY) I
Room W185a @ McCormick Place
Moderators: Michael Whalen, Stephen Boorjian & Marc-Olivier Timsit

<table>
<thead>
<tr>
<th>ABSTRACT</th>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>PD03-01</td>
<td>7:00</td>
<td>RNASEQ MICROBIAL ANALYSIS IDENTIFY VARIABILITY BETWEEN RENAL CELL CARCINOMA PRIMARY TUMOR AND INTRAVASCULAR TUMOR EXTENSION</td>
<td>Michael Liss*, Dharam Kaushik, Yidong Chen, Teresa Johnson-Pais, Deepak Pruthi, Ahmed Mansour, San Antonio, TX, James White, Baltimore, MD, Ronald Rodriguez, San Antonio, TX</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ABSTRACT</th>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>PD03-02</td>
<td>7:10</td>
<td>UNDERSTANDING THE EFFECTIVENESS OF LYMPHADENECTOMY IN NODE ONLY RECURRENCES AFTER NEPHRECTOMY FOR KIDNEY CANCER</td>
<td>Marcelo Panizzutti Barboza*, Ryan Speir, Adam Calaway, Richard Foster, Hristos Kaimakiotis, Timothy Masterson, Ronald Boris, Clint Cary, Indianapolis, IN</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ABSTRACT</th>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>PD03-03</td>
<td>7:20</td>
<td>SINGLE CENTER OPERATIVE EXPERIENCE WITH 409 CASES OF RADICAL NEPHRECTOMY AND IVC THROMBECTOMY</td>
<td>Molly DeWitt-Foy*, Scott Lundy, Mohamed Eltemamy, Ahmed Elshafei, Venkatesh Krishnamurthi, Cleveland, OH</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ABSTRACT</th>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>PD03-04</td>
<td>7:30</td>
<td>IS CYTOREDUCTIVE NEPHRECTOMY NECESSARY IN METASTATIC RENAL CELL CARCINOMA WITH PRIMARY KIDNEY TUMOR IN SITU TREATED BY SUNITINIB: REAL WORLD DATA FROM A SINGLE CHINESE CENTER</td>
<td>Wen-Hao Xu, Wang Jun, Hong-Kai Wang, Fang-Ning Wan, Da-Long Cao, Yuan-Yuan Qu*, Hai-Liang Zhang, Dingwei Ye, Shanghai, China, People's Republic of</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ABSTRACT</th>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>PD03-05</td>
<td>7:40</td>
<td>A CONTEMPORARY HIGH-VOLUME CENTER ANALYSIS OF POSTOPERATIVE COMPLICATIONS FOLLOWING SURGICAL MANAGEMENT OF RENAL CELL CARCINOMA WITH TUMOR THROMBUS</td>
<td>Qiming Zhang*, Lulin Ma, Beijing, China, People's Republic of</td>
</tr>
<tr>
<td>Time</td>
<td>Number</td>
<td>Title</td>
<td>Authors</td>
</tr>
<tr>
<td>-------</td>
<td>--------</td>
<td>----------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------</td>
</tr>
<tr>
<td>7:00</td>
<td>PD04-01</td>
<td>STONE TARGETING MICROBUBBLES ENHANCE LASER LITHOTRIPSY BY INCREASING FRAGMENTATION AND DECREASING STONE MASS</td>
<td>Scott Wiener*, Matt Mellema, Yuri Pishchalnikov, William Behnke-Parks, Daniel Laser, Marshall Stoller, San Francisco, CA</td>
</tr>
<tr>
<td>7:10</td>
<td>PD04-02</td>
<td>THERMAL DOSE DURING HOLMIUM LASER LITHOTRIPSY: IN VITRO URETERAL MODEL</td>
<td>Ali H Aldoukhi*, Kristian M Black, Timothy L Hall, Khurshid R Ghani, Ann Arbor, MI, Adam D Maxwell, Brian MacConaghy, Seattle, WA, William W Roberts, Ann Arbor, MI</td>
</tr>
</tbody>
</table>

*Presenting author
THE ENDOCOSCOPE: A DISRUPTIVE GLOBAL OPPORTUNITY?
Sherry Lu*, Renai Yoon, Zhamshid Okhunov, Courtney Cottone, Shlomi Tapiero, Roshan Patel, Jaime Landman, Ralph Clayman, Orange, CA

URETEROSCOPIC DOPPLER ULTRASONOGRAPHY: MAPPING RENAL BLOOD FLOW FROM THE INSIDE-OUT
Roshan Patel*, Kamaljot Kaler, Mitchell O’Leary, Vinay Cooper, Egor Parkhomenko, Orange, CA, David Regan, Nashua, NH, Jaime Landman, Ralph Clayman, Orange, CA

AN ALGORITHMIC APPROACH TO IMPLEMENTATION OF A SINGLE-USE DIGITAL FLEXIBLE URETEROSCOPE RESULTS IN A DECREASE IN REUSABLE DIGITAL FLEXIBLE URETEROSCOPE REPAIR COSTS
Ravi Munver*, Johnson Tsui, Mutahar Ahmed, Gregory Lavallo, Michael Stifelman, Michael Degen, Hackensack, NJ

DEEP LEARNING COMPUTER VISION ALGORITHM FOR DETECTING KIDNEY STONE COMPOSITION: TOWARDS AN AUTOMATED FUTURE

TRIAL OF AN IOT-ENABLED DEVICE TO REMOTELY MONITOR CATHETER OUTPUTS IN THE COMMUNITY
Conor Mosli-Lynch*, David Barton-Grimley, London, United Kingdom

EXPLORATION OF THE URINARY PROTEOME IN THE SEARCH FOR NEW BIOMARKERS FOR PROSTATE CANCER: A PROMISING ROLE FOR EXTRACELLULAR VESICLES
Bert Dhondt*, Glenn Vergauwen, Jan Van Deun, Edward Geeurickx, Lien Lippens, Joeri Tulkens, Ghent, Belgium, Ilkka Minalainen, Pekka Rappu, Jyrki Helin, Oulu, Finland, Piet Ost, Olivier De Wever, An Hendrix, Nicolaas Lumen, Ghent, Belgium

HYPER SPECTRAL IMAGING CAN DISTINGUISH MORPHOLOGY PATTERNS IN PROSTATE CANCER
Hiroshi Sasaki*, Hiroyuki Inaba, Takahiro Kimura, Koki Morishita, Shin Egawa, Tokyo, Japan

MOLECULAR HALLMARKS OF MPMRI VISIBILITY IN PROSTATE CANCER
Taylor Y. Sadun*, Los Angeles, CA, Kathleen E. Houlahan, Toronto, Canada, Amirali Salmasi, San Diego, CA, Aydin Pooli, Ely R. Felker, Steven S. Raman, Preeti Ahuja, Anthony E. Sisk, Paul C. Boutros, Robert E. Reiter, Los Angeles, CA
7:30 PD05-04 CELL CYCLE GENETIC VARIANTS ASSOCIATED WITH AGGRESSIVE PROSTATE CANCER IN THE PROSTATE, LUNG, COLORECTAL, AND OVARIAN (PLCO) CANCER SCREENING TRIAL
Melissa J. Huynh*, Kathryn L. Penney, Chirag Vyasa, Adam S. Kibel, Boston, MA

7:40 PD05-05 A TRANSCRIPTOMIC SIGNATURE OF TERTIARY GLEASON 5 PREDICTS WORSE CLINICOPATHOLOGICAL OUTCOME
Alberto Martini, Joanna Wang, Nicholas Brown, Shivaram Kumarsamy*, Eithan Wajswol, John P Sfakianos, Ardesthir R Rastinehad, Kenneth G Haines III, N Peter Wiklund, Sujit S Nair, Ashutosh K Tewari, New York, NY

7:50 PD05-06 PERCENT GENOME ALTERATION PREDICTS ADVERSE ONCOLOGIC OUTCOMES AFTER RADICAL PROSTATICECTOMY IN AFRICAN AMERICAN MEN: A PROFILE OF CANCER GENOMICS BY RACIAL ANCESTRY
Farzana Faisal*, Scott Tomlins, Tamara Lotan, Edward Schaeffer, Chicago, IL

8:00 PD05-07 EPGENETIC METHYLATION DIFFERENCES DISPLAY MORE VARIATION IN TUMOR-ASSOCIATED VERSUS NON-TUMOR ASSOCIATED BENIGN PROSTATE TISSUES: THE FIELD DEFECT HYPOTHESIS
Tariq A. Khemees*, Bing Yang, Adam Schultz, Tyler Etheridge, Glen Levenson, Madison, WI, Geoffrey Sonn, Palo Alto, CA, Cristina Magi-Galluzzi, Erick A. Klein, Cleveland, OH, Michael J. Fumo, Rockford, IL, David F. Jarrard, Madison, WI

8:10 PD05-08 NITRIC OXIDE SUPPRESSES THE MACROPHAGE INDUCED RESISTANCE TOWARDS CSF-1R INHIBITION THERAPY IN CASTRATION RESISTANT PROSTATE CANCER
HIMANSHU ARORA*, Manish Kuchakulla, Joshua M Hare, RANJITH RAMASAMY, MIAMI, FL

8:20 PD05-09 FLUORESCENT-DIHYDROTESTOSTERONE BASED INHIBITOR IMPAIRED PROSTATE CANCER CELL LINE GROWTH AND ANDROGEN RECEPTOR SIGNALING

8:30 PD05-10 LOSS OF MIR-21 DELAYS MYC-DRIVEN PROSTATE CANCER PROGRESSION IN THE HI-MYC TRANSGENIC MOUSE MODEL
Kenji Zennami*, Toyoake, Japan, Fatima Rafiqi, Ross Liao, Kim Sealover, Brian Simons, Baltimore, MD, Makoto Sumitomo, Ryoichi Shiroki, Toyoake, J apan, Shawn Lupold, Baltimore, MD

8:40 PD05-11 POTENTIAL BENEFIT OF ADDING ORAL 5-AMINOLEVULINIC ACID TO PELVIC RADIOThERAPY USING A SYNGENIC MYC-CAP PROSTATE CANCER MODEL
Makito Miyake*, Nobumichi Tanaka, Takuya Owari, Shunta Hori, Yusuke Morizawa, Yoshitaka Itami, Yasushi Nakai, Kyohide Fujimoto, Nara, Japan

8:50 PD05-12 COMBINATION OF AN ANTAGONIST TO THE ANDROGEN RECEPTOR N-TERMINAL DOMAIN WITH ENZALUTAMIDE FOR THE TREATMENT OF CASTRATION RESISTANT PROSTATE CANCER
Yukiyoshi Hirayama*, Kunzhong Jian, Raymond J. Anderson, Christian D. S. Sadar, Vancouver, Canada

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
7:10 V01-02 COMPREHENSIVE CLINICAL STUDY OF SUPER PULSE TM FIBER LASER FOR TREATMENT OF STONE DISEASE

7:20 V01-09 SUPERPULSE THULIUM FIBER LASER FOR LITHOTRIPSY OF LARGE RENAL STONES: INITIAL EXPERIENCE
Etienne Xavier Keller*, Zurich, Switzerland, Vincent De Coninck, Brasschaat, Belgium, Viktoria Vinnichenko, Moscow, Russian Federation, Paul Chiron, Steeve Doizi, Paris, France, Mirab Guseynov, Dmitry Ergakov, Alexey Martov, Moscow, Russian Federation, Olivier Traxer, Paris, France

7:30 V01-11 THULIUM SUPERPULSE FIBER LASER (TSPFL) MICRO-PCNL: HOW TO IMPROVE STONE-FREE RATE (SFR)
Alexey Martov*, Andrey Andronov, Sergey Dutov, Moscow, Russian Federation, Olivier Traxer, Paris, France

7:40 V01-12 THULIUM LASER COAGULATION OF RESIDUAL URETERAL ENDOMETRIOSIS
Claudia Signorini*, San Donato Milanese, Italy, Gloria Motta, Damiano Vizziello, Maria Chiara Clementi, Sebastiano Nazzani, Sebastiano Nazzani, Oskar Bleizen, Paderno Dugnano, Italy, Robert Stubinski, Pietro Acquati, Stefano Picozzi, Elisabetta Finkelberg, Dario Ratti, Martina Manfredi, Luca Carmignani, San Donato Milanese, Italy

7:50 V01-04 HIGH-SPEED VIDEO MICROSCOPY INVESTIGATIONS OF THE MECHANISMS OF STONE BREAKAGE WITH HOLMIUM: YAG LASER LITHOTRIPSY

8:00 V01-05 SEMI-CLOSED CIRCUIT VACUUM-ASSISTED MINI-PERCUTANEOUS NEPHROLITHOTOMY WITH HOLMIUM LASER LITHOTRIPSY
Stefano Paolo Zanetti*, Gianluca Sampogna, Matteo Fontana, Elisa De Lorenzis, Andrea Gallioli, Vito Lorusso, Michele Morelli, Luca Boeri, Fabrizio Longo, Giancarlo Albo, Emanuele Montanari, Milan, Italy

8:10 V01-10 NON-BIOLOGICAL 3D PRINTED SIMULATOR FOR PERCUtANEOUS NEPHROLITHOTRIPsy
Stanislav Ali*, Evgeny Sirota, Roman Sukhanov, Stanislav Vovdenko, Caroline Plett, Evgeny Bezrukov, Moscow, Russian Federation

8:20 V01-06 MINIPERC: YES, PLEASE!
Moises Rodriguez-Socarras*, Silvia Proietti, Giuseppe Saitta, Vincent De Coninck, Guglielmo Mantica, Davide De Marchi, Piera Bellinzoni, Franco Gaboardi, Guido Giusti, Milan, Italy

8:30 V01-07 EX-VIVO URETEROSCOPY TREATMENT OF DECEASED DONOR KIDNEY CALCULI ON PERFUSION MACHINE
Samuel Chelly*, Paul Panayotopoulos, Pierre Bigot, Thibaut Culty, Angers, France

8:40 V01-08 MICRO-URETEROSCOPY AS A STRATEGY FOR MANAGEMENT OF PELVIC URETERAL STONES IN CHILDREN
Diogo Nunes-Carneiro*, Joa˜o Ferreira-Cabral, Avelino Fraga, Vitor Cavadas, Porto, Portugal

8:50 V01-03 TRANSVAGINAL CYSTOLITHOTOMY: A NOVEL APPROACH
JJ Zhang*, Cleveland, OH, Jessica Lloyd, Springfield, OR, Juan Guzman-Negron, Weston, FL, Howard Goldman, Cleveland, OH

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Friday, May 3, 2019

Forums
UROLOGIC ONCOLOGY RESEARCH SYMPOSIUM: METABOLISM AND CANCER
Room W471 @ McCormick Place

7:30 WELCOME AND SYMPOSIUM INTRODUCTION
Program Chairs: Othon Iliopoulos, Sunil Sudarshan
Research Council Chair: Aria Olumi

7:40 SESSION ONE: BASIC SCIENCE
Moderator: Sunil Sudarshan
TARGETING AUTOPHAGY IN CANCER
Ravi Amaravadi
FUELING T CELLS IN KIDNEY CANCER
Katy Beckermann

WHEN AN ONCOMETABOLITE ISN’T AN ONCOMETABOLITE: EXPLORING THE ENDOGENOUS ROLE OF L-2-HYDROXYGLUTARATE IN GROWTH AND DEVELOPMENT
Jason Tennesen

MORNING KEYNOTE ADDRESS: MITOCHONDRIA CONTROL CANCER AND IMMUNITY
Keynote Speaker: Navdeep Chandel

DISCUSSION/Q & A

9:25 BREAK
SESSION TWO: RENAL
Moderator: Othon Iliopoulos

NOVEL METABOLIC INSIGHTS INTO RCC BIOLOGY AND IMMUNE RESPONSE
A. Ari Hakimi

TARGETING GLUTAMINE METABOLISM FOR TREATMENT OF RCC AND HIF-DRIVEN TUMORS
Othon Iliopoulos

ROLE OF ONCOMETABOLITE L-2 HYDROXYGLUTARATE IN REPROGRAMMING RENAL CELL CARCINOMA METABOLISM
Garrett Brinkley

NON-INVASIVE EVALUATION OF HISTOLOGIC, MOLECULAR, AND METABOLIC HETEROGENEITY IN KIDNEY CANCER
Ivan Pedrosa

THE METABOLIC PATHOGENESIS OF CHROMOPHOBEC RENAL CELL CARCINOMA
Carmen Priolo

DISCUSSION/Q & A

11:30 LUNCH BREAK

SESSION THREE: BLADDER

METABOLIC DYSREGULATIONS AND AOX1 ROLE IN BLADDER CANCER PROGRESSION
Nagireddy Putluri

DISCOVERY OF RATIONAL COMBINATION IMMUNOTHERAPY FOR CANCER
Dan Theodorescu

THE ROLE OF PDK5 IN BLADDER CANCER CHEMORESISTANCE
John Taylor

DISCUSSION/Q & A

SESSION FOUR: PROSTATE
Moderator: Sunil Sudarshan

KEYNOTE LECTURE: INTERFERING WITH LIPID METABOLISM TO TARGET ANDROGEN RECEPTOR IN CASTRATION-RESISTANT PROSTATE CANCERS
Keynote Speaker: Massimo Loda

CHARACTERIZATION AND TARGETING OF DE NOVO PURINE BIOSYNTHETIC ENZYME PAICS IN PROSTATE CANCER
Sooyanarayan Varambally

THERAPEUTIC TARGETING OF LIPOGENESIS IN CANCERS
Anders Nää-r

TARGETING GLUTAMINE METABOLISM IN PROSTATE CANCER
Richard J. Lee

EXPLORING THE IMPACT OF NEGATIVE ENERGY BALANCE ON PROSTATE CANCER USING PRESURGICAL RANDOMIZED CONTROLLED TRIALS
Wendy Demark-Wahnefried

DISCUSSION/Q & A

CLOSING REMARKS
Program Chairs: Othon Iliopoulos, Sunil Sudarshan
Research Council Chair: Aria Olumi

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
7:53 DISCUSSION

DEVELOPMENTAL SENESCENCE IS IMPORTANT FOR EARLY PATTERNING OF THE MOUSE GENITAL TUBERCLE
Daniel Casella

HOSPITAL STAFF & NON-UROLOGIST PHYSICIANS USING AN APP, OBTAINED MORE ACCURATE PENILE CURVATURE MEASUREMENTS THAN PEDIATRIC UROLOGISTS USING A GONIOMETER OR THE EYEBALL
Carlos Villanueva

A FOLLOW-UP GEOSPATIAL ANALYSIS OF HYPOSPADIAS AND CRYPTORCHIDISM PREVALENCE RATES IN A CANADIAN PROVINCE WITH STABLE POPULATION
Kiana Mahboubi

VACUUM PHYSIOTHERAPY AFTER FIRST STAGE BUCCAL MUCOSA GRAFT (BMG) URETHROPLASTY IN PROXIMAL HYPOSPADIAS: A FEASIBILITY, SAFETY & PROTOCOL COMPLIANCE ASSESSMENT STUDY
Marco Bandini

A PILOT STUDY EVALUATING PAIN OUTCOMES IN PEDIATRIC CIRCUMCISION PATIENTS AFTER ADMINISTRATION OF KETOROLAC AS A PERIOPERATIVE ADJUNCT THERAPY
Alec Mitchell

CLINICAL IMPLICATION OF HOME-BASED GUARDIAN-CONDUCTED VIDEO VOIDING TEST TO EVALUATE URETHRAL STRicture AFTER HYPOSPADIAS REPAIR
Sang Hoon Song

8:21 DISCUSSION

GENETIC VARIANTS RELATED TO SEX HORMONE BIOSYNTHESIS, GENITAL TUBERCLE & URETHRAL DEVELOPMENT AS A PREDICTIVE MARKER FOR HYPOSPADIAS
Sang Hoon Song

THE ROLE OF HYPERBARIC OXYGEN THERAPY IN PEDIATRIC UROLOGY “CATASTROPHES”
Amos Neheman

PARENTAL DECISION MAKING REGARDING NEONATAL CIRCUMCISION: DO THE AAP GUIDELINES MATTER?
Adam Eickmeyer

GONIOMETER NOT BETTER THAN “EYE BALL” AT ESTIMATING PEDIATRIC VENTRAL PENILE CURVATURE
Carlos Villanueva

HIGH-THROUGHPUT GENE SEQUENCING TO INVESTIGATE THE METHYLATION OF THE ANDROGEN GENE IN PATIENTS WITH HYPOSPADIAS
YiDong Liu

8:48 DISCUSSION

CHALLENGING PROXIMAL HYPOSPADIAS REPAIRS: AN EVOLUTION OF TECHNIQUE FOR TWO STAGE REPAIRS
Yvonne Chan

9:00 DISCUSSION

SCIENTIFIC SESSION II: BASIC SCIENCE PRIZE FINALISTS

COMPARISON OF GLOMERULAR FILTRATION RATE ESTIMATED BY MOTION-ROBUST HIGH SPATIOTEMPORAL RESOLUTION DYNAMIC CONTRAST ENHANCED MRI & PLASMA CLEARANCE OF 99MTC-DTPA
Sila Kurugol

DECREASED BUTYRATE-PRODUCTION & OXALATE-DEGRADATION OF THE GUT MICROBIOME IN CHILDREN & ADOLESCENTS WITH CALCIUM OXALATE KIDNEY STONE DISEASE
Kristen Koepsell

GENE DOSAGE CHANGES IN KCTD13 RESULT IN PENILE & TESTICULAR ANOMALIES
Abhishek Seth

DELETION OF VOLTAGE-GATED POTASSIUM CHANNEL SUBUNIT KV6.4 CAUSES VESICOURETERAL REFLUX
Abhishek Seth

IL-6 SIGNALING MEDIATES UROPATHOGENIC BACTERIA EXPULSION FROM HOST UROTHELIAL CELLS TO LIMIT UTI CHRONICITY
Sudipti Gupta

9:20 DISCUSSION

Meredith Campbell Lecture: A Career of Innovation and Collaboration
Alberto Peña

9:30 BREAK

9:50 DISCUSSION

SCIENTIFIC SESSION III: TESTIS & SEXUAL DEVELOPMENT

LOWER NUMBER OF GERM CELLS & SERUM INHIBIN-B LEVELS IN BILATERAL CRYPTORCHIDISM THAN IN UNILATERAL CRYPTORCHIDISM
Taiki Kato

ADOLESCENTS WITH SEVERE OLIGOASTHENOSPERMIA CAN BENEFIT FROM VARICOCELECTOMY
Joan Ko

VARENICLINE PREVENTS ISCHEMIA REPERFUSION INJURY IN TESTICULAR TORSION
Christina Ho
TESTICULAR ATROPHY AFTER ORCHIOPEXY: OUTCOMES OF TESTICULAR SURVIVAL BY DIFFERENT PRIMARY LOCATIONS & AGES AT ORCHIOPEXY
Yui-Cheng Lu

HYPOTROPHY, REGARDLESS OF SIDE, IS NOT PREDICTIVE OF SEMINAL PARAMETERS
Vinaya Vasudevan

TESTIS SPARING SURGERY FOR PEDIATRIC LEYDIG CELL TUMORS: THE NEW STANDARD OF SURGICAL CARE?
Fadi Zu’bi

10:48 DISCUSSION

SPERMATOGONIAL STEM CELL ACTIVITY & INDICATION FOR SURGERY OF RETRACTILE TESTES
Hideyuki Kamisawa

CONTemporary ANALYSIS of TESTIS SPARING SURGERY FOR TESTICULAR LESIONS IN THE PEDIATRIC POPULATION
Fadi Zu’bi

PROCTORED SCROTAL EXAMS WITH PEDIATRIC UROLOGIST IMPROVE PROVIDERS’ CONFIDENCE IN EXAMINATION OF UNDESCENDED TESTIS
Devang Sharma

TESTOSTERONE PRODUCTION BY LEYDIG CELLS STIMULATES PERI-TUMORAL SPERMATOGENESIS IN PRE-PUBERTAL BOYS
Fadi Zu’bi

ABDOMINOSCROTAL HYDROCELE IS NOT A HERNIA: INGUINAL DISSECTION IS NOT NECESSARY
Weichen Xu

11:06 DISCUSSION

11:15 SCIENTIFIC SESSION IV: DSD

BEYOND CHANGING DIAPERS: PARENTAL STRESS & DECISIONS AMONG PARENTS OF GIRLS WITH CAH SEEKING CONSULTATION ABOUT FEMINIZING GENITAL RESTORATION SURGERY
Konrad Szymanski

BLADDER EXTROPHY CONSORTIUM (MIBEC) AFTER 5 YEARS: A REVIEW OF PATIENTS TREATED IN THE FIRST 3 YEARS
Joseph Borer

BODY IMAGE & PSYCHOSOCIAL ADJUSTMENT IN YOUTH & YOUNG ADULTS WITH DSD
Diane Chen

A CHEMICAL-GENETIC APPROACH TO IDENTIFYING DRUGS FOR INDUCING CYP21A2 EXPRESSION
Kiersten Craig

11:27 DISCUSSION

PROSTATE SPECIFIC ANTIGEN IN PATIENTS WITH 46,XX CONGENITAL ADRENAL HYPERPLASIA
Ubirajara Barroso Jr.

MITOCHONDRIAL DYSFUNCTION ASSOCIATION WITH GENITOURINARY BIRTH DEFECTS
Abhishek Seth

PATIENT SATISFACTION & SHARED DECISION MAKING IN A MULTI-DISCIPLINARY CARE CLINIC FOR PATIENTS WITH DIFFERENCES IN SEX DEVELOPMENT
Jonathan Walker

FEMINIZING GENITOPLASTY IN CONGENITAL ADRENAL HYPERPLASIA: A 20-YEAR EXPERIENCE OF REGIONAL COMPREHENSIVE CARE
Katie Canalichio

11:49 DISCUSSION

DSD TASK FORCE UPDATE

SPU BUSINESS MEETING

LUNCH

PANEL DISCUSSION: CHANGING CAREER FOCUS
Moderator: Christopher Cooper
Panelists: Steven Docimo, Steve Kim

SOCIETY FOR FETAL UROLOGY (SFU) PROGRAM

SFU ABSTRACT SESSION 1

UPPER OR LOWER TRACT APPROACH FOR DUPLEX ANOMALIES? A MULTI-INSTITUTIONAL COMPARATIVE ANALYSIS OF ROBOTIC ASSISTED APPROACHES
Ravindra Sahadev

SURGICAL COMPETENCE AND LIKELY MASTERY-WHEN IS IT POSSIBLE FOR PEDIATRIC ROBOTIC PYELOPLASTY – SINGLE SURGEON’S LONGITUDINAL EXPERIENCE?
Rana Kumar

ENDOSCOPIC URETEROVESICOSTOMY: A NOVEL MINIMALLY INVASIVE TECHNIQUE FOR TREATMENT OF THE ECTOPIC URETER
Martin Kaever

A MULTI-INSTITUTIONAL COMPARISON OF OPEN, LAPAROSCOPIC AND ROBOT-ASSISTED PYELOPLASTY FOR URETEROPELVIC JUNCTION OBSTRUCTION IN INFANTS
Ciro Andolfi
BOOSTING IGF SIGNALING BY MMP7 THROUGH CLEAVAGE OF IGFBP3 IN THE PATHOGENESIS OF UPJO
Hui Zhi

2:25 DISCUSSION

FAILURE OF THE URETERAL BARRIER IN THE DEVELOPING URETER CAUSES PRENATAL URETEROPELVIC JUNCTION OBSTRUCTION IN A NOVEL MOUSE MODEL
Michael Ortega

PEDIATRIC URETERAL STENT SYMPTOMS: PROSPECTIVE STUDY
Joshua Chamberlin

EFFECT OF CAP IN CHILDREN WITH POST OPERATIVE JJ STENTS: A PROSPECTIVE RANDOMIZED STUDY
Perviz Hajiyev

HOW LONG IS THE MINIMUM PERIOD OF URETERAL STENTING AFTER OPEN PYELOPLASTY FOR CHILDREN WITH URETEROPELVIC JUNCTION OBSTRUCTION?
Minki Baek

ONE WEEK STENTING AFTER PEDIATRIC LAPAROSCOPIC PYELOPLASTY: IS IT ENOUGH?
M. Abdelwahab

2:53 DISCUSSION

3:00 LECTURE

3:45 BREAK

4:00 SFU ABSTRACT SESSION 2

CAN THE UTD CLASSIFICATION SYSTEM BE MORE HELPFUL THAN THE SFU SYSTEM FOR VUR PATIENTS?
Amr Hodhod

HYDRONEPHROSIS CLASSIFICATION SYSTEMS IN THE DIAGNOSIS AND FOLLOW-UP OF POSTERIOR URETHRAL VALVES: IS ONE SUPERIOR?
Kristina Suson

AMNIOCENTESIS PERFORMANCE FOR GENETIC DISORDERS IN FETUSES WITH ISOLATED ULTRASONOGRAPHIC UROLOGICAL ABNORMALITIES
Samuel Otis

PEDIATRIC RENAL CYSTS: WHEN AND HOW DO WE INTERVENE?
Ravindra Sahadev

RENAL REPLACEMENT THERAPY RATES REMAIN STABLE OVER TIME FOR CHILDREN WITH POSTERIOR URETHRAL VALVES AND PRUNE BELLY SYNDROME
Daryl McLeod

DISCUSSION

OUTCOMES OF PYELOPLASTY IN POORLY FUNCTIONING PAEDIATRIC KIDNEYS
Nandish Rotti

ABDOMINAL LEAK POINT PRESSURE: A SIMPLE WAY TO PREDICT URINARY INCONTINENCE FOLLOWING SURGICAL TREATMENT OF UNILATERAL ECTOPIERE TE IN GIRLS
Anil Mani

MANAGEMENT AND LONG-TERM FOLLOW-UP OF PERINATALIY-DETECTED GRADE 1/2 HYDRONEPHROSIS
Akihiro Nakane

TIMING OF TERMINATION OF FOLLOW-UP OBSERVATION FOR PERINATALLY-DETECTED GRADE 2 HYDRONEPHROSIS
Akihiro Nakane

INITIAL POSTNATAL MANAGEMENT OF ANTENATALLY DETECTED HYDRONEPHROSIS IN NEWBORNS BORN WITHIN A SINGLE HOSPITAL SYSTEM
Katherine M Fischer

4:20 DISCUSSION

OUTCOMES OF PYELOPLASTY IN POORLY FUNCTIONING PAEDIATRIC KIDNEYS
Nandish Rotti

ABDOMINAL LEAK POINT PRESSURE: A SIMPLE WAY TO PREDICT URINARY INCONTINENCE FOLLOWING SURGICAL TREATMENT OF UNILATERAL ECTOPIEBRER TE IN GIRLS
Anil Mani

MANAGEMENT AND LONG-TERM FOLLOW-UP OF PERINATALIY-DETECTED GRADE 1/2 HYDRONEPHROSIS
Akihiro Nakane

TIMING OF TERMINATION OF FOLLOW-UP OBSERVATION FOR PERINATALLY-DETECTED GRADE 2 HYDRONEPHROSIS
Akihiro Nakane

INITIAL POSTNATAL MANAGEMENT OF ANTENATALLY DETECTED HYDRONEPHROSIS IN NEWBORNS BORN WITHIN A SINGLE HOSPITAL SYSTEM
Katherine M Fischer

4:48 DISCUSSION

POINT/COUNTERPOINT VS PANEL

SFU BEST CASE PRESENTATION AND AWARD

ADJOURN

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
CURRENT MANAGEMENT OF PEYRONIE’S DISEASE
Lawrence Hakim

Q & A

IAUA/SAKTI DAS RESEARCH SCHOLAR PRESENTATION

USI UPDATE: EVOLUTION OF MINI PERC IN THE MANAGEMENT OF NEPHROLITHIASIS IN INDIA
Madhu Aggarwal

HYPOGONADISM AFTER PROSTATE CANCER TREATMENT
Mohit Khera

ROBOTICS FOR RECONSTRUCTIVE UROLOGY & BEYOND
Daniel Eun

POSTER PRESENTATIONS

10:15 BREAK

10:35 SESSION 2: UROLOGIC ONCOLOGY

RECURRENT PROSTATE CANCER: ADVANCES IN IMAGING
Samir Taneja

RECURRENT PROSTATE CANCER: NEW DRUGS
Akshay Bhandari

Q & A

STANDARD OF CARE: ROBOTIC RADICAL CYSTECTOMY
Khurshid Guru

BLUE LIGHT CYSTOSCOPY FOR DIAGNOSIS OF BLADDER CANCER
Badrinath Konety

WATCHFUL WAITING FOR LOCALIZED UPPER TRACT UROTHELIAL CANCER
Jay Raman

Q & A

NON-CME INDUSTRY SPONSORED LUNCH

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
THE CLINICAL RESEARCH AND PROGRESS ON RETROGRADE EJACULATION
Long Tian

EFFECT OF ALCOHOL ON CHRONIC PROSTATITIS IN A MOUSE MODEL OF EXPERIMENTAL AUTOIMMUNE PROSTATITIS
Chaozhao Liang

DISCUSSION

10:30 BREAK

10:45 SESSION 4: BPH, LUTS, INCONTINENCE & OTHERS
Moderators: Qiang Dong, Hsi-Chin Wu, Sharon Yeo

PHOTOSELECTIVE VAPORIZATION OF THE PROSTATE: FIFTEEN YEARS EXPERIENCE
Bo Xin Xue

THE CHARACTERISTICS OF BLADDER MICROBIOTA & ITS INFLUENCE FACTORS IN PATIENTS WITH UROLITHIASIS
Ninghan Feng

CONTEMPORARY ENDOUROLOGICAL STONE TREATMENT OVER THE PAST 12 YEARS AT A UNIVERSITY TEACHING HOSPITAL IN AUSTRALIA: WHAT I HAVE LEARNT AND TIPS & TRICKS
Raymond Ko

DISCUSSION

11:15 SESSION 5: ENDOUROLOGY
Moderators: Edmund Chiong, Tao Wang, Guan Wu

ENDOSCOPIC INTERVENTION FOR MANAGEMENT OF DISTAL GENITAL TRACT CALCULI
Qiang Dong

COMPARATIVE STUDY ON SEMI-SUPINE PCNL & PRONE POSITION PCNL FOR STAGHORN CALCULI
Xianhang Jiang

PCNL WITH LITHOTOMY POSITION: PERSONAL EXPERIENCE
Daobing Li

SHORTENING THE PCNL ACCESS LEARNING CURVE USING MULTIMEDIA TRAINING & ENDOSCOPIC COMBINED INTRARENAL SURGERY (ECIRS)
Jonathan Kam

ROBOTIC RENAL TRANSPLANT: IS THERE A BENEFIT?
Jinna Yao

ROBOTICS IN UROLOGIC RECONSTRUCTION & TRANSGENDER SURGERY
Lee Yao

DISCUSSION

12:08 LUNCH SYMPOSIUM: SUPPORTED BY BEIJING WANBO MEDICAL DEVICES CO. LTD
Moderators: Tom Lue, Shujie Xia, Zhongcheng Xin

12:48 SESSION 6: BASIC SCIENCE
Moderators: Ming Chen, Benyi Li, Yuhui Wang

NON-MUSCLE INVASIVE BLADDER CANCER: DRIVERS VERSUS PASSENGERS
Xue-Ru Wu

PERSONALIZED BOTOX INJECTION IN TREATING MUSCLE SPASICITY & PELVIC PAIN GUIDED USING HIGH-DENSITY SURFACE EMG
Yuanyuan Zhang

LONG-TERM THERAPEUTIC IMPACT OF CELL THERAPY ON IMPROVEMENT IN ERECTILE FUNCTION IN A PRE-CLINICAL STUDY
Yuanyuan Zhang

DISCUSSION
EARLY EXPERIENCE WITH ROBOTIC PERINEAL PROSTATECTOMY
Mark Liu

DISCUSSION

3:05 SESSION 9: INTERNATIONAL EXCHANGING SESSION WITH TURKISH UROLOGICAL ASSOCIATION
Moderators: Kai Hong, Yeong-Shiau Pu, Mustafa Usta

NEWER INDICATIONS & TECHNIQUES FOR VARICOCELECTOMY
Ateş Kadioglu

MICROANATOMICAL FEATURES OF RECURRENT VARICOCELE AFTER HIGH LIGATION
Hecheng Li

INTRAOPERATIVE FLUORESCENCE VISUALIZATION IN ROBOT-ASSISTED PARTIAL NEPHRECTOMY
Ming Chen

CONTINENCE PRESERVING MEASURES AND ROBOTIC PROSTATECTOMY
Erdem Canda

THE IMPACTS OF ARTIFICIAL INTELLIGENCE ON HEALTHCARE
Chung-You Tsai

DISCUSSION

3:50 ADJOURN & CLOSING REMARKS
Richard Lo, Tom Lue
8:00  PRESIDENTIAL WELCOME  
Society President: Hossein Sadeghi-Nejad

8:05  CME ACTIVITY ANNOUNCEMENTS  
Serge Carrier

8:10  SESSION 1: MEDICAL & HORMONAL THERAPIES  
Moderators: Nelson Bennett, Kelly Chiles

I HAVE LOW TESTOSTERONE BUT I DO NOT WANT TO TAKE TESTOSTERONE: WHAT ARE MY OPTIONS?  
William Conners

GROWTH HORMONE: IS IT THE FOUNTAIN OF YOUTH?  
Hossein Sadeghi-Nejad

HYPOGONADISM IN THE CANCER SURVIVOR  
Faysal Yafi

TESTOSTERONE REPLACEMENT THERAPY FOR ERECTILE DYSFUNCTION TREATMENT: IS IT BENEFICIAL?  
Mohit Khera

Q & A

9:00  SESSION 2: EJACULATION DYSFUNCTION  
Moderators: Stanley Althof, Laurence Levine, Michael Perelman

EJACULATION: HOW IS IT WORKING?  
Alexander Pastuszak

PREMATURE EJACULATION: WHAT IS THE BEST TREATMENT STRATEGY?  
Alan Shindel

MALE ANORGASMIA OR DELAYED EJACULATION  
Stacy Elliott

Q & A

9:40  SESSION 3: STATE OF THE ART LECTURES  
Moderators: Lawrence Hakim, Ira Sharlip, Luiz Torres

PDE5 INHIBITORS 20 YEARS ON  
Gerald Brock

PRIAPISM: HOW TO OPTIMIZE THE PRESERVATION OF THE ERECTION  
Arthur Burnett

WHEN PDESI FAILED: WHAT’S THE NEXT BEST OPTION?  
Gregory Broderick

PEYRONIE'S DISEASE: HOW COLLAGENASE CLOSTRIDIUM HISTOLYTICUM HAS CHANGED THE TREATMENT  
Wayne Hellstrom

10:40  SESSION 4: PANEL DISCUSSION - NEUROLOGY OF ERECTILE DYSFUNCTION  
Moderators: Gregory Broderick, Melissa Farmer, Jason Jameson

NEUROANATOMY OF THE PENIS? ITS RELEVANCE TO SEXUAL DYSFUNCTION  
Trinity Bivalacqua

HOW TO ASSESS THE PATIENT WITH NUMBNESS OR COMPLAINING OF LACK OF PENILE SENSATION?  
Irwin Goldstein

CENTRAL NEUROPHARMACOLOGIC REGULATION OF ERECTION, SEXUAL INTEREST AND RESPONSES IN MALES AND FEMALES  
Arthur Burnett

PANEL DISCUSSION  
Panelists: Trinity Bivalacqua, Arthur Burnett, Irwin Goldstein

THE IRA SHARLIP LECTURE: A NON-INVASIVE STEM CELL THERAPY - FROM BENCH TO BEDSIDE  
Moderators: Serge Carrier, Ronald Lewis  
Speaker: Tom Lue

SESSION 5: CONTROVERSIES IN SEXUAL MEDICINE  
Moderators: Lawrence Jenkins, Ranjith Ramasamy, Peter Tsambarlis

AM I WRONG IF I DO NOT OFFER SHOCK WAVE THERAPY TO MY ED PATIENT?  
John Mulhall

AM I WRONG IF I DO NOT OFFER PRP OR STEM CELL THERAPY TO MY ED PATIENT?  
Andrew McCullough

Q & A

NON-CME INDUSTRY SPONSORED LUNCH SYMPOSIUM

SESSION 6: MALE SEXUAL DYSFUNCTION - THE QUEST FOR THE PERFECT PENIS  
Moderators: Rachel Rubin, Alan Shindel, Cigdem Tannikut

DOC, IS MY PENIS NORMAL?  
Serge Carrier

DOC, CAN YOU MAKE MY PENIS BETTER?  
Rafael Carrion

DOC, CAN YOU MAKE THE PENIS LONGER WITH AN IMPLANT?  
Run Wang

SESSION 7: BASIC SCIENCE  
Moderators: Kelvin Davies, Johanna Hannan

THE SCIENCE BEHIND SHOCK WAVE THERAPY  
Alexander Pastuszak

PENILE TISSUE ENGINEERING: WHERE ARE WE?  
Stéphane Bolduc

Q & A
1:50 SESSION 8: FEMALE DYSFUNCTION - THE QUEST FOR THE PERFECT GENITALIA
Moderators: Annamaria Giraldi, Daniela Wittmann

WOMEN GENITAL SELF-IMAGE?
Vanessa Schick

EFFICACY AND SAFETY OF LASER TREATMENTS FOR THE VAGINA
Irwin Goldstein

RADIOFREQUENCY AND GENITAL SURGERY: COSMETIC VERSUS FUNCTIONAL - ISSUES AND ANSWERS
Michael Krychman

PHARMACOLOGICAL HELP FOR FSD: WHAT’S AVAILABLE?
Ashley Tapscott

2:30 SESSION 9: INNOVATIONS IN SURGICAL TECHNIQUE
Moderators: Lawrence Hakim, John Mulcahy

OPTIMIZED IPP RESERVOIR PLACEMENT AND TIPS FOR REMOVAL
Steve Wilson

NEW HYPERMOBILE GLANS CORRECTION TECHNIQUE AND OTHER OFFICE ANDROLOGY PROCEDURES
Landon Trost

TACHOSIL GRAFTING WITH AND WITHOUT IPP: TECHNIQUE & LONG TERM OUTCOMES
Georgios Hatzichristodoulou

EMERGING SURGICAL MANAGEMENT OF CLIMACTURIA AND MILD SUI AT THE TIME OF IPP
Anand Shridharani

TECHNIQUE FOR PROSTHESIS IMPLANTATION IN A TRANSGENDER POPULATION
Oliver Markovsky

TECHNICAL INNOVATIONS AND INSIGHTS IN INCONTINENCE
Brian Christine

BPH STRATEGIES FOR SEXUALLY ACTIVE MEN: STEAM, STAPLE OR AQUA-ABLATE?
Tobias Köhler

OVERVIEW AND TIPS & TRICKS FOR FSD SURGERY
Andrew Goldstein

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Friday, May 3, 2019 9:30 am - 11:30 am
Moderated Poster Session 7

URODYNAMICS/Lower Urinary Tract Dysfunction/Female Pelvic Medicine: Neurogenic Voiding Dysfunction

Room W176bc @ McCormick Place
Moderators: E. Ann Gormley, Sara Lenherr & Elisabetta Costantini

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
<th>AUTHORS</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP07-01</td>
<td>A BRIEF QUESTIONNAIRE TO ASSESS SYMPTOMS IN NEUROGENIC BLADDER: THE NBSS-SF</td>
<td>Blayne Welk*, London, Canada, John Stoffel, Ann Arbor, MI, Sean Elliott, Minnesota, MN, Sara Lenherr, Chong Zhang, Jeremy Myers, Salt Lake City, UT</td>
</tr>
<tr>
<td>MP07-02</td>
<td>A PILOT TRIAL TO EVALUATE A HIGH-RESOLUTION, NON-INVASIVE URODYNAMIC STUDY TO MONITOR ELECTRICAL ACTIVITY OF THE HUMAN BLADDER</td>
<td>Sanghee Lee*, Hoang-Kim Le, Todd Coleman, Tris Mendoza, Thomas DiPina, George Chiang, Gladys Ornelas, Christina Jamieson, Yahir Santiago-Lastra, La Jolla, CA</td>
</tr>
<tr>
<td>MP07-03</td>
<td>ASSESSMENT OF BLADDER SENSATION AFTER YEAR-LONG LOWER SPINAL ROOT TRANSECTION AND SURGICAL REINERVATION USING BEHAVIORAL MEASURES</td>
<td>Danielle M. Salvadeo*, Ekta Tiwari, Nagat Frara, Lucas Hobson, Alan S. Braverman, Mary F. Barbe, Michael R. Ruggieri, Sr., Philadelphia, PA</td>
</tr>
<tr>
<td>MP07-04</td>
<td>DETECTING DIFFERENCES WITH MAGNETOENCEPHALOGRAPHY (MEG)-URODYNAMICS STUDY OF SOMATOSENSORY PROCESSING NORMAL DESIRE TO VOID AND MAXIMUM DESIRE TO VOID SENSATION</td>
<td>Takeya Kitta*, Sarporo, Japan, Hideaki Shiraishi, Kazuyori Yagyu, Atsushi Shimojo, Kiyoshi Egawa, Yukiko Kanno, Mifuka Ouchi, Madoko Higuchi, Mio Togo, Yui Takahashi, Mayuko Tsukiyama, Kimihiko Moriya, Tadashi Ariga, Nobuo Shinhara, Sapporo, Japan</td>
</tr>
<tr>
<td>MP07-05</td>
<td>URODYNAMIC TESTING IN ADULT SPINA BIFIDA PATIENTS: IS THERE USUALLY A NEED?</td>
<td>Shenelle Wilson*, L. Keith Lloyd, Tracey Wilson, Birmingham, AL</td>
</tr>
<tr>
<td>MP07-06</td>
<td>TELEMEDICINE AND HOME MONITORING OF BLADDER FUNCTION FOR MANAGEMENT OF URINARY TRACT INFECTION IN NEUROGENIC BLADDER &amp; SPINAL CORD INJURY</td>
<td>Lynn Stothers*, Emily Deegan, Alex Kavanagh, Vancouver, Canada, Blayne Welk, London, Canada, Mark Negio, Vancouver, Canada</td>
</tr>
</tbody>
</table>

*Presenting author
MP07-07 DECLINE IN RATES OF BLADDER AUGMENTATION AND INCONTINENT DIVERSION AFTER INTRODUCTION OF ONABOTULINUM TOXIN A IN PATIENTS WITH NEUROGENIC BLADDER
Rita Jen*, Irene Crescenze, Anne Cameron, Paholo Barboglio-Romo, Priyanka Gupta, Bahaa Malae, John Stoffel, Quentin Clemens, Ann Arbor, MI

MP07-08 CONTEMPORARY MULTICENTER OUTCOMES OF AUGMENTATION CYSTOPLASTY IN THE ADULT POPULATION OVER A 10-YEAR PERIOD: A NEUROGENIC BLADDER RESEARCH GROUP (NBRG) STUDY
Philip Cheng*, Sorena Keihani, Salt Lake City, UT, Sanchita Bose, Rose Khavari, Houston, TX, Sean Elliott, Joseph Pariser, Joshua Roth, Minneapolis, MN, Blayne Welk, London, Canada, Michael Kennelly, Cameron Futral, Chapel Hill, NC, David Ginsberg, Los Angeles, CA, Christopher Elliott, San Jose, CA, Kyla Valaer, Palo Alto, CA, Sara Lenherr, Salt Lake City, UT, Yahir Santiago-Lastra, San Diego, CA, John Stoffel, Ann Arbor, MI, Jeremy Myers, Salt Lake City, UT

MP07-09 INTRADETRUSOR ONABOTULINUMTOXINA FOR NON-CATHETERIZING MALES WITH NEUROGENIC DETRUSOR OVERACTIVITY
Alexandra Berger*, Cambridge, MA, Valary Raup, Graeme Steele, Elodi Dielubanza, Boston, MA

MP07-10 ARE ANTIChOLINERGICS ABLE TO BOOST THE EFFICACY OF TYPE A BOTULINUM TOXIN IN THE NEUROGENIC BLADDER PATIENT?
Cristian Persu*, Narcis Chirca, Dragos Mares, Viorel Jinga, Bucharest, Romania

MP07-11 Efficacy of Fesoterodine to Ameliorate Autonomic Dysreflexia in Patients with Spinal Cord Injury Suffering from Neurogenic Detrusor Overactivity
Matthias Walter*, Andrea L. Ramirez, Amanda H.X. Lee, Thomas E. Nightingale, Daniel Rapoport, Alex Kavanagh, Andrei V. Krassioukov, Vancouver, Canada

MP07-12 The Efficacy of Onabotulinumtoxin A in Patients with Parkinson’s Disease and Neurogenic Detrusor Overactivity
Ranj Anarianagam, Lewis Chan*, Sydney, Australia, Johan Gani, Helen O’Connell, Melbourne, Australia, Vincent Tse, Sydney, Australia, Henry Yao, Melbourne, Australia

MP07-13 SACRAL NEUROMODULATION IN PARKINSON’S DISEASE PATIENTS WITH NEUROGENIC BLADDER
Daniel Greenberg*, Ericka Sohberg, Chiyuan Zhang, Craig Comiter, Ekene Enemchukwu, Stanford, CA

MP07-14 VALIDATION OF UPPER EXTREMITY MOTOR FUNCTION AS A KEY PREDICTOR OF BLADDER MANAGEMENT FOLLOWING SPINAL CORD INJURY
Christopher Elliott, San Jose, CA, Sara Lenherr*, Jeremy Myers, Salt Lake City, UT, John Stoffel, Ann Arbor, MI, Blayne Welk, Ontario, Canada, Sean Elliott, Minneapolis, MN, Kazu Ko Shem, San Jose, CA

MP07-15 WHAT IS THE ASSOCIATION OF SEVERE BOWEL SYMPTOMS AND TYPE OF NEUROGENIC BLADDER MANAGEMENT IN PATIENTS WITH SPINAL CORD INJURY
Paholo Barboglio-Romo*, Ivana Crescenze, Ann Arbor, MI, Sara Lenherr, Jeremy Myers, Salt Lake City, UT, Blayne Welk, London, Canada, Sean Elliott, Minneapolis, MN, Diana O’Dell, Ann Arbor, MI, Angela Preson, Salt Lake City, UT, John Stoffel, Ann Arbor, MI

MP07-16 TRANSCUTANEOUS SPINAL CORD STIMULATION TO EFFECT LOWER URINARY TRACT ACTIVITY AFTER SPINAL CORD INJURY
Evgeniy Kreydin*, Parag Gad, Hui Zhong, Kyle Latack, V. Reggie Edgerton, Los Angeles, CA

MP07-17 NEUROGENIC DYSFUNCTION IN ADULTS WITH CEREBRAL PALSY: A 10 YEAR EXPERIENCE
Ruthie Su, Thomas Leffler, Gray Roberge*, Wade Bushman, Madison, WI

MP07-18 ARE WHITE MATTER TRACT INTEGRITIES DIFFERENT IN MULTIPLE SCLEROSIS FEMALES WITH VOIDING DYSFUNCTION?
Rose Khavari*, Khue Tran, Christof Karmanik, Saba Elias, Timothy Boone, Houston, TX

MP07-19 NATURAL HISTORY AND FACTORS AFFECTING URINARY SYMPTOMS IN PATIENTS WITH MULTIPLE SCLEROSIS: A PROSPECTIVE STUDY OF 120 PATIENTS
Mohammed Abdelazim, Hisham Torad, Ahmed Abdelaziz*, Hussein Hussein, Nevin Mohieldin Shalaby Shalaby, Samih Sadek, Cairo, Egypt

MP07-20 STERILE VS CLEAN INTERMITTENT BLADDER CATHETERIZATION: A RANDOMIZED CLINICAL TRIAL IN MYELOMENINGOCELE PATIENTS WITH NEUROGENIC BLADDER

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP08-01</td>
<td>RADIATION DOSE REDUCTION OF UNENHANCED CT SCAN LIMITED TO THE KIDNEYS FOR FOLLOW-UP OF ASYMPTOMATIC PATIENTS WITH KNOWN NEPHROLITHIASIS</td>
</tr>
<tr>
<td>MP08-02</td>
<td>PATTERNS OF CT AND US UTILIZATION FOR NEPHROLITHIASIS IN THE EMERGENCY DEPARTMENT</td>
</tr>
<tr>
<td>MP08-03</td>
<td>PREDICTING URETERIC STONE EXPULSION WITH PATIENT REPORTED OUTCOMES: A PROSPECTIVE OBSERVATIONAL STUDY</td>
</tr>
<tr>
<td>MP08-04</td>
<td>THE IMPACT OF TEMPERATURE AND HUMIDITY ON URINARY COMPOSITION</td>
</tr>
<tr>
<td>MP08-05</td>
<td>IMPACT OF DEMOGRAPHIC FACTORS AND SYSTEMIC DISEASE ON URINARY STONE RISK PARAMETERS AMONGST STONE FORMERS</td>
</tr>
<tr>
<td>MP08-06</td>
<td>THE ASSOCIATION BETWEEN 24-HOUR URINE COLLECTION USE AND STONE RECURRENCE AMONG HIGH RISK KIDNEY STONE FORMERS</td>
</tr>
<tr>
<td>MP08-07</td>
<td>ASSOCIATION BETWEEN 24-HOUR URINE TESTING AND CHANGES IN PRESCRIPTIONS FOR URINARY STONE DISEASE-SPECIFIC MEDICATIONS</td>
</tr>
<tr>
<td>MP08-08</td>
<td>ASSOCIATION BETWEEN METABOLIC SYNDROME (METS) AND KIDNEY STONE DISEASE RECURRENCE: OUTCOMES FROM A RETROSPECTIVE COHORT STUDY WITH A MEAN FOLLOW-UP OF 18 YEARS</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP08-09</td>
<td>POSITIVE ASSOCIATION BETWEEN HYPERINSULINEMIA AND KIDNEY STONE FORMATION IN JAPANESE MEN: A PROSPECTIVE COHORT STUDY</td>
</tr>
<tr>
<td>MP08-10</td>
<td>MEDICAL MALPRACTICE AND NEPHROLITHIASIS: U.S. APPELLATE CASES FROM 2001-18</td>
</tr>
<tr>
<td>MP08-11</td>
<td>FAILURE OF THE ELECTRONIC STENT REGISTRY: INCIDENCE OF RETAINED URETERAL STENTS AND IMPLICATIONS FOR PREVENTION</td>
</tr>
<tr>
<td>MP08-12</td>
<td>UTILIZATION TRENDS AND 90-DAY TREATMENT-FREE RATES FOR ESWL, URS, AND PCNL CASES IN THE INPATIENT AND OUTPATIENT SETTING BETWEEN 2004-2014</td>
</tr>
<tr>
<td>MP08-13</td>
<td>10 YEARS SHIFT IN THE TREATMENT MODALITIES AND OUTCOME OF UPPER URINARY TRACT STONES IN JAPAN: A SINGLE INSTITUTION STUDY</td>
</tr>
<tr>
<td>MP08-14</td>
<td>TRENDS AND PREDICTORS OF 30 DAY READMISSIONS FOLLOWING PERCUTANEOUS NEPHROLITHOTOMY IN KIDNEY STONES FORMERS AND IMPLICATIONS FOR READMISSIONS-BASED QUALITY METRICS</td>
</tr>
<tr>
<td>MP08-15</td>
<td>MANAGEMENT OF RARE COMPLICATIONS DURING PCNL – IS A FELLOWSHIP REQUIRED?</td>
</tr>
</tbody>
</table>
MP08-16 SURGICAL RISK IN URETERORENOSCOPIC LITHOLTORIPSY AMONG BEDRIDDEN ELDERLY PEOPLE: 6492 CASES FROM JAPAN NATIONWIDE DATABASE
Toru Sugihara*, Shimotsuke, Japan, Hideo Yasunaga, Hiroki Matsu, Tokyo, Japan, Yusuke Sasabuchi, Shimotsuke, J apan, Haruki Kume, Tokyo, J apan, Tetsuya Fujimura, Shimotsuke, J apan

MP08-17 BUDGET IMPACT ANALYSIS TO SUPPORT THE DECISION BETWEEN REPLACING REUSABLE FLEXIBLE URETEROSCOPES BY SINGLE USE DEVICES AND ADOPTING A HYBRID STRATEGY FOR THE UROLITHIASIS TREATMENT.
Benjamin PRADERE*, Dubnitskiy-Robin Sophie, benjamin Faivre D’Arcier, Sophie Watt, Tanguy Le Fol, Eric Rusch, Fanny Monmousseau, Sylvie Brunet-Houdard, Tours, France

MP08-18 THE TREATMENT OF 15-20 MM RENAL CALCULI: A COST-UTILITY ANALYSIS COMPARING FLEXIBLE URETEROSCOPY WITH PERCUTANEOUS NEPHROLITHOTRIPSY
Jonathan Suderman*, Shubha De, Joe Labossiere, Trevor Schuler, Edmonton, Canada, Tim Wollin, Edmonont, Canada

MP08-19 BEYOND PREVALENCE: INCIDENCE RATES OF KIDNEY STONES IN THE UNITED STATES
Gina Tundo*, Annah Vollstedt, Lebanon, NH, William Meeks, Linthicum, MD, Vernon Pais, Lebanon, NH

MP08-20 AN EVALUATION OF MULTIPLE-DRUG RESISTANCE (MDR) BACTERIA IN PATIENTS WITH URINARY STONE DISEASE: DATA FROM A HIGH-VOLUME STONE MANAGEMENT CENTER.
Shu Wang*, Baltimore, MD, Yitian Zhang, Chapel Hill, NC, Xin Zhang, Jianxing Li, Beijing, China, People’s Republic of

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
MP09-06 THE VALIDATION OF THE 2014 INTERNATIONAL SOCIETY OF UROLOGICAL PATHOLOGY (ISUP) GRADING SYSTEM FOR PATIENTS WITH HIGH-RISK PROSTATE CANCER: A SINGLE-CENTRE RETROSPECTIVE STUDY

Jiandong Liu*, Chengdu, China, People’s Republic of

MP09-07 ASSESSING THE RISK OF LYMPH NODE INVASION WITH THE NEW 2014 INTERNATIONAL SOCIETY OF UROLOGICAL PATHOLOGY CLASSIFICATION IN PATIENTS WITH PROSTATE CANCER TREATED WITH ROBOTIC RADICAL PROSTATECTOMY AND LYMPH NODE DISSECTION: A NOVEL NOMOGRAM

Cosimo De Nunzio*, Rome, Italy, Antonio Luigi Pastore, Latina, Italy, Riccardo Lombardo, Rome, Italy, Giorgio Ivan Russo, Catania, Italy, Giorgia Tema, Fabiana Cancrini, Rome, Italy, Antonio Carbone, Andrea Fuschì, Latina, Italy, Lorenzo Dutto, Joern H. Witt, Gronau, Germany, Andrea Tubaro, Rome, Italy

MP09-08 PERCENT TUMOR VOLUME VS. THE SUBCLASSIFICATION OF AMERICAN JOINT COMMITTEE ON CANCER STAGING SYSTEM ON PREDICTION OF BIOCHEMICAL RECURRENCE IN PATIENTS WITH PATHOLOGIC T2 PROSTATE CANCER

Se Young Choi, Bumjin Lim, Jae Hyeon Han, Yoon Soo Kyung, Dong Hyeon An, Hwiwoo Kim, Wonchul Lee, Han Kyu Chae, Jaehoon Lee, Wonseok Choi*, Seoul, Korea, Republic of

MP09-09 THE ASSOCIATION BETWEEN PATHOLOGIC FEATURES OF LYMPH NODE METASTASIS IDENTIFIED AFTER PROSTATECTOMY AND THE RISK OF BIOCHEMICAL RECURRENCE: A STUDY OF 280 CASES.

Shaheen Alanee*, Mustafa Deebajah, Mohamed Alhamar, Aabsa Jabbar, Mireya Diaz-Insua, Sean Williamson, Daniel Schultz, James Peabody, Mani Menon, Nilesh Gupta, Detroit, MI

MP09-10 MULTI-INSTITUTIONAL PROSPECTIVE STUDY ASSESSING THE UNFAVORABLE SUBGROUP AMONG INTERMEDIATE-RISK LOCALIZED PROSTATE CANCER PATIENTS TREATED WITH RADICAL PROSTATECTOMY: IMPLICATIONS FOR PERSONALIZING TREATMENT OF RADICAL PROSTATECTOMY-MANAGED PATIENTS

Youness AHALLAL*, Nice, France, Nicole Benfante, New York, NY, Matthieu Durand, Nice, France, Luis Felipe Snel Zanettini, Christiane Strauss, Alexandre Colau, Paris, France, Karin Touijer, New York, NY, Bertrand Guillonneau, Paris, France

MP09-11 CONTEMPORARY INCIDENCE AND PREDICTORS OF DOWNGRADING FOR GLEASON 8 PROSTATE CANCER: IMPLICATIONS FOR RISK CLASSIFICATION AND TREATMENT


MP09-12 ADDITIONAL VALUE OF A NOMOGRAM TO PREDICT THE SIDE-SPECIFIC EXTRACAPSULAR EXTENSION IN PATIENTS WITH PROSTATE CANCER SCHEDULED FOR RADICAL PROSTATECTOMY.

Timo Soeterik*, Utrecht, Netherlands, Harm van Melick, Lea Dijksman, Nieuwegein, Netherlands, Heidi Kusters, Nijmegen, Netherlands, Saskia Stomps, Almelo, Netherlands, Douwe Biesma, Nieuwegein, Netherlands, Fred Wiljes, Jean-Paul van Basten, Nijmegen, Netherlands

MP09-13 EXTERNAL VALIDATION OF A MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING-BASED NOMOGRAM FOR THE PREDICTION OF EXTRACAPSULAR EXTENSION OF PROSTATE CANCER: OUTCOMES ON A SERIES OF PATIENTS DIAGNOSED WITH MPMRI TARGETED PLUS SYSTEMATIC SATURATION BIOPSY

Ahmed Eissa, Tanta, Egypt, Maria Chiara Sighinolfi*, Modena, Italy, Marco Sandri, Brescia, Italy, Pietro Torricelli, Federica Fiocchi, Guido Ligabue, Luca Reggiani Bonetti, Stefano Puliatti, Cosimo De Carne, Salvatore Micalli, Modena, Italy, Vipul Patel, Orlando, FL, Giampaolo Bianchi, Bernardo Maria Rocco, Modena, Italy

MP09-14 HYBRID PSMA PET/MRI FOR PRIMARY STAGING IN PRESUMED LOCALISED PROSTATE CANCER: A CONTEMPORARY, TERTIARY HOSPITAL SERIES


MP09-15 68GA-PSMA-11 PET/CT IN RECURRENT PROSTATE CANCER: EFFICACY IN DIFFERENT CLINICAL STAGES OF PSA FAILURE

Francesco Ceci*, Paolo Castellucci, Tiziano Graziani, Andrea Farolfi, Cristina Fonti, Filippo Lodi, Lorenzo Bianchi, Marco Borghesi, Cristian Vincenzo Pultrone, Riccardo Schiavina, Eugenio Brunocilla, Stefano Fanti, Bologna, Italy

*Presenting author
MP09-16 18F-RHPSMA7 POSITRON EMISSION TOMOGRAPHY FOR THE DETECTION OF BIOCHEMICAL RECURRENCE OF PROSTATE CANCER FOLLOWING RADICAL PROSTATECTOMY

Tobias Maurer*, Hamburg, Germany, Markus Kroenke, Alexander Wurzer, Lena Ulbrich, Lena Joos, Thomas Horn, Bernhard Haller, Wolfgang Weber, Hans-Jürgen Wester, Matthias Eiber, Munich, Germany

MP09-17 WEIGHTED GLEASON GRADE GROUP (WGGG): A NEW PROSTATE CANCER BIOPSY REPORTING SYSTEM WITH PROGNOSTIC POTENTIAL


MP09-18 MODIFIED INJECTION TECHNIQUE IN SENTINEL LYMPH NODE DETECTION IN PROSTATE CANCER: TARGETING THE INDEX LESION.

Lluís Fumadó*, Antoni Mestre-Fusco, Jose Maria Abascal, Marc Costa, Nuria Juanpere, Josep Lloreta-Trull, Segri Vidal-Sicart, Lluís Cecchini, Barcelona, Spain

MP09-19 LOW FREE TESTOSTERONE IS AN INDEPENDENT RISK FACTOR FOR HIGH GRADE PROSTATE CANCER

Maxwell Towe*, Linda M. Huynh, Farouk M. El-Khatib, Mohamad Osman, Faysal A. Yafi, Thomas Ahlering, Orange, CA

MP09-20 THE DISTRIBUTION OF COMEDONECROSIS IN INTRADUCTAL VERSUS INVASIVE PROSTATE CANCER: ANALYSIS FROM A LARGE SINGLE CENTER PROSTATECTOMY SERIES

Mustafa Deebajah*, Shannin Carskadon, Sean Williamson, Nilesh Gupta, Nallasivam Palanisamy, James Peabody, Mani Menon, Shaheen Alane, Detroit, MI

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Friday, May 3, 2019

Moderated Poster Session 10

GENERAL & EPIDEMIOLOGICAL TRENDS & SOCIOECONOMICS: QUALITY IMPROVEMENT & PATIENT SAFETY I

Room W179a @ McCormick Place

Moderators: Roger Dmochowski, Clint Cary & Christopher Tessier

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP10-01 OVERVIEW OF 510(K) CLEARED MEDICAL DEVICES AND RECALLS IN URO-ONCOLOGY FROM 2014 THROUGH 2017: IMPLICATIONS FOR SAFETY</td>
<td>GILBERTO JOSÉ RODRIGUES*, JOINVILLE, Brazil, RAFAEL FERREIRA COELHO, WILLIAM CARLOS NAHAS, DENIS LEONARDO JARDIM, SÃO PAULO, Brazil</td>
</tr>
<tr>
<td>MP10-02 PREDICTING LOW OPIATE PILL USE AFTER ROBOTIC SURGERY: TOWARDS TARGETED PRESCRIBING</td>
<td>Kristian Stensland*, Burlington, MA, Joan Delto, Omaha, NE, Peter Chang, Sarah Hyde, Boston, MA, Aaron Berkenwald, Burlington, MA, Kyle McAnally, Catrina Crociani, Brian Holliday, Analesa Baraka, Jodi Mechaber, Boston, MA, Marc Manganiello, David Canes, Alreza Moinzadeh, Burlington, MA, Andrew Wagner, Boston, MA</td>
</tr>
<tr>
<td>MP10-05 HEALTH LITERACY AS AN INDICATOR OF OPIATE USE AND DISPOSAL PRACTICES IN UROLOGIC PATIENTS</td>
<td>Jackson Cabo*, Jeremiah Dallmer, Ryan Hsi, Kelvin Moses, Kristen Scarpato, Nashville, TN</td>
</tr>
</tbody>
</table>
MP10-06 FACTORS INFLUENCING ICU ADMISSION AND ASSOCIATED OUTCOMES IN PATIENTS UNDERGOING RADICAL CYSTECTOMY WITH ENHANCED RECOVERY PATHWAY
Kai Wen Cheng*, Ankeet Shah, Nima Nassiri, Saum Ghodoussipour, Gus Miranda, Jie Cai, Anne Schuckman, Siamak Daneshmand, Hooman Djaladat, Los Angeles, CA

MP10-07 EXPECTATION OF PAIN WITH AMBULATORY CYSTOSCOPY IN ARABIC WOMEN POPULATION AND CLINICAL PATHWAY UTILIZING ARABIC WRITTEN MEDICAL INFORMATION TO IMPROVE CARE
Jack Trebelhorn*, Detroit, MI, Michael Chancellor, Royal Oak, MI, Nivedita Dhar, Detroit, MI

MP10-08 LONG TERM CONSEQUENCE OF PERIOPERATIVE NARCOTIC EXPOSURE FOLLOWING ROBOTIC PROSTATECTOMY: AN EIGHT YEAR FOLLOW-UP STUDY
Ryan Donahue*, Basil Ferenczi, Kathryn Dahl, Daniel Warren, Neil Hanson, Christopher Porter, Paul Kozlowski, John Corman, Seattle, WA

MP10-09 PRACTICE-LEVEL VARIATION IN POSTOPERATIVE PAIN MANAGEMENT AFTER URETEROSCOPY (URS): LESSONS FROM A STATEWIDE COLLABORATIVE QUALITY INITIATIVE
Casey Dauw*, Kayya Swarna, Ji Qi, Tae Kim, Stephanie Ferrante, Jaya Telang, Kathryn Dhal, Daniel Warren, Neil Hanson, Christopher Porter, Paul Kozlowski, John Corman, Seattle, WA

MP10-10 PATIENT-LEVEL VALIDATION OF PROSTATE CANCER DATA COLLECTED VIA AUTOMATED EXTRACTION FROM STRUCTURED AND UNSTRUCTURED ELECTRONIC HEALTH RECORD (EHR) RECORDS
Matthew R. Cooperberg*, San Francisco, CA, William Meeks, Linthicum, MD, Ji Qi, Rodney L. Dunn, Ann Arbor, MI, Sanyog Pendharkar, Pune, India, Daniel Pichardo, Linthicum, MD, Anna Johnson, Susan Linseil, Ann Arbor, MI, Raymond Fang, Linthicum, MD, Steven Schlossberg, Walnut Creek, CA, James E. Montie, Ann Arbor, MI

MP10-11 PAIN MANAGEMENT IN OUTPATIENT UROLOGIC PROCEDURES – A PROSPECTIVE RANDOMIZED TRIAL OF OXYCODONE VERSUS KETOROLAC
Kirtishri Mishra*, Melody Chen, Laura Bukavina, Amr Mahran, Jonathan Kiechle, Michael Wang, Christina Buzzy, Lee Ponsky, Cleveland, OH, Christopher Gonzalez, Maywood, IL

MP10-12 COMPARISON BETWEEN THE ASA SCORE AND THE MODIFIED FRAILTY INDEX (MFI) IN UROLOGIC ONCOLOGICAL AND NON ONCOLOGICAL UROLOGICAL INTERVENTIONAL PROCEDURES.
Vincenzo Serretta, Francesco Muffoletto, Gabriele Tulone, Salvatore Dioguardi, Calogero Guzzardo, Sandro Billecci, Davide Balamonte, Sofia Giannone, Chiara Sanfilippo, Palermo, Italy, Cristina Scalici Geselio*, Marsala, Italy, Alchide Simonato, and members of the GSTU Foundation, Palermo, Italy

MP10-13 A LARGE-SCALE SOCIAL MEDIA ANALYSIS OF OVERACTIVE BLADDER POSTS: WHAT DO PATIENTS KNOW AND WANT TO KNOW?
Gabriela Gonzalez*, Yuliya Zekster, Los Angeles, CA, Carine Khall, Kristina Vulcik, Corey Arnold, Christopher V. Almario, Brennan M.R. Spiegel, Los Angeles, CA, Jennifer T. Anger, Los Angeles, CA

MP10-14 WHAT DO YOUNG ADULTS KNOW ABOUT THE RISK OF UROLOGICAL DISEASE IN SMOKERS? ... AND CAN WE INFLUENCE THEM NOT TO SMOKE?
William Fordyce, Brian Birch*, Southampton, United Kingdom

MP10-15 ANALYSIS OF PRESCRIBING PATTERNS AFTER IMPLEMENTATION OF EVIDENCE-BASED OPIOID PRESCRIBING GUIDELINES FOR THE POSTOPERATIVE UROLOGIC SURGERY PATIENT
Matthew Ziegelmann*, Jason Joseph, Amy Glasgow, Rochester, MN, Mark Tyson, Scottsdal, AZ, Raymond Pak, Jacksonville, FL, Halena Gazelka, Bradley Leibovich, Elizabeth Habermann, Matthew Gettman, Rochester, MN

MP10-16 HIGHER PROPORTION OF FEMALE UROLOGY APPLICANTS MATCH TO RESIDENCY PROGRAMS WITH HIGHER FEMALE FACULTY AND RESIDENT REPRESENTATION

MP10-17 RESIDENTS USE LEAN DAILY MANAGEMENT SYSTEM TO ENHANCE CARE EXPERIENCE AT A SAFETY NET HOSPITAL
Anas Tresh*, San Francisco, CA, Andrew Cohen, Benjamin Breyer, San Francisco, CA

MP10-18 THE DIFFICULT FOLEY: FACTORS PREDICTING APPROPRIATE UROLOGICAL CONSULTATION
Nina Mikkilineni*, Michael Lipsky, Gen Li, David Weiner, Matthew Rutman, New York, NY
**Moderated Poster Session 11**

**BLADDER & URETHRA: ANATOMY, PHYSIOLOGY & PHARMACOLOGY I**  
Room W181ab @ McCormick Place  
**Moderators:** Karl-Erik Andersson, Gamal Ghoniem & Lori Birder

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP11-01</td>
<td>MECHANICAL PROPERTIES AND BICOMPATIBILITY OF ENGINEERED COLLAGEN SCAFFOLDS FOR RECONSTRUCTIVE UROLOGY</td>
</tr>
<tr>
<td>Nikolai Sopko*, Gregory Joice, Uros Milenkovic, Xiaopu Liu, Baltimore, MD, Michael Bickell, Rafael Carrion, Tampa, FL, Ani Singh, Trinity Bivalacqua, Baltimore, MD</td>
<td></td>
</tr>
<tr>
<td>MP11-02</td>
<td>A NEW METHOD FOR HARVESTING MOUSE BLADDER UROTHELIAL TISSUE, LEAVING INTACT UROTHELIAL CELLS, ALLOWING FOR DIFFERENT EXPERIMENTS TO INVESTIGATE UROTHELIAL BIOLOGY</td>
</tr>
<tr>
<td>Ming Lu*, Kejia Zhu, Peter Schulam, Toby Chai, New Haven, CT</td>
<td></td>
</tr>
<tr>
<td>MP11-03</td>
<td>MICROFLUIDIC 3D BIOPRINTING OF MULTILAYERED CANNULET TISSUES</td>
</tr>
<tr>
<td>Xiang Yan*, Nanjing, China, People’s Republic of China</td>
<td></td>
</tr>
<tr>
<td>MP11-04</td>
<td>SYMPATHETIC AFFERENTS IN THE HYPOGASTRIC NERVE FACILITATE NOCICEPTIVE BLADDER ACTIVITY IN CATS</td>
</tr>
<tr>
<td>Yan Zheng, Shun Li, Todd Yecies*, Tara Nikonow, Haotian Cai, Bing Shen, Nathalie Pace, Jicheng Wang, James Roppolo, William de Groot, Changfeng Tai, Pittsburgh, PA</td>
<td></td>
</tr>
<tr>
<td>MP11-05</td>
<td>INVOLVEMENT OF PELVIC NERVE AFFERENT PATHWAYS IN BLADDER OVERACTIVITY AFTER PROSTATIC INFLAMMATION</td>
</tr>
<tr>
<td>Shin’ suge Mizoguchi*, Yoko Ikeda, Anthony J. Kanai, Pittsburgh, PA, Kenichi Mori, Mimata Hiromitsu, Oita, J apan, Jianshu Ni, Masahiro Kurobe, Tetsuichi Saito, Donald B. DeFranco, Zhou Wang, Naoki Yoshimura, Pittsburgh, PA</td>
<td></td>
</tr>
<tr>
<td>MP11-06</td>
<td>DONEPEZIL POTENTIATES BETAHANECHOL TO FACILITATE BLADDER EMPTYING</td>
</tr>
<tr>
<td>Sidney Goldfarb*, Princeton, NJ</td>
<td></td>
</tr>
</tbody>
</table>

**MP10-19**  
JUST A NUDGE: APPLYING BEHAVIORAL INCENTIVES TO ENGAGE RESIDENTS IN QUALITY IMPROVEMENT EDUCATION  
Ashley W. Johnston*, Eugene B. Cone, Durham, NC, Jonathan Bergman, Tannaz Moin, Arlene Fink, Los Angeles, CA, B. Price Kerfoot, Boston, MA, Charles D. Scales, Durham, NC

**MP10-20**  
INPATIENT WORKLOAD HAS INCREASED BY UP TO 300% OVER THE LAST DECADE: ANALYSIS OF A UROLOGY RESIDENCY TRAINING PROGRAM FROM 2007-2017  
Adam Kinnaid*, Logan Zemp, Andrew Rasmussen, Michael Chetnner, Keith Rourke, Trevor Schuler, Edmonton, Canada

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Friday, May 3, 2019 9:30 am - 11:30 am
MP11-12 GHRELIN-MEDIATED REGULATION OF THE MICTURITION REFLEX IN URETHANE-ANESTHETIZED RATS
Masashi Honda*, Yusuke Kimura, Panagiota Tsounapi, Katsuya Hikita, Yonago, Jp, Motoaki Saito, Nankoku, J p, Atsushi Takenaka, Yonago, J p

MP11-13 CENTRALLY ADMINISTERED BOMBESIN INDUCES FREQUENT URINATIN VIA BRAIN CORTICOTROPIN-RELEASING FACTOR RECEPTOR TYPE 1 IN RATS

MP11-14 NORMATIVE NON-INVASIVE BLADDER FUNCTION MEASUREMENTS IN HEALTHY WOMEN: A SYSTEMATIC REVIEW AND META-ANALYSIS
Jean Wyman*, Haitao Chu, Minneapolis, MN, Yvette LaCoursiere, La Jolla, CA, Alayne Markland, Birmingham, AL, Elizabeth Mueller, Maywood, IL, Laura Simon, St. Louis, MO, Ann Stapleton, Palm Springs, CA, Carolyn Stoll, Siobhan Sutcliffe, St. Louis, MO, Jincheng Zhou, Minneapolis, MN, Tamara Bavendam, Bethesda, MD, Prevention of Lower Urinary Tract Symptoms (PLUS) Research Consortium, Minneapolis, MN

MP11-15 CHRONIC HIGH FAT DIET IMPAIRS DETRUSOR MITOCHONDRIAL FATTY ACID OXIDATION IN MALE BUT NOT FEMALE MICE
Hanna Kosnik, Michael Odom, Elena Pak, Kelaey Fisher-Wellman, Johanna Hannan*, Greenville, NC

MP11-16 THE EFFECT OF CONDUCTIVE HYPERTHERMIA ON MITOMYCIN C ABSORPTION DURING INTRAVESICAL CHEMOTHERAPY.
Wei Phin Tan*, Andrew Chang, Gregory Barton, Wiguins Etienne, Brant A Inman, Durham, NC

MP11-17 IMPROVEMENT OF VOIDING AND MOTOR FUNCTION AFTER TREATMENT WITH PTEN INHIBITOR IN SPINAL CORD INJURY
Su Jin Kim*, Wonju, Korea, Republic of, Young Sam Cho, Seoul, Korea, Republic of, Khae Hawn Kim, Incheon, Korea, Republic of

MP11-18 ANALYSIS OF BLADDER CLOCK GENES IN LOWER URINARY TRACT DYSFUNCTION OF SPONTANEOUSLY HYPERTENSIVE RAT
Yusuke Kimura*, Masashi Honda, Ryo Sasaki, Panagiota Tsounapi, Shuichi Morizane, Katsuya Hikita, Mitsuhiro Osaki, Futoshi Okada, Atsushi Takenaka, Yonago, Jp

MP11-19 THE EFFECT OF INTRAVESICAL INSTILLATION OF CALCIUM-ACTIVATED CHLORIDE CHANNEL BLOCKERS ON CYCLOPHOSPHAMIDE-INDUCED OVERACTIVE BLADDER IN RATS
Yuh-Chen Kuo*, Hong-Chiang Chang, Ju-Ton Hsieh, Taipe, Taiwan

MP11-20 THE PREDICTIVE ACCURACY BETWEEN CLINICAL STAGING AND PATHOLOGICAL STAGING IN PATIENTS WITH PRIMARY URETHRAL CARCINOMA
Tina Schubert*, Wuerzburg, Germany, Kirk A. Keegan, Nashville, TN, Markus A. Kuczyk, Mario Kramer, Hannover, Germany, Oliver Patschan, Malmö, Sweden, Allen Sim, Singapore, Singapore, Tokru Nakagawa, Tokyo, J p, Daniel Joyce, Nashville, TN, Michael Drumm, Jason A. Efstathiou, Boston, MA, Hubert Kübler, Georgios Gakis, Würzburg, Germany

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
10:00  PD06-04 IMPACT OF FELLOWSHIP TRAINING ON HOSPITAL DISCHARGE DATA FOR WOMEN UNDERGOING URINARY INCONTINENCE PROCEDURES
Garrett Smith*, Natasha Ginzburg, Syracuse, NY

10:10  PD06-05 STRESS INCONTINENCE SURGERY IS NOT ASSOCIATED WITH PELVIC MALIGNANCY: THE RESULTS OF A LARGE POPULATION-BASED STUDY
Humberto R Vigil*, Christopher Wallis, Toronto, Canada, Joseph LaBossiere, Edmonton, Canada, Sender Herschorn, Lesley Carr, Toronto, Canada

10:20  PD06-06 EFFECT OF BARIATRIC SURGERY ON URINARY INCONTINENCE: A SYSTEMATIC REVIEW AND META-ANALYSIS
Yung Lee, James Yu, Hamilton, Canada, Michał Pędziwiatr, Piotr Major, Krakow, Poland, Ishan Aditya*, Toronto, Canada, Kari Tikkinen, Helsinki, Finland, Yonah Krakowsky, Toronto, Canada, Aristides Doumoureas, Scott Gmora, Mehran Anvari, Dennis Hong, Hamilton, Canada

10:30  PD06-07 PROSPECTIVE ANALYSIS OF OBESITY AND THE EFFECT OF BARIATRIC SURGERY ON URINARY INCONTINENCE
IVAN CALVO VAZQUEZ*, IVAN CALVO VAZQUEZ, CARLOS MARTINEZ ARROYO, BAUDELIO RODRIGUEZ RODRIGUEZ, ERICK A. HERNANDEZ MENDEZ, PASCUAL A. CORTES RAYGOZA, GERARDO FERNANDEZ NOYOLA, JORGE MORALES MONTOR, MAURICIO CANTELLANO OROZCO, CARLOS PACHECO GAHBLER, Mexico, Mexico

10:40  PD06-08 OUTCOMES OF PROPHYLACTIC SLING AT THE TIME OF ROBOTIC ASSISTED SACROCLOPEXY
Carrie Stewart*, Hanson Zhao, Gabriella Gonzales, Christopher Gonzales-Alabastro, A.Lenore Ackerman, Karyn Eilfer, Jennifer Anger, Beverly Hills, CA

10:50  PD06-09 ASSOCIATION OF URINARY LEAKAGE WITH DECREASED TESTOSTERONE IN OLDER WOMEN: RESULTS FROM THE HEALTH, AGING, AND BODY COMPOSITION STUDY
Joseph J. Janicki*, Royal Oak, MI, Richard D. Semba, Baltimore, MD, Michael B. Chancellor, Laura E. Lamb, Royal Oak, MI, Health ABC Study, Bethesda, MD

11:00  PD06-10 SAFETY OF INTRADETRUSOR ONABOTULINUMTOXINA INJECTION IN THE ASYMPTOMATIC PATIENT WITH A POSITIVE URINE DIP
Laura Giusto*, Patricia Zahner, Samir Derisavifard, Jessica Rueb, Michele Fascelli, Courtenay Moore, Raymond Rackley, Sandip Vaavada, Howard Goldman, Cleveland, OH

11:10  PD06-11 INTRAVESICAL BOTULINUM TOXIN A INJECTIONS IN PATIENTS ON ANTIPLATELET AND ANTICOAGULATION THERAPY
Elsie Mensah, Bodgan Toia, Andrew Brown*, Linh Trang Nguyen, Rizwan Hamid, Mahreen Pakzad, Roger Walker, Jeremy Ockrim, Dovendra Sharma, Thrani Nikunam, Tamsin Greenwell, Jai Seth, London, United Kingdom

11:20  PD06-12 FEASIBILITY AND OUTCOMES IN A PILOT RANDOMIZED CONTROLLED TRIAL OF A HOME-BASED INTEGRATED PHYSICAL EXERCISE AND BLADDER TRAINING PROGRAM VERSUS USUAL CARE FOR COMMUNITY-DWELLING OLDER WOMEN WITH URINARY INCONTINENCE.

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Friday, May 3, 2019 9:30 am - 11:30 am

Podium Session 7

KIDNEY CANCER: EPIDEMIOLOGY & EVALUATION/STAGING/SURVEILLANCE I
Room W185d @ McCormick Place

Moderators: Jose Karam, James Borin & Pilar Laguna Pes
9:40 PD07-02 DIVIDING PATHOLOGICALLY UPSTAGED T3A RENAL CELL CARCINOMA BASED ON CLINICAL T STAGE AT PRESENTATION IS ASSOCIATED WITH IMPROVED ALIGNMENT OF OUTCOMES: A CALL FOR TNM REVISION

9:50 PD07-03 PROPOSAL FOR TRIPARTITE RECLASSIFICATION OF CT1 RENAL CELL CARCINOMA INTO CT1A (VERY LOW RISK), CT1B (LOW RISK), AND CT1C (INTERMEDIATE RISK) SUBSTAGES

10:00 PD07-04 GROWTH RATES OF GENETICALLY-DEFINED RENAL TUMORS: IMPLICATIONS FOR ACTIVE SURVEILLANCE AND INTERVENTION
Mark Ball*, Rabindra Gautam, Christopher Ricketts, Cathy Vocke, Laura Schmidt, Maria Merino, Marston Linehan, Bethesda, MD

10:10 PD07-05 PATIENTS WITH SMALL RENAL Masses UNDERGOING ACTIVE SURVEILLANCE: IS YEARLY CHEST IMAGING NECESSARY?
Borna Kassiri*, Joseph Cheaib, Phillip Pierorazio, Baltimore, MD

10:20 PD07-06 COST BENEFIT ANALYSIS FAVORS SONOGRAPHIC SCREENING FOR RENAL TUMORS
Miki Haifler, Guy Verhovsky*, Yishai Hode Rappaport, Tzirffin, Israel, Michael Lashno, Tel-Aviv, Israel, Amnon Zisman, Shmuel Roizman, Tzirffin, Israel

10:30 PD07-07 GERMLINE MUTATION TESTING IN PATIENTS WITH RENAL CELL CARCINOMA IN ENRICHED PATIENT POPULATIONS
Mark Ball*, Christopher Ricketts, Cathy Vocke, Laura Schmidt, Martin Lang, Caitlin Drew, Deborah Nielsen, Lindsay Middleton, Marston Linehan, Bethesda, MD

10:40 PD07-08 MACHINE LEARNING TO PREDICT RECURRENCE OF LOCALIZED RENAL CELL CARCINOMA
Yanbo Guo*, Luis Braga, Anil Kapoor, Hamilton, Canada

10:50 PD07-09 COMPREHENSIVE ASSESSMENT OF THE MORBIDITY OF RENAL MASS BIOPSY: A POPULATION-BASED ASSESSMENT OF BIOPSY-RELATED COMPLICATIONS
Christopher Wallis*, Alaina Garbens, Zachary Klaassen, Ronald Kodama, Sender Herschorn, Robert Nam, Toronto, Canada

11:00 PD07-10 TUMOUR SEEDING IN THE TRACT OF PERCUTANEOUS RENAL TUMOUR BIOPSY. A REPORT OF SEVEN CASES FROM A UK TERTIARY REFERRAL CENTRE
Philip Macklin, Mark Sullivan*, Charles Tapping, David Cranston, Guy Webster, Ian Roberts, Clare Verrill, Lisa Browning, Oxford, United Kingdom

11:10 PD07-11 SIGNIFICANCE OF RADIOLOGICALLY UNDOCUMENTED INFILTRATIVE RENAL Masses
Hajime Tanaka*, Xiaobo Ding, Yanbo Wang, Yunlin Ye, Rebecca A. Campbell, Molly E. Dewitt-Foy, Chalairat Suk-Ouchai, Ryan D. Ward, Erick M. Reimer, Steven C. Campbell, Cleveland, OH

11:20 PD07-12 IMPACT OF IMPLEMENTATION OF STANDARDIZED CRITERIA IN THE ASSESSMENT OF COMPLICATION REPORTING AFTER ROBOTIC PARTIAL NEPHRECTOMY

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
Friday, May 3, 2019 9:30 am - 11:30 am

Podium Session 8

SURGICAL TECHNOLOGY & SIMULATION: INSTRUMENTATION & TECHNOLOGY II

Room W184d @ McCormick Place

Moderators: Duane Baldwin, Gerhard Fuchs & Prem Rashid

<table>
<thead>
<tr>
<th>Time</th>
<th>Number</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:30</td>
<td>PD08-01</td>
<td>EVALUATION OF THE HOLOLENS TO REPLACE CONVENTIONAL MONITORS IN ENDUROLOGY</td>
<td>Hasaneen Al Janabi*, Abdullatif Aydin, Sharanya Palaneer, London, United Kingdom, Nicola Macchiome, Milan, Italy, Ahmed Al-Jabir, Muhammad Shamim Khan, Prokar Dasgupta, Kamran Ahmed, London, United Kingdom</td>
</tr>
<tr>
<td>9:40</td>
<td>PD08-02</td>
<td>IMMERSIVE VIRTUAL-REALITY FOR PERCUTANEOUS NEPHROLITHOTOMY: IMPACT ON PATIENT EDUCATION, SURGICAL PLANNING AND TREATMENT OUTCOME</td>
<td>Egor Parkhomenko*, Boston, MA, Mitchell O'Leary, Orange, CA, Shoab Saffullah, Colombia, MO, Francis Jefferson, Sartaaj Walla, Orange, CA, Ryan James, Seattle, WA, Cyrus Lin, Roshan Patel, Orange, CA, Kamaljot Kaler, Calgary, Canada, Jaime Landman, Ralph Clayman, Orange, CA</td>
</tr>
<tr>
<td>9:50</td>
<td>PD08-03</td>
<td>CHARACTERIZATION OF INTRACALYCEAL PRESSURE DURING URETEROSCOPY</td>
<td>Roshan Patel*, Michael Owyong, Maged Ayad, Martin Hofmann, Jaime Landman, Ralph Clayman, Orange, CA</td>
</tr>
<tr>
<td>10:00</td>
<td>PD08-04</td>
<td>BIO-ENGINEERING OF A NOVEL BLUETOOTH TELEMETRICALLY CONTROLLED ARTIFICIAL URINARY SPHINCTER</td>
<td>Angelo E. Gousse*, Christopher Gomez, Miami, FL, Chris Ross, Pembroke Pines, FL, Peter Sayet, Miami, FL</td>
</tr>
<tr>
<td>10:10</td>
<td>PD08-05</td>
<td>CAN INTRA-VESICLE ULTRASOUND SURFACE MAPPING REPLACE CYSTOSCOPY? NOVEL TECHNIQUE AND PROOF OF CONCEPT</td>
<td>Tareq Aro*, Sunghwan Lim, Doru Petrisor, Dan Stoianovici, Baltimore, MD</td>
</tr>
<tr>
<td>10:30</td>
<td>PD08-07</td>
<td>DEVELOPMENT AND INITIAL VALIDATION OF A LOW-COST ULTRASOUND-COMPATIBLE SUPRAPUBIC CATHETER INSERTION SIMULATOR</td>
<td>Yuding Wang*, Jen Hoogenes, Udi Blankstein, Ali Al-Hashimi, Bobby Shyeg, Edward Matsumoto, Hamilton, Canada</td>
</tr>
<tr>
<td>10:40</td>
<td>PD08-08</td>
<td>LONG TERM OUTCOME OF BALLOON DILATATION OF BENIGN URETERIC STRICTURES</td>
<td>Wai Loon Yam, Foo Cheong Ng, Benjamine Tze Ying Lim*, Kok Kit Ng, Singapore, Singapore</td>
</tr>
<tr>
<td>10:50</td>
<td>PD08-09</td>
<td>THE SHANGRING MALE CIRCUMCISION DEVICE SURGICAL TRAINING MOBILE APPLICATION: AN INNOVATIVE AND MULTI-LANGUAGE LEARNING PLATFORM</td>
<td>Omar Al Hussein Alawam*H, Richard K. Lee, Soo Jeong Kim, Ryan Flannigan, New York, NY, Quentin Awori, Nairobi, Kenya, Mark Barone, Marc Goldstein, Peter N. Schlegel, Philip S. Li, New York, NY</td>
</tr>
<tr>
<td>11:00</td>
<td>PD08-10</td>
<td>SOCIAL MEDIA PRESENCE OF UNITED STATES ACADEMIC UROLOGY RESIDENCY PROGRAMS</td>
<td>Ashley Johnston*, Rohit Tejwani, Jonathan Routh, Andrew Peterson, Judd Moul, Michael Ferrandino, Durham, NC</td>
</tr>
<tr>
<td>11:20</td>
<td>PD08-12</td>
<td>INTEGRATED, REAL-TIME DIGITAL STONE MEASUREMENT IN URETEROSCOPIC STONE PROCEDURES: A WORKFLOW FEASIBILITY STUDY</td>
<td>Kevin Koo*, Tareq Aro, Sunghwan Lim, Doru Petrisor, Dan Stoianovici, Brian Matlaga, Baltimore, MD</td>
</tr>
<tr>
<td>Time</td>
<td>Number</td>
<td>Title</td>
<td>Authors</td>
</tr>
<tr>
<td>--------</td>
<td>--------</td>
<td>-----------------------------------------------------------------------------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>9:30</td>
<td>PD09-01</td>
<td>A GLOMERULUS ON A CHIP THAT RECAPITULATES THE PATHOPHYSIOLOGY OF THE HUMAN GLOMERULAR FILTRATION BARRIER</td>
<td>Astgik Petrosyan, Los Angeles, CA, Paolo Cravedi, New York, NY, Valentina Villani, Los Angeles, CA, Alessandra Renieri, Siena, Italy, Roger De Filippo, Laura Perin, Stefano Da Sacco*, Los Angeles, CA</td>
</tr>
<tr>
<td>9:40</td>
<td>PD09-02</td>
<td>IMPLANTATION OF URINE-DERIVED STEM CELL FOR CHRONIC KIDNEY DISEASE INDUCED BY NEPHROTOXIC DRUG IN A RAT MODEL WITH RENAL ISCHEMIA</td>
<td>Chao Zhang, Sunil K George, Mehran Abolbashar, Tae-Hyoung Kim, In Kap Ko, Yuanyuan Zhang*, John Jackson, Sang Jin Lee, James J Yoo, Anthony Atala, Winston Salem, NC</td>
</tr>
<tr>
<td>9:50</td>
<td>PD09-03</td>
<td>MESENCHYMAL STEM CELL-DERIVED EXOSOMES CONTRIBUTE TO SECRETOME-MEDIATED RENAL RECOVERY AFTER ISCHEMIC INJURY IN RATS</td>
<td>Daniel Sun*, Bradley Gill, Paurush Babbar, Mei Kuang, Danli Lin, Margot Damaser, Cleveland, OH</td>
</tr>
<tr>
<td>10:00</td>
<td>PD09-04</td>
<td>ACELLULAR MESENCHYMAL STEM CELL SECRETOME IMPROVES RECOVERY OF KIDNEY FUNCTION AFTER ISCHEMIC INJURY IN RATS</td>
<td>Daniel Sun*, Paurush Babbar, Mei Kuang, Danli Lin, Jesse KcKenney, Margot Damaser, Bradley Gill, Cleveland, OH</td>
</tr>
<tr>
<td>10:20</td>
<td>PD09-06</td>
<td>INTRADETRUSOR IPSC-DERIVED HUMAN PROGENITOR SMOOTH MUSCLE CELLS IN A ROWETT NUDE RAT MODEL OF RADIATION CYSTITIS</td>
<td>Amy D. Dobberfuhi*, Mason A. Briggs, Shannon L. Wallace, Yan Wen, Yining Zhou, Edward E. Graves, Edward C. Diaz, Susan J. Knox, Bertha Chen, Stanford, CA</td>
</tr>
<tr>
<td>10:30</td>
<td>PD09-07</td>
<td>ENHANCED DIFFERENTIATION AND STRATIFICATION OF BLADDER UROTHELIEL FROM HUMAN INDUCED PLURIPOTENT STEM CELL</td>
<td>Kotaro Suzuki*, Michiyo Koyanagi-Aoi, Keichiro Uehara, Nobuyuki Hinata, Masato Fujisawa, Takashi Aoi, Kobe, J apan</td>
</tr>
<tr>
<td>10:40</td>
<td>PD09-08</td>
<td>INTRAPERITONEAL ADMINISTRATION OF MESENCHYMAL STEM CELLS IS EFFECTIVE IN PREVENTING DETRUSOR DYSFUNCTION AFTER PARTIAL BLADDER OUTLET OBSTRUCTION</td>
<td>Bridgeit Waffe, Tom Churchill, Rutuja Kadam, Jennifer Carleton, Adetola Adesida, Peter Metcalf*, Edmonton, Canada</td>
</tr>
<tr>
<td>10:50</td>
<td>PD09-09</td>
<td>STEM CELLS FROM A RAT MODEL OF TYPE 2 DIABETES/OBESITY AND FEMALE STRESS URINARY INCONTINENCE ARE DAMAGED BY IN VITRO EXPOSURE TO ITS DYSLIPIDEMIC SERUM, PREDICTING INADEQUATE REPAIR CAPACITY IN VIVO</td>
<td>Istvan Kovanevez, Robert A Geifland, Torrance, CA, Guiling Lin, San Francisco, CA, Sheila Sharifzad, Randy Ricks, Tom Lue, Nestor Gonzalez-Cadavid*, Torrance, CA</td>
</tr>
<tr>
<td>11:00</td>
<td>PD09-10</td>
<td>SAFETY OF AUTOLOGOUS BONE MARROW DERIVED MESENCHYMAL STEM CELLS IN ERECTILE DYSFUNCTION: AN OPEN-LABEL PHASE 1 CLINICAL TRIAL</td>
<td>Dalsan You*, Myoung Jin Jang, Seoul, Korea, Republic of, Geethyun Song, Chuncheon, Korea, Republic of, Ha Chul Shin, Seongnam, Korea, Republic of, Nayoung Suh, Asan, Korea, Republic of, Yong Man Kim, Seongnam, Korea, Republic of, Tai Young Ahn, Choung-Soo Kim, Seoul, Korea, Republic of</td>
</tr>
<tr>
<td>11:10</td>
<td>PD09-11</td>
<td>THE NEONATAL AND ADULT HUMAN TESTIS DEFINED AT THE SINGLE-CELL LEVEL</td>
<td>Abhishek Sohni*, Kun Tan, Hye-Won Song, Dana Burow, La Jolla, CA, Dirk de Rooij, Utrecht, Netherlands, Louise Laurent, Tung-Chin Hsieh, La J olla, CA, Raja Rabab, Sue Hammoud, Ann Arbor, MI, Elena Vicini, Rome, Italy, Miles Wilkinson, La J olla, CA</td>
</tr>
<tr>
<td>11:20</td>
<td>PD09-12</td>
<td>UROLOGICAL MALIGNANCIES AND BONE MARROW TRANSPLANT FROM HLA APLOIDIDENTICAL DONOR: WHICH IS THE RELATIONSHIP?</td>
<td>Giovanni Cochettil*, Jacopo Adolfo Rossi de Vermandois, Genni Casarola, Michele Del Zingaro, Matteo Marsico, Andrea Boni, Morena Turco, Massimo Fabrizio Martelli, Ettore Mearini, Perugia, Italy</td>
</tr>
</tbody>
</table>

*Presenting author
<table>
<thead>
<tr>
<th>Time</th>
<th>Abstract Number</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:40</td>
<td>PD10-02</td>
<td>COMPARISON STUDY OF LEARNING CURVE USING CUMULATIVE SUM ANALYSIS BETWEEN HOLMIUM LASER ENUCLEATION OF THE PROSTATE AND TRANSURETHRAL RESECTION OF THE PROSTATE: IS HOLMIUM LASER ENUCLEATION OF THE PROSTATE DIFFICULT PROCEDURE IN BEGINNER UROLOGISTS?</td>
<td>Ki Hong Kim*, Hee Jo Yang, Nam Hun Heo, Si Hyun Kim, Doo Sang Kim, Chang Ho Lee, Young Sool Jeon, Cheonan, Korea, Republic of</td>
</tr>
<tr>
<td>10:00</td>
<td>PD10-04</td>
<td>PREOPERATIVE MAGNETIC RESONANCE IMAGING FACTORS TO PREDICT THE RECOVERY OF URINARY INCONTINENCE AFTER HOLMIUM LASER ENUCLEATION OF THE PROSTATE (HOLEP)</td>
<td>Zhang Fan*, Li Ke, Xiao Chunlei, Ma Lulin, Beijing, China, People's Republic of</td>
</tr>
<tr>
<td>10:10</td>
<td>PD10-05</td>
<td>CLINICAL AND PATHOLOGIC OUTCOMES FOLLOWING HOLMIUM LASER ENUCLEATION OF THE PROSTATE IN MEN UNDERGOING ACTIVE SURVEILLANCE FOR PROSTATE CANCER</td>
<td>Charles Nottingham*, Tim Large, Julia Fiuk, James Lingeman, Indianapolis, IN</td>
</tr>
<tr>
<td>10:20</td>
<td>PD10-06</td>
<td>COMPARISON OF INCIDENTAL PROSTATE CANCER DETECTION BETWEEN HOLEP AND BIPOLAR TURP WEN DONG*, CHUN JIANG, WEIBIN XIE, JIAN HUANG, HAO HUANG, XINXIANG FAN, Guangzhou, China, People's Republic of</td>
<td></td>
</tr>
<tr>
<td>10:30</td>
<td>PD10-07</td>
<td>MULTI-INSTITUTIONAL PROPENSITY MATCHED COMPARISON OF ROBOTIC-ASSISTED SIMPLE PROSTATECTOMY AND THULIUM LASER ENUCLEATION OF THE PROSTATE</td>
<td>Ryan Steinberg*, Brett Johnson, Claus Roehrbom, Dallas, TX, Leonid Rapoport, Petr Glybochko, Moscow, Russian Federation, Jeffrey Gahan, Dallas, TX, Dmitry Enikeev, Moscow, Russian Federation</td>
</tr>
<tr>
<td>10:40</td>
<td>PD10-08</td>
<td>THULIUM LASER TRANSURETHRAL VAPORESECTION OF THE PROSTATE VERSUS TRANSURETHRAL RESECTION OF THE PROSTATE: RESULTS OF THE UNBLOCS RANDOMIZED CONTROLLED TRIAL</td>
<td>Hashim Hashim, J Athene Lane*, Jo Worthington, Hilary Taylor, Grace Young, Sian Noble, Paul Abrams, Aideen Ahern, Bristol, United Kingdom, Sara Brookes, Birmingham, United Kingdom, Nikki Cotterill, Lyndsey Johnson, Rafiyah Khan, Aida Moure Fernandez, Bristol, United Kingdom, Tobias Page, Newcastle, United Kingdom, Satchi Swami, Aberdeen, United Kingdom</td>
</tr>
<tr>
<td>10:50</td>
<td>PD10-09</td>
<td>PERIOPERATIVE COURSE AND OUTCOME OF AQUABLATION, GREENLIGHT VAPORISATION, LASER ENUCLEATION, AND TUR-P.</td>
<td>Thorsten Bach*, Christian Welfing, Petra Anheuse, Stephan Tauber, Claus Brunken, Andreas Gross, Hamburg, Germany</td>
</tr>
<tr>
<td>11:00</td>
<td>PD10-10</td>
<td>3-YEAR OUTCOMES OF SEXUAL FUNCTION AFTER WATER VAPOR THERMAL THERAPY (REZUM®) AND MEDICAL THERAPY FOR TREATMENT OF LOWER URINARY TRACT SYMPTOMS DUE TO BENIGN PROSTATIC HYPERPLASIA (LUTS/BPH): RIGOROUS ASSESSMENT OF SEXUAL FUNCTION QUESTIONNAIRES WITH ITE</td>
<td>Joseph Mahon*, Maywood, IL, Nikhil Gupta, New Brunswick, NJ, Tyson Rogers, Minneapolis, MN, Bradley Holland, Springfield, IL, Kevin McVary, Maywood, IL</td>
</tr>
<tr>
<td>11:10</td>
<td>PD10-11</td>
<td>CONVEXTIVE RADIOFREQUENCY THERMAL THERAPY FOR TREATMENT OF BPH: 4 YEAR FOLLOW UP FROM A SINGLE OFFICE EXPERIENCE</td>
<td>Ryan Mooney*, Dallas, TX, Kenneth Goldberg, Lewisville, TX, Claus Roehrbom, Daniel Wong, Dallas, TX</td>
</tr>
<tr>
<td>11:20</td>
<td>PD10-12</td>
<td>WATER II: AQUABLATION THERAPY FOR BENIGN PROSTATIC HYPERPLASIA IN MEN WITH LARGE PROSTATES (60-150CC): 6-MONTH SAFETY AND EFFICACY RESULTS</td>
<td>Naeem Bhojani*, Montreal, Canada</td>
</tr>
</tbody>
</table>
**Video Session 2**

**BPH & TRANSPLANTATION**

The videos in this session as well as the video libraries from the 2012-2018 Annual Meetings may be viewed in the Surgical Video Library and purchased in the AUA Store during the Annual Meeting. AUA members receive free online access to the Surgical Video Library throughout the year through AUA University. Visit www.AUAnet.org/University to access.

**Room W187b @ McCormick Place**

**Moderators:** Justin Han, Neal Rowe & Andrea Tubaro

<table>
<thead>
<tr>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
<th>ABSTRACT</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:40</td>
<td>V02-04</td>
<td>MOSES, A NEW TECHNOLOGY FOR HOLEP</td>
<td>Yasser Hussein Mohamed Ismail*, Stefano Corti, Francesca Cerosoli, Raffaella Mles, Ivano Vavassori, Treviglio, Italy</td>
</tr>
<tr>
<td>9:50</td>
<td>V02-11</td>
<td>HOLMIUM LASER ENucleATION OF THE PROSTATE USING MOSES TECHNOLOGY IN TREATING BENIGN PROSTATE HYPERPLASIA</td>
<td>Malek Meskawi*, Marcelino Rivera, Rochester, MN</td>
</tr>
<tr>
<td>10:00</td>
<td>V02-05</td>
<td>THULIUM FIBER LASER ENucleATION OF THE SMALL GLANDS (&lt;80 CC)</td>
<td>Dmitry Enikeev*, Leonid Rapoport, Nikolay Sorokin, Roman Sukhanov, Alim Dyomov, Mikhail Enikeev, Mark Taratkin, Petr Glybochko, Moscow, Russian Federation</td>
</tr>
<tr>
<td>10:10</td>
<td>V02-06</td>
<td>TRANSURETHRAL THULIUM LASER PROSTATECTOMY IN THE OUTPATIENT SETTING: TECHNIQUE AND OUTCOMES AT A SINGLE CENTER IN THE UNITED STATES</td>
<td>Richard Grunert*, David Sobel, Curran Uppaluri, Theodore Cisu, Colchester, VT</td>
</tr>
<tr>
<td>10:20</td>
<td>V02-08</td>
<td>A COMPARISON OF TRADITIONAL HOLMIUM AND MOSES LASERS FOR PROSTATIC ENucleation IN A SINGLE PATIENT</td>
<td>Nicholas Kavoussi*, Nicole Miller, Nashville, TN</td>
</tr>
<tr>
<td>10:30</td>
<td>V02-07</td>
<td>ROBOT-ASSISTED SIMPLE PROSTATECTOMY WITH TUNNEL-SHAPED TRIGONIZATION (RASP-TST) VERSUS STANDARD RASP</td>
<td>Cristiano Linck Pazeto*, Sao Paulo, Brazil, Marcos Tobias Machado, Santo Andre, Brazil, Eliney Ferreira Faro, Barretos, Brazil</td>
</tr>
<tr>
<td>11:00</td>
<td>V02-02</td>
<td>ONE-STAGE ROBOT-ASSISTED BLADDER DIVERTICULECTOMY AND URETERAL REIMPLANTATION USING THE SP SURGICAL SYSTEM: TECHNICAL POINTS</td>
<td>Juan Garisto*, Riccardo Bertolo, Mohamed Eltemamy, Jihad Kaouk, Cleveland, OH</td>
</tr>
<tr>
<td>11:10</td>
<td>V02-03</td>
<td>APPLICATION OF ROBOTIC ASSISTANCE TO TRANSPLANT URETERONEOCYSTOSTOMY</td>
<td>Ella Doerge*, Sapan Ambani, Ann Arbor, MI</td>
</tr>
<tr>
<td>11:20</td>
<td>V02-09</td>
<td>SINGLE-PORT ROBOT-ASSISTED RENAL TRANSPLANT: INITIAL PRE-CLINICAL EXPERIENCE USING THE SP SURGICAL SYSTEM</td>
<td>Mohamed Eltemamy*, Juan Garisto, Riccardo Bertolo, Alvin Wee, Jihad Kaouk, Cleveland, OH</td>
</tr>
</tbody>
</table>

*Presenting author

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Chair/Presenter</th>
<th>Room Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00</td>
<td>INTRODUCTION BY THE GURS PRESIDENT</td>
<td>Society President: Kurt McCammon</td>
<td>W196 @ McCormick Place</td>
</tr>
<tr>
<td>10:05</td>
<td>CONGENITAL UROLOGY - TAGLINE/QUESTION?</td>
<td>Moderator: Hadley Wood</td>
<td></td>
</tr>
<tr>
<td></td>
<td>PEDIATRIC PRIMARY CLOSURE TIPS</td>
<td>Mohamed Eissa</td>
<td></td>
</tr>
<tr>
<td></td>
<td>EPISPADIAS COMPLICATIONS IN ADULTS</td>
<td>David Ralph</td>
<td></td>
</tr>
<tr>
<td></td>
<td>TIMING OF GENITOPLASTY IN DSD</td>
<td>Elizabeth Yerkes</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Q &amp; A</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:55</td>
<td>DIFFICULT CASE MANAGEMENT PFUI</td>
<td>Moderator: Pankaj Joshi</td>
<td></td>
</tr>
<tr>
<td></td>
<td>TIMING OF SURGERY</td>
<td>TBA</td>
<td></td>
</tr>
<tr>
<td></td>
<td>PROCEDURE</td>
<td>Kuncoro Adi</td>
<td></td>
</tr>
<tr>
<td></td>
<td>VESSEL SPARING</td>
<td>Reynaldo Gomez</td>
<td></td>
</tr>
<tr>
<td>11:25</td>
<td>ROBOTICS IN GENITOURINARY RECONSTRUCTION: THE USE OF THE ROBOT IN GU RECONSTRUCTION</td>
<td>Moderator: Jessica DeLong</td>
<td>W470 @ McCormick Place</td>
</tr>
<tr>
<td></td>
<td>Speaker: Jill Buckley</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:45</td>
<td>BRADLEY SCOTT LECTURE: POST-PROSTATECTOMY INCONTINENCE - CURRENT CHALLENGES AND FUTURE DISCUSSIONS</td>
<td>Keith Rourke</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Q &amp; A</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:15</td>
<td>NON-CME INDUSTRY SPONSORED LUNCH</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1:15</td>
<td>RESIDENT &amp; FELLOW ABSTRACT PRESENTATIONS</td>
<td>Moderators: Kurt McCammon, Jeremy Myers</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Q &amp; A</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1:45</td>
<td>PERSPECTIVES IN RECONSTRUCTIVE UROLOGY TRAINING</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>CHALLENGES IN STARTING A RECONSTRUCTIVE PROGRAM IN A LMIC</td>
<td>Paksi Satyagraha</td>
<td></td>
</tr>
<tr>
<td>5:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5:00</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
12:50 PLUS CONSORTIUM UPDATE: PREVENTION OF LOWER URINARY TRACT SYMPTOMS
Elizabeth Mueller

1:00 CONTEMPORARY EVALUATION & TREATMENT OF PRIMARY BLADDER NECK/OUTLET OBSTRUCTION IN WOMEN
Moderator: Benjamin Brucker
Panelists: Doreen Chung, Lara MacLachlan, Priya Padmanabhan

1:30 CHALLENGING CASE DEBATE: 55-YEAR-OLD FEMALE WITH MODERATE CYSTOCELE AND PERSISTENT LUTS AFTER MID-URETHRAL SLING PLACEMENT
Moderator: Kathleen Kobashi
Debaters: Gamal Ghoniem, Donna Deng, Nirit Rosenblum, Christian Twiss

2:00 SYMPTOMS OF LOWER URINARY TRACT DYSFUNCTION RESEARCH NETWORK: 2019 UPDATE
Anne Cameron

2:10 STATE-OF-ART: TEN YEARS AFTER THE FDA WARNING - STATUS OF VAGINAL MESH
Alvaro Lucioni

2:25 BREAK

2:40 DHC (DETRUSOR HYPERACTIVITY IMPAIRED CONTRACTILITY) IN WOMEN: DIAGNOSIS, EVALUATION AND MANAGEMENT OF DETRUSOR UNDERCONTINUITY IN WOMEN - WHAT IS OUR CONTEMPORARY PRACTICE?
Moderator: Alan Wein
Speakers: Gregory Bales, John Stoffel

3:00 POINT-COUNTER POINT: TO TURP OR NOT TO TURP, AND WHAT TO “TURP” WITH?
Moderator: Roger Dmochowski
Panelists: Arthur Mourtzinos, Matthew Rutman

3:30 ANOTHER UTI? WHAT DO EXPERTS SAY?
Moderator: Toby Chai
Panelists: Duane Hickling, Una Lee, Ariana Smith, Anne Suskind

4:00 VAGINAL LASER THERAPY IN TODAY’S UROLOGISTS’ PRACTICE: WHAT EVIDENCE TELLS US AND WHAT FDA WARNS PATIENTS ABOUT
A. Lenore Ackerman

4:15 IS THERE A FUTURE FOR REGENERATIVE MEDICINE FOR LUTS?
Margot Damaser

Friday, May 3, 2019

Moderated Poster Session 12
STONE DISEASE: MEDICAL & DIETARY THERAPY
Room W178ab @ McCormick Place
Moderators: David Goldfarb, Michael Lipkin & Kristina Penniston

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP12-01</td>
<td>RELATIONSHIP BETWEEN DAILY WATER INTAKE AND 24-HOUR URINE VOLUME IN ADOLESCENTS WITH KIDNEY STONES</td>
</tr>
<tr>
<td></td>
<td>Joshua Bernard*, Lihai Song, Brittney Henderson, Philadelphia, PA, Steven Warner, San Diego, CA, Gregory Tasian, Philadelphia, PA</td>
</tr>
</tbody>
</table>

| MP12-02         | IS THERE AN APP FOR THAT? PATIENT AND PROVIDER PREFERENCES FOR PROMOTING HYDRATION WITH MOBILE PHONE APPS: A STRATEGY FOR INCREASING URINE VOLUME AND DECREASING STONE RISK |
|                 | Marianna M. Coughlin*, R. Allan Jhagroo, Kristina L. Penniston, Madison, WI |

| MP12-03         | PROTOCOL TO DEVELOP A DIGITAL BIOMARKER TO DETECT DRINKING BEHAVIOR AMONG PATIENTS WITH KIDNEY STONES USING WRIST-WORN INERTIAL SENSORS |
|                 | Necole Streeper*, Hershey, PA, Edison Thomaz, Austin, TX, Ashley Sanders, Alexandra Dubansky, David Conroy, University Park, PA |

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP12-04</td>
<td>DILUTIONAL THERAPY USING THE VASOPRESSIN ANTAGONIST TOLVAPTAN FOR YOUNG PATIENTS WITH CYSTINURIA: A PILOT INVESTIGATION</td>
</tr>
<tr>
<td></td>
<td>Caleb Nelson*, Michael Kurtz, Bartley Ciento, Alyssia Venna, Michelle Baum, Boston, MA</td>
</tr>
</tbody>
</table>

| MP12-05         | UTILIZATION OF A SMART WATER BOTTLE TO INCREASE FLUID INTAKE IN STONE FORMERS |
|                 | Thomas Stout*, Minneapolis, MN, James Lingeman, Amy Krambeck, Indianapolis, IN, Mitchell Humphreys, Scottsdale, AZ, Anna Zisman, Chicago, IL, Sarah Elffering, Michael Borofsky, Minneapolis, MN |

| MP12-06         | REDUCING OPIATE USE IN EMERGENCY DEPARTMENT MANAGEMENT OF ACUTE RENAL COLIC |
|                 | Andrew Portis*, St. Paul, MN, Michael Borofsky, Minneapolis, MN, Suzanne Neises, St. Paul, MN |

| MP12-07         | INCIDENCE AND PREDICTORS OF REPEATED AND PROLONGED OPIOID USE AFTER KIDNEY STONE DIAGNOSIS |
|                 | Annah Vollstedt*, Lebanon, NH, Aient Ngon, William Meeks, Lindhicum, MD, Vernon Pais, Brian Sites, Lebanon, NH |

*Presenting author
MP12-08 KIDNEY STONES AND RISK OF NARCOTIC USE

MP12-09 STENT RELATED DISCOMFORT- DOES ADDING MIRABGERON TO ANTI CHOLINERGIC REGIMES HELP?
Maniyur Raghavendran*, Keyur Patel, Milan Joshi, Mysore, India

MP12-10 RISK FACTORS FOR RECURRENT INFECTION IN PATIENTS DRAINED WITH A DJ STENT FOR URETEROLITHIASIS AND SEPSIS
Eyal Kord*, Yoram I Siegel, Galina Goltsman, zefin, Israel, Sivan Hirsh, Tel aviv, Israel, Amnon Zisman, zefin, Israel

MP12-11 DIETARY ALTERNATIVES TO PRESCRIPTION POTASSIUM CITRATE
Tim Large*, James Williams, INDIANAPOLIS, IN, Ignacio Granga, John Asplin, Chicago, IL, Amy Krambeck, INDIANAPOLIS, IN

MP12-12 URIC ACID SUPERSATURATION AND ELEVATED POST VOID RESIDUALS ARE DRIVING FORCES FOR URIC ACID BLADDER STONE PATHOGENESIS AND IS MITIGATED BY COMPLIANCE TO URINARY ALKALIZATION
Julio Chong*, Conner Brown, Andrew Katims, Jake Bamberger, Stephanie Purnell, Julie Thai, Ryan Chandhoke, William Atallah, Martu Gupta, New York, NY

MP12-13 THE CYSTINURIC DIET’S IMPACT ON SYMPTOMATIC STONE EPISODES
Manuel Armas-Phan*, David Bayne, Scott Wiener, Tim Liang, Jeremy Goodman, Marshall Stoller, Tom Chi, San Francisco, CA

MP12-14 SAFETY AND EFFICACY STUDY OF LUMASIRAN, AN INVESTIGATIONAL RNA INTERFERENCE (RNAI) THERAPEUTIC, IN ADULT AND PEDIATRIC PATIENTS WITH PRIMARY HYPEROXALURIA TYPE 1 (PH1)

MP12-15 EFFECTIVENESS OF PREVENTATIVE COUNSELING IN RECURRENT STONE FORMERS
Gopal Narang*, Durham, NC, Elizabeth Stephenson, Catherine Wiener, Gary Koch, Davis Viprakasit, Chapel Hill, NC

MP12-16 RACIAL VARIATIONS IN ATTITUDES OF UROLITHIASIS PATIENTS TOWARDS ADOPTING STONE PREVENTION STRATEGIES
Anirban P Mitra*, Jamal Nabhani, Los Angeles, CA, Manoj Monga, Cleveland, OH, Mike Nguyen, Los Angeles, CA

MP12-17 NEPHROLITHIASIS AND ELEVATED URINARY AMMONIUM: A MATCHED COMPARATIVE STUDY
Joel Hancock*, Xiang Shu, Guixiao Ding, Nicole Miller, Ryan S. Hsi, Nashville, TN

MP12-18 BUYER BEWARE: EVIDENCE-BASED EVALUATION OF DIETARY SUPPLEMENTS FOR NEPHROLITHIASIS
Kevin Koo*, Tareq Aro, Brian Matlaga, Baltimore, MD

MP12-19 ASSESSMENT OF SURGICAL SUCCESS IN STONE DISEASE: THE PATIENT PERSPECTIVE
Gopal Narang*, Durham, NC, Leslie Lorbacher, Nicholas Koch, Elaine Kearney, Catherine Wiener, Gary Koch, Davis Viprakasit, Chapel Hill, NC

MP12-20 THE IMPACT OF ALTERNATIVE ALKALINIZING AGENTS ON 24-HOUR URINE COLLECTION PARAMETERS
Kohldon Boydston*, Brenton Winship, Russell Terry, Leah Davis, Michael Lipkin, Glenn Preminger, Sarah Yttri, Durham, NC

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
MP13-01 PET/CT WITH 18F-FLUCICLOVINE TO PREDICT RECURRENCE IN POST-TREATMENT PROSTATE CANCER AND ITS ROLE IN ALTERING TREATMENT PLANS

MP13-02 DOES MRI-TRUS FUSION BIOPSY OBViate THE NEED FOR SYSTEMic BIOPSY?
Michael Ahdoot*, Amir H. Lebastchi, Johnathan Bloom, Patrick Gomella, Thomas Sanford, Sandeep Gurram, Graham R. Hale, Samuel Gold, Johnathan DiBianco, Sherif Mehrailvand, Vladimir Valera Romero MD, Maria Merino, Bethesda, MD, M. Minhaj Siddiqui, College Park, MD, Peter L. Choyke, Brad Wood MD, Howard Parnes, Barris Turkbey, Peter A. Pinto, Bethesda, MD

MP13-03 NEED FOR SYSTEMIC 12-CORE BIOPSY CONCURRENT WITH MRI TARGETED BIOPSY OF PI-RADS 4 AND PI-RADS 5 LESIONS
Grace Yaguchi, Mustafa Deebajah*, Sean Williamson, Nilesh Gupta, Mani Menon, Shaheen Alanee, Ali Dabaja, Detroit, MI

MP13-04 ANALYSIS ON THE EVIDENCE OF ULTRASOUND-MRI FUSION TARGET BIOPSY ON PI-RADS SCORE 3 PROSTATE LESIONS
Kyung Hwan Kim*, Seung Ryong Baek, Jih Hoon Park, Byeong Jin Kang, Si Kyun Park, Won Young Park, Seung Baek Hong, Suk Kim, Ja Yoon Ku, Hong Koo Ha, Busan, Korea, Republic of

MP13-05 ROLE OF PI-RADS VERSION 2 FOR PREDICTION OF INCIDENTAL PROSTATE CANCER AFTER RADICAL CYSTOProSTATECTOMY
Wan Song*, Jae Yong Jeong, Seoul, Korea, Republic of, Tae Heon Kim, Seongnam, Korea, Republic of, Hyun Suk Yoon, Kwang Hyun Kim, Hana Yoon, Woo Sik Chung, Bong Suk Sim, Dong Hyeon Lee, Seoul, Korea, Republic of

MP13-06 MULTICENTER CLINICAL TRIAL OF REAL-TIME PROSTATE CANCER DIAGNOSIS USING OPTICAL SPECTROSCOPY GUIDED PROSTATE BIOPSY

MP13-07 NEXT-GENERATION LIQUID BIOPSY USING EXTRACELLULAR VESICLE DETECTION BY NANOSCALE FLOW CYTOMETRY

MP13-08 RADIOGENOMIC DISSECTION OF MULTIFOCAL PROSTATE CANCER

MP13-09 NOVEL COMBINATION OF CIRCULATING MIRNAS FOR SPECIFIC DETECTION IN PROSTATE CANCER
Fumihiko Urabe*, Juntaro Matsuzaki, Yusuke Yamamoto, Takahiro Kimura, Tomohiko Hara, Shin Egawa, Hirokiyuki Fujimoto, Takahiro Ochiya, Tokyo, Japan

MP13-10 FREEHAND ULTRASOUND-GUIDED TRANSPERINEAL PROSTATE BIOPSY WITHOUT ANTIBIOTICS
John Michael Dibianco*, Washington, DC, Patrick Gomella, Bethesda, MD, Cristina Cosner, Mathew Allaway, Cumberland, MD
LEARNING CURVES, CANCER DETECTION RATES, AND COMPLICATIONS OF TRANSPERINEAL PROSTATE BIOPSY UNDER LOCAL ANESTHESIA BY TRAINEE UROLOGISTS
Masaya Ito*, Madoka Kataoka, Kosuke Takemura, Hirotaki Suzuki, Kazumasa Sakamoto, Yasukazu Nakanishi, Kenichi Tobisu, Fumitaka Koga, Tokyo, Japan

ANALGESIC STRATEGY FOR TRANRECTAL ULTRASOUND-GUIDED PROSTATE BIOPSY: A PROSPECTIVE STUDY

ROBOTIC TRANSRECTAL COMPUTED TOMOGRAPHIC ULTRASOUND WITH ARTIFICIAL NEURAL NETWORK ANALYSIS – FIRST VALIDATION AND COMPARISON WITH MRI-GUIDED BIOPSIES AND RADICAL PROSTECTOMY
Niklas Harland*, Tübingen, Germany, Giorgio Ivan Russo, Catania, Italy, Joachim Mathes, Steffen Rausch, Eva Neumann, Sascha Kaufmann, Arnulf Stenzl, Jens Bedke, Tübingen, Germany, Stephan Kruck, Pforzheim, Germany

ANTIBIOPROPHYLAXIS FOR TRANRECTAL ULTRASOUND-GUIDED PROSTATE NEEDLE BIOPSY: IS PREVENTION OF POST-PROCEDURAL URINARY SEPSIS IMPROVED WITH THE NOVEL COMBINATION OF CIPROFLOXACIN AND FOSFOMYCIN?
Alexandre Morin*, Sherbrooke, Canada, Marco Bergevin, Nathalie Cathala, Dominique Prapotnich, Annick Mombet, Rafael Sanchez-Salas, Xavier Cathelineau, Paris, France

HEMOSTATIC EFFECT AND PSYCHOLOGICAL IMPACT OF OXIDIZED REGENERATED CELLULOSE PATCH AFTER TRANSRECTAL ULTRASOUND-GUIDED PROSTATE BIOPSY: A RETROSPECTIVE AND PROSPECTIVE STUDY
Bong Hee Park*, Sang Rak Bae, Yong Seok Lee, Sung Hak Kang, Chang Hee Han, Uijeongbu-Si, Korea, Republic of

THE COST OF PROSTATE BIOPSIES AND THEIR COMPLICATIONS: A SUMMARY OF DATA ON ALL MEDICARE FEE-FOR-SERVICE PATIENTS OVER TWO YEARS
Adam Weiner*, Adarsh Manjunath, Chicago, IL, Gary Kirsh, Cincinnati, OH, Jeffrey Scott, West Palm Beach, FL, Raoul Concepcion, Nashville, TN, John Verniero, West Palm Beach, FL, Deepak Kapoor, New York, NY, Neal Shore, Myrtle Beach, SC, Edward Schaeffer, Chicago, IL

PREVALENCE OF CRITERIA FOR GENETIC TESTING ACCORDING TO THE NATIONAL COMPREHENSIVE CANCER NETWORK GUIDELINES IN A CONTEMPORARY COHORT OF POST PROSTATECTOMY MEN WITH INTERMEDIATE AND HIGH RISK PROSTATE CANCER: THE HENRY FORD HEALTH SYSTEM EXPERIENCE
Zade Roumayah*, Mustafa Deebajah, Marcus Jamil, James Peabody, Mani Menon, Shaheen Alanee, Detroit, MI

INCIDENTAL DETECTION AND TREATMENT OF PROSTATE CANCER AFTER HOLMIUM LASER ENUCLEATION OF THE PROSTATE: A LARGE COHORT ANALYSIS
Seth Teplitzky*, Joon Yau Leong, Tomy Perez, Patrick Shenot, Akhil Das, Philadelphia, PA

COMPARISON OF CANCER DETECTION RATES IN MICRO-ULTRASOUND BIOPSIES VERSUS ROBOTIC ULTRASOUND-MAGNETIC RESONANCE IMAGING FUSION BIOPSIES FOR PROSTATE CANCER
Oliver R. Claros*, Fabio Muttin, Rafael R. Tourinho-Barbosa, Anna C. Gallardo, Eric Barret, Francois Rozet, Nathalie Cathala, Dominique Prapotnich, Annick Mombet, Rafael Sanchez-Salas, Xavier Cathelineau, Paris, France

COMBINATION OF 68GA-PSMA PET/CT AND MULTIPARAMETER MRI IMPROVES THE DETECTION OF CLINICALLY SIGNIFICANT PROSTATE CANCER: A LESION BY LESION ANALYSIS
Mengxia Chen*, Nanjing, China, People's Republic of, Qing Zhang, Nangjing, China, People's Republic of, Chengwei Zhang, Xiaozhi Zhao, Nanjing, China, People's Republic of, Giancarlo Marra, Turin, Italy, Jie Gao, Xiaoyu Lv, Bing Zhang, Yao Fu, Feng Wang, Nanjing, China, People's Republic of, Xuefeng Qiu, Nanjing, Central African Republic, Hongqian Guo, Nanjing, China, People's Republic of

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
<table>
<thead>
<tr>
<th>Abstract Number</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP14-01</td>
<td>NATURAL HISTORY OF RENAL ANGIOMYOLIPOMA (AML) FAVORS SURVEILLANCE AS AN INITIAL APPROACH</td>
</tr>
<tr>
<td>MP14-02</td>
<td>99mTc-SESTAMIBI SPECT/CT FOR THE DIAGNOSIS OF BENIGN RENAL ONCOCYTOMAS AND HYBRID ONCOCYTIC/CHROMOPHOBE TUMORS: COMBINED DATA FROM PROSPECTIVE TRIALS AND REAL-WORLD CLINICAL EXPERIENCE</td>
</tr>
<tr>
<td>Alexa Meyer*, Hiten Patel, Misop Han, Mohamad Allah, Michael Gorin, M. Som Javadi, Phillip Pierorazio, Christian Pavlovich, Steven Rowe, Baltimore, MD</td>
<td></td>
</tr>
<tr>
<td>MP14-03</td>
<td>THE UCLA HISTO-GENETIC RISK CLASSIFICATION (U-HGRC) TO PREDICT OUTCOMES OF LOCALIZED CLEAR-CELL RENAL CELL CARCINOMA</td>
</tr>
<tr>
<td>MP14-04</td>
<td>RENAL BIOPSY - WHEN WILL IT CHANGE MANAGEMENT?</td>
</tr>
<tr>
<td>Douglas Cheung*, Toronto, Canada, Patrick Richard, Sherbrooke, Canada, Diana Magee, Toronto, Canada, Luke Lavallée, Ottawa, Canada, Frédéric Pouliot, Quebec City, Canada, Maria Komisarenko, Lisa Martin, Toronto, Canada, Jean-Baptiste Lattouf, Montreal, Canada, Shabbir Alihbai, Murray Krahn, Antonio Finelli, Toronto, Canada</td>
<td></td>
</tr>
<tr>
<td>MP14-05</td>
<td>EFFECT OF RENAL BIOPSIES ON THE MANAGEMENT OF RENAL MASSES IN A HIGH-VOLUME CENTER</td>
</tr>
<tr>
<td>Valeria Tringali*, Deliu Victor Matei, Giuseppe Renne, Paolo Della Vigna, Ottavio de Cobelli, Milano, Italy</td>
<td></td>
</tr>
<tr>
<td>MP14-06</td>
<td>PREVENTION OF BENIGN KIDNEY TUMOR RESECTION USING A COMBINATION OF ROUTINE BIOPSY AND TUMOR : CORTEX PEER EVALUATION.</td>
</tr>
<tr>
<td>Arun Menon*, Aly Ahmed, Tashionna White, Gaybrielle James, Paul May, Eric Kauffman, Buffalo, NY</td>
<td></td>
</tr>
<tr>
<td>MP14-07</td>
<td>RADIOMIC AND GENOMIC APPROACHES FOR THE ENHANCED DIAGNOSIS OF RENAL CANCER (REDIRECT): A TRANSLATIONAL PILOT STUDY</td>
</tr>
<tr>
<td>Francesco Cianflone*, Dejan Lazarevic, Anna Palmasano, Massimo Freschi, Maria Giulia Scitti, Alessandro Larcher, Marco Morelli, Fabio Muttin, Anna Maria Ferrara, Federico Deho', Antonio Esposito, Roberto Bertini, Alberto Briganti, Andrea Salonia, Claudio Doglioni, Francesco De Cobelli, Giovanni Tonon, Alessandro Del Maschio, Francesco Montorsi, Umberto Capitanio, Milan, Italy</td>
<td></td>
</tr>
<tr>
<td>MP14-08</td>
<td>INITIAL OUTCOMES FOR UNIVERSAL ACTIVE SURVEILLANCE OF SMALL RENAL MASSES USING PRE-DEFINED PROGRESSION CRITERIA FOR TREATMENT CONVERSION</td>
</tr>
<tr>
<td>Arun Menon*, Aly Ahmed, Tashionna White, Gaybrielle James, Paul May, Eric Kauffman, Buffalo, NY</td>
<td></td>
</tr>
<tr>
<td>MP14-09</td>
<td>SPONTANEOUS REGRESSION OF RENAL CELL CARCINOMA TUMORS ON ACTIVE SURVEILLANCE</td>
</tr>
<tr>
<td>Ahmed Aly Hussein Aly*, Shervin Badkhshan, Arun Menon, David Abramowitz, Michael Vacchio, Daniel Wang, Amanda Sherman, Kevin Carocci, Michael Petroziello, Charles Roche, Bo Xu, Eric Kauffman, Buffalo, NY</td>
<td></td>
</tr>
<tr>
<td>MP14-10</td>
<td>USE OF DELAYED INTERVENTION FOR SMALL RENAL MASSES INITIALLY MANAGED WITH ACTIVE SURVEILLANCE</td>
</tr>
<tr>
<td>Mohit Gupta*, Hiten Patel, Ridwan Alam, Alice Semerjian, Michael Gorin, Michael Johnson, Baltimore, MD, Peter Chang, Andrew Wagner, Boston, MA, James McKiernan, New York, NY, Mohammed Allah, Phillip Pierorazio, Baltimore, MD</td>
<td></td>
</tr>
<tr>
<td>MP14-11</td>
<td>COST IMPLICATIONS OF NEPHRON SPARING OPTIONS FOR THE MANAGEMENT OF SMALL RENAL MASSES</td>
</tr>
<tr>
<td>Jeffrey Leow*, Singapore, Singapore, Ye Wang, Melissa Huynh, Alice Yu, Boston, MA, Keng Siang Png, Singapore, Singapore, Steven Chang, Boston, MA</td>
<td></td>
</tr>
<tr>
<td>MP14-12</td>
<td>NEPHRECTOMY DELAY MORE THAN TEN WEEKS FROM DIAGNOSIS IS ASSOCIATED WITH DECREASED OVERALL SURVIVAL IN PT3 RCC</td>
</tr>
<tr>
<td>Jiping Zeng*, Ken Batai, Benjamin Lee, Tucson, AZ</td>
<td></td>
</tr>
</tbody>
</table>

*Presenting author
MP14-13  PRIORITIZATION OF RENAL CANCER QUALITY INDICATORS USING VARIANCE DECOMPOSITION AND MEDIATION ANALYSIS METHODS  
Keith Lawson*, Katherine Daignault, Madhur Nayan, Bo Chen, Lisa Martin, Maria Komisarenko, Olli Saarela, Antonio Finelli, Toronto, Canada

MP14-14  ESTIMATING WHEN RENAL CELL CARCINOMA SURVEILLANCE MAY BE DISCONTINUED: A COMPETING RISK MODEL  
Suzanne Merrill*, Eric Schaefer, Hershey, PA, Viraj Master, Dattatraya Patil, Atlanta, GA, Glenn Allen, E. Jason Abel, Madison, WI, Jay Raman, Hershey, PA

MP14-15  INTRA-FAMILIAL PHENOTYPIC HETEROGENEITY IN VON HIPPEL-LINDAU DISEASE: IMPLICATIONS FOR PERSONALIZED SURVEILLANCE PLAN  
Jiangyi Wang*, Shanghai, China, People's Republic of, Kan Gong, Beijing, China, People's Republic of

MP14-16  DYNAMIC EVALUATION OF THE MODIFIED GLASGOW PROGNOSTIC SCALE IN PATIENTS WITH LOW RISK CLEAR CELL RENAL CELL CARCINOMA  
Dattatraya Patil*, KC Bleibighauser Bens, Mehrdad Alemozaffar, Aaron Lay, Mehmet Bilen, John Pattaras, Christopher Filson, Kenneth Ogan, Viraj Master, Atlanta, GA

MP14-17  SURVIVAL AND CHARACTERISTICS OF PATIENTS WITH UNCLASSIFIED RENAL CELL CARCINOMA  
Naveen Krishnan*, Jay Sulek, Indianapolis, IN, Caleb Cooper, Chicago, IL, Isamu Tachiabana, Liang Cheng, Chandru Sundaram, Indianapolis, IN

MP14-18  AN ANATOMIC CLASSIFICATION SYSTEM FOR LOCAL RECURRENCE FOLLOWING RESECTION OF INTERMEDIATE AND HIGH RISK NON-METASTATIC RENAL CELL CARCINOMA: AN ANALYSIS OF THE ASSURE (ECOG-ACRIN 2805) TRIAL  

MP14-19  SURVIVAL DIFFERENCES IN PATIENTS WITH VON HIPPEL-LINDAU DISEASE BASED ON POSITIVE AND NEGATIVE FAMILY HISTORY  
Kaifang Ma*, Baonan Hong, Haibiao Xie, Kan Gong, Beijing, China, People's Republic of

MP14-20  IMPACT OF PATHOLOGIC NODE POSITIVE RENAL CELL CARCINOMA ON SURVIVAL IN PATIENTS WITHOUT METASTASIS: EVIDENCE IN SUPPORT OF EXPANDING THE DEFINITION OF STAGE IV KIDNEY CANCER  

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
MP15-05 PROSPECTIVE EVALUATION OF OPIOID UTILIZATION AFTER MINIMALLY INVASIVE PROSTATE AND RENAL SURGERY – AN ANALYSIS OF PATIENT FACTORS
Paige Nichols*, Matthew Gettman, Jason Joseph, Daniel Ubl, Rochester, MN, Mark Tyson, Raymond Pak, Scottsdale, AZ, Halena Gazelka, Bradley Leibovich, Elizabeth Habermann, Matthew Ziegelmann, Rochester, MN

MP15-06 THE EFFECT OF A TWO-WAY RADIO SYSTEM UPON CLINICAL COMMUNICATION
Jeremy Brown, Zahabiya Campwala, Akin Amasyali, Mohammad Hajitha, Muhammad Alyouf, Phillip Stokes, Ashley Li, Hyelin You, Milan Shah*, Samuel Abourbih, D. Duane Baldwin, Loma Linda, CA

MP15-07 ‘SIMPL’ MOBILE APPLICATION FOR ASSESSMENT OF UROLOGY TRAINEE SURGICAL COMPETENCE
Daniel Nethala*, David Mikhail, Shannon Smith, Zachary Kozel, Lee Richstone, Jessica Kreshover, Lake Success, NY

MP15-08 THE INTERVENTIONS TO REDUCE RESIDENT EXHAUSTION AND DEPERSONALIZATION (TIRRED) STUDY: A PILOT STUDY EXPLORING BURNOUT IN AN ACADEMIC UROLOGY PROGRAM
Samuel Washington*, Kathryn Quanstrom, Peter Carroll, Kirsten Greene, San Francisco, CA

MP15-09 “HIDDEN” COMPUTER DECISION SUPPORT SYSTEM ALTERS UROLOGIC SURGERY VTE RATE
Rikin Patel*, Hugh Fisher, Barry Kogan, Albany, NY

MP15-10 APPLICATION OF FAILURE MODE AND EFFECTS ANALYSIS (FMEA) TO IMPROVE THE PATIENT SAFETY IN ENDOUROLOGICAL SURGERY
Gema Romeu-Magraner*, Sara Villarroya-Castillo, Alberto Budia-Alba, Pilar Bahilo-Mateu, Marta Trassieria-Villa, José Daniel López-Acón, Domingo de Guzmán Ordez-Jurado, Francisco Boronat-Tormo, Valencia, Spain

MP15-11 PILOT TRIAL OF A NEAR-MISS RESIDENT CONFERENCE
Justin Ahn*, Bruce Dalkin, Hunter Wessells, Matthew Sorensen, Seattle, WA

MP15-12 IMPLEMENTATION OF ROOT CAUSE ANALYSIS FOR QUALITY IMPROVEMENT IN UROLOGY RESIDENCY
Andrew Harris, Vince DiCarlo*, Lexington, KY

MP15-13 UROLOGISTS’ KNOWLEDGE, ATTITUDES AND PRACTICE BEHAVIORS REGARDING SEXUAL MINORITY PATIENTS
Channa Amarasekera*, Jason Cohen, Vincent Wong, Kathryn Jackson, Christopher Morrison, Oliver Ko, David Victorson, Shilajit Kundra, Chicago, IL

MP15-14 EVIDENCE FOR GREATER MISCODING DUE TO OVERLY COMPLEX ICD-10 BLADDER CANCER CODES
Hannah Schaps, Brittany Adamic*, Alexander Cope, Craig Labbate, Sangtai Park, Chicago, IL

MP15-15 A PLATFORM FOR CLINICAL TRIAL SCREENING AND ENROLLMENT INTEGRATED INTO THE ELECTRONIC HEALTH RECORD
Anobel Odisho*, Robert Krumm, Imelda Tenggara, John Kim, Clarence So, Peter Carroll, Matthew Cooperberg, San Francisco, CA

MP15-16 A SURGICAL CLINIC’S JOURNEY TOWARD A CULTURE OF SAFETY
Janelle Fox*, Ines Stromberg, Todd Sterling, Erik Grossgold, Rustin Walters, Portsmouth, VA

MP15-17 REDUCING READMISSIONS FOLLOWING RADICAL CYSTECTOMY: MOVING BEYOND ENHANCED RECOVERY
Abhinav Khanna*, Anna Zampini, Alice Crane, Byron Lee, Georges-Pascal Haber, Cleveland, OH

MP15-18 ENHANCED RECOVERY AFTER SURGERY: INITIAL RESULTS

MP15-19 COMPLICATIONS AFTER TRANSPERINEAL PROSTATE BIOPSY AMONG MEN WITH EMPLOYER-BASED INSURANCE COVERAGE
KC Biebighauser Bens*, Dattatraya Patil, Lauren Kipling, Mark Henry, Christopher Filson, Atlanta, GA

MP15-20 EFFECTIVENESS OF NARCOTICS AFTER AMBULATORY ENDOSCOPIC PROCEDURES: PATIENT REPORTED OUTCOMES
Christian Tabib*, Kevin Cwach, Michael Schwartz, New Hyde Park, NY

*Presenting author

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP16-01</td>
<td>ROLE OF FGFR4 IN CLEAR CELL RENAL CARCINOMA AND ITS POTENTIAL AS A NEW THERAPEUTIC TARGET</td>
</tr>
<tr>
<td>Takafumi Narisawa*, Sei Naito, Hiromi Ito, Toshihiko Sakurai, Osamu Ichiyanagi, Tomoyuki Kato, Yamagata, J apan, Peter Makrov, Vladimir Kofenco, Philadelphia, PA, Norihiko Tsushiya, Yamagata, J apan</td>
<td></td>
</tr>
<tr>
<td>MP16-02</td>
<td>LSD1 INHIBITION SUPPRESSES THE GROWTH OF CLEAR CELL RENAL CELL CARCINOMA VIA UPREGULATING P21 SIGNALING</td>
</tr>
<tr>
<td>Jianfeng Wang*, Liangsong Zhu, Wen Kong, Jiwei Huang, Baijun Dong, Yiran Huang, Wei Xue, Jin Zhang, Shanghai, China, People's Republic of</td>
<td></td>
</tr>
<tr>
<td>MP16-03</td>
<td>DOWNREGULATION AND FREQUENT PROMOTER HYPERMETHYLATION OF CLDN7 CORRELATE WITH TUMOR PROGRESSION AND POOR PROGNOSIS IN HUMAN CLEAR CELL RENAL CELL CARCINOMA</td>
</tr>
<tr>
<td>Yanqing Gong*, Yifan Li, BEijing, China, People's Republic of, Xianghui Ning, HENAN, China, People's Republic of, Xuesong Li, Kan Gong, Liqun Zhou, BEijing, China, People's Republic of</td>
<td></td>
</tr>
<tr>
<td>MP16-04</td>
<td>TARGETING NEWLY IDENTIFIED ERβ/TFG-β1/SMAD3 SIGNALS WITH THE FDA-APPROVED ANTI-ESTROGEN FASLODEX OR AN ERβ SELECTIVE ANTAGONIST IN RENAL CELL CARCINOMA</td>
</tr>
<tr>
<td>Wenbin Song, Xi'an, China, People's Republic of, Huiyan Xu*, Karen M. Doersch, Fu-Ju Chou, Rochester, NY, Dalin He, Yule Chen, Xi'an, China, People's Republic of, lawen Hsu, Chuan-Ren Yeh, Rochester, NY, Luke Sien-Shih Chang, Lei Li, Xi'an, China, People's Republic of, Edward Messing, Chawnsang Chang, Shuyuan Yeh, Rochester, NY</td>
<td></td>
</tr>
<tr>
<td>MP16-05</td>
<td>LOWERING MRNA EXPRESSION OF PLEKHO1 INHIBITS TUMOR GROWTH OF RCC CELLS IN VITRO AND IN VIVO, POTENTIALLY THROUGH MODULATING THE HIPPO AND MAPK/JNK SIGNALLING PATHWAYS</td>
</tr>
<tr>
<td>yu zeng*, zi yu, shui fu, gejun zhang, Chengcheng Lv, Qingzhuo Dong, Chuiize Kong, Cheng Fu, Shenyang, China, People's Republic of</td>
<td></td>
</tr>
<tr>
<td>MP16-06</td>
<td>EXPLOITING NOVEL THERAPEUTIC TARGETS TO BLOCK METASTASIS OF CLEAR CELL RENAL CELL CARCINOMA (RCC)</td>
</tr>
<tr>
<td>Jan Rudzinski*, Natasha Govindasamy, Konstantin Stoletov, Adrian Fairey, John Lewis, Edmonton, Canada</td>
<td></td>
</tr>
<tr>
<td>MP16-07</td>
<td>MITOCOCHONDRIAL PROTEIN OF RELEVANT EVOLUTIONARY AND LYMPHOID INTEREST DOMAIN CONTAINING 2 (PRELID2), A NOVEL MOLECULE IN CARCINOGENESIS OF RENAL CELL CARCINOMA</td>
</tr>
<tr>
<td>Renpei Kato*, Moriola, J apan, Tomoya Fukawa, Tetsuro Yoshimaru, Yosuke Matsushiba, Tokushima, J apan, Masaya Ono, Tokyo, J apan, Kei Daizumoto, Tokushima, J apan, Yoichiro Kato, Moriola, J apan, Toyomasa Katagiri, Tokushima, J apan, Wataru Obata, Moriola, J apan</td>
<td></td>
</tr>
<tr>
<td>MP16-08</td>
<td>TRIB3 PROMOTES THE PROLIFERATION AND INVASION OF RENAL CELL CARCINOMA CELLS VIA ACTIVATING MAPK SIGNALING PATHWAY</td>
</tr>
<tr>
<td>Baoan Hong*, Kaifang Ma, Jingcheng Zhou, Haibiao Xue, Kenan Zhang, Lei Li, Kan Gong, Beijing, China, People's Republic of</td>
<td></td>
</tr>
<tr>
<td>MP16-09</td>
<td>SET AND MYND DOMAIN-CONTAINING PROTEIN 3 EXPRESSION CONFLICTS RENAL CELL CARCINOMA PROGRESSION VIA DIRECT TRANSCRIPTIONAL ACTIVATION OF EPIDERMAL GROWTH FACTOR RECEPTOR</td>
</tr>
<tr>
<td>Cheng Liu*, Min Qiu, Runzhuo Ma, Lulin Ma, Beijing, China, People's Republic of</td>
<td></td>
</tr>
<tr>
<td>MP16-10</td>
<td>EIF4E PHOSPHORYLATION INHIBITS METASTASIS IN CLEAR CELL RENAL CELL CARCINOMA</td>
</tr>
<tr>
<td>Sei Naito*, Osamu Ichiyanagi, Ito Hiromi, Michinobu Ozawa, Masaki Ushijima, Mayu Yagi, Takafumi Narisawa, Hidenori Kanno, Yuta Kurota, Tomoyuki Kato, Norihiko Tsushiya, Yamagata, J apan</td>
<td></td>
</tr>
<tr>
<td>MP16-11</td>
<td>HYPOXIA INDUCES RENAL CELL CARCINOMA PROLIFERATION BY HIPPO-DEPENDENT AND ALKBHS-MEDIATED M6A-DEMETHYLATION OF AURKB MRNA</td>
</tr>
<tr>
<td>Haiwei Yang*, Shuhui Si, Hao Yu, Jun Tao, Jie Han, Jingzi Wang, Xiao Yang, Qiang Lu, Zengjun Wang, Nanjing, China, People's Republic of</td>
<td></td>
</tr>
</tbody>
</table>
MP16-12 THE PRIMARY IRON UPTAKE RECEPTOR, TRANSFERRIN RECEPTOR 1, MEDIATES HIF-2A OVEREXPRESSION AND PROLIFERATION IN CLEAR CELL RENAL CELL CARCINOMA CELLS

Thomas Siff*, Christopher Greene, Nikita Sharma, Peter Fiorica, Arun Menon, Gary Smith, Kenneth Gross, Eric Kauffman, Buffalo, NY

MP16-13 SETD2-MEDIATED LOSS OF MIR-339 PROMOTES TUMOR PD-L1 EXPRESSION AND ATTENUATES ANTITUMOR IMMUNITY IN RENAL CELL CARCINOMA

Haoran Liu, Libin Yan, Kun Tang, Tao Ye, Xifeng Sun, Xiaqi Yang, Hua Xu, Peng Yuan*, Wuhan, China, People’s Republic of

MP16-14 ERβ-MEDIATED ALTERATION OF CIRCATP2B1 AND MIR-204-3P SIGNALING PROMOTES INVASION OF CLEAR CELL RENAL CELL CARCINOMA

Zhenwei Han, Shijiazhuang, China, People’s Republic of, Huiyong Xu*, Fu-Ju Chou, Yin Sun, Jaqi Chen, Rochester, NY, Yong Zhang, Xiaolu Wang, Shijiazhuang, China, People’s Republic of, Chawshang Chang, Edward M. Messing, Rochester, NY

MP16-15 COMPREHENSIVE ANALYSIS OF ONCOGENIC EVENTS IN TRANSLOCATION RENAL CELL CARCINOMA


MP16-16 IDENTIFYING CLEAR CELL RCC CLONALITY THROUGH ULTRA-DEEP SEQUENCING OF POOLED REGIONAL TUMOR DNA


MP16-17 NOVEL INSIGHTS IN CANCER STEM CELL BIOLOGY: WILMS’ TUMOR AND HUMAN FETAL NEPHRON PROGENITORS

Astgik Petrosyan*, Matthew Thornton, Brendan Grubbs, Roger De Filippo, Stefano Da Sacco, Laura Penn, Los Angeles, CA

MP16-18 MOLECULAR STRATIFICATION OF HIGH-GRADE UNCLASSIFIED RENAL CELL CARCINOMA TO IMPROVE PROGNOSTICATION AND MANAGEMENT


MP16-19 MECHANISMS UNDERLYING THE ASSOCIATION BETWEEN SARCOPENIA AND POOR ONCOLOGIC OUTCOMES IN CLEAR CELL RENAL CELL CARCINOMA


MP16-20 MULTI-PHOTON MICROSCOPY FOR CHARACTERIZATION OF RENAL CELL CARCINOMA PSEUDOCAPSULE: IMPLICATIONS FOR TUMOUR ENUCLEATION

Yi Quan Tan, Wy Keat Tay*, Li Yin Ooi, Zui Chih Rachel Teo, Ho Yee Tiong, Singapore, Singapore

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Friday, May 3, 2019

Podium Session 11

PROSTATE CANCER: MARKERS I

Room W181c @ McCormick Place

Moderators: Daniel Lin, Kirsten Greene & Mark Frydenberg

<table>
<thead>
<tr>
<th>ABSTRACT TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:00</td>
<td>PD11-01</td>
<td>AUTOMATED HISTOPATHOLOGIC DIAGNOSIS AND GLEASON GRADING OF PROSTATE BIOPSIES WITH MACHINE LEARNING</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Ohad Kott*, Drew Linsley, Ali Amin, Andreas Karagounis, Dragan Goljanin, Thomas Serre, Boris Gershman, Providence, RI</td>
</tr>
</tbody>
</table>
1:10 PD11-02 DEVELOPMENT AND APPLICATION OF A DIGITAL IMAGE ANALYSIS CLASSIFIER FOR DIAGNOSTIC PROSTATE NEEDLE BIOPSIES TO PREDICT METASTASES
Nathan Ing, Fangjin Huang, Eric Miller, Arash Amighi*, Michael Lewis, Isla Garryaway, Arkadiusz Gertych, Beatrice Knudsen, Los Angeles, CA

1:20 PD11-03 RESPONSE TO APALUTAMIDE (APA) AMONG PATIENTS (PTS) WITH NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC) FROM SPARTAN BY DECIpher GENOMIC CLASSIFIER (GC) SCORE

1:30 PD11-04 GENOMIC EXPRESSION AND PROGNOSTIC SIGNIFICANCE OF STROMAL MICROENVIRONMENT IN PRIMARY PROSTATE CANCER
Brandon Mahal*, Boston, MA, Mohamed Alshalalfa, San Francisco, CA, Shuanh Zhao, Ann Arbor, MI, William Chen, Elai Davicioni, Felix Feng, San Francisco, CA, Paul Nguyen, Boston, MA

1:40 PD11-05 EPIGENETIC FIELD ALTERATIONS IN NON-TUMOR PROSTATE TISSUES CAN DETECT PROSTATE CANCER IN URINE
Tariq A. Khemees*, Bing Yang, Adam Schultz, Glenn O. Allen, Joseph Gawdzik, Kyle A. Richards, Tracy M. Downs, E. Jason Abel, David F. Jarrard, Madison, WI

1:50 PD11-06 SPINK1 EXPRESSION IS ENRICHED IN AFRICAN AMERICAN PROSTATE CANCER BUT IS NOT ASSOCIATED WITH ALTERED IMMUNE INFILTRATION OR ONCOLOGIC OUTCOMES POST-PROSTATECTOMY
Farzana Faisal*, Harsimar Kaur, Baltimore, MD, Jeffrey Tosoian, Scott Tomlins, Ann Arbor, MI, Edward Schaeffer, Chicago, IL, Tamara Lotan, Baltimore, MD

2:00 PD11-07 PREDICTING CLINICALLY SIGNIFICANT PROSTATE CANCER: COMBINING 4KSCORE AND MRI
Marc A. Lubin*, Brooklyn, NY, Hari Haran Sudhan, Rachel Weil, Alp Tuna Beksaç, Ashuotsh Tewari, New York, NY

2:10 PD11-08 A 30-GENE HEREDITARY CANCER MUTATION ANALYSIS PREDICTS TIME TO BIOCHEMICAL RECURRENCE IN CLINICALLY LOCALIZED PROSTATE CANCER
Panagiotis Vlachostergios*, Ariel Schapp, Michael Sun, Dario Villamar, Aileen Lee, Bishoy Faltas, Ana Molina, David Nanus, Himisha Beltran, Scott Tagawa, New York, NY

2:20 PD11-09 DEVELOPMENT OF RACE SPECIFIC URINE BASED GENE EXPRESSION PANELS FOR PROSTATE CANCER

2:30 PD11-10 CIRCULATING TUMOR DNA TARGETED SEQUENCING PREDICTS THE PROGNOSIS OF MCRPC PATIENTS
Baijun Dong*, Liancheng Fan, Bin Yang, Shanghai, China, People’s Republic of, Kaijie Wu, Xi’an, China, People’s Republic of, Fengbo Zhang, Beijing, China, People’s Republic of, Wei Chen, Wenzhou, China, People’s Republic of, Huihua Cheng, Fuzhou, China, People’s Republic of, Jiahua Pan, Yinjie Zhu, Chong Luo, Yining Yang, Guodong Zhao, Chunlong Wang, Shanghai, China, People’s Republic of, Lei Li, Xi’an, China, People’s Republic of, Kudong Yao, Wei Xue, Shanghai, China, People’s Republic of

2:40 PD11-11 DECIpher BIOPSY GENOMIC TEST RELATED TO GLEASON GRADE GROUP INDEPENDENT OF PROSTATE IMAGING REPORTING AND DATA SYSTEM VERSION 2
Darryl Martin, Kamary Ghobil*, Angelique Levi, Peter Humphrey, Peter Schumal, Preston Sprekle, New Haven, CT

2:50 PD11-12 DEVELOPMENT AND VALIDATION OF A NOVEL EPS-METABOLOMIC SIGNATURE FOR THE DIAGNOSIS OF CLINICALLY SIGNIFICANT PROSTATE CANCER
Annapaola Andolfo, Denise Drago, Vito Cucchiara*, Luigi Nocera, Milan, Italy, Ettore Mosca, Alessandro Orro, Segrate, 20090, Italy, Matteo Bellone, Francesco Montorsii, Alberto Briganti, Milan, Italy

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
<table>
<thead>
<tr>
<th>Time</th>
<th>Number</th>
<th>Title</th>
<th>Authors</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:00</td>
<td>PD12-01</td>
<td>ASSOCIATION OF OBESITY WITH INCREASED ENDOGENOUS OXALATE SYNTHESIS</td>
<td>Carter Boyd*, John Knight, Ross Holmes, Dean Assimos, Kyle Wood, BIRMINGHAM, AL</td>
<td></td>
</tr>
<tr>
<td>1:20</td>
<td>PD12-03</td>
<td>NEW-ONSET METABOLIC RISK FACTORS AND THE INCIDENCE OF KIDNEY STONES: A PROSPECTIVE COHORT STUDY</td>
<td>Hao Ping*, Beijing, China, People’s Republic of, Na Lu, Qingdao, China, People’s Republic of, Mingshuai Wang, Jiapeng Lu, Lixin Jiang, Beijing, China, People’s Republic of</td>
<td></td>
</tr>
<tr>
<td>1:30</td>
<td>PD12-04</td>
<td>CHRONIC HYPERGLYCAEMIA INCREASES THE RISK OF KIDNEY STONE DISEASE, RESULTS FROM A SYSTEMATIC REVIEW AND META-ANALYSIS</td>
<td>Robert Geraghty, Sarah Pratley*, Abdihakim Maalim, Bhaskar Somani, Paul Cook, Paul Roderick, Southampton, United Kingdom</td>
<td></td>
</tr>
<tr>
<td>1:40</td>
<td>PD12-05</td>
<td>ANIMAL AND NON-ANIMAL PROTEIN INTAKES AND RISK OF INCIDENT KIDNEY STONES: A REPORT FROM THE SHANGHAI MEN’S AND WOMEN’S HEALTH STUDIES</td>
<td>Joshua Calvert*, Xiang Shu, Hui Cai, Nashville, TN, Yong-Bing Xiang, Honglan Li, Shanghai, China, People’s Republic of, Nicole Miller, Wei Zhong, Xiao-Ou Shu, Ryan Hai, Nashville, TN</td>
<td></td>
</tr>
<tr>
<td>1:50</td>
<td>PD12-06</td>
<td>EXTERNAL VALIDATION OF CHOKAI SCORE AND COMPARISON WITH STONE SCORE FOR THE PREDICTION OF URETERAL STONES IN JAPAN: A MULTICENTER PROSPECTIVE OBSERVATIONAL STUDY</td>
<td>Hiroki Fukuhara*, Yamagata, J apan, Satoshi Takai, Sakata, J apan, Masato Kikuta, Kawanisi, J apan, Atsushi Yamagishi, Shinta Suenaga, Toshihiko Sakurai, Sei Naito, Hayato Nishida, Takuya Yamamoto, Tomoyuki Kato, Norihiko Tsuchiya, Yamagata, J apan</td>
<td></td>
</tr>
<tr>
<td>2:00</td>
<td>PD12-07</td>
<td>A SINGLE CENTRE EXPERIENCE OF URETERORENOSCOPY UNDER LOCAL ANAESTHETIC: A SAFER OPTION FOR ANAESTHETICALLY HIGH RISK PATIENTS?</td>
<td>Ali Tasleem*, Southend, United Kingdom, Sachin Yallappa, Glasgow, United Kingdom, Michael Mikhail, Southend, United Kingdom, Tarik Amer, Glasgow, United Kingdom, Peter Acher, Peter Pietrzak, Antony Young, Southend, United Kingdom</td>
<td></td>
</tr>
<tr>
<td>2:10</td>
<td>PD12-08</td>
<td>STENT DURATION AND INCREASED PAIN IN THE HOURS AFTER URETERAL STENT REMOVAL</td>
<td>Michael Rezaee*,Annah Vollstedt, Vernon Pais, Lebanon, NH</td>
<td></td>
</tr>
<tr>
<td>2:20</td>
<td>PD12-09</td>
<td>TAMSPULOSIN, SOLIFENACIN, AND THEIR COMBINATION FOR THE TREATMENT OF STENT-RELATED SYMPTOMS: A RANDOMIZED CONTROLLED STUDY.</td>
<td>peng zhou*, JINGYU ZHU, RUIPENG LI, HANGZHOU, China, People’s Republic of</td>
<td></td>
</tr>
<tr>
<td>2:30</td>
<td>PD12-10</td>
<td>SINGLE 24-HR URINE COLLECTION LEADS TO UNDER-DETECTION OF METABOLIC ABNORMALITIES WHEN COMPARED TO CONSECUTIVE COLLECTIONS IN PEDIATRIC STONE FORMERS</td>
<td>Michael Lam*, Casey Seideman, Solange Bassalle, Aaron Bayne, Portland, OR</td>
<td></td>
</tr>
<tr>
<td>2:40</td>
<td>PD12-11</td>
<td>24-HOUR URINE CALCIUM OXALATE SUPERSATURATION RISK CORRELATES WITH CT VOLUMETRIC CALCIUM OXALATE STONE GROWTH</td>
<td>Stanislav Yuzhakov*, Shavano Steadman, Brandon Otto, Vincent Bird, Benjamin Canales, Gainesville, FL</td>
<td></td>
</tr>
<tr>
<td>2:50</td>
<td>PD12-12</td>
<td>NEED FOR RECURRENT STONE SURGERY IS HIGHER IN PATIENTS WITH GASTROINTESTINAL DISEASE</td>
<td>Ravin J. Bastiampillai*, Shuang Li, Kristina L. Penniston, Sara L. Best, Stephen Y. Nakada, Madison, WI</td>
<td></td>
</tr>
</tbody>
</table>

*Presenting author
<table>
<thead>
<tr>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:00</td>
<td>PD13-01</td>
<td>COMPARATIVE EFFECTIVENESS OF INTRAVESICAL BCG-TICE AND BCG-MOREAU IN PATIENTS WITH NON-MUSCLE INVASIVE BLADDER CANCER</td>
</tr>
<tr>
<td></td>
<td></td>
<td>David D'Andrea, Francesco Soria, Vienna, Austria, Paolo Gontero, Turin, Italy, André T. Machado, Ricardo Waksman, SãO Paulo, Brazil, Shahrokh F. Shariat, Vienna, Austria, Daher C. Chade*, SãO Paulo, Brazil</td>
</tr>
<tr>
<td>1:10</td>
<td>PD13-02</td>
<td>PROGNOSTIC ROLE OF NEUTROPHIL-TO-LYMPHOCYTE RATIO IN PATIENT WITH NON-MUSCLE INVASIVE BLADDER CANCER WHO UNDERWENT INTRAVESICAL BCG TREATMENT</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Kyeong-Hyeon Byeon, Heon Ha*, Jae-Wook Chung, Yun-Sok Ha, Seoock Hwan Choi, Jun Nyung Lee, Bum Soo Kim, Hyun Tae Kim, Tae-Hwan Kim, Eun Sang Yoo, Tae Gyun Kwon, Sung Kwang Chung, Daugu, Korea, Republic of</td>
</tr>
<tr>
<td>1:20</td>
<td>PD13-03</td>
<td>THE IMPACT OF PREOPERATIVE CHRONIC KIDNEY DISEASE ON ONCOLOGICAL OUTCOMES AFTER TRANS-URETHRAL RESECTION OF BLADDER TUMOR IN PATIENTS WITH PRIMARY NON-MUSCLE-INVASIVE BLADDER CANCER</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Naoki Fujita*, Masaki Momota, Yuki Tobisawa, Tohru Yoneyama, Hayato Yamamoto, Atsushi Imai, Shingo Hatakeyama, Hiroaki, Japan, Hiroyuki Ito, Hachinohe, Japan, Takahiro Yoneyama, Yasuhiro Hashimoto, Chikara Ohyama, Hiroaki, Japan</td>
</tr>
<tr>
<td>1:30</td>
<td>PD13-04</td>
<td>REDUCED RECURRENTNESS OF LOW-GRADE PAPILLARY BLADDER TUMORS ASSOCIATED WITH ASYMMPTOMATIC BACTERIURIAS</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Harry Herr*, New York, NY</td>
</tr>
<tr>
<td>1:40</td>
<td>PD13-05</td>
<td>ANDROGEN SUPPRESSION THERAPY IS ASSOCIATED WITH LOWER RECURRENTNESS OF NON-MUSCLE INVASIVE BLADDER CANCER</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Shuo-chieh Wu*, Felix V. Chen, Deukwoo Kwon, Maria C. Velasquez, Sanjoy Punnen, Dipen J. Parekh, Chad R. Ritch, Mark L. Gonzalgo, Miami, FL</td>
</tr>
<tr>
<td>1:50</td>
<td>PD13-06</td>
<td>PHAGE DISPLAY-DERIVED PEPTIDE-BASED NEAR-INFRARED IMAGING PROBE FOR INTRAOPERATIVE BLADDER CANCER DETECTION POST-INSTALLATION IN HUMANS</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Li Peng*, Harbin, China, People’s Republic of, Wenting Shang, Jie Tian, Beijing, China, People’s Republic of, Wanhai Xu, Harbin, China, People’s Republic of</td>
</tr>
<tr>
<td>2:00</td>
<td>PD13-07</td>
<td>COMBINATION OF THREE URINARY EXTRACELLULAR VESICLE MRNA BIOMARKERS PREDICTS HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Takahiro Osawa*, Hiroshi Harada, Keita Minami, Nobuo Shinhara, Sapporo, Japan, Taku Murakami, Cindy M. Yamamoto, Irvine, CA, Hiroshi Tanaka, Toshimori Seki, Sapporo, Japan</td>
</tr>
<tr>
<td>2:10</td>
<td>PD13-08</td>
<td>STRATIFICATION OF INTERMEDIATE-RISK NON-MUSCLE INVASIVE BLADDER CANCER PATIENTS: IMPLICATIONS FOR ADJUVANT THERAPIES.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Francesco Soria*, Turin, Italy, David D’Andrea, Kilian Gust, Vienna, Austria, Paolo Gontero, Turin, Italy, Shahrokh Shariat, Vienna, Austria</td>
</tr>
<tr>
<td>2:20</td>
<td>PD13-09</td>
<td>DIABETES SEVERITY AND METFORMIN ARE ASSOCIATED WITH INTRAVESICAL BACILLUS CALMETTE-GUERIN OUTCOMES IN NON MUSCLE INVASIVE BLADDER CANCER</td>
</tr>
<tr>
<td>2:30</td>
<td>PD13-10</td>
<td>ONCOLOGICAL OUTCOMES OF BCG UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER PATIENTS TREATED WITH POSTOPERATIVE CHEMOHYPERTHERMIA: A MULTICENTRE EUROPEAN RETROSPECTIVE ANALYSIS.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Wei Shen Tan*, London, United Kingdom, Kees Hendrickxen, Amsterdam, Netherlands, Dan Wilby, Portsmouth, United Kingdom, Cajetan Nzhe, Gladbeck, Germany, Javier Goizueta, Madrid, Spain, Wolfgang Vilmar, Nuremberg, Germany, Aria Bello, Tenerife, Spain, Alejandro Sousa, Lugo, Spain, J Moreno, Madrid, Spain, Jose Pontones, Valencia, Spain, Felix Guerrero, Madrid, Spain, Iliya Kalchev, Sofia, Bulgaria, Eric Frank, Aachen, Germany, Joost Boormans, Rotterdam, Netherlands</td>
</tr>
</tbody>
</table>
2:40 PD13-11 UP-DATE OF PATHOLOGICAL OUTCOME AND SUBJECTIVE DEFINITION OF FAILURE FOR PATIENTS UNDER ACTIVE SURVEILLANCE FOR RECURRENT LOW-RISK NON-MUSCLE INVASIVE BLADDER CANCER: RESULT FROM BLADDER CANCER ITALIAN ACTIVE SURVEILLANCE (BIAS) PROJECT
Rodolfo Hurle, Paolo Casale, Alberto Saita, Nicolò Maria Buffi, Luigi Domanico, Silvia Zandegiacomo, Massimo Lazzeri*, Giorgio Guazzoni, Rozzano, Italy

2:50 PD13-12 TOF-MS BASED URINE DNA METHYLATION CLASSIFIER: A FAST AND EFFECTIVE TECHNIQUE FOR NON-INVASIVE DIAGNOSIS AND MONITORING OF BLADDER CANCER
Xu Chen*, Jian-bing Fan, Guangzhou, China, People’s Republic of, Darryl Luke Irwin, San Diego, CA, Ming Huang, Chunjuan Wang, Zeyu Jiang, Jingtong Zhang, Meng Yang, Xia Li, Guangzhou, China, People’s Republic of, Yu Zhou, San Diego, CA, Tianxin Lin, Guangzhou, China, People’s Republic of

Friday, May 3, 2019
Podium Session 14
BLADDER & URETHRA: ANATOMY, PHYSIOLOGY & PHARMACOLOGY II
Room W179b @ McCormick Place
Moderators: Nissrine Nakib, Michael Ruggieri & Dale Bjorling

1:00 PD14-01 ONCE-DAILY VIBEGRON, A NOVEL ORAL β3 AGONIST DOES NOT INHIBIT CYP2D6, A COMMON PATHWAY FOR DRUG METABOLISM IN PATIENTS ON OAB MEDICATIONS
Matthew P. Rutman*, New York, NY, Jennifer R. King, Nate Bennett, Durham, NC, Wendy Ankrom, Kenilworth, NJ, Paul N. Mudd, Durham, NC

1:10 PD14-02 IN VIVO SELECTIVITY OF DA-8010 FOR THE BLADDER OVER THE BRAIN: EFFECTS ON BLADDER INTRAVESICAL PRESSURE, BRAIN MUSCARINIC RECEPTOR OCCUPANCY, AND COGNITIVE FUNCTION IN MICE
Min Jung Lee*, Jun-Hwan Moon, Hyung Keun Lee, Yongin, Korea, Republic of, Yoo Mi Shin, Hyun Soo Park, Young Nang Kim, Gi Seon Park, Byung Seok Moon, Byung Chul Lee, Sang Eun Lee, Seoul, Korea, Republic of

1:20 PD14-03 ACTIVATION OF BRAIN NICOTINIC ACETYLCHOLINE RECEPTORS CAN SUPPRESS MICTURITION REFLEX IN RATS
Takahiro Shimizu*, Yohei Shimizu, Hideaki Ono, Suo Zou, Masaki Yamamoto, Shogo Shimizu, Youichirou Higashi, Takaaki Aratake, Tomoya Hamada, Yoshiki Nagao, Yusuke Ueba, Nankoku, Japan, Masashi Honda, Yonago, Japan, Motoaki Saito, Nankoku, Japan

1:30 PD14-04 BARRINGTON’S REFLEXES REVISITED: PROXIMAL URETHRAL ELECTROSTIMULATION CAUSES REMARKABLE EXCITATORY BLADDER RESPONSE IN SPINAL CORD INTACT RATS
Bradley Potts*, Matthew Fraser, Durham, NC

1:40 PD14-05 LOW AND HIGH THRESHOLD MECHANOSENSITIVE BLADDER AFFERENT PATHWAYS CONVERGE TO A SIMILAR DISTRIBUTION OF LUMBOSACRAL SPINAL NEURONS

1:50 PD14-06 STRESS-INDUCED REEMERGENCE OF EXTINGUISHED BLADDER PAIN
Vijay Samineni*, Sienna Sewell, Julian Sakey, St Louis, MO, Robert Gereau IV, St. Louis, MO

2:00 PD14-07 TARGETING ANTIOXIDANTS TO MITOCHONDRIA: A NEW THERAPY TO RESTORE MITOCHONDRIAL DAMAGE IN UT AFTER ACUTE SPINAL CORD INJURY
Amanda Wolf-Johnston*, Steven Truschel, Bronagh McDonnell, Aura Kullmann, Anthony Kanai, Gerard Apodaca, Lori Birder, Pittsburgh, PA

2:10 PD14-08 AGING-ASSOCIATED UROTHELIAL MITOCHONDRIAL DYSREGULATION CAN LEAD TO SENSORY AND BLADDER DYSFUNCTION

2:20 PD14-09 MiCR0RNA-29A INHIBITS SIGNALING FOR BLADDER FIBROSIS INDUCED BY BLADDER OUTLET OBSTRUCTION
Dale Bjorling*, Zun-Yi Wang, Madison, WI, Yongfeng Gong, Jinhui Hou, St. Louis, MO

*Presenting author
2:30 PD14-10 LOW-INTENSITY EXTRACORPOREAL SHOCK WAVE THERAPY AMELIORATES DIABETIC UNDERACTIVE BLADDER
Hsun Wang, Kaohsiung, Taiwan, Byung Oh, Bohan Wang, Yujun Ruan, Jun Zhou, Lia Banie, Arianna Tamaddon, Tie Zhou, Guifang Wang, Kelly Walker*, Guiling Lin, Tom Lue, San Francisco, CA

2:40 PD14-11 NOX-DERIVED SUPEROXIDE PRODUCTION IN BLADDER UROTHELIUM – EFFECT OF NOX SUBTYPE DELETION AND THE INFLAMMATORY FACTORS
Maxwell W. Roberts, Josephine Amosah, Guildford, United Kingdom, Guiping Sui, London, United Kingdom, Rui Wu, Coventry, United Kingdom, Simon Archer, Guildford, United Kingdom, Michael Ruggieri, Philadelphia, PA, Changhao Wu*, Guildford, United Kingdom

2:50 PD14-12 NICOTINIC RECEPTORS ON NERVE TERMINALS INDUCE ACETYLCHOLINE BUT NOT ATP RELEASE IN CANINE BLADDER
Alan Braverman*, Nagat Frara, Danielle Salvedeo, Mary Barbe, Michael Ruggieri, Sr., Philadelphia, PA

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
### 1:40 PD15-05
**WHAT IS THE RISK OF LATE RECURRENT AND MORTALITY AFTER SALVAGE RADIATION THERAPY FOR POST-PROSTATECTOMY PSA RISING? A LONG-TERM, MULTI-INSTITUTIONAL ANALYSIS**

Nicola Fossati*, Milan, Italy, R. Jeffrey Karnes, Stephen A. Boorjian, Luca Boeri, Rochester, MN, Alberto Bossi, Villejuif, France, Nadia Di Muzio, Cesare Cozzarini, Barbara Neri Chiorda, Elio Mazzone, Simone Scuderi, Giorgio Gandaglia, Milan, Italy, Detlef Bartkowiak, Ulm, Germany, Dirk Böhmer, Berlin, Germany, Shahroksh Shariat, Gregor Goldner, Vienna, Austria, Antonino Battaglia, Steven Joniau, Gaetan Devos, Karin Haustermans, Gert De Meerleer, Leuven, Belgium, Valérie Fonteyne, Piet Ost, Ghent, Belgium, Hein Van Poppel, Leuven, Belgium, Francesco Montorsi, Milan, Italy, Thomas Wiegel, Ulm, Germany, Alberto Briganti, Milan, Italy

### 1:50 PD15-06
**RATES AND PATTERNS OF METASTASES IN PATIENTS WITH NODE-NEGATIVE PROSTATE CANCER THAT EXPERIENCE PSA FAILUR: POST-HOC ANALYSIS OF RTOG 9601 TRIAL DATA**

Akshay Sood*, Jacob Keeley, Sohrab Arora, Deepansh Dalela, Wooju Jeong, Craig G Rogers, James Peabody, Mani Menon, Firas Abdollah, Detroit, MI

### 2:00 PD15-07
**IMPACT OF BONE-TARGETED THERAPIES IN PATIENTS WITH CHEMOTHERAPY-NAIVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER ON ENZALUTAMIDE: A POST HOC ANALYSIS OF PREVAIL**

Fred Saad*, Montreal, QC, Neal D. Shore, Myrtle Beach, SC, Karim Fizazi, Villejuif, France, Joyce Steinberg, Janet Kim, Northbrook, IL, Ping Lin, Katharina Modelska, San Francisco, CA, Tomasz M. Beer, Portland, OR

### 2:10 PD15-08
**SITE OF CARE AND ITS IMPACT ON RECEIPT OF PALLIATIVE CARE FOR BLACK MEN WITH METASTATIC PROSTATE CANCER?**

Alexander Putnam Cole*, Akezhan Meirkhanov, Sean Anthony Fletcher, Zara Cooper, Stuart R. Lipsitz, Joel S. Weissmann, Kerry L. Kilbridge, Adam S. Kibel, Quoc-Dien Trinh, Boston, MA

### 2:20 PD15-09
**TROMBONE: TESTING RADICAL PROSTATECTOMY IN MEN WITH OLIGOMETASTATIC PROSTATE CANCER THAT HAS SPREAD TO THE BONE- A RANDOMIZED CONTROLLED FEASIBILITY TRIAL**

Prasanna Sooriakumaran*, Prabhakar Rajan, Omar Al Kadhi, John Kelly, London, United Kingdom, Jonathan Aning, Naeem Soomro, Newcastle, United Kingdom, Richard Bryant, Alastair Lamb, Oxford, United Kingdom, Paul Cathcart, Oussama Elhage, London, United Kingdom, Christopher Eden, Guildford, United Kingdom, Imran Ahmad, Hing Leung, Glasgow, United Kingdom, Senthil Nathan, London, United Kingdom, Freddie Hamdy, Oxford, United Kingdom

### 2:30 PD15-10
**WHICH PATIENT WITH BIOCHEMICAL RECURRENCE AFTER PRIMARY TREATMENT FOR PROSTATE CANCER WOULD RESULT IN A POSITIVE 68GA-PSMA PET/CT? A CLINICAL TOOL TO GUIDE PHYSICIANS BEFORE SUGGESTING 68GA-PSMA PET/CT**

Lorenzo Bianchi*, Francesco Ceci, Marco Borghesi, Giulia Polverari, Federico Mineo Bianchi, Umberto Barbaresi, Francesco Chessa, Paolo Castellucci, Riccardo Schiavina, Stefano Fanti, Eugenio Brunocilla, Bologna, Italy

### 2:40 PD15-11
**SURVIVAL RATES AND ECONOMIC OUTCOMES IN CHEMOTHERAPY-NAIVE METASTATIC CASTRATE RESISTANT PROSTATE CANCER PATIENTS TREATED WITH ABIRATERONE ACETATE OR ENZALUTAMIDE**

Krishnan Ramaswamy, New York, NY, Stanislav Lechpammer, San Francisco, CA, Jack Mardekian, New York, NY, Neil M. Schultz, Northbrook, IL, Ahong Huang, Li Wang, Plano, TX, Onur Baser, Ann Arbor, MI, Daniel George*, Durham, NC

### 2:50 PD15-12
**HEALTH CARE SPENDING IN HIGH RESOURCE PROSTATE CANCER PATIENTS: WHAT CONTRIBUTES MOST TO HIGH PROSTATE CANCER HEALTH CARE COSTS?**

Maxine Sun*, Maya Marchese, David Fallon Friedlander, Alexander Putnam Cole, Sean Anthony Fletcher, Toni K. Choueiri, Adam S. Kibel, Quoc-Dien Trinh, Boston, MA

**APPROVED FOR AMA PRA CATEGORY 1 CREDIT™**

---

**FRIDAY**

**Forums**

**HISTORY OF UROLOGY FORUM**

181ab @ McCormick West

<table>
<thead>
<tr>
<th>ABSTRACT TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:00</td>
<td></td>
<td>POSTER VIEWING</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ABSTRACT TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>FR02-01</td>
<td></td>
<td>WILLET F. WHITMORE JR: FOUR QUESTIONS AND THE NATURAL HISTORY OF PROSTATE CANCER</td>
</tr>
</tbody>
</table>

Erin Salter*, Hugh Fisher, Albany, NY

*Presenting author
FR02-02 AGENT ORANGE-THE VIETNAM WAR'S CONTINUED HEALTH CARE COST
Michael Benson*, Chrystral Chang, John Sheng, Nitin Patel, Vladislav Bargman, Robert Weiss, Newark, NJ

FR02-03 MARCO CAINE – THE PRINCE ON A WHITE HORSE. AN INNOVATOR, MENTOR, LEGEND
Ran Linn*, Yehezkel Caine, Tirat Carmel, Israel

FR02-04 UROLOGIC HEALTH THROUGHOUT THE HISTORY OF THE WHITE HOUSE
Kamyar Ghabili Amirkhiz*, Matthew Goland-Van Ryn, Piruz Motamedinia, Michael Leapman, Preston Sprenkle, Robert Weiss, New Haven, CT

FR02-05 STONES, SPACE, AND DR. ABRAHAM T.K. COCKETT: A HISTORY OF UROLITHIASIS AND AEROSPACE MEDICINE
Michael Witthaus*, Erdal Erturk, Ronald Rabinowitz, Rochester, NY

FR02-06 TALE OF TWO JOURNALS: ANALYSIS OF HISTORY ARTICLES PUBLISHED FROM 1973 TO 2017
Sutchin R Patel*, Lake Forest, IL

FR02-07 WOMEN WHO CIRCUMCISE: CHANGING AN AGE OLD TRADITION
Alexandra Tabakin*, Robert Steckler, New Brunswick, NJ

FR02-08 THE ‘DIVINE MADMAN' AND HIS ‘THUNDERBOLD OF FLAMING WISDOM': THE ORIGINS AND VERY MODERN ROLE OF THE PHALLUS IN BHUTAN
Andrew Edsall*, Steven Brandes, Genoa Ferguson, Springfield, OR

FR02-09 GEORGE FRANK LYDSTON: CONTROVERSIES IN VENEREAL DISEASES, TESTICULAR TRANSPLANTATION, AND THE AMERICAN EUGENICS MOVEMENT
Fei Lian*, Mark White, Albany, NY

FR02-10 FROM DRINKING A PULVERIZED TESTICLE TO SNORTING A POSTERIOR PITUITARY: A HISTORY OF TREATMENTS FOR NOCTURNAL ENURESIS
Zeynep Gul*, Jeffrey Stock, New York, NY

FR02-11 SELWYN B. LEVITT; THE FIRST FULL TIME PEDIATRIC UROLOGIST IN NEW YORK
Preeya K. Mistry*, Jennifer Reifsnyder, Lane Palmer, New Hyde Park, NY

FR02-12 LAB TO LITHOTOMY – A HISTORY OF IRREVERSIBLE ELECTROPORATION FROM LABORATORY TECHNIQUE TO PROSTATE CANCER TREATMENT
Alexandar Blazevski*, Matthijs Scheltema, Brian Yuen, Thomas Cusick, Anne-Maree Haynes, Phillip Stricker, Darlinghurst, Australia

1:30 HISTORY DEBATE: CORPSES ON EXHIBIT – EDUCATION OR EXPLOITATION?
Debaters: Peter Angelos, Eric Singer
Judges: Alice Dreger, Damara Kaplan, Karim Hamawy

1:50 SPAWN OF THE DEAD: A HISTORY OF POSTMORTEM SPERM RETRIVAL
Michael Ernst*, Sean McGinley, Shervin Badkhshan, Buffalo, NY

1:57 BOSTON UNIVERSITY UROLOGY: A HISTORY OF SEXUAL MEDICINE
Wesley Pate*, Egor Parkhomenko, Linda Ng, Richard Babayan, Ricardo Munarriz, Boston, MA

2:04 THE TRANSFORMATION OF GENDER CONFIRMING SURGERY: A BRIEF HISTORY
Shannon Smith*, Justin Han, New Hyde Park, NY

2:11 DISCIPLINE AND DISPLAY: MEDICAL MUSEUMS AND SEXUAL HEALTH
Barbara Chubak*, New York, NY

2:18 “FOR MEN ONLY”: HEALTH AND SEX EDUCATION AT THE DIME MUSEUM AND THE WAXWORKS
Friedric Moll*, Thorsten Halling, Matthis Krischel, Heiner Fangerau, Düsseldorf, Germany

2:25 SAMUEL QUICCHEBERG, M.D. AND MUSEOLOGY
Michael Moran*, Whiteville, NC

2:32 THE HIDDEN MUSEUM OF UNLIKE SCIENTIST: LEEUWENHOEK COLLECTION AND PROGRESS OF MEDICINE
William Berg*, David Schulsinger, Yefim Sheynkin, Stony Brook, NY

2:39 GIOACHINO ROSSINI: COMPOSER AND CHRONIC UROLOGICAL PATIENT
Philip Van Kerrebroeck*, Maastricht, Netherlands

2:46 CHOP-ERA: THE OPERATIC HISTORY AND MODERN RELEVANCE OF THE “CASTRATO”
Alex Hennessey*, Brooke Harnisch, Farmington, CT

2:53 BLOOD GUSHING AND MUSICAL SCREAMING IN MARIN MARAIS’ CYSTOLITHOTOMY
Jubin Matloubieh*, Ronald Rabinowitz, Rochester, NY

3:00 2018 AUA EARL NATION RETROSPECTROSCOPE AWARD TO LAWRENCE WYNER, MD FOR HIS PAPER AND PRESENTATION: LESSONS LEARNED FROM A HURRICANE
HONORABLE MENTION TO MICHAEL L. ERNST, MD FOR HIS PAPER: KING OF THE QUEEN CITY: THE UROLOGIST WHO SAVED BUFFALO

3:10 BICKNELL LECTURE: COLLECTING NAPOLEON’S PENISES
Keynote Speaker: Alice Dreger
<table>
<thead>
<tr>
<th>Time</th>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:54</td>
<td>FR01-13</td>
<td>LIQUID GOLD: THE VALUE OF URINE IN THE TEXTILE INDUSTRY</td>
<td>Simone Vernez*, Sara L. Best, Madison, WI</td>
</tr>
<tr>
<td>4:01</td>
<td>FR01-14</td>
<td>UROLOGIC DISEASES IN THE PAST: THE EXAMPLE OF PORTUGUESE ROYALTY</td>
<td>Mário Pereira Lourenço*, Duarte Vieira-Brito, Ricardo Godinho, Pedro Peralta, Amilcar Sismeiro, Coimbra, Portugal</td>
</tr>
<tr>
<td>4:08</td>
<td>FR01-15</td>
<td>UROLOGICAL DISEASE AS A BASIS FOR MIRACLES IN THE CANONIZATION PROCESS OF THE ROMAN CATHOLIC CHURCH</td>
<td>Najı Touma*, Jacalyn Duffin, Kingston, ON</td>
</tr>
<tr>
<td>4:15</td>
<td>FR01-16</td>
<td>THE IMPACT OF VARICOCELES ON THE AMERICAN CIVIL WAR</td>
<td>Samuel Donnenfeld*, Marc Rogers, Salt Lake City, UT</td>
</tr>
<tr>
<td>4:22</td>
<td>FR01-17</td>
<td>DOMINIQUE-JEAN LARREY: THE FATHER OF MODERN MILITARY SURGERY</td>
<td>Varun Talanki*, Colin Ryan, Howard Adler, Stony Brook, NY</td>
</tr>
<tr>
<td>4:29</td>
<td>FR01-18</td>
<td>BEYOND PROSTATE CANCER: THE SEMINAL CONTRIBUTIONS OF HUGH HAMPTON YOUNG TO THE MANAGEMENT OF UROLOGIC TRAUMA</td>
<td>Kevin Loughlin*, Boston, MA</td>
</tr>
<tr>
<td>4:36</td>
<td>FR01-19</td>
<td>THE URETER KING OF CHICAGO: WELLER VANHOOK'S CONTRIBUTIONS TO RECONSTRUCTIVE SURGERY</td>
<td>Granville Lloyd*, Denver, CO</td>
</tr>
<tr>
<td>4:43</td>
<td>FR01-20</td>
<td>THE FREEDMEN'S HOSPITAL AND THE TRAINING OF THE AFRICAN-AMERICAN UROLOGIST</td>
<td>Unwanaobong Nseyo*, Brittney Cotta, Jill Buckley, San Diego, CA</td>
</tr>
</tbody>
</table>

### ABSTRACTS FOR MODERATED POSTER SESSION 17

**STONE DISEASE: SURGICAL THERAPY II**

Room W178ab @ McCormick Place  
Moderator: David Duchene, Andreas Skolarikos & Ravindra Sabnis

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP17-01</td>
<td>DOES URETERAL ACCESS SHEATH CAUSE URETERAL STRICTURE IN RETROGRADE INTRARENAL SURGERY?</td>
<td>Melih Balci*, Altug Tuncel, Ahmet Asfuroglu, Can Aykanat, Ozer Guzel, Yilmaz Asian, Ankara, Turkey</td>
</tr>
<tr>
<td>MP17-02</td>
<td>URETERAL STRICTURE FORMATION AFTER USE OF URETERAL ACCESS SHEATH – 4 YEAR FOLLOW-UP DATA</td>
<td>Jose Eduardo Castro Matheus Rodrigues*, Brian Eisner, Boston, MA</td>
</tr>
<tr>
<td>MP17-03</td>
<td>COMPARING SHORT, LONG, AND MOSES REGIMES OF HO:YAG LASER VS SUPER PULSE TM FIBER LASER IN VITRO: ABLATION SPEED AND RETROPULSION EFFECT</td>
<td>Olivier Traxer*, Vincent De Coninck, Etienne Xavier Keller, Steeve Doizi, Paris, France</td>
</tr>
<tr>
<td>MP17-05</td>
<td>THE IMPACT OF LASER PULSE LENGTH AND TYPE ON ‘POPCORN’ LITHOTRIPSY</td>
<td>Russell Terry*, Brenton Winship, Kohldon Boydston, Evan Carlos, Glenn Preminger, Michael Lipkin, Durham, NC</td>
</tr>
<tr>
<td>MP17-06</td>
<td>THE IMPACT OF MILLIMETRIC RESIDUAL STONES AFTER ENDouroLOGICAL PROCEDURES FOR TREATMENT OF KIDNEY CALCULI: A RETROSPECTIVE ANALYSIS.</td>
<td>Nuno Morais*, Braga, Portugal, Carla Ribeiro, Paulo Mota, Braga, Portugal, João Torres, Sara Anacleto, Ricardo Rodrigues, Braga, Portugal, Emanuel Carvalho-Dias, Braga, Portugal, Carlos Oliveira, Mário Carqueira, Estêvão Lima, Braga, Portugal</td>
</tr>
</tbody>
</table>
MP17-07 OUTCOMES OF CONSERVATIVE MANAGEMENT OF SPLENIC INJURY INCURRED DURING PCNL
Eric Raffin*, Lebanon, NH, Ben Chew, Vancouver, Canada, Bodo Knudsen, Columbus, OH, Nicole Miller, Nashville, TN, Vernon Pais, Lebanon, NH

MP17-08 FLUOROSCOPY VERSUS ULTRASOUND GUIDED PERCUtanEOUS NEPHROLITOTOMY IN UPPER CALyX ACCESS: SAFETY AND EFFECTIVENESS COMPARISON
Ahmet Sahin, Asgar Garayev, Berkan Simsek, Cengiz Canakci, Bilal Eryildirim, Yiloren Tanidir*, Istanbul, Turkey

MP17-09 A NOVEL 3D PRINTERED SOLUTION FOR PERCUtanEOUS NEPHROLITHOTRIPSY
Stanislav Ali*, Evgeny Siroti, Hyseaen Ali, Roman Sukhanov, Stanislav Vovdenko, Evgeny Bezruckov, Moscow, Russian Federation

MP17-10 CAN THE QSOFA SCORE PREDICT THE NEED FOR ICU ADMISSION AND OUTCOMES IN PATIENTS WITH OBSTRUCTED INFECTED URETERAL STONES?
Muhammad Alsayouf*, Phillip Stokes, Soungmin Cho, Zachary Gilbert, Akin Amasyali, Mohammad Hajhia, Milan Shah, Jason Groegler, D. Duane Baldwin, Loma Linda, CA

MP17-11 THE CLINICAL IMPLICATION OF RENAL STONE CULTURE DURING THE RETROGRADE INTRARENAL SURGERY
Young Cheol Hwang*, Seung-EE Kim, Sangjun Yoo, Juhyun Park, Min Chul Cho, Seoul, Korea, Republic of, Jae-Seung Paick, Incheon, Korea, Republic of, Hwancheol Son, Hyeon Jeong, Sung Yong Cho, Seoul, Korea, Republic of

MP17-12 OPTIMIZING STONE FREE RATE EVALUATION TIME POINT FOR LASER LITHOTRIPSY IN DUSTING MODE
Alim Dymov*, Leonid Rapoport, Dmitry Enikeev, Dmitry Tsarichenko, Nikolay Sorokin, Gazik Akopyan, Alexandra Proskura, Stanislav Ali, Roman Klímov, Vladimir Lekarev, Dmitry Korolev, Moscow, Russian Federation

MP17-13 CHOICE OF THE OPTIMAL METHOD OF UPPER URINARY TRACT DRAINAGE IN PATIENTS WITH ACUTE OBSTRUCTIVE PYELONEPHRITIS
Vigen Malkhasyan*, George Kasyan, Malika Dzhurava, Igor Semenjakin, Dmitry Pushkar, Vadim Ivanov, Moscow, Russian Federation

MP17-14 ROLE OF CULTURAL ANALYSIS IN PATIENTS WITH INDWELLING URETERAL STENT SUBMITTED TO URETEROSCOPY FOR STONES
Francesca Carobbio, Stefania Zamboni, Marco Lattarulo*, Damiano D’Aletti, Evelyn Van Hauwebermeen, Luca Cristinelli, Alessandro Antonelli, Claudio Simeone, Brescia, Italy

MP17-15 AMBULATORY PERCUtanEOUS NEPHROLITOTOMY PERFORMED IN A FREE-STANDING SURGERY CENTER: OUTCOMES OF THE FIRST 420 CASES
Mark V. Silva MD, Meagan M. Dunne MD*, Joel E. Abbott DO, Julio G. Davalos MD, Baltimore, MD

MP17-16 SAME-SESSION VERSUS STAGED URETEROSCOPY AND PERCUtanEOUS NEPHROLITOTOMY IN PRONE POSITION FOR UNILATERAL URETERAL AND RENAL STONES: A RETROSPECTIVE MATCHED-CONTROLLED STUDY

MP17-17 PROSPECTIVE RANDOMIZED COMPARISON OF STANDARD HAND PUMP IRRIGATION AND AN AUTOMATED IRRIGATION SYSTEM (TERMED® FLUIDSMART™) FOR OPERATIVE EFFICIENCY DURING PERCUtanEOUS NEPHROLITHOTOMY: INITIAL EXPERIENCE
Francis Jefferson*, John Sung, Courtney Cottone, Sherry Lu, Shlomi Tapiero, Roshan Patel, Peter Ghamarian, Ralph Clayman, Ramy Yaacoub, Jaime Landman, Orange, CA

MP17-18 STRUCTURAL AND MECHANICAL CHANGES OF SOFT AND FIRM POLYURETHANE STENTS: A BENCHTOP STUDY
Ashley Li, Jeremy Brown, John Smith, Hyelin You, Andrew Krause, Williamson Le, Muhammad Alsayouf, Phillip Stokes*, Mohammad Hajhia, Akin Amasyali, D. Duane Baldwin, Loma Linda, CA

MP17-19 THE SAFETY AND EFFICACY OF MINI MICRO PERCUtanEOUS NEPHROLITOTOMY IN THE MANAGEMENT OF RENAL CALCULI OF SIZE 1-2 CM
Beithangady Monu Zeeshan Hameed*, Arun Chawla, Manjunath Venkatachalahia, Manipal, India

MP17-20 A COMPARISON OF PATIENT DESIRED OUTCOMES BETWEEN PAIN AND NON-PAIN-FOCUSED PATIENTS FOLLOWING NEPHROLITHIASIS SURGERY
Nicholas B. Koch*, Elaine K. Kearney, Catherine Wiener, Gary G. Koch, Leslie D. Lorbacher, Davis Viprakasit, Chapel Hill, NC

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
**ABSTRACT**  **NUMBER**  **TITLE**

**MP18-01 PRELIMINARY RESULTS OF PROSPECTIVE EVALUATION OF URINARY ENDogenous STEROID PROFILE AND PROSTATIC CARCINOMA-INDUCED DEVIATION.**
Stefano De Luca, Cristian Fiori, Matteo Manfredi, Eleonora Amante, Orbassano, Italy, Eugenio Alladio, Turin, Italy, Francesca Ragni, Giorgio Alleva, Diletta Garrou, Enrico Checcucci, Daniele Amparore, Giovanni Cattaneo, Angela Pecoraro, Roberta Aimar, Sabrina De Cillis, Orbassano, Italy, Marco Vincenti, Turin, Italy, Francesco Porpiglia*, Orbassano, Italy

**MP18-02 RAMAN SPECTRAL SIGNATURE OF SERUM FOR PROSTATE CANCER BONE METASTASES SCREENING**
xiaoguang shao*, Jiahua Pan, Yinjie Zhu, Yinjie Zhu, Bajun Dong, Yanqing Wang, Wei Xue, shanghai, China, People’s Republic of

**MP18-03 THE CHINESE ANTI-CANCER ASSOCIATION GENITOURINARY CANCER COMMITTEE PROSTATE CANCER SCREENING PROGRAM: A PRELIMINARY REPORT AFTER RECRUITMENT OF 2162 MEN**
Yongqiang Huang*, Chengyuan Gu, Xiaojian Qin, Yuanyuan Qu, Jianfeng Yang, Jing Hong, Li Liu, Kefa Zheng, Lihua Xu, Huaiping Zhao, Xiongqiong Qian, Dingwei Ye, Shanghai, China, People’s Republic of

**MP18-04 IMPACT OF PUTATIVE CHEMOPREVENTIVE AGENTS ON PROSTATE CANCER DIAGNOSIS**

**MP18-05 METABOLIC SYNDROME EVALUATION IMPROVES PROSTATE CANCER DETECTION IN PATIENTS UNDERGOING A REPEAT BIOPSY**
Cosimo De Nunzio*, Antonio Cicione, Antonio Nacchia, Riccardo Lombardo, Alberto Trucchi, Andrea Tubaro, Rome, Italy

**MP18-06 CLINICOPATHOLOGIC IMPLICATIONS OF ATYPICAL SMALL ACINAR PROLIFERATION (ASAP) IN THE ERA OF ACTIVE SURVEILLANCE**

**ABSTRACT**  **NUMBER**  **TITLE**

**MP18-07 DOES HIGH EJACULATION FREQUENCY INCREASE THE RISK OF PROSTATE CANCER, AS HAS BEEN OBSERVED FOR BPH/LUTS?**
Phil Hyun Song*, Daegu, Korea, Republic of, Gyeong Eun Min, Seoul, Korea, Republic of, Yeong Uk Kim, Jae Young Choi, Young Hwii Ko, Ki Hak Moon, Hee Chang Jung, Daegu, Korea, Republic of

**MP18-08 DEVELOPING PROSTATE CANCER RISK CALCULATOR BY MACHINE LEARNING WITH ENSEMBLE METHODS: COMPARED WITH THE NOMOGRAM BASED RISK CALCULATORS (SNUPC-RC/ERSPC/PCPT)**
Jungyo Suh*, Young Cheol Hwang, Jae Hyun Jung, Junghoon Lee, Won Hoon Song, Yu Jin Kang, Ja Hyeon Ku, Cheol Kwak, Hyeon Hoe Kim, Chang Wook Jeong, Seoul, Korea, Republic of

**MP18-09 AGE-ADJUSTED REFERENCE VALUES FOR PROSTATE SPECIFIC ANTIGEN: A SYSTEMATIC REVIEW AND META-ANALYSIS**
Bashar Matti*, Weisi Xia, Kamran Zargar-Shohstari, Auckland, New Zealand

**MP18-10 MI TREXIT: PILOT EVALUATION OF A STATE-WIDE INITIATIVE FOR IN-OFFICE TRANSPERINEAL VERSUS TRANSRECTAL PROSTATE BIOPSY UNDER LOCAL ANESTHESIA**
Adam Cole*, Matthew Lee, Jeremy Raisky, Ji Qi, Susan Linsell, Rhabia Martin, Chandy Ellimoottil, Adam Walker, Brian Stork, Lindsey Herrel, John Wei, David Miller, Jim Montie, Arvin George, for the Michigan Urological Surgery Improvement Collaborative, Ann Arbor, MI

**MP18-11 EXTERNAL VALIDATION AND COMPARISON OF MULTIVARIABLE PROSTATE CANCER RISK CALCULATORS INCORPORATING MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING**
Karim Saba*, Marian S. Wettstein, Laura Lieger, Olivia Mätzendorfer, Andreas M. Hölker, Olov F. Donati, Cédric Poyet, Tullio Sulser, Daniel Eberli, Ashkan Mortezaei, Zurich, Switzerland

**MP18-12 OPTIMAL BIOPSY STRATEGY FOR PROSTATE CANCER DETECTION BY PERFORMING A BAYESIAN NETWORK META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS**
Xianghu Meng*, Yi Wang, Yamin Wang, Ninghong Song, nanjing, China, People’s Republic of
MP18-13 EARLY EXPERIENCE WITH WATSON FOR ONCOLOGY, A CLINICAL DECISION-SUPPORT SYSTEM FOR PROSTATE CANCER TREATMENT RECOMMENDATIONS
Seong Hyeon Yu*, Myung Soo Kim, Tae Hee Kim, Seong Jong Eun, Sumin Son, Young Ho Seo, Se Heon Jeong, Ho Seok Chung, Ho Song Yu, Eu Chang Hwang, Sun-Ouck Kim, Kyung Jin Oh, Seung Il Jung, Taek Won Kang, Dongdeuk Kwon, Kwangsung Park, Gwangju, Korea, Republic of

MP18-14 SIMULATED RESULTS OF THE PRECISION ALGORITHM FOR PROSTATE CANCER DIAGNOSIS AT A SINGLE ACADEMIC CENTER: SAFETY AND RISK FACTORS FOR FAILURE

MP18-15 A MODEL BASED ON FOUR KALLIKREIN MARKERS IN BLOOD IMPROVES THE PREDICTIVE ACCURACY OF ADVERSE PATHOLOGY AND BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY

MP18-16 INDIVIDUAL DATA META-ANALYSIS OF DISCRIMINATION OF THE STATISTICAL MODEL BASED ON THE FOUR KALLIKREIN PANEL ASSOCIATED WITH THE INCLUSION OF PROSTATE VOLUME

MP18-17 TOO OLD FOR A PROSTATE BIOPSY?
Joao Carvalho*, Pedro Nunes, Joao Lima, Rui Caetano, Hugo Antunes, Edgar Tavares-da-Silva, Belmira Parada, Vítor Sousa, Maria Cipriano, Arnaldo Figueiredo, Coimbra, Portugal

MP18-18 COMPLICATIONS AFTER RANDOM TRUS GUIDED TRANSRECTAL PROSTATE BIOPSY
Giorgio Napodano, Tommaso Realfonso, Raffaele Baio, Giovanni Molisso, Maria Addesso, Roberto Sanseverino*, Nocera Inferiore, Italy

MP18-19 A RANDOMIZED CONTROLLED TRIAL TO INVESTIGATE THE INFECTIOUS OUTCOMES OF INTRARECTAL POVIDONE-IODINE CLEANSING PLUS FORMALIN DISINFECTION OF NEEDLE TIP DURING TRANSRECTAL ULTRASOUND GUIDED PROSTATE BIOPSY

MP18-20 CAN THE USE OF RECTAL SWABS PREVENT SEPSIS FROM FLUOROQUINOLONE RESISTANT ESCHERICHIA COLI IN MEN UNDERGOING TRANSRECTAL ULTRASOUND-GUIDED PROSTATE BIOPSY?
Duncan Self*, Ashe DeBiasio, Weranja Ranasinghe, Mark Louie-Johnsun, Hugh Finlay Macneil, Rupert Ouyang, Stephen Ruthven, Gosford, Australia

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
Friday, May 3, 2019 3:30 pm - 5:30 pm

Moderated Poster Session 19

KIDNEY CANCER: EPIDEMIOLOGY & EVALUATION/STAGING/SURVEILLANCE III

Room W179a @ McCormick Place

Moderators: Walter Artibani, Stephen Savage & Gopal Gupta

ABSTRACT NUMBER | TITLE
--- | ---
MP19-01 USE OF AUTOMATION AND COMPUTER VISION IN DIFFERENTIATING BENIGN RENAL ONCOCYTOMA FROM CHROMOPHobe RENAL CELL CARCINOMA: PROOF OF CONCEPT

MP19-02 THE ROLE OF RADIOMICS IN THE PREOPERATIVE DIAGNOSIS OF RENAL CELL CARCINOMA WITH SARCOMATOID DEDIFFERENTIATION (SRCc)
Chalairat Suk-Ouichai*, Akaterini Kotrotsou, Tagwa Idris, Srishti Abrol, Eric Umbricht, Andrew G. McIntosh, Christopher G. Wood, Rivka R. Colen, Jose A. Karam, Houston, TX

MP19-03 DETERMINING FACTORS ASSOCIATED WITH OVERALL SURVIVAL BY SUBTPYING OF CLEAR CELL RENAL CELL CARCINOMA
Jacob W. Greenberg, Gabriel Z. Leinwand, M.D*, L. Spencer Krane, New Orleans, LA

MP19-04 ELEVATED CD36 EXPRESSION CORRELATES WITH INCREASED VISCERAL ADIPOSE TISSUE AND PREDICTS POOR PROGNOSIS IN CCRCC PATIENTS PROGNOSIS IN CCRCC PATIENTS.
Wen-Hao Xu, Yuan-Yuan Qu*, Wang Jun, Fang-Ning Wan, Hong-Kai Wang, Jian-Yuan Zhao, Hai-Lang Zhang, Dingwei Ye, Shanghai, China, People’s Republic of

MP19-05 CLINICOPATHOLOGIC FEATURES OF XP11.2 TRANSLOCATION RENAL CELL CARCINOMA: CHINESE MULTI-INSTITUTIONAL ANALYSIS
Ning Liu*, Nanjing, China, People’s Republic of, Weidong Gan, Nanjing, China, People’s Republic of

MP19-06 RENAL NEPHROMETRY SCORE CORRELATED WITH TUMOR PROLIFERATIVE ACTIVITY OF T1 CLEAR CELL RENAL CELL CARCINOMA
Hiroshi Kikuchi*, Takashige Abe, Ryuji Matsumoto, Jun Furumido, Haruka Miyata, Takahiro Osawa, Sachiyu Murai, Nobuo Shinohara, Sapporo, Japan

*Presenting author
MP19-13 COMPARING UROLOGIST RECOMMENDATIONS FOR SMALL RENAL MASS BIOPSY WITH PATIENT OPINIONS BEFORE AND AFTER COUNSELING

MP19-14 HIGH BURDEN OF IN-PERSON KIDNEY CANCER SURVEILLANCE IN A LOW RESOURCE POPULATION
Dima Raskolnikov*, Steven Ngo, John Gore, Seattle, WA

MP19-15 PATIENT-REPORTED BARRIERS TO OBTAINING GENETIC COUNSELING IN EARLY-ONSET RENAL CELL CARCINOMA
Brady Miller*, Jason Flamiatos, Angela Tess, Sara Best, Sean Hedican, David F. Jarrard, Kyle A. Richards, Tracy M. Downs, Steven Nakada, E. Jason Abel, Madison, WI

MP19-16 RENAL CELL CARCINOMA DISPARITIES: YOUNGER AGE AT DIAGNOSIS AND INCREASED CLEAR CELL RENAL CELL CARCINOMA INCIDENCE IN AMERICAN INDIANS AND HISPANICS
Ken Batai*, Alfredo Harb De la Rosa, Francine Gachupin, Benjamin Lee, Tucson, AZ

MP19-17 OVERALL SURVIVAL OF BIOPSY CONFIRMED T1B AND T2A KIDNEY CANCERS MANAGED WITH OBSERVATION: INFLUENCE OF TUMOR HISTOLOGY
Nermarie Velazquez*, Audrey Renson, Stella K. Kang, William C. Huang, New York, NY, Marc A. Bjurlin, Chapel Hill, NC

MP19-18 IMPAIRED SURVIVAL AMONG RENAL CELL CANCER PATIENTS WITH LEFT SIDED TUMOR
Arne Strauss, Johannes Uhlig, Joachim Lotz, Lutz Trojan, Annemarie Uhlig*, Goettingen, Germany

MP19-19 INFLUENCING FACTORS OF POSTOPERATIVE RENAL FUNCTION IN RENAL CELL CARCINOMA WITH TUMOR THROMBUS: A LARGE CHINESE CENTER EXPERIENCE
Shiying Tang*, Zhuo Liu, Hongxian Zhang, Guoliang Wang, Xiaojun Tian, Shudong Zhang, Lulin Ma, Beijing, China, People’s Republic of

MP19-20 DETECTION OF A PERITUMORAL PSEUDOCAPSULE IN PATIENTS WITH RENAL CELL CARCINOMA UNDERGOING ROBOT-ASSISTED PARTIAL NEPHRECTOMY, USING ENHANCED CT
Makoto Toguchi*, Toshio Takagi, Kazuhiro Yoshida, Jyunpei Izuka, Kazunari Tanabe, Tsunenori Kondo, Yoko Ogawa, Satoru Morita, Yoji Nagashima, Tokyo, Japan

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Friday, May 3, 2019
3:30 pm - 5:30 pm

Moderated Poster Session 20
SURGICAL TECHNOLOGY & SIMULATION: INSTRUMENTATION & TECHNOLOGY III
Room W176bc @ McCormick Place
Moderators: Michael Borofsky, William Roberts & Rajeev TP

ABSTRACT NUMBER TITLE
MP20-01 MOLECULAR CHEMICAL IMAGING ENDScope, AN INNOVATIVE IMAGING MODALITY FOR ENHANCING THE SURGEON’S VIEW DURING LAPAROSCOPIC PROCEDURES
Arash Samiei*, Ralph Miller, John Lyne, Aaron Smith, Shona Stewart, Heather Gomer, Patrick Treado, Jeffrey Cohen, Pittsburgh, PA

MP20-02 ADVERSE EVENTS DURING THERMAL CRYOABLATION REPORTED TO A LARGE ADMINISTRATIVE COMPLICATIONS DATABASE
Srinath Kotamarti*, Buddima Ranasinghe, Frederick Greenstein, Antonio Montgomery, Unni Mooppan, Ervin Teper, David Silver, Ariel Schulman, Brooklyn, NY

ABSTRACT NUMBER TITLE
MP20-03 DEVELOPMENT AND VALIDATION OF PATIENT SPECIFIC HYDROGEL KIDNEY PHANTOMS IN PREDICTING PARTIAL NEPHRECTOMY SUCCESS FOR COMPLEX RENAL MASSES
MP20-04 USABILITY AND TECHNICAL FEASIBILITY EVALUATION OF A TETHERED LAPAROSCOPIC GAMMA PROBE FOR RADIOD GUIDED SURGERY IN PROSTATE CANCER: A PELVIC PHANTOM AND PORCINE MODEL STUDY
Jim Adshead, Stevenage, United Kingdom, Francesca Oldfield, Chesham, United Kingdom, Boris Hadadachik, Essen, Germany, Wouter Everaerts, Leuven, Belgium, Antoni Mestre-Fusco, Barcelona, Spain, Miranda Newbery, Knresborough, United Kingdom, Dan Elson, London, United Kingdom, Maarten Ruben Grootendorst, Kunal Vyas, Chesham, United Kingdom, Lluis Fumado, Barcelona, Spain, Nina Natascha Harke*, Essen, Germany

MP20-05 MESH SLING COMPLICATIONS: FEASIBILITY OF ACCESSING DATA FROM PATIENTS INVOLVED IN MESH LITIGATION

MP20-06 DIGITAL KIDNEY IN LOCALIZATION OF ENDOPHYTIC RENAL TUMOR DURING PARTIAL NEPHRECTOMY
Shengkun Sun*, Xu Zhang, Beijing, China, People's Republic of

MP20-07 A NOVEL EQUIPMENT FOR THE TRAINING OF URETHRAL ANASTOMOSIS PROCEDURE: THE RESULTS OF THE PRELIMINARY STUDY
Chao Feng*, Jin-dong Xue, Shanghai, China, People's Republic of, Zhe Li, Jia xin, China, People's Republic of, Hong Xie, Yin-jong Sa, Yue-min Xu, Qiang Fu, Zu-lin Wang, Shanghai, China, People's Republic of

MP20-08 OUTCOMES OF SALVAGE CYSTECTOMY IN PATIENTS FOLLOWING PRIOR PELVIC IRRADIATION: COMPARING ROBOT-ASSISTED VERSUS OPEN CYSTECTOMY
Tack Wei Tan*, Singapore, Singapore, Kerri Beckmann, Ramesh Thurairajra, Muhammad Shamim Khan, Rajesh Nair, London, United Kingdom

MP20-09 ROBOTIC 3D ULTRASOUND-GUIDED TARGETING FOR PERCUTANEOUS RENAL ACCESS
Tareq Aro*, Sungwhan Lim, Doru Petrisor, Dan Stoianovic, Baltimore, MD

MP20-11 DECREASED RISK OF UPPER EXTREMIT Y NEUROPRAXIA DURING ROBOTIC ASSIST LAROSCOPIC PROSTATECTOMY: A NOVEL TECHNIQUE
Matthew J. Watson*, Chattanooga, TN, Brandon Koch, Denver, CO, Raymond Xu, Memphis, TN, Gregory Heath, Amar Singh, Chattanooga, TN

MP20-12 IMPROVING THE SAFETY AND EFFICACY OF PHOTODYNAMIC THERAPY FOR NMIBC– INTRAVESICAL RUTHENIUM (II)-PHOTOSENSITIZER AND LIGHT DOSIMETRY IN A PHASE 1B CLINICAL TRAIL
Lothar Lilge*, Angelica Manalac, Leonid Vesselov, Wayne Embree, Arkady Mandel, Vaughn Betz, Michael Jewett, Girish Kulkani, Toronto, Canada

MP20-13 2D TO 3D VIDEO CONVERSION IMPACT ON FUNDAMENTALS OF LAPAROSCOPIC SURGERY SKILLS TRAINING
Jason Huang*, Moshe Shapiro, Simone Criellaro, Chicago, IL

MP20-14 VAGUE SWIRLING ENDS IN NO COMMUNICATION: REFERENCING STRATEGIES DURING ROBOT ASSISTED SURGERY
Antara Satchidanand*, Jeff Higginbotham, Ann Bisantz, Naif A. Aldhaam, Ahmed S. Elsayed, Renuka Kannappan, Khurshid A. Guru, Buffalo, NY

MP20-15 PROSPECTIVE EVALUATION OF A NOVEL TRANSPERINEAL ELECTROMAGNETICALLY-TRACKED MR/US FUSION BIOPSY SYSTEM
Matthew Lee*, Adam Cole, Anna Johnson, Ji Qi, Susan Linsell, Rabia Martin, Chandry Ellimoottil, Lindsey Herrel, John Wei, Simpa Salami, Nicole Curci, Matthew Davenport, Prasad Shankar, David C. Miller, James Montie, Arvin K George, for the Michigan Urological Surgery Improvement Collaborative, Ann Arbor, MI

MP20-16 MR/US FUSION GUIDED ULTRA-FOCAL GOLD NANOSHELL DIRECTED LASER ABLATION OF PROSTATE TUMORS: SIDE EFFECTS AND 1-YEAR FUNCTIONAL OUTCOMES: PHASE III CLINICAL TRIAL
Ethan Wajswol*, Harry Anastas, Jared Winoker, Alberto Martini, John Sfakianos, Cynthia Knauer, Bachir Taouli, Sara Lewis, New York, NY, Jon Schwartz, Houston, TX, Arvin George, Ann Arbor, MI, Steven Canfield, Houston, TX, Ardeshir Rastinehad, New York, NY

*Presenting author
<table>
<thead>
<tr>
<th>Abstract Number</th>
<th>Title</th>
<th>Authors</th>
<th>Institution/Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP20-17</td>
<td>INCORPORATION OF CLINICALLY RELEVANT PERFORMANCE METRICS (CRPMS) INTO A ROBOT ASSISTED RADICAL PROSTATECTOMY SIMULATION MODEL</td>
<td>Michael Witthaus*, Timothy Campbell, Rachel Melnyk, Erin Coppola, Shamroz Farooq, Katherine Cameron, Bahie Ezzat, Ashkan Ertefaie, Thomas Frye, Guan Wu, Han Rashid, Jean Joseph, Ahmed Ghazi</td>
<td>Rochester, NY</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MP20-19</td>
<td>THE NOVEL SP PURPOSE-BUILT SINGLE-SITE DEDICATED PLATFORM: REPORT OF THE INITIAL EXPERIENCE</td>
<td>Riccardo Bertolo*, Juan Garisto, Jose Agudelo, Mohamed Eltemamy, Jihad Kaouk, Cleveland, OH</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MP20-20</td>
<td>SIMULATED REALITY-ASSISTED RESECTION OF ENDOPHTHYC RENAL TUMORS CAN ACHIEVE EQUIVALENT RESULTS TO EXOPHTHYC TUMOR IN ROBOT-ASSISTED PARTIAL NEPHRECTOMY.</td>
<td>Atsushi Okada*, Kazuya Ohashi, Takumi Ohno, Haruka Kyoshima, Takaya Terada, Harumasa Kasai, Hiroshi Kunitomo, Yasujiro Hirose, Taku Naiki, Ryosuke Ando, Shuzo Hamamoto, Yukihiro Umemoto, Norigasu Kawai, Keiichi Tozawa, Katsushi Kunimoto, Kenjiro Kohri, Takahiro Yasui, Nagoya, Japan</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>APPROVED FOR AMA PRA CATEGORY 1 CREDIT™</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Friday, May 3, 2019 3:30 pm - 5:30 pm**

**Moderated Poster Session 21**

**KIDNEY CANCER: BASIC RESEARCH & PATHOPHYSIOLOGY II**

*Room W175ab @ McCormick Place*

**Moderators:** Peter Clark & Ithaar Derweesh

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
<th>Authors</th>
<th>Institution/Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP21-01</td>
<td>SINGLE CELL TRANSCRIPTIONAL PROFLING OF IMMUNE POPULATIONS WITHIN RENAL CELL CARCINOMA TUMOR MICROENVIRONMENT</td>
<td>Vinson Wang*, Aleksandar Obradovic, Nivedita Chowdhury, David Aggen, Erin Bush, Guarionex Joel Decastro, Christopher B. Anderson, James M. McKiernan, Hongxu Ding, Peter Sims, Andrea Califano, Charles G. Drake, New York, NY</td>
<td></td>
</tr>
<tr>
<td>MP21-02</td>
<td>TUMOR ASSOCIATED NEUTROPHILS SUPPRESS CD8+ T CELLS RESPONSIVENESS TO DETERIORATE SURVIVAL IN HUMAN RENAL CANCER</td>
<td>Huyang Xie*, Nantong, China, People's Republic of, Junyu Zhang, Yongjiang Huang, Shanghai, China, People's Republic of, Yeqing Huang, Qianwei Xing, Nantong, China, People's Republic of, Jiejie Xu, Dingwei Ye, Shanghai, China, People's Republic of</td>
<td></td>
</tr>
<tr>
<td>MP21-03</td>
<td>CD-70 BLOCKADE AS A NOVEL IMMUNOTHERAPY FOR THE TREATMENT OF CLEAR-CELL RENAL CELL CARCINOMA</td>
<td>Paras Shah*, Mario Cepeda, Vidhu Joshi, Stephen Boorjian, Brian Costello, John Cheville, Bradley Leibovich, Rochester, MN</td>
<td></td>
</tr>
<tr>
<td>MP21-04</td>
<td>NEUTROPHIL-TO-LYMPHOCYTE RATIO IN UNCLASSIFIED RENAL CELL CARCINOMA IS ASSOCIATED WITH PROGNOSIS AND VARIES BETWEEN MOLECULAR SUBGROUPS</td>
<td>Julian Marcon*, Renzo G. Di Natale, Mazyar Ghanata, Andrew W. Silagy, Roy Mano, Kyle A. Blum, Eduard Reznik, Maria I. Carlo, Robert J. Motzer, Jonathan A. Coleman, Paul Russo, A. Ari Hakimi, Yingbei Chen, New York, NY</td>
<td></td>
</tr>
<tr>
<td>MP21-05</td>
<td>A NOVEL MOUSE MODEL FOR GENETIC DRIVER DISCOVERY IN PAPILLARY RENAL CELL CARCINOMA</td>
<td>Jason Scovell*, Juan Hernandez, Zahabia Moiz, Adam Hollander, Matthew Robertson, Cristian Coarfa, Michael Ittmann, Richard Link, Houston, TX</td>
<td></td>
</tr>
</tbody>
</table>
MP21-06 LEVERAGING A ROBUST PATIENT-DERIVED XENOGRAFT PLATFORM TO CHARACTERIZE PREDICTORS FOR ENGRAFTMENT AND ONCOLOGIC OUTCOMES IN RENAL CELL CARCINOMA PATIENTS

MP21-07 THE USE OF PATIENT DERIVED XENOGRAFTS IN GENERATING ACCURATE TUMOR MODELS FOR SARCOMATOID RENAL CELL CARCINOMA
Kassem Faraj*, Kyle Rose, Melissa Stanton, Thai Ho, Alan Bryce, Douglas Lake, Phoenix, AZ, John Copland, Jacksonville, FL, Erik Castle, Phoenix, AZ

MP21-08 FEASIBILITY OF ESTABLISHING RENAL CANCER PATIENT-SPECIFIC ‘TUMOUROIDS’ AS PERSONALISED TREATMENT SCREENING TOOLS
Katerina Stamati*, Joana B. Neves, Patricia de Albuquerque Garcia Redondo, Nadege Presneau, Tayebeh Azimi, Layla Mohammad Hadi, Chris Brew-Graves, Norman R. Williams, Jack Grierson, Maxine G. B. Tran, Umbre Cheema, Marlena Loizidou, Mark Emberton, London, United Kingdom

MP21-09 NON-INVASIVE URINE MARKERS FOR THE DIFFERENTIATION BETWEEN RCCS AND ONCOCYTOMA
Melanie von Brandenstein*, Barbara Köditz, Caroline Eich, Sibel Cakir, Axel Heidenreich, Jochen W.U. Fries, Cologne, Germany

MP21-10 A URINARY PROTEOMICS ANALYSIS OF PATIENTS TREATED WITH NEOADJUVANT AXITINIB FOR NON-METASTATIC CLEAR-CELL RENAL-CELL CARCINOMA: ANALYSIS FROM A PHASE II TRIAL
Andrew McIntosh*, Hong Wang, Eric Umbreit, Chalairat Suk-Ouchai, Graciela Velotti, Alan Bryce, Douglas Lake, Phoenix, AZ, John Copland, Jacksonville, FL, Erik Castle, Phoenix, AZ

MP21-11 DIAGNOSTIC AND PROGNOSTIC VALUE OF URINE CIRCULATING CELL-FREE DNA IN RENAL CELL CARCINOMA
Julia Oto, Noelia Santillana, José Solmoirago, Javier Pérez-Ardavin, José Vicente Sánchez-González*, Emma Plana, David Hervás, Álvaro Fernández-Pardo, Marina Yelo, César D Vera-Donoso, Manuel Martínez-Sarmiento, Francisco España, Silvia Navarro, Pilar Medina, Valencia, Spain

MP21-12 CAN A URINE MICRORNA PROFILE DISPLAY DIAGNOSTIC AND PROGNOSTIC VALUE FOR CLEAR CELL RENAL CELL CARCINOMA?
Julia Oto, Mª José Solmoirago, José Vicente Sánchez-González*, Javier Pérez-Ardavin, Emma Plana, David Hervás, Álvaro Fernández-Pardo, Marina Yelo, César D Vera-Donoso, Manuel Martínez-Sarmiento, Francisco España, Silvia Navarro, Pilar Medina, Valencia, Spain

MP21-13 URINARY MIRNA 210-3P AS A SPECIFIC NON-INVASIVE BIOMARKER IN CLEAR CELL RENAL CELL CARCINOMA
Antonio Luigi Pastore*, Roma, Italy, Yazen Al salhi, Andrea Fuschi, Lorenzo Capone, Gennaro Velotti, Alessia Martoccia, Latina, Italy, Giuseppe Simone, Michele Gallicchi, Rome, Italy, Vinenzo Pertrozzi, Latina, Italy, Francesco Fazi, Rome, Italy, Antonio Carbone, Latina, Italy

MP21-14 FLUVASTATIN POTENTIATES ANTICANCER ACTIVITY OF VORINOSTAT IN RENAL CANCER CELLS BY ACTIVATING AMP-ACTIVATED PROTEIN KINASE
Kazuki Okubo*, Makoto Isono, Takako Asano, Akinori Sato, Tokorozawa, Japan

MP21-15 FUSOGENIC LIPOSOMES AS A NOVEL NANOTHERAPY AGAINST METASTATIC CLEAR CELL RENAL CELL CARCINOMA
Jan Rudzinski*, Natasha Govindasamy, Konstantin Stoletov, Adrian Fairey, John Lewis, Edmonton, Canada

MP21-16 NOVEL MOLECULARLY TARGETED COMBINATION FOR RENAL CELL CARCINOMA

MP21-17 SPHINGOSINE KINASE 1 OVEREXPRESSION CONTRIBUTES TO SUNITINIB RESISTANCE IN CLEAR CELL RENAL CELL CARCINOMA
Yunze Xu*, Yiran Huang, Shanghai, China, People’s Republic of

MP21-18 COBICISTAT, A POTENT INHIBITOR OF CYP3A, ENHANCES THE ANTINEOPLASTIC ACTIVITY OF IXAZOMIB IN RENAL CANCER CELLS
Takako Asano*, Akinori Sato, Makoto Isono, Kazuki Okubo, Tokorozawa, Japan

MP21-19 THE ANTISENSE LONG NON-CODING MITOCHONDRIAL RNA(AS-NCMTRNA) INTERFERENCE WITH ANDES-1537 AS A NOVEL TREATMENT FOR RENAL CARCINOMA
Mariela Araya, Santiago, Chile, Francisca Guevara, Jaime Villegas, Luis Alarcón, Luis Burzio, Vincenzo Borgna*, Santiago, Chile

*Presenting author
**Podium Session 16**

**GENERAL & EPIDEMIOLOGICAL TRENDS & SOCIOECONOMICS: ADVANCED PRACTICE PROVIDERS**

Room W185a @ McCormick Place

**Moderators:** Heather Schultz, Nitya Abraham & J. Quentin Clemens

<table>
<thead>
<tr>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
<th>ABSTRACT</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:30</td>
<td>PD16-01</td>
<td>FILLING THE GAPS IN NEONATAL CIRCUMCISIONS: A UROLOGIC PHYSICIAN ASSISTANT NEONATAL CIRCUMCISION CLINIC OUTCOMES AND INCREASE REVENUE STREAM</td>
<td>Kally Colon-Sanchez*, Pamela Ellsworth, Orlando, FL</td>
</tr>
<tr>
<td>3:40</td>
<td>PD16-02</td>
<td>EVALUATING CLINICAL OUTCOMES OF AN ADVANCED PRACTICE PROVIDER LED NEWBORN CIRCUMCISION CLINIC</td>
<td>Jonathan A. Gerber*, Adithya Balasubramanian, Alexandra N. Borden, Jacqueline Broda, Sarah J. Koelwyn, Huirong Zhu, Kunj R. Sheth, Carolina J. Jorgez, Angela G. Mittal, Duong D. Tu, Chester J. Koh, Nicolette J. Janzen, Ming-Hsien Wang, Paul F. Austin, Edmond T. Gonzalez, David R. Roth, Abhishek Seth, Houston, TX</td>
</tr>
<tr>
<td>3:50</td>
<td>PD16-03</td>
<td>CARDIOVASCULAR DISEASE (CVD), HYPOGONADISM &amp; ED: POSITIVE EFFECTS UNDER LONG-TERM TREATMENT WITH TESTOSTERONE UNDECANOATE INJECTIONS (TU)</td>
<td>Aksam Yassin, Karin Sultan Haider, Bremerhaven, Germany, Khalid Alrumaihi, Riaadh Alzubaidi*, Sabah Alkadhi, Abdulra Al Ansari, Doha, Qatar</td>
</tr>
<tr>
<td>4:00</td>
<td>PD16-04</td>
<td>PATIENTS RECEIVING ANDROGEN DEPRIVATION TREATMENT FOR PROSTATE CANCER: MANAGING SIDE EFFECTS</td>
<td>Anne Calvaresi*, Edouard Trabulsi, Janice Miller, Hong Truong, Mark Hurwitz, Philadelphia, PA</td>
</tr>
<tr>
<td>4:20</td>
<td>PD16-06</td>
<td>PARTICIPATION OF ADVANCED PRACTICE PROVIDERS IN CARE OF PATIENTS IN UROLOGY PRACTICES</td>
<td>Samuel Hohmann*, Chicago, IL</td>
</tr>
<tr>
<td>4:30</td>
<td>PD16-07</td>
<td>AN ASSESSMENT OF PATIENTS APPROPRIATE FOR INITIAL EVALUATION BY AN ADVANCED PRACTICE PROVIDER AT AN ACADEMIC MEDICAL CENTER</td>
<td>Brooke Moore*, Carlos Mejia Arbelaez, Dianne Sacco, Lauren Swisher, Brian Eisner, Boston, MA</td>
</tr>
<tr>
<td>4:40</td>
<td>PD16-08</td>
<td>COST SAVINGS ANALYSIS OF INPATIENT ADVANCED PRACTICE PROVIDER</td>
<td>Mitchell Ng BS, Michael Wang BS, Laura Bukavina MD MPH*, Amr Mahran MD MS, Kirtishri Mishra MD, Michael Callagari MD, MBA, Christina Buzzy PhD, Lee Ponsky MD, Cleveland, OH</td>
</tr>
<tr>
<td>4:50</td>
<td>PD16-09</td>
<td>ONLINE PATIENT RATINGS OF UROLOGISTS ARE CORRELATED WITH SHORT-TERM OUTCOMES FOLLOWING MAJOR UROLOGIC SURGERIES</td>
<td>Anthony Yang*, Mark Finkelstein, Michael Palese, New York, NY</td>
</tr>
<tr>
<td>5:00</td>
<td>PD16-10</td>
<td>RESIDENCY BY FOOT: ASSESSMENT OF WORKING SHIFT PHYSICAL EFFORT BY COUNTING STEPS</td>
<td>Reuven Ben-David*, Ziv Savin, Ofer Yossapowitch, Mario Sofer, Tek-Avi, Israel</td>
</tr>
<tr>
<td>5:10</td>
<td>PD16-11</td>
<td>UROLOGY RESIDENCY INTERVIEWS: THE PREVALENCE OF POTENTIALLY ILLEGAL QUESTIONS AND FINANCIAL BURDEN</td>
<td>Edward Capoccia*, Christopher Coogan, Chicago, IL</td>
</tr>
<tr>
<td>5:20</td>
<td>PD16-12</td>
<td>NATIONWIDE APPLICATION OF A SMART SYSTEM FOR LOCAL AND REMOTE MULTIDISCIPLINARY TEAM MANAGEMENT OF GENITOURINARY CANCERS.</td>
<td>Xiaojian Qin*, Hongkai Wang, Fangning Wan, Weijie Gu, Xiaolin Lu, CuiZhu Zhang, WeiYi Yang, Ying Shen, Dingwei Ye, Shanghai, China, People’s Republic of</td>
</tr>
<tr>
<td>TIME</td>
<td>NUMBER</td>
<td>TITLE</td>
<td>ABSTRACT</td>
</tr>
<tr>
<td>-------</td>
<td>--------</td>
<td>----------------------------------------------------------------------</td>
<td>----------</td>
</tr>
<tr>
<td>3:30</td>
<td>PD17-01</td>
<td>EXTERNAL VALIDATION OF THE PREDICT PROSTATE TOOL FOR PROGNOSTICATION IN NON-METASTATIC PROSTATE CANCER: A STUDY IN 69,206 MEN FROM PROSTATE CANCER DATA BASE SWEDEN</td>
<td>David Thurtle, Cambridge, United Kingdom, Ola Bratt, Gothenburg, Sweden, Pär Stattin, Uppsala, Sweden, Paul Pharoah, Vincent Gnanapragasam*, Cambridge, United Kingdom</td>
</tr>
<tr>
<td>3:40</td>
<td>PD17-02</td>
<td>CLINICAL RISK BASED ASSOCIATIONS OF LYMPH NODE DISSECTION AND DETECTION YIELD AMONG MEN TREATED WITH RADICAL PROSTATECTOMY FOR PROSTATE CANCER</td>
<td>Alejandro Abello*, Preston Sprenkle, Patrick Kenney, Michael Leapman, New Haven, CT</td>
</tr>
<tr>
<td>3:50</td>
<td>PD17-03</td>
<td>FIRST EVALUATION OF ONE-STEP NUCLEIC ACID AMPLIFICATION (OSNA) FOR RAPID MOLECULAR DETECTION OF LYMPH NODE METASTASES IN PROSTATE CANCER PATIENTS</td>
<td>Alexander Winter*, Svenja Engels, Friederike Hasselmann, Lutz Brautmeier, Rolf-Peter Henke, Jonas Schifflmann, Holger Gerullis, Friedhelm Wawroschek, Oldenburg, Germany</td>
</tr>
<tr>
<td>4:00</td>
<td>PD17-04</td>
<td>DIAGNOSTIC EFFICACY OF 18F-RHPSMA7, POSITRON EMISSION TOMOGRAPHY FOR N-STAGING OF PATIENTS WITH HIGH RISK PRIMARY PROSTATE CANCER</td>
<td>Tobias Maurer*, Hamburg, Germany, Markus Kroenke, Alexander Wurzer, Kristina Schwamborn, Lena Ulbrich, Lena Jooß, Thomas Horn, Bernhard Haller, Wolfgang Weber, Hans-Jürgen Wester, Matthias Eiber, Munich, Germany</td>
</tr>
<tr>
<td>4:10</td>
<td>PD17-05</td>
<td>HOW ACCURATE ARE GA68-PSMA PET/CT AND MULTIPARAMETRIC MRI IN EXCLUDING PELVIC LYMPH NODE METASTASES PRIOR TO RADICAL PROSTATECTOMY?</td>
<td>Michael Frumer*, Jack Daniel, Petach Tikva, Israel, Serge Bistritsky, Gilad E. Arniel, Aziz Hoffman, Haifa, Israel, Nadav Milik, Itay Sternberg, Ilan Leibovitch, Kfar Saba, Israel, Itay Sagy, Kfar Saba and Haifa, Israel, Gal Riniott Mizrahi, Yoram Dekel, Haifa, Israel, Amnon Zisman, Miki Haller, Rishon Lezion, Israel, Shay Golan, Petach Tikva, Israel</td>
</tr>
<tr>
<td>4:20</td>
<td>PD17-06</td>
<td>MAPPING OF SITE-SPECIFIC RELAPSE IN PATIENTS WITH BIOCHEMICAL RECURRENCE FOLLOWING RADICAL PROSTATECTOMY ASSESSED BY 68GA-PSMA-11 OR 11C-CHOLINE PET/CT: IMPACT OF POSTOPERATIVE ANDROGEN DEPRIVATION THERAPY AND RADIOTHERAPY.</td>
<td>Gaetan Devos*, Manuel Witters, Wouter Everaerts, Yannic Raskin, Lorenzo Tosco, Gert De Meerleer, Karolien Goffin, Steven Joniau, Leuven, Belgium</td>
</tr>
<tr>
<td>4:30</td>
<td>PD17-07</td>
<td>DETECTION RATE OF 68GA-PSMA-11 PET/MRI IN PATIENTS WITH RECURRENT PROSTATE CANCER FOLLOWING RADICAL PROSTATECTOMY AND LOW PSA VALUES &lt;0.5 NG/ML.</td>
<td>Benedikt Kranzbühler*, Julian Müller, Anton S. Becker, Helena Garcia Schüller, Christian D. Funkhauser, Matthias Guckenberger, Philipp A. Kaufmann, Daniel Eberli, Irene A. Burger, Zürich, Switzerland</td>
</tr>
<tr>
<td>4:40</td>
<td>PD17-08</td>
<td>COMPARING THE DIAGNOSTIC ACCURACY OF 68GA-PSMA AND 11C-CHOLINE PET/CTSCAN ACCORDING TO PSA LEVEL: A LARGE MULTI-INSTITUTIONAL ANALYSIS WITH HISTOLOGICAL VERIFICATION IN PATIENTS TREATED WITH SALVAGE LYMPH NODE DISSECTION FOR RECURRENT PROSTATE CANCER</td>
<td>Nicola Fossati*, Carlo Andrea Bravi, Nazareno Suardi, Giorgio Gandaglia, Milan, Italy, Luca Boeri, R. Jeffrey Kames, Rochester, MN, Axel Heidenreich, Cologne, Germany, Alexander Kretschmer, Alexander Buchner, Christian Stief, Munich, Germany, Antonino Battaglia, Steven Joniau, Hein Van Poppel, Leuven, Belgium, Almut Kalz, Dainari Osmonov, Klaus-Peter Juennemann, Kiel, Germany, Shahrokh Shariat, Bernhard Grumbmüller, Vienna, Austria, Andreas Hiester, Düsseldorf, Germany, Alessandro Nini, Milan, Italy, Peter Albers, Düsseldorf, Germany, Denya Tilki, Markus Graefen, Hamburg, Germany, Akbar Ashrafi, Inderbir S. Gill, Los Angeles, CA, Alexander Mottire, Melle, Belgium, Francesco Montorsi, Alberto Briganti, Milan, Italy</td>
</tr>
</tbody>
</table>
4:50 PD17-09 PROSTATE-SPECIFIC MEMBRANE ANTIGEN POSITRON EMISSION TOMOGRAPHY (PSMA-PET) IN HIGH-RISK NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC) SPARTAN-LIKE PATIENTS (PTS) NEGATIVE BY CONVENTIONAL IMAGING
Boris Hadachik*, Manuel Weber, Essen, Germany, Amir Iravani, Michael S. Hofman, Melbourne, Australia, Jérémie Calais, Johannes Czernin, Los Angeles, CA, Harun Ilhan, Munich, Germany, Fred Saad, Montréal, Canada, Eric J. Small, San Francisco, CA, Matthew R. Smith, Boston, MA, Paola M. Perez, Thomas A. Hope, San Francisco, CA, Isabel Rauscher, Munich, Germany, Anil Londhe, Titusville, NJ, Tobias Maurer, Munich, Germany, Ken Herrmann, Essen, Germany, Matthias Eiber, Munich, Germany, Wolfgang Fendler, Essen, Germany

5:00 PD17-10 QUANTITATIVE ANALYSIS BETWEEN APPARENT DIFFUSION COEFFICIENTS ON MRI AND CELLULARITY METRICS OF PROSTATE CANCER WITH WHOLE-MOUNT HISTOPATHOLOGY
Jie Gao*, Qing Zhang, Chengwei Zhang, Hongqian Guo, Nanjing, China, People’s Republic of

5:10 PD17-11 ADDED VALUE OF CONCOMITANT SYSTEMATIC BIOPSIES IN PREDICTING UPGRADING IN PATIENTS WITH LOCALIZED PROSTATE CANCER DIAGNOSED BY MRI-TARGETED BIOPSY: IMPLICATIONS FOR TREATMENT SELECTION
Giorgio Gandaglia*, Milan, Italy, Guillaume Ploussard, Toulouse, France, Massimo Valerio, Lausanne, Switzerland, Agostino Mattei, Lucerne, Switzerland, Cristian Fierri, Orbassano (Turin), Italy, Nicola Fossati, Armando Stabile, Milan, Italy, Jean-Baptiste Beauval, Bernard Malavaud, Mathieu Roumigué, Toulouse, France, Daniele Robesti, Paolo Dell’Oglio, Federico Dehò, Umberto Capitanio, Milan, Italy, Marco Moschini, Stefania Zamboni, Lucerne, Switzerland, Annas Rakauskas, Lausanne, Switzerland, Francesco De Cobelli, Milan, Italy, Francesco Porgigia, Orbassano (Turin), Italy, Francesco Montorsi, Alberto Briganti, Milan, Italy

5:20 PD17-12 FREQUENCY OF DOWNGRADING FROM MR/US FUSION BIOPSY TO RADICAL PROSTATECTOMY BASED ON ISUP 2014 GRADING MODIFICATIONS

Friday May 3, 2019
Podium Session 18
3:30 pm - 5:30 pm
BLADDER CANCER: NON-INVASIVE II
Room W184d @ McCormick Place
Moderators: Mark Soloway, Boris Gershman & Paul Anderson

3:30 PD18-01 CONTEMPORARY OUTCOMES OF T1 HIGH-GRADE (T1HG) BLADDER CANCER: A SINGLE CENTER EXPERIENCE
Courtney Yong*, Nathan Brooks, Anthony D. Oberle, Sarah L. Mott, Michael A. O’Donnell, Iowa City, IA

3:40 PD18-02 INCREASED URINARY VASCULAR ENDOTHELIAL GROWTH FACTOR D (VEGF-D) LEVELS ARE ASSOCIATED WITH RESPONSE TO COMBINED INTRAVESICAL BACILLUS CALMETTE–GUERIN (BCG) AND ORAL SUNITINIB REGIMEN FOR TREATMENT OF HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC)
Colton H. Walker*, Amir H. Lebastchi, Christopher M. Russell, Stephanie Daignault–Newton, Monica Liebert, Khaleed S. Hafez, Ann Arbor, MI, Maha H. Hussain, Chicago, IL, Jeffrey S. Montgomery, David C. Miller, Brent K. Hollenbeck, Alon Z. Weizer, Samuel D. Kaffenberger, Ann Arbor, MI

3:50 PD18-03 COMPARISON OF SURVEILLANCE REGIMENS FOR LOW RISK NON-MUSCLE INVASIVE BLADDER CANCER: A PILOT STUDY
Shane L. Barney*, San Antonio, TX, Cory M. Hugen, Irvine, CA, Yair Lotan, Dallas, TX, Edward M. Messing, Rochester, NY, Robert S. Svatek, San Antonio, TX

4:00 PD18-04 A PHASE 1 SAFETY STUDY OF ONCOFID-P-B ADMINISTERED FOR 12 CONSECUTIVE WEEKS IN BCG UNRESPONSIVE/INTOLERANT PATIENTS WITH BLADDER CARCINOMA IN SITU (CIS): PRELIMINARY RESULTS
Rodolfo Hurle*, Massimo Lazzeri, Giorgio Guazzoni, Piergiuseppe Colombo, Armando Santoro, Rozzano, Italy, Ottavio De Cobelli, Ettore Di Trapani, Milano, Italy, Gloria Nohales, Barcelona, Spain, Llorente Carlos, Ramon Duran-Merino, Madrid, Spain
PD18-05  XPERTBLADDER MONITOR TEST FOR FAILURE DEFINITION OF PATIENTS UNDER ACTIVE SURVEILLANCE FOR RECURRENT LOW-RISK NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) WITH NEGATIVE CITOLOGY
Rodolfo Hurle*, Alberto Saita, Massimo Lazzeri, Paolo Casale, Nicola Maria Buffi, Giovanni Lughezzani, Vittorio Fasulo, Giulio Bevilacqua, Marco Paciotti, Luigi Domanico, Davide Maffei, Luisa Pasini, Giorgio Guazzoni, Rozzano, Italy

PD18-06  PROSPECTIVE EVALUATION OF THE PREDICTIVE ROLE OF IMMEDIATE URINE CYTOLOGY (IUC) AFTER TRANSURETHRAL RESECTION OF NON-MUSCLE INVASIVE BLADDER CANCER
Amr Elsawy*, Fady Kamal, Ahmed Harraz, Bedeer Ali-El-Dein, Mansoura, Egypt

PD18-07  A NON-INVASIVE URINE-BASED METHYLATION BIOMARKER PANEL FOR BLADDER CANCER DETECTION
Thomas Hermanns*, Zurich, Switzerland, Andrea J. Savio, Ekaterina Otkhov-Mitsel, Toronto, Canada, Andrea Mari, Florence, Italy, Karim Saba, Zurich, Switzerland, Bimal Bhindi, Bethany Gill, Jenna Sykes, Cynthia Kuk, Toronto, Canada, Cedric Poyet, Peter J. Wild, Zurich, Switzerland, Aidan Noon, Shaheena Bashir, Tristan Juvet, Toronto, Canada, Ricardo A. Rendon, Halifax, Canada, David Waltregny, Liege, Belgium, Theodorus van der Kwast, Antonio Finelli, Girish S. Kulkarni, Neil E. Fleshner, Kirk Lo, Bharati Bapat, Alexandre R. Zlotta, Toronto, Canada

PD18-08  ACTIVE SURVEILLANCE IN LOW RISK BLADDER CANCER. IS IT A SAFE OPTION?
Fernando Lozano*, Carles X Raverotos, Albert Carrion, Jordi Ropero, Marta Allue, Luis A. Castro, Raul Cocera, Juan Morote, Barcelona, Spain

PD18-09  INCREASED BACILLUS CALMETTE-GUÉRIN TREATMENT INTENSITY ASSOCIATED WITH IMPROVED OUTCOMES IN ELDERLY PATIENTS WITH NON-MUSCLE-INVASIVE BLADDER CANCER

PD18-10  OPTIMAL SUBCLASSIFICATION SYSTEM FOR INTERMEDIATE-RISK NON-MUSCLE INVASIVE BLADDER CANCER
Kazuhiro Matsumoto*, Eiji Kikuchi, Yoshinori Yanai, Nozomi Hayakawa, Naoya Niwa, Takahiro Maeda, Hiroshi Asanuma, Mototsugu Oya, Tokyo, Japan

PD18-11  POSSIBLE ROLE OF 5-ALPHA REDUCTASE INHIBITORS IN NON-INVASIVE BLADDER UROTHELIAL NEOPLASM: MULTICENTRIC RETROSPECTIVE STUDY
Antonio Luigi Pastore*, Latina, Italy, Cosimo De Nunzio, Rome, Italy, Matteo Balzarro, Verona, Italy, Yazen Al Salhi, Andrea Fuschì, Alessia Martoccia, Latina, Italy, Nelia Amigoni, Verona, Italy, Andrea Tubaro, Rome, Italy, Walter Artibani, Verona, Italy, Antonio Carbone, Latina, Italy

PD18-12  PROGNOSTIC IMPACT OF CIS DISTRIBUTION IN A COHORT OF HIGH RISK NMIBC
Francesca Pisano*, Antoni Sanchez Pui, Oscar Rodriguez Faba, Ferran Albigea, Lucia Mosquera Secane, Jose Daniel Subiela, Alberto Breda, Joan Palou, Barcelona, Spain

*Presenting author

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
Saturday, May 4, 2019 | Plenary: Prime Time, Saturday, Morning Session | 7:30 am - 11:30 am
Room W375e @ McCormick Place

7:30 | JOURNAL OF UROLOGY 2018: YEAR IN REVIEW
Presenter: Joseph Smith

7:35 | JOURNAL OF UROLOGY: TOP PAPERS: FEMALE UROLOGY AND URODYNAMICS
Presenter: Toby Chai

7:45 | JOURNAL OF UROLOGY: TOP PAPERS: STONES, BPH AND ERECTILE DYSFUNCTION
Presenter: Jason Hedges

7:55 | JOURNAL OF UROLOGY: TOP PAPERS: PROSTATE CANCER
Presenter: Laurence Klotz

8:05 | JOURNAL OF UROLOGY: TOP PAPERS: TESTIS, BLADDER AND RENAL CANCER
Presenter: Badrinath Konety

8:15 | JOURNAL OF UROLOGY LECTURE: EVOLVING STRATEGIES IN THE MANAGEMENT OF SMALL RENAL MASSES
Presenter: Peter Clark

8:35 | PANEL DISCUSSION: OPIOIDS AND UROLOGY
Moderator: Gregory Auffenberg
Panelists: Joseph Alukal, Geeta Nagpal, Asokumar Buvanendran, Vernon Pais

9:20 | PRESIDENTIAL ADDRESS
AUA President: Robert Flanigan

9:40 | RAMON GUITERAS LECTURE: MORE ARROWS IN OUR QUIVER - TARGETING THE ADAPTIVE MOLECULAR LANDSCAPE OF ADVANCED PROSTATE CANCER
Presenter: Martin Gleave

10:00 | JOHN K. LATTIMER LECTURE: DIABETES AND UROLOGICAL DISEASE: NO SUGAR COATING
Presenter: Hunter Wessells

10:20 | PRESENTATION OF HONORARY MEMBERS AND SECRETARY COMMENDATIONS FOR GLOBAL LEADERSHIP

10:30 | CONFEDERACIÓN AMERICANA DE UROLOGÍA (CAU) LECTURE: UPPER TRACT TRANSITIONAL CELL CANCER: 2020
Presenter: Alberto Breda

10:45 | EUROPEAN UROLOGICAL ASSOCIATION (EAU) LECTURE: FERTILITY PRESERVATION IN CANCER PATIENTS
Presenter: Jens Sonksen

11:00 | UROLOGICAL ASSOCIATION OF ASIA (UAA) LECTURE: KETAMINE UROPATHY: A DECADE ON
Presenter: Peggy Chu

11:15 | SOCIÉTÉ INTERNATIONALE D’UROLOGIE (SIU) LECTURE: A PATIENT-CENTERED APPROACH TO BLADDER MANAGEMENT AFTER SPINAL CORD INJURY
Presenter: Sean Elliott

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Saturday, May 4, 2019 | Plenary: Next Frontier, Saturday, Afternoon Session | 1:00 pm - 4:00 pm
Room W375d @ McCormick Place

1:00 | AUA GUIDELINES UPDATE: OVERACTIVE BLADDER (OAB)
Presenter: Sandip Vasavada

1:15 | UROLOGY CARE FOUNDATION PRESENTATION
Presenter: Harris Nagler

1:25 | STATE-OF-THE-ART LECTURE: BURNOUT
Presenter: Chandru Sundaram

1:40 | PANEL DISCUSSION: TOP 10 APPS FOR WELLNESS, WORK AND STUDY
Moderator: Eugene Lee
Panelists: Matthew Resnick, Stacy Loeb, Anobel Odisho

2:00 | THE GREAT DEBATE
Judge: Louis Kavoussi
Moderators: Lee Richstone, Jessica Kreshover

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

*Presenting author
1:00 SETBACKS & OPERATIVE SOLUTIONS (SOS): PERCUTANEOUS NEPHROLITHOTOMY (PCNL)
Moderator: Bodo Knudsen
Panelists: James Lingeman, Jorge Gutierrez-Aceves, Mantu Gupta, Gyan Pareek, Casey Dauw

1:30 SURVIVOR DEBATE: PERCUTANEOUS NEPHROLITHOTOMY (PCNL) ACCESS
Moderator: Stephen Nakada
Debaters: Chi-Fai Ng, Jaime Landman, Michael Borofsky

2:00 LBA-01: LATE-BREAKING ABSTRACT: KIDNEY VOLUME LOSS FOLLOWING PERCUTANEOUS NEPHROLITHOTOMY UTILIZING 3D PLANIMETRY
Presenter: Laura Bukarina

2:10 COMPLEX CASES: STONE PREVENTION: DIET & MEDICATION
Moderator: David Goldfarb
Panelists: Kristina Penniston, Brian Eisner, Dean Assimos, Juan Calle, Ehud Gnessin

2:40 PANEL DISCUSSION: NEXT GENERATION LASERS
Moderator: Joel Teichman
Panelists: Khurshid Ghani, Michelle Semins, Olivier Traxer

3:00 SURGICAL TECHNIQUES: TIPS & TRICKS: PERCUTANEOUS NEPHROLITHOTOMY/URETEROSCOPY (PCNL/URS)
Moderator: Matthew Bultitude
Surgeons: Roger Sur, Robert Sweet, Damien Bolton, D. Duane Baldwin, Bradley Schwartz, Patrick Mufarrij

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP22-01</td>
<td>WHAT IS THE BEST DEFINITION OF BIOCHEMICAL RESPONSE TO SALVAGE RADIATION THERAPY IN PROSTATE CANCER PATIENTS TREATED FOR PSA RISING AFTER RADICAL PROSTATECTOMY? RESULTS FROM A MULTI-INSTITUTIONAL SERIES</td>
</tr>
<tr>
<td>MP22-02</td>
<td>GNRH ANTAGONISTS HAVE DIRECT INHIBITORY EFFECTS ON CASTRATION-RESISTANT PROSTATE CANCER VIA INTRACRINE ANDROGEN AND AR-V7 EXPRESSION</td>
</tr>
<tr>
<td>MP22-03</td>
<td>LONG-TERM ONCOLOGIC OUTCOMES OF PATIENTS TREATED WITH SALVAGE LYMPH NODE DISSECTION FOR NODAL RECURRENCE OF PROSTATE CANCER: RESULTS FROM A LARGE, MULTI-INSTITUTIONAL SERIES</td>
</tr>
<tr>
<td>MP22-04</td>
<td>INVESTIGATING THE IMPACT OF A LOWER TESTOSTERONE THRESHOLD ON CASTRATION-RESISTANT PROGRESSION IN PATIENTS ON CONTINUOUS ANDROGEN DEPRIVATION THERAPY</td>
</tr>
<tr>
<td>MP22-05</td>
<td>AKR1C3 PROMOTES AR-V7 PROTEIN STABILIZATION AND CONIFRS ANTIANDROGEN RESISTANCE IN ADVANCED PROSTATE CANCER</td>
</tr>
<tr>
<td>MP22-06</td>
<td>IMAGING TARGETED TREATMENTS VERSUS EXTENDED SALVAGE LYMPH NODE DISSECTION FOR PATIENTS WITH A SINGLE NODAL RECURRENT OF PROSTATE CANCER: A COMPARATIVE ANALYSIS FROM A LARGE MULTI-INSTITUTIONAL SERIES</td>
</tr>
<tr>
<td>MP22-07</td>
<td>INDIRECT COMPARISON OF SURVIVAL AND COST PER NUMBER NEEDED TO TREAT TO BENEFIT ANALYSIS OF ABIRATERONE, ENZALUTAMIDE, AND SIPUCEL-T IN THE TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER</td>
</tr>
</tbody>
</table>

*Presenting author
MP22-08 PROTEOSTASIS BY HSP70/STUB1 COMPLEX REGULATES ANDROGEN RECEPTOR VARIANTS EXPRESSION AND CONFFERS RESISTANCE TO ENZALUTAMIDE AND ABIRATERONE
Chengfei Liu*, Wei Lou, Joy C. Yang, Liangren Liu, Cameron M. Armstrong, Alan P. Lombard, Ruining Zhao, Onika DV Noel, Clifford G. Tepper, Mark Dall’Era, Hong-Wu Chen, Christopher P. Evans, Allen C. Gao, Sacramento, CA

MP22-09 COMBINATION THERAPIES TO PREVENT RESISTANCE TO ANDROGEN DEPRIVATION THERAPY IN PROSTATE CANCER
Zhenghong Li*, Carrie Qi Sun, Rebecca Arnold, John A. Petros, Carlos S. Moreno, Atlanta, GA

MP22-10 WHICH POSITIVE SURGICAL MARGINS FEATURES IMPACT ON THE RISK OF PROSTATE CANCER SPECIFIC MORTALITY? A DISEASE-TAILORED, COMPETING-RISK, LONG-TERM ANALYSIS
Nazareno Suardi*, Giorgio Gandaglia, Daniele Robesti, Simone Scuderi, Francesco Barletta, Paolo Dell’Oglio, Elio Mazzone, Marco Bandini, Massimo Freschi, Armando Stabile, Milan, Italy, Shahrokh Shariat, Vienna, Austria, Vincenzo Miron, Nicola Longo, Naples, Italy, Francesco Soria, David D’Andrea, Vienna, Austria, Roberta Lucianò, Umberto Capitanio, Nicola Fossati, Francesco Montorsi, Alberto Briganti, Milan, Italy

MP22-11 CHANGES IN COMORBIDITY AFTER TREATMENT WITH GONADOTROPIN-RELEASING AGONISTS VERSUS ANTI-ANDROGEN MONOTHERAPY IN MEN WITH ADVANCED NON-METASTATIC PROSTATE CANCER

MP22-12 ONCOLOGICAL OUTCOMES IN PATIENTS WITH HIGH LYMPH NODE BURDEN AFTER RADICAL PROSTATECTOMY
Raisa Pompe*, Hamburg, Germany, Pierre I. Karakiewicz, Zhe Tian, Montreal, Canada, Felix Preissier, Philipp Mandel, Frankfurt, Germany, Philipp Gild, Thomas Steuber, Georg Salomon, Markus Graefen, Margit Fisch, Hartwig Huland, Derya Tiliki, Hamburg, Germany

MP22-13 IMPACT OF RELATIONAL COHESION AND SEXUALITY ON THE QUALITY OF LIFE OF PATIENTS TREATED WITH GONADOTROPIN-RELEASING HORMONE (GNRH) AGONIST FOR PROSTATE CANCER: FINAL ANALYSIS OF THE EQUINOXE STUDY
Stéphane Droupy*, Nîmes, France, Marie-Hélène Colson, Marseille, France, Nathalie Pello-Leprince-Ringuet, Valérie Perrot, Boulogne-Billancourt, France, Aurelien Descazeaud, Limoges, France

MP22-14 DEFINITIVE THERAPY FOR MEN WITH NEWLY-DIAGNOSED OLIGOMETASTATIC PROSTATE CANCER: INITIAL SURGICAL OUTCOMES FROM A PHASE II STUDY
Mohit Gupta*, Amnav Sivastava, Hiten Patel, Diane Reyes, Bruce Trock, Phuoc Tran, Mohamed Allaf, Trinity Bivalacqua, Herbert Carter, Ashley Ross, Alan Partin, Edward Schaeffer, Kenneth Pienta, Christian Pavlovich, Baltimore, MD

MP22-15 DEPRESSION IN PROSTATE CANCER PATIENTS STARTING ANDROGEN DEPRIVATION THERAPY

MP22-16 LONG-TERM OUTCOMES AND PATTERNS OF RECURRENCE IN PATIENTS WITH CLINICAL LYMPHADENOPATHIES UNDERGOING RADICAL PROSTATECTOMY AS PART OF A MULTIMODAL TREATMENT

MP22-17 BIOCHEMICAL RECURRENCE IN PROSTATE CANCER AFTER SALVAGE SURGERY IN CORRELATION TO THE SITE OF RECURRENT DISEASE
David Pfister*, Yasin Pfallankavumkal, Friederike Haidl, Cologne, Germany
MP22-18 AGE INFLUENCE ON ADVERSE EVENTS IN PATIENTS TREATED WITH ABIRATERONE PLUS PREDNISONE, ENZALUTAMIDE AND RADIUM223 FOR METASTATIC CASTRATION RESISTANT PROSTATE CANCER: ANALYSIS OF REAL LIFE DATA FROM EUDRA VIGILANCE DATABASE.
Cosimo De Nunzio*, Giorgia Tema, Riccardo Lombardo, Olivia Voglino, Valeria Baldassarri, Fabiana Cancrini, Angela Sica, Antonio Nacchia, Andrea Tubaro, Rome, Italy

MP22-19 NEOADJUVANT APALUTAMIDE (ARN-509) AND RADICAL PROSTATECTOMY IN TREATMENT OF INTERMEDIATE TO HIGH RISK PROSTATE CANCER (NEAR)–INITIAL RESULTS OF A PHASE II TRIAL

MP22-20 ASSESSING THE IMPACT AND PREDICTORS OF OTHER-CAUSE MORTALITY IN PATIENTS TREATED WITH POST-PROSTATECTOMY SALVAGE RADIATION THERAPY IN ORDER TO AVOID POSSIBLE OVERTREATMENT: RESULTS FROM A LARGE, MULTI-INSTITUTIONAL STUDY
Elio Mazzone*, Nicola Fossati, Milan, Italy, R. Jeffrey Karnes, Stephen A. Boorjian, Luca Boeri, Rochester, MN, Alberto Bosai, Villelujif, France, Nadia Di Muzzo, Cesare Cozzarini, Barbara Noris Chiordia, Giorgio Gandaglia, Emanuele Zaffuto, Milan, Italy, Detlef Bartkowiak, UIm, Germany, Dirk Böhmer, Berlin, Germany, Shahrokh Shariat, Gregor Goldner, Vienna, Austria, Antonino Battaglia, Steven Joniau, Gaetan Devos, Karin Haustermans, Gert De Meerleer, Leuven, Belgium, Valérie Fonteyne, Piet Oat, Ghent, Belgium, Hein Van Poppel, Leuven, Belgium, Francesco Montorsi, Milan, Italy, Thomas Wiegel, Ulm, Germany, Alberto Briganti, Milan, Italy

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
MP23-09 PRE-PCNL INFECTION AND ITS EFFECT ON POST-PCNL OUTCOMES
Daron Smith*, LONDON, United Kingdom, Stuart Irving, Norwich, United Kingdom, Sarah Fowler, John Withington, London, United Kingdom, Ben Tomey, Oxford, United Kingdom, Oliver Wiseman, Cambridge, United Kingdom, Will Finch, Norwich, United Kingdom

MP23-10 STONE CULTURE SPECIES AND RISK OF SEPSIS AFTER PERCUTANEOUS Nephrolithotomy: A STUDY FROM THE EDGE RESEARCH CONSORTIUM
Carlos Mejia Arbelaez*, Alan Yaghoubian, Timothy Baltzer, Diann Sacco, Boston, MA, Ben Chew, Vancouver, Canada, Manoj Monga, Cleveland, OH, Amy Krambeck, Indianapolis, IN, Roger Sur, San Diego, CA, Bodo Knudsen, Columbus, OH, Nina Mikkilineni, Ojas Shah, New York City, NY, Karen Stern, Scottsdale, AZ, Smita De, Nicole Miller, Nashville, TN, Tarek ElBarou, Michael Souri, Justin Rose, Columbus, OH, Tim Large, Indianapolis, IN, Kymora Scotland, Colin Lunde, Dirk Lange, Vancouver, Canada, Thomas DiPina, Seth Bechis, San Diego, CA, Brian Eisner, Boston, MA

MP23-11 THE CONTINUOUS RENAL PELVIC DECOMPRESSION TECHNIQUE DURING URETEROSCOPY
Jonathan Wagmaister*, Neel H. Patel, Cristina Fox, Sean Fullerton, John L. Phillips, Majid Eshghi, Valhalla, NY

MP23-12 UNDERSTANDING URETERAL ACCESS SHEATH USE WITHIN A STATEWIDE COLLABORATIVE AND ITS EFFECTS ON SURGICAL OUTCOMES AND COMPLICATIONS
Kristen Meier*, Spencer Hiller, Royal Oak, MI, Casey Dauw, John Hollingsworth, Khurshed Ghani, Tae Kim, Kayya Swarna, Jaya Telang, Ann Arbor, MI, Mohammad Jafari, Royal Oak, MI, for the Michigan Urological Surgery Improvement Collaborative, Ann Arbor, MI

MP23-13 SAFETY AND EFFICACY OF PERCUTANEOUS Nephrolithotomy IN PATIENTS WITH NEUROGENIC BLADDER.
Issa El Chelghal*, Pascal Glemain, Francois-Xavier Madec, Loic Le Normand, Jerome Rigaud, Julien Branchereau, Marie-Aimee Perrouin-Verbe, Nantes, France

MP23-14 A COMPARISON OF PERIOPERATIVE STONE-FREE RATES AND COMPLICATIONS FOLLOWING PERCUTANEOUS Nephrolithotripsy BETWEEN LOWER, MID, AND UPPER POLE ACCESS LOCATIONS
Charles Nottingham*, Tim Large, Julia Fiuk, Amy Krambeck, Indianapolis, IN

MP23-15 EVALUATION OF STONE FREE RATE AND PERIOPERATIVE COMPLICATIONS IN PATIENTS WITH AND WITHOUT PRESTENTING TREATED FOR Nephrolithiasis WITH Ureterorenoscopy
Thilo Westhofen*, Christian G. Stief, Frank Strittmatter, Munich, Germany

MP23-16 RISK FACTORS FOR UNPLANNED ENCOUNTERS AFTER URETEROSCOPY: DEPRESSION, ANXIETY, IBS, FIBROMYALGIA, IC
Alexander Parker*, Bryan Pham, Joel Vetter, Ramakrishna Venkatesh, Alana Desai, St. Louis, MO

MP23-17 IN VITRO AND IN VIVO NEW EVIDENCE FOR FLEXOR VUE DEFLECTING ENDOSCOPIC SYSTEM USE: OPTIMIZATION OF THE STONE FREE RATE (SFR) AFTER RIRS
Alberto Saita*, Rozzano, Italy, Luca Villa, Milano, Italy, Marco Paciotti, Vittorio Pasul, Paolo Casale, Giovanni Lughezzani, Nicoletta Buffa, Rodolfo Hurle, Luigi Domanico, Giulio Bevilacqua, Roberto Peschechera, Massimo Lazzeri, Giorgio Guazzoni, Rozzano, Italy

MP23-18 A CLINICAL TRACKING PROGRAM FOR URETERAL STENTS INTEGRATED INTO EMR
Fady Ghali*, Dimitri Papagiannopoulos, Roger Sur, Seth Bechis, San Diego, CA

MP23-19 INTRODUCTION OF A NURSE LED STENT REMOVAL SERVICE USING THE SINGLE USE ISIRIS IN A TERTIARY REFERRAL STONE UNIT AND THE EFFECT ON PATIENT WAITING TIMES
Jane Collie*, Downham Market, United Kingdom, Syed Shah, Samih Al-Hayek, Jordan Durrant, Kasra Saeb-Parsy, Oliver Wiseman, Cambridge, United Kingdom

MP23-20 PEDIATRIC UROLITHIASIS: OVERVIEW OF TREATMENT OPTIONS AND OUTCOMES FROM A SINGLE CENTER
Salvatore Micali*, Luigi Bevilacqua, Modena, Italy, Ahmed Elsherbeny, Tanta, Egypt, Corrado Di Pietro, Silvia Cavallaro, Viviana Durante, Modena, Italy, Ahmed Elsaa, Tanta, Egypt, Stefano Pulitani, Nancy Ferrari, Alessandro Mofferin, Maria Chiara Sighinolfi, Giampaolo Bianchi, Bernardo Maria Rocco, Modena, Italy

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
ABSTRACT NUMBER | TITLE
--- | ---
MP24-01 | MULTIPARAMETRIC MRI FINDINGS IN PATIENTS WITH NEGATIVE CONFIRM MDX TISSUE TESTING
Daniel Artenstein*, Aaron Krug, Los Angeles, CA, Eugene Rhe, San Diego, CA, Ron Loo, Downey, CA, Stephen Williams, Polina Reyblat, Rex Parker, David Finley, Los Angeles, CA

MP24-02 | CLINICAL UTILITY OF CONFIRMMDX FOR PROSTATE CANCER IN A COMMUNITY UROLOGY PRACTICE
Paul Yonover*, Chicago, IL, Sandra Steyaert, Irvine, CA, Justin Cohen, Celeste Ruiz, Karolina Grafczynska, Elizabeth Garcia, Chicago, IL, Jessica DeHart, Michael Brawer, Jack Groskopf, Irvine, CA, Wim Van Crielinge, Ghent, Belgium

MP24-03 | RISK PREDICTION OF PROSTATE CANCER USING BASELINE PSA AND INHERITED GENETIC VARIANTS IN BLACK AND WHITE MEN
Mark Preston*, Kathryn Wilson, Boston, MA, Travis Gerke, Tampa, FL, Maxine Chen, Adam Kibel, Lorelei Mucci, Kathryn Penney, Boston, MA

MP24-04 | A 2-GENE MRNA URINE TEST FOR DETECTION OF HIGH-GRADE PROSTATE CANCER PRIOR TO INITIAL PROSTATE BIOPSY
Alexander Haee*, Hamburg, Germany, Geert Trooskens, Sandra Steyaert, Daphne Hessels, Michael Brawer, Irvine, CA, Virginie Vlaeminck-Guillen, Lyon, France, Jack Schalken, Nijmegen, Netherlands, Jack Groskopf, Irvine, CA, Wim Van Crielinge, Ghent, Belgium

MP24-05 | SELF-IDENTIFIED AFRICAN AMERICANS AND PROSTATE CANCER RISK: WEST AFRICAN GENETIC ANCESTRY IS ASSOCIATED WITH PROSTATE CANCER DIAGNOSIS AND WITH HIGHER GLEASON SUM ON BIOPSY
Sandra Gaston*, Boston, MA, Rick Kittles, Duarte, CA, Soroush Rais-Bahrami, Peter Koletjis, James Bryant, Jeffrey Nix, Birmingham, AL, Mark DeGuenter, George Adams, Homewood, AL, Ebony Shah, Indianapolis, IN, James Kearns, Ravi Chinsky, Kerry Dehimer, Norma Terrin, Hong Chang, Boston, MA, William Grizzle, Birmingham, AL

*Presenting author
MP24-11 MAGNETIC RESONANCE IMAGING-ULTRASOUND FUSION BIOPSY VERSUS TRANS-PERINEAL BIOPSY IN THE SETTING OF PRIOR NEGATIVE TRANS-RECTAL PROSTATE BIOPSY: DOES MRI-US FUSION HAVE THE EDGE?
Michael Stencel*, James Kelley, Sharon Hill, Nathan Hale, Samuel Deem, Charleston, WV

MP24-12 PSA DERIVED BIOMARKERS PREDICT CLINICALLY SIGNIFICANT CANCER ON POST-MRI BIOPSY IN PATIENTS WITH PROSTATE IMAGING REPORTING AND DATA SYSTEM (PI-RADS) CATEGORY 3 LESIONS

MP24-13 IMPACT OF THE 2012 UNITED STATES PREVENTIVE SERVICES TASK FORCE PROSTATE CANCER GUIDELINES ON PARTICIPATION IN A COUNTY WIDE FREE PROSTATE CANCER SCREENING PROGRAM
Varun Talanki*, Qinjie Wang, William Berg, Howard Adler, Stony Brook, NY

MP24-14 COMPARISON OF MICRO-ULTRASOUND AND MULTIPARAMETRIC MRI IMAGING FOR PROSTATE CANCER: AN INTERNATIONAL META-ANALYSIS
Giovanni Lughezzani*, Rozzano, Italy, Ander Astobieta, Bilbao, Spain, Frederic Staerman, Reims, France, Eric A. Klein, Robert Abouassaly, Ahmed El-Shefai, Cleveland, OH, Eure Gregg, Virginia Beach, VA

MP24-15 MR/US FUSION TARGETED BIOPSY FAILED TO DETECT PROSTATE CANCER: ROLE OF CONFIRMMDX® AS AN ADJUNCT
Michael Witthaus, Matthew Truong*, Jacob Gantz, Thomas Frye, Ahmed Ghazi, Edward Messing, Jean Joseph, Hiroshi Miyamoto, Hani Rashid, Rochester, NY

MP24-16 LOCAL ANAESTHETIC TRANS-PERINEAL PROSTATE (LATP) BIOPSY USING THE PRECISION POINT ACCESS SYSTEM: A MULTI-CENTRE OUTCOME ANALYSIS.

MP24-17 CAN WE BETTER UNDERSTAND PI-RADS 3 LESIONS AND AVOID UNNECESSARY BIOPSIES?

MP24-18 SYSTEMATIC REVIEW AND META-ANALYSIS OF SIGNIFICANT CANCER DETECTION BY MRI-TARGETED BIOPSY COMPARED TO SYSTEMATIC BIOPSY
Veeru Kasivisvanathan*, Armando Stabile, Ioana Neves, Francesco Giganti, London, United Kingdom, Massimo Valerio, Lausanne, Switzerland, Yaalini Shanmugabavan, London, United Kingdom, Keiran Clement, Glasgow, United Kingdom, Debasish Sarkar, Winchester, United Kingdom, Yiannis Philippou, Oxford, United Kingdom, David Thurtle, Cambridge, United Kingdom, Jon Deeks, Birmingham, United Kingdom, Mark Emberton, London, United Kingdom, Yemisi Takwoingi, Birmingham, United Kingdom, Caroline Moore, London, United Kingdom

MP24-19 NEGATIVE PREDICTIVE VALUE OF MULTI-PARAMETRIC MRI IN DETECTION OF CLINICALLY SIGNIFICANT PROSTATE CANCER: A SYSTEMATIC REVIEW AND META-ANALYSIS
Niranjan Sathianathen*, Minneapolis, MN, Altan Omer, Oxford, United Kingdom, Caroline Moore, Veerapan Kasivisvanathan, London, United Kingdom, Roderick van den Bergh, Utrecht, Netherlands, Shonit Punwani, London, United Kingdom, Christof Kastner, Tristan Barrett, Cambridge, United Kingdom, Declan Murphy, Melbourne, Australia, James Catto, Sheffield, United Kingdom, Ruth MacPherson, Fergus Gleeson, Richard Bryant, Freddie Hamdy, Oxford, United Kingdom, Hashim Ahmed, London, United Kingdom, Alastair Lamb, Oxford, United Kingdom

MP24-20 THE POTENTIAL FOR CIRCULATING EXTRACELLULAR VESICLE MICRORNAs TO PREDICT PROSTATE CANCER AGGRESSIVENESS
Morgan Zenner*, Michael Abern, Ruben Sauer, Gayatry Mohapatra, Klara Valyi-Nagy, Larisa Nonn, Chicago, IL

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP25-01</td>
<td>CONDITIONAL DISEASE-FREE SURVIVAL IN HIGH RISK LOCALIZED RENAL CELL CARCINOMA TREATED WITH OR WITHOUT ADJUVANT SUNITINIB</td>
</tr>
<tr>
<td></td>
<td>ning shao*, yan qu, fang wan, ding ye, shanghai, China, People’s Republic of</td>
</tr>
<tr>
<td>MP25-02</td>
<td>INTRAOPERATIVE MOLECULAR IMAGING CAN IDENTIFY THORACIC RENAL CELL CARCINOMA METASTASES</td>
</tr>
<tr>
<td></td>
<td>Christopher Corbett*, Lydia Frenzel-Sulyok, Michael Shin, Philadelphia, PA, Philip Low, West Lafayette, IN, Sunil Singhal, Thomas Guzzo, Philadelphia, PA</td>
</tr>
<tr>
<td>MP25-03</td>
<td>PRESURGICAL TREATMENT WITH PAZOPANIB IMPROVED SURGICAL OUTCOME OF ADVANCED RENAL CELL CARCINOMA WITH INFERIOR VENA CAVA TUMOR THROMBUS.</td>
</tr>
<tr>
<td></td>
<td>Yasuyoshi Okamura*, Mariko Sakamoto, Yukari Bando, Kotaro Suzuki, Takuto Hara, Tomoaki Terakawa, Junya Furukawa, Kenichi Harada, Nobuyuki Hinata, Yuzo Nakano, Masato Fujisawa, Kobe, J apan</td>
</tr>
<tr>
<td>MP25-04</td>
<td>OUTCOMES OF METASTATIC RENAL CELL CARCINOMA PATIENTS WITH SARCOMATOID HISTOLOGY - A SINGLE TERTIARY CARE CENTER STUDY IN THE TKI ERA.</td>
</tr>
<tr>
<td></td>
<td>Florian Janisch*, Constantin Fühner, Christian P. Meyer, Tobias Hillenmacher, Thomas Klotzbücher, Christina Kienapfel, Philipp Marks, Roland Dahlem, Hamburg, Germany, Shahrokh F. Shariat, Vienna, Austria, Margit Fisch, Michael Rink, Hamburg, Germany</td>
</tr>
<tr>
<td>MP25-05</td>
<td>THE IMPACT OF CYTOREDUCTIVE NEPHRECTOMY IN METASTATIC RENAL CELL CARCINOMA – A REAL-WORLD INVESTIGATION IN THE TKI ERA</td>
</tr>
<tr>
<td></td>
<td>Florian Janisch, Constantin Fühner, Christian P. Meyer, Tobias Hillenmacher, Thomas Klotzbücher, Christina Kienapfel, Malte Vetterlein, Roland Dahlem, Hamburg, Germany, Shahrokh F. Shariat, Vienna, Austria, Margit Fisch, Michael Rink*, Hamburg, Germany</td>
</tr>
<tr>
<td>MP25-06</td>
<td>COMPLETE METASTASECTOMY FOR RENAL CELL CARCINOMA IN THE CONTEMPORARY ERA</td>
</tr>
<tr>
<td></td>
<td>Timothy Lyon*, R. Houston Thompson, Christine Lohse, Parast Shin, Stephen Boorjian, Brian Costello, John Cheville, Bradley Leibovich, Rochester, MN</td>
</tr>
<tr>
<td>MP25-07</td>
<td>NEUTROPHIL-TO-LYMPHOCYTE RATIO AS A PREDICTIVE BIOMARKER FOR RESPONSE TO NIVOLUMAB IN ASIAN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA</td>
</tr>
<tr>
<td></td>
<td>Yukari Bando*, Mariko Sakamoto, Yasu Yoshii Okamura, Kotaro Suzuki, Takuto Hara, Tomoaki Terakawa, Junya Furukawa, Kenichi Harada, Nobuyuki Hinata, Yuzo Nakano, Masato Fujisawa, Kobe, J apan</td>
</tr>
<tr>
<td>MP25-08</td>
<td>THE EFFICACY AND SAFETY OF TYROSINE KINASE INHIBITORS IN PATIENTS WITH VON HIPPEL-LINDAU DISEASE</td>
</tr>
<tr>
<td></td>
<td>Kaifang Ma*, Kan Gong, Baoan Hong, Haibiao Xie, Beijing, China, People’s Republic of</td>
</tr>
<tr>
<td>MP25-09</td>
<td>EARLY FLARE-RESPONSE OF C-REACTIVE PROTEIN IS ASSOCIATED WITH EFFICACY OF NIVOLUMAB IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA</td>
</tr>
<tr>
<td></td>
<td>Shohi Fukuda*, Kazutaka Saito, Yosuke Yasuda, Tokyo, J apan, Takahiko Soma, Saitama, J apan, Masahiro Toide, Hiroshi Fukushima, Shingo Moriyama, Sho Uehara, Tokyo, J apan, Naotaka Fukui, Saitama, J apan, Toshiki Kijima, Soichiro Yoshida, Minato Yokoyama, Junichiro Ishioka, Yoh Matsuoka, Tokyo, J apan, Yukio Kageyama, Saitama, J apan, Yasuhisa Fuji, Tokyo, J apan</td>
</tr>
<tr>
<td>MP25-10</td>
<td>GENOMIC BIOMARKERS OF RESPONSE TO NIVOLUMAB/IPILIMUMAB AND NIVOLUMAB MONOTHERAPY IN 108 PATIENTS WITH METASTATIC RENAL CELL CARCINOMA</td>
</tr>
<tr>
<td></td>
<td>Renzo DiNatale*, Chung-Han Lee, Diego Chowell, Vladimir Makarov, Almedina Redzematovic, Samuel Murray, Maria Carla, Martin Voss, Jonathan Coleman, Paul Russo, Robert Motzer, Timothy Chan, Ari Hakimi, New York, NY</td>
</tr>
<tr>
<td>MP25-11</td>
<td>A MOUSE AVATAR MODEL FOR SCREENING TARGETED SEQUENTIAL THERAPIES FOR INDIVIDUAL RENAL CELL CARCINOMA PATIENTS</td>
</tr>
<tr>
<td></td>
<td>Ravan Moret*, Xin Zhang, Grace Maresh, Daniel Canter, Marc Matrana, New Orleans, LA, Christudas Morais, Glenda Gobe, Queensland, Australia, Sunil Talwar, Maria Latsis, Stephen Bardot, Li Li, New Orleans, LA</td>
</tr>
</tbody>
</table>
MP25-12 PREDICTORS OF MAJOR COMPLICATIONS AFTER CYTOREDUCTIVE NEPHRECTOMY FOR METASTATIC RENAL CELL CARCINOMA: INSIGHTS FROM A RETROSPECTIVE MULTICENTRE REGISTRY.

Riccardo Campi*, Florence, Italy, Maximilian C. Kriegmair, Mannheim, Germany, Riccardo Bertolo, Cleveland, OH, Tobias Klatte, Bournemouth, United Kingdom, Jose Rubio, Valencia, Spain, Tobias Maurer, Munich, Germany, Siaka Van Bruaene, Kortrijk, Belgium, Estefania Linares, Vital Hevia, Madrid, Spain, Mireia Musquera, Barcellona, Spain, Ithaar Derweesh, Louisiana J o lla, CA, Georgi Guruli, Richmond, VA, Eduard Rousel, Maarteen Albertsen, Leuven, Belgium, Nicola Pavan, Francesco Claps, Trieste, Italy, Alessandro Antonelli, Brescia, Italy, Shudong Zhang, Lulin Ma, Beijing, China, People's Republic of, Riccardo Autorino, Richmond, VA, Francesco Porpiglia, Torino, Italy, Umberto Capitanio, Milano, Italy, Andrea Minervini, Firenze, Italy, Maria Carmen Mir, Valencia, Spain

MP25-13 PATIENTS PERSPECTIVE ON CYTOREDUCTIVE NEPHRECTOMY AFTER CARMENTS

Dena Battle*, Alexandria, VA, Daniel George, Durham, NC, Axel Bex, Trieste, Italy, Michael Staehler, München, Germany

MP25-14 AN EVALUATION OF THE ROLE OF TUMOR LOAD IN CYTOREDUCTIVE NEPHRECTOMY

Andrew Silagy*, New York, NY, Julian Marcon, Roy Mano, Cihan Duzgol, Kyle Blum, Renzo DiNatale, Oguz Akin, Jonathan Coleman, Paul Russo, Ari Hakimi, New York City, NY

MP25-15 ATYPICAL PATTERNS AND TIMING OF RECURRENCES AFTER MINIMALLY INVASIVE SURGERY FOR LOCALIZED KIDNEY CANCER

Paul Russo, Kyle Blum*, Robert Motzer, New York, NY

MP25-16 GENOMIC CORRELATES WITH METASTATIC DISSEMINATION IN CYTOREDUCTIVE NEPHRECTOMY


MP25-17 NEUTROPHIL- AND PLATELET-TO-LYMPHOCYTE RATIOS AS PROGNOSTIC FACTORS OF DISEASE-FREE SURVIVAL IN HIGH-RISK RENAL CELL CARCINOMA

Anup Patel*, London, United Kingdom, Alain Ravaud, Bordeaux, France, Robert Motzer, New York, NY, Allan Pantuck, Los Angeles, CA, Michael Staehler, Munich, Germany, Bernard Escudier, Villejuif, France, Jean-François Martini, La J o lla, CA, Marjiaose Lechuga, Milan, Italy, Xun Lin, La J o lla, United Kingdom, Daniel George, Durham, NC

MP25-18 PURE TRANSABDOMINAL APPROACH FOR RENAL CELL CARCINOMA WITH SUPRADIAPHRAGMATIC TUMOR THROMBUS: A SINGLE-INSTITUTION INITIAL EXPERIENCE IN CHINA

Hai Bi*, Guoliang Wang, Yi Huang, Lulin Ma, Beijing, China, People's Republic of

MP25-19 IMPACT OF DISAGREEMENT BETWEEN TWO RISK GROUP MODELS ON PROGNOSIS IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA

Kazutaka Okita*, Shingo Hatakeyama, Hiroaki, J apan, Toshikazu Tanaka, Sapporo, J apan, Yoshinori Iketa, Toyama, J apan, Toshikazu Tanaka, Aomori, J apan, Naoki Fujita, Hiroaki, J apan, Yusuke Ishibashi, Aomori, J apan, Hayato Yamamoto, Takahiro Yoneyama, Yasuhiro Hashimoto, Hiroaki, J apan, Kazuaki Yoshikawa, Mutsu, J apan, Toshiaki Kawaguchi, Aomori, J apan, Naoya Masumori, Sapporo, J apan, Hiroshi Kitamura, Toyama, J apan, Chikara Ohyama, Hiroaki, J apan

MP25-20 EFFECT OF CHANGES IN SKELETAL MUSCLE MASS ON ONCOLOGICAL OUTCOMES DURING FIRST-LINE SUNITINIB THERAPY FOR METASTATIC RENAL CELL CARCINOMA

Hiroki Ishihara*, Toshio Takagi, Tsunenori Kondo, Hirofumi Fukuda, Kazuhiko Yoshida, Junpei Iizuka, Hirohito Kobayashi, Masayoshi Okumi, Hideki Ishida, Kazunari Tanabe, Tokyo, J apan

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP26-01</td>
<td>PRETREATMENT NEUTROPHIL-TO-LYMPHOCYTE RATIO IS A NOVEL BIOMARKER FOR PREDICTING WORSE CLINICAL OUTCOME IN CHEMO-RESISTANT UROTHELIAL CARCINOMA PATIENTS TREATED WITH PEMBROLIZUMAB</td>
</tr>
<tr>
<td></td>
<td>Koichiro Ogihara*, Eiji Kikuchi, Tokyo, J apan, Takashi Okabe, Saitama, J apan, Seiya Hattori, Kanagawa, J apan, Ryo Yamashita, Shizuoka, J apan, Syunsuke Yoshimine, Suguru Shirotake, Saitama, J apan, Kazuhiro Matsumoto, Ryuichi Mizuno, Tokyo, J apan, Satoshi Haru, Kanagawa, J apan, Masafumi Oyama, Takeshi Masuda, Saitama, J apan, Masashi Niwakawa, Shizuoka, J apan, Mototsugu Oya, Tokyo, J apan</td>
</tr>
<tr>
<td>MP26-02</td>
<td>CAN WE PREDICT PT0 AFTER NAC IN PTS WITH MIBC? A CHALLENGE OF OPTIMAL CANDIDATE SELECTION FOR BLADDER PRESERVATION THERAPY</td>
</tr>
<tr>
<td></td>
<td>Hirotaka Horiguchi*, Shingo Hatakeyama, Hayato Yamamoto, Atsushi Imai, Takahiro Yoneyama, Yasuhiro Hashimoto, Hiroaki, J apan, Takuya Koie, Gifu, J apan, Chikara Ohyama, Hiroaki, J apan</td>
</tr>
<tr>
<td>MP26-03</td>
<td>CONTEMPORARY ANALYSIS OF URETEROENTERIC STRICTURES AFTER OPEN AND ROBOT-ASSISTED RADICAL CYSTECTOMY: A POPULATION-BASED STUDY</td>
</tr>
<tr>
<td>MP26-04</td>
<td>ROLE OF ADJUVANT CISPLATIN-BASED CHEMOTHERAPY FOLLOWING RADICAL CYSTECTOMY IN MUSCLE-INVASIVE AND LOCALLY ADVANCED BLADDER CANCER: SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED TRIALS</td>
</tr>
<tr>
<td></td>
<td>Do Kyung Kim*, Joo Yong Lee, seoul, Korea, Republic of, Jae Hung Jung, wonju, Korea, Republic of, Yoon Soo Hah, Kyo Chul Koo, Kwang Suk Lee, Byung Ha Chung, Kang Su Cho, seoul, korea, Republic of</td>
</tr>
<tr>
<td>MP26-05</td>
<td>CONSERVATIVE MANAGEMENT FOLLOWING NON-INVASIVE DOWNSTAGING WITH NEOADJUVANT CHEMOTHERAPY FOR MUSCLE-INVASIVE BLADDER CANCER PATIENTS REFUSING RADICAL CYSTECTOMY</td>
</tr>
<tr>
<td></td>
<td>Takehisa Onishi, Sho Sekito*, Takashi Terabe, Takuji Shibahara, ise, J apan</td>
</tr>
<tr>
<td>MP26-06</td>
<td>SIGNIFICANCE OF FRAILTY ON TREATMENT SELECTION (RADICAL CYSTECTOMY OR BLADDER PRESERVATION THERAPY) IN PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER</td>
</tr>
<tr>
<td></td>
<td>Shingo Hatakeyama*, Atsushi Imai, Hayato Yamamoto, Teppi Matsumoto, Osamu Soma, Takahiro Yoneyama, Yasuhiro Hashimoto, Takuya Koie, Chikara Ohyama, Hiroaki, J apan</td>
</tr>
<tr>
<td>MP26-07</td>
<td>URETERAL STENT URINE CULTURE FOLLOWING RADICAL CYSTECTOMY WITH ILEAL CONDUIT DIVERSION PREDICTS UTI-RELATED READMISSION RATES</td>
</tr>
<tr>
<td></td>
<td>Hamza Beano*, Caitlin Hensel, Jiaxian He, William Worroll, Rupali Bose, Jared Brown, Madolin Carol Haskin, Kris Gaston, Peter Clark, Stephen Riggs, Charlotte, NC</td>
</tr>
<tr>
<td>MP26-08</td>
<td>LASIX RENAL SCINTIGRAPHY RESULTS CORRELATE WITH URETEROENTERIC STRicture RATES AND TOTAL READMISSION RATES FOLLOWING RADICAL CYSTECTOMY</td>
</tr>
<tr>
<td></td>
<td>Hamza Beano*, Jiaxian He, Caitlin Hensel, William Worroll, Jared Brown, Jaclyn Mieczkowski, Kris Gaston, Peter Clark, Stephen Riggs, Charlotte, NC</td>
</tr>
<tr>
<td>MP26-09</td>
<td>THE CONTEMPORARY USE OF NEOADJUVANT CHEMOTHERAPY PRIOR TO RADICAL CYSTECTOMY FOR UROTHELIAL CANCER: THE IMPACT OVER A 13 YEAR PERIOD</td>
</tr>
<tr>
<td></td>
<td>Anojan Navaratnam*, Kyle Rose, Haidar Abdul-Muhsin, Kassem Faraj, Laila Elias, Amit Syal, Sarah Eversman, Michael Patton, Mark Tyson, Erik Castle, Phoenix, AZ</td>
</tr>
<tr>
<td>MP26-10</td>
<td>THE ROLE OF CUTANEOUS URETEROSTOMY DIVERSION: A MULTICENTER ANALYSIS</td>
</tr>
<tr>
<td></td>
<td>Laura Izquierdo, Barcelona, Spain, Riccardo Lombardo, Giorgia Tema, Fabiana Cancrini, Rome, Italy, Giuseppe Lotrecchiano, Benevento, Italy, Andrea Minervini, Florence, Italy, Giuseppe Simone, Rome, Italy, Luca Cindolo, Carlo D’orta, Vasto, Italy, Tarek Ajami, Barcelona, Spain, Alessandro Antonelli, Brescia, Italy, Daniele Castellani, Ancona, Italy, Antonio Alcaraz, Barcelona, Spain, Andrea Tubaro, Cosimo De Nunzio*, Rome, Italy</td>
</tr>
</tbody>
</table>
MP26-11 **TEN-YEAR ONCOLOGIC OUTCOMES FOLLOWING ROBOT ASSISTED RADICAL CYSTECTOMY: RESULTS FROM THE INTERNATIONAL ROBOTIC CYSTECTOMY CONSORTIUM**

Ahmed A. Hussein*, Ahmed S. Elsayed, Naf Al-Aldhaam, Buffalo, NY, Ashok Hemal, Winston Salem, NC, Juan Palou, Catalonia, Spain, Michael Stockel, Hamburg, Germany, Jihad Kaouk, Cleveland, OH, Paul May, Buffalo, NY, Hannah Kias, Aalst, Belgium, Zhe Jing, Osei Jennifer A, Buffalo, NY, James O. Peabody, Detroit, MI, Alexandre Mottiri, Aalst, Belgium, Khurshid A. Guru, Buffalo, NY

MP26-12 **NODE-POSITIVE (CN+) UROTHELIAL CARCINOMA OF THE BLADDER TREATED WITH CHEMOTHERAPY AND RADICAL CYSTECTOMY: CLINICAL OUTCOMES AND DEVELOPMENT OF A RISK PREDICTION MODEL**

Osama Alalao*, Catrina Mueller-Leonhard, Providence, RI, Simon P. Kim, Aurora, CO, Ali Amin, Christopher Tucci, Gyan Pareek, Anthony Mega, Dragan Golijanin, Boris Gershman, Providence, RI

MP26-13 **COMPARATIVE EFFECTIVENESS OF CHEMORADIATION VERSUS CHEMOTHERAPY AND RADICAL CYSTECTOMY FOR CLINICALLY NODE-POSITIVE (CN+) BLADDER CANCER**

Osama Alalao*, Catrina Mueller-Leonhard, Providence, RI, Simon P. Kim, Aurora, CO, Ali Amin, Christopher Tucci, Gyan Pareek, Anthony Mega, Dragan Golijanin, Boris Gershman, Providence, RI

MP26-14 **CHALLENGING THE DOGMA: OUTCOMES FOLLOWING ROBOT-ASSISTED CYSTECTOMY IN PATIENTS WITH PREVIOUS PELVIC IRRADIATION**

Teck Wei Tan*, Singapore, Singapore, Kerri Beckmann, Ramesh Thuraiara, Muhammad Shamim Khan, Rajesh Nair, London, United Kingdom

MP26-15 **MOLECULAR SUBTYPING REVEALS LUMINAL BLADDER TUMORS HAVE LOWER RATES OF PATHOLOGICAL UPSTAGING AT RADICAL CYSTECTOMY**

Yair Lotan*, Dallas, TX, Stephen Boorjian, Rochester, MN, Jingbin Zhang, Vancouver, Canada, Trinity Bivalacqua, Baltimore, MD, Seth Lerner, Houston, TX, Sima Porten, San Francisco, CA, Thomas Wheeler, Houston, TX, Ryan Hutchinson, Franto Francis, Dallas, TX, Marguerite du Plessis, Vancouver, Canada, Elai Davlicioni, San Diego, CA, Robert Svette, San Antonio, TX, Peter Black, Ewan Gibb, Vancouver, Canada

MP26-16 **RACIAL AND ECONOMIC DISPARITIES IN THE USE OF NEOADJUVANT CHEMOTHERAPY FOR PATIENTS WITH UROTHELIAL MUSCLE INVASIVE BLADDER CANCER**

Dennis Robins*, Nicholas Suss, Viktor Flores, Matthew Smith, Jeffrey Weiss, Brian McNeil, Andrew Winer, Brooklyn, NY

MP26-17 **COULD A HISTORY OF NON-MUSCLE INVASIVE BLADDER CANCER HAVE A PROGNOSTIC ROLE IN CT2-4AN0M0 BLADDER CANCER PATIENTS TREATED WITH RADICAL CYSTECTOMY AND NEOADJUVANT CHEMOTHERAPY?**

Emina Kayama*, Eiji Kikuchi, Kyohei Hakozaki, Nobuyuki Tanaka, Tokyo, J apan, Gou Kaneko, Suguru Shiratake, Saitama, J apan, Yasumasa Miyazaki, Kanagawa, J apan, Shunsuke Yokomine, Saitama, J apan, Takahiro Maeda, Kanagawa, J apan, Kunimitsu Kanai, Masafumi Oyama, Saitama, J apan, Yosuke Nakajima, Satoshi Hara, Kanagawa, J apan, Tetsuo Monma, Saitama, J apan, Mototsugu Oya, Tokyo, J apan

MP26-18 **ROBOT-ASSISTED RADICAL CYSTECTOMY VERSUS OPEN: ROBOTIC CYSTECTOMY IS ASSOCIATED WITH REDUCED POSTOPERATIVE SEPSIS, SHORTER LENGTHS OF STAY, AND IS COST NEUTRAL**

Marc Nelson*, Emanuel Eguia, Patrick Sweigert, Eric Kirshenbaum, Marcus Quek, Marshall Baker, Gopal Gupta, Maywood, IL

MP26-19 **THE COMPREHENSIVE COMPLICATION INDEX CCI: A PROPOSED MODIFICATION TO OPTIMIZE COMPLICATION REPORTING AFTER CYSTECTOMY AND URINARY DIVERSION**

Marc A. Furrer*, Juerg Huesler, Adrian Fellmann, Fiona C. Burkhard, George N. Thalmann, Patrick Y. Wuethrich, Bern, Switzerland

MP26-20 **ROBOTIC RADICAL CYSTECTOMY OUTCOMES BEFORE AND AFTER ENHANCED RECOVERY AFTER SURGERY (ERAS) PATHWAY**


APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP27-01</td>
<td>MODIFIED-APPROACH FOR MINI MALE URETHRAL SLING PLACEMENT WITH INFLATABLE PENILE PROSTHESIS FOR ERECTILE DYSFUNCTION AND CLIMACTURIA OR MILD STRESS URINARY INCONTINENCE: A TWO-CENTER EXPERIENCE</td>
</tr>
<tr>
<td>MP27-02</td>
<td>GLANS HYPERMOBILITY ASSOCIATED WITH PLACEMENT OF A PENILE PROSTHESIS: INCIDENCE AND TREATMENT OPTIONS</td>
</tr>
<tr>
<td>MP27-03</td>
<td>PENILE PROSTHESIS RESERVOIR REMOVAL: SURGICAL DESCRIPTION AND PATIENT OUTCOMES</td>
</tr>
<tr>
<td>MP27-04</td>
<td>SHOULD CONTINUATION OF ANITTHROMBOTICS AT TIME OF INFLATABLE PENILE PROSTHESIS SURGERY BE STANDARD OF CARE?</td>
</tr>
<tr>
<td>MP27-05</td>
<td>PENILE IMPLANT SURGERY DOES NOT REDUCE PENILE SIZE; A PROSPECTIVE STUDY OF 122 PATIENTS FOLLOWED UP FOR TWO YEARS</td>
</tr>
<tr>
<td>MP27-06</td>
<td>IMMEDIATE PREOPERATIVE BLOOD GLUCOSE AND HEMOGLOBIN A1C LEVELS ARE NOT PREDICTIVE OF POST-OPERATIVE INFECTIONS IN DIABETIC MEN UNDERGOING PENILE PROSTHESIS PLACEMENT</td>
</tr>
<tr>
<td>MP27-07</td>
<td>EJACULATION SPARING THULIUM LASER ENUCLEATION OF THE PROSTATE (ESTHULEP): OUTCOMES ON A LARGE COHORT.</td>
</tr>
<tr>
<td>MP27-08</td>
<td>ACUTE KIDNEY INJURY AND WEIGHT-BASED GENTAMICIN: INCREASED RISK IN THE CONTEXT OF UROLOGIC PROSTHETIC SURGERY</td>
</tr>
<tr>
<td>MP27-09</td>
<td>FASTING BLOOD SUGAR AT THE TIME OF PENILE PROSTHESIS SURGERY IS NOT CORRELATED WITH THE OUTCOME OF SURGERY</td>
</tr>
</tbody>
</table>

*Presenting author
MP27-10 LARGER MALLEABLE ROD DIAMETER IS ASSOCIATED WITH MORE COMPLICATIONS AND LESS PATIENT SATISFACTION
Mohamad Habous*, Jedda, Saudi Arabia, Patrick Teloken, Queensland, Australia, Osama Abdelwahab, Jedda, Saudi Arabia, Osama Laban, Tabouk, Saudi Arabia, Saleh Binsaleh, Riyadh, Saudi Arabia, John Mulhall, New York, NY, Usama Kamil, Jedda, Saudi Arabia, David Ralph, London, United Kingdom

MP27-11 A NOVEL VIDEO-BASED PATIENT EDUCATION PROGRAM TO REDUCE PENILE PROSTHETIC SURGERY CANCELLATIONS
Tung-Chin Hsieh*, San Diego, CA, Martin Gross, Hanover, NH, Ashley Tapscott, Huntersville, NC, Ranjith Ramasamy, Miami, FL, Ashely Bowen, Oklahoma City, OK, Sheldon Freedman, Las Vegas, NV, Michael Wierschem, Plano, TX, Charles Welliver, Albany, NY, Frank Simonini, Mesa, AZ, Alberto Duboy, Tampa, FL, Raul Clavijo, Davis, CA, Jay Simhan, Philadelphia, PA, Arnold Bullock, St Louis, MO, Paul Perito, Miami, FL

MP27-12 RELATIONSHIPS BETWEEN ERECTILE DYSFUNCTION, PROSTATE CANCER TREATMENT TYPE AND INFLATABLE PENILE PROSTHESIS IMPLANTATION
Hossein sadeghi-nejad*, Dennis Fried, East Orange, NJ, Dian Gu, Shouhao Zhou, Weiguoh He, Sharon Giordano, Houston, TX, Drew Helmer, East Orange, NJ, Chan Shen, Houston, TX

MP27-13 URETHRAL REPAIR CAN BE SAFELY PERFORMED DURING PROSTHETIC SURGERY IN PLANNED OR DAMAGE CONTROL SETTING USING PROLONGED SUPRAPUBIC TUBE URINARY DIVERSION
Yooni Yi*, Joceline Fuchs, Michael Davenport, Maxim McKibben, Allen Morey, Dallas, TX

MP27-14 THE MULCAHY SALVAGE REVISITED: A CRITICAL APPRAISAL OF ANTISEPTIC IRRIGATION
Shu Pan*, Ricardo Munarriz, Boston, MA, Dayron Rodriguez, Dallas, TX

MP27-15 NEUROGENIC BLADDER IS AN INDEPENDENT RISK FACTOR FOR COMPLICATIONS ASSOCIATED WITH INFLATABLE PENILE PROSTHESIS PLACEMENT
Chirag Dave*, Ahmed Khalaf, Bruce Trock, Arthur Burnett, Baltimore, MD

MP27-16 IMPACT OF KEY PINCH STRENGTH ON PATIENT PREFERENCE FOR INFLATABLE PENILE PROSTHESIS: A PROSPECTIVE STUDY COMPARING COLOPLAST™ AND AMS™ MODELS
John Masterson*, Laura Horodyski, Ronak Patel, Omer Kineish, Miami, FL, Taylor Kohn, Baltimore, MD, Ranjith Ramasamy, Miami, FL

MP27-17 PENILE PROSTHESIS IS UNDERUTILIZED FOLLOWING RADICAL PROSTATECTOMY AND RADICAL CYSTECTOMY: RESULTS FROM A STATEWIDE CLAIMS DATABASE

MP27-18 INTRAOPERATIVE USE OF BETADINE IRRIGATION IS ASSOCIATED WITH A 9-FOLD INCREASE OF PENILE PROSTHESIS INFECTION
Madeleine Manka*, Kevin Hebert, Nicole Dodge, David Yang, Tobias Kohler, Landon Trost, Rochester, MN

MP27-19 SUPRAPUBIC CATHETER PLACEMENT DURING INFLATABLE PENILE PROSTHESIS PLACEMENT ASSOCIATES WITH IMPROVED OUTCOMES IN SPINAL CORD INJURED PATIENTS WITH NEUROGENIC BLADDER
Chirag Dave*, Ahmed Khalaf, Bruce Trock, Arthur Burnett, Baltimore, MD

MP27-20 THE REPAIR OF ABNORMALITIES IN THE PENILE SUSPENSORY LIGAMENT
Oliver Ralph*, Mattia Anfonso, Nikita Shroff, Gideon Blecher, Nim Christopher, David Ralph, Chesham, United Kingdom

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
<table>
<thead>
<tr>
<th>Time</th>
<th>Number</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00</td>
<td>PD19-01</td>
<td>DETRUSOR WALL THICKNESS DOES NOT PREDICT A SUCCESSFUL TRIAL WITHOUT CATHETER AFTER ACUTE URINARY RETENTION IN PATIENTS ON MEDICAL TREATMENT FOR BENIGN PROSTATIC HYPERPLASIA.</td>
<td>Cosimo De Nunzio*, Giorgia Tema, Riccardo Lombardo, Rome, Italy, Luca Cindolo, Maida Bada, Vasto, Italy, Fabiana Cancrini, Antonio Nacchia, Rome, Italy, Luigi Ships, Vasto, Italy, Mauro Gacci, Martina Milanesi, Gianmartin Cito, Sergio Serni, Florence, Italy, Andrea Tubaro, Rome, Italy</td>
</tr>
<tr>
<td>7:10</td>
<td>PD19-02</td>
<td>CONTEMPORARY ACTIVE CLINICAL TRIALS IN BENIGN PROSTATIC HYPERPLASIA</td>
<td>Karis Buford*, Allison Polland, Jacob Khurgin, Brooklyn, NY, Bilal Chughtai, New York, NY, Ervin Teper, David Silver, Ariel Schulman, Brooklyn, NY</td>
</tr>
<tr>
<td>7:20</td>
<td>PD19-03</td>
<td>CORRELATION OF ALPHA BLOCKER WITH DEMENTIA IN PATIENTS WITH BENIGN PROSTATE HYPERPLASIA: A NATIONALWIDE POPULATION-BASED STUDY USING THE NATIONAL HEALTH INSURANCE SERVICE DATABASE</td>
<td>Tae Bum Sik, Hoon Choi, Jae Young Park, Bae Jae Hyun, Byung Jo Jeon, Ansan, Korea, Republic of, Hong Chung, Chungju, Korea, Republic of, Sung Tae Cho*, Seoul, Korea, Republic of</td>
</tr>
<tr>
<td>7:30</td>
<td>PD19-04</td>
<td>THE PROSTATIC URETHRAL LIFT (UROLIFT) VERSUS THE THERMAL WATER VAPOR ABLATION (REZUM) FOR MINIMALLY INVASIVE TREATMENT OF BPH: A COMPARISON OF IMPROVEMENTS AND DURABILITY IN 3-YEAR CLINICAL OUTCOMES</td>
<td>Shaun Shepherd, Hossein Saddat, Toronto, Canada, Bilal Chughtai, New York, NY, Dean Elberman*, Toronto, Canada</td>
</tr>
<tr>
<td>7:40</td>
<td>PD19-05</td>
<td>THE OPTIMAL HDL CHOLESTEROL LEVEL FOR PREVENTING BPH REQUIRING TREATMENT USING NATIONAL HEALTH INSURANCE DATABASE</td>
<td>Sangjun Yoo*, Juhyun Park, Sung Yong Cho, Min Chul Cho, Seoul, Korea, Republic of, Jae-Seung Paik, Incheon, Korea, Republic of, Hyeon Jeong, Hwancheol Son, Seoul, Korea, Republic of</td>
</tr>
<tr>
<td>8:00</td>
<td>PD19-07</td>
<td>CHARACTERIZING THE TOP 100 ARTICLES IN BENIGN PROSTATIC HYPERPLASIA USING BIBLIOMETRIC ANALYSIS</td>
<td>Alan Paniagua Cruz*, Chandy Ellimoottil, Casey Dauw, Ted Skolarus, Ann Arbor, MI</td>
</tr>
<tr>
<td>8:10</td>
<td>PD19-08</td>
<td>MARIJUANA, ALCOHOL, ED AND DEPRESSION: EPIDEMIOLOGIC CORRELATIONS WITH BPH/LUTS</td>
<td>Heather Carmichael, Aurora, CO, Granville Lloyd*, Denver, CO</td>
</tr>
<tr>
<td>8:20</td>
<td>PD19-09</td>
<td>CLUSTER ANALYSIS REVEALS PROSTATE ENLARGEMENT AND DETRUSOR DYSFUNCTION DRIVE NEED FOR SURGICAL TREATMENT OF BPH/LUTS.</td>
<td>Richard Fantus*, Chicago, IL, Cecilia Chang, Brian Helfand, Evanston, IL</td>
</tr>
<tr>
<td>8:30</td>
<td>PD19-10</td>
<td>CLINICAL PRACTICE PATTERNS FOR LOWER URINARY TRACT SYMPTOMS BY UROLOGISTS AND NON-UROLOGISTS IN THE UNITED STATES: AN ANALYSIS OF THE NATIONAL AMBULATORY MEDICAL CARE SURVEY</td>
<td>Thomson Tai*, Maywood, IL, Robert Blackwell, Springfield, IL, Spencer Hart, Gopal Gupta, Maywood, IL</td>
</tr>
<tr>
<td>8:40</td>
<td>PD19-11</td>
<td>PROSTATE MRI IMPROVES VOLUME ESTIMATION COMPARED TO TRANSRECTAL ULTRASOUND IN LARGE PROSTATE GLANDS</td>
<td>Zain A Abedali*, Tim Large, Adam Calaway, Michael O Koch, James E Lingeman, Ronald S Boris, Indianapolis, IN</td>
</tr>
<tr>
<td>8:50</td>
<td>PD19-12</td>
<td>THE CRITICAL IMPORTANCE OF POST HOLMIUM LASER ENUCLERATION OF THE PROSTATE (HOLEP) PSA AND PSA DENSITY FOLLOWING SURGERY</td>
<td>Zain A Abedali*, Tim Large, Adam Calaway, Michael O Koch, James E Lingeman, Ronald S Boris, Indianapolis, IN</td>
</tr>
<tr>
<td>Time</td>
<td>Number</td>
<td>Title</td>
<td>Authors</td>
</tr>
<tr>
<td>-------</td>
<td>--------</td>
<td>-------------------------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>7:00</td>
<td>PD20-01</td>
<td>VALIDATION OF AN ANIMAL MODEL OF PELVIC RADIATION INDUCED FEMALE SEXUAL AND URINARY DYSFUNCTION</td>
<td>Lindsey Burleson*, Greenville, NC, Shelby Powers, Greenville, NC, Michael Odom, Dillon Ellis, Jae Won Jung, Greenville, NC, Bridget Koontz, Durham, NC, Johanna Hannan, Greenville, NC</td>
</tr>
<tr>
<td>7:10</td>
<td>PD20-02</td>
<td>CHARACTERIZATION OF CERVIX INNERVATION: RELEVANCE TO LOOP ELECTROSURGICAL EXCISION PROCEDURES</td>
<td>Madeline Monaghan, Olivia Giovannetti, Kingston, Canada, Johanna Hannan*, Greenville, NC, Barry Komisaruk, Newark, NJ, Sue Goldstein, Irwin Goldstein, San Diego, CA, Michael Adams, Kingston, Canada</td>
</tr>
<tr>
<td>7:20</td>
<td>PD20-03</td>
<td>FEMALE PERIURETHRAL TISSUE INNERVATION STUDIES: MID-URETHRAL SLING SURGERIES MAY RESULT IN SEXUAL DYSFUNCTION</td>
<td>Olivia Giovannetti, Madeline Monaghan, Kingston, Canada, Johanna Hannan*, Greenville, NC, Barry Komisaruk, Newark, NJ, Sue Goldstein, Irwin Goldstein, San Diego, CA, Michael Adams, Kingston, Canada</td>
</tr>
<tr>
<td>7:30</td>
<td>PD20-04</td>
<td>SEXUAL FUNCTION OUTCOMES IN PATIENTS AND PATIENTS’ SPOUSES AFTER MIDURETHRAL SLING PROCEDURE FOR STRESS URINARY INCONTINENCE: DATA FROM A MINIMUM OF 5 YEARS OF FOLLOW-UP</td>
<td>Phil Hyun Song*, Daegu, Korea, Republic of, Gyeong Eun Min, Seoul, Korea, Republic of, Yeong Uk Kim, Jae Young Choi, Young Hwii Ko, KI Hak Moon, Hee Chang Jung, Daegu, Korea, Republic of</td>
</tr>
<tr>
<td>7:40</td>
<td>PD20-05</td>
<td>RISK FACTORS FOR DYSPAREUNIA AMONG FEMALE ATHLETES</td>
<td>Kirkpatrick B. Fergus*, Andrew J. Cohen, Benjamin N. Breyer, San Francisco, CA</td>
</tr>
<tr>
<td>8:00</td>
<td>PD20-07</td>
<td>PREDICTORS OF FEMALE SEXUAL DYSFUNCTION IN INTERSTITIAL CYSTITIS/BLADDER PAIN SYNDROME, OTHER CHRONIC PAIN CONDITIONS AND HEALTHY CONTROLS IN THE MAPP RESEARCH NETWORK</td>
<td>Renee Rolston, Jamaica, NY, Alisa Stephens-Shields, Philadelphia, PA, J. Quentin Clemens, Ann Arbor, MI, John Krieger, Seattle, WA, Craig Newcomb, Philadelphia, PA, Jennifer Anger, Los Angeles, CA, Catherine Bradley, Bradley A. Erickson, Iowa City, IA, Henry Lay, St. Louis, MO, Larissa Rodriguez*, Los Angeles, CA</td>
</tr>
<tr>
<td>8:10</td>
<td>PD20-08</td>
<td>SAFETY AND EFFICACY OF CO2 FRACTIONAL LASER THERAPY IN WOMEN WITH VESTIBULODYNIA: AN INTERIM ANALYSIS</td>
<td>Irwin Goldstein*, Sue Goldstein, Noel Kim, San Diego, CA, Susan Kellogg Spadt, Rosemont, PA, Filippo Murina, Milan, Italy</td>
</tr>
<tr>
<td>8:20</td>
<td>PD20-09</td>
<td>ONOBOTULIUMTOXIN A VERSUS KENALOG FOR INTRAVAGINAL TRIGGER POINT INJECTIONS IN THE TREATMENT OF CHRONIC PELVIC PAIN</td>
<td>Jamie Bartley*, Lansing, MI, Laura Nguyen, Hamilton, Canada, Deborah Hasenau, Jason Gilgeran, Larry Sirls, Esther Han, Lauren Tenneyson, Kenneth Peters, Royal Oak, MI</td>
</tr>
<tr>
<td>8:30</td>
<td>PD20-10</td>
<td>SINGLE-CENTER EXPERIENCE WITH VESTIBULECTOMY FOR THE TREATMENT OF VESTIBULODYNIA AND DYSPAREUNIA</td>
<td>Rachel Rubin, Elizabeth Malphrus*, Washington, DC, Christine Mayuiga, Washington, DC, Lucy Teene, James Simon, Washington, DC</td>
</tr>
<tr>
<td>8:40</td>
<td>PD20-11</td>
<td>THE EFFICACY AND SAFETY OF MIRABEGRON ON URINARY SYMPTOMS AND SEXUAL DYSFUNCTION IN WOMEN WITH OVERACTIVE BLADDER SYNDROME</td>
<td>Marilena Gubbiotti*, Perugia, Italy, Maurizio Serati, Varese, Italy, Antonella Giannantoni, Siena, Italy</td>
</tr>
<tr>
<td>8:50</td>
<td>PD20-12</td>
<td>COMPARING PROVIDER-REPORTED SEXUAL HEALTH COUNSELING OF MALE AND FEMALE RADICAL CYSTECTOMY PATIENTS</td>
<td>Natasha Gupta*, Lauren Kucirka, Baltimore, MD, Alice Semerjian, Ypsilanti, MI, Trinity J. Bivalacqua, Baltimore, MD</td>
</tr>
<tr>
<td>TIME</td>
<td>NUMBER</td>
<td>TITLE</td>
<td>ABSTRACT</td>
</tr>
<tr>
<td>-------</td>
<td>--------</td>
<td>----------------------------------------------------------------------</td>
<td>----------</td>
</tr>
<tr>
<td>7:00</td>
<td>PD21-01</td>
<td>EFFICACY OF TAMSULOSIN FOR THE MANAGEMENT OF PAINFUL ORGASM AFTER RADICAL PROSTATECTOMY: A PROSPECTIVE, NON-PLACEBO CONTROLLED STUDY</td>
<td>Hyun Jun Park*, Sung Woo Park, Tae Nam Kim, Busan, Korea, Republic of</td>
</tr>
<tr>
<td>7:10</td>
<td>PD21-02</td>
<td>IMPACT OF PENILE TRICTION THERAPY ON ERECTILE DYSFUNCTION IN A COHORT OF MEN WITH PEYRONIE’S DISEASE</td>
<td>David Yang*, Rochester, MN, Yifan Meng, St. Louis, MO, Joshua Savage, Kevin Wymer, Tobias Kohler, Landon Trost, Rochester, MN</td>
</tr>
<tr>
<td>7:20</td>
<td>PD21-03</td>
<td>ARE INDUSTRY PAYMENTS FOR TADALAFIL ASSOCIATED WITH PRESCRIBING HABITS AMONG UROLOGISTS AND PRIMARY CARE PHYSICIANS?</td>
<td>Kevin Chua*, Brooklyn, NY, Gen Li, Peter Stahl, Elias Hyams, New York, NY</td>
</tr>
<tr>
<td>7:30</td>
<td>PD21-04</td>
<td>PATIENT-OFFICE PRACTICE DYNAMICS IN THE INQUIRY REGARDING RESTORATIVE THERAPIES FOR ED</td>
<td>Carolyn A. Salter*, Helen Bernie, Denise Asafu-Adjei, Elizabeth Schofield, John P. Mulhall, New York, NY</td>
</tr>
<tr>
<td>7:40</td>
<td>PD21-05</td>
<td>PRIAPISM FROM RECREATIONAL INTRACavernOSAL INJECTIONS IN A HIGH RISK METROPOLITAN COMMUNITY</td>
<td>Hanson Zhao*, Carl Berdahl, Ariel Moradzadeh, Justin Houman, Howard Kim, Karyn Elber, Joshua Pevnick, Jennifer Anger, Los Angeles, CA</td>
</tr>
<tr>
<td>7:50</td>
<td>PD21-06</td>
<td>PENILE LOW INTENSITY SHOCK WAVE TREATMENT FOR PDE5I REFRACTORY ERECTILE DYSFUNCTION: A RANDOMIZED SHAM-CONTROLLED CLINICAL TRIAL</td>
<td>Jose Vinay*, Daniel Moreno, Osvaldo Rajmil, Eduardo Ruiz-Castañé, Josvany Sanchez-Curbelo, Barcelona, Spain</td>
</tr>
<tr>
<td>8:00</td>
<td>PD21-07</td>
<td>LOW-INTENSITY EXTRACorporeal SHOCKWAVE THERAPY IMPROVES ERECTILE DYSFUNCTION IN KIDNEY TRANSPLANT RECIPIENTS. RESULTS OF A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, SHAM CONTROLLED STUDY.</td>
<td>Kleiton Yamaçake, Felipe Carneiro, Rodolfo Lourenço, Afonso Colso Piovesan, Miguel Srougi, William Carlos Nahas, Ioannis Michel Antonopoulos*, Sao Paulo, Brazil</td>
</tr>
<tr>
<td>8:10</td>
<td>PD21-08</td>
<td>EFFECTIVENESS OF EXTRA-SHOCK WAVE THERAPY FOR CHRONIC PROSTATITIS/CHRONIC PELVIC PAIN: A POPULATION-BASED PROPENSITY SCORE ADJUSTED ANALYSIS</td>
<td>Andrea Cacci*, Gianmarco Cito, Nicola Mondaini, Florence, Italy, Girolamo Morelli, Pisa, Italy, Graziano Vignolini, Riccardo Campi, Francesco Sessa, Fabrizio Di Maida, Simone Morselli, Florence, Italy, Giuseppe Morgia, Catania, Italy, Mauro Gacci, Sergio Sermi, Andrea Minervini, Florence, Italy, Giorgio Ivan Russo, Catania, Italy</td>
</tr>
<tr>
<td>8:20</td>
<td>PD21-09</td>
<td>DAILY TADALAFIL THERAPY: A NEW TREATMENT OPTION FOR PEYRONIE’S DISEASE?</td>
<td>Hyun Jun Park*, Sung Woo Park, Tae Nam Kim, Busan, Korea, Republic of</td>
</tr>
<tr>
<td>8:30</td>
<td>PD21-10</td>
<td>DUTASTERIDE IN THE LONG-TERM MANAGEMENT OF STUTTERING PRIAPISM</td>
<td>Ryan Baker*, Yooni Yi, Michael Davenport, Rachel Bergeson, Allen Morey, Dallas, TX</td>
</tr>
<tr>
<td>8:40</td>
<td>PD21-11</td>
<td>PERICYTE-DERIVED EXOSOME PROMOTES CAVEROUS ANGIogenesis AND NEURAL REGENERATION AND RESCUES ERECTILE FUNCTION</td>
<td>Anita Limanjaya, Mi-Hye Kwon, Kang-Moon Song, Kalyan Ghatak, Nguyen Nhat Minh, Min-Ji Choi, Jiyeon Ock, Guo Nan Yin, Ji-Kan Ryu, Jun-Kyu Suh*, Incheon, Korea, Republic of</td>
</tr>
<tr>
<td>8:50</td>
<td>PD21-12</td>
<td>EFFICACY AND SAFETY OF A MIXED EXTRACT OF TRIGONELLA FOENUM-GRAECUM SEED AND LESPEDEZA CUNEATA IN THE TREATMENT OF TESTOSTERONE DEFICIENCY SYNDROME: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL</td>
<td>Hyun Jun Park, Kyeong Soo Lee, Eun Kyoung Lee, Nam Cheol Park*, Busan, Korea, Republic of</td>
</tr>
</tbody>
</table>

*Presenting author
<table>
<thead>
<tr>
<th>Time</th>
<th>Number</th>
<th>Title</th>
<th>Authors/Institutions</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00</td>
<td>PD22-01</td>
<td>ANTIBIOTICS AFTER URETHROPLASTY DO NOT REDUCE URETHRAL STRICTURE DISEASE RECURRENCE</td>
<td>Omotola Ashorobi*, Joseph Fougerousse, Kimberly Martin, John Patrick Selph, Birmingham, AL</td>
</tr>
<tr>
<td>7:10</td>
<td>PD22-02</td>
<td>A MULTICENTER ASSESSMENT OF STRICTION LOCATION AND TYPE OF URETHROPLASTY ON ERECTILE FUNCTION</td>
<td>Jonathan Wingate*, Seattle, WA, Sean Elliott, Minneapolis, MN, Alex Vanni, Burlington, MA, Bradley Erickson, Iowa City, IA, Jeremy Myers, Salt Lake City, UT, Benjamin Breyer, San Francisco, CA, Nejd Alsikafi, Gurnee, IL, Jill Buckley, San Diego, CA, Bryan Voelzke, Seattle, WA</td>
</tr>
<tr>
<td>7:20</td>
<td>PD22-03</td>
<td>POST-OPERATIVE RETROGRADE URETHROGRAM FINDINGS AND URETHRAL STRICTURE RECURRENCE</td>
<td>Madeline Cancian, Atlanta, GA, Eric Jung*, Kennon Miller, Providence, RI</td>
</tr>
<tr>
<td>7:30</td>
<td>PD22-04</td>
<td>AUGMENTATION URETHRAL RECONSTRUCTION USING TISSUE-ENGINEERED ORAL MUCOSA GRAFT MUKOCELL®</td>
<td>Leonidas Karapanos*, Vahudin Zugor, Ilgar Akbarov, Caroline Eich, Axel Heidenreich, Cologne, Germany</td>
</tr>
<tr>
<td>7:40</td>
<td>PD22-05</td>
<td>SURGICAL TREATMENT FOR RECURRENT BULBAR URETHRAL STRICTURE: A RANDOMISED OPEN LABEL SUPERIORITY TRIAL OF OPEN URETHROTOMY VERSUS ENDOSCOPIC URETHROTOMY (THE OPEN TRIAL).</td>
<td>Watkin Nick*, London, United Kingdom, Beatriz Goulao, Aberdeen, United Kingdom, Sonya Carneill, Shen Jing, Newcastle, United Kingdom, Graeme MacLennan, John Norrie, Aberdeen, United Kingdom, Jonathan Cook, Oxford, United Kingdom, Elaine McColl, Matthew Breckons, Luke Vale, Rebecca Forbes, Stephanie Currer, Newcastle, United Kingdom, Mark Forrest, Aberdeen, United Kingdom, Jennifer Wilkinson, Newcastle, United Kingdom, Daniela Andruch, London, United Kingdom, Stewart Barclay, Newcastle, United Kingdom, Anthony Munday, London, United Kingdom, James N’Dow, Aberdeen, United Kingdom, Steve Payne, Manchester, United Kingdom, Robert Pickard, Newcastle, United Kingdom</td>
</tr>
<tr>
<td>7:50</td>
<td>PD22-06</td>
<td>ONE-YEAR SAFETY AND EFFICACY OUTCOMES ON A NOVEL DRUG COATED BALLOON (DCB) FOR URETHRAL STRICTURE DISEASE - THE ROBUST I STUDY</td>
<td>Sean Elliott*, Minneapolis, MN, Ramon Virasoro, Jessica DeLong, Virginia Beach, VA, Rafael Estrella, Miami, FL, Merycarla Pichardo, Merycarla Pichardo, Santo Domingo, Dominican Republic, Ramon Rodriguez, Panama City, Panama, Gustavo Espino, San Fernando, Spain, George Suarez, Miami, FL, George Webster, Durham, NC, Gerald Jordan, Virginia Beach, VA</td>
</tr>
<tr>
<td>8:00</td>
<td>PD22-07</td>
<td>ANALYSIS OF PROGRESSIVE LUMENAL EXPANSION ON URETHRAL MICROPERFUSION USING LASER DOPPLER FLOWMETRY IN NEW ZEALAND WHITE MALE RABBITS</td>
<td>Teja Maruvada*, Gregory Joice, Chanya Elakkad, Sarah Beck, E. James Wright, Baltimore, MD</td>
</tr>
<tr>
<td>8:10</td>
<td>PD22-08</td>
<td>OPIOID AND NON-OPIOID BASED CARE PATHWAYS FOR RECONSTRUCTIVE MALE ANTERIOR URETHRAL SURGERY: EVIDENCE-BASED APPROACH FOR OPIOID STEWARDSHIP</td>
<td>Jason Joseph*, Kevin Hebert, Jack Andrews, Matthew Ziegelmann, Elizabeth Habermann, Matthew Gettman, Boyd Viers, Rochester, MN</td>
</tr>
<tr>
<td>8:20</td>
<td>PD22-09</td>
<td>NATIONAL TRENDS IN URETHRAL STRICTURE MANAGEMENT</td>
<td>Jonathan Wingate*, Sarah Holt, Niels Johnsen, Seattle, WA</td>
</tr>
<tr>
<td>8:30</td>
<td>PD22-10</td>
<td>SHORT-TERM SUCCESS DOES NOT GUARANTEE LONG-TERM OUTCOMES IN THE RADIATED RECTO-URETHRAL FISTULA REPAIR PATIENT</td>
<td>Urszula Kowalk*, Brian Inouye, Stephanie Sexton, Brian Gilmore, Durham, NC, Arman Kahokehr, Adelaide, Australia, Andrew Peterson, Christopher Mantyh, John Migaly, Durham, NC</td>
</tr>
<tr>
<td>8:40</td>
<td>PD22-11</td>
<td>FEMALE URETHRAL RECONSTRUCTION IS NOT ASSOCIATED WITH POST OPERATIVE URINARY INCONTINENCE</td>
<td>Angelo E Gousse*, Jan-Michael Pohudka, Miami, FL, Hari Tungnugtulla, New Brunswick, NJ</td>
</tr>
</tbody>
</table>
BLADDER NECK/URETHRAL CLOSURE IN WOMEN USING A CONTINENT CUTANEOUS DIVERSION AND SUFFERING REFRACTORY URETHRAL URINARY INCONTINENCE


APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
<table>
<thead>
<tr>
<th>Time</th>
<th>Number</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00</td>
<td>V03-01</td>
<td>ROBOT-ASSISTED RENOVASCULAR RECONSTRUCTION FOR RENAL ARTERY ANEURYSM</td>
<td>Cristina Ferreiro*, Xavier Bonet, Jose Francisco Suarez, Esther Alba, David Leon, Luís Riera, Francesc Vigués, Barcelona, Spain</td>
</tr>
<tr>
<td>7:10</td>
<td>V03-02</td>
<td>ROBOTIC URETERAL REIMPLANTATION AFTER URINARY DIVERSION FOR ANASTOMOTIC STRicture</td>
<td>Christine White*, James Nolan, Ryan Dorin, Joseph Wagner, Hartford, CT</td>
</tr>
<tr>
<td>7:20</td>
<td>V03-03</td>
<td>ROBOTIC EXTRAVASCULAR GRAFT PLACEMENT FOR NUTCRACKER SYNDROME</td>
<td>Roger Yau*, Georges-Pascal Haber, Cleveland, OH</td>
</tr>
<tr>
<td>7:30</td>
<td>V03-04</td>
<td>ROBOTIC-ASSISTED DOUBLE BUCCAL MUCOSAL URETEROPLASTY FOR THE MANAGEMENT OF MULTIPLE URETERAL STRICTURES</td>
<td>Randall Lee*, Zho Lee, Aeen Asghar, David Strauss, Kevin Yang, Philadelphia, PA, Toshiyuki China, Tokyo, Japan, Michael Metro, Daniel Eun, Philadelphia, PA</td>
</tr>
<tr>
<td>7:40</td>
<td>V03-05</td>
<td>ROBOTIC ASSISTED LAPAROSCOPIC BUCCAL MUCOSAL GRAFT URETEROPLASTY FOR RECURRENT UPPER AND LOWER URETERAL STRICTURES</td>
<td>Michael Avallone, Alan Quach*, Brian Flynn, Aurora, CO</td>
</tr>
<tr>
<td>8:00</td>
<td>V03-07</td>
<td>TECHNICAL CONSIDERATIONS OF SINGLE PORT URETERONECYSTOSTOMY UTILIZING DA VINCI SP PLATFORM</td>
<td>Kevin Hebert*, Jason Joseph, Matthew Gettman, Matthew Tollefson, Igor Frank, Boyd Viers, Rochester, MN</td>
</tr>
<tr>
<td>8:10</td>
<td>V03-08</td>
<td>EXTRA ANATOMICAL URINARY DERIVATION (EAUD) FOR THE DEFINITIVE TREATMENT OF COMPLEX URETERAL STENOSIS: DESCRIPTION OF A MODIFIED TECHNIQUE IN THE SUPINE POSITION</td>
<td>Ioannis Kartalas Goumas*, Michele Talso, Elena Tondelli, Vimercate, Italy</td>
</tr>
<tr>
<td>8:20</td>
<td>V03-09</td>
<td>RIGHT ROBOTIC INTRACORPOREAL ILEAL URETER WITH SINGLE-POSITION PORT PLACEMENT USING DA VINCI XI®</td>
<td>Leanna Mah*, Onika Noel, Jennifer Rothschild, Marc Dalf’era, Noah Canvasser, Sacramento, CA</td>
</tr>
<tr>
<td>8:30</td>
<td>V03-10</td>
<td>ROBOTIC-ASSISTED LEFT ILEAL URETER INTERPOSITION FOR A LONG SEGMENT URETERAL STRICTURE</td>
<td>David M Strauss*, Kevin K Yang, Zho Lee, Aeen M Asghar, Randall A Lee, Michael J Metro, Daniel Eun, PHILADELPHIA, PA</td>
</tr>
</tbody>
</table>
FLEXIBLE URETEROSCOPY-ASSISTED TRANSPERITONEAL ROBOTIC SURGERY FOR THE TREATMENT OF URETERAL STRICTURES: TECHNICAL ASPECTS AND EARLY RESULTS

Gianmarco Bondonno, Umari Paolo*, Di Martino Jessica, Billia Michele, Volpe Alessandro, Afferi Luca, Novara, Italy

ROBOTIC DISTAL URETEROURETEROSTOMY FOR FOCAL DISTAL URETERAL STRICTURES

Kevin K Yang*, Ziho Lee, Aeen M Asghar, Randall A Lee, David M Strauss, Philadelphia, PA, Toshiyuki China, Tokyo, Japan, Michael J Metro, Daniel D Eun, Philadelphia, PA

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
NEUROGENIC BLADDER MONITORING USING THE CYSTOMANOMETER AND CYSTOELASTOMETER
Christopher S. Cooper

CAREGIVERS PERSPECTIVES ON DISCLOSING A CHILD’S DIAGNOSIS OF A DISORDER OF SEX DEVELOPMENT
Kaitlyn Gamwell

THE EFFECT OF EARLY OXYBUTYNIN TREATMENT ON UPPER TRACT OUTCOMES IN PATIENTS WITH POSTERIOR URETHRAL VALVES: A RANDOMIZED CONTROLLED TRIAL
Ahmed Abdelhalim

7:55 DISCUSSION

8:00 SOCIETY FOR PEDIATRIC UROLOGY LECTURE
N. Scott Adzick

8:45 SCIENTIFIC SESSION VII: ENDOUROLOGY, MIS AND STONE DISEASE

FIRST REPORTED SUCCESSFUL USE OF MAGNETIC STENTS IN PEDIATRIC PATIENTS: A CASE-CONTROL STUDY
Alec Mitchell

MINI-PERC FOR RENAL CALCULI IN PEDIATRIC PATIENTS: DOES SIZE MATTER? A PROSPECTIVE RANDOMISED STUDY
Anil Mani

CALYCEAL DIVERG Turkish in CHILDREN: LAPAROSCOPIC MARSUPIALIZATION IS THE OPTIMAL INTERVENTION
Ravindra Sahadev

DIETARY RISK FACTORS FOR PEDIATRIC KIDNEY STONES
Hsinhsiao Wang

8:57 DISCUSSION

URINARY CYSTATIN C AND NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN: NOVEL BIOMARKERS FOR DETECTION OF EARLY KIDNEY DYSFUNCTION IN CHILDREN WITH UROLITHIASIS
Larisa Kovacevic

PEDIATRIC STONE FORMERS HAVE HIGHER RATES OF STONE RECURRENT OVER TIME
Yi Li

AN IN-DEPTH COMPARISON OF THE PEDIATRIC AND ADULT URINARY GLYCOMES
Haiying Li

UNIQUE INTESTINAL TRACT METABOLITES IN CALCIUM OXALATE KIDNEY STONE DISEASE
Kristen Koepsell

OPPORTUNITIES FOR REDUCTION OF CT USE IN PEDIATRIC STONE DISEASE
Diana K. Bowen

9:21 DISCUSSION

9:30 BREAK

9:45 SCIENTIFIC SESSION VIII: LOWER URINARY TRACT

A RANDOMIZED CROSSOVER TRIAL COMPARING THE EFFICACY AND SAFETY OF FESOTERODINE AND EXTENDED-RELEASE OXYBUTYNIN IN CHILDREN WITH OVERACTIVE BLADDER WITH 12-MONTH EXTENSION ON FESOTERODINE: THE FOXY STUDY
Elizabeth Naud

FAST ON THE FAST PARTS, SLOW ON THE SLOW PARTS: GOAL DIRECTED PROCESS PATHWAY FOR IMPROVED OPERATING ROOM EFFICIENCY AND QUALITY IMPROVEMENT IN COMPLEX SURGERY
Dana Weiss

MEASURING THE VALUE OF CARE COORDINATION IN A PEDIATRIC SPINA BIFIDA CENTER
Julia Finkelstein

POTENTIAL BENEFICIAL EFFECT OF TOCOTRIENOLS ON BLADDER DYSFUNCTION DUE TO PARTIAL BLADDER OUTLET OBSTRUCTION
Nao Iguchi

OUTCOMES OF AN INTESTINAL CLEAN OUT AND MAINTENANCE (ICOM) PROGRAM IN CHILDREN WITH LOWER URINARY TRACT DYSFUNCTION
Hugh Smith

9:57 DISCUSSION

THE ROLE OF UROFLOWMETY IN THE DIAGNOSIS AND TREATMENT OF CHILDREN WITH LOWER URINARY TRACT SYMPTOMS
Rejanes Bernardes

INTERPRETATION OF UROFLOW CURVES HAS LOW INTRA AND INTER RATER RELIABILITY
Jose Murillo Netto

VALIDATION OF HYDRONEPHROSIS SEVERITY SCORE IN A LARGE PROSPECTIVE DATABASE
Smruthi Ramesh

URETHRAL LENGTH AND URINARY CONTINENCE IN PATIENTS WITH CLOACAL ANOMALIES
Michael Daugherty

RACIAL AND GENDER DISPARITIES IN SYMPTOM SEVERITY OF CHILDREN WITH DYSFUNCTIONAL ELIMINATION AT TIME OF REFERRAL TO PEDIATRIC UROLOGIST
Joan Ko

AGREEMENT BETWEEN RESIDENT AND FACULTY UROLOGISTS IN THE ASSESSMENT OF EMG-FLOW FOR CHILDREN WITH LOWER URINARY TRACT DYSFUNCTION
Chen Shenhar

10:06 DISCUSSION

THE EFFECT OF EARLY OXYBUTYNIN TREATMENT ON UPPER TRACT OUTCOMES IN PATIENTS WITH POSTERIOR URETHRAL VALVES: A RANDOMIZED CONTROLLED TRIAL
Ahmed Abdelhalim

SCIENTIFIC SESSION VIII: LOWER URINARY TRACT

A RANDOMIZED CROSSOVER TRIAL COMPARING THE EFFICACY AND SAFETY OF FESOTERODINE AND EXTENDED-RELEASE OXYBUTYNIN IN CHILDREN WITH OVERACTIVE BLADDER WITH 12-MONTH EXTENSION ON FESOTERODINE: THE FOXY STUDY
Elizabeth Naud

FAST ON THE FAST PARTS, SLOW ON THE SLOW PARTS: GOAL DIRECTED PROCESS PATHWAY FOR IMPROVED OPERATING ROOM EFFICIENCY AND QUALITY IMPROVEMENT IN COMPLEX SURGERY
Dana Weiss

MEASURING THE VALUE OF CARE COORDINATION IN A PEDIATRIC SPINA BIFIDA CENTER
Julia Finkelstein

POTENTIAL BENEFICIAL EFFECT OF TOCOTRIENOLS ON BLADDER DYSFUNCTION DUE TO PARTIAL BLADDER OUTLET OBSTRUCTION
Nao Iguchi

OUTCOMES OF AN INTESTINAL CLEAN OUT AND MAINTENANCE (ICOM) PROGRAM IN CHILDREN WITH LOWER URINARY TRACT DYSFUNCTION
Hugh Smith

9:21 DISCUSSION

9:30 BREAK
PARASACRAL TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION VERSUS PERCUTANEOUS ELECTRICAL NERVE STIMULATION FOR OVERACTIVE BLADDER IN CHILDREN
Ubirajara Barroso, Jr.

10:37 DISCUSSION

COMPARISON OF CONNECTIVE TISSUE CONTENT AND CONTRACTILITY IN EXSTROPHY AND POSTERIOR URETHRAL VALVES
Kevin Cao

CONTINENCE AFTER BNR IN THE COMPLETE REPAIR OF BLADDER EXSTROPHY (CPRE): A SINGLE INSTITUTION EXPANDED EXPERIENCE
Heather Di Carlo

NEURODEVELOPMENTAL AND PSYCHIATRIC DISORDERS IN PEDIATRIC BOWEL AND BLADDER DYSFUNCTION
Rebecca Wang

BLADDER BOWEL DYSFUNCTION SCORING SYSTEM (BBDSS). A NEW QUESTIONNAIRE FOR EVALUATION OF VOIDING DYSFUNCTION IN CHILDREN
Amr Hodhod

TBA INITIAL POSTOPERATIVE EFFECTS OF SPINAL SURGERY ON PEDIATRIC VOIDING PATTERNS
Laurel Mast

11:05 DISCUSSION

11:15 THE GREAT DEBATE: THE BEST APPROACH TO BLADDER EXSTROPHY
Moderator: Douglas Canning

STAGED REPAIR
John Gearhart

COMPLETE PRIMARY REPAIR
Pramod Reddy

12:05 PRESENTATION OF SPU RESEARCH GRANTS AND INTRODUCTION OF FELLOWS

12:15 SPU PRESIDENTIAL ADDRESS

12:30 LUNCH

1:15 SCIENTIFIC SESSION IX: GENITOURINARY IMAGING AND DIAGNOSTICS

CONTRAST ENHANCED ULTRASOUND IMAGING OF COMPLEX GENITOURINARY MALFORMATIONS
Erin McNamara

INTER-OBSERVER RELIABILITY OF THE ANTENATAL CONSENSUS CLASSIFICATION SYSTEM FOR URINARY TRACT DILATATION
Caleb Nelson

A NOVEL OBJECTIVE PARAMETER TO OPTIMALLY INTERPRET THE DIURETIC RENOGRAM WASHOUT CURVE
Ravindra Sahadev

ESTIMATED GLOMERULAR FILTRATION RATE AND RENAL ULTRASOUND FINDINGS ARE ASSOCIATED IN SPINA BIFIDA PATIENTS
Caroline Kang

SURVEY-BASED ASSESSMENT OF HYDRONEPHROSIS GRADING AMONG PEDIATRIC UROLOGISTS: INTER-RATER RELIABILITY AND MANAGEMENT STRATEGIES
Jacqueline M. Zillioux

PRELIMINARY RESULTS OF DIFFUSION TENSOR IMAGING IN THE PEDIATRIC SPINAL CORD
Ching Man Carmen Tong

CONCORDANCE OF FETAL ULTRASOUND AND MRI FOR PRENATAL DIAGNOSIS OF THE BLADDER AND CLOACAL EXSTROPHY
Dana Weiss

DISCUSSION

1:45 PANEL DISCUSSION: CONGENITALISM WITH ADULT UROLOGISTS PARTICIPATION
Moderator: Rosalia Misseri

BREAK

12:05 PRESENTATION OF SPU RESEARCH GRANTS AND INTRODUCTION OF FELLOWS

12:15 SPU PRESIDENTIAL ADDRESS

12:30 LUNCH

1:15 SCIENTIFIC SESSION X: MAJOR RECONSTRUCTION AND URODYNAMICS

BLADDER AND BOWEL MANAGEMENT IN CLOACAL EXSTROPHY: A LONG-TERM MULTI-INSTITUTIONAL RETROSPECTIVE COHORT STUDY
Molly Fuchs

BLADDER RECOVERY IN CHILDREN WITH TRANSVERSE MYELITIS
Arthi Satyanarayan

NEED FOR BOTOX INJECTION AND AUGMENTATION CYSTOPLASTY AFTER ISOLATED BLADDER NECK PROCEDURE IN PATIENTS WITH MYELOMENINGOCELE
Matthew Smith

VARIATIONS IN KIDNEY FUNCTION SURVEILLANCE IN THE NATIONAL SPINA BIFIDA PATIENT REGISTRY
David Chu

SPLIT APPENDIX MITROFANOFFS HAVE A HIGHER RISK OF COMPLICATION THAN INTACT APPENDIX OR MONTI CHANNELS
Anja Zann

DISCUSSION

1:30 MODIFIED MITCHELL BLADDER NECK RECONSTRUCTION IN THE MODERN ERA OF MYELOMENINGOCELE
Neha Malhotra

HOW DOES WORK ANALYSIS COMPARE TO STANDARD URODYNAMIC CRITERIA IN THE EVALUATION OF YOUNG CHILDREN WITH NEUROGENIC BLADDERS DUE TO SPINA BIFIDA?
Israel Franco
IMPLEMENTATION OF PREOPERATIVE NUTRITIONAL ASSESSMENT IN PEDIATRIC AND ADOLESCENT PATIENTS UNDERGOING CONTINENT URINARY TRACT RECONSTRUCTION
Michael Daugherty

HOW EARLY IS EARLY?: EFFECT OF OXYBUTYNIN ON BLADDER DYNAMICS WITHIN THE FIRST YEAR OF LIFE IN PATIENTS WITH SPINA BIFIDA
Albert Lee

FLUSH VOLUMES INCREASE WITH LONG-TERM MACE USE: A RETROSPECTIVE COHORT STUDY OF CHILDREN WITH SPINA BIFIDA
Konrad Szymanski

ERECTOR SPINAE PLANE CATHETERS CONFER EQUIVALENT BENEFITS TO STANDARD REGIONAL ANESTHETIC TECHNIQUES IN PEDIATRIC UROLOGIC RECONSTRUCTIVE PATIENTS
Kyle Rove

DISCUSSION
3:54

4:00 PANEL DISCUSSION: WOMEN IN PEDIATRIC UROLOGY-CHALLENGES AND CHANGES
Moderator: Elizabeth Yerkes

4:45 SCIENTIFIC SESSION XI: TUMORS, TRAUMA AND TRANSPLANTATION

A PROSPECTIVE STUDY OF PEDIATRIC RENAL CELL CARCINOMA: A REPORT FROM THE CHILDREN’S ONCOLOGY GROUP (COG) STUDY AREN0321
Nicholas Cost

LONG-TERM UROLOGIC OUTCOMES IN GENITOURINARY RHABDOMYOSARCOMA: A SINGLE CENTER 48-YEAR EXPERIENCE
Hsinhsiao Wang

4:51 COMPARING OUTCOMES OF CONVENTIONAL URETERONEOCYSTOSTOMY VERSUS URETEROURETEROSTOMY IN PEDIATRIC RENAL TRANSPLANTATION
Fadi Zu’bi

4:54 THE IMPACT OF MULTIPLE DONOR RENAL ARTERIES ON PERIOPERATIVE COMPLICATIONS AND ALLOGRAFT SURVIVAL IN PAEDIATRIC RENAL TRANSPLANTATION
Fardod O’Kelly

4:57 FULL THICKNESS GENITAL BURNS INDEPENDENTLY INCREASE THE ODDS OF DEATH AMONG PEDIATRIC BURN PATIENTS
Masaya Jimbo

5:00 URINARY METABOLICOMICS IN WILMS TUMOUR
Dawn MacLellan

5:03 AN INSTITUTIONAL ASSESSMENT OF FERTILITY PRESERVATION IN PUBERTAL MALE CANCER SURVIVORS
Akash Kapadia

5:06 LYMPH NODE YIELD IN PEDIATRIC, ADOLESCENT AND YOUNG ADULT RCC: HOW MANY ARE ENOUGH?
Amanda Saltzman

5:20 APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Saturday, May 4, 2019
7:55 am - 11:50 am

SOCIETY FOR BASIC UROLOGIC RESEARCH/SOCIETY OF UROLOGIC ONCOLOGY (SBUR/SUO)
Room W196 @ McCormick Place

7:55 WELCOME & INTRODUCTION

9:00 SESSION 2: BCG UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER
Moderator: James McKieman

8:00 SESSION 1: METASTATIC PROSTATE CANCER
Moderator: Daniel Lin

BASIC SCIENCE PERSPECTIVE: THE BIG PICTURE FOR MECHANISMS OF RESISTANCE IN PROSTATE CANCER
Nima Sharifi

CLINICAL PERSPECTIVE: THE EVOLVING THERAPEUTICS OF ADVANCED PROSTATE CANCER - “IT’S A NEW WORLD ORDER”
Maha Hussain

PANEL DISCUSSION
Panelists: Mark Garzotto, Maha Hussain, Nima Sharifi, Edouard Trabulsi

BRIDGE SCIENCE PERSPECTIVE: BUDDING BIOTECHNOLOGIES FOR BLADDER CANCER
Brant Inman

CLINICAL PERSPECTIVE: BCG UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER
Stephen Boorjian

PANEL DISCUSSION
Panelists: Stephen Boorjian, Peter Clark, Brant Inman, Matthew Nielsen
10:00 SESSION 3: METASTATIC KIDNEY CANCER
Moderator: Steven Campbell

BASIC SCIENCE PERSPECTIVE: BASIC/TRANSLATIONAL ASPECTS UNDERLYING CYTOREDUCTIVE NEPHRECTOMY AND INTEGRATION OF SURGERY/SYSTEMIC THERAPIES
Walter Stadler

CLINICAL PERSPECTIVE: CLINICAL AND SURGICAL PERSPECTIVES ON CYTOREDUCTIVE NEPHRECTOMY
Robert Uzzo

10:55 PANEL DISCUSSION
Panelists: Surenna Matin, Walter Stadler, Robert Uzzo

11:00 DONALD S. COFFEY LECTURE: INTRODUCTION
Kornelia Polyak

11:40 Q & A
FOR AMA PRA CATEGORY 1 CREDIT™
11:25  PANEL DISCUSSION Q&A AND ARS POST-TEST

11:55  SESSION II: PODIUM PRESENTATIONS
Moderator: Brooke Zilinskas

12:00  RISK MANAGEMENT FOR UROLOGIC ADVANCED PRACTICE PROVIDERS
Debbie Sullivan

12:10  A CASE DISCUSSION OF CHRONIC, UNEXPLAINED PENILE PAIN
Susanne Quallich

12:20  PEDIATRIC UROLOGIC PHYSICAL EXAMINATION FOR NEONATAL CIRCUMCISIONS: CAREFUL IDENTIFICATION OF STRUCTURES TO DECREASE ADVERSE OUTCOMES
Kaity Colon-Sanchez

12:30  NOT ALL INCONTINENCE IN TOILET TRAINED CHILDREN IS VOIDING DYSFUNCTION
Kaity Colon-Sanchez

12:40  TREATING PATIENTS WITH NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: CONSIDERATIONS FOR OPERATIONALIZING PATIENT IDENTIFICATION (A NON-CME LUNCH SYMPOSIUM SPONSORED BY JANSSEN BIOTECH)

1:00  REVIEW OF 2016 AUA NMIBC GUIDELINES: INCLUDING NEW DIAGNOSTIC TOOLS AND AN OVERVIEW OF INTRAVESICAL THERAPIES
Kevin Wayne

1:10  DEVELOPING A PROSTATE CANCER SURVIVORSHIP PROGRAM
Ashley Brown

1:20  PATIENTS RECEIVING ANDROGEN DEPRIVATION TREATMENT FOR PROSTATE CANCER: MANAGING SIDE EFFECTS
Anne Calvaresi

1:30  PROSTATE CANCER MANAGEMENT FOR THE ADVANCED PRACTICE PROVIDER
Aneesa Husain

2:00  REVIEW OF 2016 AUA NMIBC GUIDELINES: INCLUDING NEW DIAGNOSTIC TOOLS AND AN OVERVIEW OF INTRAVESICAL THERAPIES
Kevin Wayne

2:10  DEVELOPING A PROSTATE CANCER SURVIVORSHIP PROGRAM
Ashley Brown

2:20  PATIENTS RECEIVING ANDROGEN DEPRIVATION TREATMENT FOR PROSTATE CANCER: MANAGING SIDE EFFECTS
Anne Calvaresi

2:30  PROSTATE CANCER MANAGEMENT FOR THE ADVANCED PRACTICE PROVIDER
Aneesa Husain

2:40  CHROMOPHOBE RENAL CELL CARCINOMA: A CASE REPORT
Mary W. Dunn

2:50  URINARY DIVERSION IN A CASE OF SOLITARY ECTOPIC PELVIC KIDNEY AND MALROTATED BOWEL
Jennifer Henderson

3:00  KIDNEY STONES: EXPLORING TREATMENT OPTIONS, MANAGEMENT AND PREVENTION
Heidi Digennaro

3:10  “KIDNEY STONE CATCHER”: A NOVEL SOLUTION FOR A COMMON PROBLEM
Ghadir Omran

3:20  ADVANCED MALE URETHRAL CATHETERIZATION (AMUC) SKILLS FOR APPS AND NURSE-LED URETHRAL CATHETERIZATION SERVICES: DEVELOPMENT AND IMPLEMENTATION OF THE AMUC
Mariya Dragova

3:30  INDIVIDUAL THERAPIES FOR IC/BPS, PFD: NOVEL APPROACHES TO INTRAVESICAL THERAPY
Marina Ruzimovsky

3:40  BREAK

4:05  THE USE OF IMAGING IN KIDNEY STONE MANAGEMENT
Davis Viprakasit

4:10  DEVELOPING A PROSTATE CANCER SURVIVORSHIP PROGRAM
Ashley Brown

4:20  PATIENTS RECEIVING ANDROGEN DEPRIVATION TREATMENT FOR PROSTATE CANCER: MANAGING SIDE EFFECTS
Anne Calvaresi

4:30  PROSTATE CANCER MANAGEMENT FOR THE ADVANCED PRACTICE PROVIDER
Aneesa Husain

4:40  PANEL DISCUSSION Q&A AND ARS POST-TEST

5:00  APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Saturday, May 4, 2019
9:30 am - 11:30 am

Moderated Poster Session 28
PROSTATE CANCER: MARKERS II
Room W178ab @ McCormick Place
Moderators: Eric Klein, Jose Alvarez-Ossorio Fernandez & Peter Albertsen

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP28-01</td>
<td>ARTIFICIAL INTELLIGENCE (AI) ACCURATELY AUTOMATE AND SPEED IMMUNOFLUORESCENCE (IF)-BASED DISCOVERY AND VALIDATION OF NOVEL PROGNOSTIC AND PREDICTIVE BIOMARKERS IN PROSTATE CANCER Hao G. Nguyen, Bogdana Schmidt*, Ehsan Hosseini-Asl, Clarence So, Richard Socher, Caiming Xiong, Lingru Xue, Peter R Carroll, Matthew R. Cooperberg, San Francisco, CA</td>
</tr>
</tbody>
</table>
MP28-02 QUANTITATIVE MEASUREMENT OF PTEN LOSS IMPROVES RISK ASSESSMENT IN PROSTATE CANCER
Tamara Jamaspishvili*, Palak Patel, KINGSTON, Canada, Yi Ni, Dalian, China, People’s Republic of, Thiago Vidotto, Isabelle Caven, Rachel Livergant, Winnie Fu, Kingston, Canada, Veronique Ouellet, Montreal, Canada, Clarissa Picanço, São Paulo, Brazil, Madhuri Koti, Nathan How, Kingston, Canada, Fred Saad, Anne-Marie Mes-Masson, Montreal, Canada, Tamara Lotan, Baltimore, MD, Jeremy Squire, São Paulo, Brazil, Brazil

MP28-03 DO ELDERLY MEN (>75) HARBOR MORE AGGRESSIVE PROSTATE CANCER? COMPARISON OF DECIPHER AND PAM50 TESTS AMONG DIFFERENT AGE GROUPS.

MP28-04 CORRELATION BETWEEN MRI PHENOTYPES AND A GENOMIC CLASSIFIER OF PROSTATE CANCER
Andrei Puryshko*, Cleveland, OH, Cristina Magi-Galluzzi, Birmingham, AL, Omar Man, Cleveland, OH, Elai Davicioni, Marguerite du Plessis, Christine Buerki, Toronto, Canada, Jennifer Bollen, Lin Li, Anant Madabhushi, Andrew Stephenson, Eric Klein, Cleveland, OH

MP28-05 THE CLINICAL SIGNIFICANCE OF PERINEURAL INVASION IN PATIENTS WITH METASTATIC PROSTATE CANCER
Jinge Zhao*, Junru Chen, Mengni Zhang, Xin Tang, Guangxi Sun, Pengfei Shen, Ni Chen, Hao Zeng, Chengdu, China, People’s Republic of

MP28-06 BLACK MEN HAVE HIGHER EXPRESSION OF INFLAMMATORY MARKERS IN PROSTATE BIOPSES

MP28-07 DEVELOPMENT AND VALIDATION OF LNCRNAS-BASED NOMOGRAM FOR PREDICTION OF BIOCHEMICAL RECURRENCE IN PROSTATE CANCER BY BIOINFORMATICS ANALYSIS
ning shao*, yuan qu, fang wan, ding ye, shanghai, China, People’s Republic of

MP28-08 INCIDENCE OF DNA DAMAGE RESPONSE PATHWAY ALTERATIONS BETWEEN LOCALIZED AND METASTATIC PROSTATE CANCER

MP28-09 PROGNOSTIC SIGNIFICANCE OF EARLY CHANGES IN SERUM BIOMARKER LEVELS IN PATIENTS WITH NEWLY DIAGNOSED METASTATIC PROSTATE CANCER
Hiromi Sato*, Shintaro Narita, Kyoko Nomura, Akita, J an, Shingo Hatakeyama, Hiroaki, J an, Masahiro Takahashi, Sendai, J an, Toshihiko Sakurai, Yamagata, J an, Sadafumi Kawamura, Natori, J an, Senji Hoshi, Yamagata, J an, Masanori Ishida, Mizusawa, J an, Toshiaki Kawaguchi, Aomori, J an, Shigeto Ishidoya, Sendai, J an, Jiro Shimoda, Mizusawa, J an, Koji Mitsuzuka, Sendai, J an, Tatsuo Tochigi, Natori, J an, Nishiko Tsuchiya, Yamagata, J an, Chikara Ohyama, Hiroaki, J an, Yoichi Arai, Sendai, J an, Tomonori Habuchi, Akita, J an

MP28-10 SYSTEMIC METABOLIC RESPONSES OF PROSTATE CANCER PATIENTS TREATED WITH ANDROGEN DEPRIVATION THERAPY (ADT) WITH AND WITHOUT LOW CARB DIET
Jen-Tsan Chi*, Pao-Hwa Lin, Durham, NC, Emily Chen, Vladimir Tolstikov, Framingham, MA, Taofik Oyekunle, Durham, NC, Fei Gao, Rangaprasad Saragarajan, Niven Narain, Michael Kiebish, Framingham, MA, Stephen Freedland, Los Angeles, CA

MP28-11 ELEVATED SERUM GAMMA-GLUTAMYLTRANSFERASE IS AN ADVERSE PROGNOSTIC FACTOR IN CASTRATION-RESISTANT PROSTATE CANCER PATIENTS TREATED WITH ENZALUTAMIDE
Kosuke Takemura*, Masaya Ito, Yasukazu Nakaniishi, Madoka Kataoka, Kazumasa Sakamoto, Hiroaki Suzuki, Noriyuki Iida, Kenichi Tobisu, Fumitaka Koga, Tokyo, J an

MP28-12 SHMC LEVELS PREDICT BIOCHEMICAL FAILURE FOLLOWING RADICAL PROSTATECTOMY IN PROSTATE CANCER PATIENTS WITH ERG NEGATIVE TUMORS
Gitte Kristensen*, Copenhagen, Denmark, Siri H. Strand, Aarhus, Denmark, Martin Andrews Reder, Kasper Drimer Berg, Birgitte Grankær Toff, Copenhagen, Denmark, Søren Høyer, Michael Borre, Karina Dalsgaard Sørensen, Aarhus, Denmark, Klaus Brasso, Copenhagen, Denmark
MP28-13 IDENTIFICATION OF DIFFERENTIALLY EXPRESSED GENES TO PREDICT RADIARESISTANT PROSTATE CARCINOMAS.
Tim Nestler*, Maike Wittersheim, Martin Heilmich, David Pfister, Margarete Odenthal, Reinhard Büttner, Stephan Schaefer, Axel Heidenreich, Cologne, Germany

MP28-14 SERUM CYTOKINES AND CHEMOKINES PROFILE AND RISK OF PROSTATE CANCER IN A CASE-CONTROL STUDY AMONG BLACK AND WHITE US VETERAN MEN
Adriana Vidal*, Los Angeles, CA, Taofik Oyenikunle, Lauren Howard, Amanda DeHoedt, Durham, NC, Emanuela Taioli, New York, NY, Jay Fowke, Memphis, TN, Charles Drake, New York, NY, Stephen Freedland, Los Angeles, CA

MP28-15 SERUM BIOMARKERS FOR PROGNOSIS OF DISEASE PROGRESSION IN PROSTATE CANCER USING MULTI-OMICS

MP28-16 ELEVATED KI-67 (MIB-1) EXPRESSION AS AN INDEPENDENT PREDICTOR FOR UNFAVORABLE PATHOLOGIC OUTCOMES AND BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY IN PATIENTS WITH LOCALIZED PROSTATE CANCER: A PROPENSITY SCORE MATCHED STUDY.
Tae Jin Kim, Sang Hun Song*, Hak Ju Kim, Hak Min Lee, Seongnam, Korea, Republic of, Oh Jong Jin, Sung Kyu Hong, Seok Soo Byun, Seongnam, Korea, Republic of

MP28-17 THE ADDITION OF BIOMARKERS TO PSA AND MPMRI MAY IMPROVE PROSTATE CANCER DETECTION RATE
Patrick Whelan*, CHICAGO, IL, Wei Phin Tan, Durham, NC, Jennifer Poirier, Chicago, IL, Leslie Deane, Miami, FL

MP28-18 PROSTATE HEALTH INDEX DENSITY SIGNIFICANTLY IMPROVES THE ACCURACY OF PREDICTING CLINICALLY SIGNIFICANT PROSTATE CANCER IN MEN UNDERGOING PROSTATE BIOPSY
Yung Ting Cheng*, Shih Ting Chiu, Chih-Hung Chiang, Chung-Hsin Chen, Yeong-Shiau Pu, Jian-Hua Hong, Yu-Chuang Lu, Yi-Kai Chang, Shih-Ping Liu, Shih-Chun Hung, Hong-Chiang Chang, Po-Ming Chow, Kuo-How Huang, Yuan-Ju Lee, Chao-Yuan Huang, Taipei City, Taiwan

MP28-19 SETTING THE BAR: A 4KSCORE OF 7.5% PROVIDES HIGH SENSITIVITY AND NEGATIVE PREDICTIVE VALUE FOR DETECTING AND RULING OUT SIGNIFICANT PROSTATE CANCER.
Amit Bhattu*, Miami, FL, Yan Dong, Woburn, MA, Alexander Kong, Miami, FL, Stephen Zappala, Andover, MA, Dipen Parekh, Sanoj Punnen, Miami, FL

MP28-20 THE GERIATRIC NUTRITIONAL RISK INDEX AS AN INDEPENDENT PREDICTOR FOR MORTALITY IN PATIENTS WITH NEWLY DIAGNOSED METASTATIC PROSTATE CANCER: MULTICENTER RETROSPECTIVE COHORT STUDY
Teppei Okamoto*, Shingo Hatakeyama, Hiroasaki, J apan, Shintaro Narita, Akita, J apan, Masahiro Takahashi, Sendai, J apan, Yoshihiko Sakurai, Yamagata, J apan, Sadafumi Kawamura, Sendai, J apan, Seiji Hoshi, Yamagata, J apan, Masanori Ishida, Isawa, J apan, Yoshiaki Kawaguchi, Aomori, J apan, Shigeto Ishidoya, Sendai, J apan, Jiro Shimoda, Isawa, J apan, Hiromi Sato, Akita, J apan, Koji Mitsuzuka, Tatsuo Tochigi, Sendai, J apan, Norihiko Tsuchiya, Yamagata, J apan, Yoichi Arai, Sendai, J apan, Tomonori Habuchi, Akita, J apan, Chikara Ohyama, Hiroasaki, J apan

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
Saturday, May 4, 2019 9:30 am - 11:30 am
Moderated Poster Session 29
GENERAL & EPIDEMIOLOGICAL TRENDS & SOCIOECONOMICS: VALUE OF CARE: COST AND OUTCOMES MEASURES I
Room W176bc @ McCormick Place
Moderators: Mark Edney, John Gore & Oliver Wiseman

ABSTRACT NUMBER TITLE
MP29-01 COST COMPARISON OF OPEN AND ROBOTIC RADICAL CYSTECTOMY FOR BLADDER CANCER: A PROPENSITY SCORE MATCHED ANALYSIS
Matthew Winter*, Shane Pearce, Giovanni Cacciamani, Carey Li, Akbar Ashrafi, Luis Medina, Djiladat Homan, Anne Schuckman, Sia Daneshmand, Andre Abreu, Andre Berger, Monish Aron, Inderbir Gill, Mihir Desai, Los Angeles, CA

MP29-02 EVALUATING THE COST OF SURVEILLANCE FOR NON-MUSCLE INVASIVE BLADDER CANCER: AN ECONOMIC ANALYSIS BASED ON RISK CATEGORIES
Matthew Mossanen, Ye Wang, Julie A. Szymanick*, Boston, MA, Wei Shen Tan, London, United Kingdom, Melissa J. Huynh, Mark A. Preston, Quoc-Dien Trinh, Guru Sonpavde, Deborah Schrag, Adam S. Kibel, Steven L. Chang, Boston, MA

MP29-03 COST IMPLICATIONS OF PERIOPERATIVE INTRAVESICAL CHEMOTHERAPY FOR BLADDER TUMOR RESECTION: GEMCITABINE VERSUS MITOMYCIN-C
KC Bleibighauser Bens*, Elizabeth Traore, Mohammed Said, Jeffrey Pearl, Louis Aliperti, Mehrdad Alemozaffar, Christopher Filson, Atlanta, GA

MP29-04 READMISSION COSTS TO INDEX VS. NON-INDEX HOSPITALS FOLLOWING MAJOR UROLOGIC ONCOLOGY SURGERIES: IDENTIFYING SOURCES OF COST VARIABILITY
Meera Chappidi*, Anobel Odisho, San Francisco, CA

MP29-05 OUTCOMES OF A PROTOCOL-BASED VIRTUAL STONE (TELEPHONE-BASED, NURSE LED) CLINIC FOR ONGOING SURVEILLANCE OF PATIENTS WITH KIDNEY STONES: 5-YEAR PROSPECTIVE ANALYSIS FROM AN ENDOUROLOGY CENTRE
Matt Archer, Amelia Pietropaolo, Davis Tanya, Sarah Prattley*, Bhaskar Somani, Southampton, United Kingdom

MP29-06 DELAYS IN PRESENTATION TO UROLOGISTS FOR URINARY STONE DISEASE INCREASE UTILIZATION OF HEALTH CARE RESOURCES
David Bayne*, SAN FRANCISCO, CA, Manint Usawachintachit, Bangkok, Thailand, Manuel Armas-Phan, SAN FRANCISCO, CA, David Tzou, Tucson, AZ, Scott Wiener, Marshall Stoller, Tom Chi, SAN FRANCISCO, CA

ABSTRACT NUMBER TITLE
MP29-07 TRAVEL PATTERNS FOR PATIENTS UNDERGOING STONE SURGERY IN THE STATE OF CALIFORNIA, 2005-2016
Scott Wiener*, David Bayne, San Francisco, CA, David Tzou, Tuscon, AZ, Thomas Chi, Marshall Stoller, San Francisco, CA

MP29-08 ACCURACY OF 7- AND 30-DAY RECALL FOR SELF-REPORTED LOWER URINARY TRACT SYMPTOMS
Kathryn E. Flynn*, Milwaukee, WI, Sarah A. Mansfield, Abigail R. Smith, Brenda W. Gillespie, Ann Arbor, MI, Catherine S. Bradley, Iowa City, IA, J. Quentin Clemens, Margaret E. Helmuith, Ann Arbor, MI, Pooja Talaty, Glenview, IL, H. Henry Lai, St. Louis, MO, Ziya Karkali, Bethesda, MD, Kevin P. Weinfurt, and the LURN Study Group, Durham, NC

MP29-09 “FAMILIARITY” TRENDS OF SUCCESSFUL UROLOGY RESIDENCY MATCH APPLICANTS
Samuel Engelsjörg*, Melissa Wong, Adam Koraym, Jay Sandlow, R. Corey O’Connor, Milwaukee, WI

MP29-10 A NATIONALLY REPRESENTATIVE STUDY OF NON-INDEX HOSPITAL READMISSIONS FOLLOWING RADICAL PROSTATECTOMY: IMPLICATIONS FOR BUNDLED PAYMENT MODELS

MP29-11 IMPACT OF MULTI-PARAMETRIC MAGNETIC RESONANCE IMAGING ON MEDICARE SPENDING IN PROSTATE CANCER ACTIVE SURVEILLANCE
Michelle Yu*, Avinash Maganty, Liam C. Macleod, Pittsburgh, PA, Mina M. Fam, Neptune, NJ, Jonathan G. Yabes, Jathin Bandari, Alessandro Furlan, Pittsburgh, PA, Christopher P. Filson, Atlanta, GA, Benjamin J. Davies, Bruce L. Jacobs, Pittsburgh, PA

MP29-12 COMPARATIVE COST-EFFECTIVENESS OF ACTIVE SURVEILLANCE, RADICAL PROSTATECTOMY, AND EXTERNAL BEAM RADIOTHERAPY: LESSONS FROM PROTECT
Kevin Wymer*, Vidit Sharma, Bijan Borah, Rochester, MN, James Catto, Sheffield, United Kingdom, R. Houston Thompson, R. Jeffrey Karnes, Stephen Boorjian, Rochester, MN

*Presenting author
MP29-13 UROLOGISTS LEAD SURGICAL SUBSPECIALISTS IN MEDICARE PRESCRIPTION DRUG COSTS
George Wayne*, Miami Beach, FL, Jeffrey Wei, Vivian Wong, Elias Atri, Miami, FL, Maurilio Garcia, Juan Cedeno, Elizabeth Nagoda, Jorge Pereira, Miami Beach, FL

MP29-14 HOSPITAL CHARGES FOR UROLOGIC SURGERY EPISODES OF CARE ARE RISING IN SPITE OF DECLINING COSTS
Tyler McClintock*, Cambridge, MA, Matthew Mossanen, Ye Wang, Mahek Shah, Boston, MA, Benjamin Chung, Stanford, CA, Steven Chang, Boston, MA

MP29-15 IMPACT OF DEPENDENT COVERAGE INSURANCE EXPANSION ON EARLY TESTICULAR CANCER DIAGNOSIS
Scott R. Hawken, MD, MS*, Parth K. Modi, MD, MS, Lindsey A. Herrel, MD, MS, Ann Arbor, MI

MP29-16 THE ASSOCIATION BETWEEN THE AFFORDABLE CARE ACT, INSURANCE STATUS, AND TREATMENT AMONG PATIENTS WITH TESTICULAR CANCER
Walter Hsiang, New Haven, CT, Ahmedin Jemal, Atlanta, GA, Kevin Nguyen, Brian Shuch, Los Angeles, CA, Henry Park, James Yu, Cary Gross, Amy Davidoff, Michael Leapman*, New Haven, CT

MP29-17 CONTEMPORARY TRENDS IN READMISSION AND CARE FRAGMENTATION RATES FOLLOWING MAJOR UROLOGIC ONCOLOGY SURGERIES IN A NATIONALLY REPRESENTATIVE DATABASE
Meera Chappidi*, San Francisco, CA, Max Kates, Trinity Bivalacqua, Baltimore, MD, Anobel Odisho, San Francisco, CA

MP29-18 PHARMACEUTICAL PAYMENTS FOR OPIOIDS SIGNIFICANTLY FAVOR EXTENDED-RELEASE MEDICATION AND CORRELATE WITH PHYSICIAN PRESCRIPTIONS
Austin Lee, Omar Ayyash*, Avinash Maganty, Liam Macleod, Jathin Bandari, Bruce Jacobs, Benjamin Davies, Pittsburgh, PA

MP29-19 CHASING THE PACK: ASSOCIATION BETWEEN UROLOGY HOSPITAL RANKINGS AND SURGICAL OUTCOME
Alejandro Abello*, Jamil Syed, Michael Leapman, Patrick A. Kenney, New Haven, CT

MP29-20 EPIDEMIOLOGY OF GENITOURINARY FOREIGN BODIES IN THE UNITED STATES EMERGENCY ROOM SETTING AND ITS ASSOCIATION WITH MENTAL HEALTH DISORDERS
Dayron Rodriguez*, Nannan Thirumavalavan, Dallas, TX, Michel Apoj, Ricardo Munarriz, Boston, MA

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Saturday, May 4, 2019
Moderated Poster Session 30
PROSTATE CANCER: DETECTION & SCREENING IV
Room W180 @ McCormick Place
Moderators: Neil Fleshner & James Brooks

ABSTRACT NUMBER TITLE
MP30-01 ROLE OF PREBIOPSY MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING FOR PROSTATE CANCER DIAGNOSIS IN BIOPSY-NAIVE MEN: A LITERATURE BASED META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
Xiang Tu*, Shi Qiu, He Xu, Yige Bao, Lu Yang, Qiang Wei, Chengdu, China, People’s Republic of

MP30-02 DETECTION OF INDIVIDUAL PROSTATE CANCER FOCI BY MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING
David Johnson*, Steven Raman, Sohrab Mirak, Lorna Kwan, Amirhossein Bagirian, Izak Faeina, Aydin Pooli, Los Angeles, CA, Amirali Salmasi, San Diego, CA, Anthony Sisk, Ely Felker, David Lü, Robert Reiter, Los Angeles, CA

ABSTRACT NUMBER TITLE
MP30-03 DOES MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING PRIOR TO PROSTATE BIOPSY REDUCE HISTOLOGIC UPGRAADING AT THE TIME OF PROSTATECTOMY?
Grant M Henning*, Joel M Vetter, Gerald L Andriele, Jonathan R Weese, Eric H Kim, St. Louis, MO

MP30-04 DETECTION OF INDIVIDUAL PROSTATE CANCER FOCI BY MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING
David Johnson*, Steven Raman, Sohrab Mirak, Lorna Kwan, Amirhossein Bagirian, Izak Faeina, Aydin Pooli, Los Angeles, CA, Amirali Salmasi, San Diego, CA, Anthony Sisk, Ely Felker, David Lü, Robert Reiter, Los Angeles, CA
MP30-05 ADDED VALUE OF SYSTEMATIC PROSTATE SAMPLING TO MRI-TARGETED PROSTATE BIOPSY IN A LARGE MULTICENTER RETROSPECTIVE SERIES.

MP30-06 MULTI-PARAMETRIC PROSTATE MRI AS A SCREENING TEST AMONG MALE BRCA CARRIERS
David Margel*, Sivan Sela, Shlomit Tamir, Inbal Kedar, Yaara Ber, Daniel Kedar, Andrei Nadu, Jack Daniel, Pethah-Tikva, Israel

MP30-07 A MULTI-INSTITUTIONAL COMPARISON OF MULTI-PARAMETRIC MAGNETIC RESONANCE IMAGING PROSTATE FUSION BIOPSY METRICS: VALIDATION OF ACTIONABLE INTELLIGENCE METRIC AND REDUCTION METRIC

MP30-08 COMPARISON OF TRUS-BIOPSY TO TRANSPERINEAL TEMPLATE MAPPING BIOPSIES STRATIFIED BY MRI SCORE WITHIN THE PROMIS TRIAL
Catherine Lovegrove*, Louise Brown, Saiful Miah, Ahmed El-Shater Bosaily, Richard Kaplan, Alex Freeman, Alex Kirkham, Mathias Winkler, London, United Kingdom, Raj Persad, Bristol, United Kingdom, Richard Hindley, London, United Kingdom, Robert Oldroyd, Nottingham, United Kingdom, Tim Dudderidge, Southampton, United Kingdom, Derek Rosario, Sheffield, United Kingdom, Nick Burns-Cox, Taunton, United Kingdom, Iqbal Shergill, Wrexham, United Kingdom, Simon Bott, Farnborough, United Kingdom, Alastair Henderson, Maidstone, United Kingdom, Christopher Parker, Sutton, United Kingdom, Mark Emberton, Hashim Ahmed, London, United Kingdom

MP30-09 PROSPECTIVELY ASSIGNED POSITIVE CONTRAST ENHANCEMENT SCORE DETECTS MORE CLINICALLY SIGNIFICANT PROSTATE CANCER IN MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING USING PI-RADS V2
Daniel Costa*, Alberto Diaz de Leon, Takeshi Yokoo, Claus Roehrborn, Brad Hornberger, Kenneth Goldberg, Naveen Subramanian, Julia Lotan, Neil Rofsky, Franto Francis, Ming Zhou, Yuval Freifeld, Ivan Pedroza, Dallas, TX

MP30-10 COMPARISON OF TRUS-TARGETED VS. MRI-TARGETED VS. SYSTEMATIC PROSTATE BIOPSY IN DETECTING PROSTATE CANCER

MP30-11 UPGRADING OF GLEASON SCORE FROM PROSTATE BIOPSY TO RADICAL PROSTATECTOMY: MAGNETIC RESONANCE IMAGING-ULTRASOUND FUSION GUIDED BIOPSY VERSUS SYSTEMATIC BIOPSY OF PROSTATE
Iksander Abdullin*, Filipp Kosov, Vladimir Kapustin, Vadim Panov, Ekaterina Baranova, Nikolay Grigoriev, Moscow, Russian Federation

MP30-12 WHO BENEFITS ADDITIONALLY FROM CONCURRENT SYSTEMATIC BIOPSY AT THE TIME OF MRI-ULTRASOUND FUSION TARGETED BIOPSY TO DETECT SIGNIFICANT PROSTATE CANCER?
Yoh Matsuoka*, Sho Uehara, Soichiro Yoshida, Kenji Tanabe, Hiroshi Tanaka, Tomo Kimura, Shingo Moriyama, Yosuke Yasuda, Toshiki Kijima, Minato Yokoyama, Junichiro Ishioka, Kazutaka Saito, Yasuhsisa Fuji, Tokyo, Japan

MP30-13 INCORPORATING MPMRI BIOPSY DATA INTO ESTABLISHED PRE-RP NOMOGRAMS: POTENTIAL IMPACT OF AN INCREASINGLY COMMON CLINICAL SCENARIO
Thenappan Chandrasekar, Joon Yau Leong*, Elwin Tham, Seth Teplitsky, Costas Lalas, Leonard Gomella, Edouard Trabulsi, Philadelphia, PA

MP30-14 DIAGNOSTIC ACCURACY OF PROSTATE MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING IN AFRICAN-AMERICAN MEN
Grant M Henning*, Joel M Vetter, Gerald L Andriole, Michael S Chevinsky, Eric H Kim, St. Louis, MO

MP30-15 A PROSPECTIVE TRIAL COMPARING MRI FUSION AND COGNITIVE FUSION BIOPSY OF THE PROSTATE
Nicholas Chakiryan*, Ann Martinez-Acevedo, Luc Boileau, Angela Waldron, Bryan Foster, Fergus Coakley, Ryan Kopp, Christopher Amling, Jen Jane Liu, Portland, OR
MP30-16 LIMITED ROLE FOR A DEDICATED MRI FUSION BIOPSY PROVIDER IN DETECTING PROSTATE CANCER
Matthew Gay*, Joshua Langston, Douglas Kelly, Norfolk, VA

MP30-17 MULTIPARAMETRIC MRI- AND CONTRAST ENHANCED ULTRASOUND-TARGETED BIOPSY FOR THE DETECTION OF SIGNIFICANT PROSTATE CANCER: CAN WE REPLACE SYSTEMATIC BIOPSY?
Christophe Mannaerts*, Marc Engelbrecht, Arnoud Postema, Olivia Lodeizen, Rob van Kollenburg, Amsterdam, Netherlands, Ruud Van Sloun, Rogier Wildeboer, Massimo Mischi, Eindhoven, Netherlands, Theo De Reijke, Hessel Wijkstra, Amsterdam, Netherlands

MP30-18 A PREDICTIVE MODEL BASED ON BIPARAMETRIC MRI AND CLINICAL PARAMETERS FOR IMPROVED RISK ASSESSMENT AND SELECTION OF BIOPSY-NAIVE MEN FOR PROSTATE BIOPSIES
Lars Boesen*, Frederik B. Thomsen, Nis Nørgaard, Vibeke Legager, Ingegerd Balslev, Rasmus Bisbjerg, Henrik S. Thomsen, Henrik Jakobsen, Herlev, Denmark

MP30-19 AN UPDATE ON THE PATHOLOGIC FINDINGS OF A LARGE INSTITUTION SERIES OF PATIENTS WITH PROSTATE CANCER AND NO SIGNIFICANT REGIONS OF INTEREST ON PRE-OPERATIVE PELVIC MAGNETIC RESONANCE IMAGING
Mustafa Deebajah*, Kanika Taneja, Shadi Fakhouri, Daniel Cole, James Peabody, Mani Menon, Sean Williamson, Nilesh Gupta, Ali Dabaja, Shaheen Alane, Detroit, MI

MP30-20 POSITIVE PRE-BIOPSY MULTIPARAMETRIC MRI OF THE PROSTATE: CAN WE RESTRICT BIOPSY TO MRI-TARGETED CORES ONLY?
Christophe Mannaerts*, Amsterdam, Netherlands, Amir Kajtazovic, ‘s Hertogenbosch, Netherlands, Olivia Lodeizen, Amsterdam, Netherlands, Maudy Gayet, ‘s Hertogenbosch, Netherlands, Marc Engelbrecht, Amsterdam, Netherlands, Gerrit Jager, ‘s Hertogenbosch, Netherlands, Hessel Wijkstra, Theo De Reijke, Harrie Beerlage, Amsterdam, Netherlands

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
MP31-06 PARENCHYMAL MASS REPLACEMENT BY RENAL CELL CARCINOMA: A CONTRIBUTOR TO PREEXISTING CKD.
Diego Aguilar Palacios*, Elvis R. Caraballo, Cleveland, OH, Hajime Tanaka, Tokyo, Japan, Yanbo Wang, Changchun, China, People's Republic of, Chalairat Suk-ouichai, Bangkok, Thailand, Lin Lin, Steven C. Campbell, Cleveland, OH

MP31-07 SIMULTANEOUS VERSUS STAGED PARTIAL NEPHRECTOMIES FOR BILATERAL SYNCHRONOUS SOLID RENAL MASSES
Vignesh T. Packiam, Matvey Tsivian*, Christine M. Lohse, John C. Cheville, Stephen A. Boorjian, R. Houston Thompson, Bradley C. Leibovich, Rochester, MN

MP31-08 ESTIMATION OF SPARED RENAL PARENCHYMA BY ROBOTIC APPROACHES TO PARTIAL NEPHRECTOMIES
Asha Mannancheril*, Arpeet Shah, Sarah Capodice, Cara Joyce, Marcus Quek, Gopal Gupta, Maywood, IL

MP31-09 RETROPERITONEAL ROBOT - ASSISTED PARTIAL NEPHRECTOMY: A SINGLE INSTITUTION EXPERIENCE.
Manar Malki*, Muddassar Hussain, Neil Barber, Frimley, United Kingdom

MP31-10 ASSOCIATION OF CONTACT SURFACE AREA WITH ROBOTIC PARTIAL NEPHRECTOMY OUTCOMES
Ashley Shumate*, Isabella Galler, Colleen Ball, Kaitlynn Custer, David Thiel, Jacksonville, FL

MP31-11 THE IMPACT OF OBESITY IN PATIENTS UNDERGOING ROBOTIC PARTIAL NEPHRECTOMY

MP31-12 THE ALBUMIN-CREATININE RATIO AND KIDNEY FUNCTION OUTCOMES AFTER NEPHRECTOMY
Andrew Sun*, Stanford, CA, I-Chun Thomas, Palo Alto, CA, Calyani Ganesan, Alan Pao, Todd Wagner, James Brooks, Glenn Chertow, John Leppert, Stanford, CA

MP31-13 RADIOGRAPHIC PREDICTORS FOR INFERIOR VENA CAVA RESECTION DURING NEPHRECTOMY WITH THROMBECTOMY FOR PATIENTS WITH RENAL CELL CARCINOMA AND INFERIOR VENA CAVA TUMOR THROMBUS
Binshuai Wang*, Lulin Ma, Beijing, China, People's Republic of

MP31-14 IMPACT OF COMORBIDITY ON LONG-TERM OUTCOMES IN PATIENTS UNDERGOING RADICAL NEPHRECTOMY COMPARED TO PARTIAL NEPHRECTOMY: A POPULATION-BASED RETROSPECTIVE COHORT STUDY.

MP31-15 RENAL MASS BIOPSY VS. BIOPSY OF MASSES IN OTHER ORGANS: WHY IS IT DIFFERENT ONLY FOR THE KIDNEY?
Francis Jefferson*, Orange, CA, Egor Parkhomenko, Boston, MA, Zhamshid Okhunov, John Sung, Roshan Patel, Cyrus Lin, Orange, CA, Kei Suzuki, Boston, MA, Ralph Clayman, Jaime Landman, Orange, CA

MP31-16 ELEVATED C-REACTIVE PROTEIN IS ASSOCIATED WITH FUNCTIONAL DECLINE FOLLOWING SURGERY FOR RENAL CELL CARCINOMA: RESULTS OF AN INTERNATIONAL COHORT STUDY

MP31-17 COMPARISON OF RETROPERITONEAL AND TRANSPERITONEAL ROBOTIC PARTIAL NEPHRECTOMY BY PENTAFECTA PERIOPERATIVE AND RENAL FUNCTIONAL OUTCOMES
Chang Il Choi, Young Hyo Choi, Minyong Kang, Hyun Hwan Sung, Hwang Gyun Jeon, Byong Chang Jeong, Seong Soo Jeon, Hyun Moo Lee, Seong Il. Seo, Jiwoog Yu*, Seoul, Korea, Republic of

MP31-18 LONG-TERM ONCOLOGIC OUTCOMES AFTER LAPAROSCOPIC AND ROBOTIC TUMOR ENucleATION FOR RENAL CELL CARCINOMA
Wen Dong*, Tianxin Lin, Dehua Ou, Weibin Xie, Sheng Zhang, Guangzhou, China, People's Republic of

MP31-19 LONG-TERM FOLLOW-UP OF RENAL FUNCTION AND DEVELOPMENT OF CHRONIC KIDNEY DISEASE AFTER PARTIAL NEPHRECTOMY
Takashi Ikeda*, Toshio Takagi, Hiroki Ishihara, Hironori Fukuda, Kazuhiro Yoshida, Junpei Iizuka, Hirohito Kobayashi, Masayoshi Okumi, Hideki Ishida, Tsunenori Kondo, Kazunari Tanabe, Tokyo, Japan

*Presenting author
MP31-20 ELIMINATION OF ROUTINE SURGICAL DRAINS IS SAFE IN ROBOTIC-ASSISTED PARTIAL NEPHRECTOMIES
Ashley Shumate*, Isabella Galler, Colleen Ball, Kaitlynn Custer, David Thiel, Jacksonville, FL

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Saturday, May 4, 2019 9:30 am - 11:30 am
Moderated Poster Session 32
BLADDER CANCER: INVASIVE II
Room W179a @ McCormick Place
Moderators: Michael Koch, Stanley Malkowicz & Nathan Lawrentschuk

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP32-01</td>
<td>HIGH LEVELS OF HEAT-SHOCK FACTOR 1 (HSF1) ARE ASSOCIATED WITH POOR PROGNOSIS IN MUSCLE-INVASIVE BLADDER CANCER PATIENTS TREATED WITH CHEMORADIATION-BASED BLADDER SPARING PROTOCOL</td>
</tr>
</tbody>
</table>
  Toshiki Kijima*, Ryu Teramatsu, Shohei Fukuda, Hiroshi Fukushima, Shingo Moriyama, Sho Uehara, Yosuke Yasuda, Soichiro Yoshida, Minato Yokoyama, Junichiro Ishioka, Yoh Matsuoka, Kazutaka Saito, Yasuhisa Fujii, Tokyo, Japan |
| MP32-02         | ASSOCIATIONS BETWEEN GENETIC PATHWAYS AND RADIOMIC METRICS IN MUSCLE-INVASIVE BLADDER CANCER |
  Vinay Duddalwar*, Los Angeles, CA, Seth Lerner, Houston, TX, Enrich Huang, Bethesda, MD, Bino Varghese, Kevin King, Steven Cen, Darryl Hwang, Boston, MA, Ersan Altun, Chapel Hill, NC, Tharakeswara Bathala, Houston, TX, Steven Kennish, Sheffield, United Kingdom, Juan Ibarra Rovira, Houston, TX, Fabiano Lucchesi, Barretos, Brazil, Valdair Francisco Muglia, Sao Paulo, Brazil, Stephen Thomas, Chicago, IL, Raghu Vikram, Houston, TX, Hebert Alberto Vargas, New York, NY, Brenda Fevrier-Sullivan, Justin Kirby, Carl Jaffe, John Freymann, Bethesda, MD |
| MP32-03         | HISTOLOGICAL INVESTIGATION OF THE LYMPHATIC VESSEL CONFIGURATION IN THE HUMAN MALE URINARY BLADDER: ANATOMICAL BASIS FOR METASTATIC DISEASE |
  Nobuyuki Hinata*, Yukari Bando, Masato Fujisawa, Kobe, Japan |
| MP32-04         | IMMUNE CHECKPOINT B7X (B7-H4/B7S1/VTCN1) IS HIGHLY EXPRESSED IN SPONTANEOUS CANINE BLADDER CANCER: THE FIRST REPORT AND ITS IMPLICATIONS IN A PRECLINICAL MODEL. |
  Suraj Pursnani*, Damini Chand, Bronx, NY, Deepika Dhawan, West Lafayette, IN, Alexander Sankin, Xiaoxin Ren, Juan Lin, Mark Schoenberg, Bronx, NY, Deborah W. Knapp, West Lafayette, IN, Xingxing Zang, Bronx, NY |
| MP32-05         | CLINICAL OUTCOMES OF TETRAMODALITY BLADDER-PRESERVING THERAPY INCORPORATING CONSOLIDATIVE PARTIAL CYSTECTOMY IN MUSCLE-INVASIVE BLADDER CANCER PATIENTS WITH HYDRONEPHROSIS |
  Masahiro Toide*, Toshiki Kijima, Shohei Fukuda, Hiroshi Fukushima, Shingo Moriyama, Sho Uehara, Yosuke Yasuda, Soichiro Yoshida, Minato Yokoyama, Junichiro Ishioka, Yoh Matsuoka, Kazutaka Saito, Kazunori Kihara, Yasuhisa Fujii, Tokyo, Japan |
| MP32-06         | IMPACT OF NEOADJUVANT PEMBROLIZUMAB ON INTRA AND PERIOPERATIVE COMPLICATIONS AFTER RADICAL CYSTECTOMY: A COMPARISON WITH BOTH STANDARD CHEMOTHERAPY AND NO ADJUVANT TREATMENT |
  Emanuele Zafluto*, Milan, Italy, Marco Moschini, Lucerne, Switzerland, Giusepp Burgio, Simone Scuderi, Francesco Barletta, Luigi Nocera, Milan, Italy, Vincenzo Mirono, Naples, Italy, Andrea Salonia, Renzo Colombo, Francesco Montorsi, Alberto Briganti, Andrea Necchi, Andrea Gallina, Milan, Italy |
| MP32-07         | BLADDER CANCER PATIENTS WITHOUT PATHOLOGIC RESPONSE TO NEOADJUVANT CHEMOTHERAPY EXPERIENCE LOWER SURVIVAL RATES THAN RADICAL CYSTECTOMY ALONE |
  John Pfalt*, Francois Audenet, Alberto Martin, Kyrollis Attalla, Nikhil Waiyigankar, Matthew Galsky, John Sfakianos, New York, NY |
| MP32-08         | DO WE HARM BLADDER CANCER PATIENTS WHO DO NOT RESPOND TO NEOADJUVANT CHEMOTHERAPY? |
MP32-09 DIFFUSION OF ROBOT-ASSISTED LAPAROSCOPIC RADICAL CYSTECTOMY: NATIONWIDE TRENDS, PREDICTORS AND ASSOCIATION WITH CONTINENT URINARY DIVERSION

MP32-10 COMPARATIVE EFFECTIVENESS OF ROBOTIC ASSISTED AND OPEN RADICAL CYSTECTOMY IN CONTEMPORARY COHORTS OF BLADDER CANCER PATIENTS: AN INTERNATIONAL MULTICENTER COLLABORATION

MP32-11 PATTERNS AND PREDICTORS OF RECURRENCE AND METASTASIS AFTER ROBOT-ASSISTED RADICAL CYSTECTOMY
Jim Shen*, Patrick Kilday, Avinash Chenam, Juzar Jannagerwalla, Nora Ruel, Clayton Lau, Bertram Yuh, Duarte, CA

MP32-12 RADICAL CYSTECTOMY PENTAFECTA: A PROPOSAL FOR STANDARDIZATION OF OUTCOMES REPORTING FOLLOWING ROBOT ASSISTED RADICAL CYSTECTOMY

MP32-13 BLADDER CANCER RECURRENCE PATTERNS AFTER ROBOTIC AND OPEN RADICAL CYSTECTOMY IN 837 PATIENTS AT A HIGH-VOLUME ACADEMIC CENTER
Akbar N Ashrafi, Pierre-Alain Hueber*, Nieroshan Rajarubendra, Hooman Djaladat, Anne Schuckman, Monish Aron, Mihir Desai, Inderbir Gill, Andre Berger, Los Angeles, CA

MP32-14 URETEROENTERIC ANASTOMOSIS STRICTURES IN PATIENTS UNDERGOING ROBOT ASSISTED RADICAL CYSTECTOMY: SINGLE-CENTER EVALUATION OF RISK FACTORS AND PREDICTORS
Jose Agudelo*, Riccardo Bertolo, Juan Garisto, Amr Farghany, Jihad Kaouk, Cleveland, OH

MP32-15 CIGARETTE SMOKING IS ASSOCIATED WITH ADVERSE PATHOLOGIC RESPONSE AND INCREASED DISEASE RECURRENCE AMONG PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER TREATED WITH CISPLATIN-BASED NEOADJUVANT CHEMOTHERAPY AND RADICAL CYSTECTOMY
Luca Boeri*, Vidit Sharma, Matteo Soligo, Igor Frank, Stephen A. Boorjian, R. Houston Thompson, Matthew Tolleson, Fernando J. Quevedo, John C. Cheville, R. Jeffrey Kames, Rochester, MN

MP32-16 INCIDENCE AND IMPACT OF HISTOLOGICAL VARIANTS ON SURVIVAL IN CANDIDATES FOR RADICAL CYSTECTOMY: RESULTS FROM A MULTICENTER COLLABORATION
Marco Moschini, Stefania Zamboni*, Lucerne, Switzerland, Jeffrey R. Kames, Rochester, MN, Florian Rohrmann, Karl Tully, Hem, Germany, Paul Sargos, Bordeaux, France, Francesco Montorsì, Alberto Briganti, Renzo Colombo, Andrea Gallina, Milan, Italy, Agostino Mattei, Philipp Baumeister, Lucerne, Switzerland, Michael Rink, Hamburg, Germany, Cedric Poyet, Karim Saba, Zurich, Switzerland, Ettore Di Trapani, Ottavio De Cobelli, Gennaro Musi, Milan, Italy, Alessandro Antonelli, Claudio Simeone, Brescia, Italy, Matteo Soligo, Luca Boeri, Rochester, MN, Giuseppe Simone, Michele Gallucci, Rome, Italy, Atiqullah Aziz, Rostock, Germany, Evangelos Xylinas, Paris, France, Shahrokh F. Shariat, Vienna, Austria

MP32-17 CLINICAL RECURRENCE AFTER RADICAL CYSTECTOMY FOR BLADDER CANCER, DEFINING OPTIMAL SURVEILLANCE AFTER SURGERY

*Presenting author
**MP32-18** SURVIVAL OUTCOMES AND SALVAGE TREATMENTS FOR LOCAL BLADDER CANCER RECURRENCES AFTER RADICAL CYSTECTOMY
Matteo Soligo, Michele Colicchia*, Alessandro Morlacchi, Padova, Italy, Luca Boeri, Vidit Sharma, Igor Frank, Stephen Boorjian, R. Jeffrey Karnes, Rochester, MN

**MP32-19** ADJUVANT CHEMOTHERAPY VERSUS OBSERVATION AFTER RADICAL CYSTECTOMY FOR PATIENTS WITH NODE-POSITIVE BLADDER CANCER
Sahyun Pak*, Teak Jun Shin, Hwiwoo Kim, Donghyun Lee, Dalsan You, In Gab Jeong, Cheryn Song, Jae-Lyun Lee, Bumsik Hong, Jun Hyuk Hong, Choung-Soo Kim, Hanjong Ahn, Seoul, Korea, Republic of

---

**MP33-01** UNDERSTANDING THE CONTEMPORARY UROLOGIC WORKFORCE: ASSOCIATION BETWEEN UROLOGIST GENDER AND PRACTICE PATTERNS FOR MEDICARE BENEFICIARIES
Catherine Nam*, Frances Kim, Christopher Filson, Atlanta, GA

**MP33-02** FOCUS GROUPS VERSUS DIGITAL ETHNOGRAPHY: WHICH BETTER CAPTURES THE PERSPECTIVES OF WOMEN WITH RECURRENT URINARY TRACT INFECTIONS?
Victoria CS Scott*, Gabriela Gonzalez, Los Angeles, CA, Lauren Wood Thum, Sioux Falls, SD, Taylor Sadun, Los Angeles, CA, Sally L Maliaiski, Kansas City, KS, Brennan M Spiegell, Beverly Hills, CA, Ja-Hong Kim, Los Angeles, CA, Jennifer T Anger, Beverly Hills, CA

**MP33-03** DRAMATIC DECREASE IN UROLOGIC OPIOID PRESCRIBING AFTER IMPLEMENTATION OF STATEWIDE PRESCRIPTION DRUG MONITORING PROGRAM
John Myrga*, Michelle Yu, Jathin Bandari, Liam Macleod, Bruce Jacobs, Benjamin Davies, Pittsburgh, PA

**MP33-04** PRESCRIBING TRENDS IN POST-OPERATIVE PAIN MANAGEMENT AFTER UROLOGIC SURGERY
Jeffrey L. Ellis*, Matthew Nitti, Eric Ghiraldi, Karthik Devarajan, Justin I. Friedlander, Serge Ginzburg, Steve Sterious, Joshua A. Cohn, Erin Oehmann, Philip Abboosh, Robert Uzzo, Jay Simhan, Philadelphia, PA

**MP33-05** A 10 YEAR ANALYSIS OF CHRONIC PELVIC PAIN AND CHRONIC NARCOTIC USE IN THE MALE VETERAN POPULATION
Bryan Wilson*, Anthony Smith, Glen Murata, Allison Murata, Clifford Qualis, Sara Cichowski, Albuquerque, NM

---

**MP32-20** PREDICTORS OF POSTOPERATIVE HEALTH-RELATED QUALITY OF LIFE (HRQOL): AN ANALYSIS FROM THE RAZOR TRIAL
Vivek Venkatramani*, Maria Becerra, Miami, FL, Isildinha Reis, Miami, FL, Nachiketh Soodana-Praaksh, Miami, FL, Erik Castle, Phoenix, AZ, Mark Gonzalez, Miami, FL, Michael Woods, Chapel Hill, NC, Robert Satek, San Antonio, TX, Alan Weizer, Ann Arbor, MI, Badrinath Konety, Minneapolis, MN, Mathew Tolleson, Phoenix, AZ, Tracey Krupski, Charlotte, VA, Norm Smith, Chicago, IL, Ahmad Shabsigh, Columbus, OH, Daniel Berocas, Nashville, TN, Marcus Quik, Maywood, IL, Atreyah Dash, Seattle, WA, Adam Kibel, Boston, MA, Raj Pruthi, Chapel Hill, NC, Jeffrey Montgomery, Ann Arbor, MI, Christopher Weight, Minneapolis, MN, David Sharp, Columbus, OH, Sam Chang, Nashville, TN, Michael Cookson, Norman, OK, Gopal Gupta, Alex Gorboslo, Maywood, IL, Edward Uchio, Irvine, CA, Eila Skinner, Stanford, CA, Keni Kendrick, San Antonio, TX, Joseph Smith, Nashville, TN, Ian Thompson, San Antonio, TX, Dipen Parekh, Miami, FL

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

---

**Saturday, May 4, 2019 9:30 am - 11:30 am**

**Moderated Poster Session 33**

**GENERAL & EPIDEMIOLOGICAL TRENDS & SOCIOECONOMICS: PRACTICE PATTERNS, QUALITY OF LIFE AND SHARED DECISION MAKING I**

**Room W178ab @ McCormick Place**

**Moderators:** Mark Litwin, Philipp Dahm & Amy Guise

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP33-01</td>
<td>UNDERSTANDING THE CONTEMPORARY UROLOGIC WORKFORCE: ASSOCIATION BETWEEN UROLOGIST GENDER AND PRACTICE PATTERNS FOR MEDICARE BENEFICIARIES</td>
</tr>
<tr>
<td>MP33-02</td>
<td>FOCUS GROUPS VERSUS DIGITAL ETHNOGRAPHY: WHICH BETTER CAPTURES THE PERSPECTIVES OF WOMEN WITH RECURRENT URINARY TRACT INFECTIONS?</td>
</tr>
<tr>
<td>MP33-03</td>
<td>DRAMATIC DECREASE IN UROLOGIC OPIOID PRESCRIBING AFTER IMPLEMENTATION OF STATEWIDE PRESCRIPTION DRUG MONITORING PROGRAM</td>
</tr>
<tr>
<td>MP33-04</td>
<td>PRESCRIBING TRENDS IN POST-OPERATIVE PAIN MANAGEMENT AFTER UROLOGIC SURGERY</td>
</tr>
<tr>
<td>MP33-05</td>
<td>A 10 YEAR ANALYSIS OF CHRONIC PELVIC PAIN AND CHRONIC NARCOTIC USE IN THE MALE VETERAN POPULATION</td>
</tr>
</tbody>
</table>
MP33-06 DEPRESSION AND SUICIDAL IDEATION IN UROLOGY RESIDENTS: A SURVEY NATIONAL STUDY

MP33-07 AGGRESSIVE END-OF-LIFE CARE IN MEDICARE BENEFICIARIES DYING WITH BLADDER CANCER
Lee A Hugar, MD, MSCR*, Samia H Lopa, PhD, Jonathan G Yabes, PhD, Pittsburgh, PA, Nathan E Hale, MD, Charleston, WV, Robert M Turner, MD, Mina M Fam, MD, MBA, Liam C Macleod, MD, MPH, Benjamin J Davies, MD, Bruce L Jacobs, MD, MPH, Pittsburgh, PA

MP33-08 PROSTATE CANCER TREATMENT OPTIONS: A CONTEMPORARY WORLDWIDE TREND ANALYSIS
Giovanni Cacciamani*, Los Angeles, CA, Silvia Bassi, Marco Sebben, Anna Marcer, Verona, Italy, Luis Medina, Los Angeles, CA, Girogio Russo, Catania, Italy, Andrea Cocci, Firenze, Italy, Paolo Dell'Oglio, Milan, Italy, Nima Nassiri, Alessandro Tafuri, Andre Abreu, Los Angeles, CA, Alberto Briganti, Milan, Italy, Antonio Benito Porcaro, Verona, Italy, Francesco Montorsi, Milan, Italy, Inderbir Gill, Los Angeles, CA, Walter Artibani, Verona, Italy

MP33-09 BARRIERS AND FACILITATORS OF HEALTH CARE UTILIZATION AMONG YOUNG MEN IN THE UNITED STATES
Mohammed Said*, Atlanta, GA, Frances Kim, Atlanta, GA, Michelle Sheng, Atlanta, GA, R Craig Sineath, Atlanta, GA, Akanksha Mehta, Atlanta, GA

MP33-10 INCREASING UTILIZATION OF MULTI-PARAMETRIC MAGNETIC RESONANCE IMAGING IN PROSTATE CANCER ACTIVE SURVEILLANCE
Michelle Yu*, Avinash Maganty, Pittsburgh, PA, Mina M Fam, Neptune, NJ, Jonathan G. Yabes, Liam C. Macleod, Jathin Bandari, Alessandro Furlan, Pittsburgh, PA, Christopher P. Filson, Atlanta, GA, Benjamin J. Davies, Bruce L. Jacobs, Pittsburgh, PA

MP33-11 PROMIS® QUALITY OF LIFE MEASURES ARE ASSOCIATED WITH CURRENT PAIN AND AMPLIFIED WITH HISTORY OF PRIOR STONE
Andrew Portis*, St Paul, MN, Michael Borofsky, Minneapolis, MN, Suzanne Neises, St Paul, MN

MP33-12 DO PEDIATRICIANS ROUTINELY PERFORM GENITOURINARY EXAMINATIONS DURING WELL-CHILD VISITS? A REVIEW FROM A LARGE TERTIARY PEDIATRIC HOSPITAL
Jonathan A. Gerber*, Aditya Balasubramanian, Mihir A. Shukla, Jake S. Jacob, Huirong Zhu, Kunji R. Sheth, Carolina J. Jorgez, Angela G. Mittal, Duong D. Tu, Chester J. Koh, Nicolette K. Janzen, Ming-Hsien Wang, Paul F. Austin, Edmond T. Gonzales, David R. Roth, Abhishek Seth, Houston, TX

MP33-13 CHARACTERISTICS OF HIGH LOWER URINARY TRACT SYMPTOM (LUTS) BOTHER IN INDIVIDUALS SEEKING CARE FOR LUTS
Nnenaya O. Agochukwu*, Jonathan B. Wiseman, Abigail R. Smith, Margaret E. Helmhut, Ann Arbor, MI, Kevin P. Weinfurt, Durham, NC, Meera Tavathia, Chicago, IL, Aruna V. Sarma, Ann Arbor, MI, James W. Griffith, David Cella, Chicago, IL, Anne P. Cameron, Ann Arbor, MI, Kathryn E. Flynn, Milwaukee, WI, Bradley A. Erickson, Iowa City, IA, Ziya Kirkali, Bethesda, MD, Cindy L. Amundsen, Durham, NC, H. Henry Lai, St. Louis, MO, J. Quentin Clemens, and the LURN Study Group, Ann Arbor, MI

MP33-14 AN INVESTIGATION INTO HEALTH RELATED QUALITY OF LIFE OUTCOMES OF LOW-RISK PROSTATE CANCER PATIENTS TREATED WITH ACTIVE SURVEILLANCE VERSUS DEFINITIVE TREATMENT
Christopher C. Randall*, Mohamed H. Kamel, Mahmoud I. Khalil, L Joseph Su, Rodney Davis, Little Rock, AR

MP33-15 EPIDEMIOLOGY OF PENILE FRACTURES IN THE EMERGENCY SETTING IN THE UNITED STATES: ACCESS TO CARE AND HEALTH CARE INEQUALITY MAY LEAD TO SUBOPTIMAL OUTCOMES
Dayron Rodriguez, Kai Li*, Michel Apoj, Boston, MA, Nannan Thirumavalavan, Houston, TX, Ricardo Munarriz, St. Louis, MO

MP33-16 TRENDS IN NATIONWIDE MORTALITY FROM GENITOURINARY MALIGNANCY RELATIVE TO CARDIOVASCULAR DISEASE: DATA FROM THE CAUSES OF UROLOGIC DEATH IN AMERICA (CUDA) STUDY
Parth Thakker*, Jyoti Chouhan, Ethan Matz, Amy Pearlman, Marc Colaco, James Lovato, Ryan Terlecki, Winston-Salem, NC

MP33-17 USING A CLINICAL REGISTRY AND MACHINE LEARNING TO PREDICT URETERAL STENT PLACEMENT FOLLOWING URETEROSCOPY
Michael Inadomi*, Khurshid Ghani, Tae Kim, Casey Dauw, John Hollingsworth, Ann Arbor, MI, David Leavitt, Detroit, MI, Adharsh Murali, Kavya Swarna, Karandep Singh, for the Michigan Urological Surgery Improvement Collaborative, Ann Arbor, MI

*Presenting author
### Podium Session 24

**BENIGN PROSTATIC HYPERPLASIA: MEDICAL & NON-SURGICAL THERAPY**  
Room W185a @ McCormick Place  
**Moderators:** Seth Strope, Claus Roehrborn & Panagiotis Mourmouris

<table>
<thead>
<tr>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
</table>
| 9:30   | PD24-01| DOUBLE BLIND, RANDOMIZED, PLACEBO CONTROLLED STUDY OF TADALAFIL WITH DUTASTERIDE VERSUS TADALAFIL WITH PLACEBO FOR LOWER URINARY TRACTS SYMPTOMS SECONDARY TO BENIGN PROSTATIC HYPERPLASIA: A SINGLE CENTRE STUDY
Gopal Tak*, Abhishek Singh, Arvind Ganpule, Ravindra Sabnis, Mahesh Desai, Nadiad, India |

9:40 PD24-02 ASSOCIATIONS OF 5α-REDUCTASE INHIBITORS WITH DELAYED PROSTATE CANCER DIAGNOSIS AND INCREASED PROSTATE CANCER MORTALITY
Reith Sarkar, J Parsons*, Alex Bryant, Stephen Ryan, John Einck, A Karim Kader, Rana McKay, Arno Mundt, Christopher Kane, James Murphy, Brent Rose, La Jolla, CA

9:50 PD24-03 EFFICACY AND SAFETY OF AFALAZA IN MEN WITH SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA AT RISK OF PROGRESSION: A MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED CLINICAL TRIAL.
Andrey Vinarov*, Dmitriy Pushkar, Leonid Spivak, Moscow, Russian Federation

10:00 PD24-04 PREOPERATIVE PELVIC FLOOR MUSCLE EXERCISE FOR EARLY CONTINENCE AFTER HOLMIUM LASER ENUCLEATION OF THE PROSTATE: A RANDOMIZED CONTROLLED STUDY
Go Anan*, Hiromichi Iwamura, Jun Ito, Yasuhiro Kaino, Makoto Sato, Sendai, Japan

10:10 PD24-05 PROSTATIC ARTERY EMBOLIZATION TO TREAT LOWER URINARY TRACT SYMPTOMS ATTRIBUTABLE TO BENIGN PROSTATIC HYPERPLASIA: A SINGLE CENTER ANALYSIS OF 2-YEAR OUTCOMES
Raj Ayagani*, Taylor Powell, Julius Chapiro, Lawrence Staib, New Haven, CT, Shivan Bhatia, Miami, FL, Toby Chai, New Haven, CT, Steven Schoenberger, New London, CT, Ralph Devito, New Haven, CT

10:20 PD24-06 PROSTATIC ARTERY EMBOLIZATION TO TREAT GROSS HEMATURIA ATTRIBUTABLE TO BENIGN PROSTATIC HYPERPLASIA: A SINGLE CENTER ANALYSIS OF 3-YEAR OUTCOMES
Raj Ayagani*, Taylor Powell, Julius Chapiro, Lawrence Staib, New Haven, CT, Shivan Bhatia, Miami, FL, Toby Chai, New Haven, CT, Steven Schoenberger, New London, CT, Ralph Devito, New Haven, CT

10:30 PD24-07 REAL WORLD OUTCOMES OF PROSTATIC URETHRAL LIFT CONFIRM CLINICAL STUDY RESULTS
Steven Gange*, Salt Lake City, UT, Ansar Khan, Fremont, NE, Gregg Eure, Virginia Beach, VA, Peter Walter, Cheektowaga, NY, Charles Chabert, Benowa, Australia, Paul Cozzi, Hurstville, Australia, Doug Grier, Edmonds, WA, Manish Patel, Elgin, SC, Sheldon Freedman, Las Vegas, NV, Peter Chin, Wollongong, Australia, Steven Ochs, Canton, OH, Andrew Hirsh, Somers, NJ, Michael Trotter, Austin, TX, Thomas Mueller, Voorhees, NJ
10:40 PD24-08 PROSTATIC URETHRAL LIFT (PUL) SYMPTOM AND SEXUAL FUNCTION RESULTS MAINTAINED IN THE TREATMENT OF ALL TYPES OF PROSTATE ENLARGEMENT INCLUDING OBSTRUCTIVE MIDDLE LOBE

11:10 PD24-11 VOIDING FUNCTION IMPROVES UNDER LONG-TERM TREATMENT WITH TESTOSTERONE UNDECANOATE INJECTIONS (TU) IN HYPOGONADAL MEN FOR UP TO 14 YEARS INDEPENDENT OF PROSTATE SIZE
Khalid Alrumaihi, Riad Talib, Sabah Alkadhi, Abdulla Al Ansari, Aksam Yassin*, Doha, Qatar

10:50 PD24-09 EARLY OUTCOMES OF PROSTATIC URETHRAL LIFT IN SUBJECTS WITH ACUTE URINARY RETENTION
Mark Rochester*, Norwich, United Kingdom, Toby Page, Newcastle, United Kingdom, Neil Barber, Frimley, United Kingdom, Oliver Kayes, Leeds, United Kingdom

11:20 PD24-12 URINARY AND ERECTILE FUNCTION IMPROVEMENTS IN HYPOGONADAL MEN WITH TYPE 2 DIABETES (T2DM) TREATED UP TO 10 YEARS WITH TESTOSTERONE IN COMPARISON TO AN UNTREATED CONTROL GROUP
Ah Haider*, Karim Haider, Bremerhaven, Germany, Gheorghe Doros, Abdulmaged Traish, Boston, MA, Farid Saad, Berlin, Germany

11:00 THE CLINICAL EFFICACY OF PROLONGED RELEASE MELATONIN ON NOCTURIA WITH ELDERLY PATIENTS
SUN TAE AHN*, DONG HYUN LEE, HYEONG GUK JEONG, SANG WOO KIM, JONG WOOK KIM, DU GEON MOON, SEOUL, KOREA, REPUBLIC OF

Saturday, May 4, 2019 9:30 am - 11:30 am
Podium Session 25
PROSTATE CANCER: ADVANCED (INCLUDING DRUG THERAPY) III
Room W185d @ McCormick Place
Moderators: Judd Moul, Anup Vora & Athanasios Papatsoris

9:30 PD25-01 FUNCTIONAL OUTCOMES OF VASCULAR TARGETED PHOTOTHERAPY (VTP), ACTIVE SURVEILLANCE (AS) AND RADICAL PROSTATECTOMY (RP): MORBIDITY MODELLING USING DATA FROM TWO PROSPECTIVE RANDOMIZED CLINICAL TRIALS
Gill Inderbir*, Los Angeles, CA, Abdel Azzouzi, Angers, France, Mark Emberton, London, United Kingdom, Billy Amzal, Jie Meng, Paris, France, Peter Scardino, New York, NY

9:40 PD25-02 CONSIDERATION OF PROPER CANDIDATES FOR SELF-EXPANDABLE COVERED METALLIC STENTS IN PROSTATIC OBSTRUCTION COMPARING PROSTATE CANCER AND BENIGN DISEASE CASES
Se Young Choi, Bumjin Lim, Jae Hyeon Han, Yoon Soo Kyung, Dong Hyeon An, Hiwwoo Kim, Wonchul Lee*, Han Kyu Chae, Jaehoon Lee, Wonseok Choi, Dalsan You, In Gab Jeong, Choung-Soo Kim, Seoul, Korea, Republic of

9:50 PD25-03 DOES BASELINE SERUM TESTOSTERONE INFLUENCE ANDROGEN DEPRIVATION THERAPY OUTCOMES IN HORMONE NAiVE ADVANCED PROSTATE CANCER PATIENTS?
Anup Patel*, London, United Kingdom

10:00 PD25-04 QUALITY OF LIFE IN PROSTATE CANCER PATIENTS TREATED WITH PRIMARY ANDROGEN DEPRIVATION THERAPY: COMPARISON OF COMBINED ANDROGEN BLOCKADE VS. LHRH AGONIST ALONE
Hyun Sik Park*, Shin Hyun Shin, Seung Hyo Woo, Daejeon, Korea, Republic of, Seung Hyun Jeon, Seok Ho Kang, Dong Wook Shin, Seoul, Korea, Republic of, Jinsung Park, Daejeon, Korea, Republic of

10:10 PD25-05 UNDERSTANDING THE ROLE OF STATIN USE ON ADVANCED PROSTATE CANCER OUTCOMES: DOES THE STATIN TYPE, CUMULATIVE DOSE OR DURATION IMPACT SURVIVAL?
Tariq A. Khemees*, Jinn-ing Liou, E. Jason Abel, Tracy M. Downs, Tudor Borza, David F. Jarrard, Kyle A. Richards, Madison, WI

*Presenting author
10:20 PD25-06 CHARACTERIZATION OF LONG-TERM SURVIVORS FROM PROCEED, A REGISTRY OF SIPULEUCEL-T IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)

10:30 PD25-07 THE ROLE OF METABOLIC SYNDROME IN HIGH GRADE PROSTATE CANCER: DEVELOPMENT OF A CLINICAL NOMOGRAM
Cosimo De Nunzio*, Riccardo Lombardo, Rome, Italy, Paolo Dell'Oglio, Milan, Italy, Antonio Nacchia, Francesca Lagrimino, Giorgia Tema, Fabiana Cancrini, Andrea Tubaro, Rome, Italy

10:40 PD25-08 BODY IMAGE ISSUES AND ATTITUDES TOWARDS EXERCISE IN MEN DIAGNOSED WITH PROSTATE CANCER UNDERGOING ANDROGEN DEPRIVATION THERAPY.
Caterina Gentili*, Stuart McClean, Lucy Hackshaw-McGeagh, Amit Bahl, Raj Persad, Diana Harcourt, Bristol, United Kingdom

10:50 PD25-09 PREDICTORS OF LONG-TERM MORTALITY IN PATIENTS WITH POSITIVE LYMPH NODES AT RADICAL PROSTATECTOMY
Ulrike Heberling*, Rainer Koch, Angelika Borkowetz, Gustavo B. Baretton, Manfred P. Wirth, Michael Frohmer, Dresden, Germany

11:00 PD25-10 ESTIMATION OF THE RISK OF MISSING ADVERSE PATHOLOGICAL PROSTATE CANCER FEATURES AFTER SALVAGE RADICAL PROSTATECTOMY IN PATIENTS ELIGIBLE FOR FOCAL SALVAGE THERAPIES
Luca Boen*, Vidit Sharma, Igor Frank, Stephen A. Boorjian, R. Houston Thompson, Matthew Tollefson, John C. Cheville, R. Jeffrey Barnes, Rochester, MN

11:10 PD25-11 MULTIVISCERAL SURGERY IN MEN WITH LOCALLY ADVANCED, SYMPTOMATIC CASTRATION RESISTANT PROSTATE CANCER
Friederike Haidl*, David Pfister, Daniel Porres, Leonidas Karapanos, Johannes Salem, Axel Heidenreich, Cologne, Germany

11:20 PD25-12 INPATIENT MORBIDITY AND COST OF CYTOREDUCTIVE RADICAL PROSTATECTOMY IN THE UNITED STATES
Sohrab Arora*, Akshay Sood, Deepansh Dalela, Jacob Keeley, Audrey Fotouhi, Nikola Rakic, Uliana Prokopiv, James Peabody, Mani Menon, Firas Abdollah, Detroit, MI

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Saturday, May 4, 2019
Podium Session 26
Room W184d @ McCormick Place

Moderators: Michael Bailey, Roger Sur & Christian Chaussy

<table>
<thead>
<tr>
<th>ABSTRACT</th>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>TO INVESTIGATE THE EFFECT OF VOLTAGE ESCALATION ON TREATMENT OUTCOME IN EXTRACORPOREAL SHOCKWAVE LITHOTRTISPY OF RENAL CALCULI – FINAL ANALYSIS</td>
<td>9:50</td>
<td>PD26-03</td>
<td>Chi-Fai Ng*, Chi Hang Yee, Jeremy Teoh, Steven Leung, Becky Lau, Wong Ka Tak, Winnie Chu, Hong Kong, Hong Kong</td>
</tr>
</tbody>
</table>

132
10:10 PD26-05 INITIAL EXTRACORPOREAL SHOCKWAVE LITHOTRIPSY VERSUS URETEROSCOPY: A RETREATMENT AND COST ANALYSIS USING A LONGITUDINAL, POPULATION-BASED DATABASE

10:20 PD26-06 SHOCKWAVE LITHOTRIPSY AND URETEROSCOPY FOR THE TREATMENT OF LOWER POLE STONES: RESULTS FROM A STATEWIDE CLINICAL REGISTRY
Eric Stockall*, Jessica Shannon, Okemos, MI, Casey Dauw, Kavya Swarna, Jaya Telang, Tae Kim, Ann Arbor, MI, Joshua Leese, Ypsilanti, MI, John Hollingsworth, Khurshid Ghani, for the Michigan Urological Surgery Improvement Collaborative, Ann Arbor, MI

10:30 PD26-07 HOW DO ULTRASOUND WAVES CAUSE STONE FRACTURE IN BURST WAVE LITHOTRIPSY?
Adam Maxwell*, Brian MacConaghy, Michael Bailey, Mathew Sorensen, Oleg Sapozhnikov, Seattle, WA

10:40 PD26-08 PRECLINICAL EVALUATION OF BURST WAVE LITHOTRIPSY STONE FRAGMENTATION AND ACUTE SAFETY IN A PORCINE MODEL OF NEPHROLITHIASIS
Adam Maxwell*, Yak-Nam Wang, Wayne Kreider, Bryan Cunitz, Frank Starr, Donghoon Lee, Yasser Nazari, Seattle, WA, James Williams, Indianapolis, IN, Michael Bailey, Mathew Sorensen, Seattle, WA

10:50 PD26-09 A GLOBAL SURVEY OF UROLOGIST’S CURRENT PRACTICE: WHEN ARE THE NEW/NOVEL ORAL ANTICOAGULANTS (NOACS) DISCONTINUED AND RESUMED IN PATIENTS UNDERGOING SHOCK WAVE LITHOTRIPSY?
Abdulaziz Alathel*, Riyadh, Saudi Arabia
10:00 PD27-04 DO BRAIN FUNCTION AND EYE GAZE FEATURES BEHAVE DIFFERENTLY BASED ON CATASTROPHIC SURGICAL EVENTS?
Somayeh B Shafiei, Zaeem Lone*, Ahmed S. Elsayed, Naif A. Alldhaam, Zhe Jing, Israh Ibrahim, Khurshid A. Guru, Buffalo, NY

10:10 PD27-05 HOW DOES THE BRAIN RESPOND TO GAPS IN PRACTICE SESSIONS DURING TRAINING FOR ROBOT ASSISTED SURGERY?
Somayeh B. Shafiei, Zaeem Lone, Ahmed S. Elsayed*, Naif A. Alldhaam, Randy Selber, Sai Jayaprakash, Michael Seggio, Khurshid A. Guru, Buffalo, NY

10:20 PD27-06 AN OBJECTIVE ASSESSMENT OF PERFORMANCE DURING ROBOTIC PARTIAL NEPHRECTOMY: VALIDATION AND CORRELATION OF AUTOMATED PERFORMANCE METRICS WITH OUTCOMES
Saum Ghodoussipour*, Jian Chen, Jessica Nguyen, Sharath Reddy, Aliaijig Shakir, Rut Patel, Inderbir Gill, Andrew Hung, Los Angeles, CA

10:30 PD27-07 DEEP LEARNING MODEL TO PREDICT TIME TO URINARY CONTINENCE RECOVERY AFTER ROBOT-ASSISTED RADICAL PROSTATECTOMY USING AUTOMATED PERFORMANCE METRICS AND CLINICAL DATA
Andrew Hung*, Jian Chen, Los Angeles, CA, Zequn Liu, Beijing, China, People’s Republic of, Jessica Nguyen, Paul Oh, Devin Stewart, Daphne Remulla, Tiffany Chu, Ryan Lee, Kartik Aron, Saum Ghodoussipour, Los Angeles, CA, Sanjay Purushotham, Baltimore, MD, Inderbir Gill, Yan Liu, Los Angeles, CA

10:40 PD27-08 UROLOGY BOOTCAMP: PRELIMINARY RESULTS FROM A PILOT SIMULATION-BASED CURRICULUM
John Cooper*, Justin Rose, Cheryl Lee, Anand Khurma, Victoria Cannon, Tatevik Brouitian, Jonathan Schaffir, David Sharp, Tasha Posid, Farah Bellows, Columbus, OH

10:50 PD27-09 COMPARISON OF CLINICAL OUTCOMES AND AUTOMATED PERFORMANCE METRICS IN ROBOTIC-ASSISTED RADICAL PROSTATECTOMIES BETWEEN CASES WITH AND WITHOUT TRAINEE INVOLVEMENT
Micha Titus*, Andrew Chen, Jian Chen, Saum Ghodoussipour, Andrew Hung, Los Angeles, CA

11:00 PD27-10 SURGICAL PERFORMANCE AS A PREDICTOR OF FUNCTIONAL AND ONCOLOGICAL OUTCOMES IN ROBOTIC PROSTATECTOMY
Mitchell Goldenberg*, Alaine Garbens, Hossein Sadaat, Antonio Finelli, Rajiv Singal, Jason Lee, Teodor Grantcharov, Toronto, Canada

11:10 PD27-11 EVALUATION OF PROCEDURAL VIRTUAL REALITY SIMULATION TRAINING: A RANDOMISED CONTROLLED TRIAL
Nicholas Raison*, Patrick Harrison, London, United Kingdom, Takashige Abe, Sapporo, Japan, Abdellatif Aydin, Senthil Nathan, Shamim Khan, Kamran Ahmed, Prokar Dasgupta, London, United Kingdom

11:20 PD27-12 TOWARDS OPTIMIZING SIMULATION-BASED TRAINING FOR PERCUTANEOUS NEPHROLITHOTOMY: A PROSPECTIVE COMPARATIVE STUDY
Ahmed Ibrahim*, Montreal, Canada, Yasser Noureldin, Benha, Egypt, Sero Andonian, Montreal, Canada

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
9:50 PD28-03 EFFECTS OF FUNCTIONAL ELECTROSTIMULATION ON ERECTILE FUNCTION RECOVERY FOLLOWING BILATERAL NERVE-SARING RADICAL PROSTATECTOMY: A RANDOMIZED SHAM-CONTROLLED STUDY
Ana Paula Bispo*, Scheila Nascimento, Roberto Soler, Sao Paulo, Brazil

10:00 PD28-04 CAN A TWO-HOUR FAST BEFORE AND AFTER CONSUMING A SILDENAFIL 100 MG TABLET STATISTICALLY IMPROVE ERECTILE FUNCTION AND PATIENT SATISFACTION IN NORMAL MEN WHO OTHERWISE HAVE FAILED TO ACHIEVE FULL ERECTION WITH PRIOR SILDENAFIL USE?
Serge Marinkovic*, Joseph Ford, Detroit, MI

10:10 PD28-05 THE IMPACT OF SMOKING ON SEXUAL FUNCTION PARAMETERS.
Mahmoud Mima*, Sana Khan, Chicago, IL, Stephen J. Freedland, Los Angeles, CA, Gerald L. Andriole, St. Louis, MO, Samuel J. Ohlender, Daniel M. Moreira, Chicago, IL

10:20 PD28-06 DOES ALCOHOL CONSUMPTION AFFECT SEXUAL FUNCTION?
Mahmoud Mima*, Whitney R Halgrimson, Chicago, IL, Stephen J. Freedland, Los Angeles, CA, Gerald L. Andriole, St. Louis, MO, Samuel J. Ohlender, Daniel M. Moreira, Chicago, IL

10:30 PD28-07 HEART HEALTHY DIET AND ERECTILE DYSFUNCTION IN THE HEALTH PROFESSIONALS FOLLOW-UP STUDY

10:40 PD28-08 A DOUBLE-BLIND, PLACEBO-CONTROLLED PARALLEL GROUP STUDY TO EVALUATE THE EFFECT OF A SINGLE ORAL DOSE OF GSK958108 ON EJACULATION LATENCY TIME IN MALE PATIENTS SUFFERING FROM PREMATURE EJACULATION
Filippo Migliorini, Anna Marcero*, Paolo Bettica, Luigi Ziviani, Jesper Lund, Italy Poggesi, Walter Artibani, Stefano Milleri, Verona, Italy

10:50 PD28-09 PERCUTANEOUS ANGIOPLASTY OF INTERNAL PUDENDAL ARTERIES FOR THE TREATMENT OF ERECTILE DYSFUNCTION NOT RESPONSIVE TO PHARMACOLOGICAL THERAPY. INITIAL EXPERIENCE IN SIX PATIENTS
Filippo Migliorini, Anna Marcero*, Marco Sebben, Silvia Bassi, Arianna Mariotto, Emanuele Rubiotta, Matteo Balzarro, Flavio Ribichini, Walter Artibani, Verona, Italy

11:00 PD28-10 INCREASED PREPAREDNESS BEFORE RADICAL PROSTATECTOMY IS ASSOCIATED WITH BETTER PATIENT REPORTED POST-OPERATIVE SEXUAL OUTCOMES
Abhinav Khanna*, Anna Faris, Anna Zampini, Daniel Hettel, Hadley Wood, Bradley Gill, Edmund Sabanegh, Cleveland, OH

11:10 PD28-11 EFFECTS OF SILDENAFIL TREATMENT OF ERECTILE DYSFUNCTION CAUSED BY BILATERAL CAVERNOUS NERVE CRUSH AND BILATERAL CAVERNOUS NERVE RESECTION.
Meng Li, ZhongCheng Xin*, Beijing, China, People’s Republic of

11:20 PD28-12 SAFETY OF TESTOSTERONE REPLACEMENT THERAPY AFTER RADICAL PROSTATECTOMY (RP) FOR LOCALIZED PROSTATE CANCER: A POPULATION-BASED ANALYSIS
Reith Sarkar, J. Kellogg Parsons*, John Einck, Arno Mundt, A. Karim Kader, Christopher Kane, Paul Riviere, Rana McKay, James Murphy, Brent Rose, La Jolla, CA

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
### Video Session 4

**ED, INFERTILITY & TRANSGENDER SURGERY**

The videos in this session as well as the video libraries from the 2012-2018 Annual Meetings may be viewed in the Surgical Video Library and purchased in the AUA Store during the Annual Meeting. AUA members receive free online access to the Surgical Video Library throughout the year through AUA University. Visit [www.AUAnet.org/University](http://www.AUAnet.org/University) to access.

**Room W187b @ McCormick Place**  
**Moderators:** Daniel Dugi, Steven Wilson & Suks Minhas

<table>
<thead>
<tr>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
</table>
| 9:30 | V04-10 | MICROSURGICAL SUBINGUINAL VARICOCELECTOMY WITH TESTICULAR DELIVERY: MODIFICATIONS AND TRICKS  
RUHUI TIAN*, Huixing Chen, Peng Li, Zheng Li, SHANGHAI, China, People’s Republic of China |
| 9:40 | V04-02 | AUTOLOGOUS FASCIAL MINI-JUPETTE SLING FOR THE MANAGEMENT OF POST-PROSTATECTOMY CLIMACTURIA  
Judy Choi, Zhamshid Okhunov, Francis Jefferson, Farouk El-Khatib, Catherine Nguyen, James Furr, Faysal Yafi*, Orange, CA |
| 9:50 | V04-12 | GENDER-AFFIRMING COLPEXY AND COLPOCLEISIS OF A MCINDOE NEOVAGINA  
Nicholas Chakiryan*, Daniel Dugi, Kamran Sajadi, Portland, OR |
| 10:00 | V04-08 | SIMPLIFIED PENILE INVERSION VAGINOPLASTY  
Rajveer S. Purohit, MD, MPH, James Young, BA*, Marci Bowers, MD, New York, NY |
| 10:10 | V04-01 | DISSECTION OF NEOVAGINAL SPACE IN GENDER-AFFIRMING VAGINOPLASTY  
Poone Shoureshi*, Dave Jiang, Daniel Dugi, Portland, OR |
| 10:20 | V04-03 | ROBOTIC PERITONEAL FLAP TECHNIQUE FOR REVISION VAGINOPLASTY IN TRANSGENDER WOMEN  
Matthew Katz*, Geolani Dy, Ian Nolan, Rachel Bluebond-Langner, Lee Zhao, New York, NY |
| 10:30 | V04-06 | MULTIPLE TRANSVERSE DORSAL INCISIONS PATCHED WITH TACHIOSIL® IN THE SURGICAL TREATMENT OF PEYRONIE'S DISEASE: PRELIMINARY RESULTS  
Afonso Castro, Pedro Simões de Oliveira, Jose Dias, Tome Lopes, Francisco Martins*, Lisbon, Portugal |
| 10:40 | V04-07 | HOW TO IMPROVE YOUR XIAPEX RESULTS IN PEYRONIE'S DISEASE: THE PERCUTANEOUS NEEDLE TUNNELLING (PNT) TECHNIQUE. STEP-BY-STEP SURGICAL VIDEO  
Esau Fernández-Pasqual*, Francisco Javier González-García, Elena García-Criado, Aura Daniella Souto, Diego Marcos, Javier Angulo, Juan Ignacio Martínez-Salamanca, Joaquín Carballido, Madrid, Spain |
| 10:50 | V04-04 | MICRO-PERFORATIONS TO CORRECT CURVATURE AND FIBROSIS AT THE TIME OF PENILE PROSTHESIS PLACEMENT  
Jonathan Warner*, Duarte, CA |
| 11:00 | V04-11 | INFECTED INFLATABLE PENILE PROSTHESIS REMOVAL AND SEMI RIGID PROSTHESIS INSERTION  
Julio Slongo*, Tampa, FL, Aram Loeb, Cleveland, OH, Justin L. Parker, Rafael E. Carrion, Tampa, FL |
| 11:10 | V04-09 | CURRENT METHODOLOGY IN PENILE IMPLANT REVISION SURGERY  
Kara Choate*, Andrew Kramer, Baltimore, MD |
| 11:20 | V04-05 | SINGLE PERINEAL INCISION FOR ARTIFICIAL URINARY SPHINCTER AND SEMI-RIGID PENILE PROSTHESIS PLACEMENT  
Julio Slongo*, Adam Baumgarten, Tampa, FL, Jonathan Beilan, Houston, TX, Aram Loeb, Cleveland, OH, Lucas Wiegand, Rafael E. Carrion, Tampa, FL |

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

---

**Forums**

### Young Urologists Forum

<table>
<thead>
<tr>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
</table>
| 10:30 | WELCOME & INTRODUCTION  
Program Chair: Sero Andonian  
Vice-Chair: Steven Hudak |
| 10:35 | RECOGNITION OF YOUNG UROLOGISTS OF THE YEAR AWARD RECIPIENTS  
Program Chair: Sero Andonian |

---

Saturday, May 4, 2019  
**Video Session 4**  
9:30 am - 11:30 am

Saturday, May 4, 2019  
**Forums**  
10:30 am - 12:00 pm
SOCIETY OF UROLOGIC ONCOLOGY (SUO)
Room W196 @ McCormick Place

Saturday, May 4, 2019
12:25 pm - 5:00 pm

12:25 WELCOME AND INTRODUCTION
Program Chairs: Marc Dall’Era, Surena Matin

12:30 POPULATION CANCER DATABASES: GOLDMINES AND PITFALLS FOR THE RESEARCHER, REVIEWER AND THE READER
Peter Albertsen

12:42 GERMLINE DNA TESTING IN UROLOGY: BEST PRACTICES AND ETHICAL CONSIDERATIONS
Todd Morgan

12:54 SESSION I: KIDNEY CANCER
SHOULD I DO A PARTIAL OR RADICAL NEPHRECTOMY?: 3 CASES, 3 EXPERTS
E. Jason Abel, Mark Ball, Brian Lane

HOW ARE WE IMPROVING OUTCOMES OF LOCALLY ADVANCED RRC?
Jose Karam, Jodi Maranchie

MANAGEMENT PARADIGMS FOR ADVANCE NCCRCC IN THE MODERN ERA
Nancy Davis

THREE PAPERS IN THE PAST YEAR THAT INFLUENCED MY PRACTICE
Scott Eggener

Q&A

1:55 INTRODUCTION TO THE WHITMORE LECTURE
Society President: Christopher Evans

2:00 WHITMORE LECTURE
Joseph Smith

2:20 SUO AWARDS
Society President: Christopher Evans

2:30 BREAK

2:40 SESSION II: UROTHELIAL CANCER
IS GEMCITABINE THE NEW POST-TUR STANDARD OF CARE?
John Gore

RATIONALE FOR POST-URETEROSCOPY INTRAVESICAL CHEMOTHERAPY
Vitaly Margulis

BCG REFRACTORY DISEASE: 3 CASES, 3 EXPERTS
Trinity Bivalacqua, Sima Porten, Alexandre Zlotta

ERAS VS. ROBOTICS: WHICH PROVIDES THE MOST INCREMENTAL BENEFIT?
Siamak Daneshmand, Dipen Parekh

INSTILADRIN LATE-BREAKING PHASE 2 DATA
Colin Dinney

THREE PAPERS IN THE PAST YEAR THAT INFLUENCED MY PRACTICE
Angela Smith

Q&A

3:55 SESSION III: PROSTATE CANCER
WHAT KIND OF BIOPSY SHOULD I BE DOING?: 3 CASES, 3 EXPERTS
Mark Emberton, Jeffrey Holzbeierlein, Daniel Lin

OPIATE USE AFTER RADICAL PROSTATECTOMY: THE END IS HERE
Ben Davies

WHO SHOULD WE CONSIDER FOR FOCAL THERAPY & HOW?
Art Rastinehad

RISING PSA AFTER LOCAL THERAPY: NEW IMAGING FOR RECURRENT PROSTATE CANCER
Peter Carroll

CIRCULATING TUMOR FACTORS IN CASTRATION SENSITIVE METASTATIC PROSTATE CANCER
Amir Goldkorn

THREE PAPERS IN THE PAST YEAR THAT INFLUENCED MY PRACTICE
Brian Chapin

Q&A

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

*Presenting author
<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
</table>
| MP34-01 | **DUAL TARGETING OF EZH2 AND ANDROGEN RECEPTOR SYNERGISTICALLY INHIBITS CASTRATION-RESISTANT PROSTATE CANCER**  
Eswar Shankar*, Daniel Franco, Omair Iqbal, Stephan Moreton, Rajnee Kanwal, Sanjay Gupta, Cleveland, OH |
| MP34-02 | **VERU-111, A NOVEL ORAL INHIBITOR OF α AND β TUBULIN, INHIBITS TUMOR GROWTH IN THE HUMAN CASTRATION-RESISTANT AR VARIANT PROSTATE CANCER (PCA) MODEL 22RV1**  
Robert Getzenberg*, Fort Lauderdale, FL, Mark Markowski, Baltimore, MD, Mitchell Steiner, Miami, FL, Mario Eisenberger, Emmanuel Antonarakis, Baltimore, MD |
| MP34-03 | **AN OPEN-LABEL, NEOADJUVANT PHASE 2 CLINICAL TRIAL COMPARING THE EFFECTS OF AR INHIBITION WITH AND WITHOUT SRC OR MEK INHIBITION ON THE DEVELOPMENT OF EMT IN PROSTATE CANCER: AN OUTCOME REPORT**  
Aydin Pooli*, Matthew Rettig, Allan Pantuck, Nazy Zomorodian, Robert E. Reiter, Los Angeles, CA |
| MP34-04 | **A NEW GENERATION OF N-TERMINAL DOMAIN ANDROGEN RECEPTOR INHIBITORS IN CASTRATION-RESISTANT PROSTATE CANCER MODELS**  
Ronan Le Moigne*, Han-Jie Zhou, Houston, TX, Nasrin R. Mawji, C. Adriana Banuelos, Jun Wang, Kunzhong Jian, Vancouver, Canada, Peter Vircik, Houston, TX, Raymond J. Andersen, Marianne D. Sadar, Vancouver, Canada |
| MP34-05 | **COMBINATION THERAPY FOR CASTRATION-RESISTANT PROSTATE CANCER USING ANTAGONISTS OF THE N-TERMINAL DOMAIN OF ANDROGEN RECEPTOR WITH IONIZING RADIATION**  
Yusuke Ito*, C. Adriana Banuelos, Yukyoshi Hirayama, Kunzhong Jian, Raymond Andersen, Marianne Sadar, Vancouver, Canada |
| MP34-06 | **INFLUENCE OF DIFFERENT MODALITIES OF ANDROGEN DEPRIVATION THERAPY ON LIPID AND GLUCOSE METABOLISM AND FAT ACCUMULATION IN PATIENTS WITH PROSTATE CANCER: DEGARELIX VS LEUPROLIDE PLUS BICALUTAMIDE**  
Harutake Sawazaki*, Daaji Araki, Higashimurayama, Japan |
| MP34-07 | **ASSOCIATION OF PROSTATE-SPECIFIC ANTIGEN TRAJECTORIES WITH MORTALITY IN VETERANS WITH NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER**  
Stephen Freedland, Los Angeles, CA, Yinong Young-Xu, White River Junction, VT, Sophia Li, Titusville, NJ, Dominic Pilon*, Montreal, Canada, Rachel Bhak, Emile Duchesneau, Michael Hellstern, Boston, MA, Ajay Behl, Titusville, NJ, Patrick Lefebvre, Montreal, Canada, Alexander Pud, Durham, NC |
| MP34-08 | **HIGH CONFIRMATORY PSA AT BIOCHEMICAL RECURRENCE PREDICTS DISTANT METASTASIS**  
Yongmei Chen*, Rockville, MD, Thomas Gerald, Inger Rosner, Bethesda, MD, Huai-Ching Kuo, Rockville, MD, Timothy Brand, Tacoma, WA, John Musser, Honolulu, HI, Christopher Porter, Seattle, WA, Sean Stroup, San Diego, CA, Shiv Srivastava, Jennifer Cullen, Rockville, MD |
| MP34-09 | **IMPACT OF PROSTATE SPECIFIC ANTIGEN DOUBLING TIME ON METASTASIS AND INCREASED COSTS ASSOCIATED WITH PROGRESSION TO METASTATIC CASTRATE-RESISTANT PROSTATE CANCER**  
| MP34-10 | **PREDICTORS OF SKELETAL RELATED EVENTS AND OVERALL MORTALITY IN MEN WITH METASTATIC, CASTRATION-RESISTANT PROSTATE CANCER: RESULTS FROM THE SEARCH DATABASE**  
Ingrid Lorese Tablazon*, Lauren Howard, Amanda De Hoedt, Durham, NC, William Aronson, Los Angeles, CA, Christopher Kane, San Diego, CA, Christopher Amling, Portland, OR, Matthew Cooperberg, San Francisco, CA, Martha Teras, Augusta, GA, Stephen Freedland, Los Angeles, CA, Stephen Williams, Galveston, TX |
| MP34-11 | **METASTASES-YIELD AND PSA-KINETICS FOLLOWING SALVAGE LYMPH NODE DISSECTION FOR PROSTATE CANCER: A COMPARISON BETWEEN CONVENTIONAL SURGICAL APPROACH AND PSMA-RADIOGUIDED SURGERY**  
Sophie Knipper, Derya Tilki, Joost Mosholt, Christoph Berliner, Christian Bemreuther, Thomas Steuber, Tobias Maurer, Markus Graefen*, Hamburg, Germany |
MP34-12 THE ROLE OF SALVAGE LYMPH NODE DISSECTION IN NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS: A SINGLE CENTER EXPERIENCE
Luca Boeri*, Vidit Sharma, Igor Frank, Stephen A. Boorjian, R. Houston Thompson, Matthew Tollefson, John C. Cheville, Eugene D. Kwon, R. Jeffrey Kames, Rochester, MN

MP34-13 COMBINATION THERAPY WITH RADIUM-223 AND ABIRATERONE OR ENZALUTAMIDE IN A LARGE REAL WORLD COHORT
Hanson Zhao*, Los Angeles, CA, Lauren Howard, Amanda De Hoedt, Durham, NC, Martha Terris, Augusta, GA, Christopher Amling, Portland, OR, Christopher Kane, La Jolla, CA, Matthew Cooperberg, San Francisco, CA, William Aronson, Los Angeles, CA, Thomas Polascik, Durham, NC, Stephen Freedland, Los Angeles, CA

MP34-14 OVERALL ADVERSE EVENTS IN PATIENTS TREATED WITH ABIRATERONE AND ENZALUTAMIDE FOR METASTATIC CASTRATION RESISTANT PROSTATE CANCER: META-ANALYSIS OF RANDOMIZED CLINICAL TRIALS AND REAL-WORLD REPORTING PATTERNS FROM EUDRA VIGILANCE
Cosimo De Nunzio*, Giorgia Tema, Riccardo Lombardo, Olivia Voglino, Valeria Baldassarri, Fabiana Cancrini, Angela Sica, Luca Sarchi, Antonio Cicione, Andrea Tubaro, Rome, Italy

MP34-15 TREATMENT OUTCOME OF DOSE REDUCTION OF ENZALUTAMIDE AGAINST CRPC
Naokazu Ibuki*, Teruo Inamoto, Atsushi Ichihashi, Hirofumi Uehara, Kazumasa Komura, Hajime Hirano, Hayahito Nomiy, Haruhiito Azuma, Osaka, Japan

MP34-16 A NOVEL ANDROGEN RECEPTOR (AR) ANTAGONIST JJ-450 INHIBITS ENZALUTAMIDE-RESISTANT MUTANT AR F876L
Zeyu Wu*, Zhenyu Yang, Laura Pascal, Keita Takubo, Joel Nelson, Peter Wipf, Zhou Wang, Pittsburgh, PA

MP34-17 A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ENZALUTAMIDE IN PATIENTS WITH NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER: POST HOC ANALYSIS OF PROSPER BY PROSTATE SPECIFIC-ANTIGEN PROGRESSION
Fred Saad*, Montreal, Canada, Cora N. Sternberg, New York, NY, Eleni Efstatidou, Houston, TX, Karim Fizazi, Villejuif, France, Katharina Modeliska, Xiaowei Guan, San Francisco, CA, Jennifer Sugg, Joyce Steinberg, Northbrook, IL, Bettina Noerby, Vejle, Denmark

MP34-18 CLINICAL BENEFITS AND RISKS OF ENZALUTAMIDE AND APALUTAMIDE: NUMBER NEEDED TO TREAT AND NUMBER NEEDED TO HARM ANALYSIS FOR PATIENTS WITH NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Neil M. Schultz, Northbrook, IL, Rebecca Sugarman*, Palm Harbor, FL, Krishnan Ramaswamy, New York, NY, Ken O’Day, Palm Harbor, FL

MP34-19 EFFICACY AND SAFETY OF APALUTAMIDE (APA) IN NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC) PATIENTS (PTS) WITH OR WITHOUT PRIOR RADICAL PROSTATECTOMY (RP) AND/OR EXTERNAL RADIOThERAPY (XRT): POST HOC ANALYSIS OF SPARTAN

MP34-20 METASTASIS-FREE SURVIVAL (MFS) IN NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC) PATIENTS (PTS) WITH PROSTATE-SPECIFIC ANTIGEN (PSA) DECLINE TO < 0.2 NG/ML FOLLOWING APALUTAMIDE (APA) TREATMENT: POST HOC RESULTS FROM THE PHASE 3 SPARTAN STUDY

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
ABSTRACT NUMBER | TITLE
--- | ---
MP35-01 | BASELINE PREVALENCE AND MAGNITUDE OF SPATIAL DEVIATIONS IN A SIMULATOR FROM THE TRANSRECTAL ULTRASOUND PROSTATE BIOPSY TEMPLATE

MP35-02 | RELATIONSHIP BETWEEN LEVEL OF TASK DIFFICULTY, HUMAN-MACHINE INTERACTION COMPLEXITY, AND SIMULATION-BASED TRAINING IN ROBOT-ASSISTED SURGERY
Somayeh B Shafiei, Zaeem Lone, Kevin Stone, Jacob Braun, Syed Kamal, Ahmed S. Elsayed*, Naif A. Aldhaam, Khurshid A. Guru, Buffalo, NY

MP35-03 | ADDING CONSTRUCT VALIDITY EVIDENCE TO THE ENDOSCOPIC STONE TREATMENT STEP-1 (EST S1): A NOVEL TRAINING AND ASSESSMENT TOOL FROM COLLABORATION OF ESU, EULIS, ESUT AND EUERP
Domenico Veneziano*, Reggio Calabria, Italy, Achilles Ploumids, Athens, Greece, Giuseppe Basile, Reggio Calabria, Italy, Silvia Proietti, Milano, Italy, Theodore Tokas, Tirol, Austria, Guido Kamphuis, Amsterdam, Netherlands, Ben Van Cleymenbreugel, Louvain, Belgium, Ali Gozen, Heilbronn, Germany, Alberto Breda, Joan Palou, Barcelona, Spain, Kemal Sarica, Instambul, Turkey, Evangelos Liatakos, Patras, Greece, Kamran Ahmed, London, United Kingdom, Bhaskar Somani, southampton, United Kingdom

MP35-04 | AUTOMATED EVALUATION OF INSTRUMENT FORCE SENSITIVITY DURING ROBOTIC SUTURING UTILIZING VISION-BASED MACHINE LEARNING
Aniruddh Puranic, Jian Chen*, Jessica Nguyen, Jyotirmoy Deshmukh, Andrew Hung, Los Angeles, CA

MP35-05 | OUTCOMES OF EUROPEAN BASIC LAPAROSCOPIC UROLOGICAL SKILLS (EBLUS) EXAMS: RESULTS FROM EUROPEAN SCHOOL OF UROLOGY (ESU) OVER 6 YEARS (2013-2018)
Bhaskar Somani, Southampton, United Kingdom, Ben Van Cleymenbreugel, Leuven, Belgium, Ali Gozen, Heilbronn, Germany, Andreas Skolarikos, Athens, Greece, Christian Wagner, Gronau, Germany, John Beatty, Leicester, United Kingdom, Sas Barmoshe, Brussels, Belgium, Jose Maria Gaya, Barcelona, Spain, Theodoros Kologeropoulos, Athens, Greece, Faba Oscar Rodriguez, Barcelona, Spain, Rafael Salas Sanchez, Paris, France, Marek Schmidt, Prague, Czech Republic, Siena Giampaolo, Florence, Italy, Gio Pini, Milan, Italy, Joan Palou, Barcelona, Spain, Robert Geraghty, Southampton, United Kingdom, Domenico Veneziano*, Calabria, Italy

MP35-06 | ASSESSING THE UROLOGIC TRAINEE’S LEARNING CURVE FOR ULTRASOUND GUIDED RENAL PUNCTURES DURING PERCUTANEOUS NEPHROLITHOTOMY
Manuel Armas-Phan*, David Tzou, David Bayne, Scott Wiener, Adam Gadzinski, Ian Metzler, Kelly Walker, Marshall Stoller, Tom Chi, San Francisco, CA

MP35-07 | DEVELOPMENT AND VALIDATION OF A SIMULATOR-BASED TEST IN TRANSURETHRAL RESECTION OF BLADDER TUMORS ESTABLISHING PASS/FAIL STANDARDS
Sarah Buber*, Roskilde, Denmark, Rikke Hansen, Copenhagen, Denmark, Claus Dahl, Roskilde, Denmark, Lars Kongs, Copenhagen, Denmark, Nessa Azawi, Roskilde, Denmark

MP35-08 | IMMERSIVE VIRTUAL REALITY (IVR) SIMULATOR MODELS AS AN EDUCATIONAL AND PREOPERATIVE PLANNING TOOL FOR LAPAROSCOPIC DONOR NEPHRECTOMY: INITIAL EXPERIENCE
Francis Jefferson*, Orange, CA, Egor Parkhomenko, Boston, MA, Mitchell O’Leary, Orange, CA, Shoaib Safiullah, Columbia, MO, John Sung, Roshan Patel, Hirohito Ichii, Donald Dafoe, Jaime Landman, Orange, CA

MP35-09 | HOLOGRAPHIC SURGICAL PLANNING USING A WEARABLE MIXED REALITY COMPUTER
Soichiro Yoshida*, Shohei Fukuda, Shingo Moriyama, Minato Yokoyama, Naoki Taniguchi, Kenichi Shinjo, Maki Sugimoto, Kazutaka Saito, Yasuhisa Fujii, Tokyo, Japan
MP35-10 IMPACT OF A STANDARDIZED TRAINING TUTORIAL ON AUTOMATED PERFORMANCE METRICS AND COGNITIVE WORKLOAD DURING ROBOTIC VESICOURETHRAL ANASTOMOSIS
Daphne Remulla*, Jessica Nguyen, Ryan Lee, Tiffany Chu, Jian Chen, Vivek Singh, Andrew Chen, Los Angeles, CA, Sandra Marshall, Solana Beach, CA, Inderbir Gill, Andrew Hung, Los Angeles, CA

MP35-11 MENTAL TRAINING AND ITS EFFECT ON PROCEDURAL AND COGNITIVE LEARNING – LONGTERM OUTCOMES AFTER 1-YEAR OF FOLLOW-UP
Julia Kaulfuss*, Philipp Marks, Hamburg, Germany, Philippe Grange, Lucerne, Switzerland, Felix Chun, Luis Kluth, Frankfurt, Germany, Christian Meyer, Hamburg, Germany

MP35-12 ANALYSIS OF FORCES IN LAPAROSCOPY: THE DECONSTRUCTION OF AN INTRACORPOREAL SUTURING TASK
Kai-Ho Fok*, Sophia Duong, Brian Carrillo, J Ted Gerstle, Georges Azzie, Monica A Farcas, Toronto, Canada

MP35-13 DEVELOPMENT AND VALIDATION OF A HIGH-FIDELITY URETHRAL CATHETER SIMULATOR
Alyssa Schul*, Alex Gong, Robert Sweet M.D., FACS, Seattle, WA

MP35-14 IF IT’S NOT THE MONEY, AND IT’S NOT THE TIME. . . . . : INVESTIGATING BARRIERS TO THE RECRUITMENT OF UNDERREPRESENTED MINORITIES IN UROLOGY RESIDENCY PROGRAMS
Jorge Whitley, Byron Joyner, Kathleen Kieran*, Seattle, WA

MP35-15 THIEL-EMBALMED CADAVERS AS A NOVEL TRAINING MODEL FOR ULTRASOUND GUIDED, SUPINE, ENDOSCOPIC COMBINED INTRARENAL SURGERY
Ralf Veys*, Pieter Verpoort, Ghent, Belgium, Carl Van Haute, Brussels, Belgium, Thomas Chi, San Francisco, CA, Thomas Tailly, Ghent, Belgium

MP35-16 A RANDOMISED STUDY OF SIMULATED VERSUS VOLUNTEER DIGITAL RECTAL EXAM FOR MEDICAL STUDENT TEACHING
Kieran Beattie*, Benedict Kakala, Manish Patel, Sydney, Australia

MP35-17 DESCRIBING UROLOGY RESIDENCY SURGICAL CASE VOLUME OVER TIME: A REVIEW OF THE ACGME RESIDENT CASE LOGS
Jonathan Wingate*, Byron Joyner, Judith Hagedorn, Niels Johnsen, Seattle, WA

MP35-18 DEVELOPMENT, IMPLEMENTATION, AND EVALUATION OF A COMPETENCY-BASED DIDACTIC AND SIMULATION-FOCUSED BOOT CAMP FOR INCOMING UROLOGY RESIDENTS: REPORT OF FIRST TWO YEARS

MP35-19 UTILITY AND FEASIBILITY OF VIDEO-BASED ASSESSMENT FOR URETEROSCOPY AND LASER LITHOTRIPSY
Yuding Wang*, Kelly Dore, Dana Russell, Jen Hoogenes, Bobby Shayegan, Nathan Wong, Edward Matsumoto, Hamilton, Canada

MP35-20 EIGHTEEN-YEAR REVIEW OF RESIDENT PERFORMANCE ON THE AMERICAN UROLOGICAL ASSOCIATION IN-SERVICE EXAMINATION
Ahmad El-Arabi*, Kansas City, KS, Garth Sherman, Kansas City, MO, Moben Mirza, J. Brantley Thrasher, Ajay Nangia, Kansas City, KS
APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP36-01</td>
<td>NEGATIVE MULTI-PARAMETRIC MRI ACCURATELY PREDICTS THE ABSENCE OF CLINICALLY SIGNIFICANT PROSTATE CANCER</td>
</tr>
<tr>
<td></td>
<td>Spencer Hart*, Chirag Doshi, Thomson Tai, Ryan Dornbier, Maywood, IL, Cara Joyce, Chicago, IL, Alex Gorbonos, Michael Woods, Marcus Quek, Robert Flanigan, Gopal Gupta, Maywood, IL</td>
</tr>
</tbody>
</table>

**MP36-02** PERIPROCEDURAL AND DIAGNOSTIC OUTCOMES OF TRANRECTAL VERSUS TRANSPERINEAL US/MRI GUIDED FUSION PROSTATE BIOPSY: MULTI-INSTITUTIONAL PROPENSITY SCORE MATCHED PAIR ANALYSIS

Maria Consiglia Ferriero*, Rocco Simone
Flamnia, Rome, Italy, Marco Oderda, Turin, Italy, Valerio Forte, Rome, Italy, Alexandre Peltier, Bruxelles, France, Pardeep Kumar, London, United Kingdom, Pierre Mozer, Paris, France, Alessandro Giacobbe, Turin, Italy, Riccardo Mastroianni, Gabriele Tuderti, Umberto Anceschi, Aldo Brasseti, Rome, Italy, Jean-Baptiste Roche, Bordeaux, France, Mauro Ciccariello, Salvatore Guagianone, Rome, Italy, Thierry Piechaud, Bordeaux, France, Morgan Ropre't, Paris, France, Paolo Gontero, Giovanni Muto, Turin, Italy, Michele Gallucci, Giuseppe Simone, Rome, Italy

**MP36-03** TRANSPERINEAL VS. TRANRECTAL MRI-US FUSION FOR PROSTATE CANCER DETECTION – A PROSPECTIVE RANDOMIZED STUDY.

David Margel*, Yaara Ber, Sivan Sela, Daniel Kedar, Jack Daniel, Petah-Tikva, Israel

**MP36-04** BIPARAMETRIC MRI IN THE DETECTION OF PROSTATE CANCER: DOES EXCLUSION OF THE DYNAMIC CONTRAST ENHANCED SEQUENCE INFLUENCE THE DECISION TO DO BIOPSY?

Patrick Blaza*, Jason Letran, German Jose Albano, Manila, Philippines

**MP36-05** UTILITY OF MULTIPARAMETRIC MRI IN HIGH GRADE PIN AND ASAP

Mary E Westerman*, Vidit Sharma, Adam T. Froemming, Robert H. McLaren, Lance A. Mynderse, R. Jeffrey Karnes, Rochester, MN

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP36-06</td>
<td>COMPARISON OF MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING-FUSION BIOPSY AND STANDARD TRANSRECTAL ULTRASOUND BIOPSY: CLINICALLY SIGNIFICANT PROSTATE CANCER DETECTION RATE</td>
</tr>
<tr>
<td></td>
<td>Hye Jin Byun*, Wonho Jung, Ji Yong Ha, Byung Hoon Kim, Chol Hee Park, Chun Il Kim, Daegu, Korea, Republic of</td>
</tr>
</tbody>
</table>

**MP36-07** THE CHARACTERISTICS OF PROSTATE CANCER WITH A FALSE-NEGATIVE MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING

Hye Jin Byun*, Wonho Jung, Ji Yong Ha, Byung Hoon Kim, Chol Hee Park, Chun Il Kim, Daegu, Korea, Republic of

**MP36-08** APPLICATION OF THE PRECISION TRIAL BIOPSY STRATEGY TO A CONTEMPORARY COHORT: HOW MANY CLINICALLY SIGNIFICANT PROSTATE CANCERS ARE MISSED?

Xiaosong Meng*, Andrew B. Rosenkrantz, Richard Huang, James S. Wysock, Fang-Ming Deng, William C. Huang, Herbert Lepor, Samar S. Taneja, New York, NY

**MP36-09** DIAGNOSTIC ACCURACY OF TARGETED PROSTATE BIOPSYES: RESULTS FROM A PROSPECTIVE TRIAL COMPARING MICRO-ULTRASOUND WITH MULTIPARAMETRIC MRI FOR THE DETECTION OF PROSTATE CANCER

Davide Maffeo*, Marco Paciotti, Massimo Lazzeri, Piergiuseppe Colombo, Vittorio Fasulo, Luigi Domanico, Paolo Casale, Alberto Salta, Rodolfo Hurle, Nicolò Maria Buffi, Giorgio Ferruccio Guazzoni, Giovanni Lughezzani, Rozzano, Italy

**MP36-10** WHO BENEFITS FROM MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING AFTER THE SUSPICION OF PROSTATE CANCER?

Merce Cuadras*, Ana Celma, Lucas Regis, Aina Salazar, Enric Miret, Sarai Roche, Ines M. de Torres, Richard Mast, Maria E. Semidey, Jacques Planas, Juan Morote, Barcelona, Spain
MP36-11 WHICH CANCERS ARE STILL DIAGNOSED BY STANDARD PROSTATE BIOPSY WITHOUT AN UPFRONT MULTIPARAMETRIC MRI? RESULTS FROM A TERTIARY CARE, HIGH VOLUME CENTRE
Armando Stabile*, Paolo Dell’Oglio, Emanuele Zaffuto, Francesco De Cobelli, Antonio Esposito, Giorgio Gandaglia, Nicola Fossati, Giuseppe Rosiello, Nazareno Suardi, Scattoni Vincenzo, Andrea Gallina, Simone Scarcella, Milan, Italy, Andrea B Galosi, Ancona, Italy, Morgan Roupret. Paris, France, Francesco Montorsi, Alberto Briganti, Milan, Italy

MP36-12 WHERE IS MP-MRI MORE ACCURATE IN DETECTING CLINICALLY SIGNIFICANT PROSTATE CANCER? AN ANALYSIS BASED ON ANATOMICAL PROSTATE AREAS
Paolo Dell’Oglio*, Armando Stabile, Milan, Italy, Luca Boeri, Rochester, MN, Francesco De Cobelli, Simone Scuderi, Giorgio Brembilla, Nicola Fossati, Giorgio Gandaglia, Emanuele Zaffuto, Antonio Esposito, Milan, Italy, Matteo Soligo, Rochester, MN, Umberto Capitanio, Francesco Barletta, Milan, Italy, R. Jeffrey Karnes, Rochester, MN, Francesco Montorsi, Alberto Briganti, Milan, Italy

MP36-13 THERE IS NO WAY TO AVOID CONCOMITANT SYSTEMATIC PROSTATE BIOPSY IN ADDITION TO MP-MRI TARGETED SAMPLING IN MEN WITH POSITIVE IMAGING

MP36-14 IS ONE TARGETED BIOPSY CORE OF THE INDEX LESION SUFFICIENT TO ACCURATELY DETECT CLINICALLY SIGNIFICANT PROSTATE CANCER ACROSS ALL PI-RADS SCORES?

MP36-15 TO BIOPSY, OR NOT TO BIOPSY, THAT IS THE QUESTION: RISK STRATIFICATION OF PATIENTS WITH A NEGATIVE MRI

MP36-16 DEVELOPMENT AND EXTERNAL VALIDATION OF A NOVEL MODEL TO IDENTIFY PATIENTS WITH EQUIVOCAL LESION AT MULTIPARAMETRIC MRI WHO CAN AVOID PROSTATE BIOPSY

MP36-17 DEFINING BIOCHEMICAL RECURRENCE IN PROSTATE CANCER WITH HYBRID PSMA PET MRI

MP36-18 LOCALIZATION OF RECURRENCE OF PROSTATE CANCER WITH 18F-FLUCICLOVINE POSITRON EMISSION TOMOGRAPHY IN PATIENTS WITH AND WITHOUT PRIOR PROSTATECTOMY: RESULTS FROM LOCATE
Gerald Andriole*, Barry Siegel, Saint Louis, MO., LOCATE Study Group, x, WA

MP36-19 WHAT IS THE ACCURACY OF 68GA-PSMA PET/CT IN DETECTING PRIMARY PROSTATE CANCERS COMPARED TO MULTIPARAMETRIC MRI?
<table>
<thead>
<tr>
<th>Abstract Number</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP37-01</td>
<td>Current Trends and Disparities in Use of Partial Nephrectomy for T1A Renal Masses</td>
<td>Allison May*, Aniruddh Guduru, Johar Syed, Facundo Davaro, Sameer Siddiqui, Zachary Hamilton</td>
</tr>
<tr>
<td></td>
<td></td>
<td>St Louis, MO, MO</td>
</tr>
<tr>
<td>MP37-02</td>
<td>Temporal Trends in Surgical Approach for Nephrectomy Based on Tumor Size from the National Cancer Database (NCDB)</td>
<td>Helen Hougen*, Ann Martinez Acevedo, Lina Gao, Ryan Kopp, Christopher Amling, Jennifer Jane Liu</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Portland, OR</td>
</tr>
<tr>
<td>MP37-03</td>
<td>Robot-Assisted Partial Nephrectomy is Superior in Terms of Postoperative Acute Kidney Injury, as Compared to Open Partial Nephrectomy</td>
<td>Hidekazu Tachibana*, Tsunenori Kondo, Tokyo, Japan</td>
</tr>
<tr>
<td>MP37-04</td>
<td>Prediction of Significant Estimated Glomerular Filtration Rate (EGFR) Decline Following Renal Unit Removal to Aid in the Clinical Choice Between Radical and Partial Nephrectomy in Patients with Renal Mass</td>
<td>Andrew McIntosh*, Houston, TX, Robert Uzzo, Brian Egleston, David Chen, Richard Greenberg, Rosalia Viterbo, Shreyas Joshi, Philadelphia, PA, Daniel Parker, Oklahoma City, OK, Marc Smaldone, Alexander Kutikov, Philadelphia, PA</td>
</tr>
<tr>
<td>MP37-05</td>
<td>Impact of Prolonged Warm Ischemia on Long Term Renal Function After Laparoscopic Assisted Partial Nephrectomy</td>
<td>Trey Durdin, MD*, Wade Nedderman, Patrick Lowry, MD, Temple, TX</td>
</tr>
</tbody>
</table>
MP37-08 OUTCOMES OF ROBOT-ASSISTED PARTIAL NEPHRECTOMY FOR CLINICAL T3A RENAL MASS: ANALYSIS OF THE ROBOTIC SURGERY FOR LARGE RENAL MASS (ROSULA) GROUP

MP37-09 FACTORS ASSOCIATED WITH CONVERSION FROM MINIMALLY INVASIVE TO OPEN SURGERY DURING PARTIAL AND RADICAL NEPHRECTOMY

MP37-10 COMPARISON OF CANCER-SPECIFIC OUTCOMES FOLLOWING OPEN VERSUS MINIMALLY-INVASIVE SURGERY FOR T1 KIDNEY CANCER
Gregory Auffenberg*, Chicago, IL, Michael Curry, Renee Genarrelli, Elena Elkin, Paul Russo, New York, NY

MP37-11 TRIFECTA OUTCOMES OF OFF-CLAMP VERSUS ON-CLAMP ROBOT ASSISTED PARTIAL NEPHRECTOMY: NEPHROMETRY ADJUSTED ANALYSIS FROM ROSULA DATABASE
Aldo Brassetti*, Rome, Italy, Riccardo Bertolo, Cleveland, OH, Gabriele Tuderti, Rome, Italy, A Bindayi, San Diego, CA, Garisto, Cleveland, OH, Umberto Anceschi, Rome, Italy, Andrea Minervini, Andrea Mari, Florence, Italy, Akbar Ashrafi, Monish Aron, Los Angeles, CA, Ithaar Derweesh, San Diego, CA, Indiana Sundaram CP, Indianapolis, IN, Jihad Koauk, Cleveland, OH, Riccardo Autorino, Virginia, VA, Francesco Porpiglia, Daniele Amparore, Or巴萨sano, Italy, Luigi Schips, Chieti, Italy, KH Rha, Wonju, Korea, Republic of, Michele Gallucci, Rome, Italy, Ithaar Derweesh, San Diego, CA, Giuseppe Simone, Rome, Italy

MP37-12 CLINICAL AND SURGICAL PREDICTORS OF MEDICAL AND SURGICAL POSTOPERATIVE COMPLICATIONS IN PATIENTS WITH LIMITED LIFE EXPECTANCY TREATED WITH PARTIAL NEPHRECTOMY FOR RENAL TUMORS: INSIGHT FROM THE RECORD 2 PROJECT.
Andrea Mari*, Riccardo Tellini, Riccardo Campi, Florence, Italy, Paolo Gontiero, Daniele Amparore, Turin, Italy, Alessandro Antonelli, Brescia, Italy, Maurizio Barale, Turin, Italy, Roberto Bertini, Milan, Italy, Pierluigi Bove, Rome, Italy, Eugenio Brunocilla, Bologna, Italy, Umberto Capitainio, Milan, Italy, Luigi Da Pozzo, Bergamo, Italy, Vincenzo Mirone, Naples, Italy, Emanuele Montanari, Milan, Italy, Francesco Pisanò, Francesco Porpiglia, Turin, Italy, Riccardo Schiavina, Bologna, Italy, Sergio Sarmi, Florence, Italy, Claudio Simeone, Brescia, Italy, Carlo Trombetta, Trieste, Italy, Alessandro Volpe, Novara, Italy, Walter Artibani, Verona, Italy, Vincenzo Ficarra, Messina, Italy, Marco Carini, Andrea Minervini, Florence, Italy

MP37-13 THE ONCOLOGICAL OUTCOMES COMPARISON BETWEEN HILAR VS NON-HILAR RENAL TUMORS FOLLOWING PARTIAL NEPHRECTOMY: IS THE TUMOR LOCATION A MATTER OF CONCERN?

MP37-14 MODIFIED ROBOT-ASSISTED SIMPLE ENucleation with SINGLE LAYER REnorrhaphy Technique versus STANDARD ROBOT-ASSISTED PARTIAL NEPHRECTOMY FOR RENAL CELL CARCINOMA WITH A RENAL NEPHROMETRY SCORE ≥7
Qun Lu*, Xiaozhi Zhao, Changwei Ji, Guangxian Liu, Linfeng Xu, Shwei Zhang, Xiaogong Li, Gutian Zhang, Hongqian Guo, Nanjing, China, People’s Republic of China

MP37-15 PROGNOSTIC IMPACT OF SEX IN NON-METASTATIC CLEAR CELL RENAL CELL CARCINOMA PATIENTS UNDERGOING CURATIVE SURGERY: A MULTI-NATIONAL STUDY
Hiroshi Fukushima*, Kazutaka Saito, Yosuke Yasuda, Kenji Tanabe, Masahiro Toide, Shohel Fukuda, Minato Yokoyama, Junichiro Ishioka, Yoh Matsuoka, Tokyo, Japan, Dattatraya Patil, Atlanta, GA, Britney Cotta, Sunil Patel, San Diego, CA, Viraj Master, Atlanta, GA, Ithaar Derweesh, San Diego, CA, Yasuhisa Fuji, Tokyo, Japan

MP37-16 RENAL AUTOTRANSPLANTATION FOR RENAL CELL CANCER: THE OXFORD EXPERIENCE
Mark Sullivan*, Nile Patel, Georgios Vrakas, Anil Vaidya, Robert Ritchie, Phil Mason, Chris Winnears, Peter Friend, Freddie Hamdy, David Cranston, Oxford, United Kingdom

*Presenting author
MP37-17 COMPARING OPEN AND ROBOTIC RADICAL NEPHRECTOMY WITH TUMOR THROMBUS: EXPERIENCE AND OUTCOMES.
Kyle Rose*, Anojan Navaratnam, Kassem Faraj, Haidar Abdul-Muhsin, Amit Syal, Laila Elias, Mark Tyson, Erik Castle, Phoenix, AZ

MP37-18 ONCOLOGIC OUTCOMES AFTER ROBOT-ASSISTED RADICAL NEPHROURETERECTOMY FOR UPPER URINARY TRACT MALIGNANCY
Jim Shen*, Nora Ruel, Brian Blair, Alexander Cantrell, Mitchell Bassett, Bertram Yuh, Kevin Chan, Jonathan Yamzon, Ali Zhumkhawala, Clayton Lau, Duarte, CA

MP37-19 LAPAROSCOPIC/ROBOTIC NEPHROURETERECTOMY COMPARING INTRA-CORPOREAL VERSUS OPEN EXTRA-VESICAL BLADDER CUFF EXCISION
Chia Mu Tsai*, Wei-Ting Kuo, Chia-Cheng Yu, Jen-Tai Lin, Kaohsiung, Taiwan

MP38-01 PRIMARY URETHRAL CANCER – TREATMENT PATTERNS AND ASSOCIATED OUTCOMES
Roy Mano*, Emily Vertosick, Joseph Sarcona, Daniel Sjoberg, Nicole Benfante, Timothy Donahue, Harry Herr, S. Machele Donat, Bernard Bochner, Guido Dalbagni, Alvin Goh, New York, NY

MP38-02 UNDERSTANDING THE EFFECT OF NEOADJUVANT CHEMOTHERAPY IN THE TREATMENT OF BLADDER CANCER WITH SQUAMOUS CELL HISTOLOGIC VARIANT
Ryan Speir*, Adam Calaway, Marcelo Barboza, Richard Bihrle, Timothy Masterson, Michael Koch, Liang Cheng, Clint Cary, Hristos Kaimakliotis, Indianapolis, IN

MP38-03 PLASMACYTOID UROTHELIAL CARCINOMA: IMPLICATIONS FOR NEOADJUVANT CHEMOTHERAPY AND CLINICOPATHOLOGIC OUTCOMES
Kyle Ericson*, Lewis Thomas, University Heights, OH, Byron Lee, Cleveland, OH

MP38-04 IMPACT OF ADJUVANT CHEMOTHERAPY IN PATIENTS WITH ADVERSE FEATURES AND VARIANT HISTOLOGY AT RADICAL CYSTECTOMY FOR MUSCLE-INVASIVE CARCINOMA OF THE BLADDER: DOES HISTOLOGICAL SUBTYPE MATTER?
Sebastian Berg*, Boston, MA, David D'Andrea, Vienna, Austria, Malte Wolfram Vetterlein, Hamburg, Germany, Alexander Putnam Cole, Sean Anthony Fletcher, Marieke Johanna Krimphove, May Marchese, Stuart R. Lipsitz, Guru Sonpayde, Boston, MA, Joachim Noldus, Herne, Germany, Shahrokh F. Shariat, Vienna, Austria, Adam S. Kibel, Quoc-Dien Trinh, Matthew Mossanen, Boston, MA

MP38-05 EVOLUTION OF THE DIAGNOSIS OF THE MICROPAPILLARY VARIANT OF UROTHELIAL CARCINOMA OVER TIME
Salim Cherian*, Mounis Azizi, Charles Peyton, William Fulp, Michael Poch, Roger Li, Wade Sexton, Scott Gilbert, Tampa, FL

MP38-06 IDENTIFICATION OF NOVEL IMMUNE BASAL SUBTYPES IN MUSCLE INVASIVE BLADDER CANCER
Woonyoung Choi*, Baltimore, MD, Debashis Sundi, Columbus, OH, I-Hing Lee, Arlene Odellia Siekier-Radtke, Colin Dinney, Bogdan Czerniak, Houston, TX, Seungchan Kim, Prairie View, TX, David McConkey, Baltimore, MD
MP38-07 URETHRAL MELANOMA – CLINICAL, PATHOLOGICAL AND MOLECULAR CHARACTERISTICS
Roy Mano*, Benedikt Höh, Alejandro Sanchez, Nicole Benfante, Alvin Goh, S. Machele Donat, Harry Herr, Bernard Bochner, Guido Dalbagni, Timothy Donahue, New York, NY

MP38-08 OUTCOMES ASSOCIATED WITH MIXED AND VARIANT HISTOLOGY TREATED WITH CHEMOTHERAPY PRIOR TO CYSTECTOMY AND CYSTECTOMY ALONE

MP38-09 PREOPERATIVE IMMUNONUTRITION IN PATIENTS TREATED WITH RADICAL CYSTECTOMY, RESULTS FROM A PHASE 1, “ORAL IMMUNONUTRITION TO ENHANCE RECOVERY AFTER SURGERY” FEASIBILITY TRIAL.
Janet Baack Kukreja*, Denver, CO, Mohamed Seif, Marisa Lozano, Xuemei Wang, Hyunsoo Hwang, Ashish Kamat, Colin Dinney, Neema Navai, Houston, TX

MP38-10 WINDOW OF OPPORTUNITY STUDY EVALUATING THE ANTIproliferative EFFECTS OF NEOADJUVANT METFORMIN PLUS SIMVASTATIN PRIOR TO RADICAL CYSTECTOMY FOR BLADDER CANCER: INTERIM ANALYSIS SHOWS REDUCTION IN PI3K/AKT/MTOR SIGNALING PATHWAY.

MP38-11 “SMILEY” CUTANEOUS URETEROSTOMY: A SATISFACTORY OPTION FOR URINARY DIVERSION IN SELECTED CASES OF RADICAL CYSTECTOMY
Sanjoy Sureka*, Rahul Jena, Rakesh Kapoor, Anil Mani, Lucknow, India

MP38-12 LIPOSOMAL BUPIVACAINE (EXPAREL®) ADMINISTRATION IN OPEN RADICAL CYSTECTOMY IS ASSOCIATED WITH DECREASED POST-OPERATIVE PAIN, LENGTH OF STAY, AND OPIOID USE
Carissa Chu*, Lauren Law, Lee-Lynn Chen, Candy Tsourounis, Kirsten Greene, Maxwell Meng, Sima Porten, San Francisco, CA

MP38-13 INJECTABLE HYDROGEL AS A TEMPORARY INTRAVESICAL FIDUCIAL MARKER FOR BLADDER CANCER RADIATION THERAPY: SAFETY AND FEASIBILITY FROM A PROSPECTIVE PILOT STUDY

MP38-14 TIME-TO-EVENT ANALYSIS OF 30-DAY SHORT-TERM COMPLICATIONS AFTER RADICAL CYSTECTOMY FOR URINARY BLADDER CANCER
Jakob Klemm, Michael Rink, Philipp Gild, Florian Janisch, Armin Soave, Roland Dahlem, Margit Fisch, Malte W. Vetterlein*, Hamburg, Germany

MP38-15 SYSTEMATIC URETERAL FROZEN SECTIONS AT RADICAL CYSTECTOMY. HOW MUCH IS IT REALLY USEFUL?
Giovanni La Croce*, Michele Manica, Federico Pellucchi, Paolo Barzaghi, Antonino Saccà, Lorenzo Rocchioni, Diego Angiolilli, Luigi Filippo Da Pozzo, Richard Lawrence John Naspro, Bergamo, Italy

MP38-16 JUSTIFICATION OF 8TH EDITION AJCC TUMOR NODE METASTASIS UPDATES FOR BLADDER CANCER STAGING
Marcus Daniels*, Trinity Bivalacqua, Andres Matoso, Max Kates, Baltimore, MD

MP38-17 VALIDATION OF THE COBRA NOMOGRAM FOR THE PREDICTION OF CANCER SPECIFIC SURVIVAL IN PATIENTS WITH BLADDER CANCER TREATED WITH RADICAL CYSTECTOMY
Cosimo De Nunzio*, Giuseppe Simone, Gabriele Tuberti, Umberto Anceschi, Aldo Brusetti, rome, Italy, Daneshmand S, Miranda G, Desai M, Gill I, Los Angeles, CA, Abol Enein H, Mansoura, Egypt, Antonio Nacchia, Riccardo Lombardo, Giorgia Tema, Emilio Molinaro, Costantino Leonardo, Andrea Tubaro, Rome, Italy

MP38-18 INTRACORPOREAL URINARY DIVERSION: A RISK FACTOR FOR URETEROINAL ANASTOMOTIC STRICTURE
Kyle Ericson*, Lewis Thomas, JJ Zhang, Prithvi Murthy, Jacob Knorr, Georges-Pascal Haber, Byron Lee, Cleveland, OH

MP38-19 ADJUVANT CHEMOTHERAPY FOLLOWING RADICAL CYSTECTOMY: PROPENSITY-SCORE MATCHED EVALUATION OF SURVIVAL OUTCOMES
Matteo Soligo*, Alessandro Morlacio, Michele Colicchia, Padova, Italy, Luca Boeri, Vidit Sharma, Igor Frank, Steven Boorjian, R. Jeffrey Karnes, Rochester, MN
COMBINED REPORTING OF SURGICAL QUALITY, CANCER CONTROL AND FUNCTIONAL OUTCOMES OF ROBOT-ASSISTED RADICAL CYSTECTOMY WITH ORTHOTOPIC NEOBLADDER: THE TRIFECTA ACHIEVEMENT

Aldo Brassetti*, Gabriele Tuderti, Salvatore Guaglianone, Maria Consiglia Ferriero, Umberto Anceschi, Francesco Minisola, Riccardo Mastrolaion, Rocco Simone Flinnia, Michele Gallucci, Giuseppe Simone, Rome, Italy

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Saturday, May 4, 2019

Moderated Poster Session 39
GENERAL & EPIDEMIOLOGICAL TRENDS & SOCIOECONOMICS: PRACTICE PATTERNS, QUALITY OF LIFE AND SHARED DECISION MAKING II
Room W175ab @ McCormick Place
Moderators: Amanda North & David Penson

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP39-01</td>
<td>GEOGRAPHIC DISPARITIES IN UROLOGIC CANCER MORTALITY: WHERE SHOULD WE TEST TELEMEDICINE INTERVENTIONS?</td>
</tr>
<tr>
<td>MP39-02</td>
<td>A NOVEL APPROACH TO IDENTIFY DISPARITIES IN ACCESS TO UROLOGIC CARE BASED ON DRIVING TIME</td>
</tr>
<tr>
<td>Brock O'Neil*, Ross Anderson, Christopher Martin, Claire Leiser, Heidi Hanson, Salt Lake City, UT</td>
<td></td>
</tr>
<tr>
<td>MP39-03</td>
<td>EXTRA-REGIONAL TRAVEL FOR UROLOGIC SURGERY: OPPORTUNITIES FOR IMPROVING ACCESS</td>
</tr>
<tr>
<td>Benjamin McCormick*, Matthew Macey, Charan Mohan, Karen Stitzerberg, Hung-Jui Tan, Brad Figler, Chapel Hill, NC</td>
<td></td>
</tr>
<tr>
<td>MP39-04</td>
<td>FEASIBILITY STUDY OF VIDEO TELEHEALTH CLINIC VISITS IN UROLOGY</td>
</tr>
<tr>
<td>Kelly Walker*, James Smith, San Francisco, CA</td>
<td></td>
</tr>
<tr>
<td>MP39-05</td>
<td>CORRELATES OF 1-YEAR CHANGE IN QUALITY OF LIFE IN PATIENTS WITH UROLOGICAL CHRONIC PELVIC PAIN SYNDROMES</td>
</tr>
<tr>
<td>MP39-06</td>
<td>LOWER URINARY TRACT DISEASE PREVENTION STRATEGIES RECOMMENDED ON SOCIAL MEDIA PLATFORMS: MIXED CORRELATION WITH EVIDENCE</td>
</tr>
<tr>
<td>Claire S. Burton*, Gabriela Gonzalez, Yuliya Zektser, Corey Arnold, Christopher V. Almario, Brennan M.R. Spiegel, Jennifer T. Anger, Los Angeles, CA</td>
<td></td>
</tr>
<tr>
<td>MP39-07</td>
<td>CHARACTERISTICS OF ELECTRONIC HEALTH RECORD USE AMONG UROLOGISTS IN THE UNITED STATES</td>
</tr>
<tr>
<td>Christopher D. Tessier*, Portland, OR, Raymond Fang, William Meeks, Linthicum, MD, Matthew E. Nielsen, Chapel Hill, NC, Steven M. Schlossberg, Walnut Creek, CA, J. Stuart Wolf, Austin, TX</td>
<td></td>
</tr>
<tr>
<td>MP39-08</td>
<td>A SNAPSHOT OF CONTEMPORARY UROLOGIC PRACTICE FROM THE AMERICAN UROLOGICAL ASSOCIATION’S QUALITY REGISTRY (AQUA)</td>
</tr>
<tr>
<td>Jeremy Shelton*, Los Angeles, CA, Daniel Pichardo, William Meeks, Raymond Fang, Linthicum, MD, Matthew Cooperberg, San Francisco, CA</td>
<td></td>
</tr>
<tr>
<td>MP39-09</td>
<td>FACTORS ASSOCIATED WITH THE GENDER PAY GAP AMONG UROLOGISTS IN THE US</td>
</tr>
<tr>
<td>MP39-10</td>
<td>DOES “MYCHART” BENEFIT “MY” SURGERY? – A LOOK AT THE IMPACT OF ELECTRONIC PATIENT PORTALS ON PATIENT EXPERIENCE</td>
</tr>
<tr>
<td>Naveen Kachroo*, Sriharan Sivalingam, Cleveland, OH</td>
<td></td>
</tr>
</tbody>
</table>
MP39-11 PRACTICE LEVEL VARIATION IN THE USE OF IMAGING AFTER SHOCKWAVE LITHOTRIPSY (SWL): DATA FROM A STATEWIDE CLINICAL REGISTRY
Colton Prudnick*, East Lansing, MI, Ji Qi, Tae Kim, Jaya Telang, Archana Radhakrishnan, Ann Arbor, MI, David Leavitt, Detroit, MI, Eric Stockall, Okemos, MI, Hector Pimental, Grand Rapids, MI, Jason Wynberg, Detroit, MI, Joshua Leese, John Hollingsworth, Khurshid Ghani, Casey Dauw, Ann Arbor, MI

MP39-12 ENHANCED RECOVERY AFTER SURGERY PROTOCOL FOR URETEROSCOPY: A PROSPECTIVE COMPARATIVE STUDY EVALUATING A NO OPIOID VERSUS STANDARD PROTOCOL
Chad Gridley*, Jennifer Robles, Joshua Calvert, Nicholas Kavoussi, Taylor Winkler, Jennifer Jayaram, Matthew Fosnot, Justin Liberman, Brian Allen, Matthew McEvoy, Duke Herrell, Ryan Hsi, Nicole Miller, Nashville, TN

MP39-13 FORGOTTEN URETERAL STENT: MULTIPLE SAFEGUARDS AND SHARED RESPONSIBILITY TO MINIMIZE THE RISK
OSCAR FUGITA*, SAO PAULO, Brazil, FERNANDO GONZALES, ANDRES AVALOS, SANTIAGO, Chile, PAULO KAWANO, JOAO LUIZ AMARO, BOTUCATU, Brazil, ANA MARIA CARDENAZ-ORTIZ, BOGOTA, Colombia, LUIZ TAKANO ARAUJO, SAO PAULO, Brazil, ALFREDO LUNA, CARTAGENA, Colombia, MARCELO BAPTISTUSSI, RIBEIRAO PRETO, Brazil, MARIANO GONZALEZ, NORBERTO BERNARDO, BUENOS AIRES, Argentina

MP39-14 IS STONE-FREE STATUS AFTER SURGICAL INTERVENTION FOR KIDNEY STONES ASSOCIATED WITH BETTER HEALTH-RELATED QUALITY OF LIFE? - A MULTICENTER STUDY FROM THE NORTH AMERICAN STONE QUALITY OF LIFE CONSORTIUM
Necole Streeper*, Matthew Galida, Hershey, PA, Stephen Nakada, Shuang Li, Madison, WI, Vernon Pais, Eric Raffin, Lebanon, NH, Ben Chew, Vancouver, Canada, Kristina Penniston, Madison, WI

MP39-15 UROLITHIASIS TREATMENT PREFERENCES AND THE IMPACT OF A DECISION AID ON TREATMENT CHOICE
John Cabri*, Sylvia Lambrechts MPH MA, Matthew Pollard MD, Lorna Kwan MPH, Haoyue Zhang MPH, Adam Pena, Daniel Brownstein, Hui Liu MS, Jessica Chang, Juliana Alden, Nishant Patel MD, Matthew Dunn MD, Christopher Saigal MD, Los Angeles, CA

MP39-16 SURVEY ON CURRENT PRACTICE IN ANTIBIOTIC PROPHYLAXIS PRIOR TO URETERAL STENT REMOVAL
Claudia Berrondo*, Jennifer Ahn, Paul Merguerian, Thomas Lendvay, Margarett Shnorhavorian, Seattle, WA

MP39-17 CURRENT PUBLICATION TRENDS IN UROLOGY LITERATURE
Adam Schatz*, Anke Wang, Yasamin Ghiasi, Seamus Barrett, Aman Kumar, Jennifer Cha, Adria Lam, Shruthi Perati, Angela Zheng, Charles Welliver, Albany, NY

MP39-18 CLINICAL PRACTICE GUIDELINES USE IN UROLOGY: A GLOBAL PERSPECTIVE
Medina Ndoye, German Patino*, Andrew Cohen, Carissa Chu, Benjamin Breyer, San Francisco, CA

MP39-19 CREATION OF A SYSTEMATIC APPROACH TO IMPROVE UROLOGIC CARE IN RESOURCE POOR COUNTRIES: THE HAITI EXPERIENCE
Angelo Gousse*, Miami, FL, Henri Lanctin, Watertown, SD

MP39-20 ASSOCIATION OF SMOKING AND DEATH FORM UROLOGIC MALIGNANCIES: A CONTEMPORARY ASSESSMENT IN A NATIONALLY REPRESENTATIVE COHORT
Bashir Al Hussein Al Awamlh*, Jonathan Shoag, Jonathan Fainberg, Omar Al Hussein AlAwamlh, Douglas Scherr, New York, NY

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
Podium Session 29

INFERTILITY: EPIDEMIOLOGY & EVALUATION I

Room W185a @ McCormick Place

Moderators: Keith Jarvi, Robert Oates & Ates Kadioglu

<table>
<thead>
<tr>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:00</td>
<td>PD29-01</td>
<td>ONLY HIGH-RISK HUMAN PAPILLOMAVIRUS IN SEMEN IS ASSOCIATED WITH HIGH SPERM DNA FRAGMENTATION INDEX IN PRIMARY INFERTILE MEN</td>
</tr>
<tr>
<td>1:10</td>
<td>PD29-02</td>
<td>IMPACT OF ABNORMAL SPERM MORPHOLOGY ON LIVE BIRTH RATES FOLLOWING INTRAUTERINE INSEMINATION</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Premal Patel*, Vinayak Madhusoodanan, Miami, FL, Robert Carrasquillo, Boston, MA, Simon Dadoun, Ranjith Ramasamy, Miami, FL</td>
</tr>
<tr>
<td>1:20</td>
<td>PD29-03</td>
<td>SEASONAL VARIATION IN MALE FERTILITY MEASURES AND CORRESPONDING BIRTH PATTERNS</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Philip Cheng*, Sorena Keihani, Angela Presson, Chong Zhang, Heidi Hanson, Ken Smith, Douglas Carrell, Kenneth Aston, Alexander Pastuszak, James Hotaling, Salt Lake City, UT</td>
</tr>
<tr>
<td>1:30</td>
<td>PD29-04</td>
<td>QUALITATIVE ASSESSMENT OF MALE PARTNER NEEDS AMONG INFERTILE COUPLES</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Akanksha Mehta*, Atlanta, GA, Brent Hanson, Louisa Stark, Camille Hawkins, James Hotaling, Salt Lake City, UT</td>
</tr>
<tr>
<td>1:40</td>
<td>PD29-05</td>
<td>AVAILABILITY OF MALE AND FEMALE FERTILITY AND SEXUAL HEALTH INFORMATION ON NATIONAL CANCER INSTITUTE DESIGNATED CANCER CENTER WEBSITES</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Tejash Shah*, North Brunswick, NJ, David Shin, Hackensack, NJ</td>
</tr>
<tr>
<td>1:50</td>
<td>PD29-06</td>
<td>LOWER COGNITIVE FUNCTION IS ASSOCIATED WITH MALE INFERTILITY: AN EXTENDED LOOK</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Jonathan Beilan*, Alexander Tatem, Jabez Jabez Gondokusumo, Houston, TX, Alexander Pastuszak, Salt Lake City, UT, Dolores Lamb, New York, NY, Larry Lipshultz, Houston, TX</td>
</tr>
<tr>
<td>2:00</td>
<td>PD29-07</td>
<td>PATERNAL MEDICATION USE AND COMORBIDITY IN THE UNITED STATES: A REVIEW OF OVER 1 MILLION LIVE BIRTHS</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Andrew Sun*, Shufeng Li, Chiyuan Zhang, Michael Eisenberg, Stanford, CA</td>
</tr>
<tr>
<td>2:10</td>
<td>PD29-08</td>
<td>MALE INFERTILITY AND FUTURE HEALTH: DOES THE ASSOCIATION VARY BY SOCIODEMOGRAPHIC FACTORS?</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Michael Eisenberg, Alex Kasman*, Shufeng Li, Palo Alto, CA</td>
</tr>
<tr>
<td>2:20</td>
<td>PD29-09</td>
<td>EVALUATION, TREATMENT, AND INSURANCE COVERAGE FOR INFERTILE COUPLES WITH MALE FACTOR INFERTILITY IN THE US</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Clara Glazer*, Copenhagen, Denmark, Jake Anderson-Bialis, Deborah Anderson-Bialis, San Francisco, CA, Michael Eisenberg, Palo Alto, CA</td>
</tr>
<tr>
<td>2:30</td>
<td>PD29-10</td>
<td>COMPARISON OF INTRACYTOPLASMIC SPERM INJECTION OUTCOME WITH FRESH VERSUS FROZEN-THAWED TESTICULAR SPERM IN MEN WITH NONOBSTRUCTIVE AZOOSPERMIA: A SYSTEMATIC REVIEW AND META-ANALYSIS</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Zhe Yu*, Zhewen Wei, Jun Yang, Jihong Liu, Wuhan, China, People's Republic of</td>
</tr>
<tr>
<td>2:40</td>
<td>PD29-11</td>
<td>COST-EFFECTIVENESS OF INITIAL FINE NEEDLE ASPIRATION MAPPING VERSUS MICROSCOPIC TESTICULAR SPERM EXTRACTION FOR MEN WITH NONOBSTRUCTIVE AZOOSPERMIA.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Tony Chen*, Jennifer Ahn, Niels Johnsen, Marah Hehemann, Kevin Ostrowski, Thomas Walsh, Seattle, WA</td>
</tr>
<tr>
<td>2:50</td>
<td>PD29-12</td>
<td>USE OF SCROTAL ULTRASOUND FOR EVALUATION OF VARICOCELES: A SURVEY STUDY OF REPRODUCTIVE SPECIALISTS</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Mohit Butaney*, Jabez Gondokusumo, Alexander J. Tatem, Jonathan A. Beilan, Nannan Thirumavalavan, Houston, TX, Alexander W. Pastuszak, Salt Lake City, UT, Larry I. Lipshultz, Houston, TX</td>
</tr>
</tbody>
</table>

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
Podium Session 30

PROSTATE CANCER: EPIDEMIOLOGY & NATURAL HISTORY I
Room W185d @ McCormick Place
Moderators: James Eastham, Christopher Kane & Belinda Morrison

**ABSTRACT**

**TIME** | **NUMBER** | **TITLE** | **TIME** | **NUMBER** | **TITLE**
---|---|---|---|---|---
1:00 | PD30-01 | PROSTATE-SPECIFIC ANTIGEN (PSA) LEVELS IN MEN 60 TO 70 YEARS OF AGE PREDICT AGGRESSIVE PROSTATE CANCER IN THE PLCO SCREENING TRIAL: IMPLICATIONS FOR RISK-STRATIFIED SCREENING | 1:50 | PD30-06 | COMPARISON OF EXTERNAL BEAM RADIATION THERAPY AND ROBOTIC PROSTATECTOMY ON PATIENT REPORTED OUTCOMES AFTER 5 YEARS IN MEN WITH UNFAVORABLE INTERMEDIATE-RISK AND HIGH-RISK PROSTATE CANCER

**1:10 PD30-02**
GERMLINE GENETIC ASSOCIATIONS WITH HIGH-RISK PROSTATE CANCER AND AGE AT DIAGNOSIS
Mary Helen Black, Shuwei Li, Holly LaDuca, Stephanie Gutierrez, Hsiao-Mei Lu, Aliso Viejo, CA, Brian T. Helfand*, Evanston, IL, William B. Isaacs, Baltimore, MD, Jianfeng Xu, Evanston, IL

**1:20 PD30-03**
PSYCHOLOGICAL MORBIDITY ASSOCIATED WITH A NEW DIAGNOSIS OF PROSTATE CANCER: RATES AND PREDICTORS OF DEPRESSIVE SYMPTOMS IN THE RADICAL PC STUDY

**1:30 PD30-04**
VARIATION AND CORRELATION OF FACILITY-LEVEL PROBABILITIES OF TREATMENT IN MEN WITH LOW-RISK PROSTATE CANCER AND MEN WITH LIMITED LIFE EXPECTANCY
Marieke Johanna Krimpove*, Alexander Putnam Cole, David Fallon Friedlander, David-Dan Nguyen, Stuart R. Lipsitz, Paul L. Nguyen, Kerry L. Kilbridge, Adam S. Kibel, Quoc-Dien Trinh, Boston, MA

**1:40 PD30-05**
PREDICTING DEFINITIVE TREATMENT IN AN ACTIVE SURVEILLANCE COHORT USING GROUP-BASED TRAJECTORY MODELING
Samuel Washington*, Shoujun Zhao, Janet Cowan, Peter Carroll, San Francisco, CA

---

*Presenting author
**Saturday, May 4, 2019**

**Podium Session 31**

**URODYNAMICS/LOWER URINARY TRACT DYSFUNCTION/ FEMALE PELVIC MEDICINE: NON-NEUROGENIC VOIDING DYSFUNCTION I**

**Room W181c @ McCormick Place**

**Moderators:** Jennifer Rothschild, Gary Lemack & Suzette Sutherland

<table>
<thead>
<tr>
<th>ABSTRACT</th>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>PD31-01</td>
<td>1:00</td>
<td>1</td>
<td>CHANGES IN RESTING STATE BRAIN FUNCTIONAL CONNECTIVITY AS A FUNCTION OF URGE</td>
</tr>
<tr>
<td>PD31-02</td>
<td>1:10</td>
<td>2</td>
<td>LONG-TERM RESULTS OF SAFETY, EFFICACY, QUALITY OF LIFE AND SATISFACTION OF PATIENTS TREATED FOR REFRACTORY OAB USING AN IMPLANTABLE TIBIAL NEUROSTIMULATION SYSTEM: RENOVA ISTIM™ SYSTEM</td>
</tr>
<tr>
<td>PD31-03</td>
<td>1:20</td>
<td>3</td>
<td>PROPORTION OF WOMEN WITH OVERACTIVE BLADDER WHO PROGRESS FROM SECOND- TO THIRD-LINE TREATMENT IN A REAL-WORLD SETTING</td>
</tr>
<tr>
<td>PD31-04</td>
<td>1:30</td>
<td>4</td>
<td>LONGITUDINAL EVALUATION OF NEW OVERACTIVE BLADDER PATIENTS: ARE PATIENTS FOLLOWING UP AND UTILIZING THIRD LINE THERAPIES?</td>
</tr>
<tr>
<td>PD31-05</td>
<td>1:40</td>
<td>5</td>
<td>OVERACTIVE BLADDER IN MEN: MEDICATION ABANDONMENT AND LACK OF THIRD-LINE THERAPY</td>
</tr>
</tbody>
</table>
LONGITUDINAL CHANGES IN SYMPTOM-BASED FEMALE AND MALE LUTS CLUSTER CHARACTERISTICS AND FACTORS ASSOCIATED WITH CHANGE

CORRELATION OF SYMPTOM SEVERITY AND BOTHER IN INDIVIDUALS SEEKING CARE FOR LOWER URINARY TRACT SYMPTOMS
Nnenaya Q. Agochukwu*, Jonathan B. Wiseman, Abigail R. Smith, Margaret E. Helmuth, Ann Arbor, MI, Kevin P. Weinfurt, Durham, NC, Aruna V. Sarna, Ann Arbor, MI, James W. Griffith, David Cella, Chicago, IL, Anne P. Cameron, Ann Arbor, MI, Kathryn E. Flynn, Milwaukee, WI, Bradley A. Erickson, Iowa City, IA, Ziya Kirkali, Bethesda, MD, Cindy L. Amundsen, Durham, NC, H. Henry Lai, St. Louis, MO, Meera Tavathia, Chicago, IL, J. Quentin Clemens, and the LURN Study Group, Ann Arbor, MI

ASSOCIATION OF URINARY LEAKAGE FREQUENCY WITH BIOMARKERS OF SYSTEMIC INFLAMMATION: RESULTS FROM THE HEALTH, AGING, AND BODY COMPOSITION STUDY
Laura E. Lamb*, Ke Song, Royal Oak, MI, Richard D. Semba, Baltimore, MD, Robert H. Podolksy, Michael B. Chancellor, Royal Oak, MI, Health ABC Study, Bethesda, MD

MIRABEGRON AND THE RISK OF ARRHYTHMIAS: A POPULATION-BASED COHORT STUDY
Rano Matta*, Simon Greaves, David Juurlink, Muhammad Mamdani, Tara Gomes, Mina Tadrous, Toronto, Canada

ABSTRACT ABSTRACT
TIME NUMBER TITLE TIME NUMBER TITLE
1:00 PD32-01 LONG-TERM SUCCESS DURABILITY OF TRANSOBURATOR MALE SLING 1:10 PD32-02 IS THERE A DIFFERENCE BETWEEN ADJUSTABLE AND FIXED SLINGS?
Michael Chua*, Jack Zuckerman, James Bradley Mason, Jessica DeLong, Ramon Virasoro, Jeremy Tonkin, Kurt McCammon, Norfolk, VA
Tanja Hüsch*, Mainz, Germany, Alexander Kretschmer, Munich, Germany, Frauke Thomsen, Dominik Kronlachner, Frankfurt, Germany, Martin Kurosch, Mainz, Germany, Alice Obaje, Hildesheim, Germany, Ralf Anding, Ruth Kirschner-Hermans, Bonn, Germany, Tobias Pottek, Berlin, Germany, Achim Rose, Düsseldorf, Germany, Roberto Olanas, Lüneburg, Germany, Alexander Friedl, Vienna, Germany, Roland Homberg, Hamm, Germany, Jesco Pfitzenmaier, Bielefeld, Germany, Rudi Abdunnur, Schwelm, Germany, Fabian Queissert, Muenster, Germany, Carsten Naumann, Kiel, Germany, Josef Schweiger, Erfurt, Germany, Carola Wotzka, Stuttgart, Germany, Joanne Nyarangi-Dix, Heidelberg, Germany, Bernhard Brehmer, Schwäbisch Hall, Germany, Kurt Ullm, Munich, Germany, Wilhelm Hübner, Korneuburg, Germany, Ricarda Bauer, Munich, Germany, Axel Haferkamp, Mainz, Germany

*S Presenting author
1:20 PD32-03 GREATER PREPAREDNESS FOR PROSTATECTOMY ACHIEVES BETTER 1-YEAR PATIENT-REPORTED POSTOPERATIVE URINARY OUTCOMES
Bradley Gill*, Anna Faris, Abhinav Khanna, Anna Zampini, Daniel Hettel, Hadley Wood, Edmund Sabanegh, Cleveland, OH

1:30 PD32-04 NATURAL HISTORY OF MODERATE TO SEVERE INCONTINENCE AFTER PROSTATECTOMY
Elizabeth Roger*, Lauren Green, Kurt McCammon, Norfolk, VA

1:40 PD32-05 APPLICATION OF HYALURONIC ACID/CARBOXYMETHYL CELLULOSE MEMBRANE FOR EARLY CONTINENCE AFTER NERVE-SPARING ROBOT-ASSISTED RADICAL PROSTATECTOMY
Nobuyuki Hinata*, Yukari Bando, Tomoaki Terakawa, Junya Furukawa, Yuzo Nakano, Masato Fujisawa, Kobe, Japan

1:50 PD32-06 A NEW ARTIFICIAL URINARY SPHINCTER (VICTO) WITH CONDITIONAL OCCLUSION FOR MALE STRESS INCONTINENCE: PRELIMINARY CLINICAL RESULTS
Peter Weibl*, Ghazal Ameli, Michael Rutkowski, Wilhelm Alexander Huebner, Korneuburg, Austria

2:00 PD32-07 ANDROGEN DEPRIVATION THERAPY IS ASSOCIATED WITH URETHRAL ATROPHY AND ARTIFICIAL URINARY SPHINCTER CUFF EROSION
Michael Davenport*, Abdulhadi Akhtar, Nabeel Shakir, Yooni Yi, Rachel Bergeson, Allen Morey, Dallas, TX

2:10 PD32-08 TRENDS IN THE IMPLANTATION OF ARTIFICIAL URINARY SPHINCTERS: A POPULATION LEVEL ANALYSIS
Shyam Sukumar, Debduth Pijush, Steven Brandes*, New York, NY

2:20 PD32-09 COMPARISON OF 3.5 CM CUFFS AND TRANSCORPORAL CUFFS IN HIGH-RISK ARTIFICIAL URINARY SPHINCTER POPULATIONS
Abdulhadi Akhtar*, Michael Davenport, Nabeel Shakir, Yooni Yi, Rachel Bergeson, Allen Morey, Dallas, TX

2:30 PD32-10 EVALUATION OF EDUCATIONAL LEVEL AND COGNITIVE STATUS IN MEN UNDERGOING ARTIFICIAL URINARY SPHINCTER: A NEW INSIGHT TO PREDICTIVE FACTORS OF REVISION AND FAILURE RATES
AHMET KELES*, RAHMI ONUR, Istanbul, Turkey, MURAT AYDOS, BURHAN COŞKUN, Bursa, Turkey, ORHAN KOCA, MURAT DINÇER, Istanbul, Turkey, ABDURRAHIM IMAMOGLU, Ankara, Turkey, AHMET KARAKEÇİLİ, Elazığ, Turkey

2:40 PD32-11 DO PRIOR ANTI-INCONTINENCE SURGERIES INFLUENCE THE SUCCESS OF ARTIFICIAL URINARY SPHINCTER PLACEMENT?
Emily Yura*, Christopher Staniorski, Jason Cohen, Ashima Singal, Oluwarotimi Nettey, Matthias Hofer, Chicago, IL

2:50 PD32-12 REFILLABLE ARTIFICIAL URINARY SPHINCTER ZSI 375 PF: SPANISH MULTICENTRE EXPERIENCE
Bárbara Padilla-Fernández*, San Cristóbal de La Laguna, Spain, Raquel González-López, Luis Resel-Folkerama, Madrid, Spain, Blanca Madurga-Patuel, Cádiz, Spain, Héctor Garde-García, Madrid, Spain, David Hemández-Hernández, San Cristóbal de La Laguna, Spain, María Fernanda Lorenzo-Gómez, Salamanca, Spain, Tomás Concepción-Masip, San Cristóbal de La Laguna, Spain, Jesús Moreno-Sierra, Carmen González-Enguita, Madrid, Spain, David Manuel Castro-Díaz, San Cristóbal de La Laguna, Spain

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
<table>
<thead>
<tr>
<th>TIME</th>
<th>NUMBER</th>
<th>ABSTRACT</th>
</tr>
</thead>
</table>
| 1:00   | PD33-01| MULTI-INSTITUTIONAL EXPERIENCE WITH ROBOTIC URETERAL REIMPLANTATION IN PATIENTS WITH RADIATION-INDUCED DISTAL URETERAL STRICTURES  
| 1:10   | PD33-02| CONTEMPORARY MULTICENTER OUTCOMES COMPARING CUTANEOUS CATHETERIZABLE ILEOCOECECO CYSTOPLASTY TO ILEOCYSTOPLASTY WITH A TUNNELED CATHETERIZABLE CHANNEL IN THE ADULT POPULATION: A NEUROGENIC BLADDER RESEARCH GROUP (NBRG) STUDY  
Philip Cheng*, Sorena Keihani, Salt Lake City, UT, Sanchita Bose, Rose Khavari, Houston, TX, Sean Elliott, Joseph Pariser, Joshua Roth, Minneapolis, MN, Blayne Welk, London, Canada, Michael Kennelly, Cameron Futral, Chapel Hill, NC, David Ginsberg, Los Angeles, CA, Christopher Elliott, San Jose, CA, Kyla Valaer, Palo Alto, CA, Sara Lenherr, Salt Lake City, UT, Tahar Santiago-Lastra, San Diego, CA, John Stoffel, Ann Arbor, MI, Jeremy Myers, Salt Lake City, UT |
| 1:20   | PD33-03| CONTINENT CATHETERIZABLE CHANNEL FORMATION – LONG-TERM OUTCOMES IN A LARGE ADULT COHORT  
Eabhann O’Connor*, Sachin Malde, L Raja, London, United Kingdom, Charlotte Foley, Stevenage, United Kingdom, Claire Taylor, Daniel Wood, Jeremy Ockrim, Tamsin Greenwell, London, United Kingdom |
| 1:30   | PD33-04| STOMA COMPLICATIONS AND QUALITY OF LIFE IN INDIANA POUCH AND APPENDICO-UMBILICOSTOMY URINARY DIVERSIONS  
Kai Wen Cheng*, Ankeet Shah, Gus Miranda, Anne Schuckman, Siamak Daneshmand, Hooman Djaladat, Los Angeles, CA |
| 1:40   | PD33-05| MITROFANOFF CONTINENT URINARY DIVERSION: BETTER LIFE CONFORT IN SPITE OF SURGICAL COMPLICATIONS  
Mohamed Amine Maseddi, Anis Rekhis, Nouri Rebai, Hocine Bouchaala, Salem Mayouf, Mohamed Fournari, Walid Smaouli, Majed Hamza, Mourad Hafid Slimen, Mhiri Mohamed Nabil*, Sfax, Tunisia |
| 1:50   | PD33-06| LONG-TERM EFFECT OF BLADDER AUGMENTATION ON RENAL FUNCTION  
Anastasia Frost*, Simon Bugeja, Stella Ivaz, Nikki Jeffrey, Angelica Lomiteng, Mariya Dragova, Daniela E Andrich, Anthony R Mundy, London, United Kingdom |
| 2:00   | PD33-07| DOES INCORPORATION OF ROBOT-ASSISTED INTRA-CORPOREAL NEOBLADDER IMPACT HEALTH-RELATED QUALITY OF LIFE OUTCOMES? A MATCHED ANALYSIS  
Tomoaki Terakawa, Kobe, Japan, Ahmed A. Hussein*, Zaeem Lone, Ahmed S. Elsayed, Nafir A. Aldhaam, Zhe Jing, Paul May, Qiang Li, Khurshid A. Guru, Buffalo, NY |
| 2:10   | PD33-08| THE DECLINE IN CONTINENT URINARY DIVERSIONS IN ACADEMIC MEDICAL CENTERS  
Ryan Werntz*, Craig Labbate, Vignesh Packiam, Joshua Aizen, Brittany Adamic, Gary Steinberg, Chicago, IL |
| 2:20   | PD33-09| THE RADIOGRAPHIC INCIDENCE OF PARASTOMAL HERNIA FOLLOWING ILEAL CONDUIT URINARY DIVERSION UTILIZING THE EUROPEAN HERNIA SOCIETY CLASSIFICATION SYSTEM  
Johnny Su*, Nathan Hoy, Aldo Fafaj, Luciano Tastaldi, Andrew Strong, Michael Rosen, Hadley Wood, Cleveland, OH |
| 2:30   | PD33-10| ARTIFICIAL URINARY SPHINCTER FOLLOWING RADICAL CYSTECTOMY WITH ORTHOTOPIC BLADDER SUBSTITUTION: LONG TERM OUTCOMES EQUIVALENT TO POST-PROSTATECTOMY COHORT  
William Boysen*, Brittany Adamic, Chicago, IL, Kristine Kuchta, Sangtae Park, Evanston, IL |
| 2:40   | PD33-11| PROSPECTIVE EVALUATION OF BOWEL FUNCTION FOLLOWING RADICAL CYSTECTOMY AND URINARY DIVERSION USING TWO VALIDATED QUESTIONNAIRES: WHAT ARE THE EFFECTS ON QUALITY OF LIFE?  
Kian Asanad*, Azadeh Nazemi, Saum Ghodoussipour, Nima Nassiri, Daniel Zainfeld, Kevin Wayne, Jie Cai, Gus Miranda, Anne K. Schuckman, Hooman Djaladat, Siamak Daneshmand, Los Angeles, CA |

*Presenting author
A COMPARISON OF QUALITY OF LIFE BEFORE AND AFTER SUCCESSFUL REPAIR OF GENITOURINARY FISTULA: IS THERE IMPROVEMENT ACROSS ALL THE DOMAINS OF WHOQOL-BREF QUESTIONNAIRE? A TERTIARY CARE HOSPITAL EXPERIENCE FROM NORTHERN INDIA

VISHWAJEET SINGH*, RAHUL JANAK SINHA, SEEMA MEHROTRA, AJAY AGGARWAL, SIDDHARTH PANDEY, LUCKNOW, India

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Saturday, May 4, 2019 1:00 pm - 3:00 pm

Video Session 5

LOWER-TRACT RECONSTRUCTION

The videos in this session as well as the video libraries from the 2012-2018 Annual Meetings may be viewed in the Surgical Video Library and purchased in the AUA Store during the Annual Meeting. AUA members receive free online access to the Surgical Video Library throughout the year through AUA University. Visit www.AUAnet.org/University to access.

Room W187b @ McCormick Place

Moderators: Susan MacDonald, Benjamin Breyer & Ramon Virasoro

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>V05-01</td>
<td>FROM PUBIS TO PHALLUS: A COMPLETE DEMONSTRATION OF THE THREE STAGES OF RADIAL ARTERY FOREARM PHALLOPLASTY FORMATION</td>
</tr>
<tr>
<td>Gideon Blecher, Giovanni Chiriaco*, Andrew Christopher, David Ralph, London, United Kingdom</td>
<td></td>
</tr>
</tbody>
</table>

| V05-02          | BULBO-MEMBRANOUS URETHROPLASTY WITH “BAES-FLAP”: A DESCRIPTION OF THE SURGICAL TECHNIQUE |
| Alfredo Gil-Vernet*, Manuel Cespedes, Franklin Diaz, Jordi Ropero, Barcelona, Spain |

| V05-03          | ROBOTIC RECONSTRUCTION FOR RECALCITRANT POST-PROSTATECTOMY VESICOURETHRAL ANASTOMOSIS STENOSIS: VIDEO CASE SERIES |
| Timothy C. Boswell*, Jason P. Joseph, David Y. Yang, Boyd R. Viers, Rochester, MN |

| V05-04          | ROBOTIC ASSISTED POSTERIOR URETHROPLASTY FOR TRAUMATIC URETHRAL TRANSECTION |
| Elizabeth Roger*, Norfolk, VA, John Malcolm, Virginia Beach, VA |

| V05-05          | MINIMALLY INVASIVE MANAGEMENT OF RECTOURETHRAL FISTULAS |

| V05-06          | LONG TERM RESULTS OF OUR NOVEL 2 STAGE URETHROPLASTY FOR COMPLEX PENILE STRICTURES |
| Pankaj Joshi*, Ayman Mousa, Amar Rawal, Shreyas Badranavar, Sanjay Kulkami, Pune, India |

| V05-07          | TRANSCORPORAL ARTIFICIAL URINARY SPHINCTER- THE GULLWING MODIFICATION |
| Jyoti Chouhan*, Parth Thakker, Ryan Terlecki, Winston-Salem, NC |

| V05-08          | INTRAOPERATIVE ADJUSTIBLE NON OBSTRUCTIVE BULBOURETHRAL SUSPENSION |
| Yves Wyss*, Marco Randazzo, Hubert John, Winterthur, Switzerland |

| V05-09          | ROBOTIC BLADDER NECK CLOSURE IN THE COMPLEX NEUROGENIC BLADDER PATIENT |
| Unwanaobong Nseyo*, Michael Albo, Andrew Karim Kader, San Diego, CA |

| V05-10          | SURGICAL TECHNIQUE: POSTERIOR URETHROPLASTY FOR PELVIC FRACTURE URETHRAL URETHRAL INJURY |
| Melanie Aubé*, Montréal, Canada, Ramón Virasoro, Kurt McCammon, Norfolk, VA |

| V05-11          | NEW ADJUSTABLE ARTIFICIAL URETHRAL SPHINCTER (AUS) WITH AN ADDITIONAL STRESS BALLOON FURTHER IMPROVES TREATMENT OUTCOME IN MALE STRESS URINARY INCONTINENCE (SUI) |
| Karl-Dietrich Sievert*, Detmold, Germany, Ghazal Ameli, Korneuburg, Austria, Alfonso Gunnemann, Detmold, Germany, Wilhelm Huebner, Korneuburg, Austria |

| V05-12          | PENILE SKIN FLAP NEOURETHRA AFTER RADICAL PENILE AMPUTATION |
| Sanjay Kulkarni*, Ayman Mousa, Shreyas Badranavar, Amar Rawal, Pankaj Joshi, Pune, India |

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
## ASOCIACIÓN ESPAÑOLA DE UROLOGÍA (AEU)

**Room W185bc @ McCormick Place**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Presenter(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:00</td>
<td><strong>WELCOME MESSAGE</strong></td>
<td>Society President: Manuel Esteban</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Program Chair: Jose Luis Alvarez-Ossorio</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AUA Secretary: Manoj Monga</td>
</tr>
<tr>
<td>1:10</td>
<td><strong>CURRENT STATUS OF METASTATIC CASTRATION SENSITIVE PROSTATE CANCER</strong></td>
<td>Christopher Evans</td>
</tr>
<tr>
<td>1:25</td>
<td><strong>URODYNAMIC NEWS</strong></td>
<td>Victor Nitti</td>
</tr>
<tr>
<td>1:40</td>
<td><strong>NEW MOLECULAR TARGETS IN PROSTATE CANCER</strong></td>
<td>Danielle Lin</td>
</tr>
<tr>
<td>2:00</td>
<td><strong>BPH AND UPDATES IN SURGERY OF LOWER URINARY SYSTEM</strong></td>
<td>Eric Kocjanic</td>
</tr>
<tr>
<td>2:40</td>
<td><strong>IMMUNOTHERAPY IN UROLOGY</strong></td>
<td>Angela Smith</td>
</tr>
<tr>
<td></td>
<td><strong>UPDATES IN RENAL CANCER TREATMENT</strong></td>
<td>Jose A. Karam</td>
</tr>
</tbody>
</table>

---

## SOCIETY FOR BASIC UROLOGIC RESEARCH (SBUR)

**Room 193b @ McCormick Place**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Presenter(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:00</td>
<td><strong>WELCOME &amp; INTRODUCTION</strong></td>
<td>Program Chair: Rosalyn Adam</td>
</tr>
<tr>
<td>1:05</td>
<td><strong>SESSION I: SEX DIFFERENCES IN UROLOGIC HEALTH &amp; DISEASE</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>SEX, EPIGENETICS AND BLADDER CANCER</strong></td>
<td>X. Sean Li</td>
</tr>
<tr>
<td></td>
<td><strong>ANDROGEN RECEPTORS IN KIDNEY TUMORS AND KIDNEY STONES</strong></td>
<td>Chawnshang Chang</td>
</tr>
<tr>
<td></td>
<td><strong>SEXUAL DIMORPHISMS IN NEUROUROLOGY</strong></td>
<td>Stephen Zdenic</td>
</tr>
<tr>
<td>1:50</td>
<td><strong>SEX AND THE IMMUNE RESPONSE TO BLADDER DISEASES</strong></td>
<td>Molly Ingersoll</td>
</tr>
<tr>
<td></td>
<td><strong>DISCUSSION</strong></td>
<td></td>
</tr>
<tr>
<td>2:30</td>
<td><strong>SESSION II: MICROBES AND THE URINARY TRACT</strong></td>
<td></td>
</tr>
</tbody>
</table>

---

## AUA/BRAZILIAN PORTUGUESE UROLOGY PROGRAM (BPUP)

**Room W194 @ McCormick Place**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Presenter(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:00</td>
<td><strong>WELCOME AND INTRODUCTIONS: AUA SCHOLARS AND LEADERSHIP</strong></td>
<td>Course Director: Fernando Kim</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Moderator: Antonio Pompeo</td>
</tr>
<tr>
<td>1:10</td>
<td><strong>PROSTATE CANCER: SCIENTIFIC EVIDENCE AND MY PRACTICE</strong></td>
<td>Gerald Andriele, Jeffrey Holzbeierlein</td>
</tr>
<tr>
<td>1:30</td>
<td><strong>DISCUSSION WITH BRAZILIAN PANEL</strong></td>
<td></td>
</tr>
<tr>
<td>1:50</td>
<td><strong>WHEN DO I TREAT SMALL RENAL MASS WITH SURGERY OR ABLATION?</strong></td>
<td>Chad LaGrange, Robert Uzzo</td>
</tr>
<tr>
<td>2:10</td>
<td><strong>HOW DO I TREAT RENAL STONES &gt;2.5CM IN OBSESE PATIENTS AND PATIENTS WITH SOLITARY KIDNEY?</strong></td>
<td>Thomas Jarett, Julie Riley</td>
</tr>
<tr>
<td>2:30</td>
<td><strong>DISCUSSION WITH BRAZILIAN PANEL</strong></td>
<td></td>
</tr>
<tr>
<td>2:50</td>
<td><strong>DISCUSSION WITH BRAZILIAN PANEL</strong></td>
<td></td>
</tr>
<tr>
<td>3:10</td>
<td><strong>UPDATE IN RECONSTRUCTIVE UROLOGIC SURGERY</strong></td>
<td>Brian Flynn, Tomas Griebing</td>
</tr>
<tr>
<td>3:30</td>
<td><strong>DISCUSSION WITH BRAZILIAN PANEL</strong></td>
<td></td>
</tr>
</tbody>
</table>

*Presenting author
HOW TO TREAT PATIENTS WITH ERECTILE DYSFUNCTION POST PELVIC SURGERY AND WITH NO PREVIOUS PELVIC SURGERY

Ajay Nangia, Alan Shindel

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Saturday, May 4, 2019

KOREAN WORLD UROLOGIC CONGRESS (KWUC)
Room S102bc @ McCormick Place

1:00 WELCOME MESSAGE
Society President: Kyu-Sung Lee

1:10 SESSION 1: CONTEMPORARY CONCEPTS OF BPS & NEUROGENIC OAB
Moderators: Ja-Hong Kim, Kyu-Sung Lee

NEW INSIGHTS ABOUT INTERSTITIAL CYSTITIS & BLADDER PAINFUL SYNDROME (IC/BPS)
Robert Moldwin

NOVEL THERAPY FOR BPS/IC: BOTOX, STEM CELL, ESWT, PRP (PLATELET-RICH PLASMA)
Joon Chul Kim

USE OF CYSTOSCOPIC AND VIDEO FLUOROSCOPIC FINDINGS FOR MANAGEMENT OF NEUROGENIC VOIDING DYSFUNCTION
Seung-June Oh

Efficacy and safety of long-term botulinum toxin A treatment in the neurogenic overactive bladder
Michael Albo

PANEL DISCUSSION
Panelists: Ja-Hong Kim, Jeong-Gu Lee, Jae-Seung Paick

3:10 SESSION 2: PROSTATE CANCER
Moderators: Isaac Kim, Gyung Tak Mario Sung

ACTIVE SURVEILLANCE IN MPMRI ERA
Robert Reiter

FOCAL THERAPY OF LOCALIZED PROSTATE CANCER: CURRENT STATUS
Sung Kyu Hong

NON-METASTATIC CRPC AND ASYMPTOMATIC CRPC TREATMENT
Sung-Woo Park

ROLE OF SURGERY IN MHSPC
Brian Chapin

PANEL DISCUSSION
Panelists: Benjamin Chung, Jun Hyuk Hong, Taek Won Kang

3:10 SESSION 3: RENAL CELL CARCINOMA
Moderators: Jin Seon Cho, Jonathan Hwang

IS IT NECESSARY TO PERFORM SURGERY FOR SRM IN ELDERLY?
Eric Singer

ROBOTIC PARTIAL NEPHRECTOMY FOR COMPLEX HILAR TUMOR: HOW I DO
Seong Il Seo

WHAT ARE THE KEY FACTORS FOR PREDICTING ROBOTIC PARTIAL NEPHRECTOMY OUTCOMES?
Robert Uzzo

IS CYTOREDUCTIVE NEPHRECTOMY STILL AN ACCEPTABLE STANDARD OF CARE FOR MRCC?
Cheryn Song

PANEL DISCUSSION
Panelists: Hyung Kim, Jae Young Park, Ill Young Seo

4:10 KUA/SKAU RESIDENT & FELLOW ABSTRACT SESSION
Moderators: Chester Koh, Jun Hyuk Hong

INTRODUCTION
AUA President: Robert Flanigan
Society President: Paul Sweeney
Program Chairs: Thomas Lynch, John Mulhall

2:00 TRAINING THE NEXT GENERATION OF UROLOGIC SURGEONS: LESSONS FROM THE AVIATION INDUSTRY
Anthony Costello

2:05 INSIGHTS FROM URETEROSCOPY IN 2019: A PROCEDURE FOR THINKERS AND DOERS
James Lingeman

2:30 THE ROLE OF VARICOCELECTOMY IN THE ERA OF IVF/ICSI
Robert Brannigan

2:55
ROUND TABLE DISCUSSION: THE MANAGEMENT OF SMALL RENAL MASSES
Moderator: Catherine Dowling
Panelists: Jonathan Coleman, Inderbir Gill, Nathan Lawrentschuk, Kent Perry

Forums

SATURDAY
SATURDAY, MAY 4, 2019 3:00 PM - 5:00 PM
CLINICAL CONTROVERSIES IN MEN'S HEALTH
Room W471 @ McCormick Place

3:00 LOW-INTENSITY EXTRACORPOREAL SHOCKWAVE THERAPY (LI-ESWT) FOR THE TREATMENT OF ERECTILE DYSFUNCTION: READY FOR PRIME TIME?
Debater - Con: Arthur Burnett
Debater - Pro: Tom Lue

3:30 QUESTIONS AND ANSWERS

3:40 AUA TESTOSTERONE GUIDELINES: HOW UROLOGISTS SHOULD PRACTICE
Debater - Con: Mohit Khera
Debater - Pro: John Mulhall

4:10 QUESTIONS AND ANSWERS

4:20 THE NEW WILD WEST: MEN'S HEALTH AND THE INTERNET
Debater - Con: Adithya Balasubramanian
Debater - Pro: Aaron Spitz

4:50 QUESTIONS AND ANSWERS

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Saturday, May 4, 2019
3:00 pm - 5:00 pm
POLISH UROLOGICAL ASSOCIATION/HUNGARIAN UROLOGICAL ASSOCIATION (PTU/HUA)
Room W193a @ McCormick Place

Saturday, May 4, 2019
3:30 pm - 5:30 pm
Moderated Poster Session 40
SEXUAL FUNCTION/DYSFUNCTION: EVALUATION I
Room W175ab @ McCormick Place
Moderators: Alexander Pastuszak, Hossein Sadeghi-Nejad & Kwangsung Park

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP40-01</td>
<td>THE IMPACT OF SEXUAL ORIENTATION ON TREATMENT DECISION-MAKING AND PERCEPTIONS OF SEXUAL SIDE-EFFECTS FROM PROSTATE CANCER</td>
</tr>
<tr>
<td></td>
<td>Channa Amarasekera*, Vincent Wong, Kathryn Jackson, Christopher Morrison, Oliver Ko, David Victorson, Shilajit Kundra, Chicago, IL</td>
</tr>
<tr>
<td>MP40-02</td>
<td>GENITAL SELF-IMAGE PERCEPTIONS AND THEIR IMPACT ON SEXUAL FUNCTIONING AMONG ADULT MALES: A CLINICAL QUESTIONNAIRE BASED SURVEY.</td>
</tr>
<tr>
<td></td>
<td>Evangelos Spyropoulos*, Katherine Spyropoulos, Paleo Faliro, Greece, Dimitrios Kotsiris, Athens, Greece</td>
</tr>
<tr>
<td>MP40-03</td>
<td>OMTFSFI: OPERATED MALE TO FEMALE SEXUAL FUNCTION INDEX. DEVELOPMENT AND VALIDATION OF THE FIRST QUESTIONNAIRE TO ASSESS SEXUAL FUNCTION AFTER MALE TO FEMALE GENDER REASSIGNMENT SURGERY</td>
</tr>
<tr>
<td></td>
<td>Francesca Vedovo*, Lisa Di Bias, Chiara Perin, Nicola Pavan, Marta Zatta, Stefano Bucci, Trieste, Italy, Girolamo Morelli, Pisa, Italy, Andrea Cacci, Augusto Delle Rose, Simone Caroassai Risantsi, Florence, Italy, Giorgio Gentile, Fulvio Colombo, Bologna, Italy, Luigi Rolle, Massimiliano Timpani, Turin, Italy, Paolo Verze, Lorenzo Spirtos, Naples, Italy, Francesco Schiralli, Carlo Bettocchi, Bari, Italy, Alessandro Palmieri, Vincenzo Miron, Naples, Italy, Carlo Trombetta, Trieste, Italy</td>
</tr>
</tbody>
</table>

*Presenting author
MP40-04 PREVALENCE OF TESTOSTERONE DEFICIENCY IN MEN AGED OVER 80 YEARS IS NOT INCREASED IN NONOBESE INDIVIDUALS
Taciana Tiraboschi, Monique Caires, Eduardo P Miranda*, Caroline Silva, Mateus Alvaia, Ueslei Menezes, Leopoldo Neto, Jose Murillo Bastos Netto, Cristiano M Gomes, Jose Bessa Jr, Feira de Santana, Brazil

MP40-05 DIAGNOSIS AND MANAGEMENT OF TESTOSTERONE DEFICIENCY - COMPARISON OF CURRENT GUIDELINES
Jethro C.C. Kwong*, Yonah Krakowsky, Ethan Grober, Toronto, Canada

MP40-06 ASSESSING THE ABILITY OF THE MALE ANDROGEN DEFICIENCY SYNDROME (MADS) SCREENING QUESTIONNAIRE TO PREDICT HYPOGONADISM

MP40-07 THE PREDICTIVE EFFECT OF FREE TESTOSTERONE ON SEXUAL FUNCTION INCREASES WITH AGE
Maxwell Towe*, Linda M. Huynh, Farouk M. El-Khatib, Faysal A. Yafi, Thomas Ahlering, Orange, CA

MP40-08 DO PATIENTS WHO REPORT PREMATURE EJACULATION ACTUALLY EJACULATE QUICKER?
Jack Andrews*, Kevin Hebert, Mathew Ziegelmann, Ross Avant, David Yang, Tobias Kohler, Landon Trost, Rochester, MN

MP40-09 RE-ENGINEERING THE INTERNATIONAL INDEX OF ERECTILE FUNCTION: EVALUATION OF A LARGE CLINICAL DATA SET
Andrew Vickers*, Amy Tin, New York, NY, Karandeep Singh, Rodney Dunn, Ann Arbor, MI, John Mulhall, New York, NY

MP40-10 INTERNAL AND EXTERNAL VALIDATION OF A 90-DAY PERCENTAGE ERECTION FULLNESS SCORE MODEL PREDICTING POTENCY RECOVERY FOLLOWING ROBOT-ASSISTED RADICAL PROSTATECTOMY
Linda M. Huynh*, Douglas Skarecky, Orange, CA, Timothy Wilson, Santa Monica, CA, Clayton Lau, West Covina, CA, Christian Wagner, Gronau, Germany, James Porter, Seattle, WA, Jorn H. Witt, Gronau, Germany, Thomas Ahlnering, Orange, CA

MP40-11 LONGITUDINAL EVALUATION OF FREQUENCY OF PATIENTS TAKING PART IN SEXUAL INTERCOURSE AND SEXUAL ACTIVITIES AFTER UNDERGOING ROBOT-ASSISTED LAPAROSCOPIC RADICAL PROSTATECTOMY
Shogo Inoue*, Tetsutaro Hayashi, Jun Teishima, Akio Matsubara, Hiroshima, Japan

MP40-12 ESTABLISHING A MINIMAL CLINICALLY MEANINGFUL DIFFERENCE IN THE MSHQ: NEW INSIGHTS
Raymond C Rosen*, Watertown, MA, Claus G Roehrborn, Dallas, TX, Francois Giuliani, Garches, France, Juan Manuel Palacios-Moreno, Madrid, Spain, Timothy H Wilson, Durham, NC, Zrinka Lulic, London, United Kingdom, Michael J Manyak, Washington, DC

MP40-13 UNDERSTANDING THE SEXUAL HABITS OF MEN TAKING MEDICATION FOR ERECTILE DYSFUNCTION: SURVEY RESULTS FROM AUSTRALIA, EGYPT, MEXICO AND UNITED KINGDOM
John Dean*, Devon, United Kingdom, Ahmed El-Sakka, Ismailia, Egypt, Shaanantu Donde, Chad Harshman-Smith, Tarek Hassan, New York, NY

MP40-14 ITALIAN RESIDENTS IN UROLOGY SEXUAL HEALTH: A MULTICENTRIC STUDY.
Francesca Vedovo*, Lisa Di Blas, Chiara Perin, Michele Rizzo, Giovanni Liguori, Carlo Trombetta, Nicola Pavan, Trieste, Italy

MP40-15 CHRONOLOGICAL CHANGE IN ERECTILE DYSFUNCTION AND ITS RISK FACTORS (A COMMUNITY-BASED LONGITUDINAL SURVEY)
Atsushi Imai*, Hayato Yamamoto, Shingo Hatakeyama, Takahiro Yoneyama, Yasuhiro Hashimoto, Chikara Ohtaya, Kaori Sawada, Shigeyuki Nakaji, Hiroaki, J Japan

MP40-16 ONE OUT OF THREE MEN SEEKING MEDICAL HELP FOR ERECTILE DYSFUNCTION HAS BLOOD GLUCOSE LEVELS SUGGESTIVE FOR UNDIAGNOSED HYPERGLYCAEMIA: WORRISOME PICTURE FROM THE REAL-LIFE SETTING
Luca Boeri*, Paolo Capogrosso, Eugenio Ventrimiglia, Edoardo Pozzi, Nicola Schifano, Francesco Chiariogio, Rani Zuabi, Costantino Abbate, Federico Dehò, Milan, Italy, Vincenzo Mironi, Naples, Italy, Franco Gabbarditi, Montanari Emanuela, Francesco Montorsi, Andrea Salonia, Milan, Italy

MP40-17 STANDARD STRETCHED LENGTH ASSESSMENT UNDERESTIMATES TRUE PENILE LENGTH.
Dorota Hawsedworth*, Angela Koomson, Baltimore, MD, Emad Rajih, Madinah, Saudi Arabia, Kambiz Tajkarimi, Leesburg, VA, Arthur Burnett, Baltimore, MD

MP40-18 PROSPECTIVE EVALUATION OF PATIENT REPORTED SEXUAL HEALTH OUTCOMES IN MEN FOLLOWING RADICAL CYSTECTOMY
Saum Ghodoussipour*, Juliet Han, Nima Nassiri, Paul Oh, Ryan Atkinson, Hooman Djaladat, Anne Schuckman, Sumeet Bhanvadia, Siamak Daneshmand, Jeffrey Loh-Doyle, Los Angeles, CA
**MP40-19** VITAMIN D STATUS IS ASSOCIATED WITH SEXUAL FUNCTION IMPAIRMENT: PRELIMINARY FINDINGS FROM A CROSS SECTIONAL STUDY  
Luca Boeri, Paolo Capogrosso, Eugenio Ventimiglia, Walter Cazzaniga, Edoardo Pozzi*, Federico Belladelli, Francesco Chierigo, Costantino Abbate, Federico Dehò, Milan, Italy, Vincenzo Miron, Naples, Italy, Franco Gaboardi, Montanari Emanuele, Francesco Montorai, Andrea Salonia, Milan, Italy

**MP40-20** RELATIONSHIP BETWEEN CHRONIC PROSTATITIS/CHRONIC PELVIC PAIN SYNDROME AND ERECTILE DYSFUNCTION  
Jun Ho Lee*, Dong-Gi Lee, Seoul, Korea, Republic of

**MP40-21** HIGHER FREE TESTOSTERONE PREDICTS FASTER POTENCY RECOVERY AFTER ROBOT ASSISTED RADICAL PROSTATECTOMY  
Farouk M. El-Khatib*, Linda Huynh, Maxwell Towe, Faysal A. Yafi, Thomas Ahlering, Orange, CA

**MP40-01** THE IMPACT OF AGENT ORANGE EXPOSURE ON PROSTATE CANCER OUTCOMES  
Tyler Etheridge*, Jinn-ing Liou, Tracy M. Downs, E. Jason Abel, David F. Jarrard, Kyle A. Richards, Madison, WI

**MP40-02** ASSOCIATION BETWEEN CHRONIC INFLAMMATORY DISEASES, ANTI-INFLAMMATORY MEDICATIONS AND RISK OF PROSTATE CANCER  
Kerri Beckmann, Beth Russell, Debra Josephs, Hans Garmo, London, United Kingdom, Christel Hagstrom, Umea, Sweden, Lars Holmberg, London, United Kingdom, Par Stattin, Uppsala, Sweden, Mieke Van Hemelrijk*, London, United Kingdom, Jan Adolfsen, Stockholm, Sweden

**MP40-03** TRENDS IN DIAGNOSIS AND INITIAL MANAGEMENT OF LOCALIZED PROSTATE CANCER: A RETROSPECTIVE POPULATION-BASED TIME SERIES ANALYSIS WITHIN THE PROVINCE OF ONTARIO  
Marian S. Wettstein*, Vicki Ling, J. Michael Paterson, Toronto, Canada, Alvin H. Li, Ottawa, Canada, Adalstein Brown, Karen S. Palmer, Noah Ivers, Girish S. Kulkarni, Toronto, Canada

**MP40-04** CASCADE TESTING OF MEN WITH PROSTATE CANCER IN FAMILIES WITH A SPECTRUM OF INHERITED CANCERS: IMPORTANCE OF ATTENTION TO RACE  
Thenappan Chandrasekar*, Joon Yau Leong, Laura Gross, Sarah Hegary, Leonard Gomella, Veda Giri, Philadelphia, PA

**MP40-05** IMPACT OF A CHANGING POPULATION STRUCTURE AND CLUSTERING OF CANCER IN PROSTATE CANCER PATIENTS DEPENDING ON A FIRST-DEGREE FAMILY-HISTORY  
Kathleen Herkommer*, Robert Bittner, Valentin Henri Meissner, Munich, Germany, Martina Kron, Ulm, Germany, Stefan Schiele, Helga Schulwitz, Jürgen Erich Gschwend, Munich, Germany

**MP40-06** GERMLINE GENETIC TESTING IN MEN WITH PROSTATE CANCER: CLINICAL CHARACTERISTICS AND TESTING OUTCOMES IN A NEWLY INDICATED POPULATION  
Samantha Greenberg, Jonathan Tward, Lisa Pappas, Salt Lake City, UT, Kathleen Cooney, Durham, NC, Brock O'Neil*, Salt Lake City, UT

**MP40-07** TRENDS IN COMPLEMENTARY AND ALTERNATIVE MEDICINE USE AMONG NEWLY DIAGNOSED PROSTATE CANCER PATIENTS  

**MP40-08** ASSOCIATION BETWEEN HOSPITAL COMPETITION AND OUTCOMES AMONG PROSTATE CANCER PATIENTS  
Sumedha Chhatre*, S. Bruce Malkowicz, Bingnan Li, Thomas Guzzo, Alan Wein, Ravishankar Jayadevappa, Philadelphia, PA

---

*Presenting author
MP41-09 QUALITY OF CARE IN THE TREATMENT OF LOCALIZED INTERMEDIATE AND HIGH RISK PROSTATE CANCER AT MINORITY SERVING HOSPITALS

MP41-10 SURVIVAL OUTCOMES OF INITIAL LOCAL THERAPY ON CLINICALLY LOCALIZED GLEASON 9-10 PROSTATE CANCER: A SURVEILLANCE, EPIDEMIOLOGY, AND END RESULTS DATABASE ANALYSIS
Amy Nemirovsky*, Hubert Huang, Michael Naslund, M. Minhaj Siddiqui, Baltimore, MD

MP41-11 SOCIODEMOGRAPHICS AND OUTCOME DIFFERENCES BETWEEN TEACHING AND NON-TEACHING HOSPITALS FOR RADICAL PROSTATECTOMY
Olamide Omidele*, New York, NY, Mark Finkelstein, Khawaja Bilal, Michael Palese, New York, NY

MP41-12 IMPACT OF 5 ALPHA REDUCTASE INHIBITORS ON MORTALITY IN A PROSTATE CANCER CHEMOPREVENTION SETTING: A SYSTEMATIC REVIEW AND META-ANALYSIS

MP41-13 TIME FROM BIOCHEMICAL TO CLINICAL RECURRENCE SHOULD BE CONSIDERED AS A PROXY OF OVERALL SURVIVAL IN PATIENTS WITH CLINICALLYLOCALIZED PROSTATE CANCER WHO EXPERIENCE RECURRENCE AFTER RADICAL PROSTATECTOMY
Alberto Martini*, Nazareno Suardi, Marco Bandini, Emanuele Zaffuto, Milan, Italy, Vincenzo Mirone, Nicola Longo, Naples, Italy, Shahrokh Shariat, Vienna, Austria, Simone Scarcella, Simone Scuderi, Francesco Barletta, Armando Stabile, Renzo Colombo, Giorgio Gandaglia, Nicola Fossati, Francesco Montorsi, Alberto Briganti, Milan, Italy

MP41-14 TYPE OF PATIENTS IN WHOM BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY CAN BE OBSERVED WITHOUT SALVAGE THERAPY
Kazuhiro Matsumoto*, Naoya Niwa, Masayuki Hagiwara, Takeo Kosaka, Nobuyuki Tanaka, Toshikazu Takeda, Shinya Morita, Ryuichi Mizuno, Toshiaki Shinojima, Tokyo, j apan, Satoshi Hara, Kawasaki, j apan, Eiji Kikuchi, Hiroshi Asanuma, Mototsugu Oya, Tokyo, j apan

MP41-15 ASSOCIATION BETWEEN CONTINUITY OF CARE AND SHORT AND LONG-TERM OUTCOMES IN ADVANCED PROSTATE CANCER PATIENTS
Ravishankar Jayadevappa*, S. Bruce Malkowicz, Thomas Guzzo, Sumedha Chhatre, Alan Wein, Philadelphia, PA

MP41-16 ANALYSIS OF THE BIG DATA OF SERUM PSA VALUE BY AGE IN MEDICAL EXAMINATION FOR JAPANESE POPULATION
Mineyuki Kato*, Koji Okihara, Yoshinori Marunaka, Osamu Ukimura, Kyoto, j apan

MP41-17 RARE HISTOLOGICAL VARIANTS OF PROSTATE ADENOCARCINOIMA (PCA): A NATIONAL CANCER DATABASE (NCDB) ANALYSIS
Sohrab Arora*, Akshay Sood, Deepansh Dalela, Jacob Keeley, Alex Borchert, Lee Baumgarten, Craig G Rogers, James Peabody, Mani Menon, Firas Abdollah, Detroit, MI

MP41-18 EFFECTS OF BEHAVIORAL TREATMENTS FOR SUBSTANCE USE ON MORTALITY AMONG MEDICARE ELDERLY WITH ADVANCED STAGE PROSTATE CANCER
Sumedha Chhatre*, S. Bruce Malkowicz, Thomas Guzzo, Alan Wein, Ravishankar Jayadevappa, Philadelphia, PA

MP41-19 OPTIMIZING LIFE EXPECTANCY ESTIMATES FOR VHA PATIENTS WITH PROSTATE CANCER

MP41-20 DISEASE-SPECIFIC COSTS OF NONMETASTATIC AND METASTATIC CASTRATION-RESISTANT PROSTATE CANCER IN QUEBEC
Ivan Yanev*, Alice Dragomir, Zachary Vaillancourt, Emma Nablsi, Jonathan Primiani, Montreal, Canada, Karen Brenner, Steven M. Carcone, Nicholas Mitsakakis, Welson Rayan, Murray Krahn, Toronto, Canada, Arsen Aprkian, Montreal, Canada

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
ABSTRACT
NUMBER TITLE
MP42-01 A NOVEL TRIFECTA TO SIMPLIFY THE ASSESSMENT OF PERIOPERATIVE OUTCOMES AFTER ROBOT ASSISTED PARTIAL NEPHRECTOMY FOR CT1 RENAL MASSES: RESULTS OF A MULTICENTER SERIES
Umberto Anceschi*, Gabriele Tuderti, Maria Consiglio Ferriero, Aldo Brassetti, Salvatore Guaglianone, Rome, Italy, Bertolo Riccardo, Juan Garisto, Jhiad Koauk, Cleveland, OH, Alexandre Mottrie, Paolo Dell’Oglio, Aalst, France, Alessandro Vecchia, Alessandro Antonelli, Brescia, Italy, Umberto Capitanio, Alessandro Larcher, Francesco Montorsi, Milan, Italy, Andrea Minervini, Florence, Italy, Francesco Porpiglia, Orbassano, Italy, Daniel Eun, Philadelphia, PA, Monish Aron, Ithaar Derweesh, Philadelphia, PA, Ronald Abaza, Columbus, OH, Monish Aron, Ithaar Derweesh, Philadelphia, PA, Paolo Gortero, Turin, Italy, Vincenzo Miron, Naples, Italy, Emanuele Montanari, Francesco Montorsi, Milan, Italy, Francesco Porpiglia, Turin, Italy, Riccardo Schiavina, Bologna, Italy, Sergio Serni, Florence, Italy, Claudio Simeone, Brescia, Italy, Carlo Trombetta, Trieste, Italy, Alessandro Volpe, Novara, Italy, Walter Antibi, Verona, Italy, Vincenzo Ficarra, Messina, Italy, Marco Carini, Andrea Minervini, Florence, Italy

MP42-02 A MULTI-INSTITUTIONAL ANALYSIS OF 263 HILAR TUMORS DURING ROBOT ASSISTED PARTIAL NEPHRECTOMY

MP42-03 CT VOLUMETRY OF ESTIMATED RESIDUAL KIDNEY FOR PREDICTION OF POSTOPERATIVE CHRONIC KIDNEY DISEASE IN PATIENTS WITH RENAL CELL CARCINOMA.
Yutaro Hori*, Shugo Suzuki, Sho Hashimoto, Daigo Funakoshi, Fuminori Sakurai, Daisuke Obinata, Tsuyoshi Yoshizawa, Tsuyoshi Matsui, Junichi Machida, Kenya Yamaguchi, Nozomu Kawata, Satoru Takahashi, Tokyo, Japan

MP42-04 CLINICAL AND RADIOLOGIC TROCAR SITE HERNIA FOLLOWING ROBOTIC UPPER TRACT UROLOGIC SURGERY
Ali Reza Ghoreif*, Gilbert Whang, Mohammad Asizare, Madeleine Burg, Benjamin Liu, Xiaomeng Lei, Khoa Tran, Tapas Tejura, Vinay Duddalwar, Mihir Desai, Monish Aron, Inderbir Gill, Hooman Djaladat, Los Angeles, CA

ABSTRACT
NUMBER TITLE
MP42-05 PERIOPERATIVE COMPLICATIONS AFTER PARTIAL NEPHRECTOMY FOR COMPLEX (PADUA SCORE ≥ 10) RENAL TUMORS: A PROSPECTIVE MULTICENTER OBSERVATIONAL STUDY (THE RECORD2 PROJECT).
Andrea Mari*, Fabrizio Di Maida, Riccardo Campi, Florence, Italy, Daniele Ampanoro, Turin, Italy, Alessandro Antonelli, Brescia, Italy, Maurizio Barale, Turin, Italy, Pierluigi Bove, Rome, Italy, Eugenio Brunocilla, Bologna, Italy, Umberto Capitanio, Milan, Italy, Luigi Da Pozzo, Bergamo, Italy, Paolo Gortero, Turin, Italy, Vincenzo Miron, Naples, Italy, Emanuele Montanari, Francesco Montorsi, Milan, Italy, Franco Porpiglia, Turin, Italy, Riccardo Schiavina, Bologna, Italy, Sergio Serni, Florence, Italy, Claudio Simeone, Brescia, Italy, Carlo Trombetta, Trieste, Italy, Alessandro Volpe, Novara, Italy, Walter Antibi, Verona, Italy, Vincenzo Ficarra, Messina, Italy, Marco Carini, Andrea Minervini, Florence, Italy

MP42-06 A PREOPERATIVE NOMOGRAM TO PREDICT MAJOR COMPLICATIONS AFTER ROBOT ASSISTED PARTIAL NEPHRECTOMY
Zine-Eddine KHENE*, Benoit Peyronnet, Romain Mathieu, Jean-Christophe BERNHARD, Rennes, France, Nicolas DOUMERC, Jean-Baptiste BEAVAL, Toulouse, France, Grégory Verhoest, Rennes, France, Alexandre DE LA TAILLE, Créteil, France, Franck Bruyere, Tours, France, Morgan Roupret, Paris, France, Jay Raman, Hershey, PA, Karim Bensalah, Rennes, France

MP42-07 ONCOLOGICAL OUTCOMES OF PATIENTS WITH SPORADIC, NON-METASTATIC RENAL CELL CARCINOMA WITH RENAL VEIN OR INFERNAL VENA CAVA TUMOR THROMBUS.
Benjamin Shiff*, Winnipeg, Canada, Rodney Breau, Ottawa, Canada, Alan So, Vancouver, Canada, Frederic Pouliot, Quebec City, Canada, Jun Kawakami, Calgary, Canada, Jean-Baptiste Lattouf, Montreal, Canada, Ricardo Rendon, Halifax, Canada, Simon Tanguay, Montreal, Canada, Ranjeeta Mallick, Ottawa, Canada, Rahul Bansal, Winnipeg, Canada
MP42-08 **A PHASE II DOUBLE ARM SINGLE-BLINDED RANDOMIZED SCREENING CLINICAL TRIAL TO EVALUATE THE USE OF A DEHYDRATED HUMAN AMNION/CHORION MEMBRANE ALLOGRAFT TO FACILITATE THE RECOVERY OF RENAL FUNCTION FOLLOWING ROBOTIC PARTIAL NEPHRECTOMY**

Alp Tuna Beksac*, Amr E. Elbakry, Kennedy Okhawere, Bheesham Dayal, David Paulucci, Jing Zhi Lo, Ketan Badani, New York, NY

---

MP42-09 **ROBOT ASSISTED RADICAL NEPHRECTOMY AND INFERIOR VENA CAVA THROMBECTOMY: SURGICAL TECHNIQUE, PERIOPERATIVE AND MID-TERM ONCOLOGIC OUTCOMES**

Umberto Anceschi*, Roma, Italy, Gabriele Tuderti, Aldo Brassetti, Maria Consiglia Ferreri, Francesco Minisola, Manuela Costantini, Salvatore Guaglianone, Rocco Simone Flammia, Riccardo Mastroianni, Michele Gallucci, Giuseppe Simone, Rome, Italy

---

MP42-10 **LONG TERM TRIFECTA OUTCOMES OF PARTIAL NEPHRECTOMY VERSUS PERCUTANEOUS ABLATION IN CT1A RENAL MASSES**

Bertrand Covin*, Thibaut Benoit, Marie Charlotte Delchier, Séverine Lagarde, Mathieu Roumigué, Nicolas Doumerc, Matthieu Thoulouzan, Eric Huyghe, Xavier Gamé, Michel Soulé, Jean Baptiste Beauval, Toulouse, France

---

MP42-11 **DOES THE SURGICAL TECHNIQUE IMPACT THE ONCOLOGIC OUTCOMES AFTER PARTIAL NEPHRECTOMY? A COMPARISON BETWEEN OPEN, LAPAROSCOPIC AND ROBOTIC APPROACH IN A SINGLE HIGH-VOLUME TERTIARY CENTER.**

Francesco Chessa*, Riccardo Schiavina, Marco Borghesi, Lorenzo Bianchi, Cristian Pultrone, Serena Di Fresco, Carlo Casabianca, Carlo Beretta, Marco Guerra, Pietro Piazza, Fabrizio Sartorio, Andrea Angiolini, Umberto Barbaresi, Eugenio Brunocilla, Bologna, Italy

---

MP42-12 **ENHANCED RECOVERY AFTER NEPHRECTOMY: CONCEPTION, IMPLEMENTATION AND OUTCOMES IN A HIGH VOLUME SPECIALIST CENTRE**

John Withington*, Yuigi Yuminaga, Aziz Gulamhusein, Craig Lyness, Cullen David, Ravi Barod, London, United Kingdom

---

MP42-13 **ASSOCIATION OF PARTIAL VERSUS RADICAL NEPHRECTOMY WITH SUBSEQUENT HYPERTENSION RISK FOLLOWING RENAL TUMOR RESECTION**


---

MP42-14 **SARCOMATOID FEATURES IN RENAL CELL CARCINOMA: RETHINKING THE STAGE-SURVIVAL PARADIGM**

Kyle Blum*, Renzo DiNatale, Alejandro Sanchez, Andrew Silagy, Julian Marcon, Roy Mano, Sounak Gupta, Satish Tickoo, Victor Reuter, Jonathan Coleman, Paul Russo, A. Ari Hakimi, New York, NY

---

MP42-15 **TIMING, INCIDENCE AND MANAGEMENT OF DELAYED BLEEDING AFTER PARTIAL NEPHRECTOMY IN PATIENTS AT RISK FOR RECURRENT, BILATERAL, MULTIFOCAL RENAL TUMORS**


---

MP42-16 **TREATMENT OF VERY SMALL RENAL MASSES IN THE UNITED STATES**

Da David Jiang*, Ann Martinez Acevedo, Ryan Kopp, Mark Garzotto, Michael Conlin, Christopher Amling, Jen-Jane Liu, Portland, OR

---

MP42-17 **ONCOLOGIC AND FUNCTIONAL OUTCOMES OF RADICAL AND PARTIAL NEPHRECTOMY IN PT3A PATHOLOGICALLY UPSTAGED RENAL CELL CARCINOMA: A MULTI-INSTITUTIONAL ANALYSIS**

MP42-18 IS LONG TERM RENAL FUNCTIONAL OUTCOME AFTER PARTIAL NEPHRECTOMY FOR COMPLETELY ENDOPHYTIC RENAL TUMORS WORSE COMPARED TO EXOPHYTIC TUMORS?

MP42-19 COMPARISON OF RENAL FUNCTIONAL OUTCOMES OF ACTIVE SURVEILLANCE AND PARTIAL NEPHRECTOMY IN THE MANAGEMENT OF ONCOCYTOMA
Margaret Meagher*, La Jolla, CA, Brian Lane, Grand Rapids, MI, Aaron Bradshaw, La Jolla, CA, Sabrina Noyes, Grand Rapids, MI, Ahmed Eldrefawy, Brittny Cotta, Sunil Patel, La Jolla, CA, Jacob Brunius, Grand Rapids, CA, Stephen Ryan, Fang Wan, Ithaar Derweesh, La Jolla, CA

MP42-20 A COMPARISON OF LONG-TERM OUTCOMES BETWEEN PARTIAL NEPHRECTOMY AND RADICAL NEPHRECTOMY FOR CLINICAL STAGE T1B AND T2A RENAL TUMORS

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Saturday, May 4, 2019
Moderated Poster Session 43
3:30 pm - 5:30 pm
BLADDER CANCER: NON-INVASIVE III
Room W181ab @ McCormick Place
Moderators: Stanley Yap, Neema Navai & Guido Dalbagni

ABSTRACT NUMBER TITLE
MP43-01 PHASE 2 KEYNOTE-057 STUDY: PEMBROLIZUMAB FOR PATIENTS WITH HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER UNRESPONSIVE TO BACILLUS CALMETTE-GUERIN

MP43-02 CG0070, AN ONCOLYTIC ADENOVIRUS, FOR BCG-UNRESPONSIVE NON-MUSCLE-INVASIVE BLADDER CANCER (NMIBC): 18 MONTH FOLLOW-UP FROM A MULTICENTER PHASE II TRIAL

MP43-03 PERFORMANCE OF BLADDER EPICHECKTM FOR NMIBC MONITORING-UPDATED RESULTS OF A EUROPEAN MULTI-CENTER STUDY
J Alfred Witjes*, Nijmegen, Netherlands, Fernando Lozano, Barcelona, Spain, Ilan Leibovitch, Kfar Saba, Israel, Erik B Cornel, Hengelo, Netherlands, Joyce Baard, Amsterdam, Netherlands, Georgios Gakis, Würzburg, Germany, Mario Alvarez-Maestro, Madrid, Spain, Hans van Valenberg, Nijmegen, Netherlands, Itay Sternberg, Kfar Saba, Israel, Ellen Willemsen, Hengelo, Netherlands, Leonore F. Albers, Amsterdam, Netherlands, Miriam Lena Hegemann, Sindelfingen, Germany, Yossi Paitan, Kfar Saba, Israel, Juan Morote, Barcelona, Spain

MP43-04 CONTEMPORARY OUTCOMES OF NON-MUSCLE INVASIVE BLADDER CANCER PATIENTS TREATED WITH INDUCTION BCG
Justin Matulay*, Houston, TX, Roger Li, Tampa, FL, Neema Navai, Supriya Nagaraju, Vikram Narayan, Amy Lim, H. Barton Grossman, Bogdan Czeniaik, Charles Guo, Colin Dinney, Ashish Kamat, Houston, TX
MP43-05 THE LANDSCAPE OF CLINICALLY ACTIONABLE GENOMIC ALTERATIONS IN PATIENTS WITH BACILLE CALMETTE-GUERIN (BCG) UNRESPONSIVE BLADDER CANCER: TOWARDS TARGETED THERAPY IN NON-MUSCLE INVASIVE BLADDER CANCER  

MP43-06 FLEXIBLE BLUE LIGHT CYSTOSCOPY WITH HEXAMINOLEVULINATE PROVIDES OPPORTUNITY TO FINALIZE DIAGNOSIS AND TREATMENT OF NON-MUSCLE INVASIVE BLADDER CANCER IN THE OUTPATIENT CLINIC. RESULTS FROM A NORDIC REGISTRY.  
Gorm von Gohren Edwin*, Baerum, Norway, Anders Debes, Oslo, Norway, Per- Uno Malmstrom, Uppsala, Sweden

MP43-07 A URINE ASSAY TO TRIAGE PATIENTS WITH HEMATURIA FOR CYSTOSCOPY  

MP43-08 BCG VS CHEMOHYPERTHERMIA WITH MITOMYCIN C FOR HIGH-RISK NON-MUSCLE INVASIVE BLADDER CARCINOMA: PRELIMINARY RESULTS OF HIVERC-HR RANDOMIZED CLINICAL TRIAL  
Félix Guerrero-Ramos*, Daniel Antonio González-Padilla, Alejandro González-Diaz, José Manuel Duarte-Ojeda, Natalia Miranda-Ulterra, Felipe Villacampa-Aubá, Federico de la Rosa-Kehrmann, Madrid, Spain

MP43-09 PHASE I TRIAL OF INTRAVESICAL BACILLUS CALMETTE-GUERIN COMBINED WITH INTRAVENOUS PEMBROLIZUMAB IN HIGH GRADE NONMUSCLE INVASIVE BLADDER CANCER.  
Shaheen Alane*, Detroit, MI, Ahmed El-Zawahry, Springfield, IL, kevin McVary, Maywood, IL, Mustafa Deebajah, Detroit, MI, Sherjeel Sana, Kathy Robinson, Krishna Rao, Springfield, IL

MP43-10 INVESTIGATION FOR INTRAVESICAL RECURRENCES BETWEEN WITH AND WITHOUT BCG THERAPIES ACCORDING TO HISTORY OF THERAPEUTIC AGENTS FOR DYSURIA IN NON-MUSCLE INVASIVE BLADDER CANCER  
Yoichiro Kato*, Daichi Kikuchi, Tomohiko Matuura, Renpei Kato, Mitsugu Kanehira, Ryo Takata, Jun Sugimura, Takaya Abe, Wataru Obara, Morioka, Japan

MP43-11 CHARACTERIZATION OF THE URINARY MICROBIOME IN PATIENTS WITH NON-MUSCLE INVASIVE BLADDER CANCER TREATED WITH BACILLUS CALMETTE-GUERIN IMMUNOTHERAPY  
Randy Swais*, Shay Golari, Nimrod Barashi, Elle Hill, Ciro Andolfi, Jeffrey Bloodworth, Ryan Wernitz, Gary Steinberg, Chicago, IL

MP43-12 PREOPERATIVE SERUM APOLIPOPROTEIN A-I LEVELS PREDICT LONG-TERM SURVIVAL IN NON-MUSCLE-INVASIVE BLADDER CANCER PATIENTS  
Zhenhua Shang*, Tongwen Ou, Beijing, China, People’s Republic of

MP43-13 HIGH GAMMA-GLOBULIN LEVEL IS ASSOCIATED WITH ONCOLOGICAL OUTCOMES IN PATIENTS WITH NON-MUSCLE INVASIVE BLADDER CANCER  
Naoya Niwa*, Kazuhiro Matsumoto, Hiroki Ide, Mototsugu Oya, Tokyo, Japan

MP43-14 A PHASE 1 TRIAL OF INTRAVESICAL CABAZITAXEL, GEMCITABINE, AND CISPLATIN (CGC) FOR THE TREATMENT OF NON-MUSCLE INVASIVE BCG UNRESPONSIVE UROTHELIAL CARCINOMA OF THE BLADDER  

MP43-15 THE USEFULNESS OF NON-INVASIVE TESTS AS A REPLACEMENT FOR CYSTOSCOPY IN THE FOLLOW-UP OF NON-INVASIVE BLADDER CANCER  
Jongsoo Lee, Doo Yong Chung, Hyeok Jun Goh, Don Gu Lee*, Jin Hyung Jeon, Hyun Ho Han, Ji Eun Heo, Seoul, Korea, Republic of, Jae Won Park, Young Sig Kim, Goyang, Korea, Republic of, Dong Hoon Lim, Gwangju, Korea, Republic of, Joong Shik Lee, Seoul, Korea, Republic of, Rae Cho Im, Goyang, Korea, Republic of, Won Sik Jang, Won Sik Ham, Young Deuk Choi, Seoul, Korea, Republic of

MP43-16 MANAGEMENT OF NON-MUSCLE INVASIVE BLADDER CANCER IN THE VETERANS HEALTH ADMINISTRATION  
Joseph M Caputo*, George Moran, New York, NY, Alison Keller, Bronx, NY, Gen Li, Christopher B Anderson, New York, NY
MP43-17 SINGLE SHORT-DURATION INSTILLATION OF PIRARUBICIN FOR LOW RISK NON-MUSCLE INVASIVE BLADDER CANCER: COMPARISON WITH MITOMYCIN C
Shigehisa Kubota*, Tetsuya Yoshida, Susumu Kageyama, Otsu, Japan, Taichi Sano, Tottori, Japan, Takashi Osafune, Uji, Japan, Yuji Sakano, Higashi-Omi, Japan, Chul Jung Kim, Kohka, Japan, Akihiro Kawachi, Otsu, Japan

MP43-18 DYNAMIC REAL-TIME MICROSCOPY OF BLADDER NEOPLASMS USING Confocal LASER ENDMICROSCOPY
yiping zhu*, dingwei ye, shanghai, China, People's Republic of

MP43-19 IMPACT OF BLADDER NECK INVOLVEMENT AND POSITIVE URINE CYTOLOGY IN SUBSTRATIFYING INTERMEDIATE-RISK NON-MUSCLE-INVASIVE BLADDER CANCER PATIENTS BASED ON THE PREDICTION OF HIGH-RISK RECURRENT
Hiroshi Fukushima*, Masahiro Toide, Shohei Fukuda, Shingo Moriyama, Yosuke Yasuda, Sho Uehara, Toshiki Kijima, Junichiro Yoshida, Minato Yokoyama, Junichiro Ishioka, Yoh Matsuoka, Kazutaka Saito, Yasuhisa Fujii, Tokyo, Japan

MP43-20 SINGLE-DOSE PERIOPERATIVE MITOMYCIN VS. THIOTEPA AFTER TRANSURETHRAL RESECTION OF LOW GRADE NON-INVASIVE BLADDER CANCER
Kassem Faraj*, Yu-Hui Chang, Kyle Rose, Paul Andrews, Erik Castle, Aqsa Khan, Mitchell Humphreys, Robert Ferrigni, Christopher Wolter, Scott Swanson, Mark Tyson, Phoenix, AZ

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Saturday, May 4, 2019
Moderated Poster Session 44
GENERAL & EPIDEMIOLOGICAL TRENDS & SOCIOECONOMICS: PRACTICE PATTERNS, QUALITY OF LIFE AND SHARED DECISION MAKING III
Room W176bc @ McCormick Place
Moderators: Sung Kyu Hong, Brian Matlaga & Christopher Saigal

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP44-01</td>
<td>LARGE VARIATION AND LARGE DOSES: OPIOID PRESCRIBING PATTERNS IN A NATIONAL VA COHORT</td>
</tr>
<tr>
<td>Jennifer Robles*, Jason Denton, Robert Dittus, Matthew Resnick, Nashville, TN</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP44-02</td>
<td>POST-OPERATIVE NARCOTIC PRESCRIBING PATTERNS FOR PATIENTS UNDERGOING RADICAL CYSTECTOMY</td>
</tr>
<tr>
<td>Elizabeth Green*, Petria Thompson, Kristen Scarpato, Kirk Keegan, Sam Chang, David Penson, Daniel Barocas, Matthew Resnick, Nashville, TN</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP44-03</td>
<td>KEY OPINION LEADERS MOTIVATE INCREASED PRESCRIPTIONS AMONG THEIR LOCAL PHYSICIANS</td>
</tr>
<tr>
<td>Austin Lee, Omar Ayyash*, Avinash Maganty, Liam Macleod, Jathin Bandari, Benjamin Davies, Bruce Jacobs, Pittsburgh, PA</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP44-04</td>
<td>TRENDS IN 5-ALPHA REDUCTASE INHIBITOR USE BEFORE AND AFTER THE FOOD AND DRUG ADMINISTRATION SAFETY WARNING</td>
</tr>
<tr>
<td>Craig Labbate*, Brittany Adamic, Chicago, IL, Pooja Talaty, Avishek Datta, Chi-Hsiung Wang, Brian T Heford, Evanston, IL</td>
<td></td>
</tr>
</tbody>
</table>

*Presenting author
MP44-08 QUALITY OF UROLOGICAL CANCER CARE AT THE END OF LIFE FOR DUAL ELIGIBLE BENEFICIARIES AND THE IMPACT OF DELIVERY SYSTEM INTEGRATION
Lindsey Herrel*, Ziwei Zhu, Deborah Kaye, Chad Ellimoottil, James Dupree, Brent Hollenbeck, David Miller, Ann Arbor, MI

MP44-09 OVERTREATMENT AND UNDERUTILIZATION OF WATCHFUL WAITING IN MEN WITH LIMITED LIFE EXPECTANCY: AN ANALYSIS OF THE MICHIGAN UROLOGICAL SURGERY IMPROVEMENT COLLABORATIVE REGISTRY
Udit Singhal*, Ji Qi, David C. Miller, Susan Linsell, Ann Arbor, MI, Michael Cher, Detroit, MI, Brian Lane, Grand Rapids, MI, Nik Rakic, Ann Arbor, MI, Michael Cotant, Troy, MI, James Montie, Ann Arbor, MI, Wassim Bazzi, Troy, MI, Bradley Rosenberg, Royal Oak, MI, Arvin K. George, for the Michigan Urological Surgery Improvement Collaborative, Ann Arbor, MI

MP44-10 VARIATION IN GUIDELINE-CONCORDANT CONSERVATIVE MANAGEMENT FOR LOW-RISK PROSTATE CANCER
Stacy Loeb*, Dawn Walter, Nataliya Byrne, Danil Makarov, NEW YORK, NY

MP44-11 PATIENT SELECTION AND OUTCOMES BETWEEN LOW AND HIGH VOLUME SURGEONS IN PERFORMANCE OF RADICAL PROSTATECTOMY IN THE MICHIGAN UROLOGICAL SURGERY IMPROVEMENT COLLABORATIVE (MUSIC)
Alex Tapper*, Alec Wilson, Royal Oak, MI, Stephen Lucas, Detroit, MI, Rodney Dunn, Khurshid Ghani, Tae Kim, David Miller, James Montie, Ann Arbor, MI, James Peabody, Detroit, MI, Ji Qi, Hugh M. Solomon, Jaya Telang, Ann Arbor, MI, Frank Burks, Royal Oak, MI, for the Michigan Urological Surgery Improvement Collaborative, Ann Arbor, MI

MP44-12 CONTEMPORARY CHARACTERIZATION OF PROSTATE CANCER DISPARITIES IN AFRICAN AMERICAN MEN

MP44-13 "I DON'T KNOW WHAT A NOMOGRAM IS": A MIXED METHODS APPROACH TO THE CREATION OF A PATIENT DECISION AID FOR MEN WITH HIGH-RISK FEATURES POST PROSTATECTOMY
Jesse Sammon*, Christina Gentile, Michael Kohut, Christopher Stockdale, Moritz Hansen, Paul Han, Portland, ME

MP44-14 PATIENT-CENTERED RECONSTRUCTION AND EVALUATION OF PROSTATE CANCER INFORMATION MATERIALS
Alexander E Kicik*, Andrew Dawson, Thomas Dymond, Michael J Leveridge, D. Robert Siemens, Jason P Izard, Kingston, Canada

MP44-15 EARLY POSTOPERATIVE COMPLICATIONS OF OUTPATIENT VERSUS INPATIENT ROBOTIC RADICAL PROSTATECTOMY: REPORT FROM THE NATIONAL SURGICAL QUALITY IMPROVEMENT PROGRAM

MP44-16 INTERPRETATION OF DOMAIN SCORES ON THE EXPANDED PROSTATE CANCER INDEX COMPOSITE: HOW DOES THE DOMAIN SCORE TRANSLATE INTO FUNCTIONAL OUTCOME?
Aaron Laviana*, Agustin Hernandez, Zhiguo Zhao, Li-Ching Huang, Tatsuki Koyama, Ralph Conwill, Irene Fueroer, Nashville, TN, Karen Hoffman, Houston, TX, David Penson, Daniel Barocas, CEASAR INVESTIGATORS, Nashville, TN

MP44-17 A NATIONAL SURVEY OF RADIATION ONCOLOGISTS AND UROLOGISTS ON PREDICTION TOOLS AND NOMOGRAMS FOR LOCALIZED PROSTATE CANCER
Boris Gershman, Providence, RI, Paul Maroni, Denver, CO, Jon Tilburt, Rochester, MN, Robert Volk, PhD, Houston, TX, Badrinath Konety, MD, Minneapolis, MN, Alexander Kutikov, MD, Marc Smaldone, Marc Smaldone, Philadelphia, PA, Victor Chen, Cleveland, OH, Simon Kim*, Denver, CO

MP44-18 P-SCAN: A COMPREHENSIVE PROSTATE CANCER SCREENING PROGRAM IN LOW-INCOME MEN

MP44-19 ADHERENCE TO A BEHAVIOR MODIFICATION INTERVENTION FOR PROSTATE CANCER: THE MEN’S EATING AND LIVING (MEAL) STUDY (CALGB 70807 [ALLIANCE])
J Parsons*, Loki Natarajan, John Pierce, La Jolla, CA, James Mohler, Buffalo, NY, Electra Paskett, Columbus, OH, Cheryl Rock, La Jolla, CA, James Marshall, Buffalo, NY
**MP44-20** CORRELATES OF REFUSAL OF RADICAL CYSTECTOMY IN PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER


Approved for AMA PRA Category 1 Credit™

Saturday, May 4, 2019 3:30 pm - 5:30 pm

**Moderated Poster Session 45**

**BENIGN PROSTATIC HYPERPLASIA: SURGICAL THERAPY & NEW TECHNOLOGY III**

Room W178ab @ McCormick Place

**Moderators:** Kevin Zorn, Smita De & Joyce Baard

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP45-01</td>
<td>INFLUENCE OF HOLMIUM LASER CYSTOLITHOLAPAXY ON PERIOPERATIVE OUTCOMES DURING HOLMIUM LASER ENUCLEATION OF THE PROSTATE IN A 1000 PATIENTS’ SERIES. Javier Romero-Otero*, Esther Rojo, Bojja Garcia Gómez, Juan Justo Quintas, Javier Gil Moradillo, Daniel Antonio González Padilla, Lucía García González, Raquel Sopeña Sutil, José Manuel Duarte Ojeda, Alfredo Rodríguez Antolín, Madrid, Spain</td>
</tr>
<tr>
<td>MP45-02</td>
<td>PERIOPERATIVE OUTCOMES FOR MASSIVE GLAND BENIGN PROSTATIC HYPERPLASIA (&gt; 200CM3) TREATED WITH HOLMIUM LASER ENUCLEATION OF THE PROSTATE Michael Zell*, Anojan Navaratnam, Mitchell Humphreys, Phoenix, AZ</td>
</tr>
<tr>
<td>MP45-03</td>
<td>BPH LARGER THAN 150 CC: OUTCOMES REACHED WITH THULEP Giordano Salvatore*, Cluj Napoca, Romania, Giorgio Bazzini, Busto Arsizio VA, Italy, Ian Coman, Cluj Napoca, Romania, Umberto Becana, Sergio Antonio Turno Chisena, Carlo Buizza, Busto Arsizio VA, Italy</td>
</tr>
<tr>
<td>MP45-04</td>
<td>EFFECT OF PREOPERATIVE URETHRAL DILATATION DURING HOLEP ON PREVENTING URETHRAL STRICTURE: RANDOMIZED CONTROLLED STUDY Yu Seob Shin*, Jae Hyung You, Myung Ki Kim, Young Beom Jeong, Jong Kwan Park, Jeonju, Korea, Republic of</td>
</tr>
<tr>
<td>MP45-06</td>
<td>THE INCIDENCE OF URETHRAL COMPLICATIONS WITH USING 26-FRENCH VERSUS 28-FRENCH RESECTOSCOPE SHEATHS IN HOLMIUM LASER ENUCLEATION OF THE PROSTATE (HOLEP) Kim Thai*, Jacob Smith, Jack Stutz, John Sung, Marawan El Tayeb, Temple, TX</td>
</tr>
<tr>
<td>MP45-07</td>
<td>RELATIONSHIP BETWEEN RECOVERY OF URINARY CONTINENCE AFTER HOLMIUM LASER ENUCLEATION OF THE PROSTATE (HOLEP) AND PREOPERATIVE MEMBRANOUS URETHRAL LENGTH ON MAGNETIC RESONANCE IMAGING Zhang Fan*, Liu Ke, Zhang Shudong, Xiao Chunlei, Huang Yi, Ma Lulin, Beijing, China, People’s Republic of</td>
</tr>
<tr>
<td>MP45-08</td>
<td>PROSTATIC URETHRAL LIFT (PUL) AND MAGNETIC RESONANCE IMAGING (MRI): DEFINING ARTEFACT AND RISK OF OBSCURING SIGNIFICANT CANCER. Peter Chin*, Wollongong, Australia, Rajeev Jyoti, Canberra, Australia, David Habashy, Wollongong, Australia</td>
</tr>
<tr>
<td>MP45-09</td>
<td>PROSTATE VOLUME DOES NOT SIGNIFICANTLY AFFECT THE RISK OF POST-SURGICAL COMPLICATIONS AFTER ROBOT-ASSISTED SIMPLE PROSTATECTOMY Ryan Steinberg*, Brett Johnson, Claus Roehrborn, Jeffrey Gahan, Dallas, TX</td>
</tr>
<tr>
<td>MP45-10</td>
<td>REAL-LIFE DATA FROM 180 CONSECUTIVE PATIENTS UNDERGOING AQUABLATION OF THE PROSTATE Thorsten Bach*, Hamburg, Germany, Iannis Giannakis, Frauenfeld, Switzerland, Magdalena Karimi, Hamburg, Germany, Enrique Rijo, Barcelona, Spain</td>
</tr>
<tr>
<td>MP45-11</td>
<td>THE WATER STUDY CLINICAL RESULTS – RESULTS AT 1 YEAR AND URODYNAMIC FINDINGS. Peter Gilling*, Tauranga, New Zealand, Claus Roehrborn, Dallas, TX</td>
</tr>
</tbody>
</table>
MP45-12 CONVEXTIVE WATER VAPOR ENERGY THERAPY (WAVE) VERSUS PROSTATIC URETHRAL LIFT (PUL) FOR THE TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA (BPH): AN INDIRECT COMPARISON ANCHORED ON SHAM CONTROL.
Natalia Hernandez*, Houston, TX, Paul F Zantek, Minnetonka, MN, Christopher T Tallman, Houston, TX, Ronald A Morton Jr, Qi Dongfeng, Minnetonka, MN, Ricardo R Gonzalez, Houston, TX

MP45-13 PRECLINICAL SAFETY AND EFFICACY OF A CHITOSAN-BASED HEMOSTATIC DEVICE TO CONTROL AND PREVENT HEMORRHAGE AFTER TRANSURETHRAL PROSTATIC SURGERY
James Jones*, Jack Lazar, Meihua Zhu, Lisa Buckley, Jason Hedges, Hua Xie, Portland, OR

MP45-14 RETROSPECTIVE ANALYSIS OF BLOOD LOSS OUTCOMES DURING 10-YEAR EXPERIENCE WITH HOLMIUM LASER ENUCLEATION OF THE PROSTATE (HOLEP) FOR BENIGN PROSTATIC HYPERPLASIA.
Javier Romero-Otero*, Esther Garcia Rojo, Borja Garcia Gómez, Juan Justo Quintas, Javier Gil Moradillo, Daniel Antonio González Padilla, Lucía García González, Raquel Soperia Sutil, José Manuel Duarte Ojeda, Alfredo Rodríguez Antolín, Madrid, Spain

MP45-15 EVALUATION OF SEXUAL FUNCTION AFTER THULIUM LASER ENucleATION OF PROSTATE
Mohammad Shohrab Hossain*, Mohammad Fazal Naser, Mohammad Rabiuł Islam, Dhaka, Bangladesh

MP45-16 PHOToselectIVE VAPORIZATION OF THE PROSTATE: FAVOURABILITY OF STUDY RESULTS AS A FUNCTION OF CONFLICTS OF INTEREST AND INDUSTRIAL SPONSORSHIP
Marian S. Wettstein*, Clinsy Pazhepurackel, Aline S. Neumann, Zurich, Switzerland, Dixon T.S. Woon, Jaime O. Herrera-Caceres, Toronto, Canada, Cédric Poyet, Tullio Sulser, Zurich, Switzerland, Girish S. Kulkarni, Toronto, Canada, Thomas Hermanns, Zurich, Switzerland

MP45-17 TRANSURETHRAL RESECTION COMBINED WITH INTRA- AND POST-OPERATIVE TRIAMCINOLONE INJECTIONS TO MANAGE HIGHLY RECURRENT BLADDER NECK CONTRACTURES FOLLOWING TRANSURETHRAL RESECTION OF THE PROSTATE
LIN YANG*, Linlin Zhang, Sheng Liu, Dalin He, Xian, China, People’s Republic of

MP45-18 IS TURP SAFE WITH ROOM TEMPERATURE IRRIGATION?: A RANDOMISED CONTROL TRIAL
Benjamin Black*, Sharon English, Christchurch, New Zealand

MP45-19 A LONG-TERM, PROSPECTIVE, RANDOMIZED-CONTROLLED COMPARISON OF SURGICAL SAFETY AND CLINICAL EFFICIENCY IN MEDIUM SIZE BPH CASES – THE EVIDENCE-BASED 8 YEARS’ TEST OF TIME FOR THE MONO- AND BIPOLAR TURP VERSUS THE BIPOLAR PLASMA VAPORIZATION
Bogdan Geavlete*, Dragos Georgescu, Razvan Multescu, Catalin Bulai, Cosmin Ene, Georgiana Balan, Andrei Ene, Petrisor Geavlete, Bucharest, Romania

MP45-20 IS AQUABLATION OF THE PROSTATE EFFECTIVE IN PATIENTS WITH RECURRENT RETENTION?
Thorsten Bach*, Hamburg, Germany, Iannis Giannakis, Frauenfeld, Switzerland, Magdalena Karimi, Hamburg, Germany, Enrique Rijo, Barcelona, Spain

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
<table>
<thead>
<tr>
<th>Time</th>
<th>Abstract</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:30</td>
<td><strong>PD34-01</strong> EVALUATION OF FERTILITY PRESERVATION PRACTICES AMONG ONCOLOGISTS: REVIEW OF ASCO’S QUALITY ONCOLOGY PRACTICE INITIATIVE STANDARDS FOR CANCER CARE</td>
<td>PRESENTATION PRACTICES AMONG ONCOLOGISTS: REVIEW OF ASCO’S QUALITY ONCOLOGY PRACTICE INITIATIVE STANDARDS FOR CANCER CARE</td>
</tr>
<tr>
<td>3:40</td>
<td><strong>PD34-02</strong> UROLOGIST INVOLVEMENT IN SPERM RETRIEVAL PROCEDURES AT AMERICAN INFERTILITY CLINICS</td>
<td>UROLOGIST INVOLVEMENT IN SPERM RETRIEVAL PROCEDURES AT AMERICAN INFERTILITY CLINICS</td>
</tr>
<tr>
<td></td>
<td>Presenting author: Nima Nassiri*, Margaret English, Jenny Wei, Nassim Lashkari, Mary Samplaski, Los Angeles, CA</td>
<td>Presenting author: Nima Nassiri*, Margaret English, Jenny Wei, Nassim Lashkari, Mary Samplaski, Los Angeles, CA</td>
</tr>
<tr>
<td>3:50</td>
<td><strong>PD34-03</strong> EMPIRICAL MEDICAL THERAPY FOR IDIOPATHIC MALE INFERTILITY: A FOLLOW-UP SURVEY OF THE AMERICAN UROLOGICAL ASSOCIATION</td>
<td>EMPIRICAL MEDICAL THERAPY FOR IDIOPATHIC MALE INFERTILITY: A FOLLOW-UP SURVEY OF THE AMERICAN UROLOGICAL ASSOCIATION</td>
</tr>
<tr>
<td>4:00</td>
<td><strong>PD34-04</strong> FINDING A SPERM AMONG THE WEEDS: NOVEL NEURAL NETWORK MODEL FOR AUGMENTED SEMINIFEROUS TUBULES CLASSIFICATION IN MICROTESE</td>
<td>FINDING A SPERM AMONG THE WEEDS: NOVEL NEURAL NETWORK MODEL FOR AUGMENTED SEMINIFEROUS TUBULES CLASSIFICATION IN MICROTESE</td>
</tr>
<tr>
<td></td>
<td>Presenting author: Shrikant Pandya*, Whitney Halgrimson, Rodrigo Pagani, Chicago, IL</td>
<td>Presenting author: Shrikant Pandya*, Whitney Halgrimson, Rodrigo Pagani, Chicago, IL</td>
</tr>
<tr>
<td>4:10</td>
<td><strong>PD34-05</strong> SPERM RETRIEVAL AND INTRACYTOPLASMIC SPERM INJECTION (ICSI) OUTCOMES IN MEN WITH CYSTIC FIBROSIS (CF) DISEASE VERSUS CONGENITAL BILATERAL ABSENCE OF THE VAS DEFERENS (CBAVD)</td>
<td>SPERM RETRIEVAL AND INTRACYTOPLASMIC SPERM INJECTION (ICSI) OUTCOMES IN MEN WITH CYSTIC FIBROSIS (CF) DISEASE VERSUS CONGENITAL BILATERAL ABSENCE OF THE VAS DEFERENS (CBAVD)</td>
</tr>
<tr>
<td>4:20</td>
<td><strong>PD34-06</strong> OPIOID PRESCRIPTION PATTERNS AFTER VASECTOMY: INSIGHTS FROM A NATIONAL SURVEY OF UROLOGISTS</td>
<td>OPIOID PRESCRIPTION PATTERNS AFTER VASECTOMY: INSIGHTS FROM A NATIONAL SURVEY OF UROLOGISTS</td>
</tr>
<tr>
<td></td>
<td>Presenting author: Kian Asanad*, Mary Samplaski, Los Angeles, CA</td>
<td>Presenting author: Kian Asanad*, Mary Samplaski, Los Angeles, CA</td>
</tr>
<tr>
<td>4:30</td>
<td><strong>PD34-07</strong> A NOVEL MICROFLUIDIC DEVICE TO IMPROVE SPERM SEARCHING IN MICRODISSECTION TESE SAMPLES</td>
<td>A NOVEL MICROFLUIDIC DEVICE TO IMPROVE SPERM SEARCHING IN MICRODISSECTION TESE SAMPLES</td>
</tr>
<tr>
<td></td>
<td>Presenting author: Alex Jafek*, Haidong Feng, Timothy Jenkins, Kenneth Aston, Douglas Carrell, Bruce Gale, Raheel Samuel, Jim Hotaling, Salt Lake City, UT</td>
<td>Presenting author: Alex Jafek*, Haidong Feng, Timothy Jenkins, Kenneth Aston, Douglas Carrell, Bruce Gale, Raheel Samuel, Jim Hotaling, Salt Lake City, UT</td>
</tr>
<tr>
<td>4:40</td>
<td><strong>PD34-08</strong> GATE CALIBRATION UTILIZING PRE-SIZED BEADS FOR FLUORESCENCE ACTIVATED CELL SORTING OF SPERM</td>
<td>GATE CALIBRATION UTILIZING PRE-SIZED BEADS FOR FLUORESCENCE ACTIVATED CELL SORTING OF SPERM</td>
</tr>
<tr>
<td>4:50</td>
<td><strong>PD34-09</strong> WHICH TREATMENT IS THE BEST FOR RECURRENT VARICOCELE?: ANALYSIS OF TREATMENT METHODS TO COMPARE POST-TREATMENT SPERM PARAMETERS, PREGNYANCY AND COMPLICATION RATES</td>
<td>WHICH TREATMENT IS THE BEST FOR RECURRENT VARICOCELE?: ANALYSIS OF TREATMENT METHODS TO COMPARE POST-TREATMENT SPERM PARAMETERS, PREGNYANCY AND COMPLICATION RATES</td>
</tr>
<tr>
<td></td>
<td>Presenting author: Selahittin Çaýan*, Mersin, Turkey, İrfan Orhan, Elazığ, Turkey, Erdem Akbay, Mersin, Turkey, Ateş Kadioğlu, İstanbul, Turkey</td>
<td>Presenting author: Selahittin Çaýan*, Mersin, Turkey, İrfan Orhan, Elazığ, Turkey, Erdem Akbay, Mersin, Turkey, Ateş Kadioğlu, İstanbul, Turkey</td>
</tr>
<tr>
<td>5:00</td>
<td><strong>PD34-10</strong> PREDICTORS OF SUCCESS FOR ONCOTESIS IN TESTIS CONTAINING TUMOUR AT TIME OF RADICAL ORCHIECTOMY IN AZOOSPERMIC MEN</td>
<td>PREDICTORS OF SUCCESS FOR ONCOTESIS IN TESTIS CONTAINING TUMOUR AT TIME OF RADICAL ORCHIECTOMY IN AZOOSPERMIC MEN</td>
</tr>
<tr>
<td>5:10</td>
<td><strong>PD34-11</strong> DEFINING THE FEASIBILITY OF FERTILITY PRESERVATION IN PRE-PUBERTAL MALES SCHEDULED TO UNDERGO CHEMOTHERAPY</td>
<td>DEFINING THE FEASIBILITY OF FERTILITY PRESERVATION IN PRE-PUBERTAL MALES SCHEDULED TO UNDERGO CHEMOTHERAPY</td>
</tr>
<tr>
<td>5:20</td>
<td><strong>PD34-12</strong> “TESTOSTERONE BOOSTING” SUPPLEMENTS COMPOSITION AND CLAIMS ARE NOT SUPPORTED BY THE ACADEMIC LITERATURE</td>
<td>“TESTOSTERONE BOOSTING” SUPPLEMENTS COMPOSITION AND CLAIMS ARE NOT SUPPORTED BY THE ACADEMIC LITERATURE</td>
</tr>
<tr>
<td></td>
<td>Presenting author: Hatim Thaker*, Chase Clemesha, Mary K. Samplaski, Los Angeles, CA</td>
<td>Presenting author: Hatim Thaker*, Chase Clemesha, Mary K. Samplaski, Los Angeles, CA</td>
</tr>
</tbody>
</table>
Podium Session 35

PROSTATE CANCER: DETECTION & SCREENING VI
Room W185a @ McCormick Place

Moderators: Matthew Kaag, Adam Kibel & Peter Pinto

<table>
<thead>
<tr>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:30</td>
<td>PD35-01</td>
<td>INCREASED DETECTION RATES OF INTERMEDIATE AND HIGH-GRADE PROSTATE CANCER IN AFRICAN-AMERICAN MEN AFTER 2012 USPSTF RECOMMENDATION AGAINST PSA SCREENING</td>
</tr>
<tr>
<td>Jeffrey Arace*, Viktor Flores, Dennis Robins, Thomas Monaghan, Andrew Winer, Jeffrey Weiss, Brooklyn, NY</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3:4</td>
<td>PD35-02</td>
<td>IMPACT OF 2012 UNITED STATES PREVENTIVE SERVICES TASK FORCE STATEMENT ON PROSTATE CANCER SCREENING, DETECTION AND PRESENTATION IN MEN UNDER THE AGE OF 70 AT KAISER PERMANENTE NORTHERN CALIFORNIA</td>
</tr>
<tr>
<td>Joseph Prest*, Mill Valley, CA, Stacey Alexeiff, Brandon Horton, Stephanie Prausnitz, Andrew Avins, Oakland, CA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3:50</td>
<td>PD35-03</td>
<td>CHANGING PHYSICIAN PSA SCREENING BEHAVIOR IN MEN 70 YEARS OF AGE AND OLDER BY USE OF THE ELECTRONIC MEDICAL RECORD</td>
</tr>
<tr>
<td>Joseph Prest*, Mill Valley, CA, Stacey Alexeiff, Brandon Horton, Stephanie Prausnitz, Andrew Avins, Oakland, CA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:00</td>
<td>PD35-04</td>
<td>COULD DIFFERENCES IN TREATMENT BETWEEN TRIAL ARMS EXPLAIN THE REDUCTION IN PROSTATE CANCER MORTALITY IN THE EUROPEAN RANDOMIZED STUDY OF SCREENING FOR PROSTATE CANCER?</td>
</tr>
<tr>
<td>Sigrid Carlsson*, New York, NY, Marianne Månsson, Gothenburg, Sweden, Sue Moss, London, United Kingdom, Maciej Kwiatkowski, Franz Recker, Aarau, Switzerland, Teuvo Tammela, Tampere, Finland, Chris Bangma, Monique Roobol, Rotterdam, Netherlands, Anssi Auvinen, Tampere, Finland, Jonas Hugosson, Gothenburg, Sweden</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:10</td>
<td>PD35-05</td>
<td>CAN TESTOSTERONE TREATMENT OFFER A PREVENTIVE CONCEPT IN TERMS OF INCIDENCE AND SEVERITY OF PROSTATE CANCER: RESULT OF 203 TREATED AND UNTREATED HYPOGONADAL PATIENTS UNDERGOING PROSTATE BIOPSY IN A PROSPECTIVE DATA REGISTER</td>
</tr>
<tr>
<td>Aksam Yassin, Khalid Alrumaih*, Riad Talib, Sabah Alkadhi, Abdulla Al Ansari, Doha, Qatar</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:20</td>
<td>PD35-06</td>
<td>DIAGNOSTIC PROPERTIES OF PROSTATE-SPECIFIC ANTIGEN TO PREDICT PROSTATE CANCER AND CLINICALLY SIGNIFICANT PROSTATE CANCER AMONG MEN WITH ANDROGEN DEFICIENCY</td>
</tr>
<tr>
<td>Logan Schwarzman*, Rodrigo Pagani, Samuel Ohlander, Michael Abern, Chicago, IL, Gerald Andriole, St. Louis, MO, Stephen Freedland, Los Angeles, CA, Daniel Moreira, Chicago, IL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:40</td>
<td>PD35-07</td>
<td>ASSOCIATION OF COMMON MEDICATION WITH PROSTATE-SPECIFIC ANTIGEN LEVEL IN 45-YEAR-OLD GERMAN MEN: RESULTS OF THE PROBATE TRIAL</td>
</tr>
<tr>
<td>Kathleen Herkommer*, Valentin Henri Meissner, Zibyedey Ertilav, Munich, Germany, Martina Kron, Ulm, Germany, Helga Schulwitz, Munich, Germany, Peter Albers, Christian Arsov, Dusseldorf, Germany, Markus Kuczky, Florian Imkamp, Hannover, Germany, Markus Hohenfellner, Boris Hadaschik, Heidelberg, Germany, Jürgen Erich Gschwend, Munich, Germany</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:50</td>
<td>PD35-08</td>
<td>USE OF THE PHI ASSAY AS A FIRST LINE TRIAGING TEST IN AN IMAGE-GUIDED PROSTATE CANCER DIAGNOSTIC PATHWAY. THE PHI IN REFINING MRI STUDY (PRIM)</td>
</tr>
<tr>
<td>Vincent Gnanapragasam*, Tristan Barrett, Keith Burling, Benjamin Lamb, Kasra Saebparsy, Christof Kastner, Syed Shah, Cambridge, United Kingdom, Lorraine Starling, Anne George, Cambridge, United Kingdom, Lois Kim, Cambridge, United Kingdom</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5:00</td>
<td>PD35-10</td>
<td>PROSTATE HEALTH INDEX FOR PROSTATE CANCER DETECTION IN PATIENT UNDERWENT MAGNETIC RESONANCE IMAGING TRANSRECTAL ULTRASOUND FUSION PROSTATE BIOPSY</td>
</tr>
<tr>
<td>Po-Hsun Pan*, Tzu-Ping Lin, Yu-Hua Fan, Tzu-Chun Wei, Yi-Shen Huang, Chi-Cheh Lin, Eric Y.H. Huang, Hsiao-Jen Chung, Junne-Yih Kuo, Howard H.H. Wu, Shing-Hwa Lu, Yen-Hwa Chang, Alex T.L. Lin, William J.S. Huang, Taipei, Taiwan</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5:10</td>
<td>PD35-11</td>
<td>PSA DENSITY PERFORMS BETTER IN CAUCASIAN MEN THAN IN AFRICAN AMERICAN MEN IN PREDICTING PROSTATE CANCER AND SIGNIFICANT CANCER ON PROSTATE BIOPSY</td>
</tr>
<tr>
<td>Emily Kelly*, Kevin Morgan, Zachary Connelly, Kara Babaian, Shreveport, LA</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
**PD35-12**  ACCURACY OF PROSTATE SPECIFIC ANTIGEN DENSITY AT DETECTING PROSTATE CANCER  
Ayesha Butt*, Rahul Pandya, Ahmed Ibrahim, Iqbal Miakhil, Peterborough, United Kingdom

---

**Podium Session 36**  
URODYNAMICS/LOWER URINARY TRACT DYSFUNCTION/FEMALE PELVIC MEDICINE: FEMALE INCONTINENCE: THERAPY III  
Room W185d @ McCormick Place  
**Moderators:** Steven Siegel, Anne Suskind & Mauricio Plata

<table>
<thead>
<tr>
<th>ABSTRACT TIME</th>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
<th>ABSTRACT TIME</th>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:30</td>
<td>PD36-01</td>
<td>REAL WORLD COMPLIANCE WITH PERCUTANEOUS Tibial NERVE STIMULATION MAINTENANCE THERAPY</td>
<td>4:30</td>
<td>PD36-07</td>
<td>A HIGHER VOIDING SYMPTOM SUBSCORE AT BASELINE PREDICT POOR SATISFACTION OF ESCALATING MIRABGERON FROM 25 MG TO 50 MG FOR OVERACTIVE BLADDER PATIENTS</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Chris Du, William Berg*, Alexandra Siegal, Zhenyue Huang, Steven Weissbart, Jason Kim, Stony Brook, NY</td>
<td></td>
<td></td>
<td>Chun-Hou Liao*, New Taipei, Taiwan, Hann-Chong Kuo, Hualien, Taiwan</td>
</tr>
<tr>
<td>3:40</td>
<td>PD36-02</td>
<td>DO INTRAOPERATIVE TEST AMPLITUDES DURING STAGE I SACRAL NEUROMODULATION PREDICT PROGRESSION TO STAGE II OR DEVICE REVISION?</td>
<td>4:40</td>
<td>PD36-08</td>
<td>ADDING MIRABGERON ON INTRAVESICAL ONABOTULINUMTOXINA PROVIDES BETTER THERAPEUTIC EFFECTS IN PATIENTS WITH SEVERE OVERACTIVE BLADDER SYNDROME</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Emily Zhang, Howard Goldman, Sandip Vasavada, Courtenay Moore, Raymond Rackley, Bradley Gill*, Cleveland, OH</td>
<td></td>
<td></td>
<td>Chung-Cheng Wang*, New Taipei City, Taiwan, Yuan-Hong Jiang, Hann-Chong Kuo, Hualien, Taiwan</td>
</tr>
<tr>
<td>3:50</td>
<td>PD36-03</td>
<td>12 YEAR SINGLE CENTER RETROSPECTIVE REVIEW OF RISK FACTORS AND RATE OF TINED LEAD BREAKAGE DURING SACRAL NEUROMODULATION LEAD EXPLANT</td>
<td>4:50</td>
<td>PD36-09</td>
<td>PREVENTING Falls in older women with overactive bladder: the impact of fesoterodine on falls risk, physical functioning, and balance</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Jessica Rueb*, Cleveland, OH, Javier Pizarro-Berdichevsky, Santiago, Chile, Samir Derisavifard, Laura Giusto, Patricia Zahner, Courtenay Moore, Raymond Rackley, Sandip Vasavada, Howard Goldman, Cleveland, OH</td>
<td></td>
<td></td>
<td>Christine Chu*, Saint Louis, MO, Heidi Harvie, Uduak Andy, Lily Arya, Philadelphia, PA</td>
</tr>
<tr>
<td>4:00</td>
<td>PD36-04</td>
<td>IMPROVING PATIENT EXPERIENCE WITH SACRAL NEUROMODULATION: A HUMAN FACTORS APPROACH</td>
<td>5:00</td>
<td>PD36-10</td>
<td>BLOCKADE OF ACTIVIN TYPE II RECEPTORS WITH BIMAGRUMAB INCREASES THE URETHRAL PRESSURE IN A DUAL MUSCLE AND NERVE INJURY STRESS URINARY INCONTINENCE MODEL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Tara Cohen, Claire S. Burton*, Sarah Francis, A. Lenore Ackerman, Karyn S. Eliber, Jennifer T. Anger, Los Angeles, CA</td>
<td></td>
<td></td>
<td>Jun Yang*, Danli Lin, Brian Balog, Brett Hanzlik, Anna Retsch, Mei Kuang, Cleveland, OH, Shinni Hatakeyama, Estelle Lach-Triffleff, Basel, Switzerland, Margot S Damaser, Cleveland, OH</td>
</tr>
<tr>
<td>4:10</td>
<td>PD36-05</td>
<td>EXAMINING SUCCESSFUL TREATMENT WITH SELECTIVE BLADDER DENERVATION (SBD) AFTER 18-MONTHS: HABIT-DRIVEN VERSUS URGENCY-DRIVEN VOIDING IN REFRACTORY OAB PATIENTS</td>
<td>5:10</td>
<td>PD36-11</td>
<td>DEVELOPMENT OF A FEMALE UROLOGY VOIDING DYSFUNCTION PHENOTYPE: CORRELATION WITH MEDICATION USE AND PROGRESSION TO THIRD-LINE THERAPY</td>
</tr>
<tr>
<td>4:20</td>
<td>PD36-06</td>
<td>THE EFFECT OF SELECTIVE BLADDER DENERVATION IN FEMALE REFRACTORY OVERACTIVE BLADDER WITH OR WITHOUT DETRUSOR OVERACTIVITY</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Raphaelle Briere*, Quebec, Canada, Patrick O. Richard, Sherbrooke, Canada, Matthieu Gratton, Quebec, Canada, Le Mai Tu, Sherbrooke, Canada</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Presenting author
CHARACTERIZATION OF SAFETY EVENTS FOR ENERGY-BASED DEVICES FOR TREATMENT OF VAGINAL SYMPTOMS: AN ANALYSIS OF THE FOOD AND DRUG ADMINISTRATION MANUFACTURER AND USER FACILITY DEVICE EXPERIENCE (MAUDE) DATABASE FROM 2013 TO 2016

Shannon Wallace*, Ekene Enemchukwu, Stanford, CA

Saturday, May 4, 2019 3:30 pm - 5:30 pm
Podium Session 37
URODYNAMICS/LOWER URINARY TRACT DYSFUNCTION/FEMALE PELVIC MEDICINE: MALE INCONTINENCE: THERAPY II
Room W184d @ McCormick Place
Moderators: Brian Flynn, Veronica Triaca & Zaki Almallah

<table>
<thead>
<tr>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:30</td>
<td>PD37-01</td>
<td>EVALUATION OF COGNITIVE EFFECTS OF ANTIMUSCARINICS: A SYSTEMATIC REVIEW AND META-ANALYSIS Jung Ki Jo*, Seoul, Korea, Republic of, So Yun Lee, Ilsan, Korea, Republic of, Jun Ho Lee, Seoul, Korea, Republic of, Hong Sang Moon, Guro, Korea, Republic of</td>
</tr>
<tr>
<td>3:40</td>
<td>PD37-02</td>
<td>HIGHER SALT INTAKE AND NON-DIPPING BLOOD PRESSURE ARE ASSOCIATED WITH NOCTURNAL POLYURIA IN PATIENTS WITH LOWER URINARY TRACT SYMPTOMS Misato Takayama*, So Omori, Daiki Ikarashi, Renpei Kato, Yoichiro Kato, Mitsugu Kanemura, Ryo Takata, Wataru Obara, Iwate, Japan</td>
</tr>
<tr>
<td>3:50</td>
<td>PD37-03</td>
<td>ADJUSTABLE TRANSOBURATOR MALE SYSTEM (ATOMS®) – A NOVEL TREATMENT OPTION IN MEN WITH STRESS URINARY INCONTINENCE: THE FIRST EXPERIENCE IN THE UNITED KINGDOM BOB YANG*, CLARE JELLEY, Steve Foley, READING, United Kingdom</td>
</tr>
<tr>
<td>4:00</td>
<td>PD37-04</td>
<td>ADVANCE XP® FOR THE TREATMENT OF POST-PROSTATECTOMY-INCONTINENCE: 5 YEAR DATA OF A PROSPECTIVE MULTICENTRE STUDY Jan-Niclas Mumm*, Benedikt Klehr, Munich, Germany, Christian Gozzi, Bozen, Italy, Peter Rehder, Florian May, Dachau, Germany, Roland Homberg, Hamm, Germany, Peter Gebhart, Voellabrunn, Austria, Christian Stief, Ricarda Bauer, Munich, Germany</td>
</tr>
<tr>
<td>4:10</td>
<td>PD37-05</td>
<td>PERIOPERATIVE FACTORS CONTRIBUTING TO THE DELAYED RETURN TO CONTINENCE AFTER RADICAL PROSTATECTOMY Divya Ajay*, Hanhan Li, Brittani Barrett-Harlow, Jenny Nguyen, Houston, TX, Cooper Benson, New Orleans, LA, Xuemei Wang, Brian Chapin, John Davis, O. Lenaine Westney, Houston, TX</td>
</tr>
<tr>
<td>4:30</td>
<td>PD37-07</td>
<td>ARTIFICIAL URINARY SPHINCTER IMPLANTATION IS A SAFE PROCEDURE WITH LOW COMPLICATION RATES EVEN IN THE ELDERLY AND COMORBID POPULATION Stephanie Sexton, Brian Inouye*, Urszula Kowalik, Tracy Truong, Magaratha Kuchibhatla, Andrew Peterson, Durham, NC</td>
</tr>
<tr>
<td>4:40</td>
<td>PD37-08</td>
<td>FOLEY PLACEMENT DOES NOT INFLUENCE URETHRAL MEASUREMENT FOR ARTIFICIAL URINARY SPHINCTER CUFF SIZING AT THE TIME OF SURGERY Urszula Kowalik*, Durham, NC, Arman Kahokehr, Adelaide, Australia, Andrew Peterson, Durham, NC</td>
</tr>
<tr>
<td>5:00</td>
<td>PD37-10</td>
<td>ARTIFICIAL URINARY SPHINCTER REVISION WITH QUICK-CONNECTORS® VERSUS SUFURE-TIE CONNECTORS: DOES TECHNIQUE MAKE A DIFFERENCE? Jack Andrews*, Brian Linder, Joseph Scales, Daniel Elliott, Rochester, MN</td>
</tr>
</tbody>
</table>
5:10 PD37-11 PROSPECTIVE ANALYSIS OF CONTINENCE AND COMPLICATION RATES OF AMS 800 AUS DEVICES FOR PATIENTS WITH A HISTORY OF NEUROLOGICAL DISEASE

Tim Ludwig, Valentin Maurer*, Phillip Marks, Clemens Rosenbaum, Malte Vetterlein, Philipp Gild, Oliver Engel, Margit Fisch, Roland Dahllem, Hamburg, Germany

5:20 PD37-12 URETHRAL ATROPHY IS RARELY CAUSE FOR ARTIFICIAL URINARY SPHINCTER REVISION SURGERY IN THE CONTEMPORARY 3.5 CM CUFF ERA

Rachel Bergeson*, Yooni Yi, Michael Davenport, Allen Morey, Dallas, TX

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Saturday, May 4, 2019 3:30 pm - 5:30 pm

Podium Session 38

STONE DISEASE: BASIC RESEARCH & PATHOPHYSIOLOGY II

Room W181c @ McCormick Place

Moderators: Marshall Stoller, Paul Austin & Allen Rodgers

<table>
<thead>
<tr>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
<th>ABSTRACT</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:30</td>
<td>PD38-01</td>
<td>A PROSPECTIVE, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, CROSS-OVER STUDY UTILIZING ORALLY ADMINISTERED OXALATE DECARBOXYLASE (OXDC) TO REDUCE URINARY OXALATE</td>
<td>Emily Quintero*, Gainesville, FL, Sabrina Buzzard, High Springs, FL, Alan Ryan, Boynton Beach, FL, Gary Stevens, Bastrop, TX, Ira Klimberg, Englewood, FL, Victoria Bird, Gainesville, FL</td>
</tr>
<tr>
<td>3:40</td>
<td>PD38-02</td>
<td>IDENTIFICATION OF ABERRANT GLYCOSYLATION OF OSTEOPONTIN IN URINARY STONE FORMER PATIENTS AS A UROLITHIASIS BIOMARKER</td>
<td>Go Anan*, Sendai, JAPAN, Tohru Yoneyama, Yuki Tobisawa, Shingo Hatakeyama, Mihoko Yoneyama, Hiroaki, JAPAN, Hiromichi lwamura, Jun Ito, Yasuhiro Kato, Sendai, JAPAN, Hayato Yamamoto, Hiroaki, JAPAN, Atsushi Imai, Sendai, JAPAN, Takahiro Yoneyama, Yasuhiro Hashimoto, Hiroaki, JAPAN, Makoto Sato, Sendai, JAPAN, Chikara Ohyama, Hiroaki, JAPAN</td>
</tr>
<tr>
<td>4:00</td>
<td>PD38-04</td>
<td>NEUTROPHIL INFLTRATION AND NETOSIS IN THE PATHOGENESIS OF HUMAN KIDNEY BRUSHITE STONES</td>
<td>Mohammad Makki, Seth Winfree, Indianapolis, IN, Elaine Worcester, Cicago, IL, Frank Witzmann, James Lingeman, James Williams, Tarek El-Achkar*, Indianapolis, IN</td>
</tr>
<tr>
<td>4:10</td>
<td>PD38-05</td>
<td>A NEW METHOD OF MULTIFACETED STRUCTURE ANALYSIS: TWO-DIMENSIONAL MAPS OF “CHEMICAL ELEMENTS” AND “MATRIX PROTEIN” IN CALCIUM-CONTAINING STONES</td>
<td>Yutaró Tanaka*, Atsushi Okada, Nagoya, JAPAN, Mihoko Maruyama, Suitsa, JAPAN, Terutaka Sugino, Rei Unno, Kazumi Taguchi, Shuzo Hamamoto, Ryoosuke Ando, Nagoya, JAPAN, Masashi Yoshimura, Yusuke Mori, Suitsa, JAPAN, Kenjiro Kohri, Takahiro Yasui, Nagoya, JAPAN</td>
</tr>
<tr>
<td>4:20</td>
<td>PD38-06</td>
<td>LASER MICRODISSECTION OF HUMAN CALCIUM OXALATE MONOHYDRATE STONES ENABLES STRUCTURALLY SPECIFIC EXPLORATION OF THE STONE PROTEOME</td>
<td>Victor Hugo Canela*, Sharon Bledsoe, Daria Barwinska, James E. Lingeman, Tarek M. Ashkar, James C. Williams, Jr., Indianapolis, IN</td>
</tr>
<tr>
<td>4:30</td>
<td>PD38-07</td>
<td>ESSENTIAL ROLE OF HOST MICROBIOME IN COUNTERING EXPERIMENTAL HYPEROXALURIA, RENAL CALCINOSIS AND STONE FORMATION</td>
<td>Yan Liu, Ellen Shapiro, Herbert Lepor, Xue-Ru Wu*, New York, NY</td>
</tr>
<tr>
<td>4:40</td>
<td>PD38-08</td>
<td>VITAMIN D3 PROMOTES RENAL CAOX CRYSTALS FORMATION/ADHESION VIA INCREASING PLASMA/URINARY OXALATE THROUGH ALTERING A NOVEL VDR/MIR-125B/SLC26A6 AXIS</td>
<td>Haoran Liu*, Kun Tang, Tao Ye, Xifeng Sun, Xiaoli Yang, Zhangqin Ye, Wuhan, China, People’s Republic of</td>
</tr>
<tr>
<td>4:50</td>
<td>PD38-09</td>
<td>EXPRESSION OF BARLEY OXALATE OXIDASE ENZYME USING A PICHIA PASTORIS SECRETION SYSTEM</td>
<td>William Donelan*, ShiWu Li, Paul Dominguez-Gutierrez, Augustus Anderson IV, Cuong Nguyen, Benjamin Canales, Gainesville, FL</td>
</tr>
</tbody>
</table>

*Presenting author
5:00 PD38-10 QUANTIFYING THE FUNCTION OF THE OXALATE-DEGRADING MICROBIAL NETWORK AND ITS RELEVANCE FOR URINARY STONE DISEASE
Carlos Batagello, Sao Paulo, Brazil, Andrew Nguyen, Manoj Monga, Aaron Miller*, Cleveland, OH

5:10 PD38-11 IMPACT OF NEW DRUG SCREENING MODEL USING INDUCED PLURIPOTENT STEM CELL-DERIVED MACROPHAGES TO PHAGOCYTOSIS CALCIUM OXALATE CRYSTALS FOR PREVENTION OF URINARY STONES
Atsushi Okada*, Hiromasa Aoki, Daichi Onozato, Taiki Kato, Hiroshi Takase, Kazumi Taguchi, Tadahiro Hashita, Tamihide Matsunaga, Kenjiro Kohri, Takahiro Yasui, Nagoya, Japan

5:20 PD38-12 EFFECTS OF DRUG COATED URETERAL STENT ON URETERAL INFLAMMATION AND URINARY INFLAMMATORY MARKERS IN AN IN VIVO PORCINE MODEL
Ramakrishna Venkatesh*, Nick Staten, Michael Talcott, Suellen Greco, Colleen Haug, Neel Raval, Carlos Puyo, Saint Louis, MO

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Saturday, May 4, 2019

Video Session 6

BLADDER, UTUC & DIVERSION
The videos in this session as well as the video libraries from the 2012-2018 Annual Meetings may be viewed in the Surgical Video Library and purchased in the AUA Store during the Annual Meeting. AUA members receive free online access to the Surgical Video Library throughout the year through AUA University. Visit www.AUAnet.org/University to access.

Room W187b @ McCormick Place
Moderators: James Porter, Gilad Amiel & Kristen Scarpato

<table>
<thead>
<tr>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
</table>
| 3:30 | V06-12 | TECHNIQUE AND OUTCOMES OF LAPAROSCOPIC-ASSISTED CONTINENT CUTANEOUS ILEOCECOCYSTOPLASTY
Joshua Roth*, Minneapolis, MN, Ronak Gor, Camden, NJ, Joseph Pariser, Sean Elliott, Minneapolis, MN |
| 3:40 | V06-11 | URETERO NEOBLADDER REIMPLANTATION USING THE DA VINCI XI ROBOT AND THE FIREFLY® SYSTEM
Stefan Jeglinschi*, Brannwel Tibi, Daniel Chevallier, Matthieu Durand, Youness Ahallal, Nice, France |
| 3:50 | V06-10 | ROBOT-ASSISTED NEPHROURETERECTOMY WITH INFERIOR VENA CAVA THROMBECTOMY FOR POORLY DIFFERENTIATED VARIANT OF UROTHELIAL CARCINOMA OF RIGHT KIDNEY
Chih Wang*, Kaohsiung, Taiwan |
| 4:00 | V06-09 | SIMULTANEOUS PERINEAL URETHRECTOMY AND ROBOTIC RADICAL CYSTECTOMY WITH EXTENDED PELVIC LYMPH NODE DISSECTION AND INTRACORPOREAL ILEAL CONDUIT
Stefan Jeglinschi*, Imad Bentellis, Mathieu Carlier, Louis Denimal, Daniel Chevallier, Brannwel Tibi, Matthieu Durand, Youness Ahallal, Nice, France |
| 4:10 | V06-08 | ROBOT-ASSISTED RADICAL CYSTECTOMY AND HYBRID NEOBLADDER RECONSTRUCTION WITH THE AID OF GELPOINT DEVICE: TECHNICAL NUANCES AND PRELIMINARY RESULTS
Graziano Vignolini, Arcangelo Sebastianelli, Alessandro Pili, Campi Riccardo*, Francesco Sessa, Isabella Greco, Nicola Mormile, Pietro Spatafora, Mauro Gacci, Sergio Serni, Firenze, Italy |
| 4:20 | V06-07 | ROBOTIC-ASSISTED LAPAROSCOPIC NERVE SPARING CYSTECTOMY
Javier Estebanez Zarranz*, Laura Busto, Iitzor Crespo, Jon Belloso, Guillem Morales, Pablo Melendo, Ainara Villafruela, Adrian Recio, Juan Pablo Sanz, San Sebastian, Spain |
| 4:30 | V06-06 | EXTRAPERITONEAL LAPAROSCOPIC RADICAL NEPHROURETERECTOMY AND LYMPH NODE DISSECTION IN MODIFIED SUPINE POSITION
Qiang Liu*, Pengchao Li, Cao Qiang, Qian Jian, Xiao Yang, Nanjing, China, People’s Republic of China |
| 4:40 | V06-05 | APPLICATION OF A MODIFIED ORTHOTOPIC NEOBLADDER AFTER RADICAL CYSTECTOMY IN 16 PATIENTS
Shubo Fan*, GuangPiu Ding, Peng Hong, Han Hao, Xuesong Li, Liquan Zhou, Beijing, China, People’s Republic of China |
4:50 V06-04 SEX-SPARING VS STANDARD ROBOT ASSISTED RADICAL CYSTECTOMY WITH INTRACORPOREAL PADUA ILEAL NEOBLADDER IN FEMALE: STEP-BY-STEP SURGICAL TECHNIQUE, PERIOPERATIVE, ONCOLOGIC AND FUNCTIONAL OUTCOMES
Gabriele Tuderti*, Riccardo Mastroianni, Rocco Simone Flammia, Salvatore Guaglianone, Francesco Minisola, Umberto Anceschi, Leonardo Misuraca, Aldo Brassetti, Maria Consiglia Ferriero, Michele Gallucci, Giuseppe Simone, Rome, Italy

5:00 V06-03 ROBOT-ASSISTED LAPAROSCOPIC TRANSVAGINAL REPAIR OF ILEAL CONDUIT FISTULA TO VAGINA
Philip Wong*, Akshay Sood, Sriram Eleswarapu, James Peabody, Humphrey Atiemo, Detroit, MI

5:10 V06-02 NEOBLADDER-VAGINAL FISTULA
Philippe Zimmern*, Dallas, TX, Rena Malik, Baltimore, MD, Deborah Hess, Ganesh Raj, Dallas, TX

5:20 V06-01 ROBOT ASSISTED INTRACORPOREAL APPROACH TO W CONFIGURATION ILEAL NEOBLADDER; TECHNIQUE AND INITIAL EXPERIENCE.

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Moderator</th>
<th>Panelists</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:30</td>
<td>SECOND OPINION CASES (ASK THE GUIDELINES!): RECURRENT URINARY TRACT INFECTION</td>
<td>A. Lenore Ackerman</td>
<td>Toby Chai, Duane Hickling, Kimberly Kenton, Ann Stapleton, Jennifer Anger</td>
</tr>
<tr>
<td>8:00</td>
<td>PANEL DISCUSSION: NEW TECHNOLOGIES FOR DIAGNOSING UTIS</td>
<td>Elizabeth Mueller</td>
<td>Joseph Liao, J. Curtis Nickel</td>
</tr>
<tr>
<td>8:20</td>
<td>STATE-OF-THE-ART LECTURE: STDs AND THE CDC (CENTERS FOR DISEASE CONTROL AND PREVENTION)</td>
<td>Michel Pontari</td>
<td></td>
</tr>
<tr>
<td>8:35</td>
<td>PANEL DISCUSSION: THE URINARY MICROBIOME AND STONE DISEASE</td>
<td>Dirk Lange</td>
<td>Aaron Miller, Greg Tassin, Jeremy Burton</td>
</tr>
<tr>
<td>9:00</td>
<td>HIGHLIGHTS: SOCIETY FOR PEDIATRIC UROLOGY</td>
<td>Arun Srinivasan</td>
<td></td>
</tr>
<tr>
<td>9:15</td>
<td>JOURNAL OF UROLOGY HIGHLIGHTS: PEDIATRICS</td>
<td>Julian Wan</td>
<td></td>
</tr>
<tr>
<td>10:20</td>
<td>SURGICAL TECHNIQUES: TIPS &amp; TRICKS: 7 YEAR OLD MALE WITH A 9MM LP STONE</td>
<td>Lawrence Cisek</td>
<td>Michael Ost, John Thomas, Eugene Minevich</td>
</tr>
<tr>
<td>11:05</td>
<td>JOHN DUCKETT MEMORIAL LECTURE: THE NEUROGENIC BLADDER: WHERE WE WERE, WHERE WE ARE AND WHERE WE ARE GOING</td>
<td>Stuart Bauer</td>
<td></td>
</tr>
</tbody>
</table>

**APPROVED FOR AMA PRA CATEGORY 1 CREDIT™**

---

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Moderator</th>
<th>Panelists</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:30</td>
<td>HIGHLIGHTS: SEXUAL MEDICINE SOCIETY OF NORTH AMERICA (SMSNA)</td>
<td>Serge Carrier</td>
<td></td>
</tr>
<tr>
<td>7:40</td>
<td>PANEL DISCUSSION: NOVEL THERAPIES FOR ERECTILE DYSFUNCTION AND PEYRONIE'S DISEASE</td>
<td>Tom Lue</td>
<td>Ranjith Ramasamy, Trinity Bivalacqua, Georgios Hatzichristodoulou, Gerald Brock</td>
</tr>
<tr>
<td>8:10</td>
<td>PANEL DISCUSSION: MANAGEMENT OF CHRONIC SCROTAL PAIN</td>
<td>Nelson Bennett</td>
<td>Laurence Levine, Sijo Parekattil, Daniel Williams</td>
</tr>
<tr>
<td>8:40</td>
<td>COMPLEX CASES: ANDROGENS: CHARTING THE COURSE THROUGH THE SEA OF GUIDELINES</td>
<td>Abraham Morgentaler</td>
<td>Geoffrey Hackett, Mario Maggi, Michael Zitzmann, Adrian Dobs</td>
</tr>
<tr>
<td>9:10</td>
<td>PANEL DISCUSSION: DECREASED LIBIDO</td>
<td>John Mulhall</td>
<td>Mohit Khera, Landon Trost, Daniela Wittmann</td>
</tr>
<tr>
<td>9:40</td>
<td>SURVIVOR DEBATE: SEVERE ERECTILE DYSFUNCTION WITH 90 DEGREE CURVATURE, HOURGLASS DEFORMITY AND PENILE SHORTENING</td>
<td>Hossein Sadeghi-Nejad</td>
<td>Tobias Kohler, Brian Christine, Paulo Egydio, Run Wang</td>
</tr>
<tr>
<td>10:10</td>
<td>SURGICAL TECHNIQUES: TIPS &amp; TRICKS: VASOVASOSTOMY</td>
<td>Wayne Hellstrom</td>
<td>Larry Lipshultz, Marc Goldstein</td>
</tr>
</tbody>
</table>
10:40 CROSSFIRE: CONTROVERSIES IN UROLOGY: VASECTOMY REVERSAL SHOULD BE DONE EVEN IF THE SPouse IS 42 YEARS OLD
Moderator: Kirk Lo
Debaters - Pro: Armand Zini, Thomas Walsh
Debaters - Con: Cigdem Tanrikut

11:10 LBA-07: LATE-BREAKING ABSTRACT: EjACULATORY HOOD SPARING VS. STANDARD GREENLIGHT™ LASER PHOToselective vaporization of the prostate: Sexual and Urodynamic Assessment Through Randomized Control TRIA (RCT)
Presenter: Ahmed Elhussein Abolazm

11:19 AUA GUIDELINES UPDATE SURGICAL MANAGEMENT OF BPH
Presenter: Harris Foster

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Sunday, May 5, 2019
Plenary: Next Frontier, Sunday, Afternoon Session
1:00 pm - 5:05 pm
Room W375d @ McCormick Place

1:00 HIGHLIGHTS: BENIGN UROLOGIC RESEARCH
Presenter: Simon Hayward

1:10 LATE BREAKING ABSTRACTS: BENIGN
Moderators: Anthony Atala, Ajay Nangia

1:10 LBA-02: LATE-BREAKING ABSTRACT: INTERNATIONAL PHASE 3, DOUBLE-BLIND, PLACEBO- AND ACTIVE (TOLTERODINE)-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF VIBERGON IN PATIENTS WITH SYMPTOMS OF OVERACTIVE BLADDER: EMPOWUR
Presenter: David Staskin

1:19 LBA-03: LATE-BREAKING ABSTRACT: EFFICACY AND SAFETY OF MIRABEGRON VS. PLACEBO ADD-ON THERAPY IN MEN WITH OVERACTIVE BLADDER SYMPTOMS RECEIVING TAMUSOLIN FOR UNDERLYING BENIGN PROSTATIC HYPERPLASIA (PLUS)
Presenter: Steven Kaplan

1:28 LBA-04: LATE-BREAKING ABSTRACT: INTRADETRUSOR INJECTION OF ADULT MUSCLE-DERIVED CELLS FOR THE TREATMENT OF UNDERACTIVE BLADDER: INTERIM REPORT ON SAFETY AND EFFICACY (NCT02463448)
Presenter: Ananias Diokno

1:37 LBA-05: LATE-BREAKING ABSTRACT: TREATMENT OF URINARY URGENCY INCONTINENCE USING A NOVEL RECHARGEABLE SNM SYSTEM: 6-MONTH RESULTS OF THE ARTISAN-SNM STUDY
Presenter: Howard Goldman

1:46 LBA-06: LATE-BREAKING ABSTRACT: 12-MONTH FEASIBILITY DATA OF A FULLY-IMPLANTED, NICKEL-SIZED AND SHAPED TIBIAL NERVE STIMULATOR FOR THE TREATMENT OF OVERACTIVE BLADDER SYNDROME WITH URGENCY URINARY INCONTINENCE
Presenter: Scott MacDiarmid

1:55 HIGHLIGHTS: UROLOGIC ONCOLOGY RESEARCH
Presenter: Aria Olumi

2:05 LATE BREAKING ABSTRACTS: MALIGNANT
Moderators: Christopher Amling, Christopher Kane

2:05 LBA-08: LATE-BREAKING ABSTRACT: SCREENING OF BRCA2 MUTATED MEN FOR DETECTION OF PROSTATE CANCER: PRELIMINARY RESULTS FROM A NATIONAL HIGH VOLUME CANCER CENTER
Presenter: Massimo Lazzeri

2:14 LBA-09: LATE-BREAKING ABSTRACT: DAROLUTAMIDE DELAYS PROSTATE-SPECIFIC ANTIGEN PROGRESSION AND TIME TO NEXT ANTICANCER THERAPIES IN PATIENTS WITH NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Presenter: Neal Shore

2:23 LBA-10: LATE-BREAKING ABSTRACT: ARCHES – EFFICACY OF ANDROGEN DEPRIVATION THERAPY WITH ENZALUTAMIDE OR PLACEBO IN METASTATIC HORMONE-SENSITIVE PROSTATE CANCER: PROSTATE-SPECIFIC ANTIGEN RESULTS
Presenter: Arnulf Stenzl

2:32 LBA-11: LATE-BREAKING ABSTRACT: PAIREDCAP TRIAL: PROSPECTIVE ASSESSMENT OF IMAGE REGISTRATION IN DIAGNOSIS OF PROSTATE CANCER
Presenter: Rajiv Jayadevan
LBA-12: LATE-BREAKING ABSTRACT: CALGB 90203 (ALLIANCE): RADICAL PROSTATECTOMY WITH OR WITHOUT NEOADJUVANT CHEMOMORHONAL THERAPY IN MEN WITH CLINICALLY LOCALIZED, HIGH RISK PROSTATE CANCER
Presenter: James Eastham

LBA-13: LATE-BREAKING ABSTRACT: IMPROVED DETECTION OF INDETERMINATE RENAL MASS VASCULARITY WITH SUPERB MICRIVOCAULAR IMAGING
Presenter: Joon Yaw Leong

LBA-14: LATE-BREAKING ABSTRACT: COMPREHENSIVE CHARACTERISATION OF CIRCULATING TUMOUR DNA IN PLASMA AND URINE OF PATIENTS WITH RENAL TUMOURS: RESULTS OF THE DIAMOND AND MONREC STUDIES
Presenter: Grant Stewart

LBA-15: LATE-BREAKING ABSTRACT: RENAL HYPOTHERMIA DURING PARTIAL NEPHRECTOMY: A RANDOMIZED CONTROLLED TRIAL
Presenter: Ilias Cagiannos

LBA-16: LATE-BREAKING ABSTRACT: NEPHRON-SPARING MANAGEMENT OF LOW GRADE (LG) UTUC WITH UGN-101 (MITOMYCIN GEL) FOR INSTILLATION: THE OLYMPUS TRIAL EXPERIENCE
Presenter: Seth Lerner

LBA-17: LATE-BREAKING ABSTRACT: MULTICENTER PROSPECTIVE PHASE II CLINICAL TRIAL OF GEMCITABINE AND CISPLATIN AS NEOADJUVANT CHEMOTHERAPY IN PATIENTS WITH HIGH-GRADE UPPER TRACT UROTHELIAL CARCINOMA
Presenter: Nathan Wong

LBA-18: LATE-BREAKING ABSTRACT: PRELIMINARY PHASE 2 CLINICAL RESULTS OF IL-15RαFC SUPERAGONIST N-803 WITH BCG IN BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) PATIENTS DEMONSTRATES 82% CR OF CARCINOMA IN SITU (CIS)
Presenter: Sam Chang

LBA-19: LATE-BREAKING ABSTRACT: PHASE II TRIAL OF ESTROGEN RECEPTOR TARGETED TREATMENT OF NON-MUSCLE INVASIVE BLADDER CANCER WITH TAMOXIFEN
Presenter: Guilherme Godoy

LBA-20: LATE-BREAKING ABSTRACT: AUTOMATED CYSTOSCOPIC DETECTION OF BLADDER CANCER USING DEEP-LEARNING
Presenter: Eugene Shkolyar

LBA-21: LATE-BREAKING ABSTRACT: 68GA-PSMA-11 PET/CT DETECTS PROSTATE CANCER AT EARLY BIOCHEMICAL RECURRENCE WITH SUPERIOR DETECTION RATE AND READER AGREEMENT WHEN COMPARED TO 18F-FLUCICLOVINE PET/CT IN A PROSPECTIVE HEAD-TO-HEAD COMPARATIVE PHASE 3 STUDY
Presenter: Jeremie Calais

LBA-22: LATE-BREAKING ABSTRACT: PROSPECTIVE EVALUATION OF 18F-DCFPYL IN PATIENTS WITH BIOCHEMICALLY RECURRENT PROSTATE CANCER
Presenter: Andrei Iagaru

Presenter: Simone Crivellaro

LBA-24: LATE-BREAKING ABSTRACT: FIRST CLINICAL EVALUATION OF A NOVEL MAGNETIC RETRACTION DEVICE DURING REDUCED PORT ROBOTIC ASSISTED RADICAL PROSTATECTOMY (CLINICALTRIALS.GOV NCT03624465)
Presenter: Matthew Gettman

LBA-25: LATE-BREAKING ABSTRACT: RESIST-PC PHASE 2 TRIAL: 177LU-PSMA-617 RADIONUCLIDE THERAPY FOR METASTATIC CASTRATE-RESISTANT PROSTATE CANCER
Presenter: Jeremie Calais

LBA-26: LATE-BREAKING ABSTRACT: PIVOTAL TRIAL OF MRI-GUIDED TRANSURETHRAL ULTRASOUND ABLATION IN MEN WITH LOCALIZED PROSTATE CANCER
Presenter: Scott Eggener

*Presenting author

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
1:00  HIGHLIGHTS: SOCIETY OF URODYNAMICS, FEMALE PELVIC MEDICINE & UROGENITAL RECONSTRUCTION (SUFU)
Presenter: Aqsa Khan

1:10  PANEL DISCUSSION: VAGINAL PROCEDURES FOR FEMALE SEXUAL DYSFUNCTION
Moderator: Ashley Tapscott
Panelists: Irwin Goldstein, Andrew Goldstein, Gary Lemack

1:30  STATE-OF-THE-ART LECTURE: PRECISION MEDICINE IN BENIGN UROLOGY: MAPPING THE CLINICAL IMPLICATIONS OF PHENOTYPES AND CLUSTERS
Presenter: J. Quentin Clemens

1:45  COMPLEX CASES: PELVIC FLOOR SPASM IN MEN AND WOMEN
Moderator: Robert Moldwin
Panelists: Kenneth Peters, Daniel Shoskes, Alan Polackwich

2:15  DEBATE: MANAGEMENT OF PELVIC ORGAN PROLAPSE IN THE OCTAGENARIAN
Moderator: Michael Albo
Debater: J. Christian Winters, Jason Gilleran

2:35  PANEL DISCUSSION: NOCTURIA IN THE ELDERLY: NOT A BENIGN DISEASE
Moderator: TBD
Panelists: Tamsin Greenwell, Kari Tikkinen, Una Lee, William Reynolds

3:00  STATE-OF-THE-ART LECTURE: VAGINAL MESH – WHERE ARE WE IN 2019?
Presenter: Eric Rovner

3:10  COMPLEX CASES: PELVIC FLOOR MEDICINE
Moderator: David Ginsberg
Panelists: Claire Yang, Rose Khavari, Adonis Hijaz, Sherif Mourad, Marcus Drake

3:40  SURGICAL TECHNIQUES: TIPS & TRICKS: PUBOVAGINAL SLING
Moderator: Timothy Boone
Surgeons: Jennifer Anger, Ja-Hong Kim, Christian Twiss

4:30  SECOND OPINION CASES (ASK THE GUIDELINES!): INCONTINENCE AFTER PROSTATE TREATMENT
Moderator: Jaspreet Sandhu
Panelists: Ouida Westney, Benjamin Breyer, John Stoffel, Kurt McCammon, Daniel Kirages, Jeremy Ockrim

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
Sunday, May 5, 2019 6:45 am - 10:00 am

SOCIETY OF WOMEN IN UROLOGY (SWIU)
Prairie @ Hyatt McCormick

6:45 ANNUAL BUSINESS MEETING (SWIU MEMBERS ONLY) 8:45 SWIU AWARDS PRESENTATION
7:00 BREAKFAST & NETWORKING 9:05 SWIU ADVOCACY UPDATE
7:30 PRESIDENT'S WELCOME 9:15 NETWORKING
Society President: Teresa Beam
7:35 AUA UPDATE
AUA President-Elect: John Lynch
7:45 KEYNOTE ADDRESS: ADVANCES IN BLADDER CANCER - RECENT PROGRESS SHAPING CLINICAL CARE
Keynote Speaker: Cheryl Lee
8:45 SWIU AWARDS PRESENTATION
9:05 SWIU ADVOCACY UPDATE
Lindsey Kerr
9:15 NETWORKING
APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Sunday, May 5, 2019 7:00 am - 9:00 am

Moderated Poster Session 46
INFERTILITY: EPIDEMIOLOGY & EVALUATION II
Room W180 @ McCormick Place
Moderators: Ira Sharlip, Tung-chin Hsieh & Joseph Alukal

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP46-01</td>
<td>THE INITIAL MALE INFERTILITY EVALUATION AND PREGNANCY-- WHAT REALLY MATTERS? A STUDY FROM THE UTAH POPULATION DATABASE USING A PREDICTIVE ANALYSIS MODEL</td>
</tr>
<tr>
<td>Ross Anderson, Heidi Hanson, Chong Zhang, Angela Presson, Matthew Kingsbury, Timothy Jenkins, Ken Smith, James Hotaling*, Salt Lake City, UT</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP46-02</td>
<td>KRUGER (WHO5) STRICT MORPHOLOGY DOES NOT ADD CLINICAL VALUE OVER WHO 4TH EDITION CRITERIA</td>
</tr>
<tr>
<td>Gal Wald*, Russell Hayden, Miriam Felciano, Marc Goldstein, New York, NY</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP46-03</td>
<td>THE ASSOCIATION BETWEEN POPULAR DIETS AND SERUM TESTOSTERONE AMONG MEN IN THE UNITED STATES</td>
</tr>
<tr>
<td>Richard Fantus*, Joshua Halpern, Chicago, IL, Cecilia Chang, Evanston, IL, Mary Keeter, Nelson Bennett, Chicago, IL, Brian Helfand, Evanston, IL, Robert Brannigan, Chicago, IL</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP46-04</td>
<td>SERUM LIPID PROFILES ARE ASSOCIATED WITH SEMEN QUALITY AND HORMONAL MILIEU IN PRIMARY INFERTILE MEN – RESULTS OF A CROSS-SECTIONAL STUDY</td>
</tr>
<tr>
<td>Luca Boeri, Paolo Capogrosso, Eugenio Ventimiglia, Walter Cazzaniga, Edoardo Pozzi, Nicolò Schifano, Francesco Chierigo*, Federico Belladelli, Rani Zuabi, Costantino Abbate, Federico Dehò, Milan, Italy, Vincenzo Miron, Naples, Italy, Franco Gaboardi, Montanari Emanuele, Francesco Montorsi, Andrea Salonia, Milan, Italy</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP46-05</td>
<td>HORMONE STIMULATION PRIOR TO MICRO-TESE IMPROVES SUCCESS RATES IN KLINEFELTER SYNDROME PATIENTS</td>
</tr>
<tr>
<td>Arunan Sujenthiran, James Tracey, Philip Broussil*, Sheryl Homa, Yaser Dajani, Yulia Kopeika, Majed Shabbir, Tet Yap, London, United Kingdom</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP46-06</td>
<td>PERIPHERAL BLOOD CELL COUNTS OF AZOOSPERMIC MEN IN RELATION TO TESTICULAR HISTOPATHOLOGY</td>
</tr>
<tr>
<td>Shoichiro Iwatsuki*, Tomoki Takeda, Satoshi Nozaki, Takahiro Kobayashi, Yasue Kubota, Hiroki Kubota, Hiroyuki Kamiya, Yukihiro Unemoto, Takahiro Yasui, Nagoya, Japan</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP46-07</td>
<td>INABILITY TO OBTAIN SPERM FOR FRESH IVF CYCLES: ANALYSIS OF INCIDENCE AND OUTCOMES USING A NATIONAL DATABASE</td>
</tr>
<tr>
<td>Alexandra Berger*, Valary Raup, Ramy Abou Ghadya, Anne Thomas, Martin Kathrins, Boston, MA</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP46-08</td>
<td>REGRET REGARDING FERTILITY PRESERVATION DECISIONS AMONG MALE CANCER PATIENTS</td>
</tr>
<tr>
<td>Kelly Walker*, Joris Ramstein, James Smith, San Francisco, CA</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP46-09</td>
<td>GAY MEN SEEKING PARENTHOOD THROUGH ASSISTED REPRODUCTION: A PILOT STUDY FOR CREATION OF A STANDARDIZED QUESTIONNAIRE</td>
</tr>
<tr>
<td>Philip Cheng*, Salt Lake City, UT, Akanksha Mehta, Atlanta, GA, Alexander Pastuszak, James Hotaling, Salt Lake City, UT</td>
<td></td>
</tr>
</tbody>
</table>

*Presenting author
MP46-10 AN AT-HOME SYSTEM THAT ADAPTS TO DIFFERENT TYPES OF MOBILE PHONES FOR MEASURING SPERM MOTILITY—VERIFICATION OF ITS PERFORMANCE OF ARTIFICIAL INTELLIGENCE (AI) SPERM IMAGE RECOGNITION WITH CLOUD COMPUTING

Vincent Tsai*, Taoyuan, Taiwan, Bin Zhuang, Shenzhen, China, People's Republic of

MP46-11 PREVALENCE OF POSITIVE SEMEN CULTURES IN INFERTILE MEN WITHOUT LEUKOCYTOPSPERMA: A CROSS SECTIONAL STUDY

Walter Cazzaniga*, Paolo Capogrosso, Eugenio Ventimiglia, Luca Boeri, Edoardo Pozzi, Francesco Chieriga, Nicolò Schifano, Federico Belladelli, Rani Zuabi, Costantino Abbate, Federico Deò, Milan, Italy, Vincenzo Mirone, Naples, Italy, Franco Gaboardi, Francesco Montorsi, Andrea Salonia, Milan, Italy

MP46-12 CAN SEMEN PARAMETERS PREDICT CHROMOSOMAL ANOMALY IN MALE FACTOR INFERTILITY?

Chiung-Kun Huang*, Wei-Jen Chen, I-Shen Huang, Eric Yi-Hsiu Huang, William J.S. Huang, Taipei, Taiwan

MP46-13 PEAK RETROGRADE FLOW IN VARICOCELES INFLUENCES SPERM DNA INTEGRITY IN ADOLESCENTS.

Gunter De Win, Edegem, Belgium, Eline Coeck*, Sarah Stuer, Wilrijk, Belgium, Stefan De Wachter, Diane De Neubourg, Usha Punjabi, Edegem, Belgium

MP46-14 VARICOCELE AND MAY-THURNER SYNDROME: THE ETIOLOGICAL LINK.

Peter Chin*, Laurencia Villalba, Sean Huang, Lovelace Osei-Tutu, Wollongong, Australia

MP46-15 DEMOGRAPHIC, HEALTH STATUS, AND HEALTHCARE UTILIZATION CHARACTERISTICS OF MEN UNDERGOING VASECTOMY IN THE UNITED STATES

Michael Siev*, Michael Schulster, Wen Liu, Jesse Persily, Bobby Najari, New York, NY

MP46-16 PREDICTORS OF POST-VASECTOMY SEMEN ANALYSIS NON-COMPLIANCE

Alexandra Berger*, Valary Raup, Alexander Cole, Ramy Abou Ghadya, Michael O'Leary, Martin Kathrins, Boston, MA

MP46-17 POOR COMPLIANCE WITH POST-VASECTOMY SEMEN ANALYSIS: ANALYSIS OF FACTORS AND BARRIERS

Aaron Bradshaw*, Richmond Owusu, Eric Ballon-Landa, Tung-Chin Hsieh, San Diego, CA

MP46-18 A SYSTEMATIC EVALUATION OF YOUTUBE AS AN INFORMATION SOURCE FOR MALE INFERTILITY

Adithya Balasubramanian*, Justin Yu, Ashwin Srivatsav, Jabez Gondokusumo, Alexander J. Tatem, Jonathan A. Beilan, Asad Hasan, Houston, TX, James M. Hotaling, Salt Lake City, UT, Larry I. Lipshultz, Houston, TX, Alexander W. Pastuszak, Salt Lake City, UT

MP46-19 CHANGING PATTERNS OF MALE INFERTILITY TWITTER TRAFFIC BETWEEN 2015 AND 2018

Margaret G. English*, Hatim Thaker, Mary K. Samplaski, Los Angeles, CA

MP46-20 FINDING MALE FERTILITY CARE PRICES ONLINE-OPAQUE AT BEST

Jonathan A Seaman*, Omaha, NE, James M Dupree, Ann Arbor, MI, Christopher M. Deibert, Omaha, NE

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
<table>
<thead>
<tr>
<th>Abstract Number</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP47-02</td>
<td>Proteomic Analysis of Interstitial Cystitis Bladder Samples of Hunner's Lesions and Adjacent Tissue Reveals Alterations in Ubiquitination Pathways</td>
<td>Sarah N. Bartolone*, Elijah P. Ward, Michael B. Chancellor, Kenneth M. Peters, Laura E. Lamb, Royal Oak, MI</td>
</tr>
<tr>
<td>MP47-03</td>
<td>Chronic Exposure to Pentosan Polysulfate Sodium is Associated with Retinal Pigmentary Changes and Vision Loss</td>
<td>Jenelle Foote*, Adam Hanif, Nieraj Jain, Atlanta, GA</td>
</tr>
<tr>
<td>MP47-04</td>
<td>Cyclophosphamide-Induced Cystitis Triggers NLRP3-Dependent Neuroinflammation in the Hippocampus and Depression in Rats</td>
<td>Todd Purves*, Nathan Hirshman, Huixia Jin, Isabelle Doan, Simon White, Shelby Harper, Francis Hughes Jr., Durham, NC</td>
</tr>
<tr>
<td>MP47-05</td>
<td>Characterization of the “End Stage Bladder” in Chronic Cystitis</td>
<td>Giulia Lane*, Iryna Crescenze, Priyanka Gupta, Anne Cameron, Ann Arbor, MI</td>
</tr>
<tr>
<td>MP47-06</td>
<td>The Serum Proteome Correlates with Clinical Phenotypes of UCPPS: A MAPP Study</td>
<td>Jennifer Anger*, Weston Spivia, A. Lenore Ackerman, Karyn Elbier, Jayoung Kim, Qin Fu, Michael Freeman, Jennifer Van Eyk, Los Angeles, CA</td>
</tr>
<tr>
<td>MP47-07</td>
<td>Comparative Value of Chronic Urinary Tract Infection (UTI) Diagnosis Between Standard Culture Sensitivity and Next Generation Sequence (NGS) in Urine Samples</td>
<td>George Coba*, Timothy Koo, Salf Zaman, Tampa, FL, Maria Stefili, Matthew Dixon, Norwich, United Kingdom, Liqiang Ni, Orlando, FL, Michael McDonald, Celebration, FL, Vladimir Mouraviev, Orlando, FL</td>
</tr>
<tr>
<td>MP47-08</td>
<td>Opioid Prescription Use in Patients with Interstitial Cystitis</td>
<td>Matthew Clements*, C William Pike, Jacqueline Zillioux, David Rapp, Charlotte, VA</td>
</tr>
<tr>
<td>MP47-09</td>
<td>Comorbid Conditions in a Nationwide, Heterogeneous Population of Veterans with Interstitial Cystitis/Bladder Pain Syndrome</td>
<td>Bethany Laden*, Amanda De Hoedt, April Scharfenberg, Roopali Saxena, Justin Senechal, Durham, NC, Catherine Bresee, Jayoung Kim, Stephen Freedland, Jennifer Anger, Los Angeles, CA</td>
</tr>
<tr>
<td>MP47-10</td>
<td>Intravesical Tacrolimus Dissolved in Water is Absorbed Through Bladder Mucosa in Interstitial Cystitis (IC)/Bladder Pain Syndrome (IC/BPS)</td>
<td>Nagendra Nath Mishra*, Anand, India</td>
</tr>
<tr>
<td>MP47-11</td>
<td>Downregulation of Pro-Inflammatory Pathways by IPSE, a Urogenital Parasite-Derived Immunomodulatory Protein, Reduces Ifosfamide-Induced Hemorrhagic Cystitis</td>
<td>Evaristus Mbanefo*, Loc Le, Rockville, MD, Rebecca Zee, Washington DC, DC, Nirad Banskota, Rockville, MD, Kenji Ishida, Rockville, MD, Luke Pennington, Stanford, CA, Justin Odegaard, Redwood, CA, Theodore Jardetzky, Stanford, CA, Abdulaziz Alouffi, Franco Falcone, Nottingham, United Kingdom, Michael Hsieh, Washington DC, DC</td>
</tr>
<tr>
<td>MP47-12</td>
<td>Peroxisome Proliferator-Activated Receptor Gamma Agonist as a Novel Treatment for Interstitial Cystitis: A Rat Model</td>
<td>Craig Comiter*, Nichole Younglin, Arman Mahal, Amy Dobberfuhl, Stanford, CA</td>
</tr>
</tbody>
</table>
MP47-13 INTERSTITIAL CYSTITIS/BLADDER PAINFUL SYNDROME: THE USE OF PALMITOYLETHANOLAMIDE/POLYDATIN AS ADD-ON THERAPY IN PAIN-RESISTANT PATIENTS
Marilena Gubbiotti*, Perugia, Italy, Antonella Giannantoni, Siena, Italy

MP47-14 BLADDER DYSFUNCTION, ENHANCED PAIN SENSATION AND MOLECULAR CHANGES IN BLADDER MUCOSA INDUCED BY PSYCHOLOGICAL STRESS IN RATS
Tetsuichi Saito*, Shinsuke Mizoguchi, Masahiro Kurobe, Jianshu Ni, Daisuke Gotoh, Pradeep Tyagi, Pittsburgh, PA, Osamu Ishizuka, matsumoto, Japan, Naoki Yoshimura, Pittsburgh, PA

MP47-15 GENE EXPRESSION PROFILES OF BLADDER MUCOSA STRATIFIES IC/BPS PATIENTS BASED ON ANESTHETIZED BLADDER CAPACITY
Stephen Walker*, Jeffrey Schachar, Gopal Badiani, Catherine Matthews, Joao Zambon, Robert Evans, Winston Salem, NC

MP47-16 PUDENDAL NEUROMODULATION FOR PELVIC PAIN: OPTIMIZING PATIENT SELECTION
Iryna Crescenze, Giulia Lane*, Priyanka Gupta, Ann Arbor, MI

MP47-17 FEMALE LOWER URINARY TRACT MICROBIOTA DO NOT CORRESPOND TO IC/PBS SYMPTOMS: A CASE-CONTROLLED STUDY.
Larissa Bresler*, Travis Price, Lauren Westbay, Cara Joyce, Mary Tulke, Colleen Fitzgerald, Alan Wolf, Maywood, IL

MP47-18 SIMPLE CYSTECTOMY FOR FEMALE PATIENTS WITH REFRACTORY INTERSTITIAL CYSTITIS/BLADDER PAIN SYNDROME: IS THERE ANY LONG-TERM IMPACT ON QUALITY OF LIFE, BODY IMAGE, AND SEXUAL FUNCTION?
Joao Zambon*, Kshipra Hemal, Robert Evans, Gopal Badiani, Steve Walker, Andre Plair, Whitney Smith, Candice Parker-Autry, Catherine Matthews, Winston Salem, NC

MP47-19 THE RULE OF INTRA-VESICAL GENTAMICIN (IVG) AS PROPHYLAXIS FOR RECURRENT UTIS AND ITS IMPACT ON QOL IN INTRACTABLE UTI.
Abdel Hamid Hamed, Jenny Jones*, Suzanne Mcphee, Ayr, United Kingdom, Ursula Allmeyer, Kilmarnock, United Kingdom, Robert N Meddings, Brian Little, Holly Bekarma, Ayr, United Kingdom

MP47-20 ACUPUNCTURE FOR FEMALE PAINFUL BLADDER SYNDROME: A RANDOMIZED CONTROLLED TRIAL.
Larissa Bresler*, Lauren Westbay, Cara Joyce, Mary Tulke, Colleen Fitzgerald, Alan Wolf, Maywood, IL

MP47-21 DOES CANCER GRADE IMPACT MRI ACCURACY IN ESTIMATING LESION SIZE FOR PROSTATE FOCAL THERAPY?

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
MP48-02 DISCONTINUATION OF ACTIVE SURVEILLANCE OF MEN WITH GG2 PCA: ASSESSMENT OF 14 CENTRES IN 8 COUNTRIES IN THE MOVEMBER GAP3 CONSORTIUM
Jozien Helleman*, Sebastiaan Remmers, Daan Nieboer, Chris Bangma, Monique Roobol, Rotterdam, Netherlands, Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3), Melbourne, Australia

MP48-03 TRACKING, TARGETING, AND DE NOVO TUMOR DEVELOPMENT IN MEN UNDERGOING ACTIVE SURVEILLANCE

MP48-04 ACTIVE SURVEILLANCE OF MEN YOUNGER THAN 60: ASSESSMENT OF DIFFERENCES IN DISCONTINUATION AND TREATMENT CHOICE IN THE MOVEMBER GAP3 CONSORTIUM
Sebastiaan Remmers*, Jozien Helleman, Daan Nieboer, Chris. H. Bangma, Monique J. Roobol, Rotterdam, Netherlands, Movember Foundation’s Global Action Plan Prostate Cancer Active Surveillance (GAP3) consortium, Melbourne, Australia

MP48-05 COMPARATIVE OUTCOMES OF GLEASON GRADE 2 AND 3 PROSTATE CANCER ON INITIAL VERSUS CONFIRMATORY BIOPSY: IMPLICATIONS FOR ACTIVE SURVEILLANCE
Samuel Haywood*, Amy Tin, James Eastham, Vincent Laudone, Karim Touijer, Peter Scardino, Andrew Vickers, Behfar Ehdaiie, New York, NY

MP48-06 EVALUATING PERCEIVED SUGGESTION OF TREATMENT RECOMMENDATION FOR MEN WITH LOW RISK PROSTATE CANCER

MP48-07 THIRTY-YEAR NATIONWIDE POPULATION-BASED FOLLOW-UP OF MEN ON ACTIVE SURVEILLANCE FOR PROSTATE CANCER: WHO BENEFITS THE MOST? A STATE-TRANSITION ANALYSIS
Eugenio Ventimigila*, Milan, Italy, Mieke Van Hemelrijck, London, United Kingdom, Lars Lindhagen, Pär Stattin, Uppsala, Sweden, Hans Garmo, London, United Kingdom

MP48-08 THE LONG-TERM OUTCOMES OF GRADE GROUPS 2 AND 3 PROSTATE CANCER MANAGED BY ACTIVE SURVEILLANCE: RESULTS FROM A LARGE POPULATION-BASED COHORT
Patrick Richard*, Saint-denis-de-Brampton, QC, Canada, Narhari Timishina, Maria Komisarenko, Lisa Martin, Ardalan Ahmad, Shabbir Aliabhai, Robert Hamilton, Girish Kulkarni, Antonio finelli, Toronto, Canada

MP48-09 GRADE RECLASSIFICATION IN ACTIVE SURVEILLANCE FOR AFRICAN AMERICAN MEN WITH VERY LOW RISK PROSTATE CANCER
Demetrios Simopoulos*, Patricia Landis, Jonathan Epstein, H. Ballentine Carter, Michael Gorin, Mufaddal Mamawala, Baltimore, MD

MP48-10 USING PROGNOSIS TO GUIDE INCLUSION CRITERIA, STRATIFY FOLLOW UP AND DEFINE STANDARDIZED END-POINTS IN ACTIVE SURVEILLANCE FOR PROSTATE CANCER
Vincent Gnnaprapagasam*, Tristan Barrett, Vineetha Thankappannair, David Thurtle, Cambridge, United Kingdom, Ola Bratt, Gothenburg, Sweden, Par Stattin, Uppsala, Sweden, Kenneth Muir, Arttaya Lophatananon, Manchester, United Kingdom

MP48-11 USE OF CONSERVATIVE MANAGEMENT FOR VERY LOW RISK PROSTATE CANCER IN THE VETERANS AFFAIRS INTEGRATED HEALTHCARE SYSTEM
Stacy Loeb*, Danil Makarov, Nataliya Byrne, Dawn Walter, NEW YORK, NY

MP48-12 ACTIVE SURVEILLANCE OF VERY LOW AND LOW RISK PROSTATE CANCER: LONG-TERM OUTCOMES FROM A LARGE PROSPECTIVE COHORT
Mufaddal Mamawala*, Baltimore, MD, Jeffrey Tosoian, Ann Arbor, MI, Jonathan Epstein, Patricia Landis, Demetrios Simopoulos, Katarzyna Macura, Michael Gorin, H. Ballentine Carter, Baltimore, MD

MP48-13 A NOVEL PREDICTOR OF CLINICAL PROGRESSION IN PATIENTS ON ACTIVE SURVEILLANCE FOR PROSTATE CANCER
Guan Hee Tan*, Antonio Finelli, Ardalan Ejaz Ahmad, Marian Wettstein, Alexandre Zlotta, Neil Fleschner, Robert Hamilton, Girish Kulkarni, Khaled Ajib, Gregory Nason, Nathan Perlis, Toronto, Canada

MP48-14 OUTCOMES OF RADICAL PROSTATECTOMY AFTER A PERIOD OF ACTIVE SURVEILLANCE
Ashwin Balakrishnan*, Janet Cowan, Peter Carroll, San Francisco, CA

MP48-15 EVALUATION OF POTENTIAL BIAS IN RISK FACTOR ASSESSMENT IN THE CANARY PROSTATE ACTIVE SURVEILLANCE STUDY (PASS)

*Presenting author
MP48-16 ATENOLOL REDUCES INCIDENT LOW AND INTERMEDIATE RISK PROSTATE CANCER

Ali Zahalka*, Ethan Fram, Wilson Lin, Larkin Mohn, Paul Frenette, Ilir Agalli, Kara Watts, Bronx, NY

MP48-17 DO PROGRESSION RATES ON FOLLOW-UP BIOPSY OVER TIME DIFFER BETWEEN MEN WITH VERY LOW RISK AND LOW RISK PROSTATE CANCER ON ACTIVE SURVEILLANCE?


MP48-18 IS PSA ‘SCREENING’ BEHAVIOUR ASSOCIATED WITH UPTAKE OF ACTIVE SURVEILLANCE IN MEN WITH LOW RISK PROSTATE CANCER?


MP48-19 NEED FOR INTERVENTION AND SURVIVAL IN A COHORT OF PATIENTS ON ACTIVE SURVEILLANCE FOR PROSTATE CANCER


MP48-20 PREDICTORS OF UPGRADING IN A DIVERSE GROUP OF MEN ELECTING ACTIVE SURVEILLANCE.


APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
MP49-07 A MODIFIED PATHOLOGICAL TUMOR STAGING SYSTEM FOR SURVIVAL PREDICTION OF PATIENTS WITH PENILE CANCER
Li Zaishang, Shenzhen, China, People’s Republic of, Han Hui*, Zhou Fangqian, Guangzhou, China, People’s Republic of

MP49-08 IS AGE AN INDEPENDENT PREDICTOR FOR SURVIVAL OUTCOMES IN PENILE CANCER
Louise English*, Mehran Afshar, Lisa Pickering, Alison Tree, Benjamin Ayres, Nick Watkin, London, United Kingdom

MP49-09 ADJUVANT CHEMOTHERAPY IN THE TREATMENT OF LYMPH NODE POSITIVE SQUAMOUS CELL CARCINOMA OF THE PENIS: ANALYSIS OF THE NATIONAL CANCER DATA BASE
Valary Raup, Julie Szymaniak*, Nawar Hanna, Alexandra Berger, Jairam Eswara, Boston, MA

MP49-10 PROGNOSTICATORS OF INGUINAL LYMPH NODE METASTASIS AND SURVIVAL IN CLINICAL NODE-NEGATIVE SQUAMOUS CELL CARCINOMA PATIENTS
Mounsif Azizi*, Tampa, FL, David C. Boulware, Tampa, FL, Salim K. Cherian, Charles C. Peyton, Tampa, FL, Salvatore Lo Vullo, Luigi Mariani, Milan, Italy, Yao Zhu, Ding-Wei Ye, Shanghai, China, People’s Republic of, Antonio Ornellas, Rio de Janeiro, Brazil, Nick Watkin, Michael Ager, London, United Kingdom, Oliver Hakenberg, Rostock, Germany, Daniele Raggi, Mario Catanzaro, Roberto Salvioni, Roberto Salvioni, Milan, Italy, Juan Chipollini, Scott M. Gilbert, Tampa, FL, Andrea Necchi, Milan, Italy, Philippe E. Spiess, Tampa, FL

MP49-11 RESULTS OF A 10 YEAR MULTICENTRE EXPERIENCE OF ADJUVANT RADIOTHERAPY FOR PN3 SQUAMOUS CELL CARCINOMA OF THE PENIS (SCCP)
Michael Ager*, London, United Kingdom, Kelechi Njoku, Leeds, United Kingdom, Maria Serra, Mehran Afshar, Lisa Pickering, London, United Kingdom, Sharon Beesley, Maidstone, United Kingdom, Angus Roninson, Brighton, United Kingdom, Peric Crellin, Poole, United Kingdom, Lona Vyas, Mamoun Elmammoun, Oliver Kayes, Ian Eardley, Leeds, United Kingdom, Benjamin Ayres, London, United Kingdom, Ann Henry, Leeds, United Kingdom, Alison Tree, Nick Watkin, London, United Kingdom

MP49-12 PENILE AND UTERINE CERVICAL SQUAMOUS CELL CARCINOMAS: A COMPARATIVE GENOMIC PROFILING STUDY

MP49-13 IMPACT OF MISMANAGEMENT ON QUALITY OF LIFE IN TESTICULAR CANCER SURVIVORS
Joshua Aizen*, Ciro Andolfi, Chicago, IL, Madeleine Burg, Los Angeles, CA, Nimrod Barashi, Brittany Adamic, Craig Labbate, Chicago, IL, Siamak Daneshmand, Los Angeles, CA, Scott Eggener, Chicago, IL

MP49-14 PRIMARY TUMOR SIZE THRESHOLDS IN STAGE IA TESTICULAR SEMINOMA: IMPLICATIONS FOR ADJUVANT THERAPY AFTER ORCHIECTOMY AND SURVIVAL

MP49-15 SURVEILLANCE CT ALGORITHM FOR NODE POSITIVE SQUAMOUS CELL CARCINOMA OF THE PENIS
Michael Ager*, Aditya Manjunath, Sylvia Yan, Cathy Corbishley, Brendan Tinwell, Mehran Afshar, Alison Tree, Benjamin Ayres, Nick Watkin, London, United Kingdom

MP49-16 A CONTEMPORARY REVIEW OF MIDLINE EXTRAPERITONEAL RETROPERITONEAL LYMPH NODE DISSECTION FOR TESTICULAR GERM CELL TUMOR
Madeleine L. Burg*, Laya Jacob, Saum Ghodoussipour, Shane M. Pearce, Suneeet Bhanavadia, Hooman Djadidat, Anne K. Schuckman, Siamak Daneshmand, Los Angeles, CA

MP49-17 INTERNATIONAL MULTI-CENTER ANALYSIS OF FACTORS PREDICTING THE PRESENCE OF NON-SENTINEL NODE INGUINAL METASTASES IN PENILE CANCER PATIENTS UNDERGOING COMPLETION INGUINAL LYMPH NODE DISSECTION FOLLOWING POSITIVE SENTINEL NODE BIOPSY
Jennifer Nowers*, Mehran Afshar, London, United Kingdom, Sarah Ottenhof, Rosa Djadidinigrat, Amsterdam, Netherlands, Caroline English, London, United Kingdom, Wayne Lam, Hong Kong, Hong Kong, Benjamin Ayres, London, United Kingdom, Simon Horenblas, Amsterdam, Netherlands, Nick Watkin, London, United Kingdom

*Presenting author
### MP49-18 NATIONAL MANAGEMENT TRENDS IN CLINICAL STAGE IIA NON-SEMINOMATOUS GERM CELL TUMOR (NSGCT) AND OPPORTUNITIES TO AVOID DUAL THERAPY
Ryan Werntz*, Craig Labbate, Vignesh Packiam, Scott Eggener, Chicago, IL

### MP49-19 RACIAL DISPARITIES BETWEEN BLACK AND WHITE MEN WITH TESTICULAR CANCER
Alexandr Pinkhasov*, Ruben Pinkhasov, Garrett Smith, Michael Daneshvar, Stephanie Gleicher, Jeffrey Johnson, Oleg Shapiro, Elizabeth Ferry, Gennady Bratslavsky, Joseph Jacob, Syracuse, NY

### MP49-20 CORRELATION BETWEEN MICRORNAs AND mRNA EXPRESSION PROFILES WITH THE PROGNOSIS OF CLINICALLY LOCALIZED PENILE CANCER.
Claudio Murta*, Sao Paulo, Brazil, Jose Pontes Jr, Tatiane Furuya, Miyuki Uno, Alexis Carrasco, Rafael Coelho, Giuliano Guglielmetti, Mauricio Cordeiro, Sheila Faraj, Katia Leite, Laura Sichero, Luisa Villa, Miguel Srougi, Roger Chammaas, William Nahas, Sao Paulo, Brazil

### APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

**Moderated Poster Session 50**

**BLADDER CANCER: UPPER TRACT TRANSITIONAL CELL CARCINOMA I**

**Room W181ab @ McCormick Place**

**Moderators:** Kamal Pohar, Mantu Gupta & Anup Patel

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>MP50-01</strong></td>
<td>PERCUTANEOUS BIOPSY FOR UPPER TRACT UROTHELIAL CARCINOMA - SAFETY AND DIAGNOSTIC ACCURACY</td>
</tr>
<tr>
<td><strong>Jason Joseph</strong>*, Amir Toussi, Theodora Potretzke, Tanner Miest, Thomas Atwell, Bradley Leibovich, Matthew Tollefson, Aaron Potretzke, Rochester, MN</td>
<td></td>
</tr>
<tr>
<td><strong>MP50-02</strong></td>
<td>PREOPERATIVE PREDICTIVE FACTORS FOCUSED ON INFLAMMATION-, NUTRITION-, AND MUSCLE-STATUS IN PATIENTS WITH UPPER UINARY TRACT UROTHELIAL CARCINOMA UNDERGOING NEPHROURETERECTOMY</td>
</tr>
<tr>
<td><strong>Yoshitaka Itami</strong>*, Makito Miyake, Shunta Hori, Yosuke Morizawa, Kota Iida, Kenta Ohnishi, Takuya Owari, Yasushi Nakai, Nobumichi Tanaka, Shuya Hirao, Kiyohide Fujimoto, Kashihara, Nara, J apan</td>
<td></td>
</tr>
<tr>
<td><strong>MP50-03</strong></td>
<td>ENDOSCOPIC TREATMENT FOR UPPER URINARY TRACT UROTHELIAL CARCINOMA – DOES SIZE MATTER?</td>
</tr>
<tr>
<td><strong>Asaf Shvero</strong>*, Dont Zilberman, Menahem Laufer, Yasmin Abu-Ghanem, Zohar A, Dotan, Eddie Fridman, Orith Portnoy, Jacob Ramon, Harry Winkler, Nir Kleinmann, Ramat Gan, Israel</td>
<td></td>
</tr>
<tr>
<td><strong>MP50-04</strong></td>
<td>ADJUVANT SINGLE-DOSE UPPER URINARY TRACT INSTILLATION OF MITOMYCIN C AFTER THERAPEUTIC URETEROSCOPY FOR UPPER TRACT UROTHELIAL CARCINOMA: PRELIMINARY RESULTS</td>
</tr>
<tr>
<td><strong>Andrea Gallioli</strong>*, Alberto Breda, Helena Vila-Reyes, Angelo Territo, Romain Boissier, Francesco Sanguedolce, Olga Mayordomo, Federica Regis, Joan Palou Redorta, Barcelona, Spain</td>
<td></td>
</tr>
<tr>
<td><strong>MP50-05</strong></td>
<td>IMPACT OF BACILLUS CALMETTE-GUÉRIN THERAPY OF UPPER URINARY TRACT CARCINOMA IN SITU: COMPARISON OF ONCOLOGICAL OUTCOMES WITH RADICAL NEPHROURETERECTOMY</td>
</tr>
<tr>
<td><strong>Hirotaka Horiguchi</strong>*, Shingo Hatakeyama, Hayato Yamamoto, Atsushi Imai, Takahiro Yoneyama, Yasuhiro Hashimoto, Hiroaki, J apan, Takuya Koie, Gifu, J apan, Chikara Ohyama, Hiroaki, J apan</td>
<td></td>
</tr>
<tr>
<td><strong>MP50-06</strong></td>
<td>COULD LAPAROSCOPIC SURGERY HAVE SAME LONG-TERM ONCOLOGICAL OUTCOMES AS OPEN RADICAL NEPHROURETERECTOMY IN T3N0M0 UPPER TRACT UROTHELIAL CARCINOMA? A MULTICENTER COHORT STUDY ADJUSTED BY PROPSENSITY SCORE MATCHING</td>
</tr>
<tr>
<td><strong>Keisuke Shigeta</strong>*, Eiji Kikuchi, Takayuki Abe, Masayuki Hagiwara, Koichiro Oghira, Toshikazu Takeda, Kauhiro Matsumoto, Ryuichi Mizuno, Masahiro Jinzaki, Mototsugu Oya, Tokyo, J apan</td>
<td></td>
</tr>
<tr>
<td><strong>MP50-07</strong></td>
<td>THE SURVIVAL PREDICTION WITH TIME OF INTRAVESICAL RECURRENCE IN UPPER TRACT UROTHELIAL CARCINOMA</td>
</tr>
<tr>
<td><strong>Koichiro Ogihara</strong>*, Eiji Kikuchi, Masayuki Hagiwara, Ryuichi Mizuno, Mototsugu Oya, Tokyo, J apan</td>
<td></td>
</tr>
<tr>
<td><strong>MP50-08</strong></td>
<td>SIMULATING THE SURVEILLANCE DURATION OF INTRAVESICAL RECURRENCE AFTER RADICAL NEPHROURETERECTOMY: AN INDIVIDUALIZED RISK BASED APPROACH APPLYING THE WEBULL MODEL</td>
</tr>
<tr>
<td><strong>Shigeta Keisuke</strong>*, Eiji Kikuchi, Masayuki Hagiwara, Takayuki Abe, Koichiro Oghira, Ryuichi Mizuno, Mototsugu Oya, Tokyo, J apan</td>
<td></td>
</tr>
</tbody>
</table>
MP50-09 BLADDER RECURRENCE IN PATIENTS WITH UPPER TRACT UROTHELIAL CARCINOMA
Joseph Cheaib*, Ross Liao, Mohit Gupta, Max Kates, Michael Johnson, Noah Hahn, Jean Hoffman-Censits, Trinity Bivalacqua, Phillip Pierorazio, Baltimore, MD

MP50-10 PATHOLOGICAL ROLES OF PROGRAMMED DEATH LIGAND 1 EXPRESSION IN PATIENTS WITH UPPER TRACT UROTHELIAL CARCINOMA: CORRELATION WITH VASCULAR ENDOTHELIAL GROWTH FACTOR-A, MATRIX METALLOPROTEINASE (MMP)-2 AND -9, AND CYCLOOXYGENASE-2
Yuji Sagara*, Yasuyoshi Miyata, Kyohei Araki, Yuichiro Nakamura, Takuji Yasuda, Tomohiro Matsuo, Kojiro Ohba, Hideki Sakai, Nagasaki, Japan

MP50-11 PARALLELS BETWEEN IMMUNOHISTOCHEMICAL CLASSIFICATION OF UPPER AND LOWER TRACT UROTHELIAL CARCINOMA USING MARKERS OF UROTHELIAL DIFFERENTIATION
Tetsutaro Hayashi*, Kazuhiro Sentani, Hiroshima, Japan, Kenichiro Ikeda, Vancouver, Canada, Keisuke Goto, Hawaii, Hi, Htoo Zarni Oo, Vancouver, Canada, Hamidreza Abdi, Ottawa, Canada, Shunsuke Shinmei, Shogo Inoue, Jun Teishima, Wataru Yasui, Hiroshima, J apan, Peter C Black, Vancouver, Canada, Akio Matsubara, Hiroshima, J apan

MP50-12 GENOMIC LANDSCAPE DEFINES MOLECULAR SUBTYPES OF UPPER TRACT UROTHELIAL CARCINOMA
Xuesong Li*, Huan Lu, Bao Guan, Liqun Zhou, Juan Li, Zhengzheng Xu, Qun He, Ding Peng, Weimin Ci, Yue Shi, Beijing, China, People’s Republic of

MP50-13 DEVELOPING A PREDICTION MODEL FOR DISEASE-FREE SURVIVAL FROM UPPER URINARY TRACT UROTHELIAL CARCINOMA IN THE KOREAN POPULATION: A RETROSPECTIVE MULTICENTER STUDY
Sung Han Kim, Mi Kyung Song, Bumsik Hong, Goyang, Korea, Republic of, Seok Ho Kang, Byong Chang Jeong, Ja Hyeon Ku, seoul, Korea, Republic of, Ho Kyung Seo*, Goyang, Korea, Republic of

MP50-14 PERIOPERATIVE AND ONCOLOGIC OUTCOME OF UPPER TRACT UROTHELIAL CARCINOMA WITH VARIANT HISTOLOGY FOLLOWING RADICAL NEPHROURETERECTOMY
Willem Xu*, Saum Ghodoussipour, Gus Miranda, Jie Cai, Anne Schuckman, Siamak Dameshmand, Hooman Djaladat, Los Angeles, CA

MP50-15 SITE SPECIFIC DIFFERENCES IN SURVIVAL AMONG BLADDER, RENAL PELVIC, AND URETERAL UROTHELIAL CARCINOMA PATIENTS TREATED WITH RADICAL SURGERY.
Tadatsugu Anno*, Eiji Kikuchi, Koichiro Oghara, Mototsugu Oya, Tokyo, J apan

MP50-16 NOVEL PERIOPERATIVE PARAMETERS-BASED NOMOGRAMS FOR SURVIVAL OUTCOMES IN UPPER TRACT UROTHELIAL CARCINOMA AFTER RADICAL NEPHROURETERECTOMY
PING TAN*, HANG XU, LU YANG, QIANG WEI, Chengdu, China, People’s Republic of

MP50-17 PROGNOSTIC VALUE OF THE SYSTEMIC INFLAMMATION MODIFIED GLASGOW PROGNOSTIC SCORE IN PATIENTS WITH UPPER TRACT UROTHELIAL CARCINOMA (UTUC) TREATED WITH RADICAL NEPHROURETERECTOMY: RESULTS FROM A LARGE MULTICENTER INTERNATIONAL COLLABORATION.
Francesco Soria*, Turin, Italy, David D’Andrea, Vienna, Austria, Jose Karam, Christopher Wood, Houston, TX, Morgan Rouprêt, Paris, France, Vitaly Margulis, Dallas, TX, Pierre Karakiewicz, Montreal, Canada, Alberto Briganti, Milan, Italy, Jay Raman, Hershey, PA, Karim Bensalah, Rennes, France, Yair Lotan, Dallas, TX, Paolo Gontier, Turin, Italy, Mesut Remzi, Kilian Guat, Shahroksh Shariat, Vienna, Austria

MP50-18 OPTIMIZING THE SEQUENCE OF CHEMOTHERAPY IN UPPER TRACT UROTHELIAL CARCINOMA WITH CLINICALLY POSITIVE REGIONAL LYMPH NODES
Nicholas Chakiryan*, Ann Martinez-Acevedo, Linda Gao, Jen Jane Liu, Christopher Amling, Mark Garzotto, Ryan Kopp, Portland, OR

MP50-19 PATIENTS UNDERGOING LYMPH NODE DISSECTION FOR UPPER TRACT UROTHELIAL CARCINOMA HAVE IMPROVED OVERALL SURVIVAL: RESULTS FROM SEER DATABASE
Michael Daneshvar*, Michael Daugherty, Oleg Shapiro, Syracuse, NY

MP50-20 IMPLICATIONS OF DISCORDANT DIAGNOSTIC TO FINAL SURGICAL PATHOLOGY IN HIGH-GRADE UPPER TRACT UROTHELIAL CARCINOMA
Joseph Cheaib*, Ross Liao, Mohit Gupta, Max Kates, Michael Johnson, Noah Hahn, Jean Hoffman-Censits, Trinity Bivalacqua, Phillip Pierorazio, Baltimore, MD

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
<table>
<thead>
<tr>
<th>Abstract Number</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP51-01</td>
<td>HYAL4: FIRST STUDY ON A MOLECULAR DRIVER AND POTENTIAL BIOMARKER OF INVASIVE BLADDER CANCER</td>
</tr>
<tr>
<td>Soum Lokeshwar*, Miami, FL, Daley Moreira, Sarrah Lahorewala, Zachary Klaassen, Augusta, GA, Bruce Kava, Miami, FL, Vinata Lokeshwar, Augusta, GA</td>
<td></td>
</tr>
<tr>
<td>MP51-02</td>
<td>TUMOR TARGETING HYALURONIC ACID NANOPARTICLES WITH COMBINED PHOTOTHERAPY AND HYPOXIA-ACTIVATED CHEMOTHERAPY FOR BLADDER PRESERVATION IN MIBC</td>
</tr>
<tr>
<td>Tingsheng Lin*, Nanjing, China, People's Republic of</td>
<td></td>
</tr>
<tr>
<td>MP51-03</td>
<td>INHIBITION OF G9A BY A SMALL MOLECULE INHIBITOR, UNC0642, INDUCES APOPTOSIS OF HUMAN BLADDER CANCER CELLS</td>
</tr>
<tr>
<td>Xiang Yan*, Nanjing, China, People's Republic of</td>
<td></td>
</tr>
<tr>
<td>MP51-04</td>
<td>AN L-TYPE AMINO ACID TRANSPORTER 1 INHIBITOR: JPH203 SUPPRESSES BLADDER CANCER GROWTH AND INVASION VIA IGFBP-5</td>
</tr>
<tr>
<td>Mahulian Maimaiti*, Shinichi Sakamoto, Masahiro Sugihara, Minhui Xu, Yasutaka Yamada, Kosuke Higuchi, Keisuke Ando, Nobushige Takeshita, Akira Komiyama, Yuzuru Ikehara, Chiba, Japan, Yoshikatsu Kanai, Osaka, Japan, Naohiko Anzai, Tomohiko Ichikawa, Chiba, Japan</td>
<td></td>
</tr>
<tr>
<td>MP51-05</td>
<td>PHGDH CAN BE A THERAPEUTIC TARGET IN BLADDER CANCER</td>
</tr>
<tr>
<td>Yoichi Osako*, Hirofumi Yoshino, Masaya Yonemori, Shuichi Tatarano, Hideki Enokida, Masayuki Nakagawa, Kagoshima, Japan</td>
<td></td>
</tr>
<tr>
<td>MP51-06</td>
<td>SMYD3 INHIBITION INDUCES PROTECTIVE AUTOPHagy IN BLADDER CANCER VIA mTOR PATHWAY</td>
</tr>
<tr>
<td>Cheng Liu*, Beijing, China, People's Republic of, Luchao Li, Jilin, China, People's Republic of, Lulin Ma, Beijing, China, People's Republic of</td>
<td></td>
</tr>
<tr>
<td>MP51-07</td>
<td>TRANSGELIN PROMOTES BLADDER CANCER INVASION THROUGH REGULATING INVADOPODIA FORMATION</td>
</tr>
<tr>
<td>Zhicong Chen*, Yonghao Zhan, Shiming He, Xuesong Li, Ligun Zhou, Beijing, China, People's Republic of</td>
<td></td>
</tr>
<tr>
<td>MP51-08</td>
<td>PANOBINOSTAT AND RITONAVIR CAUSE BLADDER CANCER APOPTOSIS BY INDUCING ENDOPLASMIC RETICULUM STRESS AND HISTONE ACETYLATION SYNERGISTICALLY</td>
</tr>
<tr>
<td>Akinori Sato*, Takako Asano, Makoto Isono, Kazuki Okubo, Tokorozawa, Japan</td>
<td></td>
</tr>
<tr>
<td>MP51-09</td>
<td>COBICISTAT, A POTENT CYP3A4 INHIBITOR, ACTS SYNERGISTICALLY WITH OPROZOMIB TO CAUSE ENDOPLASMIC RETICULUM STRESS IN BLADDER CANCER CELLS</td>
</tr>
<tr>
<td>Akinori Sato*, Takako Asano, Makoto Isono, Kazuki Okubo, Tokorozawa, Japan</td>
<td></td>
</tr>
<tr>
<td>MP51-10</td>
<td>ATF2 PROMOTES UROTHELIAL TUMORIGENESIS AND TUMOR PROGRESSION VIA THE ANDROGEN RECEPTOR PATHWAY</td>
</tr>
<tr>
<td>MP51-11</td>
<td>EPIGENETIC REGULATION OF FORKHEAD BOX A1 IN ADVANCED BLADDER CANCER</td>
</tr>
<tr>
<td>Jenna Buckwalter*, Vasty Osei-Ampoas, Lauren Shuman, Vonin Walter, Joshua Warrick, Hershey, PA, Xue-Ru Wu, New York, NY, Ray Raman, David DeGraff, Hershey, PA</td>
<td></td>
</tr>
<tr>
<td>MP51-12</td>
<td>INACTIVATION OF FOXA1 COOPERATES WITH PTEN COPY NUMBER LOSS IN BLADDER CANCER TO PROMOTE TUMOR HETEROGENEITY</td>
</tr>
<tr>
<td>MP51-13</td>
<td>HYPER-PHOSPHORYLATION OF PTEN IS A PRINCIPAL MECHANISM OF PTEN INACTIVATION IN HUMAN BLADDER CANCER</td>
</tr>
<tr>
<td>Feng He, Fenglin Zhang, Yan Liu*, Ellen Shapiro, Herbert Lepor, Moon-shong Tang, Chuanshu Huang, Xue-Ru Wu, New York, NY</td>
<td></td>
</tr>
</tbody>
</table>
MP51-14 HYPERCHOLESTEROLEMIA PROMOTES THE PROGRESSION OF BLADDER CANCER IN SEVERAL MICE MODELS.
Lin Yang*, Jun Yan, Hongqian Guo, Nanjing, China, People’s Republic of China

MP51-15 PREDICTIVE VALUE AND POTENTIALS FOR CO-TARGETED THERAPY OF STAT1 SIGNALING IN GEMCITABINE/CISPLATIN RESISTANT BLADDER CANCER
Tetsutaro Hayashi, Hiroshima, Japan, Kenichiro Ikeda*, Vancouver, Canada, Roland Seiler, Bern, Switzerland, Robert H Bell, Susan Ettinger, Kendric Wang, Htoo Zarni Oo, Hamidreza Abdi, Wolfgang Jaeger, Tilman Todenhoefer, Colin Collins, Vancouver, Canada, Akio Matsubara, Hiroshima, Japan, Peter C Black, Vancouver, Canada, Peter C Black, Vancouver, Canada, Akio Matsubara, Hiroshima, Japan

MP51-16 SPIRONOLACTONE, A NUCLEOTIDE EXCISION REPAIR INHIBITOR, POTENTIATES CYTOTOXIC EFFECT OF CISPLATIN IN BLADDER CANCER CELLS
Dongbo Xu*, Li Wang, Yue Wu, Gary Smith, Eric Kauffman, James Mohler, David Goodrich, Qiang Li, Buffalo, NY

MP51-17 CIRCULAR RNA CDR1AS SENSITIZES BLADDER CANCER TO CISPLATIN BY SPONGING MIR-1270 AND REGULATING APAF1 EXPRESSION
Qiang Lu*, Xiao Yang, Wenbo Yuan, Rui Zhou, Jingzi Wang, Jie Han, Hao Yu, Hongcheng Lu, Pengchao Li, Jun Tao, Haiwei Yang, Min Gu, Nanjing, China, People’s Republic of China

MP51-18 ESR1-MEDIATED ALTERATION OF CIRC_0023642 AND MIR-490-5P SIGNALING SUPPRESSES INVASION OF BLADDER CANCER
Zhenyu Ou*, Yongjie Wang, Longxiang Wu, Mengda Zhang, Long Wang, Changsha, China, People’s Republic of China

MP51-19 LONG NON-CODING RNA DANCR PROMOTES MALIGNANT PHENOTYPES OF BLADDER CANCER CELLS BY MODULATING THE MIR-149 / MSI2 AXIS
Yonghao Zhao*, Zhicong Chen, Shiming He, Xuesog Li, Liquan Zhou, Beijing, China, People’s Republic of China

MP51-20 LONG NONCODING RNA DANCR FACILITATES METASTASIS AND PROLIFERATION IN BLADDER CANCER CELLS BY ACTIVATING IL-11-STAT3 SIGNALING
Xu Chen*, Ziyue Chen, Ruihui Xie, Ming Huang, Qianghua Zhou, Jingtong Zhang, Jian Huang, Tianxin Li, Guangzhou, China, People’s Republic of China

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Sunday, May 5, 2019 7:00 am - 9:00 am
Podium Session 39
TRAUMA/RECONSTRUCTION/DIVERSION: TRANSITIONAL UROLOGY & GU CONGENITALISM
Room W179b @ McCormick Place
Moderators: John Lacy, Rosalia Misseri & Melissa Kaufman

<table>
<thead>
<tr>
<th>ABSTRACT</th>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00</td>
<td>PD39-01</td>
<td></td>
<td>VAGINOPLASTY IN ADOLESCENTS AND YOUNG ADULTS BORN WITH BLADDER EXSTROPHY</td>
</tr>
<tr>
<td>7:10</td>
<td>PD39-02</td>
<td></td>
<td>“IF EVERYONE ELSE IS HAVING THIS TALK WITH THEIR DOCTOR, WHY AM I NOT HAVING THIS TALK WITH MINE?”: THE EXPERIENCES OF SEXUALITY AND SEXUAL HEALTH EDUCATION OF YOUNG WOMEN WITH SPINA BIFIDA</td>
</tr>
<tr>
<td>7:20</td>
<td>PD39-03</td>
<td></td>
<td>“WE CAN SET YOU UP FOR AN ABORTION!”: THE IMPORTANCE OF REPRODUCTIVE HEALTH TO YOUNG WOMEN WITH SPINA BIFIDA AND THE LACK OF SUPPORT FROM THEIR DOCTORS</td>
</tr>
<tr>
<td>7:30</td>
<td>PD39-04</td>
<td></td>
<td>VARIABILITY IN KIDNEY FUNCTION ESTIMATES IN EMERGING ADULTS WITH SPINA BIFIDA: IMPLICATIONS FOR TRANSITIONAL CARE</td>
</tr>
</tbody>
</table>

*Presenting author
7:40 PD39-05 DEMOGRAPHICS AND BASELINE CARE AMONG NEWLY TRANSITIONING ADULT CONGENITAL UROLOGY PATIENTS
Natalia Leva*, San Francisco, CA, Kathryn Quanstrom, Ann Arbor, MI, Puneet Kamal, Hillary Copp, Lindsay Hampson, San Francisco, CA

7:50 PD39-06 MENTAL HEALTH AND SOCIAL ISOLATION IN ADULTS WITH CONGENITAL UROLOGIC CONDITIONS
Aron Liaw*, San Francisco, CA, Nima Baradaran, Columbus, OH, Kathryn Quanstrom, Benjamin Breyer, Hillary Copp, Lindsay Hampson, San Francisco, CA

8:00 PD39-07 SEXUAL SATISFACTION IN ADULTS WITH GENITOURINARY CONGENITALISM: RESULTS FROM A POPULATION BASED SURVEY STUDY
Nima Baradaran*, Columbus, OH, Elaine Allen, Kathryn Quanstrom, Michael Sadighian, Aron Liaw, Hillary Copp, Benjamin Breyer, Lindsay Hampson, San Francisco, CA

8:10 PD39-08 LONG-TERM URINARY CONTINENCE OUTCOMES IN CLASSIC BLADDER EXSTROPHY
Mahir Maruf*, Jason Michaud, Matthew Kasprenski, Mohammad Zaman, Karl Benz, John Jayman, Marlo Eldridge, Heather Di Carlo, John Gearhart, Baltimore, MD

8:20 PD39-09 PATTERNS OF CARE AND OUTCOMES AROUND TRANSITION IN PATIENTS WITH SPINAL DYSraphISM: A POPULATION-BASED STUDY IN ONTARIO, CANADA
Rano Matta*, Christopher J.D. Wallis, Humberto Vigil, Armando Lorenzo, Ronald T. Kodama, Robert K. Nam, Sidney B. Radomska, Lesley K. Carr, Sender Herschorn, Toronto, Canada

8:30 PD39-10 MANAGEMENT OF PELVIC ORGAN PROLAPSE IN THE ADULT CONGENITAL GENITOURINARY PATIENT
Jeremy Lair*, Antoinette Oot, Diana Bowen, Stephanie Kielb, Chicago, IL

8:40 PD39-11 ADMISSION RATES AMONG ADULT SPINA BIFIDA PATIENTS PRESENTING TO THE EMERGENCY ROOM
Oluwarotimi Netty*, Beverly Onyekwuji, Alicia Roston, Stephanie Kielb, Chicago, IL

8:50 PD39-12 UNDERSTANDING CAREGIVERS AND CAREGIVER BURDEN AMONG THOSE CARING FOR PATIENTS WITH CONGENITAL UROLOGIC CONDITIONS
Michael Sadighian*, Elaine Allen, San Francisco, CA, Nima Baradaran, Columbus, OH, Kathryn Quanstrom, Benjamin Breyer, Hillary Copp, Lindsay Hampson, San Francisco, CA

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
7:40 PD40-05 LYMPH NODE YIELD AND METASTATIC PATTERN AFTER EXTENDED PELVIC LYMPH NODE DISSECTION IN ROBOTIC-ASSISTED LAPAROSCOPIC PROSTATECTOMY: 14 YEARS OF EXPERIENCE
Silvan Sigg*, Fabienne Lehner, Etienne Xavier Keller, Karim Saba, Tullio Sulser, Daniel Eberli, Ashkan Mortezaei, Zurich, Switzerland

7:50 PD40-06 A COMPARATIVE STUDY OF ROBOT-ASSISTED LAPAROSCOPIC AND OPEN RETROPUBIC RADICAL PROSTATECTOMY IN 10,790 MEN TREATED BY HIGHLY TRAINED SURGEONS FOR BOTH PROCEDURES – THE MARTINI-KLINIK EXPERIENCE
Alexander Haese, Hendrik Isbarn, Sophie Knipper*, Hans Heinzer, Derya Tilki, George Salomon, Uwe Michl, Thomas Steuber, Lars Budäus, Tobias Maurer, Pierre Tennstedt, Hartwig Huland, Markus Graefen, Hamburg, Germany

8:00 PD40-07 VALIDATION OF AN EASILY APPLICABLE QUESTIONNAIRE-SUITED COMORBIDITY INDEX IN 5050 CONSECUTIVE PATIENTS UNDERGOING RADICAL PROSTATECTOMY
Michael Froehner, Ulrike Heberling*, Christoph Heitmann, Samaneh Farahzadi, Marcus Lindner, Angelika Borkowetz, Rainer Koch, Matthias Hübner, Manfred P. Wirth, Dresden, Germany

8:10 PD40-08 IMPACT OF POSITIVE SURGICAL MARGIN AND NERVE-SPARING STATUS ON BIOCHEMICAL RECURRENCE IN PATIENTS WITH PROSTATE CANCER TREATED WITH RADICAL PROSTATECTOMY: A MULTICENTER RETROSPECTIVE STUDY

8:20 PD40-09 EVALUATING THE IMPACT OF LENGTH OF TIME FROM DIAGNOSIS TO SURGERY IN PATIENTS WITH UNFAVORABLE INTERMEDIATE TO VERY HIGH-RISK CLINICALLY LOCALIZED PROSTATE CANCER
Natasha Gupta*, Trinity J. Bivalacqua, Misop Han, Michael A. Gorin, Baltimore, MD, Ben J. Challacombe, London, United Kingdom, Alan W. Partin, Mufaddal K. Mamawala, Baltimore, MD

8:30 PD40-10 MORTALITY FOLLOWING RADICAL PROSTATECTOMY (RP) OR INTENSITY MODULATED RADIATION THERAPY (IMRT) FOR LOCALIZED PROSTATE CANCER (PCA) – AN ANALYSIS OF THE CDC PROSTATE CANCER DATA QUALITY AND PATTERNS OF CARE STUDY (CDC POC-BP)
Kenan Celtik*, Houston, TX, Christopher Wallis, Toronto, Canada, Mary Lo, Ann Hamilton, Los Angeles, CA, Steven Fleming, Lexington, KY, Xiao-Cheng Wu, New Orleans, LA, Roger Anderson, Charlottesville, VA, Brian Miles, Raj Satkunasivam, Houston, TX

8:40 PD40-11 THE ROLE OF 68GA-PSMA PET-CT IN INITIAL STAGING OF TREATMENT-NAÏVE HIGH RISK PROSTATE CANCER.

8:50 PD40-12 IMPACT OF SINGLE DOSE PERIOPERATIVE ENOXAPARIN ON RATE OF THROMBOEMBOLIC EVENTS FOLLOWING ROBOTIC ASSISTED PROSTATECTOMY: A HOSPITAL SYSTEM-WIDE ANALYSIS
Nabeel Shakir*, Daniel Wong, Jeffrey Cadeddu, Claus Roehrborn, Dallas, TX

*Presenting author

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
<table>
<thead>
<tr>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00</td>
<td>PD41-01</td>
<td>RADIOFREQUENCY ABLATION-ASSISTED, CLAMPLESS ROBOTIC PARTIAL NEPHRECTOMY WITH INTRAOPERATIVE PATHOLOGY EVALUATION: EIGHT-YEAR, 187-CONSECUTIVE PATIENT EXPERIENCE</td>
</tr>
<tr>
<td>7:10</td>
<td>PD41-02</td>
<td>FEASIBILITY OF OMITTING OUTER (CORTICAL) RENORRHAPHY DURING ROBOTIC PARTIAL NEPHRECTOMY - A MULTI-INSTITUTIONAL ANALYSIS</td>
</tr>
<tr>
<td>7:20</td>
<td>PD41-03</td>
<td>THREE DIMENSIONAL VOLUMETRICS OF INFERIOR VENA CAVA TUMOR THROMBUS PREDICTS SURGICAL OUTCOMES</td>
</tr>
<tr>
<td>7:30</td>
<td>PD41-04</td>
<td>IMPACT OF SHORT WARM ISCHEMIC TIME ON RENAL FUNCTION AFTER PARTIAL NEPHRECTOMY FOR RENAL CELL CARCINOMA IN PATIENTS WITH PRE-EXISTING CHRONIC KIDNEY DISEASE STAGE III: A MULTIINSTITUTIONAL PROPENSITY SCORE-MATCHED STUDY</td>
</tr>
<tr>
<td>7:40</td>
<td>PD41-05</td>
<td>PROPENSITY SCORE MATCHED COMPARISON OF MINIMALLY INVASIVE PARTIAL AND RADICAL NEPHRECTOMY FOR CLINICAL T2A RENAL MASS: ANALYSIS OF THE ROBOTIC SURGERY FOR LARGE RENAL MASSES (ROSULA) GROUP</td>
</tr>
</tbody>
</table>
7:50 PD41-06 RATE AND TYPE OF SURGICAL INTERVENTION FOR T1A KIDNEY CANCER IN THE UNITED STATES FROM 2011 TO 2015
Clark Higganbotham*, Cameron Britton, Brian Cross, Jonathan Heinten, Oklahoma City, OK

8:00 PD41-07 PREDICTING FUNCTIONAL OUTCOMES AFTER PARTIAL NEPHRECTOMY
Hajime Tanaka*, Yanbo Wang, Yunlin Ye, Chalarat Suk-Ouchai, Diego Aguilar Palacios, Elvis R. Caraballo, Erick M. Remer, Jianbo Li, Robert Abouassaly, Steven C. Campbell, Cleveland, OH

8:10 PD41-08 CHRONIC KIDNEY DISEASE AND END-STAGE RENAL DISEASE AFTER RADICAL OR PARTIAL NEPHRECTOMY FOR T1A RENAL CELL CARCINOMA: A POPULATION-BASED STUDY
Madhur Nayan*, Olli Saarela, Keith Lawson, Lisa Martin, Maria Komisarenko, Antonio Finelli, Toronto, Canada

8:20 PD41-09 DOES SELECTIVE CLAMPING IMPROVE KIDNEY FUNCTION DURING ROBOT-ASSISTED PARTIAL NEPHRECTOMY? A PROPENSITY SCORE MATCHED COMPARISON OF DIFFERENT CLAMPING TECHNIQUES.
Junya Furukawa*, Nobuyuki Hinata, Yuzo Nakano, Masato Fujisawa, Kobe, Japan

8:30 PD41-10 PHASE III TRIAL OF INTRAVENOUS MANNITOL VERSUS PLACEBO DURING NEPHRON SPARING SURGERY: 3-YEAR OUTCOMES

8:40 PD41-11 ASSOCIATION OF ELEVATED C-REACTIVE PROTEIN WITH ONCOLOGIC OUTCOMES IN RENAL CELL CARCINOMA: A MULTICENTER ANALYSIS

8:50 PD41-12 RENAL MASS BIOPSY MAY IMPACT SURGICAL TREATMENT DECISION MAKING IN PATIENTS WITH A >4CM RENAL MASS: A MULTI-INSTITUTIONAL ANALYSIS
Aeen Asghar*, Andrew McIntosh, Philadelphia, PA, Zachary Smith, Chicago, IL, Neil Kocher, Hershey, PA, Zihu Lee, Philadelphia, PA, Nimrod Barashi, Chicago, IL, Jay Raman, Hershey, PA, Scott Eggener, Chicago, IL, Robert Uzzo, Alexander Kutikov, Philadelphia, PA

*Sponsoring author

Approved for AMA PRA Category 1 Credit™
SECONDARY INTERVENTION DUE TO SYMPTOMATIC URETERAL STONES IS NOT NECESSARY IN THE MAJORITY OF PATIENTS AFTER PREVIOUS STENTING

OUTCOMES OF ENDouroLOGIC INTERVENTIONS IN PATIENTS WITH PRE-OPERATIVE FUNGURIA

TEMPERATURE RISE DURING LASER LITHOTRIPSY: COMPARISON OF SUPER PULSE THULIUM FIBER LASER (SPTF) VS HIGH POWER 120W HOLMIUM-YAG LASER (HO:YAG)

THE RISE AND FALL OF DANGEROUS TEMPERATURE CHANGES DURING URETEROSCOPIC LASER LITHOTRIPSY

RISK FACTORS FOR SEPSIS FOLLOWING PERCUTANEOUS NEPHROLITHOTOMY IN THE UNITED KINGDOM

ARE ANTIBIOTICS NECESSARY DURING ROUTINE CYSTOSCOPIC STENT REMOVAL? A RANDOMIZED CONTROLLED TRIAL AT UC SAN DIEGO

SYSTEMATIC REVIEW AND META-ANALYSIS OF CYCLING AND ERECTILE DYSFUNCTION

ACCESS GAPS TO ED TREATMENTS FOR MEN WITH EMPLOYER-SPONSORED HEALTH INSURANCE

EFFECTIVENESS OF DIFFERENT POSTOPERATIVE ANALGESICS IN THE MANAGEMENT OF ACUTE PAIN AFTER URETEROSCOPY.

EFFECTS OF SILICONE HYDROCOATED DOUBLE LOOP URETERAL STENT (DJ) ON SYMPTOMS AND QUALITY OF LIFE IN PATIENTS UNDERGOING F-URS FOR KIDNEY STONE: FINAL RESULTS OF A PROSPECTIVE RANDOMIZED MULTICENTRE CLINICAL STUDY

CAN TAMsULOSIN OR MIRABEGRON IMPROVE RIGID URETEROLITHOTRIPSY OUTCOMES: PROSPECTIVE RANDOMIZED STUDY

EFFECTIVENESS OF DIFFERENT POSTOPERATIVE ANALGESICS IN THE MANAGEMENT OF ACUTE PAIN AFTER URETEROSCOPY.

IMPACT OF SURGICAL TREATMENT OF PENILE FRACTURE ON SEXUAL FUNCTION

EFFECTIVENESS OF DIFFERENT POSTOPERATIVE ANALGESICS IN THE MANAGEMENT OF ACUTE PAIN AFTER URETEROSCOPY.

EFFECTS OF SILICONE HYDROCOATED DOUBLE LOOP URETERAL STENT (DJ) ON SYMPTOMS AND QUALITY OF LIFE IN PATIENTS UNDERGOING F-URS FOR KIDNEY STONE: FINAL RESULTS OF A PROSPECTIVE RANDOMIZED MULTICENTRE CLINICAL STUDY

CAN TAMsULOSIN OR MIRABEGRON IMPROVE RIGID URETEROLITHOTRIPSY OUTCOMES: PROSPECTIVE RANDOMIZED STUDY

EFFECTIVENESS OF DIFFERENT POSTOPERATIVE ANALGESICS IN THE MANAGEMENT OF ACUTE PAIN AFTER URETEROSCOPY.

IMPACT OF SURGICAL TREATMENT OF PENILE FRACTURE ON SEXUAL FUNCTION

EFFECTIVENESS OF DIFFERENT POSTOPERATIVE ANALGESICS IN THE MANAGEMENT OF ACUTE PAIN AFTER URETEROSCOPY.
CHARACTERIZING THE RISK FACTORS OF RECURRENT PRIAPISM: A POPULATION BASED STUDY

EXTERNAL VALIDATION OF A PRIAPISM QUESTIONNAIRE IN A JAMAICAN COHORT OF SICKLE CELL DISEASE PATIENTS
Ayodeji Sotimehin*, Bruce Trock, Baltimore, MD, Uzoma Anele, Richmond, VA, Wendy Madden, Belinda Morrison, Kingston, Jamaica, Arthur Burnett, Baltimore, MD

PHOSPHODIESTERASE-5 INHIBITORS AND THE RISK OF MELANOMA: NO SIGNIFICANT PUBLIC HEALTH RISK.
George Wayne*, Miami Beach, FL, Bryan Herzog, Elias Atri, Miami, FL, Maurillo Garcia, Juan Cedeno, Elizabeth Nagoda, Alan Polackwich, Miami Beach, FL

WHAT IS THE FACTOR INFLUENCING ERECTILE DYSFUNCTION AFTER ACUTE MYOCARDIAL INFARCTION?
Phil Hyun Song*, Daegu, Korea, Republic of, Gyeong Eun Min, Seoul, Korea, Republic of, Yeong Uk Kim, Jae Young Choi, Young Hwi Ko, Hee Chang Jung, Jong Seon Park, Ki Hak Moon, Daegu, Korea, Republic of

LONGITUDINAL RISK OF DEVELOPING CARDIOVASCULAR DISEASES AMONG PATIENTS WITH ERECTILE DYSFUNCTION - WHICH PATIENTS DESERVE MORE ATTENTION?

THE EFFECTS OF POPULAR DIETS ON ERECTILE FUNCTION AMONG MEN IN THE UNITED STATES
Richard Fantus*, Joshua Halpern, Chicago, IL, Cecilia Chang, Evanston, IL, Mary Keeter, Chicago, IL, Brian Helfand, Evanston, IL, Robert Brannigan, Nelson Bennett, Chicago, IL

CURRENT CUT-OFF VALUE FOR PEAK SYSTOLIC VELOCITY AND RESISTANCE INDEX UNDER PENILE DOPPLER ULTRASOUND NOT ADEQUATE ENOUGH FOR PATIENT WITH ERECTILE DYSFUNCTION
Sheng-Yung Tung, Yi-Kai Chang, Hong-Chiang Chang, Tsung-Dau Wang, Lee Wen-Jeng, Shih-Ping Liu, Ju-Ton Hsieh, Wei-Lun Huang*, Taipei, Taiwan

PREOPERATIVE ERECTILE DYSFUNCTION IS A PROXY OF CHRONIC KIDNEY DISEASE AFTER SURGERY FOR RENAL CELL CARCINOMA - A PILOT STUDY
Paolo Capogrosso*, Umberto Capitano, Alessandro Larcher, Eugenio Ventimiglia, Walter Cazzaniga, Francesco Trevisani, Daniela Canibus, Cristina Carenzi, Franco Gaboardi, Roberto Bertini, Francesco Montorsì, Andrea Salonia, Milan, Italy

PROMIS INTEREST IN SEXUAL ACTIVITY AND SATISFACTION WITH SEX LIFE MEASURES IN MEN WITH PROSTATE CANCER UNDERGOING RADICAL PROSTATECTOMY
Nnenaya Agochukwu*, Daniela Wittmann, Nicholas Boileau, Rodney Dunn, James Montle, Tae Kim, David Miller, James Peabody, Noelle Carozzi, for the Michigan Urological Surgery Improvement Collaborative, Ann Arbor, MI

*Presenting author

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
7:10  V07-08  LAPAROSCOPIC PEDIATRIC PYELOPLASTY USING THE FLEXDEX® ARTICULATING NEEDLE DRIVER

7:20  V07-03  ROBOTIC ILEO-VAGINOPLASTY IN A PATIENT WITH CONGENITAL VAGINAL AGENESIS.
  Rana Kumar*, mohammad mahmoud, Mohan S Gundeti, CHICAGO, IL

7:30  V07-05  COMPLETE PRIMARY REPAIR OF BLADDER EXSTROPHY IN THE GIRL: RISK FACTORS FOR URINARY RETENTION LESSONS LEARNED AND CURRENT TECHNIQUE

7:40  V07-07  DIAGNOSTIC LAPAROSCOPY IN CLOACAL EXSTROPHY
  Evalynn Vasquez*, Paul Kokorowski, Roger De Filippo, Christopher Gayer, Cathy Shin, Los Angeles, CA

7:50  V07-04  ROBOT-ASSISTED LAPAROSCOPIC AUGMENTATION IEOCYSTOPLASTY AND MITROFANOFF APPENDICOVESICOSTOMY (RALIMA): UNIVERSITY OF CHICAGO EXPERIENCE
  Brittany Adamic*, Lakshmi Kirkire, Ciro Andolfi, Joshua Aizen, Craig Labbate, Mohan Gundeti, Chicago, IL

8:00  V07-02  ANASTOMOTIC POSTERIOR URETHROPLASTY IN FIRST YEAR OF LIFE
  Sanjay Kulkarni*, Ayman Mousa, Shreyas Badranavar, Amar Rawal, Pankaj Joshi, Pune, India

8:10  V07-01  ROBOT ASSISTED LAPAROSCOPIC EXTRAVESICAL CROSS-TRIGONAL URETERAL RE-IMPLANTATION WITH TAILORING FOR OBSTRUCTIVE MEGA-URETER.
  Amos Neheman*, Jonathan Gal, Leon CHERTIN, Tzrifin, Israel, Jaudat Gaber, Stanislav Kocherov, Jerusalem, Israel, Amnon Zisman, Tzrifin, Israel, Paul Noh, Cincinnati, OH, Boris Chertin, Jerusalem, Israel

8:20  V07-09  THE KIDNEY THAT WASN'T
  Anne-Sophie Blais, Douglas Cheung, Fadi Zu’bi*, Martin Koyle, Wald Farhat, Toronto, Canada

8:30  V07-12  ROBOT-ASSISTED LAPAROSCOPIC TRANSPLANT URETERAL REIMPLANTATION AND MITROFANOFF
  Rachel Shannon*, Deborah L Jacobson, Elizabeth B Yerkes, Edward M Gong, Chicago, IL

8:40  V07-10  NOVEL COMPRESSIVE BULBAR SLING VIA SCROTAL MOBILIZATION
  Gregory Dean*, Nathan Peffer, Zihno Lee, Martin Herman, Voorhees, NJ

8:50  V07-06  NONDISMEMBERED URETEROCYSTOSTOMY FOR OBSTRUCTING MEGAURETER USING THE DAVINCI ROBOT
  Chirag Gordhan*, Rebecca Zee, Michael Hsieh, Washington, DC

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Sunday, May 5, 2019
7:00 am - 11:00 am

Forums

RESIDENTS FORUM
Room 470 @ McCormick Place

7:00  REGISTRATION
7:15  WELCOME
  Program Chair: Kevin Koo
7:20  SPONSOR TALK
7:40  PANEL: MANUSCRIPT WRITING & REVIEWING
  Panelists: Toby Chai, Todd Morgan, Joseph Smith, Hadley Wood
8:00  QUESTIONS & DISCUSSION

8:05  CONTRACT NEGOTIATION: WHAT RESIDENTS NEED TO KNOW
  Roger Bonds
8:25  QUESTIONS & DISCUSSION
8:35  AUA RESIDENTS & FELLOWS COMMITTEE TEACHING AWARD PRESENTATION
8:50  AUA OFFICE OF EDUCATION
9:00  AMERICAN BOARD OF UROLOGY
  Society Secretary: Gerald Jordan
9:05 BREAK
9:20 ROUNDTABLE: NON-TRADITIONAL PRACTICE
Panelists: Aseem Shukla, Gary Kirsh, Joseph Macaluso
9:50 ROUNDTABLE: TRADITIONAL PRACTICE
Panelists: Cheryl Lee, Michael Lipkin Eugene Rhee, Sanford Siegel, Aaron Spitz

10:35 AUA YOUNG UROLOGISTS COMMITTEE
Chair: Sero Andonian
10:45 RAFFLE & CLOSING REMARKS
10:50 LUNCH & ADJOURN

Sunday, May 5, 2019 7:30 am - 11:30 am
Forums
BASIC SCIENCES SYMPOSIUM: SOCIAL (AND ANTISOCIAL) CELL SIGNALING NETWORKS IN THE URINARY TRACT
Room W471 @ McCormick Place

7:30 WELCOME AND OPENING REMARKS
Program Chair: Simon Hayward
Research Council Chair: Aria Olumi

7:40 SESSION ONE: INTRINSIC AND INFILTRATING CELL TYPES OF THE URINARY TRACT
Moderator: William Ricke
EXTRACELLULAR MATRIX-CELL INTERACTIONS IN THE BLADDER
Darius Bagli
CELL TYPES OF DEVELOPMENT, HOMEOSTASIS, AND DISEASE IN THE UROGENITAL TRACT
Chad Vezina
A CELLULAR ANATOMY OF HUMAN BPH
Douglas Strand
IDENTIFYING THE TROUBLEMAKERS (CELLS AND PATHWAYS) IN BPH WITH MULTISPECTRAL IMAGING
Teresa Liu

11:00 CLOSING REMARKS
Program Chair: Simon Hayward
11:05 POSTER SESSION
APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Sunday May 5, 2019 7:50 am - 3:30 pm
ENGINEERING & UROLOGY SECTION OF THE ENDOUROLOGICAL SOCIETY (EUS)
Great Lakes D @ Marriott Marquis

7:50 WELCOME
Program Chairs: Jaime Landman, Zhamshid Okhunov

8:00 THE DISTURBATORS OF TRANSLATIONAL SUCCESS

LASERS IN UROLOGY: THE ROLE OF THULIUM FIBER LASERS
Gregory Altshuler

MRI FUSION IMAGING: PAST, PRESENT AND FUTURE
Peter Pinto

AQUABLATION: A TRANSFORMATIVE ABLATION
Nikolai Aljuri
STATE-OF-THE-ART ROBOTICS
Mihir Desai
SIMULATION IN UROLOGY: WHERE WE ARE AND WHERE ARE WE GOING?
Robert Sweet
IMMERSIVE VIRTUAL REALITY (IVR): A DISRUPTIVE TECHNOLOGY
Ralph Clayman

*Presenting author
9:30 ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING IN UROLOGY: PRESENT AND FUTURE
Peter Chang

10:00 NEXT GENERATION APPROACHES FOR UROLOGIC TISSUE REPAIR AND REGENERATION
SURGICAL AND PHARMACOLOGICAL BREAKTHROUGHS IN THE MANAGEMENT OF OBSTRUCTIVE BLADDER DISEASE
Joshua Mauney

10:30 AWARDS PRESENTATION
Dan Stoianovici

11:00 CEO/CHAIR ROUNDTABLE: THE REAL TRANSFORMERS OVERCOMING CHALLENGES IN TRANSLATION
Panelists: Abel Ang, Kurt Azarbarzin, Arie Belldegrun, Ralph Clayman, Frederic Moll

11:45 PANEL DISCUSSION Q & A

12:00 ADJOURN

Sunday, May 5, 2019 8:00 am - 5:00 pm

Forums

UROLOGIC CARE FOR THE ADVANCED PRACTICE PROVIDER II
Room W192 @ McCormick Place
Co-Course Directors: Kenneth Mitchell, Heather Schultz

11:05 FEMALE PELVIC PAIN/PELVIC FLOOR DYSFUNCTION
A. Lenore Ackerman

11:45 PANEL DISCUSSION Q&A

12:05 LATEST PERSPECTIVES IN OVERACTIVE BLADDER (NON-CME LUNCH SYMPOSIUM SPONSORED BY ASTELLAS PHARMA US, INC.)
<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
</table>
| MP52-01         | THE EFFECT OF BUSPIRONE ON REFRACTORY NEUROGENIC RETROGRADE EJACULATION TO PSEUDOEPHEDRINE  
Sun Tae Ahn*, Dong Hyun Lee, Hyeong Guk Jeong, Sang Woo Kim, Jong Wook Kim, Jeong Kim, Du Geon Moon, Seoul, Korea, Republic of |
| MP52-02         | SAFETY AND EFFECTIVENESS OF PLATELET-RICH PLASMA FOR MALE INFERTILITY IMPROVEMENT IN RATS  
Maya Epifanova*, Badri Gvasalia, Maksim Durashov, Sergey Artemenko, Moscow, Russian Federation |
| MP52-03         | BARIATRIC SURGERY IMPACT ON ERECTILE FUNCTION, SEMEN PARAMETERS AND SEXUAL HORMONES IN OBSENE MEN  
Guilherme Wood*, Bruno Tiseo, Joao Paulo Cardoso, Hamilton de Martin, Marco Aurelio Santo, Miguel Srougi, Marcello Antonio Cocuzzza, Sao Paulo, Brazil |
| MP52-04         | ROUND SPERMATID INJECTION INTO HUMAN OOCYTES: A SYSTEMATIC REVIEW AND META-ANALYSIS  
Brent Hanson*, Basking Ridge, NJ, Taylor Kohn, Baltimore, MD, Alexander Pastuszak, Salt Lake City, UT, Richard Scott, Basking Ridge, NJ, James Hotaling, Salt Lake City, UT |
| MP52-05         | RAPID MICROFLUIDIC SPERM PREPARATION FOR INTRAUTERINE INSEMINATION  
Alex Jafek*, Hayden Brady, Haidong Feng, Jim Hotaling, Douglas Carrell, Bruce Gale, Raheel Samuel, Kenneth Aston, Timothy Jenkins, Salt Lake City, UT |
| MP52-06         | MICROFLUIDIC SPERM SORTING BY USING MICROCHIP AS A NEW METHOD FOR REPEATED IVF FAILURE CASES: COMPARISON ITS' EFFECT WITH CONTROL GROUP AND PRELIMINARY RESULTS  
MEHMET MURAD BASAR*, IŞTANBUL, Turkey, HAKAN YELKE, IŞTANBUL, Turkey, SERKAN SELIMOGLU, IŞTANBUL, Turkey, EMRE SOYSLA, IŞTANBUL, Turkey, YESIM KUMTEPE-COLAKOGLU, SEMRA KAHRAMAN, IŞTANBUL, Turkey |
| MP52-07         | IDIOPATHIC NON-OBSTRUCTIVE AZOOSPERMIA: SPERM RETRIEVAL SUCCESS AND TESTICULAR HISTOPATHOLOGY  
Annie Darves-Borno*, Nashville, TN, Joshua Halpern, James Wren, Matthew Fakhoury, Mehul Patel, Mary Kate Keeter, Nelson Bennett, Robert Brannigan, Chicago, IL |
| MP52-08         | PREOPERATIVE AND INTRAOPERATIVE CHARACTERISTICS OF MEN WHO IMPROVED AND DID NOT IMPROVE SEMEN PARAMETERS AFTER MICROSURGICAL VARIPOSECTOMY  
Filipe Lira Neto*, Ricardo Jose Lisboa Lyra, Jarys Cabral Borges Junior, Recife, Brazil |
| MP52-09         | BODY MASS INDEX AND AGE CORRELATE WITH ANTIOXIDANTS SUPPLEMENTATION EFFECT ON SPERM QUALITY: A DOUBLE BLIND PLACE CONTROLLED TRIAL ON PATIENTS WITH VARIPOSECE & OLIGOASTHENOazoospermia  
Gian Maria Busetto*, Francesco Del Giudice, Roma, Italy, Ashok Agarwal, Cleveland, OH, Sava Mioic, Belgrade, Serbia, Ashraf Virmani, Utrecht, Netherlands, Ettore De Berardinis, Roma, Italy |
| MP52-10         | HIGHER TRAIT EMOTIONAL INTELLIGENCE CORRELATES TO LOWER CHRONIC SCROTAL CONTENT PAIN AND BETTER WORK ENGAGEMENT  
Richard Mendelson*, Ft. Lauderdale, FL, Mohamed Efatty, Jamin Brahmbhatt, Sijo Parekattil, Clermont, FL |
| MP52-11         | TESTICULAR SPERM ASPIRATION IN MEN WITH SEVERE OLIGOZOOSPERMIA AND CRYPTOZOOSPERMIA: SPERM RETRIEVAL RATES AND ICSI OUTCOMES  
Mohannad Alharbi*, Ahmad Almarzouq, armand zini, Montreal, Canada |
| MP52-12         | USEFULNESS OF HORMONAL EVALUATION POST TESE  
Giovanni La Croce*, Michele Manica, Federico Pellucchi, Maria Nicolai, Diego Angiollili, Richard Lawrence John Naspro, Marco Roscigno, Luigi Filippo Da Pozzo, Antonino Saccà, Bergamo, Italy |
| MP52-13         | INFLUENCE OF AGING ON SPERM RETRIEVAL AND TUBULAR HYALINIZATION IN MEN WITH IDIOPATHIC NONOBSTRUCTIVE AZOOSPERMA  
Shoichiro Iwatsuki*, Tomoki Takeda, Satoshi Nozaki, Takahiro Kobayashi, Yasue Kubota, Hiroki Kubota, Hiroyuki Kamiya, Yukihiro Umemoto, Takahiro Yasui, Nagoya, Japan |
MP52-14 FOLLICLE-STIMULATING HORMONE THERAPY AFTER MICROSURGICAL VASOEPIDIDYMOSTOMY
Dmitry Pushkar, Nika Akhvlediani*, Alexander Bernikov, Igor Reva, Moscow, Russian Federation

MP52-15 A PREDICTIVE MODEL FOR SUCCESSFUL MICROSCOPIC TESTICULAR SPERM EXTRACTION BASED UPON SEMEN VOLUME, PH, AND FSH
Scott Lundy*, Neel Parekh, Tianming Gao, Edmund Sabanegh, Sarah Vij, Cleveland, OH

MP52-16 EFFICACY OF NON-TESTOSTERONE BASED TREATMENT IN HYPOGONADIC MEN: A META-ANALYSIS AND SYSTEMATIC REVIEW

MP52-17 CUTTING THE COST OF PARENTHOOD: THE EFFICACY AND COST SAVINGS OF COMPOUNDED FOLLICLE STIMULATING HORMONE
Alexander Tatem*, J. Abram McBride, Jonathan Beilan, Jabez Gondokusumo, Daniel J. Mazur, Larry Lipshultz, Houston, TX

MP52-18 PREDNISONE AFTER VASECTOMY REVERSAL MAY IMPROVE SEMEN PARAMETERS
Graham Machen*, Jay Sandlow, Milwaukee, WI

MP52-19 THE EFFECT OF MALE AGE OVER 50 YEARS ON VASECTOMY REVERSAL OUTCOMES
Mary K. Samplaski, Nusbaum David J.*, Los Angeles, CA, Matthew B. F. Marks, Sheldon F. Mark, Tuscon, AZ

MP52-20 VASOEPIDIDYMOSTOMY: AN INSIGHT INTO CURRENT PRACTICE PATTERNS
Jonathan Beilan*, Alexander Tatem, Jabez Jabez Gondokusumo, Nannan Thirumavalavan, Larry Lipshultz, Houston, TX

MP52-21 VARICOCELE SIZE RELATES TO DEGREE OF SEMEN IMPROVEMENT
Graham Machen*, Pranav Dadhich, Jay Sandlow, Milwaukee, WI

MP52-22 THE RISK OF DEEP VEIN THROMBOSIS ASSOCIATED WITH TREATMENTS FOR HYPOGONADISM
Jessica Wenzel*, Austin, TX, Luke Machen, Milwaukee, WI, Alex Ellis, Round Rock, TX, Mehraban Kavoussi, Dallas, TX, Keikhosrow Kavoussi, Shahryar Kavoussi, Parviz Kavoussi, Austin, TX

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Sunday, May 5, 2019 9:30 am - 11:30 am
Moderated Poster Session 53
INFECTIONS/INFLAMMATION/CYSTIC DISEASE OF THE GENITOURINARY TRACT: PROSTATE & GENITALIA
Room W181ab @ McCormick Place
Moderators: J. Curtis Nickel, Robert Moldwin & Dirk Lange

ABSTRACT NUMBER TITLE
MP53-01 MICROSCOPY SPERMATIC CORD DENERVATION FOR CHRONIC ORCHIALGIA/CHRONIC SCROTAL CONTENTS PAIN: PREDICTORS OF SURGICAL SUCCESS
Sarah Vij, Neel Parekh, Daniel Shoskes*, Cleveland, OH

MP53-02 MICROSURGICAL SUBINGUINAL CREMASTER MUSCLE RELEASE FOR CHRONIC ORCHIALGIA SECONDARY TO HYPERACTIVE CREMASTER MUSCLE REFLEX
Parviz Kavoussi*, Austin, TX

MP53-03 ORIGIN OF FOURNIER GANGRENE AS A PROGNOSTIC FACTOR IN MORTALITY: ANALYSIS OF 121 CASES
David Adrian Fernandez Alcaraz*, Guadalupel, Mexico, Jhonataan Uribe Montoya, Andres Guillen Lozoya, Rodrigo Romero Mata, Monterrey, Mexico

MP53-04 COMPARISON OF DELAYED PRIMARY CLOSURE VERSUS SECONDARY INTENTION HEALING IN FOURNIER’S GANGRENE
Joshua Palka*, Detroit, MI, William Du Comb, Evan Begun, Omar Soto-Aviles, Detroit, MI

MP53-05 PARAURETHRAL CYSTS IN ADULT WOMEN – SYMPTOMS AND OUTCOMES OF COMPLETE EXCISION
Eabhanh O’Connor*, Huriye Kocadag, Mahreen Pakzad, Rizwan Hamid, Jeremy Ockrim, Tamsin Greenwell, London, United Kingdom

MP53-06 BACTERIAL OR NONBACTERIAL EPIDIDYMITIS IN BOYS: A PRELIMINARY STUDY COMPARING C-REACTIVE PROTEIN AND URINALYSIS IN DIAGNOSTIC ACCURACY
Chi-Shin Tseng, Shin-Mei Wong, Ming-Chieh Kuo, J-Ni Chiang, Kuo-How Huang, Chao-Yuan Huang, Yeong-Shiaw Pu, Hong-Chiang Chang, Yu-Cheng Lu*, Taipei, Taiwan
MP53-07 PREVALENCE OF LICHEN SCLEROSUS IN MEN PRESENTING FOR CIRCUMCISION
Ross Calopedos*, Katherine Richards, Prem Rashid, Port Macquarie, Australia, Sanjeev Bandi, Mackay, Australia, Amila Siriwardana, Michael Kwok, John Hempenstall, Devang Desai, Toowoomba, Australia

MP53-08 EARLY AND LATE EFFICACY ON WOUND HEALING OF SILVER NANOPARTICLES GEL (PEONIL®) IN MALES UNDERWENT CIRCUMCISION
Matteo Balzarro*, Emanuele Rubilotta, Anna Marcer, Antonio Soldano, Nicolò Trabacchin, Verona, Italy, Vito Mancini, Foggia, Italy, Filippo Migliorini, Verona, Italy, Antonio Luigi Pastore, Antonio Carbone, Latina, Italy, Luigi Cormio, Giuseppe Carriero, Foggia, Italy, Walter Antilani, Verona, Italy

MP53-09 A CROSS-SECTIONAL STUDY OF PREVALENCE AND GENOTYPES OF URINARY TRACT INFECTION IN MEN WITH URETHRAL STRicture ATTENDING A WESTERN HIGH VOLUME CENTER
Benedetta Valli, Guido Barbagli, Sofia Balò, Arezzo, Italy, Massimo Lazzeri*, Rozzano, Italy

MP53-10 BACTERIAL PROSTATITIS IS A SIGNIFICANT FINDING IN PATIENTS WITH SYMPTOMATIC URETHRAL STRicture DISEASE
Delia Toomey*, Jade Harrison, London, United Kingdom, Anthony Adimonye, Justin Bendig, Pareeta Patel, Surrey, United Kingdom, Nicholas Watkin, London, United Kingdom

MP53-11 IS HEMATOSPERMIA A SIGN OF CANCER?: LESSONS LEARNED FROM 15-YEARS OF EXPERIENCE WITH 342 CASES
Ozan Efesoy, Selahtitn Çayıran*, Mersin, Turkey, Ramazan Aşıçı, Samsun, Turkey, Irfan Orhan, Elazığ, Turkey, Önder Yaman, Ankara, Turkey

MP53-12 THERAPEUTIC EFFECT OF TADALAFIL IN THE CHRONIC PROSTATITIS
Norifumi Nishishita*, Kurashki, Japan, Shin Ohira, Kurashki, Japan, Shigenobu Tone, Hiki-gun, Saitama, Japan, Ryoei Hara, Tomohiro Fujii, Shinya Uehara, Yoshiyuki Miyaji, Atsushi Nagai, Kurashki, Japan

MP53-13 EFFICACY OF TADALAFIL FOR TREATING CHRONIC PROSTATITIS/CHRONIC PELVIC PAIN SYNDROME IN PATIENTS WITHOUT ERECTILE DYSFUNCTION
Hyun Jun Park*, Sung Woo Park, Nam Cheol Park, Busan, Korea, Republic of

MP53-14 IS THERE A ROLE FOR PELVIC MPMRI IN THE EVALUATION OF THE MALE CHRONIC PROSTATITIS/CHRONIC PELVIC PAIN SYNDROME (CP/CPPS)?
Andrew Ng*, Robert Moldwin, New Hyde Park, NY

MP53-15 TOTAL TESTOSTERONE LEVEL AND INFILTRATING LYMPHOCYTE DENSITY WITHIN THE PROSTATE: IS THERE AN OPTIMAL WINDOW?

MP53-16 ADAPTED BACTERIOPHAGES FOR TREATING URINARY TRACT INFECTIONS
Lorenz Leitner*, Zürich, Switzerland, Aleksandre Ujmajuridze, Nina Chanishvili, Marina Goderdzishvili, Tbilisi, Georgia, Ulrich Mehnert, Zürich, Switzerland, Archil Chkhotua, Tbilisi, Georgia, Wilbert Sybesma, Thomas M. Kessler, Zürich, Switzerland

MP53-17 INCREASING INCIDENCE OF INFECTIONS AFTER PROSTATE BIOPSY IN THE UNITED STATES

MP53-18 PROSTATE BIOPSY SEPSIS: A META-ANALYSIS OF TRANSRECTAL VERSUS TRANSPERINEAL PROSTATE BIOPSY INFECTION RATES
Michael Gross, Mark Alshak, Peter Y Cai*, Michelle Demetres, Elizabeth Mauer, Jim Hu, New York, NY

MP53-19 A PROSPECTIVE, RANDOMIZED CONTROLLED TRIAL (RCT) REGARDING ANTIMICROBIAL PROPHYLAXIS IN TRANSURETHRAL RESECTION OF THE PROSTATE (TURP): AN INTERIM ANALYSIS OF THE PROPHYLAXIS001-TRIAL.
Evert Baten, Kessel-lo, Belgium, Ingrid Arijs, Hasselt, Belgium, Hans Goethuys, Genk, Belgium, Machteld Vandecandelaere, Herent, Belgium, Reinout Cartuyvels, Hasselt, Belgium, Frank Van der Aa, Leuven, Belgium, Koenraad van Renteghem, Hasselt, Belgium, Thomas Van den Broeck*, Leuven, Belgium

MP53-20 REGULATION OF CHRONIC PELVIC PAIN VIA THE TRPV1 CHANNEL IN A MURINE MODEL OF CHRONIC PROSTATITIS
Kenny Roman*, Christel Hall, Anthony Schaeffer, Praveen Thumbikat, Chicago, IL
APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

*Presenting author
**ABSTRACT TITLE**

**ABSTRACT NUMBER**

**MP54-01**

**FACILITY-LEVEL VARIATION IN PELVIC LYMPH NODE DISSECTION DURING RADICAL PROSTATECTOMY AND EFFECT ON OVERALL SURVIVAL IN MEN WITH CLINICALLY LOCALIZED HIGH-RISK PROSTATE CANCER**

David F. Friedlander*, Brighton, MA, Marieke J Krimphove, Alexander P. Cole, Stuart R. Lipsitz, Adam S. Kibel, Quoc-Dien Trinh, Boston, MA

**MP54-02**

**THE ADDED VALUE OF A GENOMIC SIGNATURE IN NON-ORGAN-CONFINED PROSTATE CANCER**

Alberto Martini*, Dmitry Rykunov, Shivaram Cumarsamy, John P Sfakianos, Ardsheir Rastinehad, Kenneth G Haines III, Sujit S Nair, Boris Reva, Ashutosh K Tewari, New York, NY

**MP54-03**

**PREDICTIVE FACTORS OF POSTOPERATIVE QUALITY OF LIFE, ERECTILE FUNCTION AND CONTINENCE AFTER ROBOT-ASSISTED RADICAL PROSTATECTOMY: A MULTICENTRE STUDY**

Wout Devlies*, Leuven, Belgium, Greet De Coster, Nancy Van Damme, Thierry Roumeguère, Thierry Quakels, Brussels, Belgium, Ben Van Cleynenbreugel, Leuven, Belgium, Peter Dekyper, Filip Ameye, Ghent, Belgium, Wouter Everaerts, Steven Joniau, Leuven, Belgium

**MP54-04**

**UTILIZATION OF MAGNETIC RESONANCE IMAGING TO OPTIMIZE NEUROVASCULAR TISSUE PRESERVATION AND MINIMIZE THE RISK OF POSITIVE SURGICAL MARGINS**

Amir Lebastchi*, Samuel Gold, Michael Ahdoot, Jonathan Bloom, Sherif Mehralivand, Patrick Gomella, Thomas Sanford, Graham Hale, Vladimir Valera Romero, Mark Ball, Peter Choyke, Brad Wood, Maria Merino, Bethesda, MD, Minhaj Siddiqui, Baltimore, MD, Baris Turkbey, Peter Pinto, Bethesda, MD

**MP54-05**

**LOWER URINARY TRACT SYMPTOMS (LUTS) AFTER ROBOTIC ASSISTED LAPAROSCOPIC PROSTATECTOMY (RALP) IN A LARGE, MULTI-SURGEON COHORT: IMPLICATIONS FOR SURVIVORSHIP AND TREATMENT SELECTION**

Thomas Ahn, Matthew Roberts*, Andrew Strahan, Gregory Malone, Jason Paterdis, Glen Wood, Peter Heathcote, Brisbane, Australia

**MP54-06**

**STRIATED URETHRAL SPHINCTER FUNCTION FOLLOWING TRAINING IN MEN PRIOR TO RADICAL PROSTATECTOMY**

Sean F. Mungovan*, Westmead, Australia, Petra L. Graham, Sydney, Australia, Daniel I. Vukovic, Christopher S. Han, Henk B. Luiting, Westmead, Australia, Jasper S. Sandhu, Oguz Akin, Sigrid V. Carlsson, James A. Eastham, New York, NY, Manish I. Patel, Westmead, Australia

**MP54-07**

**CRYOPRESERVED PLACENTAL TISSUE ALLOGRAFT ACCELERATES TIME TO CONTINENCE AFTER ROBOTIC RADICAL PROSTATECTOMY**

Ramkishen Narayanan*, Stephanie Hsiang, Christopher Slayden, Santa Monica, CA, Shuching Chang, Portland, OR, Timothy Wilson, Santa Monica, CA

**MP54-08**

**LATE BIOCHEMICAL RECURRENCE POST-PROSTATECTOMY IS ASSOCIATED WITH A SLOWER RATE OF PROGRESSION**

Ken Chow*, Pia Herrera, Ryan Stuchbery, Justin S. Peters, Anthony J. Costello, Christopher M. Hovens, Niall M. Corcoran, Melbourne, Australia

**MP54-09**

**PROSTATECTOMY IN MEN WITH CLINICALLY POSITIVE LYMPH NODES: COMPARING SURVIVAL IN HIGH RISK CN-, PATHOLOGICALLY NEGATIVE NODES, AND PATHOLOGICALLY POSITIVE NODAL DISEASE**


**MP54-10**

**COMPARISON BETWEEN LIMITED AND EXTENDED LYMPH NODE DISSECTION FOR PROSTATE CANCER: RESULTS FROM A LARGE, CLINICALLY-INTEGRATED, RANDOMIZED TRIAL**

Karim Touijer*, Daniel Sjoberg, Nicole Benfante, James Eastham, Vincent Laudone, Ehdal Behfar, Peter Scardino, Andrew Vickers, New York, NY

**MP54-11**

**PELVIC LYMPH NODE DISSECTION DURING ROBOTIC PROSTATECTOMY IN THE MUSIC COLLABORATIVE**

Hernan Lescay*, Grand Rapids, MI, Firas Abdullah, Michael Cher, Detroit, MI, Susan Linsell, David Miller, James Montie, Ann Arbor, MI, James Peabody, Detroit, MI, Ji Qi, Hugh Solomon, Ann Arbor, MI, Aram Loeb, Detroit, MI, Brian Lane, Grand Rapids, MI, for the Michigan Urological Surgery Improvement Collaborative, Ann Arbor, MI
MP54-12 PROSPECTIVE RANDOMIZED TRIAL OF GENE EXPRESSION CLASSIFIER UTILITY IN MEN AT HIGH RISK OF RECURRENCE FOLLOWING RADICAL PROSTATECTOMY
Todd Morgan*, Linda Okoth, Ann Arbor, MI, Felix Feng, San Francisco, CA, Anna Johnson, Ann Arbor, MI, Brian Lane, Grand Rapids, MI, Susan Linsell, Khurshid Ghani, James Montie, Ann Arbor, MI, Nick Fishbane, Tara Marti, Marguerite du Plessis, Vancouver, Canada, Rohit Mehra, Ann Arbor, MI, Elai Davicioni, Vancouver, Canada, Thomas Maatman, Grand Rapids, MI, Kirk Wojno, Frank Burks, Royal Oak, MI, Paul Rodriguez, Grand Rapids, MI, Nick Liu, Ypsilanti, MI, Richard Sarle, Troy, United Kingdom, David Miller, Ann Arbor, MI, Michael Cher, Detroit, MI, Michigan Urological Surgery Improvement Collaborative, Ann Arbor, MI

MP54-13 EVALUATING THE VALUE OF MRI IN PREDICTING RADICAL PROSTATECTOMY PATHOLOGIC OUTCOMES
Adharsh Murali, Sean R. Meyer, Arvin George, Nnenaya Agochukwu, Ji Qi, Tae Kim, Prasad Shankar, Matthew Davenport, Karandeep Singh*, for the Michigan Urological Surgery Improvement Collaborative, Ann Arbor, MI

MP54-14 TIME TRENDS IN USE OF RADICAL PROSTATECTOMY BY TUMOR RISK AND LIFE EXPECTANCY IN A NATIONAL VA COHORT FROM 2000 TO 2017
Kristina Vaculik, Vancouver, Canada, Michael Luu, Los Angeles, CA, Lauren Howard, Durham, NC, William Aronson, Los Angeles, CA, Martha Terris, Augusta, GA, Christopher Kane, San Diego, CA, Christopher Amling, Portland, OR, Matthew Cooperberg, San Francisco, CA, Stephen Freedland, Timothy Daskivich*, Los Angeles, CA

MP54-15 CONTINENCE OUTCOMES OF ANTERIOR SUPPORT RECONSTRUCTION (ASURE) TECHNIQUE DURING ROBOT ASSISTED RADICAL PROSTATECTOMY (RAP)
Ashwin Mallya*, Feroz Amir Zafar, Sachin Arakere Nataraj, Pankaj Wadhwa, Rajesh Kumar Ahlawat, Gurugram, India

MP54-16 HIGHER FREE TESTOSTERONE PROTECTS AGAINST EARLY RECURRENCE IN MEN UNDERGOING RADICAL PROSTATECTOMY
Maxwell Towe, Linda M Huynh, Farouk M El-Khatib, Faysal A Yafi, Thomas Ahlering*, Orange, CA

MP54-17 THE PREVALENCE, RISK FACTORS AND IMPACT ON QUALITY OF LIFE OF LYMPHEDEMA AFTER ROBOT-ASSISTED RADICAL PROSTATECTOMY WITH EXTENDED PELVIC LYMPH NODE DISSECTION.
Yannick Raskin*, Cedric Jorissen, Steven Joniau, Wouter Everaerts, Leuven, Belgium

MP54-18 IMPACT OF PELVIC LYMPH NODE YIELD DURING RADICAL PROSTATECTOMY ON LONG TERM CSS AND OS: A RETROSPECTIVE 5- AND 10-YEARS ANALYSIS ON A 1274 SERIES
Maria Chiara Sighinolfi*, Modena, Italy, Ahmed Eissa, Tanta, Egypt, Marco Sandri, Brescia, Italy, Stefano Pulitelli, Maria Giuseppa Vitale, Alessio Bruni, Modena, Italy, Alberto Romano, Capri, Italy, Luca Reggiani Bonetti, Ilaria Bagni, Modena, Italy, Giancarlo Peracchia, Capri, Italy, Riccardo Grisanti, Sassuolo, Italy, Ahmed Zoori, Tanta, Egypt, Salvatore Micali, Modena, Italy, Vipul Patel, Orlando, FL, Giampaolo Bianchi, Bernardo Maria Rocco, Modena, Italy

MP54-19 REFINING PATIENT SELECTION FOR SALVAGE RADICAL PROSTATECTOMY: EAU GUIDELINES-COMPLIANT PATIENTS SHOW BETTER OUTCOMES

MP54-20 LONGITUDINAL QOL IN PATIENTS WITH HIGH VERSUS LOW-INTERMEDIATE RISK PROSTATE CANCER TREATED BY RALP: A MULTICENTRE STUDY
Wout Devlies*, Leuven, Belgium, Greet De Coster, Nancy Van Damme, Thierry Roumeguère, Thierry Quakels, Brussels, Belgium, Ben Van Cleynenbreugel, Leuven, Belgium, Peter Dekuyper, Filip Ameye, Ghent, Belgium, Wouter Everaerts, Steven Joniau, Leuven, Belgium

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

*Presenting author
**ABSTRACT**

**MP55-01** PROTEIN EXPRESSION PROFILES AMONG LICHEN SCLEROSUS URETHRAL STRICTURES: CAN URETHROPLASTY SUCCESS BE PREDICTED?

Alison Levy*, Matthew Moynihan, Burlington, MA, Jennifer Bennett, Chicago, IL, Travis Sullivan, Kristian Stensland, Brendan Browne, Ariel Fredrick, Burlington, MA, Jason Badrinarain, Jorge Yao, Ramsey, NJ, Jaime Cavallo, Burlington, MA, Elizabeth Pagura, Rafael Tua-Caraccia, Boston, MA, Kimberly Rieger-Christ, Alex Vanni, Burlington, MA

**MP55-02** REPEATED TRANSURETHRAL INTERVENTIONS INCREASE URETHRAL FIBROGENESIS AND STRICTURE SEVERITY IN A RABBIT MODEL

Mahadevan Rajasekaran*, Hosong Yu, SeungMo Yuk, Raag Bhargava, Rucha Deshpande, Jessica Magana, Thomas Fuller, Jill Buckley, Valtimk Bhargava, San Diego, CA

**MP55-03** TRAINING THE NEXT GENERATION OF GENITOURINARY RECONSTRUCTIVE SURGEONS: FEEDBACK AND FUTURE DIRECTIONS

Brittney Cotta*, San Diego, CA, Kurt McCammon, Virginia Beach, VA, Keith Rourke, Edmonton, Canada, Daniel Rosenstein, San Jose, CA, Jill Buckley, San Diego, CA

**MP55-04** ASSOCIATION OF PREOPERATIVE MRI FINDINGS AND THE COMPLEXITY OF URETHROPLASTY FOR TRAUMATIC BULBAR URETHRAL STRICTURE

akio horiguchi*, saitama, japan, hiromi edo, tokyo, japan, shigeyoshi soga, ruyiichi azuma, masayuki shinchi, tomohiko asano, keiichi ito, hiroshi shinmoto, Saitama, Japan

**MP55-05** COMPUTATIONAL FLUID DYNAMIC MODELLING OF URETHRAL STRICTURES


**MP55-06** THE ROLE OF POST-OPERATIVE IMAGING AFTER VENTRAL ONLAY BUCCAL MUCOSAL GRAFT BULBAR URETHROPLASTY

Nathan Hoy*, Hadley Wood, Kennneth Angermeier, Cleveland, OH

**MP55-07** THE EFFECT OF ANNUAL HOSPITAL VOLUME (AHV) ON PERIOPERATIVE OUTCOMES AFTER URETHROPLASTY

Marco Bandini*, Milan, Italy, Rados Djimovic, Belgrade, Serbia, Francesco Montorsi, Milan, Italy, Sasha Sekulovic, Nikola Stanojievic, Milan Slavkovic, Belgrade, Serbia, Bogdan Spiridonescu, Bucharest, Romania, Zhe Tian, Montréal, Canada, Vladimir Pasic, Belgrade, Serbia, Pramod Krishnapa, Bangalore, India, Anuj Deep Dangi, Tamil Nadu, India, Salvatore Sansalone, Roma, Italy, Andrea Salonia, Alberto Briganti, Milan, Italy, Pierre Karakiewicz, Montréal, Canada
MP55-13 URETHRAL STRICTURE IS FREQUENTLY A MORBID CONDITION: IDENTIFYING PATIENTS AT INCREASED RISK FOR COMPLICATIONS DUE TO URETHRAL STRICTURE

Christopher King*, Keith Rourke, Edmonton, Canada

MP55-14 LONG TERM OUTCOMES OF ONE-STAGE AUGMENTATION ANTERIOR URETHROPLASTY: A META-ANALYSIS

Cooper Benson*, New Orleans, LA, Gen Li, Steven Brandes, New York, NY

MP55-15 OUTCOMES AFTER PENILE ONE-STAGE DORSAL INLAY BUCCAL MUCOSAL GRAFT URETHROPLASTY USING THE ASOPA TECHNIQUE: A DETAILLED EVALUATION OF ETIOLOGY, CHARACTERISTICS, RECURRENCE, AND PATIENT-REPORTED TREATMENT SATISFACTION

Valentin Zumstein, Roland Dahlem, Clemens M. Rosenbaum, Valentin Maurer, Hamburg, Germany, Luis A. Kluth, Frankfurt (Main), Germany, Margit Fisch, Malte W. Vetterlein*, Hamburg, Germany

MP55-16 COMPREHENSIVE PROSPECTIVE ASSESSMENT OF PATIENT REPORTED OUTCOMES AFTER URETHROPLASTY

Jordan Bekkema*, Keith Rourke, Edmonton, Canada

MP55-17 URINARY AND SEXUAL FUNCTION AFTER PERINEAL URETHROSTOMY FOR URETHRAL STRICTURE DISEASE: AN ANALYSIS FROM TRAUMA AND UROLOGIC RECONSTRUCTIVE NETWORK OF SURGEONS (TURNS)

Gregory Murphy*, Saint Louis, MO, Kirk Ferguson, San Francisco, CA, Thomas Gaither, Los Angeles, CA, Nima Baradaran, Columbus, OH, Bryan Voelzke, Seattle, WA, Jeremy Myers, Salt Lake City, UT, Bradley Erickson, Iowa City, IA, Sean Elliott, Minneapolis, MN, Nejd Alsikafi, Chicago, IL, Alex Vanni, Burlington, MA, Jill Buckley, San Diego, CA, Benjamin Breyer, San Francisco, CA

MP55-18 THE EVOLUTION OF URETHRAL STRICTURE TREATMENT OVER 15 YEARS: A SINGLE-CENTRE, SINGLE-SURGEON 1319 URETHROPLASTY ANALYSIS

R. Christopher Doiron*, Keith Rourke, Edmonton, Canada

MP55-19 THE OUTCOME OF REVISIONAL URETHROPLASTY SURGERY

Stella Ivaz*, Simon Bugeja, Anastasia Frost, Nikki Jeffrey, Angelica Lomiteng, Mariya Dragova, Daniela E Andrich, Anthony R Mundy, London, United Kingdom

MP55-20 OBJECTIVE ASSESSMENT OF MOUTH OPENING AFTER BUCCAL MUCOSAL GRAFT (BMG) URETHROPLASTY: A PROSPECTIVE STUDY

Jaisukh Kalathia*, Indore, India, Kaushal Patel, Venkatesh Krishnamoorthy, anantapur, India

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Sunday, May 5, 2019

Moderated Poster Session 56

9:30 am - 11:30 am

URODYNAMICS/LOWER URINARY TRACT DYSFUNCTION/ FEMALE PELVIC MEDICINE: INCONTINENCE: EVALUATION (URODYNAMIC TESTING)

Room W 179a @ McCormick Place

Moderators: Courtenay Moore, Cristiano Gomes & Jerry Blaivas

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP56-01</td>
<td>VALIDATION OF BEST PRACTICE POLICY STATEMENT ON URODYNAMIC ANTIBIOTIC PROPHYLAXIS IN THE NON-INDEX PATIENT IN THE ERA OF STEWARDSHIP</td>
</tr>
<tr>
<td>Cristina Fox*, Valhalla, NY, Brian Kim, Ali Omar, Michelle Kim, Debra Fromer, Hackensack, NJ</td>
<td></td>
</tr>
<tr>
<td>MP56-02</td>
<td>MULTI-CHANNEL URODYNAMICS IN HEALTHY VOLUNTEERS: CHALLENGES IN DEFINING NORMAL</td>
</tr>
<tr>
<td>Natalie Swavely*, John Speich, Naveen Nandanana, Andrea Balthazar, Adam Klausner, Richmond, VA</td>
<td></td>
</tr>
<tr>
<td>MP56-03</td>
<td>ARE PREOPERATIVE URODYNAMICS IMPORTANT FOR THE SUCCESS OF RENAL TRANSPLANT GRAFTS?</td>
</tr>
<tr>
<td>Sida Niu*, Connor Chestnut, Priya Padmanabhan, Kansas City, KS</td>
<td></td>
</tr>
<tr>
<td>MP56-04</td>
<td>URODYNAMIC FINDINGS IN PATIENTS WITH NOCTURIA: AN AGE- AND GENDER-MATCHED STUDY</td>
</tr>
<tr>
<td>Elisabeth M. Sebesta*, Joseph M. Caputo, Dina Manasherova, Carrie M. Aisen, Doreen E. Chung, New York, NY</td>
<td></td>
</tr>
</tbody>
</table>

*Presenting author
MP56-05 SLING REVISION FOR BLADDER OUTLET OBSTRUCTION IN WOMEN WITH PRIMARILY STORAGE SYMPTOMS: WHAT ARE THE BEST URODYNAMIC CRITERIA TO PREDICT OUTCOMES?
Christina Escobar*, Benoit Peyronnet, Rachael Sussman, Ricardo Palmerola, Nirit Rosenblum, Benjamin Brucker, Victor Nitti, Dominique Malacarne Pape, New York, NY

MP56-06 A COMPARISON OF FREE FLOW CONFIGURATION AND VIDEO-URODYNAMIC FINDINGS IN WOMEN WITH LOWER URINARY TRACT SYMPTOMS: IS CONFIGURATION PREDICTIVE OF OBSTRUCTION
Bogdan Toia*, Richard Axell, Habiba Yasmin, Mahreen Pakzad, Rizwan Hamid, Tamsin Greenwell, Jeremy Ockrim, London, United Kingdom

MP56-07 EFFECT OF 6F DUAL LUMEN CATHETER ON FLOW RATE DURING VIDEO-URODYNAMIC INVESTIGATIONS
Habiba Yasmin*, Bogdan Toia, Richard Axell, Megan Duffy, Mahreen Pakzad, Rizwan Hamid, Jeremy Ockrim, Tamsin Greenwell, London, United Kingdom

MP56-08 DOES USE OF A NORMALIZING ALGORITHM CHANGE KEY ANALOG UROFLOW CHARACTERISTICS?
John Onofrey, New Haven, CT, Jose Murillo Netto, new Haven, CT, Israel Franco*, New Haven, CT

MP56-09 EFFECT OF FILLING RATE ON BLADDER SENSATION EVENT DESCRIPTORS IN OVERACTIVE VERSUS HEALTHY BLADDERS DURING NON-INVASIVE HYDRATION STUDIES
Blessan Sebastian*, Dhruv Sethi, Anna Nagle, Devina Thapa, Naomi Vinod, Zachary Cullingsworth, Andrea Balthazar, Adam Klausner, John Speich, Richmond, VA

MP56-10 BLADDERS EXHIBITING DYNAMIC ELASTICITY ACCOMMODATE GREATER VOLUMES DURING URODYNAMICS COMPARED TO MAXIMUM VOLUMES FROM 3-DAY VOID DIARIES
Zachary Cullingsworth*, Andrea Balthazar, Naveen Nandanan, Anna Nagle, Adam Klausner, John Speich, Richmond, VA

MP56-11 CHANGES OF LOWER URINARY TRACT FUNCTION AFTER ROBOTIC-ASSISTED RADICAL PROSTATECTOMY: A URODYNAMIC FOLLOW-UP WITHIN ONE YEAR
Yuan-Hong Jiang*, Hann-Choming Kuo, Hualien, Taiwan

MP56-12 UROFLOW STOP TEST WITH EMG AFTER RARP: A NOVEL INDEX OF EARLY RECOVERY OF PREOPERATIVE CONTINENCE CAPACITY
Morena Turco*, Andrea Boni, Alessio Paladinini, Michele Dei Zingaro, Giovanni Cochetto, Mattia Panciariola, Ettore Mearini, Perugia - Terni, Italy

MP56-13 MALE STRESS INCONTINENCE GRADING SCALE (MSIGS) CORRELATES STRONGLY WITH 24-HOUR PAD WEIGHTS: EXTERNAL VALIDATION OF STANDING COUGH TEST FOR RAPID OBJECTIVE EVALUATION OF MALE STRESS URINARY CONTINENCE
Yooni Yi*, Dallas, TX, Christopher Graziano, Birmingham, AL, Nabeel Shakir, Michael Davenport, Dallas, TX, Brian Christine, Birmingham, AL, Rachel Bergeson, Allen Morey, Dallas, TX

MP56-14 MODERATE MALE STRESS URINARY INCONTINENCE IS OFTEN WORSE THAN ADVERTISED: REFERRAL CENTER EXPERIENCE USING STANDING COUGH TEST TO STRATIFY SLING PATIENTS
Yooni Yi*, Rachel Bergeson, Nabeel Shakir, Michael Davenport, Allen Morey, Dallas, TX

MP56-15 SCREENING FOR URINARY INCONTINENCE IN MINNESOTA WOMEN USING A VALIDATED EPIDEMIOLOGIC SURVEY: A CROSS-SECTIONAL STUDY
Makinna Oestreich*, Martina Gabra, Katelyn Tessier, Cynthia Fok, Nisrine Nakib, John Fischer, Minneapolis, MN

MP56-16 CORRELATING PREDOMINANT SYMPTOM IN MIXED URINARY INCONTINENCE AND VIDEO-URODYNAMIC FINDINGS IN WOMEN – ARE THE PROPOSED UPDATED NICE 2018 GUIDELINES REASONABLE?
Habiba Yasmin*, Bogdan Toia, Richard Axell, Megan Duffy, Mahreen Pakzad, Rizwan Hamid, Jeremy Ockrim, Tamsin Greenwell, London, United Kingdom

MP56-17 USE OF PRE-OPERATIVE URODYNAMICS FOR STRESS URINARY INCONTINENCE SURGERY FOLLOWING THE VALUE STUDY
Matthew Clements*, C William Pike, Jacqueline Zilloux, David Rapp, Charlottesville, VA

MP56-18 DEVELOPMENT OF VOIDING RECOGNITION TECHNOLOGY IN MOBILE ENVIRONMENT
Kyung Jin Chung, Khae-Hawn Kim*, Incheon, Korea, Republic of

MP56-19 EFFECTS OF BOWEL HABITS ON SOCIAL BEHAVIOR
Sophia Goodridge*, Nashville, TN, Casey Kowalk, Lawrence, KS, Siobhan Hartigan, Melissa Kaufman, Roger Dmochowski, Stuart Reynolds, Nashville, TN

MP56-20 MASS SPECTROMETRY ANALYSIS OF INTERSTITIAL CYSTITIS BLADDER BIOPSIES REVEALS SIGNIFICANT DIFFERENCES IN INFLAMMATION AND LOSS OF CELLULAR STRUCTURE PATHWAYS IN INTERSTITIAL CYSTITIS WITH HUNNER’S LESIONS SAMPLES
Eljah P. Ward, Sarah N. Bartholome, Michael B. Chancellor, Kenneth M. Peters, Laura E. Lamb*, Royal Oak, MI

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP57-01</td>
<td>MULTILINEAGE PLASTICITY AND HETEROGENEITY IN MUSCLE INVASIVE BLADDER CANCER.</td>
</tr>
<tr>
<td>MP57-02</td>
<td>“NEXT-GEN STING-AGONIST LIKE BCG CONFRS ENHANCED IMMUNOGENICITY AND ANTITUMOR EFFICACY IN VITRO AND IN VIVO”</td>
</tr>
<tr>
<td>MP57-03</td>
<td>COMBINATION OF ANDROGEN RECEPTOR INHIBITOR AND CISPLATIN, AN EFFECTIVE TREATMENT STRATEGY FOR UROTHELIAL CARCINOMA OF THE BLADDER</td>
</tr>
<tr>
<td>MP57-04</td>
<td>HUMAN BLADDER TRANSCRIPTOME AT SINGLE CELL RESOLUTION IN DISEASE-FREE AND TUMOR-BEARING TISSUE</td>
</tr>
<tr>
<td>MP57-05</td>
<td>NOVEL DEEP LEARNING COMPUTER VISION APPROACH FOR DRUG SENSITIVITY PREDICTION</td>
</tr>
<tr>
<td>MP57-06</td>
<td>SURGICALLY-INDUCED STRESS ALTERS TUMOR SURVIVAL AND RESPONSE TO ADJUVANT IMMUNOTHERAPY IN BLADDER CANCER</td>
</tr>
<tr>
<td>MP57-07</td>
<td>LONG NON-CODING RNA SOX20T PROMOTES STEMNESS CHARACTERISTICS AND DRUG-RESISTANCE OF BLADDER CANCER CELLS BY MODULATING SOX2</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP57-08</td>
<td>ANDROGEN RECEPTOR SIGNALING REDUCES DIRECT CYTOTOXICITY OF BACILLUS CALMETTE-GUÉRIN (BCG) IN BLADDER CANCER CELLS VIA MODULATING RAB27B</td>
</tr>
<tr>
<td>MP57-09</td>
<td>MOLECULAR PROFILING OF SMALL CELL BLADDER CANCER: IMPLICATIONS FOR IMMUNOTHERAPEUTIC STRATEGIES</td>
</tr>
<tr>
<td>MP57-10</td>
<td>CHARACTERIZATION OF MOLECULAR DIFFERENCES BETWEEN SMOKERS AND NON-SMOKERS WITH UROTHELIAL CARCINOMA</td>
</tr>
<tr>
<td>MP57-11</td>
<td>PD-1/PD-L1 IMMUNE-CHECKPOINT INHIBITION WITH RADIATION IN BLADDER CANCER: IN SITU AND ABSCOPAL EFFECTS</td>
</tr>
<tr>
<td>MP57-12</td>
<td>PYRUVATE DEHYDROGENASE KINASE 4 (PDK4) AS A NOVEL TARGET FOR SENSITIZING BLADDER CANCER TO CISPLATIN</td>
</tr>
<tr>
<td>MP57-13</td>
<td>INDOLEAMINE-2,3-DIOXYGENASE -1 EXPRESSION UPREGULATES ZEB2 EXPRESSION THOUGH MICRORNA-200C SIGNALING IN HUMAN BLADDER CANCER</td>
</tr>
</tbody>
</table>

*Presenting author
**MP57-14 TOXICITY AND BIODISTRIBUTION OF GOLD NANOPARTICLE-BASED PHOTO-IMMUNO-NANOTHERAPY FOR BLADDER CANCER**

Gregory Barton*, Yang Liu, Paolo Maccarini, Gregory Palmer, Wiguins Etienne, Wei Phin Tan, Tuan Vo-Dinh, Brant Inman, Durham, NC

**MP57-15 EVALUATION OF A BLOOD-BASED ASSAY TO PREDICT CLINICAL RESPONSE TO INTRAVESICAL BACILLUS CALMETTE-GUERIN IN PATIENTS WITH UROTHELIAL CARCINOMA OF THE BLADDER**

Michael B. Rothberg*, Wenjun Le, Ronald L. Davis, Zheng Cui, Winston-Salem, NC

**MP57-16 TUMOR DERIVED EXTRACELLULAR VESICLES PROMOTE BLADDER TUMORIGENESIS BY INDUCING ENDOPLASMIC RETICULUM STRESS.**

Chia-Hao Wu*, Christopher Silvers, Edward Messing, Yi-Fen Lee, Rochester, NY

**MP57-17 TARGETING METABOLIC VULNERABILITIES IN BLADDER CANCER USING NOVEL THERAPEUTIC STRATEGIES**

Mamatha Garige, Silver Spring, MD, Sandeep Gurram*, Daniel Crooks, Nobu Oshima, Anton Simeonov, Matthew Hall, Gustavo Pena-La Grave, Bethesda, MD, Andrew Lane, Teresa Fan, Lexington, KY, Carole Sourbier, Silver Spring, MD, Murali Cherukuri, Len Neckers, Piyush Agarwal, Bethesda, MD

**MP57-18 PROGNOSTIC IMPACT OF TUMOR-ASSOCIATED ROUND CELL INFILTRATES AT RADICAL CYSTECTOMY FOR BLADDER CANCER**

Tina Schubert, Wuerzburg, Germany, Fahmy Hassan, Würzburg, Germany, Alexander Schmid, Markus Renninger, Arnulf Stenzl, Tuebingen, Germany, Hubert Kübler, Georgios Gakis*, Würzburg, Germany

**MP57-19 TIM-3 AND TIGIT ARE POTENTIAL IMMUNE CHECKPOINT TARGETS IN PATIENTS WITH BLADDER CANCER**

John Sfakianos*, Adam Farkas, Jorge Daza, Harry Anastos, Matthew Galsky, Nina Bhardwaj, New York, NY

**MP57-20 PARP INHIBITORS AS POTENTIAL THERAPEUTIC AGENTS AGAINST BLADDER CANCER**

Matthew Sullivan, Sayani Bhattacharjee, Rebecca Wynn, Nagalakshmi Nadiminty*, Toledo, OH

---

**Podium Session 44**

**SEXUAL FUNCTION/DYSFUNCTION: SURGICAL THERAPY II**

Room W179b @ McCormick Place

Moderators: Ian Eardley, Laurence Levine & Martin Dineen

<table>
<thead>
<tr>
<th>ABSTRACT</th>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>9:30</strong></td>
<td>PD44-01</td>
<td>A COMPARISON BETWEEN EARLY AND DELAYED PENILE PROSTHESIS INSERTION IN MEN WITH REFRACTORY ISCHAEMIC PRIAPISM</td>
<td></td>
</tr>
<tr>
<td><strong>9:40</strong></td>
<td>PD44-02</td>
<td>A MULTI-INSTITUTIONAL ASSESSMENT OF MULTIMODAL ANALGESIA IN PENILE IMPLANT RECIPIENTS DEMONSTRATES DRAMATIC NARCOTICS REDUCTION</td>
<td></td>
</tr>
<tr>
<td><strong>9:50</strong></td>
<td>PD44-03</td>
<td>OUTCOMES OF 764 INFLATABLE PENILE PROSTHESSES IN 547 FEMALE-TO-MALE TRANSSEXUALS UNDERGOING PHALLOPLASTY</td>
<td></td>
</tr>
<tr>
<td><strong>10:00</strong></td>
<td>PD44-04</td>
<td>THE EFFECT OF BUPIVACAINE ON THE EFFICACY OF ANTIBIOTIC COATING ON PENILE IMPLANTS IN PREVENTING INFECTION.</td>
<td></td>
</tr>
<tr>
<td><strong>10:10</strong></td>
<td>PD44-05</td>
<td>POPULATION LEVEL TRENDS IN THE SURGICAL TREATMENT OF PEYRONIE’S DISEASE: OVER USE OF PENILE PROSTHESSES? UNDER USE OF PLACER INCISION AND GRAFTING?</td>
<td></td>
</tr>
</tbody>
</table>
10:20 PD44-06 POSTOPERATIVE PENILE PROSTHESIS PAIN: IS IT WORSE IN DIABETIC PATIENTS?
Michel Apoj*, Mark Blebel, Archana Rajender, Didi Theva, Dayron Rodriguez, Boston, MA, Martin Gross, Dartmouth, NH, Ricardo Munarriz, Boston, MA

10:30 PD44-07 PENOSCROTAL DECOMPRESSION AS A GLANS SPARING ALTERNATIVE TO SHUNT PROCEDURES FOR SURGICAL RELIEF OF REFRACATORY ISCHEMIC PRIAPISM
Yooni Yi*, Michael Davenport, Dallas, TX, Billy Cordon, Miami, FL, Jeffrey Gahan, Rachel Bergeson, Allen Morey, Dallas, TX

10:40 PD44-08 PENILE PROSTHESIS IMPLEMENTATION WHILE ON ANTICOAGULANT THERAPY: A RETROSPECTIVE STUDY
Alfredo Suarez-Sarmiento Jr.*, Matthew Brennan, Alfredo Suarez-Sarmiento, Paul Perito, Coral Gables, FL

10:50 PD44-09 ADHERENCE TO THE AUA ANTIBIOTIC PROPHYLAXIS GUIDELINES IN DIABETIC PATIENTS IS ASSOCIATED WITH SIGNIFICANTLY HIGHER RISKS OF PENILE PROSTHESIS INFECTION

11:00 PD44-10 SEXUAL FUNCTION AFTER PENILE INVERSION VAGINOPLASTY
Virginia Li*, Amanda Chi, Melissa Poh, Polina Reyblat, Los Angeles, CA

11:10 PD44-11 AN ARGUMENT FOR PRE-OPERATIVE PELVIC IMAGING PRIOR TO SECONDARY PENILE PROSTHESIS SURGERY
Joseph M Caputo*, Christopher I Sayegh, Shyam Sukumar, Denise Asafu-Adjei, Doron S Stember, Peter J Stahl, New York, NY

11:20 PD44-12 20-YEAR FOLLOW-UP AFTER PENILE PROSTHESIS IMPLANTATION – FUNCTIONAL AND QUALITY OF LIFE OUTCOMES
Francesco Chierigo*, Paolo Capogrosso, Federico Dehè, Eugenio Ventimiglia, Walter Cazzaniga, Luca Boeri, Edoardo Pozzi, Nicolò Schifano, Rani Zuabi, Federico Belladelli, Milan, Italy, Vincenzo Mirone, Naples, Italy, Francesco Montorsi, Andrea Salonia, Milan, Italy

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

*Presenting author
ABSTRACT

**ASSOCIATION OF LOCAL ANAESTHETIC WOUNDS INFILTRATION AND ULTRASOUND TRANSVERSUS ABDOMINAL PLANE (US-TAP) BLOCK IN PATIENTS UNDERGOING ROBOT-ASSISTED RADICAL PROSTATECTOMY: A DOUBLE-BLIND RANDOMIZED CONTROLLED TRIAL**

Giovanni E. Cacciamani*, Nicola Menestrina, Marco Pirozzi, Paolo corsi, Davide De Marchi, Davide Inverardi, Tania Processali, Nicolò Trabacchin, Mario de Michele, Alessandro Tafuri, Marco Sebben, Maria Angela Cerruto, Vincenzo De Marco, Filippo Migliorini, Antonio Benito Porcaro, Walter Artibani, Verona, Italy

9:30 PD45-01

**OPIOID USE BEFORE AND AFTER RADICAL PROSTATECTOMY: NATIONALWIDE POPULATION-BASED STUDY**


9:40 PD45-02

**SUPERIOR SHORT- AND LONG-TERM CONTINENCE AFTER EARLY MICTURITION ON DAY TWO AFTER ROBOT-ASSISTED RADICAL PROSTATECTOMY WITH SUPRAPUBIC TUBE PLACEMENT – A RANDOMIZED PROSPECTIVE TRIAL**

Nina Harke*, Essen, Germany, Christian Wagner, Katarina Urbanova, Mustapha Addali, Jorn H. Witt, Gronau, Germany

9:50 PD45-03

**IMPROVING QUALITY OF PROSTATE CANCER SURGERY BY PROVIDING FEEDBACK TO SURGEONS: THE SURGICAL REPORT CARD (SUREP) STUDY**


10:00 PD45-04

**SELECTING IDEAL INTERMEDIATE RISK PATIENTS FOR ACTIVE SURVEILLANCE; A LOOK AT ADVERSE PATHOLOGY AFTER RADICAL PROSTATECTOMY FOR GLEASON SCORE 3+4 ON TARGETED BIOPSY**


10:10 PD45-05

**IMPACT OF AGE ON HEALTH-RELATED QUALITY OF LIFE IN PATIENTS UNDERGOING RADICAL PROSTATECTOMY FOR LOCALIZED PROSTATE CANCER**

Jason Frankel*, Katherine Levie, Fernando Caumont, Seattle, WA, Claire Kuo, Rockville, MD, Timothy Brand, Tacoma, WA, Inger Rosner, Bethesda, MD, Sean Stroup, San Diego, CA, John Musser, Honolulu, HI, John Paul Flores, Seattle, WA, Jennifer Cullen, Rockville, MD, Christopher Porter, Seattle, WA

10:20 PD45-06

**ASSESSING THE QUALITY OF SURGICAL CARE FOR CLINICALLY LOCALIZED PROSTATE CANCER: RESULTS FROM THE CEASAR STUDY**

Peter Reisz*, NASHVILLE, TN, Zhiguo Zhao, Nashville, TN, TN, Li-Ching Huang, Tatsuki Koyama, NASHVILLE, TN, Karen Hoffmann, Houston, TX, Ralph Conwill, David Penson, Daniel Barocas, NASHVILLE, TN

10:30 PD45-07

**DEFINING OBJECTIVE SCORING METRICS FOR PROFICIENCY-BASED PROGRESSION TRAINING IN RARP**

Justin Collins*, Melle, Belgium, Anthony Gallagher, Cork, Ireland, Markus Graefen, Hamburg, Germany, Alessandro Larcher, Milano, Italy, Paolo Dell’Oglio, Aalst, Belgium, Peter Wiklund, Stockholm, Sweden, Alexander Mottrie, Aalst, Belgium

10:40 PD45-08

**THE PREDICTIVE FACTORS AND ONCOLOGIC OUTCOMES OF DECREASING TO PATHOLOGIC GLEASON SCORE 6-7 AFTER RADICAL PROSTATECTOMY IN PATIENTS WITH BIOPSY GLEASON SCORE 8-10**

Doo Yong Chung*, Jong Soo Lee, Won Sik Jang, Seoul, Korea, Republic of, In Rae Cho, Gimhae, Korea, Republic of, Young Sig Kim, Goyang, Korea, Republic of, Joong Shik Lee, Seoul, Korea, Republic of, Dong Hoon Lim, Gwangju, Korea, Republic of, Don Gu Lee, Jeon, Kyung Seok, Won Sik Ham, Young deuk Choi, Seoul, Korea, Republic of
11:00   PD45-10 IMPACT OF CLINICAL TUMOR STAGE AND PREOPERATIVE PSA-VALUE ON CANCER SPECIFIC SURVIVAL AND OVERALL SURVIVAL IN PATIENTS WITH GLEASON 9-10 ON PROSTATE BIOPSY.
Gaetan Devos*, Leuven, Belgium, Alberto Briganti, Milan, Italy, Jeffrey Karnes, Rochester, NY, Bertrand Tombal, Brussels, Belgium, Henk Van Der Poel, Amsterdam, Netherlands, Jochen Walz, Marseille, France, Alberto Bossi, Villejuif, France, Gert De Meerleer, Hein Van Poppel, Leuven, Belgium, Gian Silvio Marchioro, Novara, Italy, Lisa Moris, Thomas Van den Broeck, Leuven, Belgium, Markus Graefen, Hamburg, Germany, Christian Gratze, Munich, Germany, Rafael Sanchez-Salas, Paris, France, Martin Spahn, Zürich, Switzerland, Wouter Everaerts, Leuven, Belgium, Paolo Gontierro, Turin, Italy, Steven Joniau, Leuven, Belgium

11:10   PD45-11 IDENTIFYING THE OPTIMAL DEFINITION FOR EARLY BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY: A RISK-STRATIFIED APPROACH TO OPTIMIZE POSTOPERATIVE FOLLOW-UP AND THE USE OF TIMELY SALVAGE THERAPIES
Elio Mazzone*, Giorgio Gandaglia, Milan, Italy, Sophie Knipper, Markus Graefen, Hamburg, Germany, Andrea Gallina, Milan, Italy, Derya TIlki, Hamburg, Germany, Nazareno Suardi, Marco Bandini, Milano Cucchiara, Armando Stabile, Paolo Dell'Oglio, Nicola Fossati, Francesco Montorsi, Alberto Briganti, Milan, Italy

11:20   PD45-12 DEVELOPMENT AND EXTERNAL VALIDATION OF A NOVEL RISK SCORE TO PREDICT LONG-TERM CLINICAL RECURRENCE AFTER RADICAL PROSTATECTOMY
Elio Mazzone*, Giorgio Gandaglia, Milan, Italy, Sophie Knipper, Markus Graefen, Derya TIlki, Hamburg, Germany, Giuseppe Rosiello, Giuseppe Fallara, Marco Bandini, Armando Stabile, Carlo Bravi, Paolo Dell'Oglio, Nicola Fossati, Francesco Montorsi, Alberto Briganti, Milan, Italy

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Sunday, May 5, 2019 9:30 am - 11:30 am
Podium Session 46
KIDNEY CANCER: LOCALIZED: SURGICAL THERAPY V
Room W184d @ McCormick Place
Moderators: Ashok Hemal, Casey Ng & Alejandro Rodriguez

<table>
<thead>
<tr>
<th>ABSTRACT TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:30</td>
<td>PD46-01</td>
<td>IMPACT OF TIME-TO-SURGERY AND SURGICAL DELAY ON ONCOLOGIC OUTCOMES FOR RENAL CELL CARCINOMA</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Benjamin Shift*, Winnipeg, Canada, Rodney Breau, Ottawa, Canada, Premal Patel, Miami, FL, Anil Kapoor, Hamilton, Canada, Frederic Pouliot, Quebec City, Canada, Alan So, Vancouver, Canada, Ricardo Rendon, Halifax, Canada, Ron Moore, Edmonton, Canada, Antonio Pinelli, Toronto, Canada, Simon Tanguay, Montreal, Canada, Luke Lavallee, Calgary, Canada, Jean-Baptiste Lattouf, Montreal, Canada, Jun Kawakami, Calgary, Canada, Daniel Heng, Edmonton, Canada, Ranjeeta Mallick, Ottawa, Canada, Darrell Drachenberg, Winnipeg, Canada</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ABSTRACT TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:40</td>
<td>PD46-02</td>
<td>DELAYED NEPHRECTOMY HAS COMPARABLE LONG-TERM OVERALL SURVIVAL TO IMMEDIATE NEPHRECTOMY FOR CT1A RENAL CELL CARCINOMA: A RETROSPECTIVE COHORT STUDY.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Wei Shen Tan*, London, United Kingdom, Quoc-Dien Trinh, Boston, MA, Matthew Hayn, Portland, MA, Maya Marchese, Stuart Lipsitz, Junaid Nabi, Kerry Kilbridge, Adam Kibel, Maxine Sun, Steven Chang, Jesse Sammon, Boston, MA</td>
</tr>
</tbody>
</table>

*Presenting author
9:50 PD46-03 NEGATIVE IMPACT OF POSITIVE MARGINS IN PARTIAL NEPHRECTOMY IN STAGE 1 RENAL CELL CARCINOMA: A MULTICENTER ANALYSIS

10:00 PD46-04 IMPACT OF POSITIVE SURGICAL MARGINS AFTER PARTIAL NEPHRECTOMY

10:10 PD46-05 A PROSPECTIVE, MULTICENTER EVALUATION OF PREDICTIVE FACTORS FOR POSITIVE SURGICAL MARGINS AFTER PARTIAL NEPHRECTOMY FOR RENAL CELL CARCINOMA: THE RECORD2 PROJECT.
Andrea Mari*, Riccardo Tellini, Riccardo Campi, Firenze, Italy, Riccardo Schiavina, Bologna, Italy, Daniele Amparore, Orbassano, Torino, Italy, Alessandro Antonelli, Brescia, Italy, Maurizio Barale, Torino, Italy, Roberto Bertini, Milano, Italy, Marco Borghesi, Bologna, Italy, Pierluigi Bove, Roma, Italy, Eugenio Brunocicl, Bologna, Italy, Umberto Capitanio, Milano, Italy, Luigi Da Pozzo, Bergamo, Italy, Paolo Gontero, Torino, Italy, Nicola Longo, Naples, Italy, Emanuele Montanari, Milano, Italy, Francesco Porpiglia, Orbassano, Torino, Italy, Sergio Sanni, Florence, Italy, Claudio Simeone, Brescia, Italy, Salvatore Siracusano, Verona, Italy, Carlo Trombettta, Trieste, Italy, Alessandro Volpe, Novara, Italy, Vincenzo Ficarra, Messina, Italy, Marco Carini, Andrea Minervini, Firenze, Italy

10:20 PD46-06 PLATELET COUNT IS AN INDEPENDENT PREDICTOR OF POST-SURGICAL RECURRENCE IN HIGH RISK NON-METASTATIC RENAL CELL CARCINOMA
Emily L Davidson*, Madison, WI, Viraj A. Master, Atlanta, GA, Jay D. Raman, Brian Sohl, Hershey, PA, Philippe E. Spiess, Charles C. Peyton, Tampa, FL, Suzanne B Merril, Brian Sohl, Hershey, PA, Dattatraya Patil, Atlanta, GA, Daniel D. Shapiro, Glenn O. Allen, Edwin Jason Abel, Madison, WI

10:40 PD46-08 EARLY RECURRENCE PATTERNS SHOULD INFORM SURVEILLANCE PROTOCOLS FOLLOWING SURGERY FOR HIGH RISK NON-METASTATIC RENAL CELL CARCINOMA
Leo D. Dreyfuss*, Madison, WI, Viraj A. Master, Atlanta, GA, Jay D. Raman, Hershey, PA, Philippe E. Spiess, Charles C. Peyton, Tampa, FL, Suzanne B Merril, Brian Sohl, Hershey, PA, Dattatraya Patil, Atlanta, GA, Daniel D. Shapiro, Glenn O. Allen, Edwin Jason Abel, Madison, WI

10:50 PD46-09 DEVELOPMENT AND VALIDATION OF A RISK SCORE BASED ON PATIENT CHARACTERISTICS TO PREDICT MAJOR COMPLICATIONS AFTER PARTIAL NEPHRECTOMY
Melissa J. Huynh*, Ye Wang, Daniel Pucheril, Dimitar V. Zlatev, Alice X. Yu, Boston, MA, Benjamin I. Chung, Stanford, CA, Steven L. Chang, Boston, MA

11:00 PD46-10 CLINICAL OUTCOME AND CHARACTERISTICS OF 41 PATIENTS UNDERWENT SELECTIVE ARTERY EMBOLIZATION FOR POSTOPERATIVE BLEEDING FOLLOWING 2076 PARTIAL NEPHRECTOMY
Doo Yong Chung*, Jong Soo Lee, AHMAD ALMUJALHEM, Ali Raheem, Ki don Chang, Jin Hyeong Jeon, Don Gu Lee, Jang Hwan Kim, Sung Jun Hong, Byung Ha Chung, Young deuk Choi, Koon Ho Rha, seoul, Korea, Republic of

11:10 PD46-11 OUTCOMES FOLLOWING VENA CAVA LIGATION DURING RADICAL NEPHRECTOMY AND IVC THROMBECTOMY
Scott Lundy*, Mohamed Eltemamy, Molly DeWitt-Foy, Ahmed Elshafei, Venkatessh Krishnamurthi, Cleveland, OH

11:20 PD46-12 LONG TERM OUTCOMES OF PATIENTS WITH LOW GRADE CYSTIC EPITHELIAL RENAL NEOPLASMS
Mary E Westerman*, Vidit Sharma, Christine Lohse, Stephen A. Boorjian, Bradley C. Leibovich, John C. Cheville, R. Houston Thompson, Rochester, MN

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
**Podium Session 47**

**BLADDER CANCER: INVASIVE IV**

Room W185a @ McCormick Place

**Moderators:** Esuvaranathan Kesavan, Sherri Donat & Alan Nieder

<table>
<thead>
<tr>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
<th>ABSTRACT</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:30</td>
<td>PD47-01</td>
<td>BMS-986205, AN INDOLEAMINE 2,3-DIOXYGENASE 1 INHIBITOR, PLUS NIVOLUMAB: UPDATED SAFETY ACROSS ALL TUMOR COHORTS AND EFFICACY IN ADVANCED BLADDER CANCER</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><em>Jason Luke</em>, Chicago, IL, Josep Tabernero, Barcelona, Spain, Karen Gelmon, Vancouver, Canada, Andrea Varga, Villejuif, France, Victor Moreno, Madrid, Spain, Jayesh Desai, Ben Markman, Melbourne, Australia, Carlos Gomez-Roca, Toulouse, France, Filippo De Braud, Milan, Italy, Sandip Patel, La Jolla, CA, Matteo Carlino, Sydney, Australia, Lillian Siu, Toronto, Canada, Giuseppe Curigliano, Milan, Italy, Zhaohui Liu, Yuko Ishii, Megan Wind-Rotolo, Paul Basciano, Alex Azrilevich, Princeton, NJ, Anthony Joshua, Sydney, Australia</td>
<td></td>
</tr>
<tr>
<td>9:40</td>
<td>PD47-02</td>
<td>INTENSIFIED AND STANDARDIZED DIGITAL COMMUNICATION WITH CYSTECTOMY PATIENTS POTENTIALLY IS A SIMPLE AND EFFECTIVE WAY TO DECREASE READMISSIONS</td>
<td><em>Frederic Birkhäuser, Felix Moltzahn, Jean-Luc Zehnder, Sebastian Flückiger, Daniel Hasler, Pascal Zehnder</em>, Lucerne, Switzerland</td>
</tr>
<tr>
<td>9:50</td>
<td>PD47-03</td>
<td>CHARACTERIZING THE LANDSCAPE OF ACTIONABLE GENOMIC ALTERATIONS TO IDENTIFY OPPORTUNITIES FOR TARGETED THERAPY TRIALS IN PATIENTS WITH LOCALIZED BLADDER CANCER</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><em>Nima Almassi</em>, Eugene Pietzak, Nikolaus Schultz, Aleksandra Walasek, Hikmat Al-Ahmadie, Min Yuen Teo, Samuel Funt, Dean Bajorin, Jonathan Rosenberg, Gopa Iyer, Guido Dalbagni, Bernard Bochner, David Solit, New York, NY</td>
<td></td>
</tr>
<tr>
<td>10:00</td>
<td>PD47-04</td>
<td>SURGICAL AND ONCOLOGIC OUTCOMES IN PATIENTS UNDERGOING RADICAL CYSTECTOMY FROM 1995-2015: THE MEMORIAL SLOAN KETTERING EXPERIENCE</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><em>Nima Almassi</em>, Eugene Cha, Emily Vertosick, Chun Huang, Nathan Wong, Shawn Dason, Victor McPherson, Lucas Dean, Nicole Benfante, Daniel Sjoberg, Dean Bajorin, Jonathan Rosenberg, Guido Dalbagni, Andrew Vickers, Bernard Bochner, New York, NY</td>
<td></td>
</tr>
<tr>
<td>10:10</td>
<td>PD47-05</td>
<td>PREVALENCE OF ACTIONABLE GENOMIC ALTERATIONS AND THE USE OF TARGETED THERAPY IN METASTATIC UROTHELIAL CARCINOMA</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><em>Nima Almassi</em>, Eugene Pietzak, Samuel Funt, Aleksandra Walasek, Nikolaus Schultz, Guido Dalbagni, Bernard Bochner, Hikmat Al-Ahmadie, Min Yuen Teo, Dean Bajorin, Jonathan Rosenberg, Gopa Iyer, David Solit, New York, NY</td>
<td></td>
</tr>
<tr>
<td>10:20</td>
<td>PD47-06</td>
<td>THE PROGNOSTIC SIGNIFICANCE OF THE ANDROGEN RECEPTOR GENE AND SINGLE NUCLEOTIDE POLYMORPHISMS IN ANDROGEN-REGULATED GENES IN PATIENTS WITH CONCOMITANT BLADDER AND PROSTATE CANCER</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><em>Georgios Gakis</em>, Tina Schubert, Würzburg, Germany, Maritta Munz, Arnulf Stenzl, Markus Renninger, Tübingen, Germany</td>
<td></td>
</tr>
<tr>
<td>10:30</td>
<td>PD47-07</td>
<td>UTILITY OF ROUTINE PREOPERATIVE 18-FLOURODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY IN IDENTIFYING PATHOLOGIC LYMPH NODE METASTASES AT RADICAL CYSTECTOMY</td>
<td></td>
</tr>
<tr>
<td>10:40</td>
<td>PD47-08</td>
<td>FIERCE-21: PHASE 2 STUDY OF VOFATMAB (B-701), A SELECTIVE INHIBITOR OF FGFR3, AS SALVAGE THERAPY IN METASTATIC UROTHELIAL CARCINOMA (MUCC)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><em>Andrea Necchi</em>, Milan, Italy, Daniel Castellano, Madrid, Spain, Begona Mellado, Barcelona, Spain, See Tong Pang, Taoyuan, Taiwan, Urun Yuksel, Ankara, Turkey, Se Hoon Park, Seoul, Korea, Republic of, Ulka Vaishampayan, Detroit, MI, Graeme Currie, Steve Abella, San Ramon, CA, Sumanta Pal, Los Angeles, CA</td>
<td></td>
</tr>
</tbody>
</table>

*Presenting author*
10:50 PD47-09 FIRST SURVIVAL OUTCOMES AND ADDITIONAL SECONDARY ANALYSES FROM PURE-01: PEMBROLIZUMAB (PEMBRO) BEFORE RADICAL CYSTECTOMY (RC) IN MUSCLE-INVASIVE UROTHELIAL BLADDER CARCINOMA (MIBC)
Andrea Necchi*, Marco Bandini, Andrea Gallina, Marco Bianchi, Daniele Raggi, Antonella Messina, Milan, Italy, Jon Chung, Siraj Ali, Jeffrey Ross, Cambridge, MA, Andrea Anichini, Andrea Anichini, Maurizio Colecchia, Giorgio Gandaglia, Nicola Fossati, Simone Scuderi, Filippo Pederzoli, Andrea Salonia, Renzo Colombo, Alberto Briganti, Francesco Montorsi, Milan, Italy

11:00 PD47-10 EPIDURAL USE AT RADICAL CYSTECTOMY IS ASSOCIATED WITH HIGHER PERIOPERATIVE MORBIDITY AND INCREASED READMISSION RATES WITHOUT IMPROVING DISEASE SPECIFIC SURVIVAL: A POPULATION BASED STUDY
Brady L. Miller*, E. Jason Abel, Glenn O. Allen, Jessica R. Schumacher, David F. Jarrard, Tracy M. Downs, Kyle A. Richards, Madison, WI

11:10 PD47-11 A RANDOMIZED CONTROLLED TRIAL COMPARING PERIOPERATIVE OUTCOMES, LENGTH OF HOSPITAL STAY AND COMPLICATIONS FOLLOWING RADICAL CYSTECTOMY WITH AND WITHOUT ENHANCED RECOVERY AFTER SURGERY (ERAS) PROTOCOL
Devanshu Bansal, Brusabhanu Nayak*, Prabhjot Singh, Rishi Nayyar, Amlesh Seth, Rashmi Ramachandran, New Delhi, India

11:20 PD47-12 ENZALUTAMIDE AND PD-L1 INHIBITORS EXERT ANTI-PROLIFERATIVE EFFECTS ON DIFFERENT SIGNALING PATHWAYS IN UROTHELIAL CANCER
Georgios Gakis*, Tina Schubert, Markus Krebs, Hubert Kübler, Elke Butt-Döpke, Burkhard Kneitz, Würzburg, Germany

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Sunday, May 5, 2019
Podium Session 48
9:30 am - 11:30 am

STONE DISEASE: EPIDEMIOLOGY & EVALUATION III
Room W181c @ McCormick Place
Moderators: Amy Krambeck, Matthew Bultitude & Glenn Preminger

ABSTRACT TIME NUMBER TITLE
9:30 PD48-01 ANALGESIC PRESCRIBING PATTERNS IN EMERGENCY DEPARTMENTS FOR ACUTE SYMPTOMATIC UROLITHIASIS IN THE UNITED STATES, 2006-2014
Leonid Aksenov*, Ashley Johnston, Brenton Winship, Russell Terry, Michael Lipkin, Jonathan Routh, Glenn Preminger, Charles Scales Jr., Durham, NC

9:40 PD48-02 PRESCRIPTION OPIOID USE AMONG NEW STONE FORMERS: A MEDICAL EXPENDITURES PANEL STUDY ANALYSIS
Annah Vollstedt*, Lebanon, NH, William Meeks, Aient Ngon, Linthicum, MD, Vernon Pais, Lebanon, NH

9:50 PD48-03 RISK FACTORS FOR PROLONGED OPIATE USE IN PATIENTS WITH ACUTE NEPHROLITHIASIS
Brittney Cotta*, Seth Bechis, San Diego, CA

10:00 PD48-04 UPDATE ON INITIAL EXPERIENCE WITH NARCOTIC FREE URETEROSCOPY (NF-URS)
Crystal Valadon*, Louisville, KY, Tim Large, Julia Fiuk, Charles Nottingham, Amy Krambeck, INDIANAPOLIS, IN

10:10 PD48-05 A LONGITUDINAL ASSESSMENT OF THE REPORTING QUALITY OF DEVICE-BASED RANDOMIZED CONTROLLED TRIALS TO TREAT UROLITHIASIS OVER 16 YEARS (2002 TO 2017)
Ellen C Thompson*, Minneapolis, MN, Andrew Lai, Chicago, IL, Luke B Morrey, Philipp Dahm, Minneapolis, MN

10:20 PD48-06 VALIDATION OF A NATURAL LANGUAGE PROCESSING METHOD FOR PHENOTYPING KIDNEY STONE COMPOSITION FROM LARGE-SCALE ELECTRONIC HEALTH RECORDS
Ryan Hsi*, Nashville, TN, Daniel Lee, Philadelphia, PA, Yaomin Xu, Cosmin Bejan, Nashville, TN
10:30 PD48-07 COMPUTER-AIDED DIAGNOSIS WITH A CONVOLUTIONAL NEURAL NETWORK ALGORITHM FOR AUTOMATED DETECTION OF URINARY TRACT STONES USING KUB
Junichiro Ishioka*, Tokyo, Japan, Masaki Kobayashi, Tsuchiura, Japan, Motohiro Fujiwara, Naoko Kawamura, Tetsuo Okuno, Toride, J apan, Yuichi Fukuda, Tomoaki Kohno, Keizo Kawano, Shinji Morimoto, Tsuchiura, J apan, Sho Uehara, Yosuke Yasuda, Toshiki Kijima, Soichiro Yoshida, Minato Yokoyama, Yoh Matsuoka, Kazutaka Saito, Ryota Saiki, Itsuo Kumazawa, Yasuhisa Fuji, Tokyo, J apan

10:40 PD48-08 THE EPIDEMIOLOGY OF URINARY STONE DISEASE IN PREGNANCY: A CLAIMS-BASED ANALYSIS OF 1.2 MILLION PATIENTS
Ericka Sohlberg*, William Brubaker, Chiyuan Amy Zhang, Kai Dallas, Calyani Ganesan, Shen Song, Alan Pao, Joseph Liao, John Leppert, Christopher Elliott, Simon Conti, Stanford, CA

10:50 PD48-09 REVISITS AFTER AMBULATORY SURGICAL STONE REMOVAL: AN ANALYSIS OF THE HEALTHCARE COST AND UTILIZATION PROJECT
Katharine Michel*, Philadelphia, PA,_Hiten Patel, Brian Matlaga, Baltimore, MD, Justin Ziemb, Philadelphia, PA

11:00 PD48-10 A QUALITATIVE ANALYSIS OF DECISIONAL CONFLICT IN KIDNEY STONE PATIENTS
Daniel Brownstein*, Sylvia Lambrechts, Matthew Dunn, Chris Saigal, Nishant Patel, Los Angeles, CA

11:10 PD48-11 IMPACT OF ACUTE CARE UROLOGY SERVICE ON CARE OF THE ACUTE STONE PATIENT
Nina Mikkilineni*, David Weiner, Gen Li, Ojas Shah, Kelly A. Healy, New York, NY

11:20 PD48-12 DEVELOPMENT AND VALIDATION OF THE CAMBRIDGE RENAL STONE PATIENT (CRESPP) REPORTED OUTCOME MEASURE
Mostafa Ragab, Salisbury, United Kingdom, Jane Collie, Nikolay Baldin, Cambridge, United Kingdom, Maxine Tran, London, United Kingdom, James Armitage, Samih Al Hayek, Oliver Wiseman*, Cambridge, United Kingdom

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Sunday, May 5, 2019 9:30 am - 11:30 am

Video Session 8

RENAI AND PROSTATE II: TECHNIQUES
The videos in this session as well as the video libraries from the 2012-2018 Annual Meetings may be viewed in the Surgical Video Library and purchased in the AUA Store during the Annual Meeting. AUA members receive free online access to the Surgical Video Library throughout the year through AUA University. Visit www.AUAnet.org/University to access.

Room W187b @ McCormick Place
Moderators: Jim Hu, Robert Figenshau & Manish Patel

<table>
<thead>
<tr>
<th>ABSTRACT</th>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:30</td>
<td>V08-01</td>
<td>ROBOT-ASSISTED SINGLE PORT PARTIAL NEPHRECTOMY USING THE SP SURGICAL SYSTEM: FIRST CLINICAL EXPERIENCE</td>
<td>Juan Garisto*, Riccardo Bertolo, Mohamed Ellemamy, Jihad Kaouk, Cleveland, OH</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ABSTRACT</th>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00</td>
<td>V08-04</td>
<td>MAGNETIC RESONANCE / ULTRASOUND FUSION-GUIDED CRYOABLATION OF THE PROSTATE</td>
<td>Robert Wang*, Matthew Davenport, Nicole Curi, Prasad Shankar, David Miller, Arvin George, Ann Arbor, MI</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ABSTRACT</th>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:40</td>
<td>V08-02</td>
<td>OFFICE-BASED, ULTRASOUND-GUIDED RENAL MASS BIOPSY: TECHNIQUE AND RESULTS</td>
<td>Francis Jefferson*, Zhamshid Okhunov, John Sung, Courtney Cottone, Roshan Patel, Jaime Landman, Orange, CA</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ABSTRACT</th>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:10</td>
<td>V08-05</td>
<td>3D ELASTIC AUGMENTED REALITY ROBOT ASSISTED PARTIAL NEPHRECTOMY FOR INTRARENAL AND POSTERIOR RENAL MASSES: THE NEW COMPASS TO SAIL INTO THE SEASTORM</td>
<td>Francesco Porpiglia, Enrico Checucci, Daniele Amparone, Federico Piramide, Pietro Piazzolla, Andrea Bellin, Cristian Fion*, Orbassano, Italy</td>
</tr>
</tbody>
</table>

*Presenting author
10:00 V08-06  VALIDATION OF A FULL-IMMERSION SIMULATION PLATFORM WITH PERFORMANCE METRICS FOR ROBOTIC RADICAL PROSTATECTOMY (RARP) USING THREE-DIMENSIONAL PRINTING AND HYDROGEL MOLDING TECHNOLOGY


11:00 V08-10  MANAGEMENT OF INTRAOPERATIVE COMPLICATIONS DURING ROBOTIC RENAL AND URETERAL ONCOLOGIC SURGERY: THE LESSONS WE LEARNED

Saman Shafaat Talab*, Newark, NJ, Michael Stifelman, Hackensack, NJ

10:30 V08-07  PROSTATE CANCER: USE OF TARGETED BIOPSY INFORMATION FOR PLANNING PARTIAL GLAND ABLATION WITH HIGH-INTENSITY FOCUSED ULTRASOUND

Alan Priester*, Rajiv Jayadevan, Maxime Rappaport, Danielle Barsa, Merdie Delfin, Felker Ely, Shyam Natarajan, Leonard Marks, Los Angeles, CA

11:10 V08-11  3D DIGITAL RECONSTRUCTION OF RENAL MODEL TO IMPROVE PREOPERATIVE PLANNING OF ROBOT ASSISTED PARTIAL NEPHRECTOMY

Riccardo Schiavina*, Lorenzo Bianchi, Andrea Angiolini, Umberto Barbaresi, Barbara Bortolani, Laura Cercenelli, Marco Borghesi, Francesco Chessa, Elisa Sessagesimi, Caterina Gaudiano, Enrico Molinaroli, Emanuela Marcelli, Eugenio Brunocilla, Bologna, Italy

10:40 V08-08  A NOVEL CASE COMBINING PSMA BASED (18)F-DCFPPYL PET/CT AND MRI/ULTRASOUND FUSION GUIDED BIOPSY TO ASSESS LOCAL RECURRENCE OF PROSTATE CANCER

Gustavo Pena*, Shawn Marhamati, Peter Pinto, Baris Turkbey, Bradford Wood, Sandeep Gurram, Peter Choyke, Bethesda, MD

11:20 V08-12  NEW FRONTIERS: EXTRACORPOREAL VASCULAR RECONSTRUCTION WITH ROBOTIC RENAL AUTOTRANSPLANTATION

Jinna Yao*, Ahmer Hameed, Richard Allen, Henry Pleas, Vincent Lam, Scott Leslie, Lawrence Kim, Howard Lau, Sydney, Australia

10:50 V08-09  IMAGE-GUIDED ROBOT-ASSISTED PARTIAL NEPHRECTOMY (IGRAPN): COMBINING 3 IMAGING TECHNIQUES TO PERFORM AN ANATOMICAL ZERO ISCHEMIA HEMI-NEPHRECTOMY.

Lambert Gury*, Pietro Grande, Jean-Christophe Bernhard, Bordeaux, France

Sunday, May 5, 2019

Forums

10:00 am - 4:15 pm

10:00 18TH IPF INTRODUCTIONS & AUA PCA PROGRAMS

Co-Chairs: John Davis, Neal Shore

10:05 SESSION I: BEST OF CHICAGO!

Moderator: Neal Shore

HOW ADVANCED IMAGING & ADVANCED SURGICAL TECHNIQUE CAN IMPACT MANAGEMENT OF LOCALIZED, HIGH-RISK PROSTATE CANCER

Edward Schaefller

10:25 POTENT ANDROGEN RECEPTOR TARGETED COMBINATION THERAPY IN CASTRATION SENSITIVE DISEASE: WHEN, WHY, & HOW

Walter Stadler

10:45 GERMLINE TESTING FOR PROSTATE CANCER DECISION MAKING: FROM SCREENING TO ADVANCED DISEASE

Brian Helfand

11:05 ADVANCED PROSTATE CANCER: PROGRESS AND ONGOING DISCOVERIES

Maha Hussain

11:25 SESSION II: PSA SCREENING AND DIAGNOSTIC CONTROVERSIES

Moderators: John Davis, Derya Tilki

PSA SCREENING: WHAT MORE CAN WE LEARN FROM PIVOTAL RCT’S?

Jeremy Shelton

11:40 NEXT GENERATION BIOMARKERS: AS REFLEX, COMBINATION, OR FIRST LINE?

E. David Crawford

11:55 DISCUSSION POINTS: MAXIMIZING RISK STRATIFICATION WITHOUT MRI

John Davis, Derya Tilki, Jeremy Shelton, E. David Crawford

12:05 BREAK FOR LUNCH

1:05 SESSION III: IMAGING UPDATE

Moderators: Brian Chapin, Osamu Ukimura
PSMA PET IMAGING: AUSTRALIAN EXPERIENCE AND INTRODUCTION TO THERANOSTICS
Nathan Lawrentschuk

1:30 IMAGING CASE DISCUSSIONS
Panelists: Brian Chapin, Nathan Lawrentschuk Osamu Ukimura

1:45 SESSION IV: PROSTATE CANCER AND ECONOMICS
Moderators: Badar Mian, Neal Shore

COST EFFECTIVE MANAGEMENT OF PROSTATE CANCER IN 2019
Michael Fabrizio, Yair Lotan

2:30 Q&A WITH MODERATORS
Moderators: Badar Mian, Neal Shore

2:45 SESSION V: RAPID FIRE TOPICS IN CLINICALLY SIGNIFICANT LOCALIZED TO METASTATIC DISEASE
Moderators: Mevlana Derya Balbay, Satoru Takahashi

WHAT IS CLINICALLY SIGNIFICANT PROSTATE CANCER IN 2019? IMPLICATIONS FOR DIAGNOSTIC AND THERAPEUTIC STRATEGIES
Peter Albertsen

ERECTILE FUNCTION IN TREATED PATIENTS WITH PROSTATE CANCER: ARE WE MAKING ANY PROGRESS?
John Mulhall

RADIATION THERAPY IN 2019: PRACTICE CHANGING CLINICAL TRIALS
Daniel Spratt

EARLY PSA FAILURE: UPDATE ON SALVAGE THERAPY, NOVEL IMAGING, CLINICAL TRIALS
Judd Moul

HORMONE NAÎVE METASTATIC DISEASE: ABLIRATERONE VS CHEMOTHERAPY
William Oh

CONCLUDING REMARKS
Co-Chairs: John Davis, Neal Shore

Sunday, May 5, 2019

Moderated Poster Session 58
SEXUAL FUNCTION/DYSFUNCTION: MEDICAL, HORMONAL & NON-SURGICAL THERAPY III
Room W175ab @ McCormick Place
Moderators: Nelson Bennett, Boback Berookhim & Serge Carrier

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP58-01</td>
<td>TESTOSTERONE PROFILES AFTER BRACHYTHERAPY FOR LOCALIZED PROSTATE CANCER</td>
</tr>
<tr>
<td></td>
<td>Hisanori Taniguchi*, Shigenari Kawakita, Hidefumi Kinoshita, Takashi Murota, Tadashi Matsuda, Hirakata, Japan</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP58-02</td>
<td>ANDROGENS AND GEOGRAPHY: VARIATIONS IN ANDROGEN LEVELS AND SEXUAL FUNCTION BETWEEN NORTH AMERICAN AND EUROPEAN MEN</td>
</tr>
<tr>
<td></td>
<td>Mahmoud Mima*, C.Danielle Tan, Rodrigo L Pagani, Chicago, IL, Stephen J Freedland, Los Angeles, CA, Gerald L Andriole, St. Louis, MO, Samuel J Ohlander, Daniel M Moreira, Chicago, IL</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP58-03</td>
<td>OCCURRENCE OF PULMONARY OIL MICROEMBOLISM AFTER TESTOSTERONE UNDECANOATE INJECTION: A POSTMARKETING SAFETY ANALYSIS</td>
</tr>
<tr>
<td></td>
<td>Alexander Pastuszak*, Salt Lake City, UT, Yiqun Hu, Chace Wayne, Jeffrey Freid, Malvern, PA</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP58-04</td>
<td>A RANDOMIZED DOUBLE BLINDED PLACEBO CONTROLLED CROSSOVER PILOT TRIAL BETWEEN ANASTROZOLE AND CLOMIPHENE TO EVALUATE IMPROVEMENT IN HYPOGONADAL SYMPTOMS AND ERECTILE FUNCTION</td>
</tr>
<tr>
<td></td>
<td>Joseph Mahon*, MAYWOOD, IL, Sevann Helo, Minneapolis, MN, Joseph Ellen, Richmond, VA, Paul Fuestel, Charles Welliver, Albany, NY, Andrew McCullough, Burlington, MA</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP58-05</td>
<td>A NOMOGRAM PREDICTING TESTOSTERONE RESPONSE IN MEN ON CLOMIPHENE</td>
</tr>
<tr>
<td></td>
<td>Carolyn A. Salter*, New York, NY, Alexander Zajichek, Cleveland, OH, Nicole Benfante, New York, NY, Michael Kattan, Cleveland, OH, John P. Mulhall, New York, NY</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP58-06</td>
<td>ASSESSMENT OF ERYTHROCYTOSIS FOLLOWING LONG-ACTING TESTOSTERONE SUPPLEMENTATION</td>
</tr>
<tr>
<td></td>
<td>Garrick M. Greear*, LA Jolla, CA, Yash Khandwala, Stanford, CA, Brian Nguyen, Tung-Chin Hsieh, LA Jolla, CA</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP58-07</td>
<td>ERYTHROCYTOSIS DURING TESTOSTERONE THERAPY: ROLE OF UNDIAGNOSED OBSTRUCTIVE SLEEP APNEA</td>
</tr>
<tr>
<td></td>
<td>Neel Parekh*, Daniel Shoskes, Cleveland, OH</td>
</tr>
</tbody>
</table>
MP58-08 OSTEOCALCIN AS A NOVEL REGULATOR OF TESTOSTERONE PRODUCTION: A BENCH TO BEDSIDE STUDY IN RATS AND HUMANS
Natasza Posielski*, Jordan Krieger, Madison, WI, Arthur Burnett, Haolin Chen, Barry Zirkin, Baltimore, MD, Brian Le, Madison, WI

MP58-09 EFFECT OF TESTOSTERONE SUPPLEMENTATION THERAPY ON BONE HEALTH AMONGST MEN WITH TESTOSTERONE DEFICIENCY: A META-ANALYSIS OF RANDOMIZED PLACEBO-CONTROLLED TRIALS
Alexandra Berger*, Valary Raup, Ramy Abou Ghadha, Paul Bain, Martin Kathrins, Boston, MA

MP58-10 BIOCHEMICAL RECURRENCE RATES IN MEN WITH HIGH GRADE PROSTATE CANCER ON TESTOSTERONE THERAPY
Helen Levey Bernie*, Carolyn A. Salter, Elizabeth A Schofield, Nicole Benfante, John P Mulhall, NY, NY

MP58-11 TESTOSTERONE RECOVERY AFTER CHEMOTHERAPY
Helen Levey Bernie*, Carolyn A. Salter, Elizabeth A Schofield, Nicole Benfante, John P Mulhall, NY, NY

MP58-12 SAFETY OF TESTOSTERONE REPLACEMENT AFTER RADIATION THERAPY FOR LOCALIZED PROSTATE CANCER: A POPULATION-BASED ANALYSIS
Reith Sarkar, J Parsons*, John Einck, Arno Mundt, A Karim Kader, Christopher Kane, Paul Riviere, Rana McKay, James Murphy, Brent Rose, La Jolla, CA

MP58-13 TESTOSTERONE THERAPY IN MEN WITH GLEASON 6-7 PROSTATE CANCER
John Mulhall*, Nicole Benfante, New York, NY, Patrick Teloken, Dutton Park, Australia, Boback Berookhim, Lawrence Jenkins, New York, NY

MP58-14 TESTOSTERONE THERAPY IN MEN ON ACTIVE SURVEILLANCE FOR PROSTATE CANCER
John Mulhall*, Nicole Benfante, New York, NY, Patrick Teloken, Dutton Park, Australia, Boback Berookhim, Lawrence Jenkins, New York, NY

MP58-15 HYPOGONADISM IS ASSOCIATED WITH DEATH BUT NOT CARDIOVASCULAR DISEASE
Taylor P. Kohn, Baltimore, MD, Katherine M. Rodriguez*, Houston, TX, Daniel Pichardo, William Meeks, Linthicum, MD, Larry I. Lipshultz, Houston, TX, James M. Hotaling, Alexander Pastuszak, Salt Lake City, UT

MP58-16 PELVIC MUSCLE FLOOR REHABILITATION IN LIFELONG PREMATURE EJACULATION: 48 MONTHS FOLLOW-UP OUTCOMES.
Antonio Luigi Pastore*, Andrea Fuschi, Lorenzo Capone, Gennaro Velotti, Alessia Martoccia, Yazen Al Salhi, Latina, Italy, Ester Illiano, Elisabetta Costantini, Temi, Italy, Antonio Carbone, Latina, Italy

MP58-17 MONITORING TESTOSTERONE (T) LEVELS IN MEN RECEIVING ORAL TESTOSTERONE UNDECANOATE (TU): DEALING WITH POST-COLLECTION CONVERSION OF TU TO T

MP58-18 LARGER THAN LIFE: MOTIVATIONS FOR BODYBUILDING AND ANABOLIC STEROID USAGE
Jonathan Beilan*, Alexander Tatem, Houston, TX, Daniel Mazur, Denver, CO, Jabez Jabez Gordokusu, Nannan Thirumavalavan, Nelson Vergel, Larry Lipshultz, Houston, TX

MP58-19 IMPACT OF WEEKLY SUBCUTANEOUS TESTOSTERONE ENANTHATE ON BLOOD PRESSURE IN A 26-WEEK SAFETY STUDY
Jed Kaminetsky, New York, NY, Marc Gittelman, Adventura, FL, Mohit Khera*, Houston, TX, Martin Miner, Providence, RI, Alexander Pastuszak, Houston, TX, James Tursi, Jonathan Jaffe, Ewing, NJ

MP58-20 PREVALENCE OF BONE DENSITY LOSS IN MEN WITH LOW AND EQUIVOCAL TESTOSTERONE LEVELS
Carolyn A. Salter*, Elizabeth Schofield, Nicole Benfante, John P. Mulhall, New York, NY

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
ABSTRACT NUMBER TITLE
MP59-01 PEYRONIE’S DISEASE PLAQUE TRANSCRIPTOME-WIDE ANALYSIS USING RNA SEQUENCING REVEALS TARGETABLE SIGNALLING PATHWAYS FOR MEDICAL TREATMENT.
Uros Milenkovic*, Rekin’s Janky, Leuven, Belgium, Georgios Hatzichristodoulou, Wurzburg, Germany, Koen van Renterghem, Hasselt, Belgium, Selim Celek, Chelmsford, United Kingdom, Trinity Bivalacqua, Baltimore, MD, Dirk De Ridder, Maarten Albersen, Leuven, Belgium

MP59-02 EVALUATION OF PARACRINE FACTORS CRITICAL FOR HUMAN LEYDIG STEM CELL FUNCTION
HIMANSHU ARORA*, Evert Gonzalez, Joshua M Hare, RANJITH RAMASAMY, MIAMI, FL

MP59-03 Hedgehog signalling regulates leydig stem cell function in subcutaneous autograft
HIMANSHU ARORA*, Maria Sanches Santos Rizzo Zutti, Bruno Nahar, Joshua M Hare, RANJITH RAMASAMY, MIAMI, FL

MP59-04 Caspase signalling in ed patients and animal models
Elizabeth Kalmanek, Shawn Choe, Chicago, IL, Daniel Harrington, Houston, TX, Samuel Stupp, Kevin McVary, Carol Podlasek*, Chicago, IL

MP59-05 SONIC HEDGEHOG RESPONSIVE APOPTOTIC SIGNALLING IN CONTROL AND CN CRUSHED RAT PENIS.
Shawn Choe, Elizabeth Kalmanek, Chicago, IL, Daniel Harrington, Houston, TX, Samuel Stupp, Kevin McVary, Carol Podlasek*, Chicago, IL

MP59-06 RECEPTORS AND SENSORY NERVE PATHWAYS OF THE PENIS: A THREE DIMENSIONAL COMPUTER ASSISTED ANATOMICAL DISSECTION (3DCAAD).
Morgane Flochlay, Nîmes, France, Djibril Diallo, Thomas Bessede, Le Kremlin Bicêtre, France, Evgeny Kharlamov, Oslo, Norway, Vadim Mitrokhin, Moscow, Russian Federation, Michel Prudhomme, Nimes, France, Boris Aleksandrov, Moscow, Russian Federation, Stéphane Droupy*, Nîmes, France

MP59-07 EFFECTS OF EXOSOMES FROM ADIPOSE-DERIVED STEM CELLS ON RECOVERY OF ERECTILE FUNCTION IN A BILATERAL CAVERNOSAL NERVE INJURY RAT MODEL
Yong Hyun Park*, Ae Ryang Jung, Ga Eun Kim, Mee Young Kim, Hyong Woo Moon, Ji Youl Lee, Seoul, Korea, Republic of
MP59-14 TESTOSTERONE ASSOCIATED RELAXATION OF HUMAN CORPUS CAVERNOSUM OF PATIENTS WITH ERECTILE DYSFUNCTION: ARE NON GENOMIC PATHWAYS INVOLVED?
M Ayodhia Soebadi, Leuven, Belgium, Thomas van den Broeck*, Lore Raets, Bert Brone, Koenraad van Renterghem, Hasselt, Belgium

MP59-15 AGE INDUCED NITROSO-REDOX IMBALANCE IS ASSOCIATED WITH SUBCLINICAL HYPOGONADISM
John Lee*, Manish Kuchakulla, Himanshu Arora, Shathiya Kulandavelu, Evert Gonzalez, Thomas Masterson, Joshua Hare, Ranjith Ramasamy, Miami, FL

MP59-16 RESPONSE OF ENDOMETRIUM TO TESTOSTERONE THERAPY IN TRANS MEN AND NON-BINARY PEOPLE UNDERGOING HYSTERECTOMY
OLIVER RALPH*, Nikita Shroff, NIM CHRISTOPHER, Chesham, United Kingdom, ali ahmed, ALISON BERNER, JAMES BARRETT, ANN SANDISON, LONDON, United Kingdom, David Ralph, Chesham, United Kingdom

MP59-17 COMPARISON OF SHORT-ACTING VS. LONG-ACTING TESTOSTERONE GELS ON FSH
Thomas Masterson*, Miami, FL, Gerwin Westfield, Denver, CO, Nathan Bryson, Ross Ormsby, Mississauga, Canada, Ranjith Ramasamy, Miami, FL

MP59-18 CONTRIBUTION OF ORAI CHANNELS TO CONTRACTION OF RAT AND HUMAN CORPUS CAVERNOSUM INCREASES WITH AGING
Esther García Rojo*, Javier Angulo, Borja García Gómez, Juan Justo Quintas, Rocio Santos Pérez de la Blanca, José Medina Polo, Javier Romero-Otero, Madrid, Spain

MP59-19 CYTOKINE ANALYSIS OF PLATELET RICH PLASMA FOR USE IN UROLOGIC THERAPEUTICS
Ethan Matz, Winston Salem, NC, Trent VanHorn*, Ryan Terlecki, Winston-Salem, NC, John Jackson, Winston Salem, NC

MP59-20 EFFICIENCY OF COLONY FORMATION AND DIFFERENTIATION OF HUMAN SPERMATOGENIC CELLS IN TWO DIFFERENT CULTURE SYSTEMS
Keykavos Gholami, Gholamreza Pourmand*, Morteza Koruji, Mohammadali Sadighigilani, Shadan Navid, Mehdi Abbasi, Tehran, Islamic Republic of Iran, Fariborz Izadyar, California, CA

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
MP60-02 FUNCTIONAL OUTCOMES AND COMPLICATIONS OF SALVAGE RADICAL PROSTATECTOMY FOR RECURRENT PROSTATE CANCER: A LARGE, RECENT MULTICENTER SERIES
Paolo Gontero*, Giancarlo Marra, Paolo Alessio, Giorgio Callenis, Antonino Battaglia, Claudia Filippini, Stefania Munegato, Torino, Italy, Fernando Munoz, Aosta, Italy, Marco Oderda, Anna Palazettz, Francesca Pisano, Umberto Ricardi, Torino, Italy, Estefanía Linares, Rafael Sanchez-Salas, Paris, France, Ben Challacombe, Paul Cathcart, Prokar Daspuya, Sanchia Goonewardene, Rick Popert, Declan Cahill, London, United Kingdom, David Gillatt, Raj Persad, Bristol, United Kingdom, Juan Palou, Barcelona, Spain, Steven Joniau, Leuven, Belgium, Thierry Piechaud, Salvatore Smeriz, Bordeaux, France, Alexandre De La Taille, Créteil, France, Morgan Roupert, Paris, France, Simone Alibianni, Roland Van Velthoven, Bruxelles, Belgium, Alessandro Morlacco, Sharma Vidit, Rochester, MN, Giorgio Gandaglia, Alexander Mottie, Aalst, Belgium, Joseph Smith, Shreyas Joshi, Gabriel Fiscus, Nashville, TN, Andre Berger, Monish Aron, Andre Abreu, Inderbir S. Gill, Los Angeles, CA, Henk Van Der Poel, Amsterdam, Netherlands, Derya Tılkı, Hamburg, Germany, Nathan Lawrence, Declan G. Murphy, Melbourne, Victoria, Australia, Gordon Leung, John Davis, Houston, TX, Robert J. Karnes, Rochester, MN

MP60-03 CLINICAL SIGNIFICANCE AND PREDICTORS OF ONCOLOGIC OUTCOME AFTER RADICAL PROSTATECTOMY FOR INVISIBLE PROSTATE CANCER ON MULTIPARAMETRIC MRI
Doo Yong Chung*, Jong Soo Lee, Won Sik Jang, Seoul, Korea, Republic of, In Rae Cho, Gimhae, Korea, Republic of, Young Sig Kim, Goyang, Korea, Republic of, Joong Shik Lee, Seoul, Korea, Republic of, Dong Hoon Lim, Gwangju, Korea, Republic of, Don Gu Lee, Jin Hyung Jeon, Young deuk Choi, Seoul, Korea, Republic of

MP60-04 LONG-TERM ONCOLOGICAL AND FUNCTIONAL OUTCOMES OF HIGH-RISK PROSTATE CANCER FOLLOWING ROBOT-ASSISTED LAPAROSCOPIC PROSTATECTOMY: MINIMUM FOLLOW-UP OF 10 YEARS
Pratik Gurung*, Elizabeth Ellis, Jasmine Wood, Stephen Hassig, Changyong Feng, Ahmed Ghazi, Jean Joseph, Rochester, NY

MP60-05 DE NOVO OVERACTIVE BLADDER AFTER RADICAL PROSTATECTOMY IN PATIENTS WITH PROSTATE CANCER
Jun Nyung Lee, Kyeong-Hyeon Beyeon*, Heon Ha, Jae-Wook Chung, Yun-Sok Ha, Seock Hwan Choi, Bum Soo Kim, Hyun Tae Kim, Tae-Hwan Kim, Eun Sang Yoo, Tae Gyun Kwon, Sung Kwang Chung, Daugyu, Korea, Republic of

MP60-06 90-DAY READMISSION AFTER RADICAL PROSTATECTOMY - A PROSPECTIVE COMPARISON BETWEEN ROBOT-ASSISTED AND OPEN SURGERY

MP60-07 EFFECT OF BLADDER NECK SPARING AT ROBOT-ASSISTED LAPAROSCOPIC PROSTATECTOMY ON POSTOPERATIVE CONTINENCE RATES AND BIOCHEMICAL RECURRENCE
Felix Preissner*, Frankfurt, Germany, Luis Busto, Alexander Haese, Raisa Pompe, Markus Graefen, Derya Tılkı, Hamburg, Germany

MP60-08 INCIDENCE OF PATHOLOGICAL HIGH GRADE AND STAGE CANCERS IN PATIENTS DIAGNOSED WITH MICROFOCAL ADENOCARCINOMA OF THE PROSTATE AT BIOPSY: A MULTICENTER STUDY
Alberto Abrate*, Palermo, Italy, Daniele Romagnoli, Federico Mineo Bianchi, Bologna, Italy, Nicola Pavan, Trieste, Italy, Guglielmo Mantica, Andrea Romagnoli, Carlo Terrone, Genoa, Italy, Carlo Pavone, Vincenzo Serretta, Marco Vella, Palermo, Italy, Eugenio Brunocilla, Bologna, Italy, Andrea Gregori, Virginia Varca, Garbagnate Milanese, Milan, Italy, Alberto Diminutto, Salvatore Siracusano, Verona, Italy, Andrea Lissiani, Trieste, Italy, Angelo Porreca, Abano Terme, Padua, Italy, Riccardo Schiavi, Bologna, Italy, Alchide Simonato, Palermo, Italy

MP60-09 EFFECT OF EXTENDED PELVIC LYMPH NODE DISSECTION ON ONCOLOGIC OUTCOMES IN D’AMICO INTERMEDIATE-AND HIGH-RISK RADICAL PROSTATECTOMY PATIENTS
Felix Preissner*, Frankfurt, Germany, Roderick van den Bergh, Amsterdam, Netherlands, Gorgio Gandaglia, Milan, Italy, Piet Ost, Ghent, Belgium, Christian Sucel, Bucharest, Romania, Prasanna Sooriakumaran, London, United Kingdom, Francesco Montorsi, Milan, Italy, Markus Graefen, Hamburg, Germany, Henk van der Poel, Amsterdam, Netherlands, Alexandre de la Taille, Creteil, France, Alberto Briganti, Milan, Italy, Laurent Salomon, Guillaume Ploussard, Creteil, France, Derya Tılkı, Hamburg, Germany
MP60-10 IMPACT OF POSITIVE SURGICAL MARGIN LENGTH AND GLEASON GRADE AT THE MARGIN ON BIOCHEMICAL RECURRENCE IN PATIENTS WITH ORGAN-CONFINED PROSTATE CANCER.
Felix Preisser*, Frankfurt, Germany, Gilberto Coxilha, Alexander Heinze, Raisa Pompe, Hamburg, Germany, Felix Chun, Frankfurt, Germany, Markus Graefen, Hartwig Huland, Derya Tilki, Hamburg, Germany

MP60-11 HOW DOES SURGEON VARIABILITY IMPACT OVERALL OPERATIVE TIMES FOR ROBOT ASSISTED RADICAL PROSTATECTOMY?
Zaeem Lone*, Ahmed S. Elsayed, Naif A. Aldhaam, Jacob Braun, Rocco Corbisiero, Brett Hull, Sarah Khan, Zhe Jing, Paul May, Gaybrielle B James, Eric Kauffman, James L. Mohler, Khurshid A. Guru, Buffalo, NY

MP60-12 NOMOGRAM WITH PREDICTORS OF BIOCHEMICAL RECURRENCE IN MARGIN POSITIVE PROSTATE CANCER AFTER RADICAL PROSTATECTOMY WITHOUT ADJUVANT RADIOTHERAPY
Dong Hoon Koh*, Jongsoo Lee, Hyeok Jun Goh, Hyun Ho Han, Ji Eun Heo, Seoul, Korea, Republic of, Jae Won Park, Young Sig Kim, Goyang, Korea, Republic of, Dong Hoon Lim, Gwangju, Korea, Republic of, Joong Shik Lee, Seoul, Korea, Republic of, Rae Lim, Goyang, Korea, Republic of, Won Sik Jang, Won Sik Ham, Young Deuk Choi, Seoul, Korea, Republic of

MP60-13 PERIOPERATIVE MANAGEMENT OF DIRECT ORAL ANTIICOAGULANTS IN PATIENTS UNDERGOING RADICAL PROSTATECTOMY; RESULTS OF A PROSPECTIVE ASSESSMENT

MP60-14 COMPARING DEEP LEARNING, MACHINE LEARNING, AND CONVENTIONAL REGRESSION AS PREDICTIVE MODELS OF TIME TO URINARY CONTINENCE AFTER ROBOT-ASSISTED RADICAL PROSTATECTOMY
Andrew Hung*, Jian Chen, Los Angeles, CA, Zequn Liu, Beijing, China, People’s Republic of, Jessica Nguyen, Los Angeles, CA, Sanjay Purushotham, Baltimore, MD, Yan Liu, Los Angeles, CA

MP60-15 USE OF INTRAOPERATIVE 68GALLIUM-PSSMA CERENKOV LUMINESCENCE IMAGING FOR SURGICAL MARGINS IN RADICAL PROSTATECTOMY – A FEASIBILITY STUDY
Nina Harke*, Christopher Darr, Essen, Germany, Maarten Grootendorst, Chesham, United Kingdom, Ina Binse, Pedro Fragoso Costa, Ken Herrmann, Boris Hadaschik, Essen, Germany

MP60-16 THE EORTC QUALITY OF LIFE QUESTIONNAIRE PREDICTS LONG-TERM OVERALL SURVIVAL IN PATIENTS TREATED WITH ROBOTIC ASSISTED RADICAL PROSTATECTOMY: ANALYSIS OF A LARGE SINGLE CENTER COHORT
Cosimo De Nunzio*, Rome, Italy, Antonio Luigi Pastore, Latina, Italy, Riccardo Lombardo, Antonio Nacchia, Rome, Italy, Antonio Carbone, Andrea Fuschi, Latina, Italy, Lorenzo Dutto, Glasgow, United Kingdom, Andrea Tubaro, Rome, Italy, Joem H. Witt, Gronau, Germany

MP60-17 COMPARISON OF OUTCOMES IN SALVAGE ROBOTIC-ASSISTED LAPAROSCOPIC PROSTATECTOMY FOR POST-PRIMARY RADIATION VS. ABLATION THERAPIES
Fikret Onol*, Seetharam Bhat, Travis Rogers, Haritharan Ganapathi, Cathy Jenson, Vipul Patel, Orlando, FL

MP60-18 ROBOT-ASSISTED RADICAL PROSTATECTOMY IN THE ELDERLY: A PROPENSITY-MATCHED COMPARISON OF ONCOLOGICAL AND FUNCTIONAL OUTCOMES

MP60-19 VALIDATION OF MSKCC PRE-PROSTATECTOMY NOMOGRAM IN MEN WHO UNDERGO MRI-TARGETED PROSTATE BIOPSY PRIOR TO RADICAL PROSTATECTOMY
Zachary Glaser*, Jennifer Gordetsky, Sejong Bae, Jeffrey Nix, Kristin Porter, Soroush Rais-Bahrami, Birmingham, AL

MP60-20 LONG-TERM ONCOLOGIC OUTCOMES IN PATIENTS WITH METASTASIS TO THE PROSTATIC ANTERIOR FAT PAD LYMPH NODE
Akhil A. Chandra*, Nadege J. Assassi, Piscataway, NJ, Young Suk Kwon, Nicholas J. Farber, Isaac Y. Kim, New Brunswick, NJ

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP61-01</td>
<td>LONG TERM FUNCTIONAL OUTCOMES AND COMPLICATIONS OF STUDER ORTHOTOPIC NEobladder</td>
</tr>
<tr>
<td></td>
<td>Ernest Chan*, Khalil Hetou, Shiva Nair, Emily Stephenson, Jonathan Izawa, Joseph Chin, London, Canada</td>
</tr>
<tr>
<td>MP61-02</td>
<td>INTRACORPOREAL STUDER ROBOTIC ORTHOTOPIC NEobladder: 1-YEAR FUNCTIONAL RESULTS</td>
</tr>
<tr>
<td></td>
<td>Fabian Obrecht*, Orlando Burkhardt, Christoph Schregel, Marco Randazzo, Christian Padevit, Hubert John, Winterthur, Switzerland</td>
</tr>
<tr>
<td>MP61-03</td>
<td>RENAL FUNCTIONAL ASSESSMENT IN PATIENTS WITH URINARY DIVERSION: WHICH MODALITY FOR WHICH PATIENT?</td>
</tr>
<tr>
<td></td>
<td>Nabil El-Ashry, Ahmed Harraz*, Mohamed Zahran, Mansoura, Egypt, Hossam Nabeeh, Kaf El-Sheikh, Egypt, Rasha Abouelkheir, Mohamed El-Ghara, Ahmed Mosbah, Hassan Abol-Enein, Mansoura, Egypt</td>
</tr>
<tr>
<td>MP61-04</td>
<td>10-YEAR EXPERIENCE WITH NEW MODIFICATION OF THE INDIANA-POUCH CONCERNING THE URETERO-INTESTINAL ANASTOMOSIS: LOW STRICUTURE RATE</td>
</tr>
<tr>
<td></td>
<td>Rolf von Knobloch*, Wasim Abdul Samad, Monika Kibeie, Marc Seybold, Kempten, Germany</td>
</tr>
<tr>
<td>MP61-05</td>
<td>TIME COURSE OF URETEROENTERIC STRICTURES AFTER RADICAL CYSTECTOMY WITH URINARY DIVERSION</td>
</tr>
<tr>
<td></td>
<td>Jim Shen*, Juzar Jamnangerwalla, Bertram Yuh, Jonathan Warner, Avinash Chenam, Patrick Kilday, Ali Zhumkhawala, Jonathan Yamzon, Clayton Lau, Kevin Chan, Duarte, CA</td>
</tr>
<tr>
<td>MP61-06</td>
<td>USE OF INDOCYANINE GREEN TO MINIMIZE URETERO-ENTERIC STRICTURES AFTER ROBOTIC CYSTECTOMY</td>
</tr>
<tr>
<td>MP61-07</td>
<td>INCIDENCE OF PARASTOMAL HERNIA IN ILEAL CONDUIT IS ASSOCIATED WITH SIZE OF PASSAGE THROUGH ABDOMINAL MUSCLE</td>
</tr>
<tr>
<td></td>
<td>Kazutaka Maruo*, Toshiaki Tanaka, Tetsuya Shindo, Kohei Hashimoto, Ko Kobayashi, Fumimasa Fukuta, Naoya Masumori, Sapporo, Japan</td>
</tr>
<tr>
<td>MP61-08</td>
<td>COST-EFFECTIVENESS OF PROPHYLACTIC MESH PLACEMENT FOR PREVENTION OF PARASTOMAL HERNIA IN PATIENTS UNDERGOING ILEAL CONDUIT URINARY DIVERSION FOR BLADDER CANCER</td>
</tr>
<tr>
<td></td>
<td>Diboro Kanabolo*, Chicago, IL, Sangtatee Park, Evanston, IL</td>
</tr>
<tr>
<td>MP61-09</td>
<td>A COMPARATIVE STUDY IN THE SURGICAL MANAGEMENT OF URETEROPERINEAL JUNCTION OBSTRUCTION – OPEN VERSUS RETROPERITONEOSCOPIC PYELOPLASTY</td>
</tr>
<tr>
<td></td>
<td>Venugopalan Chettiyar*, Trivandrum, India</td>
</tr>
<tr>
<td>MP61-10</td>
<td>MULTI-INSTITUTIONAL EXPERIENCE WITH ROBOTIC URETERAL RECONSTRUCTION OF LONG-SEGMENT (&gt;4 CM) PROXIMAL AND MIDDLE URETERAL STRICTURES</td>
</tr>
<tr>
<td>MP61-11</td>
<td>IS ROUTINE POST-OP IMAGING NECESSARY IN THE FIRST YEAR AFTER URETERONEOCYSTOSTOMY?</td>
</tr>
<tr>
<td></td>
<td>Sapan Ambani*, Peyton Skupin, Bahaa Malaeb, Paholo Barboglio-Romo, John Stoffel, Ann Arbor, MI</td>
</tr>
<tr>
<td>MP61-12</td>
<td>AVOID THE DELAY? DOES IMMEDIATE URETERAL RECONSTRUCTION FOR IATROGENIC URETERAL INJURY JEOPARDIZE OUTCOME?</td>
</tr>
<tr>
<td></td>
<td>Sapan Ambani*, Peyton Skupin, Bahaa Malaeb, Paholo Barboglio-Romo, John Stoffel, Ann Arbor, MI</td>
</tr>
<tr>
<td>MP61-13</td>
<td>MODIFIED PSOAS HITCH CAN REPLACE BOARI FLAP WITHOUT COMPROMISING VASCULARITY</td>
</tr>
<tr>
<td></td>
<td>Majid Mirzazadeh, Whitney Smith*, Winston Salem, NC</td>
</tr>
<tr>
<td>MP61-14</td>
<td>SURGICAL OUTCOMES OF RADIATED URETERAL REPAIRS ARE SIMILAR TO NON-RADIATED URETERAL REPAIRS IN APPROPRIATELY SELECTED PATIENTS</td>
</tr>
<tr>
<td></td>
<td>Matthew D Grimes*, Morgan E Schubbe, Bradley A Erickson, Iowa City, IA</td>
</tr>
</tbody>
</table>
MP61-15 UROLOGIC COMPLICATIONS REQUIRING INTERVENTION FOLLOWING HIGH-DOSE PELVIC RADIATION FOR CERVICAL CANCER
Haerin Lee*, Jacqueline Zillioux, David Rapp, Tracey Krupski, Linda Duska, Timothy Showalter, Jennifer Lobo, Noah Schenkman, Charlottesville, VA

MP61-16 OUTCOMES OF URINARY DIVERSION CREATED FOR LATE ADVERSE EFFECTS OF GYNECOLOGIC RADIOTHERAPY
Daniel Smith*, Joseph Pariser, Jacob Albersheim-Carter, Minneapolis, MN, Rachel Moses, Salt Lake City, UT, Diana O’Dell, John Stoffel, Ann Arbor, MI, Jeremy Myers, Salt Lake City, UT, Sean Elliott, Minneapolis, MN

MP61-17 OUTCOMES OF CONTINENT AND INCONTINENT URINARY DIVERSION DURING PELVIC EXENTERATION FOR NON-UROLOGIC MALIGNANCY: A CANCER CENTER EXPERIENCE
Brian M. Blair*, Nora Ruel, Jonathan Yamzon, Ali Zhumkhawala, Clayton Lau, Bertram Yuh, Kevin Chan, Duarte, CA

MP61-18 WHEN ALL ELSE FAILS – A GASTRIC URINARY CONDUIT
Stella Ivaz*, Simon Bugaja, Anastasia Frost, Nikki Jeffrey, Angelica Lomiteng, Mariya Dragova, Daniela E Andrich, Anthony R Mundy, London, United Kingdom

MP61-19 ASSESSMENT OF CAREGIVER BURDEN AFTER URINARY DIVERSION FOR BLADDER CANCER
Wai Lee*, Seattle, WA, Chris Du, Stony Brook, NY, Una Lee, Kathleen Kobashi, John Corman, Alvaro Lucioni, Seattle, WA

MP61-20 PUBECTOMY WITH URINARY RECONSTRUCTION EFFECTIVELY IMPROVES QUALITY OF LIFE AND FUNCTION IN MEN WITH UROSYMPHYSEAL FISTULA AFTER PROSTATE CANCER THERAPY

MP61-21 VESICO-VAGINAL FISTULA REPAIR BY TRANSVAGINAL ROUTE: COMPARISON OF RESOURCE UTILIZATION AND POSTOPERATIVE OUTCOME WITH LITERATURE REPORTED POPULATION MINIMALLY INVASIVE APPROACH COHORT
Rakesh Kapoor*, Sanjay Kumar Sureka, Rahul Jena, Lucknow, India

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
MP62-05 BLOCKADE OF CENTRAL ANGIOTENSIN II TYPE 1 RECEPTORS SUPPRESSES MICTURITION REFLEX IN RATS
Shogo Shimizu*, Takahiro Shimizu, Yoshih Nagao, Kumiko Nakamura, Tamaki Kataoka, Shih Kamada, Youichirou Hiagashi, Takakii Aratake, Soo Zou, Tomoya Hamada, Yusuke Ueba, Masaki Yamamoto, Motoaki Saito, Nankoku, Japan

MP62-06 INJECTING RNA INTERFERENCE LENTIVIRUSES TARGETING THE MUSCARINIC 3 RECEPTOR GENE INTO THE BLADDER WALL INHIBITS NEUROGENIC DETERUSOR OVERACTIVITY IN RATS WITH SPINAL CORD INJURY
Zhenhua Shang*, Tongwen Ou, Beijing, China, People’s Republic of China

MP62-07 PROTECTIVE EFFECT OF L-CITRULINE AND L-ARGININE ON BLADDER FUNCTION IN A RAT MODEL OF CHRONIC PELVIC ISCHEMIA
Nonfumi Sawada, Takahiko Mitsu*, Hiroshi Nakagomi, Satoru Kira, Tatsuya Ibara, Takanori Mochizuki, Masayuki Takeda, Yamanashi, Japan

MP62-08 FIBERPHOTOMETRY AND OPTOGENETICS AS NOVEL TECHNOLOGIES REVEALED REGULATORY FUNCTION OF THE MOUSE ANTERIOR CINGULATE CORTEX IN MICTURITION REFLEX
Takanori Mochizuki*, Satoshi Manita, Takahiko Mistui, Kazuo Kitamura, Tatsuya Ibara, Chuo, Japan

MP62-09 DETERUSOR RELAXATION MEDIATED BY ACTIVATION OF THE SUCCINATE RECEPTOR GPR91.
Abubakr Mossa, Monica Velasquez-Flores, Philippe Cammisotto, Lysanne Campeau*, Montreal, Canada

MP62-10 EVIDENCE OF THE INVOLVEMENT OF TRK A-ALPHA 1A ADRENOCEPTORS IN THE MECHANISMS OF BLADDER PAIN INDUCED BY CHRONIC STRESS
Bruno Dias, Francisco Cruz, Ana Charrua*, Porto, Portugal

MP62-11 SUPERNATANT FROM ACUTE UROPATHOGENIC E-COLI INFECTION EXCLUSIVELY SENSITISES HIGH THRESHOLD BLADDER AFFERENTS AND RECRUITS ‘SILENT NOCICEPTORS’
Luke Grundy*, Adelaide, Australia, Glen Ulett, Gold Coast, Australia, Stuart Brierley, Adelaide, Australia

MP62-12 DYNAMIC ELASTICITY INDUCED VIA EXTERNAL COMPRESS-RELEASE PROTOCOL IN A PERFUSED PORCINE BLADDER MODEL
Andrea Balthazar*, Zachary Cullingsworth, Naveen Nandanan, Uzoma Anle, John Speich, Adam Klausner, Richmond, VA

MP62-13 BDNF IS ESSENTIAL FOR PUDENDAL NERVE MOTOR BRANCH FUNCTIONAL RECOVERY
Kangli Deng*, Brian Balog, Tessa Askew, Danli Lin, Brett Hanzlik, Margot Damaser, Cleveland, OH

MP62-14 MODELING THE AGING BLADDER USING KLOTHO DEFICIENT MICE
Sarah N. Bartolone, Elijah P. Ward, Bernadette M.M. Zwaans, Royal Oak, MI, Zunyi Wang, Madison, WI, Michael B. Chancellor, Laura E. Lamb*, Royal Oak, MI

MP62-15 PHYSIOPATHOLOGY OF NEUROGENIC DETERUSOR OVERACTIVITY : ROLE OF NEUROTROPHINS, INFLAMMATION AND EXTRACELLULAR MATRIX ACCORDING TO THE NEUROLOGICAL DISEASE.

MP62-16 LIQUID CRYSTAL ELASTOMERS AS DYNAMIC MATERIALS FOR THE TREATMENT OF INCONTINENCE
Julia Henricks*, Cedric Ambulo, Mario Romero-Ortega, Richardson, TX, Philippe Zimmern, Dallas, TX, Taylor H. Ware, Richardson, TX

MP62-17 SEQUENTIAL CHANGE FROM BLADDER OVERACTIVITY TO UNDERACTIVITY ON RATS ISCHEMIC BLADDER MODEL INDUCED BY BILATERAL PARTIAL ILIAC ARTERIAL OCCLUSION
Bing-Juin Chiang*, New Taipei City, Taiwan, Chiang-Ting Chien, Taipei, Taiwan

MP62-18 MUSCARINIC RECEPTOR EXPRESSION IN SPINAL CORD TRANSECTED RATS WITH EARLY ANTICHOLINERGIC TREATMENT
George Loutochin, Nikolaj Przydacz, Philippe Cammisotto, Xavier Brardieu, Lysanne Campeau, Jacques Corcos*, Montreal, Canada

MP62-19 LOCALIZATION AND EXPRESSION OF EXTRACELLULAR MATRIX COMPONENTS VERSICAN AND HYALURONAN IN URETHRAL AND VAGINAL TISSUES IN HUMAN SPECIMENS AND IN RAT MODEL OF URINARY INCONTINENCE
Ingrid Harten, Stephen Evanko, Seattle, WA, Jay Choe, San Diego, CA, Eugene Lee, Hayward, CA, Marika Bogdani, Thomas Wight, Una Lee*, Seattle, WA

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
<th>AUTHORS</th>
<th>INSTITUTIONS</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP63-01</td>
<td>PREVENTATIVE EFFECT OF OMEGA-3 POLYUNSATURATED FATTY ACIDS (N-3 PUFA's) AGAINST INDUCTION OF BLADDER CANCER (BC) IN A RAT MODEL.</td>
<td>Mohamed Fadallah*, EL Housseny I., Ibrahim, Ahmed M., El-Assmy, Nashwa M., Barakat, Sherry Khater, Amira Awadalla, Asmaa E. Ahmed, Ahmed Samy, Mahmoud Gaber, M. Abdelbaset, Yara A. Elshennawi, Ahmed A. Shokeir</td>
<td>Mansoura, Egypt</td>
</tr>
<tr>
<td>MP63-02</td>
<td>E-CIGARETTE SMOKE IS POTENTIALLY BLADDER CARCINOGENIC - IT INDUCES DNA DAMAGE AND UROTHELIAL HYPERPLASIA IN MICE</td>
<td>Moon-shong Tang*, Hyun-Wook Lee, New Yok City, NY, Lung-Chi Chen, Fang-Ming Deng, Yong Xia, William Huang, Lepor Herbert, Yue-Ru Wu, New York, NY</td>
<td></td>
</tr>
<tr>
<td>MP63-03</td>
<td>PROBE-BASED CONFOCAL LASER ENDOMICROSCOPY DURING TRANSURETHRAL RESECTION OF BLADDER TUMORS IMPROVES THE DIAGNOSTIC ACCURACY AND THERAPEUTIC EFFICACY</td>
<td>Jongsoo Lee, Doo Yong Chung, Hyeok Jun Goh, Don Gu Lee*, Jin Hyung Jeon, Hyun Ho Han, Ji Eun Heo, Seoul, Korea, Republic of, Jae Won Park, Young Sig Kim, Goyang, Korea, Republic of, Dong Hoon Lim, Gwangju, Korea, Republic of, Joong Shik Lee, Seoul, Korea, Republic of, Rae Cho In, Goyang, Korea, Republic of, Won Sik Jang, Won Sik Ham, Young Deuk Choi, Seoul, Korea, Republic of</td>
<td></td>
</tr>
<tr>
<td>MP63-04</td>
<td>QUANTITATIVE NUCLEAR FEATURES OF HEMATOXYLIN-EOSIN SPECIMENS FROM INITIAL TRANSURETHRAL RESECTION FOR PREDICTING NON-MUSCLE INVASIVE BLADDER CANCER RECURRENCE</td>
<td>Naoto Tokuyama*, Akira Saito, Yosuke Hirasawa, Takeshi Hashimoto, Naoya Satake, Noriko Watanabe, Tatsuo Gondo, Yoshihiro Nakagami, Kazunori Namiki, Masahiko Kuroda, Yoshio Ohno, Tokyo, Japan</td>
<td></td>
</tr>
<tr>
<td>MP63-05</td>
<td>DETECTION OF TELOMERASE ACTIVITY IN URINE FOR NON-INVASIVE DIAGNOSIS OF URINARY BLADDER CANCER</td>
<td>Konstantin Polyakovskiy*, Natalia Potolskaya, Aleksey Glukhov, Sergei Gordeev, Andrei Vinarov, Dmitrii Enikeev, Leonid Rapoport, Petr Glybochko, Moscow, Russian Federation</td>
<td></td>
</tr>
<tr>
<td>MP63-06</td>
<td>COMPARATIVE DETERMINATION OF TERT MUTATIONS IN URINARY SEDIMENT DNA BY NGS AND DDCPR FOR BLADDER CANCER DETECTION</td>
<td>Friederich Stoeckel, Karsten Salomo, Stasik Sebastian, Christian Thiede, Mario Menschikowski, Uliike Heberling, Manfred P. Wirth, Susanne Fuessel*, Dresden, Germany</td>
<td></td>
</tr>
<tr>
<td>MP63-07</td>
<td>URINARY CELL-FREE DNA IQGAP3/BMP4 AND IQGAP3/FAM107A EXPRESSION SIGNATURES SERVE AS BIOMARKERS FOR PROGNOSTIC PREDICTION OF PRIMARY NON-MUSCLE INVASIVE BLADDER CANCER</td>
<td>Won Tae Kim*, Ho Won Kang, Sung Pil Seo, Cheonju, Korea, Republic of, In-Chang Cho, Seoul, Korea, Republic of, Yong-Jeon Kim, Seok-Joong Yun, Sang-Cheol Lee, Wun-Jae Kim, Cheonju, Korea, Republic of</td>
<td></td>
</tr>
<tr>
<td>MP63-08</td>
<td>CD44 VARIANT 9 EXPRESSION IS A NOVEL INDICATOR FOR IDENTIFYING POOR SURVIVAL IN PATIENTS WITH INVASIVE UROTHELIAL CARCINOMA</td>
<td>Koichiro Oghara*, Eiji Kikuchi, Masayuki Hagiwara, Kazuhiro Matsumoto, Shuji Mikami, Hideyuki Saya, Mototsugu Oya, Tokyo, Japan</td>
<td></td>
</tr>
<tr>
<td>MP63-09</td>
<td>IMPACT OF RAGE GENE POLYMORPHISMS ON UROTHELIAL CELL CARCINOMA CLINICOPATHOLOGIC CHARACTERISTICS AND LONG TERM SURVIVAL</td>
<td>Sheng Chun Hung*, Shian-Shiang Wang, Jean-Ri Li, Chuan-Shu Chen, Li-Wen Chang, Chun-Kuang Yang, Kun-Yuan Chiu, Chen-Li Cheng, Yen-Chuan Huo, Hao-Chung Ho, Shun-Fa Yang, Taichung, Taiwan</td>
<td></td>
</tr>
<tr>
<td>MP63-10</td>
<td>FAM81A Germline Copy Number Polymorphism May Predict the Efficacy of BCG Therapy for Non-Muscle Invasive Bladder Cancer</td>
<td>Yoshiaki Yamamoto*, Masahiro Samoto, Junichi Mori, Kosuke Shimizu, Ryo Inoue, Seiji Yano, Hiroki Matsumoto, Hideyasu Matsuyama, Ube, Japan</td>
<td></td>
</tr>
<tr>
<td>MP63-11</td>
<td>CIRCULATING TUMOR CELLS ARE A STRONG PREDICTOR OF CANCER SPECIFIC SURVIVAL IN HIGH RISK NONMUSCLE INVASIVE BLADDER CANCER: FINAL ANALYSIS OF A PROSPECTIVE OBSERVATIONAL STUDY</td>
<td>Gian Maria Busetto*, Francesco Del Giudice, Cristina Raimondi, Paola Gazzangia, Ettore De Berardinis, Roma, Italy</td>
<td></td>
</tr>
</tbody>
</table>
MP63-12 EMPLOYMENT OF A METAGENOMIC APPROACH TO IDENTIFY PUTATIVE PROGNOSTIC BIOMARKERS THAT PERTURB THE CELLULAR CIRCUITY IN BLADDER CANCER
Anirban P Mitra*, Sheetal A Mitra, Siamak Daneshmand, Los Angeles, CA

MP63-13 NEXT-GENERATION SEQUENCING REVEALS GENOMIC DIFFERENCES BETWEEN MALE AND FEMALE PATIENTS WITH UROTHELIAL CARCINOMA

MP63-14 EIGHT GENE EXPRESSION CLASSIFIER FOR NON INVASIVE BLADDER CANCER SURVEILLANCE
Ruth Montalbo*, Juan Jose Lozano, Laura Izquierdo, Mercedes Ingelmo-Torres, Maria Pilar Oria, Juan Palou, Barcelona, Spain, Antoine G. van der Heijden, Nijmegen, Netherlands, Rafael Medina, Sevilla, Spain, Joerg Schmidbauer, Vienna, Austria, Alexi Prat, Maria J. Ribal, Antonio Alcaraz, Lourdes Mengual, Barcelona, Spain

MP63-15 COMPREHENSIVE MOLECULAR CLASSIFICATION OF BLADDER CANCER REVEALS DISTINCT PROGNOSTIC SUBGROUPS WITH DIFFERENT SENSITIVITIES TO IMMUNOTHERAPY
Jongsoo Lee*, Doo Yong Chung, Hyeok Jun Goh, Hyun Ho Han, Ji Eun Heo, Seoul, Korea, Republic of, Jae Won Park, Young Sig Kim, Goyang, Korea, Republic of, Dong Hoon Lim, Gwangju, Korea, Republic of, Joong Shik Lee, Seoul, Korea, Republic of, Rae Cho In, Goyang, Korea, Republic of, Won Sik Jang, Won Sik Ham, Seoul, Korea, Republic of, Sun-Hee Leem, In-Sun Chu, Daejeon, Korea, Republic of, Young Deuk Choi, Seoul, Korea, Republic of

MP63-16 IDENTIFICATION OF NEOANTIGEN CANDIDATES IN BLADDER CANCER REVEALS NEGATIVE CORRELATION BETWEEN ANTIGEN-SPECIFIC IMMUNOREACTIVITY AND INFLAMMATION
Haibo Shen*, Chen Wang, Yuanyong Liu, Qingshen Zhang, Ying Wang, ShangHai, China, People’s Republic of

MP63-17 MITOMYCIN C TRIGGERS IMMUNOGENIC CELL DEATH IN BLADDER CANCER CELLS
Bianca Oresta*, Chiara Pozzi, Rodolfo Hurle, Massimo Lazzeri, Cristina Faccani, Piergiuseppe Colombo, Grazia Elefante, Paolo Casale, Giorgio Guazzoni, Maria Rascigno, Rozzano, Italy

MP63-18 THE IMMUNOTHERAPEUTIC EFFECTS OF RECOMBINANT BACILLUS CALMETTE-GUÉRIN RESISTANT TO ANTIMICROBIAL PEPTIDES ON BLADDER CANCER CELLS
In Ho Chang*, Byung Hoon Chi, Jin Wook Kim, Tae-Hyoun Kim, Kyung Do Kim, Young Tae Moon, Seoul, Korea, Republic of

MP63-19 IMMUNOGENICITY INVESTIGATION ON RECOMBINANT BCG CONTAINING NY-ESO-1 UPON VACCINATION
Haibo Shen*, Chen Wang, Yingying Chen, Jingman Wang, Ying Wang, ShangHai, China, People’s Republic of

MP63-20 STANDARD ANTICANCER AGENTS INCREASE THE CYTOTOXICITY OF HUMAN V199A2T CELL VIA UPREGULATION OF NKG2D LIGANDS IN BLADDER CANCER CELLS
Teruki Shimizu*, Osaka, Japan, Masatsugu Miyashita, Atsuko Fujihara, Fumiya Hongo, Osamu Ukimura, Eishi Ashihara, Kyoto, Japán

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
1:20 PD49-03 TESTING AND VALIDATION OF ISC-Q IN PEDIATRIC PATIENTS AND THEIR CAREGIVERS
Azadeh Wickham*, Susan McElroy, Kansas City, MO

1:30 PD49-04 SOCIETIES FOR PEDIATRIC UROLOGY MEETINGS – ARE WOMEN ADEQUATELY REPRESENTED?
Vi Tran*, Lexington, KY, Madeline Koerner, Elizabeth Tullos, New Orleans, LA, Alison Rasper, Katie Ballert, Deborah Erickson, Amanda Saltzman, Lexington, KY

1:40 PD49-05 PRACTICE TRENDS IN THE MANAGEMENT OF POSTERIOR URETHRAL VALVE OVER A 20 YEAR PERIOD AS REPORTED IN THE PEDIATRIC HEALTH INFORMATION SYSTEM (PHIS) DATABASE
Oluwaseye Ayoola Ogun, John Makari*, Omaha, NE

1:50 PD49-06 ASSESSING THE METHODOLOGICAL AND REPORTING QUALITY OF CLINICAL SYSTEMATIC REVIEWS AND META-ANALYSES IN PAEDIATRIC UROLOGY: CAN WE BUILD PRACTICES ON CONTEMPORARY HIGHEST LEVELS OF EVIDENCE?
Fardod O’Kelly*, Keara De Cotiis, Toronto, Canada, Luis Braga, Hamilton, Canada, Armando Lorenzo, Martin Koyle, Toronto, Canada

2:00 PD49-07 BODY IMAGE AND SEXUAL RISK IN THE NATIONAL LONGITUDINAL STUDY OF ADOLESCENT TO ADULT HEALTH: A NATIONALLY REPRESENTATIVE PROSPECTIVE COHORT STUDY
Kirkpatrick B. Fergus*, Hillary L. Copp, Jason M. Nagata, San Francisco, CA

2:10 PD49-08 SOCIOECONOMIC FACTORS IN THE PRESENTATION AND PROGRESSION OF POSTERIOR URETHRAL VALVES
Devin Rogers BS*, Rajeev Chaudhry MD, Pittsburgh, PA, Patrick Fox MD, Charlotte, NC, Mary Killian MD, Pittsburgh, PA

2:20 PD49-09 INFORMATION THAT MAKES THE CUT: A QUALITATIVE ANALYSIS OF PARENTAL DECISION MAKING FOR NEWBORN CIRCUMCISION
Allison Morgan*, Yue-Yung Hu, Chicago, IL, Gina Lockwood, Iowa City, IA

2:30 PD49-10 NATIONWIDE NEONATAL CIRCUMCISION TRENDS: 2003-2016
Deborah L. Jacobson*, Jane L. Holl, Timothy B. Lautz, Ilina Rosoklija, Emilie K. Johnson, Chicago, IL

2:40 PD49-11 A CRITICAL ANALYSIS OF COMPLICATIONS IN MINIMALLY INVASIVE SURGERY IN PEDIATRIC UROLOGY
Leonid Aksenov*, Durham, NC, Candace Granberg, Patricio Gargollo, Rochester, MN

2:50 PD49-12 NARCOTIC USE IN THE PEDIATRIC POPULATION AFTER UROLOGICAL SURGERY: ARE THEY REALLY NEEDED?
Kelly Parker, Gwen Grimsby*, Phoenix, AZ

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Sunday, May 5, 2019 1:00 pm - 3:00 pm
Podium Session 50
PROSTATE CANCER: LOCALIZED: ACTIVE SURVEILLANCE II
Room W185d @ McCormick Place
Moderators: Martha Terris, Joseph Smith & Laurence Klotz

1:00 PD50-01 ASSESSMENT OF MRI PERFORMANCE IN THE CANARY PROSTATE ACTIVE SURVEILLANCE STUDY (PASS)
Michael Liss*, San Antonio, TX, Michael Garcia, Yingye Zheng, Lisa Newcomb, Seattle, WA, Christopher Filson, Atlanta, GA, Hiliary Bayer, Seattle, WA, James Brooks, Stanford, CA, Peter Carroll, San Francisco, CA, Martin Gleave, Vancouver, Canada, Francis Martin, Virginia Beach, VA, Todd Morgan, Ann Arbor, MI, Peter Nelson, Seattle, WA, Andrew Wagner, Boston, MD, Ian Thompson, San Antonio, TX, Daniel Lin, Seattle, WA

1:10 PD50-02 NATURAL HISTORY OF PROSTATE CANCER ON ACTIVE SURVEILLANCE: STRATIFICATION BY MRI USING THE PRECISE RECOMMENDATIONS IN A UK COHORT OVER 11 YEARS.
Francesco Giganti*, Armando Stabile, Vasillis Stavrinides, Adam Retter, Clement Orczyk, London, United Kingdom, Valeria Panebianco, Rome, Italy, Alex Freeman, Charles Jameson, Shonit Punwani, Clare Allen, Alex Kirkham, Mark Emberton, Caroline M Moore, London, United Kingdom
1:20 PD50-03 IN THE DECADE OF MRI BASED ACTIVE SURVEILLANCE, WHEN DO BIOPSY UPGRAADING RATES STABILIZE?
Michael Ahdoot*, Amir H. Lebastchi, Johnathan Bloom, Patrick Gomella, Sandeep Gurram, Thomas Sanford, Johnathan DiBianco, Samuel Gold, Graham R. Hale, Sherif Mehralivand, Vladimir Valera Romero MD, Maria Merino, Bethesda, MD, M. Minhaj Siddiqui, College Park, MD, Peter L. Choyke, Brad Wood MD, Howard Parnes, Barris Turkbey, Peter A. Pinto, Bethesda, MD

1:30 PD50-04 UTILITY OF MULTIPARAMETRIC MRI IN THE RISK STRATIFICATION OF MEN WITH GRADE GROUP 1 PROSTATE CANCER ON ACTIVE SURVEILLANCE
Mufaddal Mamawala*, Alexa Meyer, Patricia Landis, Katarzyna Macura, Jonathan Epstein, Alan Partin, H. Ballentine Carter, Micheal Gorin, Baltimore, MD

1:40 PD50-05 VISIBLE DISEASE AT BASELINE ACCELERATES TIME TO EXIT FROM MRI-BASED ACTIVE SURVEILLANCE.
Vasilis Stavrinides*, Francesco Giganti, Clement Orczyk, Shonit Punwani, Clare Allen, Alex Kirkham, Alex Freeman, Hayley Whitaker, Mark Emberton, Caroline M Moore, London, United Kingdom

1:50 PD50-06 A 17-GENE GENOMIC PROSTATE SCORE AS A PREDICTOR OF ADVERSE PATHOLOGY FOR MEN ON ACTIVE SURVEILLANCE
Zachary T. Kornberg*, Matthew R. Cooperberg, Janet E. Cowan, June M. Chan, Jeffry P. Simko, Imelda Tenggara, Peter R. Carroll, San Francisco, CA

2:00 PD50-07 GERMLINE GENETIC RISK FACTORS HELP PREDICT BIOPSY UPGRADE DURING ACTIVE SURVEILLANCE OF PROSTATE CANCER
Craig Labbate*, Chicago, IL, Chi-Hsiung Wang, Kristian Novakovic, Jacqueline Petkewicz, Cecilia Chang, Brian T Helfand, Jianfeng Xu, Evanston, IL

2:10 PD50-08 MEN WITH BRCA1 AND BRCA2 MUTATIONS AND LOW/INTERMEDIATE GRADE PROSTATE CANCER MAY HARBOR ADDITIONAL GENOMIC ALTERATIONS OF MORE AGGRESSIVE DISEASE: IMPLICATIONS FOR ACTIVE SURVEILLANCE
Marc Dall’Era*, Christopher Evans, Primo Lara, John Mcpherson, Sacramento, CA

2:20 PD50-09 QUANTIFICATION OF THE IMPACT OF PATIENT PREFERENCES ON DECISION MAKING IN MEN WITH LOW-RISK PROSTATE CANCER
Zhiyu Qian*, Sylvia Lambbrechts, Lorna Kwan, Christopher Saigal, Los Angeles, CA

2:30 PD50-10 AFRICAN AMERICAN RACE IS NOT ASSOCIATED WITH RECLASSIFICATION DURING ACTIVE SURVEILLANCE: RESULTS FROM THE CANARY PROSTATE CANCER ACTIVE SURVEILLANCE STUDY (PASS)

2:40 PD50-11 A RISK CALCULATOR INTERFACE AND PREDICTION MODEL FOR UPGRADING ON ACTIVE SURVEILLANCE FOR PROSTATE CANCER: RESULTS FROM THE CANARY PROSTATE ACTIVE SURVEILLANCE STUDY

2:50 PD50-12 CHARACTERIZATION OF FACTORS UNDERLYING PHYSICIAN-LEVEL VARIATION IN THE USE OF ACTIVE SURVEILLANCE AMONG MEN WITH LOW RISK PROSTATE CANCER: DATA FROM THE PENNSYLVANIA UROLOGIC REGIONAL COLLABORATIVE (PURC)

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
<table>
<thead>
<tr>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
</table>
| 1:00 | PD51-01 | RENAL CELL CARCINOMA IS NOT RADIO-RESISTANT: THE SAFETY AND EFFICACY OF STEREOTACTIC BODY RADIATION THERAPY FOR PRIMARY LESION OF RENAL CELL CARCINOMA  
Hiroshi Nakagomi*, Manabu Kamiyama, Takafumi Komiyama, Kan Marino, Shinnichi Aoki, Yoshyasu Maehata, Norifumi Sawada, Takahiko Mitsuhi, Hiroshi Onishi, Masayuki Takeda, Chuo, Japan |
| 1:10 | PD51-02 | ONCOLOGIC EFFECTIVENESS OF IMAGE GUIDED THERMAL ABLATION FOR RECURRENT RENAL CELL CARCINOMA (RCC) AFTER IPSILATERAL PARTIAL NEPHRECTOMY: TERTIARY CANCER CENTER EXPERIENCE.  
Mohamed Abdelsalam*, Tessa Hudspeath, Sharjeel Sabir, Samuel Kusin, Jose Karam, Surena Matin, Christopher Wood, Kamran Ahrar, Houston, TX |
| 1:20 | PD51-03 | PERCUTANEOUS ABLATION OFFERS COMPARABLE ONCOLOGIC CONTROL COMPARED WITH PARTIAL NEPHRECTOMY FOR CT1 RENAL Masses  
Jack Andrews*, Tom Atwell, Grant Schmit, Christine Lohse, Nicholas Kurup, Adam Weisbrod, Matthew Callstrom, John Cheville, Stephen Boorjian, Bradley Leibovich, R. Houston Thompson, Rochester, MN |
| 1:30 | PD51-04 | TEN-YEAR EXPERIENCE WITH PERCUTANEOUS CRYOABLATION OF RENAL TUMORS: TUMOR SIZE PREDICTS TREATMENT FAILURE  
Nicholas Pickersgill*, Joel Vetter, Eric Kim, Kefu Du, Ramakrishna Venkatesh, Sam Bhayani, Robert Figenshau, Saint Louis, MO |
| 1:40 | PD51-05 | ACTIVE SURVEILLANCE VS. NEPHRON SPARING SURGERY FOR SMALL RENAL MASS IN VERY ELDERLY PATIENTS: A COMPETING RISK ANALYSIS  
Maria Carmen Mir Maresma*, Valencia, Spain, Michele Marchioni, Chiisti, Italy, Nicola Pavan, Trieste, Italy, Alessandro Antonelli, Brescia, Italy, Umberto Capitanio, Milan, Italy, Tosio Takagi, Tokyo, Japan, Ithaar Derweesh, San Diego, CA, Estefania Linares, Madrid, Spain, Koon Rha, Seoul, Korea, Democratic People’s Republic of, Tobias Maurer, Munich, Germany, Alexandre Mottrie, Aalst, Belgium, Jean Alexander Long, Grenoble, France, Maria Furlan, Brescia, Italy, Alessandro Larcher, Milan, Italy, Alberto Breda, Barcelona, Spain, Francesco Porpiglia, Turin, Italy, Cheab Joseph, Baltimore, MD, Juan Garisto, Cleavland, OH, Wouter Everaerts, Steven Joniau, Leuven, Belgium, Jihad Kaouk, Cleveland, OH, Riccardo Autorino, Richmond, VA, Phillip Pierorazio, Baltimore, MD |
| 1:50 | PD51-06 | DEVICE-RELATED COMPLICATIONS DURING RENAL CRYOABLATION: LESSONS FROM THE MANUFACTURER AND USER FACILITY DEVICE EXPERIENCE (MAUDE) DATABASE  
Srinath Kotamarti*, Buddima Ranasinghe, Frederick Greenstein, Antonio Montgomery, Unni Mooppan, Ervin Teper, David Silver, Ariel Schulman, Brooklyn, NY |
| 2:00 | PD51-07 | EVALUATING RECURRENCE PATTERNS FOR PERCUTANEOUS MICROWAVE AND CRYOABLATION OF T1A RENAL CELL CARCINOMA TO OPTIMIZE SURVEILLANCE PROTOCOLS  
Leo D. Dreyfuss*, Shane A. Wells, Sara L. Best, Timothy J. Ziemlewicz, Meghan G. Lubner, J. Louis Hinshaw, Fred T. Lee, Stephen Y. Nakada, E Jason Abel, Madison, WI |
| 2:10 | PD51-08 | COMPARISON OF PERIOPERATIVE AND ONCOLOGIC OUTCOMES BETWEEN CRYOABLATION AND PARTIAL NEPHRECTOMY FOR SMALL RENAL Masses: A PROPENSITY-SCORE MATCHING ANALYSIS  
Federico Mineo Bianchi, Francesco Chessa*, Riccardo Schiavina, Bologna, Italy, Bernardino De Concilio, Bassano del Grappa, Italy, Marco Borghesi, Pietro Piazza, Lorenzo Bianchi, Cristian Vincenzo Pultrone, Fabrizio Sartorio, Serena Di Fresco, Marco Guerra, Andrea Angiolini, Carlo Beretta, Umberto Barbaresi, Eugenio Brunocilla, Bologna, Italy, Antonio Cella, Bassano del Grappa, Italy |
2:20 PD51-09 IRREVERSIBLE ELECTROPORATION FOR THE TREATMENT OF SMALL RENAL MASSES: A 5-YEAR EXPERIENCE
Ryan Steinberg*, Brett Johnson, Jeffrey Cadeddu, Dallas, TX

2:30 PD51-10 MICROWAVE ABLATION HAS COMPARABLE ONCOLOGIC OUTCOMES VS. SURGERY IN CO-MORBID PATIENTS WITH 4-7CM RENAL CELL CARCINOMA

2:40 PD51-11 UTILITY OF SALVAGE PERCUTANEOUS CRYOABLATION FOR LOCALLY RECURRENCE RCC AFTER PRIMARY CRYOABLATION
Takahumi Yanagisawa*, Jun Miki, Takayuki Sano, Takashi Otsuka, Yuki Enei, Kosuke Iwatani, Daigo Kobayashi, Mahito Atsuta, Seiro Tanaka, Koki Obayashi, Kenji Motohashi, Keitaro Enoki, Shimizu Kanicirho, Kashiwa, I Japan, Shin Egawa, Tokyo, Japan

2:50 PD51-12 PROGNOSTIC VALUE OF HISTOLOGIC SUBTYPE AND TREATMENT MODALITY FOR T1A KIDNEY CANCERS
Michael Siev*, Audrey Renson, Stella Kang, William Huang, Marc Bjurlin, New York, NY, Chapel Hill, NC

Sunday, May 5, 2019 1:00 pm - 3:00 pm
Podium Session 52
BLADDER CANCER: INVASIVE V
Room W184b @ McCormick Place
Moderators: Matthew Nielsen, Brant Inman & Arturo Mendoza-Valdes

1:00 PD52-01 THE NATURAL HISTORY OF UNTREATED MUSCLE INVASIVE BLADDER CANCER

1:10 PD52-02 FGFR3 MUTATIONS AND THEIR RELATION TO FGFR3 EXPRESSION AND CLINICAL OUTCOME IN A LARGE RADICAL CYSTECTOMY COHORT: IMPLICATIONS FOR ANTI-FGFR3 BLADDER CANCER TREATMENT?
Bas van Rhijn, Laura Mertens, Amsterdam, Netherlands, Roman Mayr, Regensburg, Germany, Peter Bostrom, Turku, Finland, Mirari Marquez, Madrid, Spain, Ellen Zwarthoff, Joost Boormans, Cheno Abas, Geert van Leenders, Rotterdam, Netherlands, Stefanie Gotz, Turku, Finland, Simone Bortz, Erlangen, Germany, Yann Neuzillet, Joyce Sanders, Annegien Broeks, Michel van der Heijden, Amsterdam, Netherlands, Michael Jewett, Toronto, Canada, Francisco Real, Madrid, Spain, Robert Stohr, Erlangen, Germany, Alexandre Zlotta, Toronto, Canada, Markus Eckstein, Erlangen, Germany, Yanis Soorajbally, Paris, France, Max Burger, Wolfgang Otto, Regensburg, Germany, Francois Radvanyi, Nanour Sirab, Damien Pouessell, Paris, France, Theo van der Kwast, Toronto, Canada, Nuria Malats, Madrid, Spain, Arndt Hartmann, Erlangen, Germany, Yves Allory, Paris, France, Deric van der Schoot, Breda, Netherlands, Tahlija Zuiverloon*, Rotterdam, Netherlands

1:20 PD52-03 A MULTICENTER PHASE 1B/2 STUDY OF NEoadjuvant PemBrolizumab and CisPlatin CHEMOTHERAPY FOR Muscle InvasionUrothelial CANCer
Hristos Kaimakliotis*, Costantine Albany, Indianapolis, IN, Jean Hoffman-Censits, Edouard Trabulsii, W. Kevin Kelly, Philadelphia, PA, Joel Picus, St. Louis, MO, Nabil Adra, Clint Cary, Michael Koch, Indianapolis, IN, Mark Fleming, Norfolk, VA, Radhika Walling, Indianapolis, IN, J. Luke Godwin, Kenilworth, NJ, Robert Abouassaly, Matthew Cooney, Pinglu Fu, Ariel Nelson, Cleveland, OH, Ginu Xavier, Indianapolis, IN, Lee Ponsky, Christopher Holmes, Cleveland, OH

1:30 PD52-04 THE IMPACT OF NEoadjuvant CHEMOTHERAPY FOR SQUAMOUS HISTOLOGY IN PATIENTS WITH MUSCLE INVASIVE BLADDER CANCER
Justin Matulay*, Houston, TX, Solomon Woldu, Dallas, TX, Vikram Narayan, Amy Lim, Andrew McIntosh, Ashish Kamat, Houston, TX, Christopher Anderson, New York, NY

1:40 PD52-05 TRENDS IN TREATMENT AND COMPARISON OF OUTCOMES IN LYMPH NODE POSITIVE BLADDER CANCER
Christina Darwish*, Andrew Sparks, Richard Amdur, Michael Whalen, Washington, DC

*Presenting author
1:50  PD52-06  CLINICAL PREDICTORS AND SURVIVAL OUTCOME OF PATIENT RECEIVING SUBOPTIMAL NEOADJUVANT CHEMOTHERAPY AND RADICAL CYSTECTOMY FOR MUSCLE-INVASIVE BLADDER CANCER: A SINGLE-CENTER EXPERIENCE
Luca Boeri*, Vidit Sharma, Matteo Soligo, Igor Frank, Stephen A. Boorjian, R. Houston Thompson, Matthew Tollefson, Robert Tarrell, Fernando J. Quevedo, John C. Cheville, R. Jeffrey Karnes, Rochester, MN

2:00  PD52-07  THE FEASIBILITY, SAFETY AND IMPACT OF A PREHABILITATION PROGRAM FOR PATIENTS UNDERGOING CYSTECTOMY
Deborah R. Kaye*, Steven Thelen-Perry, Christine Schafer, Yongmei Qin, Heidi IglayReger, Christine Parker, Samuel Kaffenberg, Lindsay Herrel, Todd Morgan, Alon Weizer, Khaled Hafez, Jeffrey S. Montgomery, Ann Arbor, MI

2:10  PD52-08  PRE-OPERATIVE NARCOTIC USE IS ASSOCIATED WITH INCREASING LENGTH OF STAY AND POST-OPERATIVE COMPLICATIONS IN PATIENTS UNDERGOING RADICAL CYSTECTOMY
Elizabeth Green*, Petria Thompson, Kristen Scarpato, Kirk Keegan, Sam Chang, David Penson, Daniel Barocas, Matthew Resnick, Nashville, TN

2:20  PD52-09  LATE RECURRENCES FOLLOWING RADICAL CYSTECTOMY HAVE DISTINCT PROGNOSTIC AND MANAGEMENT CONSIDERATIONS
Shawn Dason*, Eugene K. Cha, Cristina Falavolti, Emily A. Vertosick, Lucas W. Dean, Victor A. McPherson, Daniel D. Sjoberg, Nicole E. Benfante, Timothy F. Donahue, Guido Dalbagni, Bernard H. Bochner, New York City, NY

2:30  PD52-10  EARLY POSTOPERATIVE MORBIDITY OF ROBOTIC VERSUS OPEN RADICAL CYSTECTOMY IN THE OBESE PATIENT WITH BLADDER CANCER: REPORT FROM NATIONAL SURGICAL QUALITY IMPROVEMENT PROGRAM DATABASE

2:40  PD52-11  HEALTH RELATED QUALITY OF LIFE OUTCOMES BY URINARY DIVERSION: AN ANALYSIS FROM THE RANDOMIZED ROBOTIC VERSUS OPEN RADICAL CYSTECTOMY (RAZOR) TRIAL
Maria Becerra*, Vivek Venkatramani, Miami, FL, Isildinha Reis, Miami, FL, Nachiketh Soodana-Prakash, Miami, FL, Erik Castle, Phoenix, AZ, Mark Gonzalez, Miami, FL, Michael Woods, Chapel Hill, NC, Robert Svatek, San Antonio, TX, Alon Weizer, Ann Arbor, MI, Badrinath Konety, Minneapolis, MN, Mathew Tollefson, Phoenix, AZ, Tracey Krupski, Charlotteville, VA, Norm Smith, Chicago, IL, Ahmad Shabsigh, Columbus, OH, Daniel Berocas, Nashville, TN, Marcus Quek, Maywood, IL, Atrey Dash, Seattle, WA, Adam Kibel, Boston, MA, Raj Pruthi, Chapel Hill, NC, Jeffrey Montgomery, Ann Arbor, MI, Christopher Weight, Minneapolis, MN, David Sharp, Columbus, OH, Sam Chang, Nashville, TN, Michael Cookson, Norman, OK, Gopal Gupta, Alex Gorbonos, Maywood, IL, Edward Uchio, Irvine, CA, Eila Skinner, Stanford, CA, Kerri kendrick, San Antonio, TX, Joseph Smith, Nashville, TN, Ian Thompson, San Antonio, TX, Dipen Parekh, Miami, FL

2:50  PD52-12  PREDICTORS OF COMPLIANCE WITH MUSCLE INVASIVE BLADDER CANCER QUALITY MEASURES AND ITS EFFECT ON SURVIVAL OUTCOMES

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
<table>
<thead>
<tr>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
<th>ABSTRACT</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:00</td>
<td>PD53-01</td>
<td>INCREASED WAIT TIMES FOR NEW PATIENTS MAY RESULT IN DECREASED</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>UROLOGIST PRODUCTIVITY</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Joseph M Caputo*, Elisabeth M Sebesta,</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Christopher R Haas, Matthew P Rutman,</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Kimberly L Cooper, New York, NY</td>
<td></td>
</tr>
<tr>
<td>1:10</td>
<td>PD53-02</td>
<td>INCIDENCE, RISK FACTORS, AND IMPACT OF CARDIOVASCULAR EVENTS IN</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>PATIENTS UNDERGOING RADICAL PROSTATECTOMY: ANALYSIS OF THE AMERICAN</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>COLLEGE OF SURGEONS NATIONAL SURGICAL QUALITY IMPROVEMENT DATABASE</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Kevin Ginsburg*, John Cochrane, Rohith Arcot, Detroit, MI, Scott</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Egggener, Chicago, IL, Michael Cher, Detroit, MI</td>
<td></td>
</tr>
<tr>
<td>1:20</td>
<td>PD53-03</td>
<td>AN INTERACTIVE APPLICATION FOR HOSPITALIZED PATIENTS PROVIDING REAL-</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>TIME FEEDBACK TO CARE GIVERS</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Omri Nativ*, Samira Abbadi, Bilal Hassadieh, Ariel Zisman, Gilad</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Amiel, Haifa, Israel</td>
<td></td>
</tr>
<tr>
<td>1:30</td>
<td>PD53-04</td>
<td>THE IMPACT OF INTRAOPERATIVE NARCOTICS FOR ROBOTIC UROLOGIC SURGERY</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>PATIENTS ON AN ERAS PROTOCOL</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Elliot Dubowitch*, Mohit Garg, Dimitre Stefanov, Buddima Ranasinghe,</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Piyush Gupta, David Silver, Ervin Teper, Ariel Schulman, Brooklyn, NY</td>
<td></td>
</tr>
<tr>
<td>1:40</td>
<td>PD53-05</td>
<td>A RANDOMIZED CONTROLLED TRIAL OF A MODIFIED CYSTOSCOPY TECHNIQUE</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>TO DECREASE PATIENT'S PAIN AND ANXIETY</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Khalil Hetou*, Ailsa May Li Gan, Jonathan Izawa, Joseph L. Chin,</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Nicholas Edgar Power, London, Canada</td>
<td></td>
</tr>
<tr>
<td>1:50</td>
<td>PD53-06</td>
<td>A QUALITY COLLABORATIVE CAN FACILITATE CONSOLIDATION OF ANTIBIOTIC</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>REGIMENS PRIOR TO TRUS PNB—EXPERIENCE FROM THE PENNSYLVANIA UROLOGIC</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>REGIONAL COLLABORATION (PURC)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Adrian Sosenko*, Thomas Lanchoney, Hershey, PA, Thomas Guzzo, Edouard</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Trabulsi, Philadelphia, PA, John Danella, Hershey, PA, Mark Mann,</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Adam Reese, Philadelphia, PA, Jeffrey Tomaszewski, Hershey, PA, Serge</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Ginzburg, Philadelphia, PA, Robert Uzzo, Marc Smaldone, Claudette</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Fonsshell, Bret Marlowe, Jay Raman, Adrian Sosenko, Hershey, PA</td>
<td></td>
</tr>
<tr>
<td>2:00</td>
<td>PD53-07</td>
<td>ANALYZING PATIENT-SPECIFIC FACTORS CONTRIBUTING TO EXTENDED PACU</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>LENGTH OF STAY AND SUBSEQUENT COST: A QUALITY IMPROVEMENT INITIATIVE</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Patrick Hensley*, Jeffrey Goodwin, Adam Dugan, Mauro Hanaoka, Jason</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Bylund, Adrew Harris, Lexington, KY</td>
<td></td>
</tr>
<tr>
<td>2:10</td>
<td>PD53-08</td>
<td>NON-INFECTIOUS COMPLICATIONS AFTER PROSTATE NEEDLE BIOSPY – OUTCOMES</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>FOLLOWING OVER 8000 BIOSPIES FROM THE PENNSYLVANIA UROLOGIC REGIONAL</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>COLLABORATION (PURC)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Adrian Sosenko*, Thomas Lanchoney, Thomas Guzzo, Edouard Trabulsi,</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Hershey, PA, John Danella, Hershey, PA, Mark Mann, Adam Reese,</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Philadelphia, PA, Jeffrey Tomaszewski, hershey, PA, Serge Ginzburg,</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>philadelphia, PA, Robert Uzzo, Marc Smaldone, hershey, PA, Claudette</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Fonsshell, hershey, PA, Bret Marlowe, Jay Raman, hershey, PA</td>
<td></td>
</tr>
<tr>
<td>2:20</td>
<td>PD53-09</td>
<td>PREOPERATIVE CHECKLISTS AND PERIOPERATIVE SAFETY: THE YIN AND YANG</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>OF QUALITY AND EFFICIENCY?</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Neil J. Kocher*, Amber Schilling, Chris Hollenbeak, Jay D. Raman,</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Hershey, PA</td>
<td></td>
</tr>
<tr>
<td>2:30</td>
<td>PD53-10</td>
<td>READABILITY AND COMPREHENSION LEVELS OF PATIENT INFORMATION SHEETS</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>USED IN RESEARCH ETHICS COMMITTEE APPLICATIONS</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Ceri Honey-Jones, Brian Birch*, Southampton, United Kingdom</td>
<td></td>
</tr>
<tr>
<td>2:40</td>
<td>PD53-11</td>
<td>INPATIENT OPIOID USE POORLY PREDICTS DISCHARGE OPIOID PRESCRIPTIONS</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>FOLLOWING NEPHRECTOMY</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dima Raskolnikov*, Steven Ngo, Sarah Holt, Chinonyerem Okoro, John</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Gore, Seattle, WA</td>
<td></td>
</tr>
<tr>
<td>2:50</td>
<td>PD53-12</td>
<td>INCIDENCE, RISK FACTORS, AND PERIOPERATIVE OUTCOMES ASSOCIATED WITH</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>CLOSTRIDIUM DIFFICILE INFECTION IN UROLOGIC SURGERY: ANALYSIS OF THE</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>AMERICAN COLLEGE OF SURGEONS NATIONAL SURGICAL QUALITY IMPROVEMENT</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>PROJECT DATABASE</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Kevin Ginsburg*, Andrew Mcelroy, Detroit, M1, Alex Tapper, Frank Burks</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>, Royal Oak, MI, M1, Michael Cher, Amanath Rambhatla, Detroit, MI</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>APPROVED FOR AMA PRA CATEGORY 1 CREDIT™</td>
<td></td>
</tr>
</tbody>
</table>
Video Session 9

MISC GU ONCOLOGY, COMPLICATIONS & TECHNIQUES

The videos in this session as well as the video libraries from the 2012-2018 Annual Meetings may be viewed in the Surgical Video Library and purchased in the AUA Store during the Annual Meeting. AUA members receive free online access to the Surgical Video Library throughout the year through AUA University. Visit www.AUAnet.org/University to access.

Room W187b @ McCormick Place
Moderator: James Mohler, Sebastian Westphal & Benjamin Ristav

<table>
<thead>
<tr>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
<th>ABSTRACT</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:00</td>
<td>V09-01</td>
<td>OPEN FIELD FLUORESCENCE IMAGING (SPY-PHI) IS A USEFUL TOOL TO ASSESS TISSUE INTEGRITY IN COMPLEX, OPEN, GENITOURINARY RECONSTRUCTIVE SURGERY</td>
<td>Kevin Hebert*, Jason Joseph, Boyd Viers, Rochester, MN</td>
</tr>
<tr>
<td>1:10</td>
<td>V09-02</td>
<td>ROBOT ASSISTED SALVAGE RETROPERITONEAL LYMPH NODE DISSECTION OF RETROCRURAL TERATOMA</td>
<td>Anojan Navaratnam*, William Critchlow, Haidar Abdul-Muhsin, Erik Castle, Phoenix, AZ</td>
</tr>
<tr>
<td>1:20</td>
<td>V09-03</td>
<td>FIRST HAND PIECE TYPE SURGICAL SEWING MACHINE USING TWO THREADS: ANIMAL STUDY FOR THE FEASIBILITY OF INTESTINAL AND VASCULAR USE.</td>
<td>Sang Jin Yoon*, Chang Hee Kim, Kyung Jin Chung, Kwang Taek Kim, Han Jung, Tae Beom Kim, Kwon Soo Chun, Incheon, Korea, Republic of, Tae-Youl Choi, Denton, TX, Kwonsoo Chun, Houston, TX</td>
</tr>
<tr>
<td>1:30</td>
<td>V09-04</td>
<td>ROBOTIC ASSISTED TRANSPERITONEAL INFERIOR VENA CAVA FILTER REMOVAL: FEASIBILITY AND TECHNIQUE</td>
<td>Amit Patel*, Taylor Poleskey, Judith Lin, Craig Rogers, Detroit, MI</td>
</tr>
<tr>
<td>1:40</td>
<td>V09-05</td>
<td>AN IMPROVED SURGICAL “SEWING MACHINE” FOR RAPID GRAFT QUILTING AND SUTURING IN CHALLENGING SPACES</td>
<td>Jessica Phelps*, Kathryn Scott, Stephen Blakely, Gennady Bratslavsky, Dmitry Nikolavsky, Syracuse, NY</td>
</tr>
<tr>
<td>2:00</td>
<td>V09-07</td>
<td>SURGICAL AND ONCOLOGICAL OUTCOMES OF THERAPEUTIC POST-CHEMOTHERAPY ROBOT-ASSISTED RETROPERITONEAL LYMPH NODE DISSECTION FOR TESTICULAR CANCER</td>
<td>Hailiu Yang*, Vijay Raj, Robert Brown, Jeffrey Tomaszewski, Camden, NJ</td>
</tr>
<tr>
<td>2:10</td>
<td>V09-08</td>
<td>LAPAROSCOPIC (ROBOT-ASSISTED) VEIL - A SINGLE CENTRE EXPERIENCE - SAPPHENOUS SPARING VS NON SAPPHENOUS SPARING</td>
<td>Srivathsan Ramani*, TB Yuvaraja, MUMBAI, India</td>
</tr>
<tr>
<td>2:20</td>
<td>V09-09</td>
<td>CASTLEMAN’S DISEASE: ROBOTIC EXCISION OF A RETROPERITONEAL MASS</td>
<td>Daniel Rittenberg*, Centereach, NY, Olga Povcher, Wayne Waltzer, Stony Brook, NY</td>
</tr>
<tr>
<td>2:30</td>
<td>V09-10</td>
<td>EXTERNAL IliAC VEIN INJURY FROM PENILE IMPLANT RESERVOIR REMOVAL - HOW TO MANAGE AND AVOID</td>
<td>Kara Choate*, Andrew Kramer, Baltimore, MD</td>
</tr>
<tr>
<td>2:40</td>
<td>V09-11</td>
<td>NEEDLE IN A HAYSTACK: PREVENTION AND MANAGEMENT OF NEEDLE LOSS DURING ROBOTIC SURGERY</td>
<td>Ashwin Mallya, Feroz Amir Zafar*, Sachin Arakere Nataraj, Pankaj Wadhwa, Rajesh Kumar Ahlawat, Gurugram, India</td>
</tr>
<tr>
<td>2:50</td>
<td>V09-12</td>
<td>TESTICULAR CONSERVATIVE SURGERY IN SMALL TESTICULAR MASS TREATMENT</td>
<td>Gema del Pozo Jiménez*, Ignacio Castillón Vela, Gabriel Rodríguez Reina, Jorge Turo Antona, Maria Rodríguez Monsalve, Joaquin Carballido Rodríguez, Majadahonda (Madrid), Spain</td>
</tr>
</tbody>
</table>

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Sunday, May 5, 2019

RESEARCH FORUM I: FUNDING OPPORTUNITIES AND GRANT WRITING GUIDANCE FOR EARLY-CAREER INVESTIGATORS

Room W471 @ McCormick Place

<table>
<thead>
<tr>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
<th>ABSTRACT</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:00</td>
<td>INTRODUCTION</td>
<td>Director of Research: Carolyn Best</td>
<td></td>
</tr>
<tr>
<td>1:05</td>
<td>KEYNOTE: GRANTWRITING 101</td>
<td>Erika Wolff</td>
<td></td>
</tr>
<tr>
<td>1:25</td>
<td>NIDDK TRAINING AND RESEARCH MECHANISMS</td>
<td>Tracy Rankin</td>
<td></td>
</tr>
</tbody>
</table>
1:40 UROLOGY RESEARCH FUNDING AT THE DOD CDMRP
Melissa Cunningham
1:55 VA CAREER DEVELOPMENT AWARDS
Michael Burgio
2:10 NATIONAL CANCER INSTITUTE FUNDING OPPORTUNITIES
Susan Lim
2:25 AMERICAN CANCER SOCIETY FUNDING OPPORTUNITIES
Ellie Daniels

2:40 UROLOGY CARE FOUNDATION FUNDING OPPORTUNITIES
Krystal Brinson
2:50 Q & A WITH THE SPEAKER PANEL
APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Sunday, May 5, 2019 1:00 pm - 3:00 pm
SOCIETY FOR INFECTION AND INFLAMMATION IN UROLOGY (SIIU)
Hyde Park AB @ Hyatt McCormick

1:00 SOCIETY FOR INFECTION AND INFLAMMATION IN UROLOGY & EUROPEAN SOCIETY FOR INFECTION IN UROLOGY JOINT SYMPOSIUM: POST-PROSTATE BIOPSY INFECTIONS - WHERE ARE WE NOW & WHERE ARE WE GOING?
PROSTATE BIOPSY SEPSIS: RISK FACTORS, PATHOPHYSIOLOGY & THERAPY
Florian Wagenlehner
ANTIMICROBIAL RESISTANCE IN USA & EUROPE: COMPARISON OF GUIDELINES FOR PROSTATE BIOPSY PROPHYLAXIS
Truls Erik Bjerklund-Johansen

2:00 ROLE OF TARGETED PROPHYLAXIS
Robert Nadler
NEW APPROACHES IN PREVENTING POST-BIOPSY INFECTIONS
Vladimir Mouraviev
RESIDENT & FELLOW PODIUM PRESENTATIONS

Sunday, May 5, 2019 1:00 pm - 5:00 pm
GERIATRIC UROLOGICAL SOCIETY (GUS)
Jackson Park AB @ Hyatt McCormick

1:00 URINARY CARE DEVICES, CATHETERS, AND INFECTIONS IN GERIATRICS: A CLINICAL PANEL DISCUSSION
Moderator: Tomas Griebling
URINARY DEVICES AND ABSORBENT PRODUCTS IN OLDER ADULTS
Panelist: Diane Newman
USE OF URINARY CATHETERS IN NURSING HOMES, PERIOPERATIVE SETTINGS, AND OTHER GERIATRIC CARE
Panelist: Tomas Griebling
CATHETER ASSOCIATED URINARY TRACT INFECTIONS: CLINICAL AND POLICY IMPLICATIONS
Panelist: Timothy Averch

2:15 STATE-OF-THE-ART LECTURE: NOCICEPTIVE MECHANISMS IN THE AGING PATIENT
Gerald Gebhart
2:50 BREAK

3:00 GENITOURINARY PAIN IN OLDER ADULTS: A TRANSLATIONAL SCIENCE PANEL DISCUSSION
Moderator: Lori Birder
Panelist: Gerald Gebhart
THE IMPACT OF AGING AND OXIDATIVE STRESS ON BLADDER HEALTH
Panelist: Lori Birder
STRESS AND SYMPTOM SEVERITY IN CHRONIC PELVIC PAIN IN OLDER ADULTS
Panelist: Larissa Rodriguez
PELVIC PAIN IN GERIATRIC PATIENTS
Panelist: H. Henry Lai

4:00 INTERNATIONAL ROUNDTABLE DISCUSSION
Moderator: Ananias Diokno
ANALYSIS OF BLADDER VOIDING EFFICIENCY (BVE) IN OLDER ADULT WOMEN
Panelist: Françoise Valentini

*Presenting author
TRANSOBTRATOR TENSION-FREE VAGINAL TAPE SURGERY FOR STRESS URINARY INCONTINENCE INCREASES POST-OPERATIVE RESIDUAL URINE AND DECREASES THE PEAK FLOW RATE IN ELDERLY FEMALES
Panelist: Yu-Chao Hsu

THE ASSOCIATION OF HYPOANDROGENISM IN URETHRAL STRICTURE DISEASE IN THE GERIATRIC PATIENT
Panelist: Jeffrey Spencer

PATIENT-REPORTED OUTCOMES OF PATIENT WITH LOCALIZED PROSTATE CANCER TREATED BY EITHER SURGERY OR RADIOTHERAPY IN THE CHINESE POPULATION
Panelist: Chi-Fai Ng

REPRODUCTIVE AGING IN MALES: EVALUATION AND TREATMENT - LACK OF CONSENSUS ACROSS COUNTRIES AND SPECIALTIES
Panelist: Sara Perkins

INTRAPROSTATIC BOTULINUM TOXIN A INJECTION IS A VIABLE OPTION IN PATIENTS UNFIT FOR PROSTATE SURGERY
Panelist: Ibrahim Cevik

MORBIDITY AND MORTALITY OF UROLOGICAL SURGERY IN OCTOGENARIANS AND BEYOND
Panelist: Deepak Batura

ESWL IN ELDERLY PATIENTS

CLOSING REMARKS & ADJOURN

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Sunday, May 5, 2019

R. FRANK JONES UROLOGICAL SOCIETY (RFJ)
Jackson Park CD @ Hyatt McCormick

1:00 WELCOME & PRESIDENT'S UPDATE
Society President: Tracy M. Downs

1:05 WELCOME FROM THE AUA

1:15 AUA PUBLIC POLICY COUNCIL LIAISON UPDATE
Robert L. Waterhouse

3:05 BREAK

1:30 AFRICAN AMERICAN UROLOGY PIONEERS: THIS IS MY STORY – A HISTORICAL PERSPECTIVE
Issac J. Powell

3:50 ENVIRONMENTAL HEALTH: CHALLENGES FACING BLACK FAMILIES IN THE UNITED STATES
Shaneda Warren Anderson

2:10 Q & A

2:20 JOURNAL CLUB & PAPER SPOTLIGHT: PROSTATE CANCER AND MINORITY PATIENTS
QUALITY OF CARE IN THE TREATMENT OF LOCALIZED INTERMEDIATE AND HIGH-RISK PROSTATE CANCER AT MINORITY SERVING HOSPITALS
Chinonyerem Okoro

A HEAD TO HEAD COMPARISON OF FOUR PROGNOSTIC MODELS FOR PREDICTION OF LYMPH NODE INVASION IN AFRICAN-AMERICAN AND CAUCASIAN INDIVIDUALS
Yaw Nyame

3:15 DISPARITIES IN ACCESS TO NEONATAL CIRCUMCISION
Emilie Johnson

3:50 ENVIRONMENTAL HEALTH: CHALLENGES FACING BLACK FAMILIES IN THE UNITED STATES
Shaneda Warren Anderson

4:40 WHY HEALTH EQUITY?
Sheri P. Johnson

4:50 CONCLUDING REMARKS

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Sunday, May 5, 2019

SOCIETY FOR THE STUDY OF MALE REPRODUCTION (SSMR)
Room S103 @ McCormick Place

1:00 INTRODUCTION: HELIXES TO HASHTAGS - NEW TECHNOLOGIES IN MALE INFERTILITY
Daniel Williams

1:10 SESSION I

BEYOND THE Y CHROMOSOME AND KARYOTYPE: ARE ANY NEW GENETIC MARKERS FOR MALE INFERTILITY NEAR PRIME TIME?
Dolores Lamb
SESSION I: KIDNEY UPDATE
Moderators: Mohamad Allaf, Francesco Porpiglia, Craig Rogers

ESTABLISHING AN OFFICE BASED RENAL MASS BIOPSY
Jaime Landman

NUCLEAR IMAGING ROLE IN MANAGEMENT OF SMALL RENAL MASSES
Mohamad Allaf

SELECTIVE HILAR CLAMPING: HOW AND WHY
Craig Rogers

ROBOTIC SURGERY FOR INFERIOR VENA CAVAL THROMBUS
Ketan Badani

RADICAL NEPHROURETERECTOMY WITH ROBOTIC ASSISTANCE: SHOULD IT BE STANDARD CARE?
Ronney Abaza

ROBOTIC KIDNEY TRANSPLANT SURGERY
Alberto Breda

Q & A

SESSION II: PROSTATE UPDATE
Moderators: Thomas Ahlering, Ali Riza Kural, Ashutosh Tewari

OUTPATIENT ROBOTIC RADICAL PROSTATECTOMY
David Lee

PRECISION FOCAL PROSTATECTOMY
Mani Menon

TIPS & TRICKS FOR EXTRAPERITONEAL ROBOTIC RADICAL PROSTATECTOMY
Jean Joseph

REZIUS-SPARING TRANS-DOUGLAS ROBOTIC RADICAL PROSTATECTOMY
John Davis

PERINEAL ROBOTIC PROSTATECTOMY
Jihad Kaouk

RADIO-ANATOMY FOR TRIFECTA IN RADICAL PROSTATECTOMY
Ashutosh Tewari

LESSONS LEARNED FROM 12,000 ROBOT RADICAL PROSTATECTOMY: IS THE JOURNEY AS IMPORTANT AS THE OUTCOME?
Vipul Patel

ROBOTIC TOTAL PROSTATECTOMY: A NOVEL TECHNIQUE FOR LOW RISK PROSTATE CANCER
Ashok Hemal

Q & A

SESSION III: BLADDER/URETER/RECONSTRUCTION
Moderators: Alvin Goh, Khurshid Guru, Sudhir Rawal

ROBOTIC RADICAL CYSTECTOMY AND EXTENDED PELVIC LYMPHNODE DISSECTION: WHAT IS NEW?
Khurshid Guru

WHEN TO CONSIDER INTRACORPOREAL NEobladder AND HOW TO DO IT?
Peter Wiklund

ROBOTIC MANAGEMENT OF POST CYSTECTOMY ILEO-URETERAL STRICTURES
Mihir Desai

FIREFLY AND UPPER TRACT RECONSTRUCTION
Michael Stifelman

ROBOTIC REPAIR OF GENITOURINARY FISTULA
Rene Sotelo

Q & A

SESSION IV: INNOVATIONS, NEW ROBOTS, AND MORE
Moderators: Riccardo Autorino, Jens Rassweiler, Gyung Tak Mario Sung

SINGLE PORT ROBOTIC SURGERY: A NEW ERA OF ROBOTIC SURGERY
Jihad Kaouk

SINGLE PORT RECONSTRUCTIVE SURGERY USING THE SP ROBOT
Lee Zhao

MAGNETIC-ASSISTED ROBOTIC SURGERY: REDUCING PORTS AND THE SP ROBOT
Jeffrey Cadeddu

NEW SURGICAL ROBOTS ON THE HORIZON
Prokar Dasgupta

SURG BUSINESS MEETING

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Sunday, May 5, 2019
2:00 pm - 5:00 pm

JAPANESE UROLOGICAL ASSOCIATION (JUA)
Room S101 @ McCormick Place

Society President: Masato Fujisawa
Program Chair: Yoshihiko Tomita

OPENING REMARKS

THEME 1: BLADDER CANCER
Moderators: Sam Kaffenberger, Hiroshi Kitamura

TRI-MODALITY TREATMENT FOR MIBC
Soichiro Yoshida

KEY POINTS OF THE AUA GUIDELINES FOR INVASIVE CANCER
Sam Chang
PANEL DISCUSSION ON CLINICAL CASES: WHAT IS YOUR CHOICE OF TREATMENT?
Panelists: Sam Chang, Rikiya Taoka, Mark Tyson, Kazutoshi Yamana

3:00 THEME 2: PROSTATE CANCER
Moderators: Brian Chapin, Masatoshi Eto
Efficacy and Safety of Brachytherapy in Japanese PCA Patients: A Single-Institution Results
Hirofumi Yoshino
Intraoperative Molecular Imaging for Prostate Cancer
Thomas Guzzo
Panel Discussion on Clinical Cases: How Do You Treat This Patient? Differences in Approaches?
Panelists: Ben Davies, James Eastham, Kosuke Mizutani, Kiyoshi Takahara

4:05 THEME 3: STONE
Moderators: Bradley Schwartz, Takahiro Yasui
Surgical Treatment of Ureteropelvic Junction Stone
Yota Nakajima
Contemporary Outcomes of Ureteroscopy
Margaret Pearle
Panel Discussion on Clinical Cases: How to Approach This Situation?
Panelists: Dean Assimos, Bodo Knudsen, Shuzo Hamamoto, Nobuyo Morita

4:55 CLOSING REMARKS
Society President: Masato Fujisawa
Approved for AMA PRA Category 1 Credit™
2:50 CIRUGÍA DE READECUACIÓN GENITAL FEMENINA: UNA CIRUGÍA UROLÓGICA (FEMALE GENITAL REASSIGNMENT SURGERY: A UROLOGICAL SURGERY)
Moderator: Ignacio Serra
Speaker: Javier Belinky

3:10 NUEVAS INDICACIONES DE LA PROSTATECTOMÍA RADICAL: OLIGOMETASTÁSICO, CPRC, ADUTO MAYOR, ETC. (NEW INDICATIONS FOR RADICAL PROSTATECTOMY: OLIGOMETASTATIC, CRPC, ELDERLY MEN, ETC.)
Moderator: Carlos Ameri
Speaker: Carlos Scorticati

3:30 UTILIZACIÓN DE CATÉTERES METÁLICOS EN PACIENTES CON OBSTRUCCIÓN URETERAL SECUNDARIA A COMPRESIÓN EXTRÍNSECA (USE OF METALLIC STENTS IN PATIENTS WITH URETERAL OBSTRUCTION SECONDARY TO EXTRINSIC COMPRESSION)
Moderator: Roberto Hernández
Speaker: Gustavo Villoldo

4:00 BREAK

4:30 ENUCLEACIÓN ENDOSCÓPICA CON LÁSER DE HOLMIUM: ¿DÓNDE ESTAMOS HOY? (HOLMIUM LASER ENucleATION OF THE PROSTATE: WHERE ARE WE TODAY?)
Moderator: Alejandro Nolazco
Speaker: Norberto Bernardo

4:50 CIRUGÍA MÍNIMAMENTE INVASIVA EN EL CÁNCER RENAL AVANZADO (MINIMALLY INVASIVE SURGERY FOR ADVANCED KIDNEY CANCER)
Moderator: Martín del Sordo
Speaker: Alberto Jurado

5:10 CÁNCER DE TESTÍCULO: LO QUE NO HAY QUE HACER (TESTICULAR CANCER: WHAT WE SHOULDN'T DO)
Moderator: Norberto Lafos
Speaker: Ricardo Nardone

5:30 NEFRECTOMÍA PARCIAL ELECTIVA MÁS ALLÁ DEL T1A: ¿HASTA DÓNDE PODEMOS IR? (ELECTIVE PARTIAL NEPHRECTOMY BEYOND T1A TUMORS: HOW FAR CAN WE GO?)
Moderator: Claudio Koren
Speaker: José Rozanec

5:50 CONCLUSIONES Y CIERRE DEL SIMPOSIO (CONCLUSIONS AND CLOSING OF THE SYMPOSIUM)
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>5:20</td>
<td>THE ITALIAN REGISTRY OF CISTECTOMY</td>
</tr>
<tr>
<td></td>
<td>Walter Artibani</td>
</tr>
<tr>
<td>5:30</td>
<td>BEST ITALIAN ABSTRACT PRESENTED AT THE 2019 AUA ANNUAL MEETING</td>
</tr>
<tr>
<td></td>
<td>S. Voce</td>
</tr>
</tbody>
</table>

### Sunday, May 5, 2019

**RESEARCH FORUM II: EARLY-CAREER INVESTIGATORS SHOWCASE**

**Room W471 @ McCormick Place**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:00</td>
<td>POSTER VIEWING</td>
</tr>
<tr>
<td>3:30</td>
<td>INTRODUCTION AND WELCOME</td>
</tr>
<tr>
<td></td>
<td>Carolyn Best</td>
</tr>
<tr>
<td>3:35</td>
<td>TARGETING SECRETED ANTIGENS FOR MOLECULARLY SPECIFIC PROSTATE CANCER</td>
</tr>
<tr>
<td></td>
<td>THERANOSTICS</td>
</tr>
<tr>
<td></td>
<td>H. David Ulmert</td>
</tr>
<tr>
<td>3:43</td>
<td>THE ROLE OF THE TUMOR MICROENVIRONMENT IN SENSITIVITY AND</td>
</tr>
<tr>
<td></td>
<td>RESISTANCE TO SYSTEMIC THERAPY IN RENAL CELL CARCINOMA</td>
</tr>
<tr>
<td></td>
<td>Abraham Hakimi</td>
</tr>
<tr>
<td>3:51</td>
<td>IL-6 SIGNALING MEDIATES UROPATHOGENIC BACTERIA EXPULSION FROM HOST</td>
</tr>
<tr>
<td></td>
<td>UROTHELIAL CELLS TO LIMIT UTI CHRONICITY</td>
</tr>
<tr>
<td></td>
<td>Christina Ching</td>
</tr>
<tr>
<td>3:59</td>
<td>NEW TECHNIQUES TO MEASURE COORDINATED CALCIUM SIGNALS, MICROMOTIONS,</td>
</tr>
<tr>
<td></td>
<td>AND TRANSIENT PRESSURE EVENTS IN THE MOUSE URINARY BLADDER</td>
</tr>
<tr>
<td></td>
<td>Nathan Tykocki</td>
</tr>
<tr>
<td>4:07</td>
<td>EMULATING A TARGET CLINICAL TRIAL WHEN CLINICAL TRIAL EVIDENCE IS</td>
</tr>
<tr>
<td></td>
<td>LIMITED: EXAMINING THE ROLE OF LYMPH NODE DISSECTION IN HIGH-RISK</td>
</tr>
<tr>
<td></td>
<td>RENAL CELL CARCINOMA</td>
</tr>
<tr>
<td></td>
<td>Boris Gershman</td>
</tr>
<tr>
<td>4:15</td>
<td>IMMUNOMODULATORY EFFECTS OF BOILING HISTOTRIPSY ABLATION OF RENAL</td>
</tr>
<tr>
<td></td>
<td>CARCINOMA IN THE EKER RAT</td>
</tr>
<tr>
<td></td>
<td>George Schade</td>
</tr>
<tr>
<td>4:23</td>
<td>FUNCTIONAL OUTCOMES AFTER “MINOR” UROLOGICAL SURGERY AMONG NURSING</td>
</tr>
<tr>
<td></td>
<td>HOME RESIDENTS: A NATIONAL STUDY</td>
</tr>
<tr>
<td></td>
<td>Anne Suskind</td>
</tr>
<tr>
<td>4:31</td>
<td>THE EFFECT OF RENAL HYPOTHERMIA DURING PARTIAL NEPHRECTOMY: A</td>
</tr>
<tr>
<td></td>
<td>MULTICENTER RANDOMIZED CONTROLLED TRIAL</td>
</tr>
<tr>
<td></td>
<td>Rodney Breau</td>
</tr>
<tr>
<td>3:39</td>
<td>DEFINING THE DISTINCTIVE CLINICAL AND BIOLOGICAL BEHAVIOR OF THE SPOP</td>
</tr>
<tr>
<td></td>
<td>MUTANT SUBCLASS</td>
</tr>
<tr>
<td></td>
<td>Jonathan Shoag</td>
</tr>
<tr>
<td>4:47</td>
<td>COMMENTS FROM THE DIRECTOR OF RESEARCH</td>
</tr>
<tr>
<td></td>
<td>Carolyn Best</td>
</tr>
<tr>
<td>4:52</td>
<td>WINNERS ANNOUNCED &amp; PRESENTATION OF AWARDS</td>
</tr>
<tr>
<td></td>
<td>Carolyn Best</td>
</tr>
</tbody>
</table>

**ASSOCIATION FRANÇAISE D'UROLOGIE (AFU)**

**Grant Park CD @ Hyatt McCormick**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:30</td>
<td>WELCOME</td>
</tr>
<tr>
<td></td>
<td>Society Delegate: Jean-Nicholas Cornu</td>
</tr>
<tr>
<td></td>
<td>Society Vice-President: Georges Fournier</td>
</tr>
<tr>
<td>3:35</td>
<td>MANAGEMENT OF NON-METASTATIC RENAL CELL CARCINOMA: RECENT ADVANCES IN</td>
</tr>
<tr>
<td></td>
<td>SURGICAL TECHNIQUES AND INDICATIONS</td>
</tr>
<tr>
<td></td>
<td>Jean-Christophe Bernhard, Alexander Kutikov</td>
</tr>
<tr>
<td>4:30</td>
<td>SURGERY FOR FEMALE STRESS URINARY INCONTINENCE: THE CURRENT ROLE OF</td>
</tr>
<tr>
<td></td>
<td>SLINGS AND POTENTIAL ALTERNATIVES</td>
</tr>
<tr>
<td></td>
<td>Benjamin Brucker, Benoit Peyronnet</td>
</tr>
<tr>
<td>ABSTRACT NUMBER</td>
<td>TITLE</td>
</tr>
<tr>
<td>-----------------</td>
<td>-------</td>
</tr>
</tbody>
</table>
| MP64-01 | VOIDING CYSTROURETHROGRAMS FOR INFANTS WITH ISOLATED HIGH-GRADE PRENATAL HYDRONEPHROSIS AND HYDRoureteronephrosis WITHOUT A HISTORY OF PREVIOUS UTI: IS IT REALLY NECESSARY?  
George Goucher*, Melissa McGrath, Alanna Webster, Luis H. Braga, Hamilton, Canada |
| MP64-02 | INCREASED RISK OF REPEAT INFECTIONS PRIOR TO VESICO-URETERAL REFUX DIAGNOSIS SINCE THE 2011 AAP GUIDELINES  
Ted Lee*, Lauren Corona, Kathryn Marchetti, Bloom David, Vesna Ivancic, Kate Kraft, John Park, Bryan Sack, Courtney Streur, Julian Wan, Ann Arbor, MI |
| MP64-03 | SELECTING CHILDREN WITH VUR WHO ARE MOST LIKELY TO BENEFIT FROM ANTIbiotic PROPHYLAXIS: APPLICATION OF MACHINE LEARNING TO RIVUR DATA  
Hsinhsiao Wang*, Boston, MA, Michael Li, Dimitri Bertsimas, Cambridge, MA, Carlos Estrada, Caleb Nelson, Boston, MA |
| MP64-04 | CHALLENGING THE STATUS QUO: A PROSPECTIVE STUDY OF EARLY DISCONTINUATION OF CONTINUOUS ANTIbiotic PROPHYLAXIS IN CHILDREN WITH VESICOURETERAL REFUX  
Melissa McGrath*, Smruthi Ramesh, Hamilton, Canada, Alanna Webster, Hamilton, Canada, Kornelia Palczewski, Hamilton, Canada, Luis H Braga, Hamilton, ON |
| MP64-05 | PREDICTING VESICOURETERAL REFUX RESOLUTION: ANALYSIS OF VUR INDEX, DISTAL URETERAL DIAMETER RATIO, AND INTERNATIONAL REFUX GRADE  
Charlotte Q Wu*, Andrew J Kirsch, Traci Leong, Atlanta, GA, Christopher S Cooper, Iowa City, IA, Angela M Arlen, New Haven, CT |
| MP64-06 | SPONTANEOUS VESICOURETERAL REFUX RESOLUTION CURVES BASED ON URETERAL DIAMETER RATIO  
Angela M. Arlen*, New Haven, CT, Traci Leong, Andrew J. Kirsch, Atlanta, GA, Christopher S. Cooper, Iowa City, IA |
| MP64-07 | REVISITING RISK FACTORS FOR FEBRILE URINARY TRACT INFECTION USING A LARGE PRENATAL HYDRONEPHROSIS DATASET  
Luis H Braga*, Hamilton, ON, Smruthi Ramesh, Melissa McGrath, Hamilton, Canada, Armando J Lorenzo, Toronto, Canada, C.D Anthony Herndon, Richmond, VA, Forough Farrokhyar, Hamilton, Canada |
| MP64-08 | DELAYED CONTRAST DRAINAGE ON VOIDING IS NOT A RISK FACTOR OF BREAKTHROUGH URINARY TRACT INFECTION IN CHILDREN WITH PRIMARY VESICOURETERAL REFUX  
Jun Nyung Lee*, Kyeong-Hyeon Byeon, Heon Ha, Jae-Wook Chung, Yun-Sok Ha, Soock Hwan Choi, Bum Soo Kim, Hyun Tae Kim, Tae-Hwan Kim, Eun Sang Yoo, Tae Gyun Kwon, Sung Kwang Chung, Daegu, Korea, Republic of, Se Yun Kwon, Gyeongju, Korea, Republic of |
| MP64-09 | URINE FROM THE PATIENTS WITH VESICOURETERAL REFUX REVEALS CHANGES IN HOST AND BACTERIAL METABOLISM AFTER URINARY TRACT INFECTION  
| MP64-10 | RETRACTABLE FORESKIN REDUCES URINARY TRACT INFECTIONS IN INFANT BOYS WITH VESICOURETERAL REFUX  
Joshua Chamberlin*, Dao Le, Vincent Delgado, Crystal Dorgalli, Kai-Wen Chuang, Heidi Stephany, Irene McAleer, Elias Wehbi, Antoine Khoury, Orange, CA |
| MP64-11 | PREFERENCE AND USE OF MINIMALLY-INVASIVE TECHNIQUES IN VESICOURETERAL REFUX: CORRELATING A CROWDSOURCED SURVEY AND AMERICAN BOARD OF UROLOGY CASE LOGS  
Tijani Osumah*, Derek Gearman, Mohamed Ahmed, Mohit Butaney, Candace Granberg, Patricio Gargollo, Rochester, MN |
| MP64-12 | DOES DE-NOVO HYDRONEPHROSIS AFTER PEDIATRIC ROBOT-ASSISTED LAPAROSCOPIC URETERAL REimplantation BEHAVE SIMILARLY TO OPEN REimplantation?  
Esther Kim, Jeffrey White, Kunj Sheth, Rodolfo Elizondo, Truc Baccam, Houston, TX, Minki Baek, Seoul, Korea, Democratic People's Republic of, Chester Koh*, Houston, TX |
**MP64-13** RESULTS OF OPEN, LAPAROSCOPIC AND ENDOSCOPIC SURGERY FOR INTERMEDIATE GRADE VESICOURETERAL REFLUX (VUR) IN CHILDREN: A COMPARATIVE MULTICENTRIC STUDY  
Benoit TESSIER*, Montpellier, France, Sophie VERMERSCH, Saint-Priest-en-Jare, France, Luke HARPER, Bordeaux, France, Sarah Garnier, Leslie REMONT, Christophe LOPEZ, Montpellier, France, Francois VARLET, Saint-Priest-en-Jare, France, Nicolas KALFA, Montpellier, France

**MP64-14** RENAL SCARRING IS ASSOCIATED WITH ADVERSE RENAL OUTCOMES DURING LONGITUDINAL ASSESSMENT  
Julia Finkelstein*, James Rague, Briony Varda, Alyssia Hanna, Meghan Somanathan, Nehizada Aihie, Deborah Stein, Michael Ferguson, Tanya Logvinenko, Caleb Nelson, Richard S Lee, Boston, MA

**MP64-15** HYDRONEPHROSIS FOLLOWING URETERAL REIMPLANTATION: WHEN IS IT CONCERNING?  
Ciro Andolfi*, Diboro Kanabolo, Veronica M. Rodriguez, Joshua Aizen, Brittany L. Adamic, Craig V. Labbate, Mohan S. Gundeti, Chicago, IL

**MP64-16** IMPACT OF THE 2011 AMERICAN ACADEMY OF PEDIATRICS (AAP) URINARY TRACT INFECTION (UTI) GUIDELINE ON VESICOURETERAL REFLUX INDEX (VURX)  
Aylin Bilgutay*, Michael Garcia-Roig, Courtney McCracken, Andrew Kirsch, Atlanta, GA

**MP64-17** INCIDENCE OF FEBRILE URINARY TRACT INFECTION IN CHILDREN WITH HIRSCHSPRUNG DISEASE IS INCREASED IN THE FIRST MONTHS OF LIFE  
Faten LETAIREF*, Montpellier, France, Anne DARIEL, Marseille, France, Benoit TESSIER, Montpellier, France, Claude BORRIONE, Marseille, France, Sarah Garnier, Christophe LOPEZ, Dominique FORGUES, Hossein ALLAL, Marie-Pierre GUibal, Olivier MAILLET, Montpellier, France, Jean-Michel GUYS, Thierry MERROT, Montpellier, France

**MP64-18** PARENTAL PERCEPTION OF BLADDER SPASMS AND HEMATURIA AFTER SURGERY FOR REFLUX: A PROSPECTIVE MULTICENTER STUDY  
Aaron Bayne*, Portland, OR, Kathy Herbst, Hartford, CT, Sean Corbett, Charlottesville, VA, Eric Nelson, Richmond, VA

**MP64-19** THE IMPACT OF OBESITY ON FEBRILE URINARY TRACT INFECTION IN INFANT YOUNGER THAN 3 MONTHS  
Hye Jin Byun*, Wonho Jung, Ji Yong Ha, Byung Hoon Kim, Chol Hae Park, Chun Il Kim, Daegu, Korea, Republic of

**MP64-20** ARE RENAL BLADDER ULTRASOUNDS NECESSARY FOR ROUTINE FOLLOW-UPS OF VUR PATIENTS AFTER CAP DISCONTINUATION?  
Smruthi Ramesh*, Melissa McGrath, Kornelia Palczek, Hamilton, Canada, Luis H Braga, Hamilton, ON

**APPROVED FOR AMA PRA CATEGORY 1 CREDIT™**

---

**Sunday, May 5, 2019**  
**Moderated Poster Session 65**

**SEXUAL FUNCTION/DYSFUNCTION: PEYRONIE’S DISEASE**  
Room W181ab @ McCormick Place  
**Moderators:** Gregory Broderick, Faysal Yafi & Luiz Torres

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP65-01</td>
<td>BIOENGINEERING CORPORAL TISSUE CONSTRUCTS USING NON-HUMAN PRIMATE SMOOTH MUSCLE AND ENDOTHELIAL CELLS FOR CLINICAL APPLICATIONS Joao Zambon*, Young Min Ju, Koudy Williams, Ryan Terlecki, Sita Somara, John Jackson, Julie Allickson, James Yoo, Anthony Atala, Winston Salem, NC</td>
</tr>
<tr>
<td>MP65-02</td>
<td>EVALUATING THE IMPACT OF PENILE GIRTH DISCREPANCY ON PENILE INSTABILITY AND PATIENT BOTHER IN MEN WITH PEYRONIE’S DISEASE Carolyn A. Salter*, Bruno Nascimento, Jean-Etienne Terrier, Hisanori Taniguchi, Helen Bernie, Eduardo Miranda, Lawrence Jenkins, Elizabeth Schofield, John P. Mulhall, New York, NY</td>
</tr>
<tr>
<td>MP65-03</td>
<td>LONG-TERM PATIENT REPORTED OUTCOMES IN MEN WITH PEYRONIE’S DISEASE WHO UNDERGO CONSERVATIVE MANAGEMENT Edward Capoccia*, Matthew Ziegelmann, Jacob Emerson, Claudia Ofori-Marfoh, Joseph Lankford, Laurence Levine, Chicago, IL</td>
</tr>
<tr>
<td>MP65-04</td>
<td>CHARACTERISTICS AND CURVATURE IMPROVEMENT IN MEN WHO UNDERGO MORE THAN ONE ROUND (&gt;8 INJECTIONS) OF CLOSTRIDIUM COLLAGENASE HISTOLYTICUM FOR PEYRONIE’S DISEASE Sriram Eleswarapu*, Arash Amighi, Neil Mendhiratta, Jesse Mills, Los Angeles, CA</td>
</tr>
</tbody>
</table>
MP65-05 COMPARATIVE COST-EFFECTIVENESS OF SURGERY, COLLAGENASE CLOSTRIDIUM HISTOLYTICUM, AND PENILE TRACTION THERAPY IN THE TREATMENT OF PEYRONIES DISEASE
Kevin Wymer*, Kevin Hebert, Tobias Kohler, Landon Trost, Rochester, MN

MP65-06 LONG-TERM SAFETY AND CURVATURE DEFORMITY CHARACTERIZATION IN PATIENTS PREVIOUSLY TREATED WITH COLLAGENASE CLOSTRIDIUM HISTOLYTICUM FOR PEYRONIE'S DISEASE
Irwin Goldstein*, San Diego, CA, Larry Lipshtultz, Houston, TX, Michael McLane, Yiqun Hu, Steve Xiang, Genezhi Liu, Saji Vijayn, Malvern, PA, Martin Gelbard, Burbank, CA

MP65-07 ADHERENCE TO COLLAGENASE CLOSTRIDIUM HISTOLYTICUM LABEL RECOMMENDATIONS AND PROVIDER SATISFACTION: A SURVEY OF INTERNATIONAL SOCIETY FOR SEXUAL MEDICINE MEMBERS
Alex Galante*, Gainesville, FL, Thomas Masterson, Mohit Butaney, Miami, FL, Alexander Pastuszak, Salt Lake City, UT, Hossein Sadeghi-Nejad, Newark, NJ, Ranjith Ramasamy, Miami, FL

MP65-08 INTRALESIONAL INJECTION OF COLLAGENASE CLOSTRIDIUM HISTOLYTICUM FOR THE MANAGEMENT OF PEYRONIE'S DISEASE WITH INDENTATION OR HOURGLASS DEFORMITY
Mahdi Osman*, Maxwell Towe, Farouk M. EL-Khatib, Linda Huynh, Faysal A. Yafi, Orange, CA

MP65-09 HOW UNCOMMON PENILE CURVATURES INFLUENCE CLINICAL OUTCOMES IN PATIENTS WITH PEYRONIE'S DISEASE RECEIVING COLLAGENASE CLOSTRIDIUM HISTOLYTICUM THERAPY?
Andrea Cocci*, Florence, Italy, Giorgio Ivan Russo, Catania, Italy, Gianmartin Cito, Andrea Minervini, Mauro Gacci, Sergio Serni, Pierangelo Vernieri, Florence, Italy, Bruno Giammusso, Catania, Italy, Nicola Mondaini, Florence, Italy

MP65-10 COMPARISON OF STANDARDIZED INTRALESIONAL INJECTION OF INTERFERON 2-ALPHA-2B (IFN) AND COLLAGENASE CLOSTRIDIUM HISTOLYTICUM (CCH) FOR PEYRONIE'S DISEASE (PD) AT SINGLE HEALTH CENTER
Kyle Gillis*, Portland, OR, Ashley Winter, Clackamas, OR

MP65-11 EFFECT OF LOW-DOSE PDESI AND LOW-ENERGY SHOCK WAVE ON ACUTE PHASE OF PEYRONIE DISEASE
Mujun Lu*, Shanghai, China, People's Republic of

MP65-12 DEFINING THE IMPACT OF PEYRONIE'S DISEASE ON PSYCHOSOCIAL STATUS IN GAY VERSUS HETEROSEXUAL MEN
Carolyn A. Sailer*, Bruno Nascimento, Jean-Etienne Terrier, Hisanori Taniguchi, Helen Bernie, Eduardo Miranda, Lawrence Jenkins, Elizabeth Schofield, John P. Mulhall, New York, NY

MP65-13 HOME-MODELING AFTER PENILE PROSTHESIS IMPLANTATION IS A VIABLE OPTION FOR MANAGEMENT OF RESIDUAL CURVATURE IN PEYRONIE'S DISEASE
Ignacio Moncada, Madrid, Spain, Pramod Krishnappa*, Bangalore, India

MP65-14 A NOVEL LASER SPECKLE CONTRAST IMAGING (LSCI) TECHNIQUE TO EVALUATE PENILE MICROCIRCULATORY DYSFUNCTION IN PATIENTS WITH PEYRONIE'S DISEASE
Aaron Bradshaw*, SeungMo Yuk, Mahadevan Rajasekaran, Valmik Bhargava, Tung-Chin (Mike) Hsieh, San Diego, CA

MP65-15 SIMULATION TRAINING IN PENILE IMPLANT SURGERY: ASSESSMENT OF SURGICAL CONFIDENCE AND KNOWLEDGE WITH CADAVERIC LABORATORY TRAINING
Aaron Lentz, Raleigh, NC, Dayron Rodriguez*, Boston, MA, Leah Davis, Durham, NC, Michel Apoj, Price Kerfoot, Boston, MA, Paul Perito, Coral Gables, FL, Gerard Henry, Bossier City, LA, LeRoy Jones, San Antonio, TX, Rafael Carrion, Tampa, FL, John Mulcahy, Madison, AL, Ricardo Munarriz, Boston, MA

MP65-16 PREVENTING NEED FOR REVISION SURGERY AFTER PENILE PLICATION RECONSTRUCTION OF PEYRONIE'S DEFORMITIES
Rohit Reddy*, Yooni Yi, Jorge Fuentes, Michael Davenport, Rachel Bergeson, Allen Moyer, Dallas, TX

MP65-17 TREATMENT RELATED OUTCOMES FOR PATIENTS WITH ATYPICAL PEYRONIE'S DISEASE
Farouk M. El-Khatib*, Mohamad Osman, Maxwell Towe, Linda Huynh, Faysal A. Yafi, Orange, CA

MP65-18 PRELIMINARY OUTCOMES OF A NOVEL PENILE TRACTION DEVICE (RESTOREX) IN MEN WITH PEYRONIE'S DISEASE: A RANDOMIZED, CONTROLLED TRIAL
Matthew Ziegelmann*, Joshua Savage, Manal Alom, Ross Avant, David Yang, Landon Trost, Rochester, MN

MP65-19 ERECTILE DYSFUNCTION IN PEYRONIE'S DISEASE IS INDEPENDENT OF Cavernosal Inflammation and Fibrosis
Jeffrey Campbell*, London, Canada, Uros Milenkovic, Leuven, Belgium, Dorota J. Harksworth, Xiaopu Liu, Baltimore, MD, Maarten Albersen, Leuven, Belgium, Arthur L. Burnett, Trinity J. Bivalacqua, Baltimore, MD
<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
</table>
| MP66-01 | APICAL INVOLVEMENT IS ASSOCIATED WITH ADVERSE PATHOLOGICAL OUTCOMES IN MEN WITH LOW RISK PROSTATE CANCER ELIGIBLE FOR ACTIVE SURVEILLANCE  
Ahmed Elshafei*, Khaled Fareed, Cleveland, OH, Ayman S. Moussa, Beni Suef, Egypt, Scott Lundy, Molly E DeWitt-Foy, Lewis Thomas, Ahmed Khalifa, Shih-Chieh Chueh, Amr Fergany, Andrew Stephenson, Eric Klein, Cleveland, OH |
| MP66-02 | NUMBER OF BIOPSY CORES CONTAINING GRADE GROUP 2 IS PROGNOSTIC FOR ADVERSE PATHOLOGIC FEATURES AND PROSTATE CANCER RECURRENTNESS  
John Cooper*, Columbus, OH, Mufaddal Mamawala, Baltimore, MD, Jason Cohen, Chicago, IL, Jeffrey Tosbian, Ann Arbor, MI, Misop Han, Baltimore, MD, Debasish Sundi, Columbus, OH |
| MP66-03 | AMONG MEN WITH GLEASON GRADE GROUP 3, INTERMEDIATE-RISK PROSTATE CANCER, STAGE CT2 IS ASSOCIATED WITH METASTATIC RECURRENCE  
John Cooper*, Columbus, OH, Mufaddal Mamawala, Baltimore, MD, Jason Cohen, Chicago, IL, Jeffrey Tosbian, Ann Arbor, MI, Misop Han, Baltimore, MD, Debasish Sundi, Columbus, OH |
| MP66-04 | IMPLICATION OF MISSED POSTEROLATERAL TUMOR ON MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING FOR NERVE-SPARING DURING RADICAL PROSTATECTOMY  
Arveen Kalapara*, Henry Pan, Mark Frydenberg, Jeremy Grummet, Melbourne, Australia |
| MP66-05 | VARIATION IN POSITIVE SURGICAL MARGIN STATUS FOLLOWING RADICAL PROSTATECTOMY FOR PT2 PROSTATE CANCER  
Wei Shen Tan*, London, United Kingdom, Marieke Krimpfove, Alexander Cole, Sebastian Berg, Maya Marchese, Stuart Lipsitz, Boston, MA, Björn Loppenberg, Herne, Germany, Junaid Nabi, Boston, MA, Firas Abdollah, Detroit, MI, Toni Choueiri, Adam Kibel, Quoc-Dien Trinh, Boston, MA, Prasanna Sooriakumaran, London, United Kingdom |
| MP66-06 | APPLICATION OF CHITOSAN MEMBRANES AFTER NERVE-SPARING RADICAL PROSTATECTOMY: RESULTS OF A ONE YEAR FOLLOW UP COMPARATIVE STUDY.  
Francesco Porpiglia, Matteo Manfredi, Enrico Checcucci, Diletta Garrou, Sabrina De Cillis, Gabriele Volpi, Giovanni Cattaneo, Federico Piramide, Alberto Piana, Daniele Amparore, Francesca Ragni, Cristian Pient*, Orbassano, Italy |
| MP66-07 | OMITTING A LYMPH NODE DISSECTION AT RADICAL PROSTATECTOMY: ARE THERE CONSEQUENCES FOR UNEXPECTED UPGRADING/UPSTAGING?  
Muammer Altok, Brian Chapin, Surena Matin, Mary Achim, John Davis*, Houston, TX |
| MP66-08 | SUPERIORITY OF RETZIUS-SPARING ROBOT ASSISTED RADICAL PROSTATECTOMY IN CONTINENCE RESULT COMPARED TO CONVENTIONAL METHOD: SINGLE SURGEON EXPERIENCE WITH PROPENSITY SCORE MATCHING TOTAL OF 1218 PATIENTS  
Jongsoo Lee, Ahmad Almujalhem, Seoul, Korea, Republic of, Ali Raheem, Tanta, Egypt, Doo Yong Chung, Don Gu Lee, Jin Hyung Jeon*, Seoul, Korea, Republic of, Kidon Chang, Wonju, Korea, Republic of, Jang Hwan Kim, Sung Joon Hong, Byung Ha Chung, Young Deuk Choi, Koon Ho Rha, Seoul, Korea, Republic of |
MP66-09 A CONTEMPORARY ANALYSIS OF TREATMENT SELECTION AND COMPARATIVE EFFICACY OF TREATMENT FOR MEN WITH DUCTAL CARCINOMA OF THE PROSTATE
Millard Henry*, Daniel Parker, Cameron Britton, Sanjay Patel, Oklahoma City, OK

MP66-10 IDENTIFYING CAPSULAR INVOLVEMENT DURING DISSECTION OF PERIPROSTATIC TISSUE USING 3D ELASTIC AUGMENTED-REALITY DURING ROBOT-ASSISTED RADICAL PROSTATECTOMY: A FEASIBILITY STUDY
Francesco Porpiglia, Enrico Checcucci, Daniele Amparore, Matteo Manfredi, Federica Massa, Daniele Tota, Diletta Garrou, Alberto Piana, Angela Pecoraro, Roberta Ainar, Enrico Bollito, Cristian Fiori*, Orbassano, Italy

MP66-11 TRANSVESICAL ROBOT ASSISTED RADICAL PROSTATECTOMY
Gongxian Wang*, Xiaochen Zhou, Bin Fu, Cheng Zhang, Nanchang, China, People’s Republic of

MP66-12 NEOADJUVANT ANDROGEN DEPRIVATION THERAPY PRIOR TO RADICAL PROSTATECTOMY FOR LOCALLY VERY ADVANCED (CT4) PROSTATE CANCER
Raisa Pompe*, Robert Hagen, Hamburg, Germany, Philipp Mandel, Felix K. Chun, Frankfurt, Germany, Philipp Gild, Thomas Steuber, Georg Salomon, Markus Graefen, Margit Fisch, Hartwig Huland, Derya Tiki, Hamburg, Germany

MP66-13 EVALUATION OF RADIOTHERAPY, TIMING, AND ONCOLOGIC OUTCOMES FOR POST RADICAL PROSTATECTOMY PATIENTS
Huang Wei Su, Linda M Huynh, Orange, CA, Stephen B. Williams, Galveston, TX, Thomas Ahlering*, Orange, CA

MP66-14 PSA PERSISTENCE AFTER RADICAL PROSTATECTOMY AND ITS IMPACT ON ONCOLOGIC OUTCOMES
Felix Preisser*, Frankfurt, Germany, Raisa Pompe, Hamburg, Germany, Felix Chun, Frankfurt, Germany, Markus Graefen, Hartwig Huland, Derya Tiki, Hamburg, Germany

MP66-15 PREDICTING FACTORS FOR PROGRESSION TO CASTRATION-RESISTANT PROSTATE CANCER AFTER BIOCHEMICAL RECURRENCE IN PATIENTS WITH CLINICALLY LOCALIZED PROSTATE CANCER WHO UNDERWENT RADICAL PROSTATECTOMY
Takeshi Hashimoto*, Jun Nakashima, Yutaka Nakata, Yuki Hiratsawa, Naohiro Kamoda, Yosuke Hiratsawa, Naoya Satake, Tatsu Gondo, Yoshio Nakagami, Kazunori Namiki, Yoshio Ohno, Tokyo, Japan

MP66-16 CLINICAL SIGNIFICANCE OF MULTIPARAMETRIC MRI AND PSA DENSITY AS PREDICTORS OF RESIDUAL TUMOR (PT0) FOLLOWING RADICAL PROSTATECTOMY FOR T1A-T1B (INCIDENTAL) PROSTATE CANCER
Doo Yong Chung*, Jong Soo Lee, Won Sik Jang, Seoul, Korea, Republic of, In Rae Cho, Gimhae, Korea, Republic of, Young Sig Kim, Goyang, Korea, Republic of, Joong Shik Lee, Seoul, Korea, Republic of, Dong Hoon Lim, Gwangju, Korea, Republic of, Don Gu Lee, Jin Hyung Jeon, Hyun Ho Han, Won Sik Ham, Young deuk Choi, Seoul, Korea, Republic of

MP66-17 DEVELOPMENT OF A PROCEDURE-SPECIFIC CLASSIFICATION SYSTEM FOR REPORTING POSTOPERATIVE COMPLICATIONS IN PROSTATE CANCER PATIENTS UNDERGOING ROBOT-ASSISTED RADICAL PROSTATECTOMY
Giorgio Gandaglia, Simone Scuderi*, Daniele Robesti, Antony Pellegrino, Donato Cannetoletta, Francesco Barletta, Armando Stabile, Alberto Martini, Vito Cucchiara, Antonio Costa, Milan, Italy, Andrea B Galosi, Ancona, Italy, Roberto Bertini, Renzo Colombo, Nazareno Suardi, Andrea Gallina, Nicola Fossati, Francesco Montorsi, Alberto Briganti, Milan, Italy

MP66-18 PREOPERATIVE FACTORS ASSOCIATED WITH REDUCED LENGTH OF STAY FOLLOWING ROBOTIC-ASSISTED RADICAL PROSTATECTOMY: WHO TO TREAT IN THE AMBULATORY SETTING?
Grace Chen*, Lily Kaufman, Stephanie Stillings, Justin Rose, Tatevik Broultian, Amy Lehman, Mariily Palettas, Ahmad Shabsigh, David Sharp, Geoffrey Box, Debasish Sundi, Cheryl Lee, Columbus, OH

MP66-19 RACIAL DIFFERENCES IN PATIENT-REPORTED OUTCOMES OF MEN TREATED FOR LOCALIZED PROSTATE CANCER
Pauline Filippou*, Cleo Samuel, Antonia Bennett, Mian Wang, Arlene Chung, Ethan Basch, Ronald Chen, Bryce Reeve, Angela B. Smith, Chapel Hill, NC

MP66-20 ISUP SCORE AS BEST PROGNOSTIC FACTOR FOR PERFORMING LYMPHADENECTOMY DURING RADICAL PROSTATECTOMY FOR BLACK MEN.
Emmanuel PERROT*, Sofiane SEDDIK, Gilles COURTAUD, Rémi EYRAUD, Virginie ROUX, Clément MOUREAUX, Pascal BLANCHET, Laurent BRUREAU, Pointe-à-Pitre CEDEX, BP 465, Guadeloupe

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
**ABSTRACT NUMBER** | **TITLE** |
---|---
**MP67-01** | DEVELOPMENT AND CONTENT VALIDATION OF THE URETHROPLASTY TRAINING AND ASSESSMENT TOOLS (UTAT)  
Sara Jasionowska*, Majed Shabbir, Oliver Brunckhorst, Muhammad Khan, London, United Kingdom, Hussain Manzoor, Karachi, Pakistan, Prokar Dasgupta, London, United Kingdom, Paul Anderson, Dudley, United Kingdom, Guido Barbagni, Arezzo, Italy, Kamran Ahmed, London, United Kingdom |
**MP67-02** | TRENDS IN URETHRAL RECONSTRUCTION TRAINING: A REVIEW OF ACGME RESIDENT CASE LOGS  
Jonathan Wingate*, Byron Joyner, Judith Hagedorn, Niels Johnsen, Seattle, WA |
**MP67-03** | PREDICTING URETHRAL STRICTION SYMPTOM SEVERITY USING RETROGRADE URETHROGRAMS AND UROFLOWMETRY  
Bradley Webster*, Maxx Gallegos, Albuquerque, NM |
**MP67-04** | CATHETERS IN URETHROPLASTY: A PROSPECTIVE RANDOMIZED ANALYSIS BETWEEN LATEX AND SILICONE  
**MP67-05** | INCIDENCE AND PATTERNS OF CATHETER ASSOCIATED UTIS (CAUTIS) POST URETHROPLASTY  
Hack Jae Lee*, Nick Watkin, Davendra Sharma, Pareeta Patel, Justin Bendig, London, United Kingdom |
**MP67-06** | ANTIBIOTIC RESISTANCE IN PATIENTS UNDERGOING URETHRAL SURGERY  
Bruno Müller*, Ricardo Bertolla, Julio Geminiani, São Paulo, Brazil |
**MP67-07** | OUTCOME OF DORSAL VERSUS VENTRAL APPROACH IN DOUBLE FACE GRAFT URETHROPLASTY IN NEAR OBLITERATED URETHRAL STRICTION – A COMPARATIVE ANALYSIS  
Rajiv Kore*, Kolhapur, India |
**MP67-08** | OUTPATIENT BUCCAL MUCOSAL GRAFT URETHROPLASTY OUTCOMES ARE COMPARABLE TO INPATIENT PROCEDURES  
Michael Davenport*, Maxim McKibben, Nabeel Shakir, Joceline Fuchs, Yooni Yi, Jeremy Scott, Rachel Bergeson, Allen Morey, Dallas, TX |
**MP67-09** | RISK FACTORS FOR FAILURE AFTER STAGED URETHRAL RECONSTRUCTION: RESULTS FROM LONG-TERM FOLLOW UP.  
James Furr*, Martin Hofmann, Joel Gelman, Orange, CA |
**MP67-10** | A SIMPLIFIED SURGICAL ALGORITHM FOR THE MANAGEMENT OF BULBAR URETHRAL STRICTURES: COMPARISON OF TRANSECING VERUS NON-TRANSECING URETHROPLASTY AT A SINGLE INSTITUTION  
Jason Warncke*, Jeffrey Marks, David Koslov, Humberto Villarreal, Lisa Parrillo, Brian Flynn, Aurora, CO |
**MP67-11** | RISK FACTORS FOR DE NOVO SEXUAL DYSFUNCTION IN TRANSECING BULBAR URETHROPLASTY  
James Furr*, Quynh Mai, Phil Bucur, Joel Gelman, Orange, CA |
**MP67-12** | ASSOCIATION OF BUCCAL MUCOSAL GRAFT HISTOLOGY AND MOUTH ANATOMY TO BULBAR URETHROPLASTY GRAFT TAKE AND FACIAL MORBDITY  
Shyam Sukumar*, New York, NY, Cooper Benson, New Orleans, LA, Debduh Plish, Carlos Pagan, Steven Brandes, New York, NY |
**MP67-13** | QUALITATIVE ANALYSIS OF ONLINE DISCUSSION BOARDS FOR URETHROPLASTY  
Benjamin Cedars*, Philadelphia, PA, Andrew Cohen, San Francisco, CA, Nima Baradaran, Columbus, OH, Medina Ndoye, Puneet Kaman, Benjamin Breyer, San Francisco, CA |
**MP67-14** | BULBAR SPARING ‘Z’ ANASTOMOTIC PRIMARY REPAIR OF URETHRAL STRICTURES  
Raul Ordonica*, Riverside, CA
MP67-15 URETHRAL RECONSTRUCTION PERFORMED DURING UROLOGIC GLOBAL OUTREACH: DELIVERING ON OUR PROMISE?

MP67-16 OUTCOMES OF RECTO-URETHRAL FISTULA REPAIR USING A YORK-MASON PROCEDURE – RETURN TO CONTINUITY OF URINARY AND BOWEL FUNCTION
Urszula Kowalik*, Brian Inouye, Stephanie Sexton, Brian Gilmore, Andrew Peterson, John Migaly, Christopher Mantyh, Durham, NC

MP67-17 A NOVEL TECHNIQUE FOR REPAIR OF URETHROPERINEAL FISTULA COMPLICATING ABDOMINOPERINEAL RESECTION OF RECTAL CARCINOMA
Ayman Atwa*, Amar Rawal, pankaj joshi, sanjay kulkarni, shreyas bhadranaar, pune, India

MP67-18 TWO-STAGE MANAGEMENT OF COMPLEX POST PROSTATE CANCER TREATMENT BLADDER NECK CONTRACTURE ASSOCIATED WITH STRESS INCONTINENCE.
Jan-Michael Pohudka*, Angelo E Gousse, Miami, FL

MP67-19 URETHRAL STRicture AFTER HIGH-INTENSITY FOCUSED ULTRASOUND
Martin Hofmann*, James Furr, Joel Gelman, Orange, CA

MP67-20 DIRECTED NON-ONCOLOGIC PATHOLOGY REVIEW IDENTIFIES A HIGH PREVALENCE OF CHRONIC INFLAMMATION WITHIN ANTERIOR URETHROPLASTY STRICTURE SPECIMENS
Matthew D Grimes*, James Furr, Joel Gelman, Orange, CA

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Sunday, May 5, 2019 3:30 pm - 5:30 pm
Moderated Poster Session 68
PROSTATE CANCER: BASIC RESEARCH & PATHOPHYSIOLOGY II
Room W179a @ McCormick Place
Moderators: Magdalena Grabowska, Christopher Evans & Marianne Sadar

ABSTRACT NUMBER TITLE
MP68-01 IMMUNE COMPOSITION CONTRIBUTES TO PROSTATE MRI APPEARANCE
Eric Kim*, Dengfeng Cao, Joseph Ippolito, Russell Pachynski, Gerald Andriole, St. Louis, MO

MP68-02 NEUROIMMUNE REGULATION OF METASTATIC PROSTATE CANCER-ASSOCIATED BONE PAIN
Zhiquang Liu*, Stephen Murphy, Christel Hall, Edward Schaeffer, Praveen Thumbikat, Chicago, IL

MP68-03 DUTASTERIDE ENHANCES PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) SURFACE EXPRESSION AND UPTAKE OF 177LU-PSMA-617 IN VITRO
Benedikt Kranzbihler*, Souzan Salem, Zurich, Switzerland, Christoph A. Umbricht, Cristina Muller, Villigen, Switzerland, Tullio Sulser, Irene A. Burger, Daniel Eberli, Zurich, Switzerland

MP68-04 ACTIVATABLE PHOTODYNAMIC THERAPY FOR PROSTATE CANCER BY NIR DYE/PHOTOSENSITIZER LOADED ALBUMIN NANOPARTICLES
Changwei Ji*, Nanjing, China, People’s Republic of

MP68-05 “SEQUENCING IS MY CO-PILOT”: USING NEXT-GENERATION SEQUENCING TO GUIDE THE SENTINEL NODE CONCEPT IN PROSTATE CANCER
Ramkishen Narayanan*, Darryl Nousome, Matthew Salomon, David Krasne, John Jalas, Kevin Tran, Rebecca Gentry, Jennifer Linehan, Dave Hoon, Timothy Wilson, Santa Monica, CA

MP68-06 MIR-1227 ALTERS EXTRACELLULAR VESICLE SHEDDING IN PROSTATE CANCER
Andrew Chin*, Valentina R. Minciacchi, Tatjana Vagner, Javier Mariscal, Minhyung Kim, Cristina Spinelli, Mariana Sobreiro, Mandana Zandian, Sungyong You, West Hollywood, CA, Shivani Sharma, Los Angeles, CA, Nadia Zaffaroni, Paolo Gandellini, Milan, Italy, Dolores Di Vizio, West Hollywood, CA

MP68-07 SIGNIFICANCE OF CANONICAL WNT10B IN PROSTATE GLAND DEVELOPMENT AND CARCINOGENESIS
Ikenna Madueke*, Wen-Yang Hu, Danping Hu, Michael Abern, Gail Prins, Chicago, IL
**MP68-08** A 'BROKEN CTCF' GENE SIGNATURE, A MASTER EPIGENETIC REGULATOR, PREDICTS ADVERSE CANCER OUTCOME AND ALTERED AMINO ACID TRANSPORT IN PROSTATE CANCER.
Joseph Gawdzik, Bing Yang*, Reehan Machhi, Avtar Roopra, Tariq Khemees, David Jarrard, Madison, WI

**MP68-09** OVERCOMING PROSTATE CANCER THERAPEUTIC RESISTANCE BY MODULATING MITOCHONDRIA-MEDIATED CELL METABOLISM AND DEATH SIGNALING

**MP68-10** HOXB13 EXPRESSION AND ITS ROLE IN PROSTATE CANCER PROGRESSION AND NEUROENDOCRINE DIFFERENTIATION
Farzana Faisal*, Mohammed Alshalalfa, Elai Davicioni, Vancouver, Canada, R. Jeffrey Karnes, Rochester, MN, William Isaacs, Tamara Lotan, Baltimore, MD, Edward Schaeffer, Chicago, IL

**MP68-11** IDENTIFICATION OF INTERMEDIATE CELL POPULATIONS DURING TREATMENT INDUCED LINEAGE CONVERSION TO NEUROENDOCRINE PROSTATE CANCER.
Harkirat S. Sandhu*, David J. Mulholland, New York, NY

**MP68-12** IMPACT OF SPOP MUTATION ON PROSTATE CANCER PROGNOSIS
Jonathan Shoag*, Deli Liu, Xiaoyue Ma, Clara Oromendia, Cynthia Angulo, New York, NY, Seagle Liu, Yang Liu, Elai Davicioni, Vancouver, Canada, Christopher Barbieri, New York, NY

**MP68-13** DDX3-MEDIATED TRANSLATIONAL REGULATION OF ANDROGEN RECEPTOR IN PROSTATE CANCER PROGRESSION
Jordan Vellky*, William Ricke, Madison, WI

**MP68-14** MOLECULAR DISSECTION OF ANDROGEN RECEPTOR SIGNALING IN PROSTATIC ENDOTHELIAL, EPITHELIAL, AND STROMAL CELLS
Nelson Gross, Jianmin Wang, Gary Smith, Yue Wu*, Buffalo, NY

**MP68-15** TARGETING STEROID SULFATASE SUPPRESSES ANDROGEN RECEPTOR SIGNALING AND TUMOR GROWTH IN CRPC
Chengfei Liu, Liangren Liu, Cameron Armstrong*, Joy Yang, Wei Lou, Sacramento, CA, Pui-Kai Li, Clombokus, OH, Christopher Evans, Allen Gao, Sacramento, CA

**MP68-16** XENOBIOTIC METABOLISM OF ABIRATERONE ACETATE AND GLUCOCORTICOIDS BY THE GUT MICROBIOTA
Kamilah Abdur-Rashid*, Shiva Nair, Ryan Chanyi, Joseph Chin, Jeremy Burton, London, Canada

**MP68-17** ENZALUTAMIDE-INDUCED ANTIANDROGEN-RESISTANCE VIA A UNIQUE TRANS-SPICING MECHANISM TO INDUCE A NOVEL ANDROGEN RECEPTOR MUTANT ARV33
Ronghao Wang*, Chawnshang Chang, Shuyuan Yeh, Rochester, NY

**MP68-18** ENZALUTAMIDE TREATMENT RESULTS IN ANTI-ANDROGEN RESISTANCE IN PATIENT-DERIVED BONE METASTATIC PROSTATE CANCER MODELS
Christina Jamieson*, Michelle Muldongs, Danielle Burner, Christina Wu, Theresa Mendoza, Sanghee Lee, Catalina Arreola, Tris Mendoza, LA J olla, CA, Nicholas Cacalano, Los Angeles, CA, Catriona Jamieson, Terry Gaasterland, Anna Kulidjian, Christopher Kane, La J olla, CA

**MP68-19** DEVELOPMENT AND CHARACTERISATION OF A SPONTANEOUSLY METASTATIC PATIENT-DERIVED XENOGRAFT (PDX) MODEL OF HUMAN PROSTATE CANCER (PCA)
Tobias Lange, Su Jung Oh-Hohenhorst*, Simon Joosse, Hamburg, Germany, Oliver Hahn, Goettingen, Germany, Tobias Gosau, Susanne Feldhaus, Hanna Maar, Renate Gehrcke, Martina Kloth, Ronald Simon, Thorsten Schiomm, Hartwig Huland, Udo Schumacher, Hamburg, Germany

**MP68-20** ESTABLISHING A NEGATIVE FEEDBACK LOOP BETWEEN FIBROBLAST GROWTH FACTOR 5 AND ANDROGEN RECEPTOR IN PROSTATE CANCER
Dalton McLean*, Katelin Cunningham, William Ricke, Madison, WI

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP69-01</td>
<td>VALIDATION OF PRIMARY ALDOSTERONISM (PA) DISCRIMINATION SCORE FOR CONFIRMATORY TESTS OF PA</td>
</tr>
<tr>
<td>Hayato Yamamoto*, Shingo Hatakeyama, Teppei Matsumoto, Yuichi Suzuki, Tohru Yoneyama, Atsushi Imai, Takahiro Yoneyama, Yasuhiro Hashimoto, Shinobu Takayasu, Shige yuki Nakaji, Chikara Ohyama, Hiroaki, J apan</td>
<td></td>
</tr>
<tr>
<td>MP69-03</td>
<td>IMPACT OF LAPAROSCOPIC ADRENALECTOMY ON CARDIAC FUNCTION IN PATIENTS WITH PRIMARY ALDOSTERONISM</td>
</tr>
<tr>
<td>Yoshihide K awasaki*, Shigeto Ishidoya, Yasuhiro Ka h o, Shuichi Shimada, Tomonori Sato, Shinichi Yamashita, Koji Mitsuzuka, Akhiro Ito, Sendai, J apan</td>
<td></td>
</tr>
<tr>
<td>MP69-04</td>
<td>A NEW INSIGHT FOR THE TREATMENT OF PRIMARY MACRONODULAR ADRENAL HYPERPLASIA: ADRENAL SPARING SURGERY EARLY OUTCOMES</td>
</tr>
<tr>
<td>Fabio Tanno*, Maria Candida B V Fragoso, Victor Srougi, Madson Queiroz Almeida, Berenice Bilitanino Mendonça, Fernando I de Yamauchi, Fernando Morbeck, Willian Carlos Nahas, Miguel Srougi, José Luis Chambô, São Paulo, Brazil</td>
<td></td>
</tr>
<tr>
<td>MP69-05</td>
<td>MIR-193A-3P INHIBITS ALDOSTERONOMA GROWTH BY DOWN-REGULATING CYP11B2 EXPRESSION</td>
</tr>
<tr>
<td>Zhang Guoxi, Qu K aiyang, Zou xiaofeng*, Liu Quanliang, Xie Tianpeng, He zhihua, Ganzhou, China, People's Republic of</td>
<td></td>
</tr>
<tr>
<td>MP69-06</td>
<td>RISK FACTORS FOR HEMODYNAMIC INSTABILITY DURING LAPAROSCOPIC ADRENALECTOMY FOR PHEOCHROMOCYTOMA</td>
</tr>
<tr>
<td>Toshikazu Takeda*, Kimiharu Takamatsu, Yu Teranishi, Kyohei Hako zaki, Nobuyuki Tanaka, Kazuhiro Matsumoto, Shinya Morita, Takeo Kosaka, Ryuichi M izuno, Toshiaki Shinjojima, Eiji Kikuchi, Hiroshi Asanuma, Mototsugu Oya, Tokyo, J apan</td>
<td></td>
</tr>
<tr>
<td>MP69-07</td>
<td>LONG-TERM FUNCTIONAL AND ONCOLOGIC OUTCOMES OF PARTIAL ADRENALECTOMY FOR PHEOCHROMOCYTOMA</td>
</tr>
<tr>
<td>Patrick T. Gomella*, Peter A. Pinto, Adam R. Metwalli, Gennady Bratslavsky, W. Marston Linehan, Mark W. Ball, Bethesda, MD</td>
<td></td>
</tr>
<tr>
<td>MP69-08</td>
<td>MECA 79 POSITIVE HIGH ENDO THELIAL VENULE (HEV) DENSITY MAY ASSOCIATE WITH TUMOR AGGRESSIVENESS OF PHEOCHROMOCYTOMA</td>
</tr>
<tr>
<td>Yasuhiro Hashimoto*, Hayato Yamamoto, Atsushi Imai, Shingo Hatakeyama, Takahiro Yoneyama, Chikara Oh yama, Hiroaki, J apan</td>
<td></td>
</tr>
<tr>
<td>MP69-09</td>
<td>MALIGNANT PHEOCHROMOCYTOMA: A COMPREHENSIVE GENOMIC PROFILING STUDY</td>
</tr>
<tr>
<td>MP69-10</td>
<td>PROGNOSIS OF ADULT ADRENAL NEOBLASTOMA AND CONDITIONAL PROBABILITY SURVIVAL ANALYSIS BASED UPON POPULATION LEVEL</td>
</tr>
<tr>
<td>Wenjun Xiao*, Yao Zhu, Dingwei Ye, Yuanyuan Qu, Jun Wang, Shanghai, China, People's Republic of</td>
<td></td>
</tr>
<tr>
<td>MP69-11</td>
<td>A RETROSPECTIVE STUDY OF THREE TERTIARY CARE CENTERS IN WESTERN CHINA: THE EFFECT OF 8 AM SERUM CORTISOL CONCENTRATION ON THE PROGNOSIS AND CLINICAL SIGNIFICANCE OF ADRENOCORTICAL CARCINOMA PATIENTS</td>
</tr>
<tr>
<td>Chuan Zhou*, Zhihong Liu, Jiayu Liang, Kan Wu, Fuxun Zhang, Fan Zhang, Yipeng Lu, Yuchun Zhu, Chengdu, China, People's Republic of</td>
<td></td>
</tr>
<tr>
<td>MP69-12</td>
<td>SURGERY FOR RECURRENT ADRENOCORTICAL CARCINOMA: A RETROSPECTIVE SINGLE-CENTER STUDY</td>
</tr>
<tr>
<td>Kan Wu*, Zhihong Liu, Jiayu Liang, Chuan Zhou, Fuxun Zhang, Fan Zhang, Yipeng Lu, Yuchun Zhu, Chengdu, China, People's Republic of</td>
<td></td>
</tr>
</tbody>
</table>
**MP69-13** PATTERNS OF TREATMENT APPROACHES AND OUTCOME OF ADRENOCORTICAL CARCINOMA: ANALYSIS FROM THE NATIONAL CANCER DATABASE
Ahmed Eldefrawy*, Stephen Ryan, Brittnay Cotta, Reith Sarkar, Aaron Bradshaw, Margaret Meagher, Zachary Hamilton, James Murphy, Ithaa Derweesh, San Diego, CA

**MP69-14** CONSTRUCTION OF A TUMOR MICROENVIRONMENT-BASED RISK ASSESSMENT MODEL IN ADRENOCORTICAL CARCINOMA
Jiayu Liang, Zhihong Liu*, Chuan Zhou, Kan Wu, Fuxun Zhang, Fan Zhang, Yiping Lu, Yuchun Zhu, Chengdu, China, People's Republic of

**MP69-15** UPREGULATION OF CDK1 AND TOP2A IS ASSOCIATED WITH POOR PROGNOSIS IN ADRENOCORTICAL CARCINOMA
Hengchuan Su*, Dingwei Ye, Shanghai, China, People's Republic of

**MP69-16** CIRCULAR RNA CIRC0066659 FUNCTIONS AS A COMPETITIVE ENDogenous RNA BY Sponging MIR-506-3P IN ADRENOCORTICAL CARCINOMA
Yunze Xu*, Yiran Huang, Shanghai, China, People's Republic of

**MP69-17** THE EXPRESSION OF EMERGING IMMUNE CHECKPOINT GENE B7-H3 IS ASSOCIATED WITH THE PROGNOSIS OF ADRENOCORTICAL CANCER PATIENTS
Jiayu Liang*, Zhihong Liu, Chuan Zhou, Kan Wu, Fuxun Zhang, Fan Zhang, Yiping Lu, Yuchun Zhu, Jiayu Liang, Zhihong Liu, Chuan Zhou, Kan Wu, Fuxun Zhang, Fan Zhang, Yiping Lu, Chengdu, China, People's Republic of

**MP69-18** ELECTIVE ADRENALECTOMY IN ELDERLY PATIENTS: PROCEED WITH CAUTION
Valary Raup*, Pamela Lu, Alexandra Berger, Julie Szymanik, Abraham Chiang, Michael Malone, Quoc-Dien Trinh, Jairam Eswara, Boston, MA

**MP69-19** TRANSPERITONEAL LAPAROSCOPIC PARTIAL ADRENALECTOMY USING INDOCYANINE GREEN DYE WITH NEAR-INFRARED IMAGING: THE INITIAL EXPERIENCE
Altug Tuncel*, Melih Balci, Can Aykanat, Yilmaz Aslan, Dilek Berker, Ozer Guzel, Ankara, Turkey

**MP69-20** RETROPERITONEAL VERSUS TRANSPerITONEAL LAPAROSCOPic ADRENALECTOMY: A COMPARISON OF PERIOPERATIVE OUTCOMES IN MORE THAN TWENTY YEARS SINGLE SURGEON'S EXPERIENCE.
Francesco Porpiglia*, Roberto Mario Scarpa, Daniele Amparore, Matteo Manfredi, Enrico Cheuccci, Gabriele Volpi, Diletta Garrou, Giovanni Cattaneo, Razvan Gabriel Niculescu, Giorgio Alleva, Roberta Aimar, Cristian Fiori, Orbassano, Italy

---

**Podium Session 54**

**TRANSPLANTATION & VASCULAR SURGERY: RENAL TRANSPLANTATION & VASCULAR SURGERY I**

**Room W181c @ McCormick Place**

**Moderators:** David Goldfarb, Patrick Luke & Alp Sener

**ABSTRACT**

**TIME** | **NUMBER** | **TITLE** | **TIME** | **NUMBER** | **TITLE**
---|---|---|---|---|---
3:30 | PD54-01 | MISSED OPPORTUNITIES FOR DCD KIDNEY DONORS: EVALUATION OF WARM ISCHEMIC TIME AND ASSOCIATED FUNCTIONAL WARM ISCHEMIC TIME | 3:50 | PD54-03 | RECELLULARIZATION OF RAT KIDNEY SCAFFOLD VASCULARITY WITH HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS
4:00 | PD54-04 | MANAGEMENT OF END-STAGE RENAL DISEASE PATIENTS DIAGNOSED WITH ACTIVE SURVEILLANCE-ELIGIBLE PROSTATE CANCER DURING PRE-TRANSPLANTATION WORK-UP: A DECISION ANALYSIS | 

*Presenting author*
4:10  PD54-05  ROBOT-ASSISTED SURGERY OF THE VENA CAVA: PERIOPERATIVE OUTCOMES, TECHNIQUE, AND LESSONS LEARNED

4:20  PD54-06  TREATMENT OF RENAL ARTERY IN-STENT RESTENOSIS: A BAYESIAN NETWORK META-ANALYSIS

4:30  PD54-07  IMPACT OF OBESITY ON SURGICAL COMPLICATIONS OF KIDNEY TRANSPLANT. SHOULD WE SIT TILL TRANSPLANT MORBITY OBESITY PATIENTS?

4:40  PD54-08  THE IRISH EXPERIENCE OF KIDNEY TRANSPLANTATION AMONG RECIPIENTS WITH PRIOR NONRENAL SOLID ORGAN TRANSPLANT AND REPEAT KIDNEY TRANSPLANT
Atakelet A Ferede*, Gordon Smyth, Ponnusamy Mohan, Richard Power, James Forde, Dilly M Little, Dublin, Ireland

4:50  PD54-09  RESULTS OF THE 50 FIRST CASES OF ROBOTIC ASSISTED KIDNEY TRANSPLANTATION COMPARED TO MATCHED-PAIR OPEN CASES
Mireia Musquera, Tarek Ajami*, Luis Peri, Maurizio D’anna, Laura Izquierdo, Antonio Alcaraz, Barcelona, Spain

5:00  PD54-10  TRENDS IN INCIDENCE OF DEPRESSION IN DONOR NEPHRECTOMY PATIENTS: A 5-YEAR STATEWIDE ANALYSIS
Nir Tomer*, New York, NY, Khawaja Bilal, Elie Kaplan-Marans, Juan Fulla, Michael Palese, New York, NY

5:10  PD54-11  NOVEL DEVICE FOR RENAL COOLING DURING TRANSPLANTATION

5:20  PD54-12  UTILIZATION OF HBA1C IN SCREENING LIVING KIDNEY DONORS WITH PREDIABETES
Joon Chae Na*, Min-Gee Yoon, Jun Jinhoong, Seoul, Korea, Republic of, Hyung Ho Lee, Goyang, Korea, Republic of, Young Eun Yoon, Kwang Hyun Kim, Woong Kyu Han, Seoul, Korea, Republic of

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Sunday, May 5, 2019 3:30 pm - 5:30 pm
Podium Session 55
PROSTATE CANCER: LOCALIZED: ACTIVE SURVEILLANCE III
Room W185d @ McCormick Place
Moderators: Joel Nelson, Matthew Resnick & Anthony Costello

3:30  PD55-01  ACTIVE SURVEILLANCE FOR LOW RISK PROSTATE CANCER AMONG MEN WITH HIGH RISK GENETIC PREDISPOSITION
Daniel Halstuch*, Chen shenar, Sivan Sela, Yaara Ber, Daniel Kedar, Jack Daniel, David Margel, Petah Tiqva, Israel

3:40  PD55-02  COMPARISON OF TWO PROSPECTIVE COHORTS IN ACTIVE SURVEILLANCE FOR LOW RISK PROSTATE CANCER: AFRO-CARIBBEAN VERSUS CAUCASIAN, ONCOLOGIC AND PATHOLOGICAL OUTCOMES

3:50  PD55-03  THE ROLE OF MRI AND FUSION BIOPSY IN THE INITIAL DIAGNOSIS AND FOLLOW-UP OF PATIENTS UNDERGOING ACTIVE SURVEILLANCE OF PROSTATE CANCER
4:00 PD55-04 MAGNETIC RESONANCE IMAGING ALONE SHOULD NOT BE CONSIDERED AS A STAND-ALONE TEST FOR DISEASE RECLASSIFICATION OF MEN IN ACTIVE SURVEILLANCE.

Marco Roscigno*, Bergamo, Italy, Armando Stabile, Milan, Italy, Giovanni Lughezzani, Rozzano, Italy, Pietro Pepe, Catania, Italy, Lucio Dell’Atti, Ancona, Italy, Maria Nicolai, Giovanni La Croce, Michele Manica, Bergamo, Italy, Angelo Naselli, Milan, Italy, Giorgio Guazzoni, Rozzano, Italy, Alberto Briganti, Francesco Montorsi, Milan, Italy, Sandro Sironi, Luigi Filippo Da Pozzo, Bergamo, Italy

4:10 PD55-05 NEGATIVE MRI CANNOT BE USED TO AVOID BIOPSY IN ACTIVE SURVEILLANCE FOR PROSTATE CANCER

Gregory Chesnut*, Emily Vertosick, Nicole Benfante, Daniel Sjoberg, James Eastham, Jonathan Fainberg, Vincent Laudone, Taehyoung Lee, Peter Scardino, Karim Touijer, Andrew Vickers, Behfar Ehdai, New York, NY

4:20 PD55-06 COMPARISON OF MRI/FUSION VERSUS TRUS CONFIRMATORY BIOPSY IN ACTIVE SURVEILLANCE PATIENTS

David Feng, Nashville, TN, Jeremiah R Dallmer, Svetlana Avulova*, Amy N Luckenbaugh, Aaron A Laviana, Sam S Chang, David Penson, Matthew J Resnick, Kristen R Scarpato, Daniel A Barocas, Nashville, TN

4:30 PD55-07 MRI WITH OR WITHOUT BIOPSY AS A CONFIRMATORY TEST IN NEWLY DIAGNOSED FAVORABLE RISK PROSTATE CANCER AIDS IN DECISION-MAKING

Rohith Arcot*, Kevin Ginsburg, Detroit, MI, Ji Qi, Susan Linsell, Deborah Kaye, Ann Arbor, MI, Arvin George, Michael Cher, Detroit, MI, for the Michigan Urological Surgery Improvement Collaborative, Ann Arbor, MI

4:40 PD55-08 WIDESPREAD USE OF MULTIPARAMETRIC MRI IN AN ACTIVE SURVEILLANCE COHORT RESULTS IN EARLIER IDENTIFICATION AND TREATMENT OF CLINICALLY SIGNIFICANT PROSTATE CANCER

Alice Yu*, Timothy Baloda, Eduoard Nicaise, Andrew Gusev, Mukes Harisinghani, Amirkasra Mojtahed, Douglas Dahl, Matthew Wszolek, Anthony Zietman, Adam S. Feldman, Boston, MA

4:50 PD55-09 OUTCOMES OF THE PATIENTS WITH PT0 ON FIRST PROTOCOL BIOPSY DURING ACTIVE SURVEILLANCE FOR EARLY PROSTATE CANCER: FROM THE PRIAS-JAPAN STUDY

Takuma Kato*, Mikio Sugimoto, Yoshiyuki Kakehi, Kitagun Michiko, Japan

5:00 PD55-10 DISOBSTRUCTION AFTER RARP IN LOW-RISK PROSTATE CANCER: A CASE-CONTROL STUDY

Andrea Boni*, Morena Turco, Giovanni Cocheti, Paolo Guiggi, Michele Del Zingaro, Emanuele Leprì, Alessio Paladini, Ettore Mearini, Perugia, Italy

5:10 PD55-11 BIOPSY, LABORATORY, AND IMAGING RISK FACTORS PREDICT GLEASON UPGRADE ON ACTIVE SURVEILLANCE.


5:20 PD55-12 INCREMENTAL UTILITY OF MP-MRI PERFORMED BEFORE CONFIRMATORY BIOPSY IN REDUCING THE RISK OF PROGRESSION DURING ACTIVE SURVEILLANCE FOR MEN WITH LOW RISK PROSTATE CANCER: IS IMAGING ALWAYS USEFUL?

Marco Bandini, Luigi Nocera*, Simone Scarcella, Nazareno Suardi, Giorgio Gandaglia, Nicola Fossati, Armando Stabile, Milan, Italy, Shahrokh Shariati, Vienna, Austria, Pierre Karakiewicz, Montreal, Canada, Paolo Dell’Oglio, Milan, Italy, Nicola Longo, Vincenzo Mirone, Naples, Italy, Simone Scuderi, Daniele Robesti, Aldo Rizzo, Donato Canoletta, Francesco Barletta, Antony Pellegrino, Francesco Montorsi, Alberto Briganti, Milan, Italy

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
### Podium Session 56

**PENILE & TESTICULAR CANCER: PENILE & TESTICULAR CANCER II**

Room W179b @ McCormick Place

**Moderators:** Chad Ritch, Timothy Masterson & Bradley Leibovich

<table>
<thead>
<tr>
<th>Time</th>
<th>Number</th>
<th>Title</th>
<th>Time</th>
<th>Number</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:30</td>
<td>PD56-01</td>
<td><strong>LONG-TERM ONCOLOGIC OUTCOMES AFTER PRIMARY RETROPERITONEAL LYMPH NODE DISSECTION: MINIMIZING THE NEED FOR ADJUVANT CHEMOTHERAPY</strong></td>
<td>4:20</td>
<td>PD56-06</td>
<td><strong>CLINICAL FEATURES AND OUTCOMES OF SECONDARY SOMATIC MALIGNANCY ARISING FROM TERATOMA IN LATE RELAPSE GERM CELL TUMOR</strong></td>
</tr>
<tr>
<td>3:40</td>
<td>PD56-02</td>
<td><strong>IS THE PERCENTAGE OF TERATOMA IN THE ORCHIECTOMY SPECIMEN PREDICTIVE OF TERATOMA IN THE RETROPERITONEUM AT THE TIME OF POST-CHEMOTHERAPY RETROPERITONEAL LYMPH NODE DISSECTION IN MEN WITH NON-SEMINOMATOUS GERM CELL TUMORS?</strong></td>
<td>4:30</td>
<td>PD56-07</td>
<td><strong>OUTCOMES OF PENILE CANCER PATIENTS WITH MICRO-METASTASES IN DYNAMIC SENTINEL LYMPH NODE BIOPSY SPECIMENS. AN EUROGEN COLLABORATION.</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Adam Calaway*, Ryan Speir, Marcelo Barboza, Antoin Dougwali, Timothy Masterson, Richard Foster, Lawrence Einhorn, Clint Cary, Indianapolis, IN</td>
<td></td>
<td></td>
<td>Rachel A Khaw*, Manchester, United Kingdom, Joren Van Thoor, Maarten Albersen, Leuven, Belgium, Pedro Oliveira, Tony Elliott, Vijay Sangar, Maurice Lau, Arie Panhnam, Manchester, United Kingdom</td>
</tr>
<tr>
<td>4:00</td>
<td>PD56-03</td>
<td><strong>INDEPENDENT VALIDATION OF TWO MODELS TO PREDICT NECROSIS/FIBROSIS IN POST CHEMOTHERAPY RESIDUAL RETROPERITONEAL MASSES OF PATIENTS WITH ADVANCED TESTICULAR CANCER</strong></td>
<td>4:40</td>
<td>PD56-08</td>
<td><strong>LONG TERM EVALUATION OF QUALITY ASSURANCE AND LEARNING CURVE FOR DYNAMIC SENTINEL INGUINAL LYMPH NODE BIOPSY SPECIMENS.</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Pia Paffenholz*, Tim Nestler, Simon Hoier, David Pfister, Martin Hellmich, Axel Heidenreich, Cologne, Germany</td>
<td></td>
<td></td>
<td>Delia Toomey*, Sylvia Yan, Jade Harrison, Michael Ager, James Pilcher, Sue Heenan, Benjamin Ayres, London, United Kingdom, Simon Horenblas, Amsterdam, Netherlands, Nicholas Watkin, London, United Kingdom</td>
</tr>
<tr>
<td>4:10</td>
<td>PD56-04</td>
<td><strong>SURVEILLANCE OF POST CHEMOTHERAPY NON SEMINOMATOUS GERM CELL TUMOR (NSGCT) RESIDUAL (≤1CM) MASSES</strong></td>
<td>4:50</td>
<td>PD56-09</td>
<td><strong>LYMPH NODE MAPPING IN PENILE CANCER PATIENTS UNDERGOING PELVIC LYMPH NODE DISSECTION</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Gregory Nason*, Aaron Hansen, Philippe Bedard, Padraig Warde, Peter Chung, Michael Jewett, Lynn Anson-Cartwright, Joan Sweet, Martin O'Malley, Robert Hamilton, Toronto, Canada</td>
<td></td>
<td></td>
<td>kai yao*, Zhi-yong Li, Xing-liang Tan, Dong Chen, Fang-jian Zhou, Guang zhou, China, People's Republic of</td>
</tr>
<tr>
<td>4:10</td>
<td>PD56-05</td>
<td><strong>THE PRIMETEST TRIAL – INTERIM ANALYSIS OF A PHASE II TRIAL FOR PRIMARY RETROPERITONEAL LYMPH NODE DISSECTION (RPLND) IN STAGE II A/B SEMINOMA PATIENTS WITHOUT ADJUVANT TREATMENT</strong></td>
<td>5:00</td>
<td>PD56-10</td>
<td><strong>SUPERFICIAL INGUINAL LYMPH NODE DISSECTION IS AN EFFECTIVE STAGING TOOL FOR CLINICALLY NODE-NEGATIVE HIGH RISK PENILE CANCER: RESULTS FROM A MULTI-INSTITUTIONAL REVIEW WITH LONG-TERM FOLLOW-UP</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Achim Lusch*, Andreas Hiester, Robert Grosse Siemer, Dusseldorf, Germany, Pia Paffenholz, Axel Heidenreich, Cologne, Germany, Peter Albers, Dusseldorf, Germany</td>
<td></td>
<td></td>
<td>Barrett McCormick*, Matthew Meissner, Houston, TX, Mounif Azizi, Julio Slongo, Philippe Spiess, Tampa, FL, Curtis Pettaway, Houston, TX</td>
</tr>
<tr>
<td>5:10</td>
<td>PD56-11</td>
<td><strong>RADIOThERAPY PLUS CHEMOTHERAPY VERSUS CHEMOTHERAPY ALONE IN PENILE CANCER PATIENTS WITH EXTRACAPSULAR NODAL EXTENSION AFTER INGUINAL LYMPH NODE SURGERY: A MULTI-INSTITUTIONAL STUDY</strong></td>
<td></td>
<td></td>
<td>Li Zaishang*, Shenzen, China, People’s Republic of, Zhou Fangjian, Han Hui, Guangzhou, China, People’s Republic of</td>
</tr>
</tbody>
</table>
Sunday, May 5, 2019

Podium Session 57

BLADDER CANCER: INVASIVE VI
Room W185a @ McCormick Place
Moderators: Eugene Lee, Luca Carmignani & Michael Risk

<table>
<thead>
<tr>
<th>ABSTRACT</th>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>3:30</strong></td>
<td>PD57-01</td>
<td>THE IMPACT OF NMIBC ON OUTCOMES FOLLOWING COMPLETE RESPONSE TO NEOADJUVANT CHEMOTHERAPY FOR MIBC.</td>
<td>Christopher R Haas*, New York, NY, Kevin Lee, Notre Dame, IN, Christopher B Anderson, Guarionex Joel DeCastro, James M McKiernan, New York, NY</td>
</tr>
<tr>
<td><strong>3:40</strong></td>
<td>PD57-02</td>
<td>THE PRESENCE OF LYMPHOVASCULAR INVASION AT TURBT PREDICTS NODAL POSITIVITY AND UPSTAGING AT TIME OF RADICAL CYSTECTOMY</td>
<td>Alexander Parker*, Jonathan Weese, Joel Vetter, Zachary Smith, St. Louis, MO</td>
</tr>
<tr>
<td><strong>3:50</strong></td>
<td>PD57-03</td>
<td>IMPACT OF LYMPH NODE DENSITY IN CARCINOMA BLADDER UNDERGOING RADICAL CYSTECTOMY: AN OUTCOME ANALYSIS OVER CONSECUTIVE FIVE YEARS</td>
<td>GANESH BAKSHI*, Mahendra Pal, Gagan Prakash, Ashwin Tamhankar, MUMBAI, India</td>
</tr>
<tr>
<td><strong>4:00</strong></td>
<td>PD57-04</td>
<td>MOLECULAR PREDICTORS OF RESPONSE TO NEOADJUVANT CHEMOTHERAPY AND PROGNOSIS IN MUSCLE-INVASIVE BLADDER CANCER</td>
<td>Mauro Ragonese*, Luca Di Gianfrancesco, Giovanni Schinzari, Giuseppe Palermo, Marco Racioppi, PierFrancesco Bassi, Rome, Italy</td>
</tr>
<tr>
<td><strong>4:10</strong></td>
<td>PD57-05</td>
<td>COMPARISON OF PERI-OPERATIVE COMPLICATIONS ACCORDING TO SURGICAL APPROACH AND URINARY DIVERSION IN PATIENTS TREATED WITH NEOADJUVANT PEMBROLIZUMAB (PURE-01) AND RADICAL CYSTECTOMY FOR MIBC</td>
<td>Simone Scuderi*, Giorgio Gandaglia, Nicola Fossati, Emanuele Zaffuto, Paolo Dall’Oglio, Giusy Burgio, Federico Dehò, Marco Bianchi, Andrea Salonia, Renzo Colombo, Francesco Montorsi, Alberto Briganti, Andrea Nechhi, Andrea Gallina, Milan, Italy</td>
</tr>
<tr>
<td><strong>4:30</strong></td>
<td>PD57-07</td>
<td>ETIOLOGY OF TREATMENT DELAYS IN PATIENTS RECEIVING NEOADJUVANT CHEMOTHERAPY FOR MUSCLE-INVASIVE BLADDER CANCER</td>
<td>Ahmad El-Arabi*, Kansas City, KS, Garth Sherman, Kansas City, MO, Jeffrey Holzbierlein, Eugene Lee, Elizabeth Wulff-Burchfield, Kansas City, KS</td>
</tr>
<tr>
<td><strong>4:40</strong></td>
<td>PD57-08</td>
<td>LARGE SINGLE-INSTITUTION COMPARISON OF PERIOPERATIVE OUTCOMES AND COMPLICATIONS BETWEEN OPEN RADICAL CYSTECTOMY, INTRACORPOREAL ROBOTIC-ASSISTED RADICAL CYSTECTOMY, AND ROBOTIC CYSTECTOMY WITH EXTRACORPOREAL URINARY DIVERSION</td>
<td>JJ Zhang*, Kyle Ericson, Lewis Thomas, Alice Crane, Abhinav Khanna, Jacob Knorr, Michele Fasceelli, Anna Zampini, Georges-Pascal Haber, Byron Lee, Cleveland, OH</td>
</tr>
<tr>
<td><strong>4:50</strong></td>
<td>PD57-09</td>
<td>WHICH FRAILTY ASSESSMENTS ARE MOST PREDICTIVE OF COMPLICATIONS AFTER RADICAL CYSTECTOMY?</td>
<td>Madeleine L. Burg*, Thomas G. Clifford, Michael Lin-Brande, Gus Miranda, Jie Cai, Sument Bhavan, Hooman Djaladat, Anne K. Schuckman, Siamak Daneshmand, Los Angeles, CA</td>
</tr>
<tr>
<td><strong>5:00</strong></td>
<td>PD57-10</td>
<td>IMPACT OF THE NUMBER OF RADICAL CYSTECTOMIES PER HOSPITAL ON 90-DAY MORTALITY IN SPAIN</td>
<td>Ana Guijarro*, Carlos Llorente, Virginia Hernandez, Elia Pérez- Fernández, Guillermo Fernandez Conejo, Enrique De la Peña, Madrid, Spain</td>
</tr>
</tbody>
</table>
### Podium Session 58

**GENERAL & EPIDEMIOLOGICAL TRENDS & SOCIOECONOMICS: QUALITY IMPROVEMENT & PATIENT SAFETY IV**

Room W184d @ McCormick Place  
**Moderators:** Howard Goldman, Fernando Kim & Danil Makarov

<table>
<thead>
<tr>
<th>Time</th>
<th>Number</th>
<th>Title</th>
<th>Author(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:30</td>
<td>PD58-01</td>
<td>RECOMMENDATIONS FOR OPIOID PRESCRIBING AFTER MINIMALLY INVASIVE УРОЛОГICAL SURGERY: A MULTIDISCIPLINARY EXPERT PANEL CONSENSUS</td>
<td>Kevin Koo*, Farzana Faisal, Natasha Gupta, Alexa Mayer, Hiten Patel, Anastasia Padilla, Whitney Sharpe, Michael Gorin, Mohit Gupta, Misop Han, Michael Johnson, Christian Pavlovich, Phillip Pierorazio, Mohamad Aliaf, Brian Matlaga, Baltimore, MD</td>
</tr>
<tr>
<td>3:40</td>
<td>PD58-02</td>
<td>OVER USE OF OPIOIDS AFTER PROSTATECTOMY: STATEWIDE EXPERIENCE FROM THE MICHIGAN UROLOGICAL SURGERY IMPROVEMENT COLLABORATIVE (MUSIC)</td>
<td>Parth Shah*, Ji Qi, Stephanie Ferrante, David Miller, M. Hugh Solomon, Ann Arbor, MI, Jason Hafron, Richard Sarle, Troy, MI, Brian Lane, Sabrina Noyes, Grand Rapids, MI, James Peabody, Detroit, MI, Alex Hallway, William Palazzolo, Tae Kim, Susan Linsell, Ann Arbor, MI, Ivan Rakic, East Lansing, MI, James Dupree, for the Michigan Urological Surgery Improvement Collaborative, Ann Arbor, MI</td>
</tr>
<tr>
<td>4:00</td>
<td>PD58-04</td>
<td>EFFECT OF A PROSPECTIVE OPIOID REDUCTION INTERVENTION ON OPIOID PRESCRIBING AND USE AFTER RADICAL PROSTATECTOMY: RESULTS OF THE ORIOLES INITIATIVE</td>
<td>Hiten Patel*, Farzana Faisal, Neil Patel, Christian Pavlovich, Mohammad Aliaf, Misop Han, Amin Herati, Baltimore, MD</td>
</tr>
<tr>
<td>4:20</td>
<td>PD58-06</td>
<td>IMPLEMENTING AND EVALUATING THE EFFICACY OF AN ACUTE CARE UROLOGY MODEL OF CARE IN A LARGE COMMUNITY HOSPITAL</td>
<td>Abirami Kirubarajan*, Roger Buckley, Shawn Khan, Rebecca Richard, Toronto, Canada, Veselina Stefanova, London, Canada, Nicole Golda, Toronto, Canada</td>
</tr>
<tr>
<td>4:30</td>
<td>PD58-07</td>
<td>HEALTH SYSTEM CHARACTERISTICS AND THE QUALITY OF UROLOGICAL CANCER CARE AT THE END OF LIFE</td>
<td>Deborah Kaye*, Ziwei Zhu, Chad Elmootttil, James Dupree, David Miller, Lindsey Herrel, Ann Arbor, MI</td>
</tr>
<tr>
<td>4:40</td>
<td>PD58-08</td>
<td>A STATEWIDE QUALITY IMPROVEMENT COLLABORATIVE'S ADHERENCE TO 2017 AUA GUIDELINES REGARDING INITIAL EVALUATION OF RENAL MASSES</td>
<td>Kyle Johnson*, Alon Weizer, Anna Johnson, Ann Arbor, MI, Sanjeev Kaul, Royal Oak, MI, Tae Kim, James Montie, Ann Arbor, MI, Tony Pinson, J ackson, MI, Zack Prebay, Milwaukee, WI, Ji Qi, Ann Arbor, MI, Craig Rogers, Detroit, MI, Michael Traver, Holland, MI, Brian Lane, Grand Rapids, MI, for the Michigan Urological Surgery Improvement Collaborative, Ann Arbor, MI</td>
</tr>
<tr>
<td>4:50</td>
<td>PD58-09</td>
<td>EXTRACTING STRUCTURED INFORMATION FROM PATHOLOGY REPORTS USING NATURAL LANGUAGE PROCESSING AND MACHINE LEARNING</td>
<td>Anobel Odisho*, San Francisco, CA, Briton Park, Nicholas Altieri, William Murdoch, Berkeley, CA, Peter Carroll, Matthew Coopberberg, San Francisco, CA, Bin Yu, Berkeley, CA</td>
</tr>
</tbody>
</table>
### Video Session 10

**RENAI ONCOLOGY I**

The videos in this session as well as the video libraries from the 2012-2018 Annual Meetings may be viewed in the Surgical Video Library and purchased in the AUA Store during the Annual Meeting. AUA members receive free online access to the Surgical Video Library throughout the year through AUA University. Visit [www.AUAnet.org/University](http://www.AUAnet.org/University) to access.

Room W187b @ McCormick Place

**Moderators:** Robert Stein, Jay Raman & Mark Tyson

<table>
<thead>
<tr>
<th>TIME</th>
<th>ABSTRACT ABSTRACT</th>
<th>NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>4:00</td>
<td>ROBOTIC PARTIAL Nephrectomy for Completely Endophytic Renal Tumors</td>
<td>V10-11</td>
<td>ROBOTIC PARTIAL Nephrectomy for Completely Endophytic Renal Tumors</td>
</tr>
<tr>
<td>4:20</td>
<td>NEPHRON SPARING SURGERY OF A HUGE ENDOPHYTIC PERINLAR TUMOR BY VIDEO-ASSISTED MINI LAPAROTOMY SURGERY (VAMS)</td>
<td>V10-10</td>
<td>NEPHRON SPARING SURGERY OF A HUGE ENDOPHYTIC PERINLAR TUMOR BY VIDEO-ASSISTED MINI LAPAROTOMY SURGERY (VAMS)</td>
</tr>
<tr>
<td>4:30</td>
<td>LAPAROSCOPIC MANAGEMENT OF LOCALLY ADVANCED KIDNEY TUMOR: LEFT NephRECTOMY WITH DISTAL SPLENO-PANCREACTECTOMY</td>
<td>V10-07</td>
<td>LAPAROSCOPIC MANAGEMENT OF LOCALLY ADVANCED KIDNEY TUMOR: LEFT NephRECTOMY WITH DISTAL SPLENO-PANCREACTECTOMY</td>
</tr>
<tr>
<td>4:40</td>
<td>ROBOTIC RADICAL NephRECTOMY WITH PARTIAL PANCREACTECTOMY, SPLENECTOMY AND PARTIAL GASTRECTOMY FOR A LOCALLY ADVANCED RENAL TUMOR</td>
<td>V10-09</td>
<td>ROBOTIC RADICAL NephRECTOMY WITH PARTIAL PANCREACTECTOMY, SPLENECTOMY AND PARTIAL GASTRECTOMY FOR A LOCALLY ADVANCED RENAL TUMOR</td>
</tr>
</tbody>
</table>

*Presenting author
4:50 V10-12 ROBOT-ASSISTED CYTOREDUCTIVE NEPHRECTOMY AND RESECTION OF PELVIC METASTASIS AFTER RENAL CRYOABLATION  
Jim Shen*, Patrick Kilday, Avinash Chenam, Juzar Jamnagerwalla, Bertram Yuh, Clayton Lau, Duarte, CA

5:00 V10-03 INDOCYANINE GREEN GUIDED ROBOT ASSISTED RADICAL NEPHRECTOMY AND LEVEL III INFERIOR VENA CAVA TUMOR THROMBECTOMY  
Gabriele Tuderti*, Leonardo Misuraca, Francesco Minisola, Maria Consiglia Ferriero, Umberto Anceschi, Riccardo Mastroianni, Rocco Simone Flammia, Aldo Brassetti, Salvatore Guaglianone, Michele Gallucci, Giuseppe Simone, Rome, Italy

5:10 V10-05 LEVEL 2 VENA CAVA RENAL CELL CARCINOMA THROMBUS MANAGEMENT WITH ROBOTIC ASSISTANCE  
Laura CALÈN*, BORDEAUX, France, Lambert GURY-COUPIER, PARIS, France, Clément MICHELS, Nam Son VUONG, Adeline GUILLAUME, Grégoire CAPON, Henri BENSADOUN, Jean-Marie FERRIERE, Grégoire ROBERT, Jean-Christophe BERNHARD, BORDEAUX, France

5:20 V10-08 ROBOTIC ASSISTED CAVAL REPLACEMENT FOR RECURRENT RENAL CELL CARCINOMA  
Kathryn Scott*, Gennady Bratslavsky, Syracuse, NY

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
Monday, May 6, 2019  
Plenary, Prime Time I, Monday, Morning Session  
7:30 am - 11:30 am  
Room W375e @ McCormick Place

7:30  
HIGHLIGHTS: SOCIETY FOR UROLOGIC ONCOLOGY (SUO) PROGRAM  
Presenter: Marc Dall’Era

7:40  
SURGICAL TECHNIQUES: TIPS & TRICKS: PARTIAL CYSTECTOMY  
Moderator: Piyush Agarwal  
Surgeons: Douglas Scherr, Timothy Donanue, Georges Pascal Haber

8:10  
SETBACKS AND OPERATIVE SOLUTIONS (SOS): RADICAL CYSTECTOMY  
Moderator: Seth Lerner  
Panelists: Bernard Bochner, Alvin Goh, Khurshid Guru, Arnulf Stenzl

8:40  
PANEL DISCUSSION: PROSTATE CANCER IN AFRICAN AMERICANS  
Moderator: Kelvin Moses  
Panelists: Willie Underwood, III, Christopher Warlick, Walter Rayford

9:10  
PANEL DISCUSSION: UROLOGIC MALIGNANCY AND TRANSPLANT PATIENTS: SPECIAL CONSIDERATIONS FOR SCREENING & MANAGEMENT  
Moderator: Alp Sener  
Panelists: Robert Uzzo, Siyam Ganesh, Herbert Leopold, John Barry

9:40  
CROSSFIRE: CONTROVERSIES IN UROLOGY: CYTOREDUCTIVE RADICAL THERAPY STILL HAS A ROLE IN THE ERA OF TARGETED THERAPY FOR METASTATIC RCCA  
Moderator: Christopher Wood  
Debaters - Pro: Alexander Kutikov, Chung Han Lee  
Debaters - Con: Jonathan Coleman, Matthew Campbell

10:10  
PANEL DISCUSSION: ENHANCED PET IMAGING FOR HIGH RISK AND ADVANCED PROSTATE CANCER: READY FOR PRIME TIME?  
Moderator: Robert Reiter  
Panelist: Martin Samba, Mark Frydenberg, Joseph Pappolito

10:30  
CROSSFIRE: CONTROVERSIES IN UROLOGY: MRI TARGETED THERAPIES FOR PROSTATE CANCER: READY FOR PRIME TIME?  
Moderator: E. David Crawford  
Debaters - Pro: Samir Taneja, Peter Pinto  
Debaters - Con: Scott Eggner, Arturo Mendoza-Valdes

11:00  
PANEL DISCUSSION: BIOMARKERS IN PROSTATE CANCER  
Moderator: Ganesh Raj  
Panelists: Leonard Gomella, Eliezer Van Allen

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Monday, May 6, 2019  
Plenary, Prime Time II, Monday, Morning Session  
7:30 am - 11:35 am  
Room W375d @ McCormick Place

7:30  
HIGHLIGHTS: SOCIETY FOR BASIC UROLOGIC RESEARCH  
Presenter: Dolores Lamb

7:45  
HIGHLIGHTS: SOCIETY OF GENITOURINARY RECONSTRUCTIVE SURGEONS (GURS) PROGRAM  
Presenter: J. Patrick Selph

7:55  
UROLOGY CARE FOUNDATION RISING STARS LECTURE  
Introduction  
Presenter: Aria Olumi  
Presenter: Christopher Barbieri

8:10  
SECOND OPINION CASES (ASK THE GUIDELINES!): TESTICULAR CANCER  
Moderator: Andrew Stephenson  
Panelist: Phillip Pierroz, Joel Sheinfeld, Jose Karam, Scott Eggner, Timothy Gilligan

8:35  
CROSSFIRE: CONTROVERSIES IN UROLOGY: PRIMARY BULBAR STRICTION: DVIU IS WHAT TO DO  
Moderator: Jeremy Myers  
Debaters - Pro: Hunter Wessells, Reynaldo Gomez  
Debaters - Con: Jill Buckley, Steven Brandes

9:05  
PANEL DISCUSSION: SCROTAL LYMPHEDEMA: BIGGER ISN'T BETTER  
Moderator: Hadley Wood  
Panelists: Joel Gelman, Ben Adusei

9:35  
SURGICAL TECHNIQUES: TIPS & TRICKS: PROSTATE CANCER SURVIVORSHIP  
Moderator: Brian Flynn  
Surgeons: Amy Guise, Michael Kennelly

*Presenting author
10:05 **COMPLEX CASES: UROLOGIC TRAUMA**  
Moderator: Steven Hudak  
Panelists: Bryan Voelzke, Bahaa Malaeb, Leo Doumanian, Niels Johnsen

10:35 **PANEL DISCUSSION: SEVERE URETHRAL STRICTURE DISEASE IN THE OCTOGENARIAN**  
Moderator: Jessica DeLong  
Panelists: Tomas Griebling, Boyd Viers, Joshua Broghammer, Sean Elliott

11:05 **COMPLEX CASES: PENILE CANCER**  
Moderator: Philippe Spiess  
Panelists: Curtis Pettaway, Viraj Master, Chad Ritch, Anne Schuckman

**APPROVED FOR AMA PRA CATEGORY 1 CREDIT™**

---

**Monday, May 6, 2019**  
**Plenary Prime Time, Monday, Take Home Messages**  
**Room W375e @ McCormick Place**

1:00 **TAKE HOME MESSAGES: BASIC SCIENCE (BENIGN)**  
Presenter: Travis Jerde

1:10 **TAKE HOME MESSAGES: RECONSTRUCTION**  
Presenter: Giulia Lane

1:20 **TAKE HOME MESSAGES: ENDOUROLOGY/STONES**  
Presenter: Nishant Patel

1:30 **TAKE HOME MESSAGES: INFECTION/INFLAMMATION**  
Presenter: Christina Ching

1:40 **TAKE HOME MESSAGES: INFERTILITY/ANDROLOGY**  
Presenter: Sarah Vij

1:50 **TAKE HOME MESSAGES: SEXUAL DYSFUNCTION**  
Presenter: Faysal Yafi

2:00 **TAKE HOME MESSAGES: PEDIATRICS**  
Presenter: Mark Faasse

2:10 **TAKE HOME MESSAGES: TRANSPLANTATION**  
Presenter: Nicholas Cowan

2:20 **TAKE HOME MESSAGES: FEMALE UROLOGY/INCONTINENCE**  
Presenter: Ariana Smith

2:30 **TAKE HOME MESSAGES: BPH/LUTS**  
Presenter: Bradley Gill

2:40 **TAKE HOME MESSAGES: QIPS**  
Presenter: C.J. Stimson

2:50 **TAKE HOME MESSAGES: IMAGING**  
Presenter: Ryan Hsi

3:00 **TAKE HOME MESSAGES: OUTCOMES**  
Presenter: Simon Kim

3:10 **TAKE HOME MESSAGES: PENILE/URETHRAL CANCER**  
Presenter: Sima Porten

3:20 **TAKE HOME MESSAGES: PROSTATE CANCER**  
Presenter: Sanjay Patel

3:30 **TAKE HOME MESSAGES: MINIMALLY INVASIVE SURGERY**  
Presenter: Robert Stein

3:40 **TAKE HOME MESSAGES: BASIC SCIENCE (MALIGNANT)**  
Presenter: Donald Vander Griend

3:50 **TAKE HOME MESSAGES: KIDNEY CANCER**  
Presenter: Kara Babaian

4:00 **TAKE HOME MESSAGES: BLADDER CANCER**  
Presenter: Amirali Salmasi

**APPROVED FOR AMA PRA CATEGORY 1 CREDIT™**
ABSTRACT
MP70-01 EARLY APPLICATION OF MTOR INHIBITORS REDUCE VASCULAR INFLAMMATORY RESPONSE AFTER ISCHEMIA-REPERFUSION INJURY
Mike Wenzel*, Frankfurt, Germany, Henryk Haffer, Berlin, Germany, Isabella Werner, Frankfurt, Germany, Manfred Richter, Bad Nauheim, Germany, Felix Chiu, Frankfurt, Germany, Andres Beiras-Fernandez, Mainz, Germany

MP70-02 SIXTEEN YEARS AFTER THE FIRST LAPAROSCOPIC LIVING DONOR NEPHRECTOMY
Mireia Musquera*, Maurizio D’Anna, Lluis Peri, Tarek Ajami, Maria José Ribal, Laura Izquierdo, Ricardo Alvarez-Vijande, Antonio Alcaraz, Barcelona, Spain

MP70-03 COMPARISON OF HISTIDINE-TRYPTOPHAN-KETOGGLUTARATE (HTK) SOLUTION AND INDIGENOUS NACL BASED SOLUTION IN LIVE RENAL TRANSPLANTATION:
mohankumar vijayakumar*, sudharshan balaji, Abhishek Singh, Arvind Ganpule, Ravindra Sabnis, Mahesh Desai, nadiad, India

MP70-04 NOMOGRAM FOR PREDICTING CHRONIC KIDNEY DISEASE III FOR LIVING DONOR NEPHRECTOMY
Hyung Ho Lee*, Gyeonggi-do, Korea, Republic of, Joon Chae Na, Dae Keun Kim, Young Eun Yoon, Woong Kyu Han, Seoul, Korea, Republic of

MP70-05 INCIDENCE, MANAGEMENT AND CLINICAL OUTCOMES OF PROSTATE CANCER IN KIDNEY TRANSPLANT RECIPIENTS
Usman M Haroon*, Niall F Davis, D M Little, Gordon Smyth, P Mohan, James C Forde, Richard E Power, Dublin, Ireland

MP70-06 PREOPERATIVE ANTIBODY TITER AGAINST BK POLYMOMAVIRUS MAY PREDICT BK POLYMOMAVIRUS-ASSOCIATED NEPHROPATHY AFTER KIDNEY TRANSPLANTATION

MP70-07 ABO INCOMPATIBLE KIDNEY TRANSPLANTS IN DEVELOPING NATIONS... SINGLE CENTRE PERSPECTIVE IN INDIA
VIPIN TYAGI*, SUDHIR CHADHA, NEW DELHI, India

ABSTRACT
MP70-08 LONGITUDINAL SERUM N-GLYCAN PROFILING PREDICT BIOPSY-PROVEN GRAFT REJECTION AFTER A LIVING DONOR KIDNEY TRANSPLANTATION

MP70-09 OUTCOME OF LIVING KIDNEY DONORS WITH MICROPROTEINURIA: EXPANDING THE DONOR CRITERIA
Joon Chae Na*, Min-Gee Yoon, Lee Dongu, Seoul, Korea, Republic of, Hyung Ho Lee, Goyang, Korea, Republic of, Young Eun Yoon, Kwang Hyun Kim, Woong Kyu Han, Seoul, Korea, Republic of

MP70-10 BODY FAT AREA AS A PREDICTIVE MARKER OF NEW-ONSET DIABETES MELLITUS AFTER KIDNEY TRANSPLANTATION
Rikiya Taoka*, Yohei Abe, Hirohito Naito, Yasuyuki Miyazaki, Yuki Matsuoka, Motofumi Tajima, Takuma Kato, Hirokuni Tsunemori, Nobufumi Ueda, Mikio Sugimoto, Yoshiyuki Kakehi, Kaga, Japan

MP70-11 ZINC PRECONDITIONING PROTECTS THE KIDNEY AGAINST ISCHAEMIA-REPERFUSION INJURY
Dermot O’Kane*, Justin Du Plessis, Graham Baldwin, Arthur Shulkes, Damien Bolton, Oneel Patel, Joseph Ischia, Melbourne, Australia

MP70-12 INCREASING KIDNEYS GRAFTS FOR TRANSPLANTATION
Mireia Musquera, Alba Sierra del Rio*, Lluis Peri, David Paredes, Claudia Mercader, Meritxell Pérez, Nuria Esforzado, Maria Carme Sebastia, Maria Jose Ribal, Nacho Revuelta, Antonio Alcaraz, Barcelona, Spain

MP70-13 DOES OLDER CONTROLLED DONORS AFTER CIRCULATORY DEATH INFLUENCE ON DGF OR KIDNEY SURVIVAL?
Begoña Etcheverry Giadrosich*, Maria Fiol Riera, Lluis Riera Canals, Jaime Fernandez-Concha Schwabl, Xavier Bonet Punti, Jose Francisco Suarez Novo, Oriol Bestard Matamoros, Francesc Viques Julia, Barcelona, Spain

*Presenting author
MP70-14 IMPACT OF EARLY BLOOD TRANSFUSION AFTER KIDNEY TRANSPLANTATION ON THE INCIDENCE OF DE NOVO DONOR-SPECIFIC ANTI-HLA ANTIBODIES
Mitsuru Saito*, Shigeru Satoh, Takuro Saito, Ryoei Yamamoto, Taketoshi Nara, Syuji Chiba, Sohei Kanda, Kazuyuki Numakura, Shintaro Narita, Takamitsu Inoue, Tomonori Habuchi, Akita, Japan

MP70-15 CHANGE IN GLOMERULAR VOLUME AND ITS CLINICAL SIGNIFICANCE IN PROTOCOL BIOPSIES AFTER KIDNEY TRANSPLANTATION
Satoshi Ogawa*, Takeshi Ishimura, Yuzo Nakano, Masato Fujisawa, Kobe, Japan

MP70-16 PRELIMINARY IDENTIFICATION OF IMMUNE CELLS IN THE PERFUSATE OF RENAL ALLOGRAFTS UNDERGOING HYPOThERMIC MACHINE PERFUSION
Jordan Foreman*, Devon Chabot-Richards, Barbara Masten, Julie Riley, Michael Davis, Albuquerque, NM

MP70-17 RETROPERITONEOSCOPIC NATIVE NEPHRECTOMY IN RENAL TRANSPLANT RECIPIENTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE

MP70-18 FACTORS PREDICTING DELAYED GRAFT FUNCTION AT A TERTIARY HOSPITAL
Da David Jiang*, John Barry, David Scott, Portland, OR

MP70-19 DOES EARLY WITHDRAWAL OF URINARY CATHETER FOLLOWING KIDNEY TRANSPLANT REDUCE URINARY TRACT INFECTIONS (UTI)?
Felipe Hirasaki*, Rogerio Sayao Filho, Renato Falci, Ioannis Antonopoulos, Kleiton Yamaçake, Hideki Kanashiro, Gustavo Ebaïd, Gustavo Messi, Alexandre Bull, Rafael Locali, Affonso Piovesan, William Nahas, Sao Paulo, Brazil

MP70-20 MACROSCOPIC APPRAISAL OF KIDNEY GRAFTS AND ITS ASSOCIATION WITH DELAYED GRAFT FUNCTION
Enric Miret Alomar*, Enrique Trilla Herrera, Francesc Moreso Mateos, Nestor Toapanta Galbor, Mercè Cuadras Solé, Aina Salazar Gabarre, Oriol Moreno Ribera, Lucas Regis Plácido, David Lorente Garcia, Teresa Pont Castellana, Daniel Serón Micas, Juan Morote Robles, BARCELONA, Spain

MP71-01 GENETICALLY DIVERSE UROPATHOGENIC ESCHERICHIA COLI ADOPT A COMMON TRANSCRIPTIONAL PROGRAM IN PATIENTS WITH URINARY TRACT INFECTIONS
Anna Sintsova*, Ali Pirani, Ann Arbor, MI, Sargurunathan Subashchandrabose, Winston-Salem, NC, Evan Snitkin, Harry L. T. Mobley, Ann Arbor, MI

MP71-02 HYPERMOTILITY OF ESCHERICHIA COLI ISOLATED FROM THE UROTHELIUM OF POSTMENOPAUSAL WOMEN WITH RECURRENT URINARY TRACT INFECTION.
Cristian Trejo*, Bryan, TX, Vivian Nguyen, Nicole J. DeNisco, Kelli L. Palmer, Richardson, TX, Philippe Zimmern, Dallas, TX

MP71-03 COMPARISON OF NOVEL DNA-BASED TOOLS FOR BACTERIAL DETECTION IN PATIENTS WITH CHRONIC URINARY TRACT INFECTION (CUTI)
George Coba, Timothy Koo, Saif Zaman, Tampa, FL, Maria Stefil, Matthew Dixon, Norwich, United Kingdom, Liqiang Ni, Orlando, FL, Michael McDonald, Celebration, FL, Vladimir Mouraviev*, Davenport, FL

MP71-04 PCR BASED URINARY TRACT INFECTION ANALYSIS COMPARED TO TRADITIONAL URINE CULTURE IN IDENTIFYING SIGNIFICANT UROPATHOGENS IN SYMPTOMATIC PATIENTS
Larry T Sirls*, Frank Burks, Howard Korman, Mohammad Jafri, Royal Oak, MI, Natalie Luke, Colleen Kelly, Michael Opol, David Bannouch, Miguel Penarranda, Irvine, CA, Kirk Wojno, Royal Oak, MI

Monday, May 6, 2019
Moderated Poster Session 71
INFECTIONS/INFLAMMATION/CYSTIC DISEASE OF THE GENITOURINARY TRACT: KIDNEY & BLADDER I
Room W179a @ McCormick Place

Moderators: Daniel Shoskes, M. Lynn Stothers & Philip Bosch
MP71-05 PHOSPHORYLATION OF CREB IN DORSAL ROOT GANGLIA AFTER UROPATHOGENIC ESCHERICHIA COLI INFECTION IN RAT URINARY BLADDER
Taesoo Choi, Sung Tae Cho, Koo Han Yoo, Dong-Gi Lee*, Gyeong Eun Min, Seung Hyun Jeon, Hyung-Lae Lee, Seoul, Korea, Republic of

MP71-06 INSULIN RECEPTOR SIGNALING REGULATES THE BLADDER’S ANTIBACTERIAL DEFENSES
Laura Schwartz, Tad Eichler, Kristin Bender, Matthew Murtha, John Spencer*, Columbus, OH

MP71-07 HIPPO/YAP PATHWAY IN OBSTRUCTIVE UROPATHY: A NOVEL CONTRIBUTOR AND PROMISING THERAPEUTIC TARGET
Erin Salter*, Jiaqi Tang, Paul Higgins, Rohan Samarakoon, Albany, NY

MP71-08 A NOVEL CLINICAL RISK SCORE TO PREDICT TRUE INFECTION IN THE SETTING OF OBstructING UROLITHIASIS
Madeleine Manka*, Kevin Wymer, Vidit Sharma, Nicole Dodge, Deepak Agarwal, Matthew Gittman, Marcelino Rivera, Rochester, MN

MP71-09 IN VITRO EVALUATION OF NOVEL SURFACE MODIFYING MOLECULES TO PREVENT BACTERIAL ADHESION TO UROLOGICAL DEVICES

MP71-10 THE DIAGNOSTIC VALUES OF SYMPTOMS FOR ACUTE UNCOMPLICATED CYSTITIS – EVALUATION OF THE PROPOSED UPDATED FDA GUIDELINES
Jakhongir Alidjanov*, Gießen, Germany, Kurt Naber, Straubing, Germany, Adrian Pilatz, Gießen, Germany, Ulugbek Abdurafien, Tashkent, Uzbekistan, Florian Wagenlehner, Gießen, Germany

MP71-11 PATIENT PERSPECTIVES ABOUT URINARY TRACT INFECTIONS: RESULTS OF LARGE-SCALE SOCIAL MEDIA ANALYTICS TO UNDERSTAND PUBLIC KNOWLEDGE AND EXPERIENCE
Yuliya Zekster, Gabriela Gonzalez*, Los Angeles, CA, Carine Khalil, Kristina Vaculik, Corey Arnold, Brennan M.R. Spiegel, Los Angeles, CA, Jennifer T. Anger, Los Angeles, CA, Christopher V. Almario, Los Angeles, CA

MP71-12 THE CLINICAL RATE OF ANTIBIOTIC CHANGE FOLLOWING EMPIRIC TREATMENT FOR SUSPECTED URINARY TRACT INFECTIONS
Jonathan Dokter, Rochester, MI, Laura Nguyen, Lauren Tennyson*, Esther Han, Larry T Sirs, Royal Oak, MI

MP71-13 PRIOR CULTURE DATA CAN SIGNIFICANTLY ENHANCE PREDICTION OF NEGATIVE CULTURE AND THUS ELIMINATE UNNECESSARY ANTIMICROBIAL THERAPY IN WOMEN WITH POSSIBLE UNCOMPLICATED URINARY TRACT INFECTIONS
Jason E Cohen*, Emily M Yura, Liqi Chen, Anthony J Schaeffer, Chicago, IL

MP71-14 SAFETY AND EFFICACY OF CHRONIC SUPPRESSIVE THERAPY WITH NITROFURANTOIN IN OLDER WOMEN
Navin Maredia*, Bonnie C Prokesch, Michael Fanning, Alana Christie, Philippe Zimmern, Dallas, TX

MP71-15 PREVALENCE OF RECURRENT EXTENDED-SPECTRUM BETALACTAMASE (ESBL) URINARY TRACT INFECTIONS (UTIS) IN PATIENTS WITHIN A UROLOGY SERVICE. INTRODUCING THE CONCEPT OF FAECAL MICROBIOTA TRANSPLANTATION (FMT) AS A TREATMENT MODALITY.
Rohma Ghan*, Christine Gan, Benjamin Mullish, Vaishali Ferzoli, Julian Marchesi, Mark Thursz, Frances Davies, Ranan Dasgupta, Suks Minhas, London, United Kingdom

MP71-16 ANTIBIOTIC SPARING APPROACHES TO TREATING RUTI: A SYSTEMATIC REVIEW
Sanjeev Sharma, Nicholas Raison*, Kamran Ahmed, Vibhash Mishra, London, United Kingdom

MP71-17 IMPROVING THE MANAGEMENT OF RECURRENT URINARY TRACT INFECTIONS IN WOMEN UNDER 30 – DOES CONSERVATIVE TREATMENT REALLY WORK?
Abdel Hamed, Lorna Cameron, Susanne McPhee, Louise Granger, Annette Bell, Elaine Crombie, Kate Larkin, Ross Clark, Holly Bekarma*, ayr, United Kingdom

MP71-18 FEMTOUCH®: FIRST EXPERIENCE OF A NOVEL TREATMENT IN PREVENTING RECURRENT URINARY TRACT INFECTIONS AND RESTORING VAGINAL HEALTH IN POST MENOPAUSAL WOMEN
BOB YANG*, Claire Foley, Steve Foley, Reading, United Kingdom

MP71-19 ROLE OF VACCINES FOR RECURRENT URINARY TRACT INFECTIONS: A SYSTEMATIC REVIEW
Sarah Prattley*, Francesca New, Rob Geraghty, Bhaskar Somani, Southampton, United Kingdom

MP71-20 REDUCING OVER-PRESCRIBING OF ANTIBIOTICS FOR SUSPECTED URINARY TRACT INFECTIONS IN A HEALTH SCIENCES CAMPUS STUDENT HEALTH SERVICE
Elisabeth M. Sebesta*, Anika March, Christopher Sayegh, Gen Li, Michelle Love, Gia M. Badalato, Marcy Ferschneider, Kimberly L. Cooper, New York, NY

*Presenting author

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP72-01</td>
<td>IMPROVEMENTS IN FREEDOM FROM PROGRESSION WITH SHORT TERM ANDROGEN DEPRIVATION THERAPY AND PELVIC LYMPH NODE TREATMENT ADDED TO PROSTATE BED SALVAGE RADIOTHERAPY: THE NRG ONCOLOGY/ RTOG 0534 SUPPORT TRIAL</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>MP72-02</th>
<th>EXPOSURE TO CYBERKNIFE ADVERTISING IS ASSOCIATED WITH OVER-ESTIMATION OF OBJECTIVE BENEFITS COMPARED WITH OTHER PROSTATE CANCER TREATMENTS</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>MP72-03</th>
<th>IMPACT OF TIMING ON RADIATION THERAPY ADVERSE EVENTS FOLLOWING RADICAL PROSTATECTOMY: A SECONDARY ANALYSIS OF THE RTOG 9601 COHORT</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Lee Baumgarten*, Alex Borchert, Detroit, MI, Deepansh Delela, Akshay Sood, Sohrab Arora, Jacob Keeley, Detroit, MI, MI, Quoc Trinh, Boston, MA, Craig Rogers, James Peabody, Mani Menon, Firas Abdollah, Detroit, MI</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>MP72-04</th>
<th>PROSTATE IMAGING REPORTING AND DATA SYSTEM SCORE BEFORE PROSTATE BIOPSY CAN PREDICT BIOCHEMICAL RECURRENCE IN PATIENTS WITH PROSTATE CANCER TREATED WITH RADIOTHERAPY</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Keisuke Hata*, Junpo Iizuka, Yaichiro Hashimoto, Tokyo, Japan, Yasunobu Hashimoto, Kawaguchi, Japan, Kazuhiko Yoshida, Toshih Takagi, Masayoshi Okumi, Tsumenori Kondo, Hideki Ishida, Kumiko Karasawa, Kazunari Tanabe, Tokyo, Japan</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>MP72-05</th>
<th>COMPLICATIONS OF THE SPACEOAR HYDROGEL SYSTEM</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Buddima Ranasinghe*, Brooklyn, NY, Beshoy Nazeer, West Indies, Grenada, David Silver, Ariel Schulman, Brooklyn, NY</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>MP72-06</th>
<th>EVALUATING THE IMPACT OF LEAD-TIME BIAS ON THE OBSERVED EFFICACY OF EARLY SALVAGE RADIATION THERAPY IN PROSTATE CANCER: A POST-HOC ANALYSIS OF THE RTOG 9601 TRIAL</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Firas Abdollah*, Deepansh Delela, Akshay Sood, Sohrab Arora, Hoang Tang, Jacob Keeley, Shaheen Alane, Craig G Rogers, James Peabody, Mani Menon, Detroit, MI</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>MP72-07</th>
<th>HEALTH-RELATED QUALITY OF LIFE OUTCOMES FOR MEN WITH PROSTATE CANCER RECEIVING RADIATION THERAPY AFTER RADICAL PROSTATECTOMY</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Fernando Caumont*, Katherine Levine, Jason Frankel, John Paul Flores, Seattle, WA, Timothy Brand, Tacoma, WA, Inger Rosner, Bethesda, MD, Sean Srou, San Diego, CA, John Musser, Honolulu, HI, Claire Kuo, Jennifer Cutler, Rockville, MD, Christopher Porter, Seattle, WA</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>MP72-08</th>
<th>NATIONAL TRENDS IN MANAGEMENT OF LOCALIZED HIGH RISK PROSTATE CANCER</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Allison May*, Joshua Trierweiler, Anirudh Guduru, Jyor Syed, Facundo Davaro, Sameer Siddiqui, Zachary Hamilton, Saint Louis, MO</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>MP72-09</th>
<th>CHARLSON COMORBIDITY INDEX PREDICTS CHRONIC RATHER THAN ACUTE RADIATION THERAPY INDUCED TOXICITY IN MEN WITH PROSTATE CANCER</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Ahmed Ghanem*, Detroit, MI, Gihan Khedr, Alexandria, Egypt, Remonda Khalil, Amy Tang, Detroit, MI, Amr Elsaid, Alexandria, Egypt, Indrin Chetty, Benjamin Movas, Mohamed Elshaikh, Detroit, MI</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>MP72-10</th>
<th>WHICH PATIENTS SHOULD BE CANDIDATES FOR ADJUVANT RADIOTHERAPY FOLLOWING RADICAL PROSTATECTOMY?</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Henk Luiting*, Sebastiaan Remmers, Monique Roobol, Rotterdam, Netherlands</td>
</tr>
</tbody>
</table>
MP72-11 PERSISTENT UNDER-UTILIZATION OF ADJUVANT RADIOTHERAPY IN PATIENTS WITH ADVERSE PATHOLOGICAL FEATURES AT RADICAL PROSTATECTOMY (RP): A NATIONAL CANCER DATABASE (NCDB) ANALYSIS
Nikola Rakic*, Audrey Fotouhi, Lee Baumgarten, Alex Borchert, Deepansh Delela, Akshay Sood, Sohrab Arora, Jacob Keeley, Mani Menon, Firas Abdollah, Detroit, MI

MP72-12 COMPARISON OF LONG-TERM OUTCOMES BETWEEN RADICAL PROSTATECTOMY AND INTENSITY-MODULATED RADIATION THERAPY FOR HIGH-RISK LOCALIZED PROSTATE CANCER: A SINGLE-CENTER PROPENSITY SCORE-MATCHED ANALYSIS
Ryuji Matsumoto*, Satoru Maruyama, Jun Furumido, Haruka Miyata, Hiroshi Kikuchi, Takahiro Osawa, Takashige Abe, Nobuo Shinohara, Sapporo, Japan

MP72-13 LONG-TERM OUTCOMES OF COMBINING PROSTATE BRACHYTHERAPY AND METASTASIS-DIRECTED RADIOTHERAPY IN DE NOVO OLIGOMETASTATIC PROSTATE CANCER: A RETROSPECTIVE COHORT STUDY
Hideyasu Tsumura*, Hiromichi Ishiyama, Ken-ichi Tabata, Yasukiyo Murakami, Akane Sekiguchi, Masashi Kitan, Takefumi Sato, Masatsugu Iwamura, Sagamihara, Japan

MP72-14 DISCORDANCE BETWEEN PATIENT-REPORTED INCONTINENCE AND PATIENT-REPORTED PAD USE FOLLOWING PERMANENT PROSTATE BRACHYTHERAPY

MP72-15 DETERMINING THE MARGINAL BENEFIT OF ADJUVANT HORMONAL THERAPY IN INTERMEDIATE RISK PROSTATE CANCER PATIENTS WITH INSUFFICIENT DOSE DELIVERED BY PERMANENT PROSTATE BRACHYTHERAPY

MP72-16 COMPARISON BETWEEN 3 TECHNIQUES FOR THE TREATMENT OF RADIATION-INDUCED HEMORRHAGIC CYSTISIS: GREENLIGHT XPS LASER, HOLMIUM LASER, AND MONOPOLAR ELECTROCOAGULATION
Ismaïl Chelghaf*, Quentin Alimi, Karim Bensalah, Peyronnet Benoit, Nantes, France

MP72-17 IMPACT OF PRIMARY GLEASON PATTERN ON RESULTS OF EARLY SALVAGE RADIOTHERAPY AFTER RADICAL PROSTATECTOMY
Felix Preisser*, Frankfurt, Germany, Raisa Pompe, Hamburg, Germany, Felix Chun, Frankfurt, Germany, Markus Graefen, Hartwig Huland, Derya Tilki, Hamburg, Germany

MP72-18 BODY MASS INDEX AND ANTERIOR PERIRECTAL FAT THICKNESS IS A PREDICTOR OF RECTAL COMPLICATION AFTER LOW DOSE RATE PROSTATE BRACHYTHERAPY
Young Dong Yu*, Tae Heon Kim, Seung Ryeol Lee, Young Kwon Hong, Dong Soo Park, Gyeonggi-Do, Korea, Republic of

MP72-19 HIGH-DOSE RATE BRACHYTHERAPY AND HYPOFRACTIONATED EXTERNAL BEAM RADIOTHERAPY COMBINED WITH LONG-TERM HORMONAL THERAPY FOR VERY HIGH-RISK PROSTATE CANCER: PRIMARY GLEASON 5 IMPLIES WORSE OUTCOMES.
Takashii Kasahara*, Kazutoshi Yamana, Ryo Maruyama, Motoki Kaid, Hidefumi Aoyama, Niigata, Japan, Tsutomu Nishiyama, Uonuma, Japan, Yoshikio Tomita, Niigata, Japan

MP72-20 IMPACT OF TADALAFIL ON ADVERSE EVENTS AFTER LOW DOSE RATE BRACHYTHERAPY FOR PROSTATE CANCER- A MULTI CENTER RANDOMIZED OPEN LABEL TRIAL-
Tomohiko Oguchi*, Nagano, Japan, Tomonori Minagawa, Ayumu Fukasawa, Matsumoto, Japan, Kazuyoshi Iijima, Nagano, Japan, Keichiro Kowai, Matsumoto, Japan, Iwao Hashida, Nagano, Japan, Teruyuki Ogawa, Matsumoto, Japan, Haruaki Kato, Nagano, Japan, Osamu Ishizuka, Matsumoto, Japan

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

*Presenting author
<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP73-01</td>
<td>TEMPLATE VERSUS BILATERAL POSTCHEMOTHERAPY RETROPERITONEAL LYMPH NODE DISSECTION IN PATIENTS WITH TESTICULAR CANCER</td>
</tr>
<tr>
<td></td>
<td>Andreas Hiester*, Alessandro Nini, Anna Fingerhut, Robert großé Siemer, Christian Winter, Peter Albers, Achim Lusch, Düsseldorf, Germany</td>
</tr>
<tr>
<td>MP73-02</td>
<td>A SELECTIVE LYSINE-SPECIFIC DEMETHYLASE 1 INHIBITOR SUPPRESSES TESTICULAR TUMOR PROLIFERATION</td>
</tr>
<tr>
<td></td>
<td>Toshiki Etani*, Taku Naiki, Satoshi Nozaki, Takashi Nagai, Keitaro Iida, Ryosuke Ando, Noriyasu Kawai, Satoru Takahashi, Nagoya, J apan, Takayoshi Suzuki, Kyoto, J apan, Takahiro Yasui, Nagoya, J apan</td>
</tr>
<tr>
<td>MP73-03</td>
<td>A HISTOLOGIC COMPARISON OF PATIENTS PRESENTING WITH PURE CHORIOCARCINOMA VS MIXED NSGCT WITH SERUM HCG LEVELS &gt;20,000 IN PATIENTS UNDERGOING PC-RPLND</td>
</tr>
<tr>
<td></td>
<td>Ryan Speir*, Adam Calaway, Marcelo Barboza, Richard Foster, Clint Cary, Indianapolis, IN</td>
</tr>
<tr>
<td>MP73-04</td>
<td>DIFFERENCES IN SEMEN PARAMETERS BETWEEN PATIENTS WITH TESTICULAR CANCER AND OTHER MALIGNANCIES USING VARIOUS CUT-OFF VALUES</td>
</tr>
<tr>
<td></td>
<td>Itsuto Hamano*, Shingo Hatakayama, Rika Nakamura, Rie Fukuhara, Daisuke Noro, Toshikazu Tanaka, Tohru Yoneyama, Hayato Yamamoto, Takahiro Yoneyama, Yasuhiro Hashimoto, Hiroaki, J apan, Takuya Koie, Gifu, J apan, Yoshito Yokoyama, Chikara Ohyma, Hiroaki, J apan</td>
</tr>
<tr>
<td>MP73-05</td>
<td>NEWLY IDENTIFIED REGULATION MECHANISM IN EBV POSITIVE SEMINOMA</td>
</tr>
<tr>
<td></td>
<td>Pia Paffenholz*, Melanie von Brandenstein, Barbara Köditz, Jennifer Thönnissen, Johannes Salem, Tim Nestler, Heike Göbel, Jochen W.U. Fries, Axel Heidenreich, Cologne, Germany</td>
</tr>
<tr>
<td>MP73-06</td>
<td>THE SYSTEMIC INFLAMMATORY MARKERS IN PERIPHERAL BLOOD BEFORE RADICAL INGUINAL LYMPH NODE DISSECTION IN PENILE SQUAMOUS CELL CARCINOMA CAN PREDICT PATHOLOGIC POSITIVE NODES.</td>
</tr>
<tr>
<td></td>
<td>Emanuel Albuquerque*, Giuliano Guglielmetti, Pablo Sierra, José Pontes Jr, Alexandre Cavalcante, Rafael Coelho, William Nahas, SÃO PAULO, Brazil</td>
</tr>
<tr>
<td>MP73-07</td>
<td>BODY COMPOSITION PARAMETERS PREDICT A POOR PROGNOSIS IN PATIENTS DIAGNOSED WITH NON-METASTATIC PENILE CANCER</td>
</tr>
<tr>
<td></td>
<td>Michelle Christodoulidou*, Ramachandran Navin, LONDON, United Kingdom, Burden Sorrel, Debra Gibson, Simon Lal, Manchester, United Kingdom, Toby Richards, Asif Munee, LONDON, United Kingdom</td>
</tr>
<tr>
<td>MP73-08</td>
<td>POST-OPERATIVE HEART RATE PREDICTS EJACULATORY FUNCTION IN PATIENTS UNDERGOING RETROPERITONEAL LYMPH NODE DISSECTION</td>
</tr>
<tr>
<td></td>
<td>Elizabeth Green*, Kelvin Moses, Nashville, TN</td>
</tr>
<tr>
<td>MP73-09</td>
<td>POST-ORCHIECTOMY HORMONE LEVELS IN TESTICULAR GERM CELL TUMORS</td>
</tr>
<tr>
<td></td>
<td>Madeleine L. Burg*, Zhoobin H. Bateni, Shane M. Pearce, Jamal Nabhani, Hooman Djaladat, Anne K. Schuckman, Siamak Daneshmand, Los Angeles, CA</td>
</tr>
<tr>
<td>MP73-10</td>
<td>SIMULTANEOUS VERSUS SEQUENTIAL RETROPERITONEAL AND THORACIC RESECTION OF POST CHEMOTHERAPY RESIDUAL MASSES IN PATIENTS WITH METASTATIC NON-SEMINOMATOUS GERM CELL TUMORS OF THE TESTIS.</td>
</tr>
<tr>
<td></td>
<td>Gregory Nason*, Laura Donahoe, Ishan Adiya, Marc De Perrot, Lynn Anson-Cartwright, Michael Jewett, Aaron Hansen, Philippe Bedard, Padraig Warde, Peter Chung, Joan Sweet, Martin O’Malley, Robert Hamilton, Toronto, Canada</td>
</tr>
<tr>
<td>MP73-11</td>
<td>PENILE SQUAMOUS CELL CARCINOMA IS GENOMICALLY SIMILAR TO OTHER HPV-DRIVEN TUMORS</td>
</tr>
<tr>
<td></td>
<td>Barrett McCormick*, Jad Chahoud, Frederico Netto, Priya Rao, Curtis Pickering, Curtis Pettaway, Houston, TX</td>
</tr>
<tr>
<td>MP73-12</td>
<td>HISTOPATHOLOGIC FINDINGS AND SURVIVAL CHARACTERISTICS FOR POST-CHEMOTHERAPY ORCHIECTOMY IN ADVANCED GERM CELL CANCER</td>
</tr>
<tr>
<td></td>
<td>Levi Holland*, Eric Umbrett, Andrew McIntosh, Jose Karam, Christopher Wood, Houston, TX</td>
</tr>
</tbody>
</table>
MP73-13 COMPREHENSIVE ANALYSIS OF METASTATIC SEMINOMA GERM CELL TUMORS SHOWS DIVERGENT EXPRESSION OF IMMUNE-RELATED PATHWAYS.
Tim Nestler*, Friederike Haidl, Maike Wittersheim, Priya Dalvi, Pia Paffenholz, Svenja Wagener-Ryczek, David Pfister, Martin Hellmich, Reinhard Büttner, Margarete Oderenthal, Axel Heidenreich, Cologne, Germany

MP73-14 RED CELL DISTRIBUTION WIDTH (RDW) AS A PREDICTOR OF SURVIVAL OUTCOMES WITH PALLIATIVE CHEMOTHERAPY FOR METASTATIC PENILE CANCER
Mehran Afshar, Reena Patel*, Louise English, Mark Mikhaeel, Unaiza Qureshi, Alison Tree, Benjamin Ayres, Nick Watkin, Lisa Pickering, London, United Kingdom

MP73-15 THE SYSTEMIC INFLAMMATORY MARKERS IN PERIPHERAL BLOOD BEFORE SURGICAL TREATMENT IN PENILE SQUAMOUS CELL CARCINOMA ARE PREDICTORS OF SURVIVAL.
Emanuel Albuquerque*, Giuliano Guglielmetti, Pablo Sierra, José Pontes Jr, Alexandre Cavalcante, Rafael Coelho, William Nahas, SÃO PAULO, Brazil

MP73-16 PENILE CANCER STAGE-INCIDENCE TRENDS IN THE UNITED STATES
Daniela Kaefer*, Paul Sutcliffe, Shaelyn Cavanaugh, Joseph Jacob, Elizabeth Ferry, Syracuse, NY

MP73-17 RAB20, AIM2, AND BCL2A1 INHIBIT PENILE SQUAMOUS CELL CARCINOMA CELL PROLIFERATION
kai yao*, Dong Chen, Xing-liang Tan, Qiang-hua Zhou, Fang-jian Zhou, Guang zhou, China, People’s Republic of

MP73-18 IDENTIFYING FACTORS WHICH PROLONG LENGTH OF STAY FOLLOWING OPEN RETROPERITONEAL LYMPH NODE DISSECTION
Adam Pearce*, Jessica Whibley, Susanna Walker, Erik Mayer, David Nicol, London, United Kingdom

MP73-19 VALIDATION OF PRIMARY TUMOR SURGERY AS A PROGNOSTIC INDICATOR IN SEMINOMA PATIENTS WITH DISTANT METASTASIS AT DIAGNOSIS: A POPULATION-BASED STUDY
Shengming Jin*, Beihua Wang, Weijie Gu, Dingwei Ye, Shanghai, China, People’s Republic of

MP73-20 PREDICTORS OF SURGICAL REFERRAL FOR RECONSTRUCTION IN PATIENTS UNDERGOING MOHS SURGERY FOR SQUAMOUS CELL CARCINOMA OF THE MALE GENITALIA
Alexander Skokan*, Raju Chelluri, Leilei Xia, Matthew Heavner, Ibarbo Zambrano, Christopher Miller, Robert Caleb Kovell, Philadelphia, PA

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
MP74-04 BLADDER SHAPE DIFFERENCES IN INDIVIDUALS WITH HEALTHY AND OVERACTIVE BLADDERS IDENTIFIED WITH NON-INVASIVE ULTRASOUND DURING AN ORAL HYDRATION STUDY

Dhruv Sethi*, Blessan Sebastian, Devina Thapa, Naomi Vinod, Zachary Cullingsworth, Andrea Balthazar, Anna Nagle, Laura Carucci, John Speich, Adam Klausner, Richmond, VA

MP74-05 INCREASED BLADDER TRABECULATION ON CYSTOGRAM PREDICTS WORSE POST PROSTATECTOMY INCONTINENCE

Jeannie Su*, New Haven, CT, Jane Choe, Boston, MA, Ingrid Xu, Thomas Martin, David Hesse, New Haven, CT

MP74-06 PREOPERATIVE FUNCTIONAL ULTRASOUND IMAGING OF THE PELVIC FLOOR: CORRELATION WITH EARLY CONTINENCE OUTCOMES POST RADICAL PROSTATECTOMY

Danielle Van Diepen, Lewis Chan*, Vincent Tse, Ruban Thanigasalam, Scott Leslie, Andre Lalak, Sydney, Australia

MP74-07 ROLE OF SONOURETHROGRAM IN EVALUATION OF SHORT SEGMENT ANTERIOR URETHRAL STRICTION.

anuj kumar*, RAJEEV SOOD, HEMANT GOEL, UMESH SHARMA, SUMIT GAHLAWAT, HARSH JAIN, NEW DELHI, India

MP74-08 FOCAL TESTICULAR LESIONS. MULTIPARAMETRIC US FEATURES AND ASSOCIATION WITH HISTOPATHOLOGY

Riccardo Boschian*, Irene Campo, Camilla Sachs, Francesca Curro, Francesco Claps, Rossana Bussani, Maria Cova, Giovanni Ligouri, Carlo Trombetta, Michele Bertolotto, Trieste, Italy

MP74-09 MRI PRO: A GLOBAL ONLINE SOLUTION FOR CASE-BASED TRAINING IN PROSTATE MRI - THE INITIAL LEARNER ANALYSIS

Jeremy Grummet*, Rowan Miller, Melbourne, Australia, Antonio Westphalen, Spencer Behr, Derek Sun, San Francisco, CA, Geoffrey Sonn, Nancy Wang, Stanford, CA, Jeries Zawarideh, Dorota Czyzewska, Iztok Cagic, Nienke Hansen, Tristan Barrett, Christof Kastner, Cambridge, United Kingdom, Shengfei Oon, Renu Eapen, Wayland Wang, Melbourne, Australia, Boris Hadadchik, Lukas Puellen, Essen, Germany, Hiroshi Sasaki, Tokyo, Japan, Svenja Dieffenbacher, Heidelberg, Germany, Muhammad Kahloon, Canberra, Australia, Samir Taneja, New York City, NY, Caroline Moore, London, United Kingdom, Jelle Barentsz, Nijmegen, Netherlands

MP74-10 DEEP LEARNING FOR SEMI-AUTOMATED PIRADS V2 SCORING ON MULTIPARAMETRIC PROSTATE MRI

Tom Sanford*, Stephanie Harmon, Bethesda, MD, Manuel Madariaga, Santiago, Chile, Deepak Kesani, sherif mehralivand, Nathan Lay, Sheng Xu, Jonathan Bloom, Amir Lebastic, Michael Ahdoot, Maria Merino, Brad Wood, Vladimir Valera, Peter Choyke, Peter Pinto, Baris Turkbey, Bethesda, MD

MP74-11 NETWORK-BASED TRANSCRIPTOMIC ANALYSIS IDENTIFIES GENE SIGNATURES ASSOCIATED WITH MPMRI-VISIBLE PROSTATE CANCER

Alp Tuna Bekศาส*, Ishan Paranjape, Ugo Falagarino, Alberto Martini, Shivaram Cumarasamy, Sara Lewis, Bachir Taouli, Art Rastinehad, Ash Tewari, New York, NY

MP74-12 PATIENT SELECTION FOR PROSTATE BIOPSY USING A MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING (MPMRI) BASED TRIAGE PATHWAY: FEASIBILITY, PERFORMANCE IN AN ACADEMIC, TERTIARY CENTER

Matthew Roberts*, Peter Donato, Andrew Morton, Geoff Coughlin, Rachel Esler, Nigel Dunglishon, Robert Gardiner, John Yaxley, Brisbane, Australia

MP74-13 A PROSPECTIVE VALIDATION OF THE DIAGNOSTIC ACCURACY OF PRI-MUS FOR PROSTATE CANCER RISK IDENTIFICATION

Ferdinand Luger*, Andreas Gusenleitner, Jasmin Kaar, Clemens Mayr, Wolfgang Loidl, Linz, Austria

MP74-14 COMPARISON OF TRANSABDOMINAL AND TRANSRECTAL ULTRASOUND FOR SIZING OF THE PROSTATE

Wesley R Pate*, Liz B Wang, Nishant Garg, Philip V Barbosa, Shaun E Wason, Boston, MA

MP74-15 IMPROVED ACCURACY OF MRI/US FUSION PROSTATE BIOPSY USING A STRETCHED EXPONENTIAL DIFFUSION PARAMETER

Hari T. Vigneswaran*, Meltem Uyanik, Rolf Reiter, Virgilia Macias, Winnie Mar, Karen L. Xie, Richard L. Magin, Michael R. Abern, Chicago, IL

MP74-16 DIAGNOSTIC ACCURACY OF MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING TO DETECT RESIDUAL PROSTATE CANCER FOLLOWING FOCAL THERAPY WITH IRREVERSIBLE ELECTROPORATION

Alexandar Blazevski*, Matthijs Scheltema, Brian Yuen, Thomas Cusick, Anne-Maree Haynes, Phillip Stricker, Darlinghurst, Australia
MP74-17 THE EFFECT OF ANDROGEN DEPRIVATION THERAPY ON PSMA EXPRESSION EVALUATED WITH 68GA-PSMA-11 PET/MRI: A PROSPECTIVE, REGISTERED CLINICAL TRIAL
Otto Ettala*, Simona Malaspina, Terhi Tuokkola, Peter Boström, Jukka Kemppainen, Turku, Finland

MP74-18 PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) TO BETTER CHARACTERISE INTRAPROSTATIC TUMOUR BURDEN: REVIEW OF AN ACADEMIC, TERTIARY CENTER SERIES
Matthew Roberts*, Peter Donato, Andrew Morton, Samuel Kyle, Geoff Coughlin, Rachel Esler, Nigel Dunglison, Robert Gardiner, John Yaxley, Brisbane, Australia

MP74-19 ASSESSMENT OF RADIATION SAFETY KNOWLEDGE AMONG UROLOGY RESIDENTS IN THE UNITED STATES
Marilyn Hopkins*, John Loomis, Jason Bylund, Andrew Harris, Lexington, KY

MP74-20 DIAGNOSTIC ACCURACY OF THE NOVEL 29 MHZ MICRO-ULTRASOUND “EXACTVUTM” FOR THE DETECTION OF CLINICALLY SIGNIFICANT PROSTATE CANCER: A PROSPECTIVE SINGLE INSTITUTIONAL STUDY
Francesco Chessa*, Riccardo Schiavina, Eugenio Brunocilla, Borghesi Marco, Lorenzo Bianchi, Cristian Pultrone, Amelia Errcolino, Davide Giusti, Bologna, Italy, Luca Lodigiani, Italy, Italy, Caterina Gaudiano, Eugenio Brunocilla, Bologna, Italy

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Monday, May 6, 2019
7:00 am - 9:00 am
Moderated Poster Session 75
INFERTILITY: BASIC RESEARCH & PATHOPHYSIOLOGY
Room W181ab @ McCormick Place
Moderators: Kirk Lo, Robert Brannigan & Sidney Glina

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP75-01</td>
<td>EVIDENCE THAT TESTICULAR SPERM HAS IMPROVED DNA INTEGRITY COMPARED TO EJACULATED SPERM IN INFERTILE MEN</td>
</tr>
<tr>
<td>Lona Vyas*, London, United Kingdom, Sheena Lewis, Belfast, United Kingdom, Tharu Tharakan, Channa Jayasena, Sukas Minhas, Jonathan Ramsay, London, United Kingdom</td>
<td></td>
</tr>
</tbody>
</table>

| MP75-02 | PATERNAL EXPOSURE TO NICOTINE AFFECTS THE BIRTH WEIGHT AND OFFSPRING DEVELOPMENT IN A RAT MODEL |
| Panagiota Tsounapi*, Masashi Honda, Shogo Teraoka, Yusuke Kimura, Katsuya Hikita, Yonago, Japan, Fotois Dimitriadis, Thessaloniki, Greece, Nikolaos Sofikitis, Ioannina, Greece, Motoaki Saiko, Nankoku-shi, Japan, Atsushi Takenaka, Yonago, Japan |

| MP75-03 | MEN WITH SERTOLI CELL ONLY SYNDROME UNDER EXPRESS LONG NON-CODING RNAs ASSOCIATED WITH CHROMATIN-MODIFYING COMPLEXES: LINC00467, LINC00958, AND LINC01016 |
| Russell Hayden*, Anna Mielnik, Peter Schlegel, Darius Paduch, New York, NY |

| MP75-04 | LH SIGNAL IN TESTIS CONTRIBUTES TO THE MAINTENANCE OF INTERSTITIAL FLUID HOMEOSTASIS |
| Satoshi Nozaki*, Shoiciro Ishikawa, Tomoki Takeda, Hiroki Kubota, Hiroyuki Kaniya, Shoichi Sasaki, Yukihiro Umemoto, Takahiro Yasui, Nagoya, Japan |

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP75-05</td>
<td>THE IMPACT OF THE EXTRACELLULAR MICROENVIRONMENTS ON SPERMATOGENESIS IN IDIOPATHIC NON-OBSTRUCTIVE AZOSPERMIA</td>
</tr>
<tr>
<td>Filippo Pederzoli*, Irene Locatelli, Paolo Capogrosso, Eugenio Ventimigla, Manuela Nebuloni, Massimo Clementi, Nicasio Mancini, Ferrarese Roberto, Francesco Montorsi, Andrea Salonia, Massimo Alfonso, Milan, Italy</td>
<td></td>
</tr>
</tbody>
</table>

| MP75-06 | FUNCTIONAL IMAGING OF THE TESTES AND TRACING SPERMATOGENESIS HOTSPOTS WITH FDG-PET/CT – A RAT PILOT STUDY |
| Antoni Bochinski*, Arunan Sujenthiran, Majed Shabbir, Gilbert Fruhwirth, Ewelina Kurty, Tet Yap, London, United Kingdom |

| MP75-07 | SOX2, A MASTER REGULATOR OF STEMNESS, IS OVEREXPRESSED IN TESTICULAR TISSUE OF MEN WITH SERTOLI CELL ONLY SYNDROME |
| Russell Hayden*, Anna Mielnik, New York, NY, Ryan Flannigan, Vancouver, Canada, Peter Schlegel, Darius Paduch, New York, NY |

| MP75-08 | WHOLE EXOME SEQUENCING IDENTIFIES A RARE NONSENSE MUTATION IN FAM47C AS A POSSIBLE CAUSE OF SEVERE OLIGOSPERMIA IN BROTHERS WITH VARICOCELE |
| Willy Chertman, Diana M. Lopategui, Anthony J Griswold, Himanshu Arora*, Ranjith Ramasamy, MIAMI, FL |

*Presenting author
MP75-09 MARIJUANA CONSUMPTION HAS A DIRECT RIOUS EFFECT ON SPERMATOZOA BY INCREASING INTRACELLULAR REACTIVE OXYGEN SPECIES LEVELS 20 TIMES MORE THAN TOBACCO SMOKING: REASONS FOR CONCERN ON WIDESPREAD USE
Jorge Hallak*, Thiago Afonso Teixeira, Juliana Risso Pariz, Sao Paulo, Brazil, Ivan Iori, Campinas, Brazil, Elaine Costa, Paulo Hilario Saldiva, Sao Paulo, Brazil

MP75-10 DRUG-INDUCED DEPLETION AND REPLACEMENT OF THE TESTIS GERM CELL NICHE
TETSUHIRO YOKONISHI*, BLANCHE CAPEL, Durham, NC

MP75-11 PRSS50-NFKB-LRW: A NOVEL PATHWAY IN SPERMATOGENESIS
Jason Scovell*, Abhishek Seth, Juan Bournat, Joshua Moore, Minerva Solis, Adam Szafran, Carolina Jorgez, Houston, TX

MP75-12 DIFFERENTIATION OF FETAL SERTOLI CELLS IN ADULT TESTIS
TETSUHIRO YOKONISHI*, BLANCHE CAPEL, Durham, NC

MP75-13 IN-VIVO INHIBITION OF MIR-202-5P RESULTS IN SPERMATOGENIC KNOCKDOWN THROUGH TARGETING EPIDERMAL GROWTH FACTOR PATHWAYS & CELL CYCLE REGULATION
Ryan Flannigan*, Vancouver, Canada, Russell Hayden, Anna Mielnik, Alex Bolyakov, Peter Schlegel, Darius Paduch, New York, NY

MP75-14 E2F1 IS A MASTER REGULATOR OF TESTICULAR DESCENT AND SPERMATOGENESIS VIA ITS REGULATION OF THE WNT4 PATHWAY
Carolina Jorgez, Jason Scovell*, Abhishek Seth, Nathan Wilken, Juan Bournat, Houston, TX, Dolores Lamb, New York, NY

MP75-15 IN VITRO PROPAGATION OF KLINEFELTER SYNDROME SPERMATOGENIC STEM CELLS: A TRANSLATIONAL SYSTEM FROM MOUSE TO HUMAN

MP75-16 25-HYDROXYCHOLESTEROL AS A MARKER OF SPERM FUNCTION: OXYSTEROLS PROFILE OF SEMEN
Antonio Luigi Pastore*, Roma, Italy, Andrea Fusch, Lorenzo Capone, Gennaro Velotti, Alessia Martocchia, Yazan Al salhi, Antonio Carbone, Latina, Italy

MP75-17 3-DIMENSIONAL (3D) HUMAN TESTICULAR ORGANOID SYSTEM FROM KLINEFELTER (XXY) TESTICULAR CELLS SUPPORTS IN VITRO HAPLOID GERM CELL FORMATION

MP75-18 A NOVEL NANO-ENCAPSULATED ANTIOXIDANT THERAPY AMELIORATES TESTICULAR GERM CELL APOPTOSIS INDUCED BY A HIGH-DOSE IONIZING IRRADIATION IN RATS.
Omri Nativ*, Igor Sukhotnik, Yoav Ben-Shahar, Hila Shefer, Jacob Bejar, Miguel Gorenberg, Haifa, Israel

MP75-19 ISOLATION OF TESTICULAR SOMATIC CELLS USING DSA LECTIN AND PERCOLL
Satoshi Nozaki*, Shoiciro Iwatsuki, Tomoki Takeda, Hiroyuki Kubota, Hiroyuki Kamiya, Shoichi Sasaki, Yukihiro Umemoto, Takahiro Yasui, Nagoya, Japan

MP75-20 HIGHER SPERM LEUKOCYTE COUNT IS ASSOCIATED WITH INCREASED SPERM DNA FRAGMENTATION INDEX IN MEN WITH NEGATIVE SEMEN CULTURES: A PATHOPHYSIOLOGICAL PATHWAY
Eugenio Ventimiglia*, Paolo Capogrosso, Luca Boeri, Walter Cazzaniga, Edoardo Pozzi, Francesco Chierigo, Nicolò Schifano, Federico Belladelli, Rani Zuabi, Costantino Abbate, Federico Dehò, Milan, Italy, Vincenzo Miron, Naples, Italy, Franco Gaboardi, Francesco Montorsi, Andrea Salonia, Milan, Italy

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
<table>
<thead>
<tr>
<th>Time</th>
<th>Number</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00</td>
<td>PD59-01</td>
<td>EFFECT OF STONE COMPOSITION ON SURGICAL STONE RECURRENCE: SINGLE CENTER LONGITUDINAL ANALYSIS</td>
<td>Shuang Li*, Simone L. Vernez, Kristina L. Penniston, R. Allan Jhagroo, Stephen Y. Nakada, Madison, WI</td>
</tr>
<tr>
<td>7:10</td>
<td>PD59-02</td>
<td>ROLE OF GENERAL ANESTHESIA VERSUS GENERAL ANESTHESIA WITH SHORT INTRAOPERATIVE APNEA FOR RETROGRADE INTRARENAL SURGERY AND FOR URETEROSCOPIC LASER Lithotripsy FOR PROXIMAL URETERIC STONE. A SINGLE INSTITUTION RANDOMIZED CONTROL STUDY.</td>
<td>Arun Panackal*, Manjeet Singh, Lal Krishnan, Srinivas Rao, muscat, Oman</td>
</tr>
<tr>
<td>7:20</td>
<td>PD59-03</td>
<td>URETEROSCOPIC ASSESSMENT OF STONE BURDEN AFTER DUSTING CORRELATES WITH CLINICAL OUTCOMES DESPITE POOR STONE-FREE RATES ON POST-PROCEDURAL IMAGING</td>
<td>Ohad Kott*, Alison Chambers, Osama Al-Alao, Eric Jung, Timothy O'Rourke, Meredith Wasserman, Alejandra Balon, Mina Ghaly, Timothy Wright, Stefan Rodriguez, Siddharth Marthi, Christopher Tucci, Gyan Pareek, Providence, RI</td>
</tr>
<tr>
<td>7:30</td>
<td>PD59-04</td>
<td>EMERGENCY VERSUS ELECTIVE URETEROSCOPY: RETROSPECTIVE ANALYSIS OF 4 021 CASES</td>
<td>Vigen Malkhasyan*, George Kasyan, Malika Dzhuravaev, Igor Semenyakin, Dmitriy Pushkar, Vadim Ivanov, Moscow, Russian Federation</td>
</tr>
<tr>
<td>7:40</td>
<td>PD59-05</td>
<td>OUTCOMES OF MEDICAL VS INTERVENTIONAL MANAGEMENT FOR ACUTE URETERAL COLIC IN EMERGENCY DEPARTMENT PATIENTS</td>
<td>Grant Innes, Alec Mitchell*, Bryce Weber, Calgary, Canada, Joel Teichman, Kevin Carlson, Vancouver, Canada, Andrew McRae, Calgary, Canada, Michael Law, Frank Scheuermann, Eric Graftstein, Vancouver, Canada, James Andruchow, Calgary, Canada</td>
</tr>
<tr>
<td>7:50</td>
<td>PD59-06</td>
<td>IN VITRO COMPARISON OF EFFICIENCY BETWEEN SUPERPULSED THULIUM FIBER LASER AND HO:YAG LASER FOR ENDOCORPOREAL LITHOTRIPSY</td>
<td>Paul Chiron*, Saint Mandé, France, Laurent Berthe, Mattieu Haddad, Steeve Doizi, Olivier Traxer, Paris, France</td>
</tr>
<tr>
<td>8:00</td>
<td>PD59-07</td>
<td>COMPARISON OF ANTEGRADE PERCUTANEOUS URETEROLITHOTRIPSY (APCUL) AND RETROGRADE URETEROSCOPIC LITHOTRIPSY (URSL) FOR UPPER URETERIC CALCULUS WITH REGARD TO STONE CLEARANCE, MORBIDITY AND COMPLICATIONS.</td>
<td>Nikhil Khandelwal*, Bikaner, India, Mahakshit Bhat, Amilal Bhat, J alipur, India, Akshita Bhat, Bikaner, India, Vikash Singh, J odhpur, India</td>
</tr>
<tr>
<td>8:10</td>
<td>PD59-08</td>
<td>PROCEDURAL COSTS AND OUTCOMES FOLLOWING MINI-PERCUTANEOUS NPHROLITHOTOMY OR FLEXIBLE URETEROSCOPIC LITHOTRIPSY FOR NPHROLITHIASIS: DATA FROM A PROSPECTIVE, RANDOMIZED CLINICAL TRIAL</td>
<td>Ilan Klein*, Rahul Dutta, Marc Colaco, Manish Patel, Jorge Gutierrez-Aceves, Winston Salem, NC</td>
</tr>
<tr>
<td>8:20</td>
<td>PD59-09</td>
<td>FACTORS INFLUENCING THE COST OF URETEROSCOPY</td>
<td>Muhammad Alsyoud*, Dan Hur, Phillip Stokes, Sue Min Sophia Kown, Akin Amasyali, Mohammad Hajihja, Milan Shah, D Duane Baldwin, Loma Linda, CA</td>
</tr>
<tr>
<td>8:30</td>
<td>PD59-10</td>
<td>IMPACT OF AN ENHANCED RECOVERY AFTER SURGERY PROTOCOL ON PATIENT SYMPTOMS IN THE INTERMEDIATE POSTOPERATIVE PERIOD AFTER URETEROSCOPY FOR STONES</td>
<td>Brett Johnson*, Abdulhadi Akhtar, Joseph Crivelli, Ryan L. Steinberg, Jun Sasaki, Austin Street, Dallas, TX, Igor Sorokin, Worcester, MA, Jodi Antonelli, Margaret Pearle, Dallas, TX</td>
</tr>
<tr>
<td>8:40</td>
<td>PD59-11</td>
<td>COMPARISON OF TADALAFIL AND TAMSOLOLIN IN RELIVING STENT RELATED SYMPTOMS: A RANDOMISED STUDY</td>
<td>mohankumar vijayakumar*, sudharshan balaji, Abhishek Singh, Arvind Ganpule, Ravindra Sabnis, Mahesh Desai, nadiad, India</td>
</tr>
<tr>
<td>8:50</td>
<td>PD59-12</td>
<td>IMPACT OF INTRAOPERATIVE USE OF TRANEXAMIC ACID ON TRANSFUSION RATE IN PATIENTS WITH COMPLEX KIDNEY STONES UNDERGOING PERCUTANEOUS NPHROLITHOTOMY: RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED TRIAL</td>
<td>Carlos Alfredo Batagello*, Fabio Carvalho Vicentini, Sao Paulo, Brazil, Manoj Monga, Cleveland, OH, Giovanni Scala Marchini, Fabio Cesar Miranda Torricelli, Alexandre Danilovic, Miguel Srougi, Willian Carlos Nahas, Eduardo Mazzucch, Sao Paulo, Brazil</td>
</tr>
</tbody>
</table>

*Presenting author
Podium Session 60

PROSTATE CANCER: DETECTION & SCREENING VII
Room W185d @ McCormick Place

Moderators: Salvatore Giuseppe Voce, James McKiernan & S. Stephen Jones

<table>
<thead>
<tr>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
<th>AUTHORS</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:30</td>
<td>PD60-04</td>
<td>PROSTATE MRI, WITH OR WITHOUT TARGETED BIOPSY, AND STANDARD BIOPSY FOR DETECTING PROSTATE CANCER: A COCHRANE SYSTEMATIC REVIEW AND META-ANALYSIS.</td>
<td>Frank-Jan Drost*, Daniël Osse, Daan Nieboer, Chris Bangma, Ewout Steyerberg, Monique Roobol, Ivo Schoots, Rotterdam, Netherlands</td>
</tr>
<tr>
<td>7:40</td>
<td>PD60-05</td>
<td>AUTOMATED DETECTION OF PROSTATE CANCER ON MULTIPARAMETRIC MRI USING DEEP NEURAL NETWORKS TRAINED ON SPATIAL COORDINATES AND PATHOLOGY OF BIOPSY CORES</td>
<td>Leo Chen*, Nicholas Bien, Richard Fan, Robin Cheong, Pranav Rajpurkar, Alan Thong, Nancy Wang, Sarir Ahmad, Mirabela Rusu, James Brooks, Andrew Ng, Geoffrey Sonn, Stanford, CA</td>
</tr>
<tr>
<td>7:50</td>
<td>PD60-06</td>
<td>USING MACHINE LEARNING TO PREDICT PROSTATE CANCER UPGRADING AFTER ROBOTIC RADICAL PROSTECTOMY</td>
<td>Daniele Panfilo, Trieste, Italy, Cosimo De Nunziot, rome, Italy, Antonio Luigi Pastore, Latina, Italy, Sebastiano Saccani, Boudewijn Alexander, Pietro Tortella, Trieste, Italy, Manuela Mattioli, Riccardo Lombardo, rome, Italy, Antonio Carbone, Andrea Fuschi, Latina, Italy, Lorenzo Dutto, Glasgow, United Kingdom, Joern Witt, Gronau, Germany, Eric Medvet, Trieste, Italy, Andrea Tubaro, rome, Italy</td>
</tr>
<tr>
<td>8:10</td>
<td>PD60-08</td>
<td>BRCA MUTATIONS IN HISPANIC MEN WITH FIRST DEGREE PROSTATE AND BREAST CANCER HISTORY</td>
<td>Michael Lips*, Eric Stutz, Teresa Johnson-Pais, Ian Thompson, Robin Leach, San Antonio, TX</td>
</tr>
<tr>
<td>8:20</td>
<td>PD60-09</td>
<td>ROLE AND VALUE OF SECOND OPINION REVIEWS IN DNA METHYLATION POSITIVE EPIGENETICAL ASSAYS IN NEGATIVE HISTOPATHOLOGICAL PROSTATE BIOPSY</td>
<td>John Lam*, David Finley, Stephen Poon, William Sohn, Yu Wang, Philip Kim, Stephen Williams, Eugene Rhein, Ronald Loo, Gary Gochman, Jeffrey Shiffer, Pasadena, CA</td>
</tr>
</tbody>
</table>
8:30 PD60-10 A PROSPECTIVE PHASE 2/3 MULTI-CENTER STUDY OF 18F-DCFPYL PET/CT IMAGING IN PATIENTS WITH PROSTATE CANCER – EXAMINATION OF DIAGNOSTIC ACCURACY (OSPREY)
Michael A. Gorin*, Kenneth J. Pienta, Baltimore, MD, Barry A. Siegel, St. Louis, MO, Peter Carroll, San Francisco, CA, Frédéric Pouliot, Quebec, Canada, Stephan Probst, Montreal, Canada, Lawrence Saperstein, New Haven, CT, Mark A. Preston, Boston, MA, Ajai Shivaram Alva, Ann Arbor, MI, Akash Patnaik, Chicago, IL, Jeremy C. Durack, New York, NY, Steven P. Rowe, Baltimore, MD, Melissa Nichols, Tess Lin, Thomas Strack, Vincent A. DiPippo, Syed Mahmood, Jessica Jensen, Vivien Wong, Michael J. Morris, New York, NY

8:40 PD60-11 A PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF 99MTC-MIP-1404 SPECT/CT IMAGING TO DETECT CLINICALLY SIGNIFICANT PROSTATE CANCER IN MEN WITH BIOPSY PROVEN LOW GRADE PROSTATE CANCER WHO ARE CANDIDATES FOR ACTIVE SURVEILLANCE (PROSPECT-AS)

8:50 PD60-12 SITES OF PROSTATE CANCER RECURRENCE DELINEATED WITH 18F-FLUCICLOVINE POSITRON EMISSION TOMOGRAPHY IN PATIENTS WITH NEGATIVE OR EQUIVOCAL CONVENTIONAL IMAGING
Gerald Andriole*, Barry Siegel, Saint Louis, MO, LOCATE Study Group, x, WA

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Monday, May 6, 2019 7:00 am - 9:00 am
Podium Session 61
URODYNAMICS/LOWER URINARY TRACT DYSFUNCTION/FEMALE PELVIC MEDICINE: NON-NEUROGENIC VOIDING DYSFUNCTION II
Room W181c @ McCormick Place
Moderators: Lindsey Cox & Alan Wein

<table>
<thead>
<tr>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00</td>
<td>PD61-01</td>
<td>DOES VIDEOURODYNAMIC DIAGNOSIS OF PRIMARY BLADDER NECK OBSTRUCTION IN WOMEN PREDICT SUCCESS AFTER BLADDER NECK INCISION INDEPENDENT OF DETRUSOR PRESSURE? Rachaël Sussman, Ricardo Palmerola*, Benoît Peyronnet, Christina Escobar, Dominique Pape, Nint Rosenblum, Benjamin Brucker, Victor Nitti, New York, NY</td>
</tr>
<tr>
<td>7:10</td>
<td>PD61-02</td>
<td>OUTFLOW OBSTRUCTION IS ASSOCIATED WITH (EARLIER) FILLING SENSATION AND DETRUSOR OVERACTIVITY AND (HIGHER) DETRUSOR FILLING PRESSURES IN MAN BUT ALSO IN WOMEN. Peter Rosier*, Utrecht, Netherlands</td>
</tr>
<tr>
<td>7:20</td>
<td>PD61-03</td>
<td>DETRUSOR UNDERACTIVITY: ARE DIFFERENT DIAGNOSTIC CRITERIA OFTEN RELIABLE IN CLINICAL PRACTICE? Rapisarda Sebastiano*, Giorgio Ivan Russo, Catania, Italy, Riccardo Lombardo, Cosimo De Nunzio, Rome, Italy, Carmen Scandura, Beatrice Carbonaro, Catania, Italy, Angela Sica, Carlo Vicentini, Rome, Italy, Sebastiano Cimino, Andrea Tubaro, Giuseppe Morgia, Catania, Italy</td>
</tr>
<tr>
<td>7:30</td>
<td>PD61-04</td>
<td>CLINICAL SYMPTOMS AND URODYNAMIC PARAMETERS OF AN UNDERACTIVE BLADDER COHORT Elodi Dielubanza*, Elise De, Boston, MA, Tamara Bavendam, Bethesda, MD, Wesley Wang, Boston, MA, Michael Maurao, Rebekah Zincavage, Watertown, MA, Michael O’Leary, Boston, MA, Raymond Rosen, Watertown, MA</td>
</tr>
</tbody>
</table>

*Presenting author
7:30 PD62-04 ROLE OF DIFFUSION-WEIGHTED MRI IN PREDICTING >PT2 AND >PT3 UPPER TRACT UROTHELIAL CANCER
Fumitaka KOGA*, Kazumasa Sakamoto, Kosuke Takemura, Hiroaki Suzuki, Madoka Kakaoka, Masaya Ito, Yasukazu Nakanishi, Ken-ichi Tobisu, Tokyo, Japan

7:40 PD62-05 THE IMPACT OF HISTOLOGICAL VARIANTS ON SURVIVAL IN IN UPPER URINARY TRACT UROTHELIAL CARCINOMA PATIENTS TREATED WITH NEPHROURETERECTOMY: A MULTICENTER COLLABORATION
Stefania Zamboni*, Lucerne, Switzerland, Beat Foerster, Mohammad Abufaraj, Vienna, Austria, Morgan Rouprêt, Thomas Seisen, Paris, France, Pierre Colin, Lille, France, De la Taille Alexandre, Paris, France, Benoit Peyronnet, Karim Bensalah, Rennes, France, Roman Herout, Manfred Peter Wirth, Vladimir Novotny, Dresden, Germany, Francesco Soria, Vienna, Austria, Plot Chiosta, Krakow, Poland, Agostino Mattei, Philipp Baumeister, Lucerne, Switzerland, Alessandro Antonelli, Claudio Simeone, Brescia, Italy, Francesco Montorsi, Milan, Italy, Giuseppe Simone, Michele Gallucci, Giuseppe Romeo, Rome, Italy, Kazumasa Matsumoto, Kanagawa, Japan, Pierre I Karakiewicz, Montreal, Canada, Alberto Briganti, Milan, Italy, Evanguelos Xylinas, Paris, France, Shahrokh F. Shariat, Marco Moschini, Vienna, Austria

7:50 PD62-06 DISTINCT GENOMIC HALLMARKS EXIST BETWEEN METASTATIC UPPER AND LOWER TRACT UROTHELIAL CARCINOMA

8:00 PD62-07 PROPENSITY-SCORE MATCHED COMPARISON OF ONCOLOGIC AND FUNCTIONAL OUTCOMES BETWEEN RADICAL NEPHROURETERECTOMY AND SEGMENTAL URETERECTOMY

8:10 PD62-08 USING MICRORNA EXPRESSION FROM BIOPSY SAMPLES IN UPPER TRACT UROTHELIAL CARCINOMA AS A PREDICTIVE MODEL FOR TUMOR GRADE AND INVASION
Aaron Berkenwald*, Erik Katz, Brendan Brown, Chintan Patel, Travis Sullivan, Burlington, MA, Erik Burks, Boston, MA, Jay Raman, Joshua Warrick, Hershey, PA, David Canes, Kimberly Rieger-Christ, Burlington, MA

8:20 PD62-09 MICRORNAS AS BIOMARKERS TO DETERMINE RISK OF BLADDER CANCER RECURRENCE FOLLOWING NEPHROURETERECTOMY FOR UPPER TRACT UROTHELIAL CARCINOMA
Kareem Alazem*, Woburn, MA, Alison Levy, Travis Sullivan, Kristian Stensland, Eric Burks, Brendan Browne, Chintan Patel, David Canes, Kimberly Rieger-Christ, Burlington, MA, Joshua Warrick, Jay Raman, Hershey, PA

8:30 PD62-10 TOPICAL TREATMENT FOR HIGH-GRADE UPPER TRACT CYTOLOGY WITH NEGATIVE IMAGING (HGUTCNI)
Andrew Vitale*, Jeremy West, Brenton Sherwood, Kenneth Nepple, Sarah Mott, Michael O’Donnell, Iowa City, IA

8:40 PD62-11 PATHOLOGIC STAGE AS A SURROGATE FOR ONCOLOGIC OUTCOMES AFTER RECEIPT OF NEOADJUVANT CHEMOTHERAPY FOR HIGH-GRADE UPPER TRACT UROTHELIAL CARCINOMA
Nirmish Singla*, Alana Christie, Timothy Clinton, Yuval Freiffeld, Rashed Ghandour, Solomon Woldu, Dallas, TX, Firas Petros, Wei Qiao, Houston, TX, Haley Robyak, Hershey, PA, Aditya Bagrodia, Yair Lotan, Dallas, TX, Jay Raman, Hershey, PA, Surenna Matin, Houston, TX, Vitaly Margulis, Dallas, TX

8:50 PD62-12 DOES MUTATIONAL BURDEN AFFECT RESPONSE TO CISPLATIN-BASED NEOADJUVANT CHEMOTHERAPY IN UPPER TRACT UROTHELIAL CARCINOMA?
Andrew Silagy*, New York, NY, Nirmal John, Renzo DiNatale, Roy Mano, Julian Marcon, Kyle Blum, Alejandro Sanchez, Ari Hakimi, Eugene Pietzak, Jonathan Coleman, New York City, NY

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
<table>
<thead>
<tr>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
<th>ABSTRACT</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00</td>
<td>PD63-01</td>
<td>UROLOGY GROUP PRACTICE ORGANIZATION AND USE OF OBSERVATION FOR PROSTATE CANCER</td>
<td>Parth K. Modi*, Samuel R. Kaufman, Lindsey A. Herrel, James M. Dupree, Brent K. Hollenbeck, Vahakn B. Shahinian, Ann Arbor, MI</td>
</tr>
<tr>
<td>7:10</td>
<td>PD63-02</td>
<td>IMPACT OF THE AFFORDABLE CARE ACT ON PAYER DISTRIBUTION FOR UROLOGIC STONE SURGERY IN THE STATE OF CALIFORNIA</td>
<td>Scott Wiener*, David Bayne, San Francisco, CA, David Tzou, Tuscon, AZ, Thomas Chi, Marshall Stoller, San Francisco, CA</td>
</tr>
<tr>
<td>7:20</td>
<td>PD63-03</td>
<td>RELATIONSHIP BETWEEN THE WISCONSIN STONE QUALITY OF LIFE (WISQOL) AND PREFERENCE-BASED / HEALTH UTILITY MEASURES OF HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN KIDNEY STONE PATIENTS</td>
<td>Charles Polotti*, Bryan Tan, Nicole Borglum, Ephrem Olweny, New Brunswick, NJ</td>
</tr>
<tr>
<td>7:30</td>
<td>PD63-04</td>
<td>ENGAGING STAKEHOLDERS IN UROLOGIC RESEARCH: THE PATIENT-CENTERED DESIGN OF A PRAGMATIC CLINICAL TRIAL IN BLADDER CANCER</td>
<td>John Gore*, Erika Wolff, Seattle, WA, Stephanie Chisolm, Robert Liptman, Bethesda, MD, Angela Smith, Chapel Hill, NC</td>
</tr>
<tr>
<td>7:40</td>
<td>PD63-05</td>
<td>GEOGRAPHIC VARIABILITY IN THIRD LINE OVERACTIVE BLADDER TREATMENT AVAILABILITY FOR MEDICARE PATIENTS</td>
<td>Erin Salter*, Gillian Wolff, Laura Chang Kit, Albany, NY</td>
</tr>
<tr>
<td>8:00</td>
<td>PD63-07</td>
<td>UNDERSTANDING OF PROGNOSIS IN NON-METASTATIC PROSTATE CANCER: A RANDOMISED COMPARATIVE STUDY OF CLINICIAN ESTIMATES AGAINST THE PREDICT PROSTATE TOOL</td>
<td>David Thurtle, Cambridge, United Kingdom, Valerie Jenkins, Brighton, United Kingdom, Paul Pharoah, Vincent Gnanapragasam*, Cambridge, United Kingdom</td>
</tr>
<tr>
<td>8:10</td>
<td>PD63-08</td>
<td>LOCALISED PROSTATE CANCER COMBINED CLINIC: A PROSPECTIVE MIXED METHODS PILOT STUDY OF MEN WITH LOCALISED PROSTATE CANCER CHOOSING BETWEEN ROBOTIC PROSTATECTOMY AND RADIOTherAPY TREATMENT</td>
<td>Sunny Nalavenkata*, Allman Smith, Orlando Rincones, Mark Sidhom, Pascal Mancuso, Karen Wong, Megan Berry, Dion Forstner, Leslie Bokey, Aif Girgis, Sydney, Australia</td>
</tr>
<tr>
<td>8:30</td>
<td>PD63-10</td>
<td>THE VALUE OF ACUPUNCTURE FOR REDUCING PERIOPERATIVE ANXIETY IN PATIENTS UNDERGOING TRANSETHRAL RESECTION OF BLADDER TUMOR: A PROSPECTIVE RANDOMIZED CONTROLLED STUDY</td>
<td>Sagi Shprits*, Gil Meyer, sare Halachmi, Nadav Stoppelman, David Avshalomov, Kochava Bilton, Samuel Atttes, Elad Schiff, Ofir Nativ, Haifa, Israel</td>
</tr>
<tr>
<td>8:50</td>
<td>PD63-12</td>
<td>SURVIVAL DISPARITY BY RACE IN RENAL CELL CARCINOMA PATIENTS</td>
<td>Brittany Adamic*, Alexander Cope, Kristine Kuchta, Craig Labbate, Joshua Aizen, Sangtane Park, Chicago, IL</td>
</tr>
</tbody>
</table>

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
**PROSTATE CANCER I**

The videos in this session as well as the video libraries from the 2012-2018 Annual Meetings may be viewed in the Surgical Video Library and purchased in the AUA Store during the Annual Meeting. AUA members receive free online access to the Surgical Video Library throughout the year through AUA University. Visit www.AUAnet.org/University to access.

Room W187b @ McCormick Place
Moderators: Isaac Kim, William Parker & Stephen Pautler

<table>
<thead>
<tr>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
</table>
| 7:00 | V11-01 | SALVAGE ROBOT-ASSISTED LAPAROSCOPIC PROSTATECTOMY: DOES PRIMARY TREATMENT MAKE A DIFFERENCE?  
  Fikret Onol*, Seetharam Bhat, Travis Rogers, Cathy Jenson, Shannon Roof, Vipul Patel, Celebration, FL |
| 7:10 | V11-02 | DYNAMIC UMBILICAL LIGAMENT ANASTOMOTIC SLING DURING RALRP: A PILOT STUDY  
  Gregory Joice*, Kevin Koo, Hiten Patel, Zeyad Schwen, Michael Gorin, Alan Partin, Mohamad Allaf, Baltimore, MD |
| 7:20 | V11-03 | INITIAL EXPERIENCE WITH DA VINCI SINGLE PORT (SP) ROBOT-ASSISTED RADICAL PROSTATECTOMIES  
| 7:30 | V11-04 | 3D ELASTIC AUGMENTED REALITY ROBOT-ASSISTED RADICAL PROSTATECTOMY: FURTHER EVOLUTION OF THE STANDARD PROCEDURE  
  Francesco Porpiglia*, Enrico Checucci, Daniele Amaparo, Alberto Piana, Gabriele Volpi, Pietro Piazzolla, Diego Manfrin, Cristian Fiori, Orbassano, Italy |
| 7:40 | V11-05 | STANDARDIZED AND SIMPLIFIED ROBOT-ASSISTED SUPER-EXTENDED FELVIC LYMPH NODE DISSECTION FOR PROSTATE CANCER: THE MONOBLOCK TECHNIQUE  
  Christoph Wuemschimmel, Pietro Grande*, Ajet Hyseni, Philipp Baumeister, Marco Moschini, Livio Mordasini, Agostino Mattei, Lucerne, Switzerland |
| 7:50 | V11-06 | SUBCUTANEOUS ABDOMINAL WALL LIFT GASLESS LAPAROSCOPIC RADICAL PROSTATECTOMY: INITIAL EXPERIENCE  
  Bin Xu, Shuqiu Chen, Jianping Wu, Lijie Zhang, Yiduo Wang, Ming Chen*, Nanjing, China, People’s Republic of |
| 8:00 | V11-07 | PROSTATIC ARTERY PRESERVATION (PAP): A NOVEL TECHNIQUE FOR ROBOTIC ASSISTED RADICAL PROSTATECTOMY  
  Keegan Zuk*, Halle Foss, Viraj Maniar, Andrew Radtke, Scott Johnson, Kenneth Jacobsohn, Milwaukee, WI |
| 8:10 | V11-08 | SUPER-EXTENDED ROBOTIC-ASSISTED RADICAL PROSTATECTOMY FOR LOCALLY ADVANCED PROSTATE CANCER  
  Paolo Dell’Oglio, Nicholas Brook, Aalst, Belgium, Filippo Turri, Pisa, Italy, Alessandro Larcher, Milan, Italy, Brendan Dias, Indraneel Banerjee, Melle, Belgium, Frederik D’Hondt, Peter Schatteman, Geert De Naeyer, Alexandre Mottrie*, Aalst, Belgium |
| 8:20 | V11-09 | MAGNETIC-ASSISTED ROBOTIC SURGERY TO FACILITATE REDUCED-PORT RADICAL PROSTATECTOMY  
  Ryan Steinberg*, Brett Johnson, Jeffrey Cadeddu, Dallas, TX |
| 8:30 | V11-10 | ANTERIOR RETZIUS SPARING TECHNIQUE FOR ROBOTIC ASSISTED RADICAL PROSTATECTOMY  
  Jonathan Noel*, Samer Jallad, Mark Liu, Netty Kinsella, Ramanathan Kasivisvanathan, Declan Cahill, London, United Kingdom |
| 8:40 | V11-11 | THE MICHL TECHNIQUE TO REDUCE THE INCIDENCE OF SYMPTOMATIC LYMPHOCELES FOLLOWING ROBOT ASSISTED RADICAL PROSTATECTOMY.PATHOPHYSIOLOGY, SURGICAL PROCEDURE, AND EARLY RESULTS OF A RANDOMISED TRIAL  
  Uwe Michl*, Alexander Haese, Markus Graefen, Hans Heinzer, Thomas Steuber, Georg Salomon, Lars Budäus, Derya Tilk, Tobias Maurer, Imke Thederan, Hartwig Hulan, Hamburg, Germany |
| 8:50 | V11-12 | THE DETRUSOR APRON SPARING HOOD (DASH) TECHNIQUE FOR ROBOT-ASSISTED RADICAL PROSTATECTOMY  
  Shivaram Cumarasamy*, Alberto Martini, Vinayak G Wagaskar, Nicholas Brown, Kenneth G Haines III, Ashutosh K Tewari, New York, NY |

*Presenting author
**AMERICAN SOCIETY FOR MEN’S HEALTH (ASMH)**  
*Room W194 @ McCormick Place*

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:30</td>
<td>BREAKFAST</td>
<td></td>
</tr>
<tr>
<td>8:00</td>
<td>BATTLE PLAN &amp; INTRODUCTION</td>
<td>Steven Kaplan, Bruce Kava, Allen Seftel</td>
</tr>
<tr>
<td>8:05</td>
<td>MAGNITUDE OF PROBLEM &amp; CURRENT LANDSCAPE</td>
<td>Charles Welliver</td>
</tr>
<tr>
<td>8:15</td>
<td>YOU TOOK CARE OF MY DRIBBLING BUT HOW ABOUT MY NOCTURIA?</td>
<td>Roger Dmochowski</td>
</tr>
<tr>
<td>8:25</td>
<td>CASE DISCUSSION: WELTER WEIGHT</td>
<td></td>
</tr>
<tr>
<td>8:30</td>
<td>MEDICAL THERAPY</td>
<td>J. Kellog Parsons</td>
</tr>
<tr>
<td>8:35</td>
<td>BIPOLAR TURP</td>
<td>Bilal Chugthai</td>
</tr>
<tr>
<td>8:40</td>
<td>UROLIFT</td>
<td>Claus Roehrborn</td>
</tr>
<tr>
<td>8:45</td>
<td>REZUM</td>
<td>Kevin McVary</td>
</tr>
<tr>
<td>8:50</td>
<td>AQUABLATION</td>
<td>Mitch Humphrey</td>
</tr>
<tr>
<td>8:55</td>
<td>QUESTIONS TO PANELISTS</td>
<td></td>
</tr>
<tr>
<td>9:00</td>
<td>VOTE FOR 3 SEMI-FINALISTS</td>
<td></td>
</tr>
<tr>
<td>9:05</td>
<td>WELTERWEIGHT ROUND 2</td>
<td></td>
</tr>
<tr>
<td>9:10</td>
<td>SEMI-FINALISTS MAKE THEIR FINAL CASE</td>
<td></td>
</tr>
<tr>
<td>9:15</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:20</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:25</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:35</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:40</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:45</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:50</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:55</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**AMERICAN BOARD OF UROLOGY TOWN HALL**  
*Room W193b @ McCormick Place*

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:30</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Moderated Poster Session 76**  
*Room W175ab @ McCormick Place*

<table>
<thead>
<tr>
<th>Abstract Number</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP76-01</td>
<td>IMMEDIATE POST-DONATION HYPERFILTRATION IS ASSOCIATED WITH DECREASED FUNCTIONAL RECOVERY IN LIVING KIDNEY DONORS</td>
<td>Joon Chae Na*, Min-Gee Yoon, Lee Dongu, Seoul, Korea, Republic of, Hyung Ho Lee, Goyang, Korea, Republic of, Young Eun Yoon, Kwang Hyun Kim, Woong Kyu Han, Seoul, Korea, Republic of</td>
</tr>
<tr>
<td>MP76-02</td>
<td>LATE EVEROLIMUS ADDITION CONCOMITANT WITH TACROLIMUS REDUCTION ON MAINTENANCE IMMUNOSUPPRESSANT FOR KIDNEY TRANSPLANT RECIPIENTS AMELIORATE PATHOLOGICAL FINDINGS AND GRAFT FUNCTION</td>
<td>Takeshi Ishimura*, Takahito Endo, Shun Nishioka, Naoki Yokoyama, Teruyuki Oda, Satoshi Ogawa, Masato Fujisawa, Kobe, Japan</td>
</tr>
</tbody>
</table>
MP76-03 KIDNEY GRAFT DAMAGE AFTER LONG COLD ISCHEMIA TIME IS ATTENUATED BY RECOMBINANT THROMBOMODULIN ALPHA IN A RAT KIDNEY TRANSPLANT MODEL
Satoshi Tamaki*, Kazunobu Shinoda, Masayuki Shimoda, Shinya Morita, Ryohei Takahashi, Soutaro Kitao, Nobuyuki Tanaka, Toshihiko Takeda, Kazuhiro Matsumoto, Takeo Kosaka, Ryuichi Mizuno, Toshiaki Shinohara, Eiji Kikuchi, Hiroshi Asanuma, Mototsugu Oya, Tokyo, Japan

MP76-04 RENOPROTECTIVE EFFECT OF CARBON MONOXIDE RELEASING MOLECULES IN RENAL ISCHEMIA REPERFUSION INJURY
Dae Keun Kim*, A Ra Jung, Jung Ki Jo, Seoul, Korea, Republic of; Hyung Ho Lee, Goyang, Korea, Republic of; Joon Chae Na, Woong Kyu Han, Sung Yul Park, Hong Sang Moon, Young Eun Yoon, Seoul, Korea, Republic of

MP76-05 MANIFESTATION OF SHORT-TERM AND LONG-TERM BLADDER DYSFUNCTION IN ADULT RENAL TRANSPLANT RECIPIENTS WITH NO PRE-EXISTING BLADDER OR THE OUTLET ABNORMALITY: NOT TO BE IGNORED
Sanjay Kumar Sureka*, Rahul Jena, Uday Pratap Singh, Aneesh Srivastava, Sanchit Rustagi, Lucknow, India

MP76-06 GENETIC PREDISPOSITION WITH REGARDS TO THE ROLE OF MMPs IN ALLOGRAFT REJECTIONS FOLLOWING RENAL TRANSPLANTATION
Aneesh Srivastava*, Narayan Prasad, Mansi Bhatt, Lucknow, India

MP76-07 RITUXIMAB INDUCTION THERAPY IS EFFECTIVE WITHOUT INCREASING ADVERSE EVENTS IN IMMUNOLOGICAL HIGH RISK RECIPIENTS
Kasumi Kawamura*, Motoo Araki, Yuki Maruyama, Yosuke Mitsui, Takuya Sadahira, Risa Kubota, Shingo Nishimura, Koichiro Wada, Yasuyuki Kobayashi, Toyohiko Watanabe, Yasutomo Nasu, Okayama, Japan

MP76-08 HYPOGONADISM IN MEN OF A KIDNEY TRANSPLANT WAITING LIST (KTWL). COMPARISON AND ASSESSMENT OF HORMONE PROFILE, QOL AND SEXUAL FUNCTION BETWEEN AGE MATCHED HYPOGONADIC AND NON-HYPOGONADIC MEN
Felipe Hirakaki*, Rogerio Sayao Filho, Ioannis Antonopoulos, Kleiton Yamaçake, Hideki Kanashiro, Affonso Piovesan, William Nahas, Sao Paulo, Brazil

MP76-09 REDUCTION IN EARLY HOSPITAL READMISSION FOR KIDNEY RECIPIENTS AT 1 YEAR AFTER STANDARDIZATION OF AN INTENSIVE FOLLOW-UP STRATEGY
Alice Crane*, Mohamed Eltemamy, Alvin Wee, Richard Fatica, Charles Modlin, Emilio Poggio, Venkatesh Krishnamurthi, Cleveland, OH

MP76-10 SHORT-TERM INFERIOR VENA CAVA PATENCY OUTCOMES FOR PATIENTS WITH RADICAL NEPHRECTOMY & TUMOR THROMBUS MANAGED WITH PRIMARY IVC CLOSURE
Kevan Iffrig, Dharam Kaushik, Hanzhang Wang, Michael Liss, Ahmed Mansour, Wasim Chowdhury, Ronald Rodriguez, Deepak Pruthi*, San Antonio, TX

MP76-11 DEVELOPMENT OF A ROBOTIC KIDNEY TRANSPLANTATION PROGRAM FROM DECEASED DONORS IN A REFERRAL ACADEMIC CENTRE: TECHNICAL NUANCES AND PRELIMINARY RESULTS
Riccardo Campi*, Graziano Vignolini, Francesco Sessa, Isabella Greco, Firenze, Italy, Aida Larti, Florence, Italy, Saviero Giancane, Arcangelo Sebastianelli, Mauro Gacci, Adriano Peris, Firenze, Italy, Alberto Breda, Barcellona, Spain, Giampaolo Siena, Vincenzo Li Marzi, Florence, Italy, Sergio Scemi, Firenze, Italy

MP76-12 ROBOT-ASSISTED KIDNEY TRANSPLANTATION IN THE OBESE: RESULT AT 2 YEARS OF THE FIRST FRENCH SERIES
Marine Lesourd*, Jean-Baptiste Beauval, Federico Battisti, Assaf Kamar, Michel Soulé, Xavier Gamé, Pascal Rischmann, Mathieu Roumiqüel, Nicolas Doumerc, Toulouse, France

MP76-13 PROSPECTIVE PROPENSITY MATCHED NON-RANDOMIZED COMPARISON BETWEEN OPEN AND ROBOT ASSISTED KIDNEY TRANSPLANTATION
Anant Kumar*, Noida, India, Ruchir Maheshwari, Samit Chaturvedi, Yasir Qadri, Delhi, India

MP76-14 PROSPECTIVE COMPARATIVE STUDY ON ROBOT-ASSISTED VS OPEN KIDNEY TRANSPLANTATION: TREND TO LESS PERIOPERATIVE INFLAMMATORY RESPONSE AND SIMILAR FUNCTIONAL RESULTS
Angelo Territo*, Jose Daniel Subiela, Barcelona, Spain, Gerit Theil, Halle, Germany, Lluis Gausa, Giuseppe Basile, Federica Regis, Barcelona, Spain, Romain Boissier, Marseille, France, Mohammed Nasredin, Halle, Germany, Andrea Gallioli, Barcelona, Spain, Paolo Formaro, Halle, Germany, Lluis Guirado, Alberto Breda, Barcelona, Spain

MP76-15 ROBOT-ASSISTED KIDNEY AUTOTRANSPLANTATION (RAKAT): UPDATE FROM THE FIRST SERIES IN EUROPE.
Benjamin Van Parys*, Jeroen Van Besien, Ghent, Belgium, Nicolas Doumerc, Toulouse, France, Liesbeth Desender, Caren Randen, Frederik De Ryck, Thomas Tailly, Matthias Beysens, Carl Van Haute, Ghent, Belgium, Diederik Ponette, Ostend, Belgium, Kathia De Man, Piet Hoebeke, Frank Vermassen, Karel Decaesstecker, Ghent, Belgium

*Presenting author
DUAL KIDNEY TRANSPLANTATION: WHICH TECHNIC TO USE?
Lionel Mendel*, Imad Bentellis, Thierry Yandza, Laetitia Albano, Jean Amiel, Daniel Chevallier, Matthieu Durand, Nice, France

OPTIMIZATION OF KIDNEY DECELLULARIZATION METHODS UTILIZING A QUANTITATIVE VASCULAR CASTING TECHNIQUE FOR LONG-TERM IMPLANTATION
Joao Zambon, In Kap Ko, Mehran Abolbashari, Jennifer Huling, Tae Hyoun Kim, John Jackson*, James Yoo, Anthony Atala, Winston Salem, NC

INCIDENCE OF ACUTE PROSTATITIS IN RENAL TRANSPLANT RECIPIENTS AFTER TRANSRECTAL ULTRASOUND (TRUS)-GUIDED PROSTATE BIOPSY
ROGERIO SAYAO*, FRANCISCO BATISTA JUNIOR, WILLIAM NAHAS, AFFONSO PIOVESAN, FELIPE HIRASAKI, ALEXANDRE BULL, GUSTAVO MESSI, GUSTAVO EBAID, HIDEKI KANASHIRO, IOANNIS ANTONOPOULOS, RENATO FALCI JUNIOR, SAO PAULO, Brazil

ONE IN THE SAME? THE HISTOPATHOLOGICAL DIFFERENCES IN RADICAL VS DONOR NEPHRECTOMY SPECIMENS
Deepak Pruthi*, San Antonio, TX, Vivian Lu, Winnipeg, Canada, Jonathan Gelfond, San Antonio, TX, Ian Gibson, Winnipeg, Canada, Thomas McGregor, Kingston, Canada

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
**MP77-05** GAS-FORMING URINARY TRACT INFECTIONS: BACTERIOLOGY AND ANTIMICROBIAL SUSCEPTIBILITY. 144 CASES 5-YEAR-EXPERIENCE
Jose Arrambide Herrera*, Lauro Gomez Guerra, Rodrigo Romero Mata, Pedro Madero Morales, Ivan Robles Torres, Monterrey, Mexico

**MP77-06** POSTOPERATIVE URINARY TRACT INFECTION: TIMING AND UROPATHOGENS
Kelly Bree*, Carrie Jung, Linda Brubaker, San Diego, CA

**MP77-07** FLEXIBLE CYSTOSCOPY FOR URERETAL STENT REMOVAL WITHOUT ANTIMICROBIAL PROPHYLAXIS. A PROSPECTIVE OBSERVATIONAL STUDY.
Alberto Olivero*, Niccolò Ricciardi, Drilona Ndrevataj, Federica Balzarini, Mattia Cerasuolo, Paolo Bottino, Ferdinando Dodi, Carlo Terrrone, Genoa, Italy

**MP77-08** VANIN-1, A NOVEL ACUTE KIDNEY INJURY MARKER, IS A USEFUL BIOMARKER FOR ADULT UPPER URINARY TRACT OBSTRUCTION-INDUCED KIDNEY INJURY
Satoshi Washino*, Saitama, Japan, Keiko Hosohata, Osaka, Japan, Masashi Oshima, Tsuzumi Konishi, Kimitoshi Saito, Tomoaki Miyagawa, Saitama, Japan

**MP77-09** RISK FACTORS ASSOCIATED WITH INFECTION-RELATED HOSPITALIZATION FOLLOWING URETEROSCOPIC STONE TREATMENT ACROSS DIVERSE UROLOGY PRACTICES IN MICHIGAN
Adam Cole*, Jaya Telang, Tae Kim, Kavya Swarna, Anna Johnson, Ji Qi, Ann Arbor, MI, Brian Seifman, Troy, MI, Jason Wynberg, Detroit, MI, John Hollingsworth, William Roberts, Casey Dawu, Khurshid Ghani, for the Michigan Urological Surgery Improvement Collaborative, Ann Arbor, MI

**MP77-10** PROGRESSION AND FORMATION OF BACTERIAL BIOFILMS ON INDWELLING URINARY CATHETERS OVER TIME
Glenn T. Werneburg*, Shaker Heights, OH, Anh Nguyen, Nadine Henderson, Stony Brook, NY, Amanda Le Sueur, Anthony Corcoran, Aaron Katz, Mineola, NY, Jason Kim, Annie Rohan, David G. Thanassi, Stony Brook, NY

**MP77-11** IMPACT OF A LONG-TERM ANTIBIOTIC PROPHYLAXIS ON THE BLADDER COLONISATION BY E. COLI IN CLEAN INTERMITTENT SELF-CATHETERISATION PATIENTS
Maxime Vallée*, Catherine Mowbray, Holly Fisher, Aaron Ming Zhi Tan, Christopher Harding, Judith Hall, Phillip Aldridge, Newcastle upon Tyne, United Kingdom

**MP77-12** THE EFFECTS OF INTERVENTION BY A DEDICATED UROLOGY TEAM ON REDUCTION OF CATHETER ASSOCIATED URINARY TRACT INFECTIONS, MORBIDITY AND MORTALITY IN HOSPITALIZED PATIENTS
Omer Sadeh*, Valentin Shabataev, Shay Ram, Michal Paul, Gilad E. Amiel, Haifa, Israel

**MP77-13** PREOPERATIVE OUTPATIENT ANTIBIOTICS INCREASE RISK OF POSTOPERATIVE INFECTION IN PATIENTS UNDERGOING RADICAL CYSTECTOMY FOR BLADDER CANCER
Craig Labbate*, Chicago, IL, Kristine Kuchta, Evanston, IL, Brittany Adamic, Joshua Alzen, Ryan Werntz, Chicago, IL, Norm Smith, Evanston, IL

**MP77-14** COST AND UTI RATE FOLLOWING OFFICE CYSTOSCOPY BEFORE AND AFTER IMPLEMENTING NEW STANDARDIZED HANDLING AND STORAGE PRACTICES
Vincent Roth*, Pedro Espino-Grosso, Carl Henriksen, Benjamin Canales, Gainesville, FL

**MP77-15** URINE VS. URERETAL STENT CULTURES DURING URERETAL STENT REMOVAL
Bijan Salari*, Muhamad Khalid, Samuel Ivan, Puneet Sindhwani, Toledo, OH

**MP77-16** MYO-INOSITOL OXYGENASE PROMOTES FERROPTOSIS IN CISPLATIN-INDUCED NEPHROPATHY
Fei Deng*, Changsha, China, People’s Republic of, Yingbo Dai, Zhuhai, China, People’s Republic of, Isha Sharma, Yashpal S Kanwar, Chicago, IL

**MP77-17** ADMISSION RATES, HEALTHCARE UTILIZATION, AND ECONOMIC BURDEN OF RADIATION CYSTITIS (RC) IN THE UNITED STATES
Sohrab Arora*, Akshay Sood, Deepansh Dalela, Alex Borchert, Lee Baumgartner, Detroit, MI, Quoc-Dien Trinh, Boston, MA, Craig G. Rogers, James O. Peabody, Mani Menon, Firas Abdollah, Detroit, MI

**MP77-18** DEFINITIVE SURGICAL MANAGEMENT FOR INTRACTABLE RADIATION CYSTITIS
Isamu Tachibana*, Zain A Abedali, Ronald Boris, Indianapolis, IN

**MP77-19** DEVELOPMENT OF RADIATION CYSTITIS BIOMARKER: ELEVATED FIBROTIC MARKERS IN URINE OF RADIATION CYSTITIS PATIENTS
Bernadette M.M. Zwaans*, Royal Oak, MI, Heinz E. Nicholai, Santiago, Chile, Klaudia Stangel-Wójcikiewicz, Krakow, Poland, Michael B. Chancellor, Laura E. Lamb, Royal Oak, MI

*Presenting author
**MP77-20** GRADE 2+ BLADDER TOXICITY IN PATIENTS RECEIVING SBRT FOR PROSTATE CANCER: INCIDENCE AND DOSIMETRIC CHARACTERIZATION IN A LARGE PATIENT COHORT


---

### Moderated Poster Session 78

**PROSTATE CANCER: LOCALIZED: ABLATIVE THERAPY**

**MONDAY, MAY 6, 2019**

**Moderated Poster Session 78**

**PROSTATE CANCER: LOCALIZED: ABLATIVE THERAPY**

**Room W180 @ McCormick Place**

**Moderators: Aaron Katz, Joseph Chin & Mark Katz**

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP78-01</td>
<td>SAFETY PROFILE OF OFFICE BASED MR/US FUSION CRYOABLATION: A MULTI-CENTER ASSESSMENT</td>
</tr>
<tr>
<td>MP78-02</td>
<td>PREDICTORS OF BIOCHEMICAL RECURRENCE AFTER PRIMARY WHOLE GLAND CRYOTHERAPY FOR PROSTATE CANCER</td>
</tr>
<tr>
<td>MP78-03</td>
<td>TUMOR CONTROL OUTCOMES OF SALVAGE CRYOTHERAPY FOR RADIORECURRENT PROSTATE CANCER AT MEDIAN 12 YEARS FOLLOW-UP.</td>
</tr>
<tr>
<td>MP78-04</td>
<td>PREDICTING PROSTATE CANCER FOCAL THERAPY ELIGIBILITY WITH MACHINE LEARNING</td>
</tr>
<tr>
<td>MP78-05</td>
<td>MEDIUM TERM ONCOLOGICAL OUTCOMES IN A LARGE COHORT OF MEN TREATED WITH EITHER FOCAL- OR HEMI-ABALTION WITH HIFU FOR PRIMARY LOCALIZED PROSTATE CANCER</td>
</tr>
<tr>
<td>MP78-06</td>
<td>MEDIAN 5-YEAR ONCOLOGICAL OUTCOMES OF SALVAGE HIGH INTENSITY FOCUSED ULTRASOUND FOR PROSTATE CANCER RECURRENCES AFTER PRIMARY RADIOTHERAPY.</td>
</tr>
<tr>
<td>MP78-07</td>
<td>DO CONTEMPORARY IMAGING AND BIOPSY TECHNIQUES RELIABLY IDENTIFY UNILATERAL PROSTATE CANCER? IMPLICATIONS FOR HEMIABLA TION PATIENT SELECTION</td>
</tr>
</tbody>
</table>

---

**APPROVED FOR AMA PRA CATEGORY 1 CREDIT™**

**Monday, May 6, 2019 9:30 am - 11:30 am**

MP78-08 PREDICTIVE FACTORS OF FAILURE FOLLOWING FOCAL THERAPY FOR PROSTATE CANCER
Rafael R Tourinho-Barbosa*, Rafael Sanchez-Salas, Sylvain Collura-Merlier, Fabio Muttin, Armas Bakavicuicis, Eric Barret, Francois Rozet, Paris, France, Arie Carneiro, Sao Paulo, Brazil, Nathalie Cathala, Dominique Prapotnich, Annick Mombet, Paris, France, Marcus Tobias-Machado, Santo Andre, Brazil, Xavier Cathelineau, Paris, France

MP78-09 FOCAL CRYOABLATION IS ASSOCIATED WITH IMPROVED PATHOLOGICAL PROGRESSION-FREE COMPARED TO ACTIVE SURVEILLANCE IN GLEASON 6 PROSTATE CANCER

MP78-10 A COMPARISON OF CANCER CONTROL OUTCOMES AT 5 YEARS OF FOCAL THERAPY (USING HIFU & CRYOTHERAPY) TO RADICAL PROSTATECTOMY FOR CLINICALLY SIGNIFICANT NON-METASTATIC PROSTATE CANCER: PROPENSITY SCORE-MATCHED ANALYSIS
Taimur T. Shah, LONDON, United Kingdom, Max Peters, Utrecht, Netherlands, Deepika Reddy*, Daniel Ball, Annie Kim, London, United Kingdom, Enrique Gomez Gomez, Cordoba, Spain, Saiful Miah, David Eldred-Evans, Stephanie Guillamier, Feargus Hosking-Jervis, LONDON, United Kingdom, Peter S.N. van Rossum, Utrecht, Netherlands, Tim Duddridge, Southampton, United Kingdom, Richard Hindley, Basingstoke, United Kingdom, Stuart McCracken, Damian Greene, Sunderland, United Kingdom, Raj Nigam, Guildford, United Kingdom, Massimo Valerio, Lausanne, Switzerland, Suks Minhas, London, United Kingdom, Naveed Afzal, Dorchester, United Kingdom, Henry Lewi, Chelmsford, United Kingdom, Neil McCartan, Chris Ogden, London, United Kingdom, Raj Persad, Bristol, United Kingdom, Jaspal Virdi, Harlow, United Kingdom, Caroline Moore, Manit Arya, Mark Emberton, Hashim U. Ahmed, Mathias Winkler, London, United Kingdom

MP78-11 RANDOMIZED CONTROL TRIAL COMPARING FOCAL PROSTATE ABLATION AND RADICAL PROSTATECTOMY IN PATIENTS WITH INTERMEDIATE RISK PROSTATE CANCER. INITIAL EXPERIENCES.
Eduard Baco*, Ljiljana Vlatkovic, Erik Rud, Oslo, Norway

MP78-12 ROBOTIC ASSISTED RADICAL PROSTATECTOMY AFTER FOCAL THERAPY: ONCOLOGICAL AND FUNCTIONAL OUTCOMES

MP78-13 ALL SALVAGE ROBOTIC RADICAL PROSTATECTOMIES ARE NOT CREATED EQUAL: COMPARISON OF FUNCTIONAL AND PERIOPERATIVE OUTCOMES ON POST FOCAL THERAPY VS. POST RADIOTHERAPY PATIENTS
Lorenzo Marconi*, Thomas Stonier, London, United Kingdom, Rafael Tourinho-Barbosa, Xavier Cathelineau, Paris, France, Ben Challacombe, Prokar Dasgupta, Rick Popert, London, United Kingdom, Sanchez-Salas Rafael, Paris, France, Declan Murphy, Melbourne, Australia, Paul Cathcart, London, United Kingdom

MP78-14 SITE OF DISEASE RECURRENCE FOLLOWING PROSTATE FOCAL THERAPY PREDICTS ONCOLOGICAL OUTCOME AFTER SALVAGE ROBOTIC ASSISTED RADICAL PROSTATECTOMY

MP78-15 CONCOMITANT FOCAL THERAPY AND ROBOTIC LYMPHADENECTOMY IN PROSTATE CANCER: INITIAL SERIES

MP78-16 SALVAGE POSSIBILITIES AFTER FOCAL THERAPY FAILURE: REDO FOCAL TREATMENT VERSUS ROBOTIC RADICAL PROSTATECTOMY ANALYSIS
Rafael R Tourinho-Barbosa*, Caio PD Santos, Oliver R Claros, Armas Bakavicuicis, Eric Barret, Francois Rozet, Paris, France, Arie Carneiro, Sao Paulo, Brazil, Nathalie Cathala, Dominique Prapotnich, Annick Mombet, Rafael Sanchez-Salas, Xavier Cathelineau, Paris, France

MP78-17 A PHASE II STUDY TO EVALUATE OUTPATIENT, TRANSRECTALLY-DELIVERED, MRI-GUIDED LASER FOCAL THERAPY OF PROSTATE CANCER: 9 YEAR INTERIM RESULTS (NCT 02243033)
John Feller*, Bernadette Greenwood, Steven Gunberg, Jeffrey Hertz, Wesley Jones, Indian Wells, CA, Robert Toth, Parlin, NJ
MP78-18 LONG TERM ONCOLOGICAL OUTCOMES OF CRYOABLATION AND HIFU IN WHOLE GLAND AND FIRST LINE TREATMENT FOR LOCALIZED PROSTATE CANCER
Romain Boissier*, Marseille, France, Federica Regis, Barcelona, Spain, Kevin Loverde, Marseille, France, Angelo Territo, Barcelona, Spain, Harry Toledano, Marseille, France, Andrea Gallioli, Barcelona, Spain, Cyril Bastide, Cyril Bastide, Dominique Rossi, Marseille, France, Alberto Breda, Joan Palou, Barcelona, Spain

MP78-19 A CONTEMPORARY SYSTEMATIC REVIEW OF PARTIAL PROSTATE GLAND ABLATION OUTCOMES: A COMPARATIVE STUDY OF THERMAL VERSUS NON-THERMAL TECHNOLOGIES
Jonathan Fainberg*, Stamford, CT, Bashir Al Hussein Al Awamleh, Antonio Primo de Rosa, Gregory Chesnut, Taehyoung Lee, Behfar Ehdai, New York, NY

MP78-20 PREDICTING PATHOLOGIC TUMOR SIZE IN PROSTATE CANCER BASED ON MULTIPARAMETRIC PROSTATE MRI AND PREOPERATIVE FINDINGS.

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Monday, May 6, 2019 9:30 am - 11:30 am

Moderated Poster Session 79
STONE DISEASE: SURGICAL THERAPY VI
Room W17bab @ McCormick Place
Moderators: Jodi Antonelli, Fabio Vicentini & Jens Rassweiler

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP79-01</td>
<td>COMPARING MICRO-PERCUTANEOUS NEPHROLITHOTOMY AND FLEXIBLE URETEROSCOPIC LITHOTRIPSY IN TREATING 1-2 CM SOLITARY RENAL STONES IN INFANTS</td>
</tr>
</tbody>
</table>
wenying wang*, Jun Li, beijing, China, People’s Republic of China |

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP79-02</td>
<td>PCNL: A SAFE ALTERNATIVE TO GUIDELINE RECOMMENDATIONS FOR STONES LESS THAN 1CM</td>
</tr>
</tbody>
</table>
David Bayne*, Manuel Armas-Phan, Scott Wiener, SAN FRANCISCO, CA, Weiguo Hu, Bo Xiao, Boxing Su, Wonjie Bai, Beijing, China, People’s Republic of, Marshall Stoller, Tom Chi, SAN FRANCISCO, CA, Jianxing Li, Beijing, China, People’s Republic of China |

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP79-03</td>
<td>PERCUTANEOUS NEPHROLITHOTOMY IN KIDNEYS WITH IMPAIRED RENAL FUNCTION: RECOVERABILITY ASSESSMENT USING DIURETIC SCINTIGRAPHY</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP79-04</td>
<td>AN OBSERVATIONAL 1-YEAR FOLLOW-UP STUDY ABOUT PERIOPERATIVE RENAL FUNCTIONAL OUTCOMES ASSESSED BY 99MTC-DTPA SCINTIGRAPHY AFTER MINIMALLY INVASIVE KIDNEY STONE SURGERY</td>
</tr>
</tbody>
</table>
Jae Hyun Jung*, Sangjun You, Juhyun Park, Min Chul Cho, Hwancheol Son, Hyeon Jeong, Sung Yong Cho, Jungyo Suh, Seoul, Korea, Republic of Korea |

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP79-05</td>
<td>ENHANCED SUPER MINI-PCNL (ESMP): LOW PRESSURE IN RENAL PELVIC AND HIGH EFFICACY IN STONE EXTRACTION</td>
</tr>
</tbody>
</table>
Wen Zhong*, Guohua Zeng, Guangzhou, China, People’s Republic of China |

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP79-06</td>
<td>COMPARISON OF NEPHROSTOMY TECHNIQUES IN THE PORCINE KIDNEY: RETROGRADE LASER ENDOSCOPIC X-RAY-GUIDED INTRARENAL TRACT (LEXIT) VERSUS RETROGRADE LAWSON ROCKET WIRE ACCESS VERSUS STANDARD NEPHROSTOMY NEEDLE ANTEGRADE ACCESS</td>
</tr>
</tbody>
</table>
Kamaljot Kaler*, Calgary, Canada, Vinay Cooper, Mitchell O’Leary, Zachary Valley, Thomas Lee, Roshan Patel, Jaime Landman, Ralph Clayman, Orange, CA |
MP79-07 RETROGRADE INTRARENAL SURGERY IN THE TREATMENT OF LOWER POLE STONES: IS A BETTER CLINICAL SCENARIO FOR USING SINGLE-USE FLEXIBLE URETEROSCOPY? RESULTS OF A PROSPECTIVE CASE - CONTROL STUDY.
José Salvadó*, Rodrigo Sanchez, José Cabello, Renato Cabello, Sergio Moreno, Álvaro Kompatski, Ruben Olivares, Alfredo Velasco, Santiago, Chile

MP79-08 COMPARISON OF CLINICAL OUTCOMES WITH THE USE OF TWO TYPES OF DIGITAL DISPOSABLE FLEXIBLE URETEROSCOPIES (BOSTON SCIENTIFIC LITHOVUE VERSUS PUSEN USCOPE 3022), A PROSPECTIVE STUDY
José Salvadó*, Rodrigo Sanchez, José Cabello, Renato Cabello, Sergio Moreno, Álvaro Kompatski, Ruben Olivares, Alfredo Velasco, Santiago, Chile

MP79-09 CRITICAL ASSESSMENT OF SINGLE-USE URETEROSCOPIES IN AN IN VIVO PORCINE MODEL
Seth Bechis*, San Diego, CA, Amy Krambeck, Indianapolis, IN, Roger Sur, San Diego, CA, Brian Matlaga, Baltimore, MD

MP79-10 URINARY STONE TREATMENT. TWENTY ONE YEARS TRENDS IN A LATIN AMERICAN HIGH VOLUME CENTER
Mariano González*, Christian Cristallo, Federico Tirapegui, Ignacio Toba Gonzalez, Francisco Daels, Buenos Aires, Argentina

MP79-11 ULTRASOUND-GUIDED PERCUTANEOUS NEPHROLITHOTOMY: TOTAL VERSUS PARTIAL FLUOROSCOPY-FREE
Yanbo Wang*, Yuchuan Hou, Chunxi Wang, Changchun, China, People’s Republic of

MP79-12 TO INVESTIGATE THE CLINICAL EFFICACY OF TRANURETHRAL URETEROSCOPIC LASER LITHOTripsY IN THE TREATMENT OF URETERAL CALCULI UNDER ULTRASOUND GUIDED PARAVERTERBAL NERVE BLOCK ANESTHESIA
Yue Wu*, Yunpeng Zhu, Yang Xun, Wuhan, China, People’s Republic of, Shaogang Wang, Whhan, China, People’s Republic of

MP79-13 ANALYSIS OF URETERAL STENTS ENCRRUSTATION AND BIOFIlM FORMATION AFTER 3-WEEK DWELL TIME: RESULTS OF A PROSPECTIVE RANDOMIZED MULTICENTRE CLINICAL COMPARATIVE STUDY OF SILICONE HYDROCOATED (IMAJIN® HYDRO) VERSUS PERCUFLEX™ PLUS
Oliver Wiseman, Cambridge, United Kingdom, Julien Letendre, Montreal, Canada, Jonathan Cloutier, Quebec, Canada, Michel Daudon, Paris, France, Francois Kleinclauss, Besancon, France, Steeve Doizi, Olivier Traxer, Paris, France, Oliver Wiseman*, Cambridge, United Kingdom

MP79-14 RISK FACTORS OF SYSTEMIC INFLAMMATORY RESPONSE SYNDROME FOLLOWING RETROGRADE INTRARENAL SURGERY IN PATIENTS WITH UROLITHIASIS
Wen Zhong*, Guohua Zeng, Guangzhou, China, People’s Republic of

MP79-15 THE IMPACT OF LASER PULSE TYPE ON TEMPERATURE CHANGES DURING URETEROSCOPIC LASER LITHOTripsY
Brenton Winship*, Daniel Wollin, Evan Carlos, Chloe Peters, Durham, NC, Jinggu Li, Singapore, Singapore, Russell Terry, Kohldon Boydston, Glenn Preminger, Michael Lipkin, Durham, NC

MP79-16 SUPER PULSE THULIUM FIBER LASER COMPARED TO 120W HOLMIUM:YAG LASER: IMPACT ON RETROPULSION AND LASER FIBER BURN BACK
Bodo Knudsen*, Columbus, OH, Ben Chew, Vancouver, Canada, Wilson Molina, Kansas City, KS

MP79-17 THE IMPACT OF INTRAOPERATIVE KETOROLAC ON OVERALL NARCOTIC REQUIREMENTS IN PATIENTS UNDERGOING URETEROSCOPY: A RANDOMIZED, CONTROLLED TRIAL
Jamil Syed, Matthew Goliand-Van Ryn*, Jonathan Huang, Piruz Motamedinia, New Haven, CT

MP79-18 INFLUENCE OF INFUNDIBULOPELVIC ANGLE (IPA) ON SUCCESS OF RETROGRADE FLEXIBLE URETEROSCOPY AND LASER LITHOTripsY FOR TREATMENT OF RENAL STONES
Stephanie Dresner*, Viacheslav Iremashvili, Sara Best, Sean Hedican, Stephen Nakada, Madison, WI

MP79-19 COMPARISON OF DUSTING AND FRAGMENTING USING THE NEW SUPER PULSE THULIUM FIBER LASER TO A 120W HOLMIUM:YAG LASER.

MP79-20 AVOIDING A LEMON: PERFORMANCE CONSISTENCY OF SINGLE-USE URETEROSCOPIES
Brenton Winship*, Daniel Wollin, Evan Carlos, Durham, NC, Jinggu Li, Singapore, Singapore, Russell Terry, Kohldon Boydston, Glenn Preminger, Michael Lipkin, Durham, NC

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP80-02</td>
<td>DERIVATION AND VALIDATION OF TEXT SEARCH ALGORITHMS FOR RENAL AND ADRENAL LESION IDENTIFICATION IN RADIOLOGY TEXT REPORTS Luke Lavallee, Christopher Knee, James Ross*, Johnathan Lau, Nikhilie Mookerje, Carl van Walraven, Ottawa, Canada</td>
</tr>
<tr>
<td>MP80-03</td>
<td>STAGING ACCURACY OF VESICAL IMAGING-REPORTING AND DATA SYSTEM (VI-RADS) FOR BLADDER CANCER Soichiro Yoshida*, Hiroshi Tanaka, Toshiki Kijima, Minato Yokoyama, Junichiro Ishioka, Yoh Matsuoka, Kazutaka Saito, Yasuhisa Fujii, Tokyo, Japan</td>
</tr>
<tr>
<td>MP80-05</td>
<td>PSA LEVEL PREDICTS POSITIVITY OF 18F-FLUCICLOVINE PET/CT IN PATIENTS WITH BIOCHEMICALLY RECURRENT PROSTATE CANCER Nirajan Sathanathan*, Mehmet Genturk, Ali Salavati, Badrinath Konety, Jerry Froelich, Minneapolis, MN</td>
</tr>
<tr>
<td>MP80-06</td>
<td>* GA-PSMA PET-CT AND MULTI-FREQUENCY-BAND RASTER-SCAN OPTOACOUSTIC MEOSCOPY AS IMAGING METHODS FOR RELAPSE DETECTION AND SUCCESS PREDICTION OF VASCULAR TARGETED PHOTODYNAMIC THERAPY IN A PROSTATE CANCER MODEL Ricardo Alvim*, Katja Haedicke, Karan Nagar, Sudeep Das, Alexander Somma, Christopher Hughes, New York, NY, Avigdor Scherz, Rehovot, Israel, Kwanghee Kim, Jan Grimm, Jonathan Coleman, New York, NY</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP80-07</td>
<td>USEFULNESS OF APPARENT DIFFUSION COEFFICIENT RATIO BETWEEN TUMOR AND NONTUMOR AS AN IMAGING BIOMARKER FOR PROSTATE CANCER Yoh Matsuoka*, Hiroshi Tanaka, Tomo Kimura, Shingo Moriyama, Sho Uehara, Yosuke Yasuda, Toshiki Kijima, Soichiro Yoshida, Minato Yokoyama, Junichiro Ishioka, Kazutaka Saito, Yasuhisa Fujii, Tokyo, Japan</td>
</tr>
<tr>
<td>MP80-08</td>
<td>RATES OF PATHOLOGIC UPGRADING ON FIRST MRI-GUIDED FUSION BIOPSY IN MEN ON ACTIVE SURVEILLANCE FOR PROSTATE CANCER Nina Mikkilineni*, Vinson Wang, Gen Li, Sven Wenske, New York, NY</td>
</tr>
<tr>
<td>MP80-09</td>
<td>MINIMAL RESIDUAL MEMBRANOUS URETHRAL LENGTH AND MEMBRANOUS URETHRAL LENGTH CAN BE PREDICTIVE FACTORS FOR POOR RECOVERY FROM INCONTINENCE AFTER RADICAL PROSTATECTOMY Eiichiro Ohara*, Naoki Kawamorita, Sendai, j ohan, Hideo Saito, Shigeto Ishidoya, Sendai, j ohan, Yoichi Arai, Natori, j ohan</td>
</tr>
<tr>
<td>MP80-10</td>
<td>CT-BASED SHAPE AND TEXTURE METRICS INDEPENDENTLY DISCRIMINATE BENIGN FROM MALIGNANT RENAL MASSES Felix Yap*, Aliasger Shakir, Bino Varghese, Steven Cen, Darryl Hwang, Christopher Lau, Lindsay Yang, Derek Liu, Marielena Rivas, Passant Mohamed, Xiaomeng Lei, Manju Aron, Mihir Desai, Inderbir Gill, Vinay Duddalwar, Los Angeles, CA</td>
</tr>
<tr>
<td>MP80-11</td>
<td>MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING IDENTIFIES CLEAR CELL RENAL CELL CARCINOMA WITH GREATER ACCURACY IN HIGHER STAGE LESIONS Ryan Steinberg*, Brett Johnson, Ivan Pedrosa, Jeffrey Cadeddu, Dallas, TX</td>
</tr>
</tbody>
</table>
| MP80-12         | GREAT CLINICAL VALUE OF (68)GA-PSMA PET-CT IMAGING FOR CLEAR CELL RENAL CELL CARCINOMA Chengwei Zhang*, Xiaozhi Zhao, Feng Wang, Hongqian Guo, Nanjing, China, People’s Republic of
MP80-13 ANATOMICALLY ACCURATE OF 3D PRINTED PATIENT-SPECIFIC KIDNEY MODELS USED FOR ROBOT-ASSISTED PARTIAL NEPHRECTOMY PREOPERATIVE PLANNING (UROCCR STUDY N° 39 : 3D-PRINT)
Clement Michiels*, Eva Jambon, Joffrey Sarrazin, Chrystelle Lefkague, Astrid Bourelange de Hauteclercq, Gregoire Capon, Henri Bensadoun, Gregoire Robert, Jean-Marie Ferriere, Frederic Bos, Nicolas Grenier, Jean-Christophe Bernhard, Bordeaux, France

MP80-14 ONCOLOGIC IMAGING IN PATIENTS WITH CLEAR CELL RENAL CELL CARCINOMA TREATED WITH TARGETED THERAPY: ASSESSING THE ROLE OF NON-TARGET DISEASE AND NEW LESIONS AS DEFINED BY RECIST 1.1 IN DETERMINING RADILOGICAL PROGRESSION

MP80-15 PREDICTORS OF RENAL ANGIOEMBOLIZATION OUTCOME: A RETROSPECTIVE ANALYSIS WITH 202 PATIENTS

MP80-16 PERCUTANEOUS RENAL TRACT DILATION CAN BE SAFELY GUIDED UNDER ULTRASOUND IMAGING
Manuel Armas-Phan*, David Tzou, David Bayne, Scott Wiener, Tim Liang, Marshall Stoller, Tom Chi; San Francisco, CA

MP80-17 A PROSPECTIVE RANDOMIZED STUDY ASSESSING THE SAFETY AND EFFICACY OF TOTALLY ULTRASOUND GUIDED PERCUTANEOUS NEPHROLITHOTOMY V/S COMBINED ULTRASOUND AND FLUOROSCOPY GUIDED PERCUTANEOUS NEPHROLITHOTOMY V/S COMPLETELY FLUOROSCOPY GUIDED PERCUTANEOUS NEPHROLIT
Satyajeet Pattnaik*, PRASHANT KUMAR PATTNNAIK, Mumbai, India

MP80-18 A RETROSPECTIVE AUDIT EVALUATING THE RADIATION EXPOSURE DURING CT KUB AT TWO SITES OF THE NATIONAL HEALTH SERVICES (NHS) TRUST IN THE UNITED KINGDOM- ARE PATIENTS BEING SUBJECTED TO OVER-RADIATION?
Karlisa Crooks*, Victoria Durajaiye, Ben Horsburgh, Epsom, United Kingdom

MP80-19 DEVELOPMENT AND IMPLEMENTATION OF COMPETENCY-BASED ASSESSMENT FOR UROLOGICAL ULTRASOUND TRAINING USING HUMAN MODELS AND SONOSIM TESTING

MP80-20 RACIAL DISPARITIES IN AXIAL IMAGING UTILIZATION ACROSS THE PENNSYLVANIA UROLOGIC REGIONAL COLLABORATIVE (PURC).

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Monday, May 6, 2019
Moderated Poster Session 81
9:30 am - 11:30 am
PROSTATE CANCER: BASIC RESEARCH & PATHOPHYSIOLOGY III
Room W179a @ McCormick Place
Moderators: Christopher Barbieri & David Jarrard

ABSTRACT NUMBER TITLE
MP80-01 MICROVASCULATURE ON CHIP: CANCER CELLS EXTRAVASATION IN VITRO MODELING
Marta De Menna*, Elisa Rodrigues Sousa, Federico La Manna, Soheila Zeinali, Olivier Guenat, Marianna Kruthof-de Julio, George N. Thalmann, Bern, Switzerland

ABSTRACT NUMBER TITLE
MP80-02 LARGE, LOCALLY ADVANCED TUMOR PROGRESSION IN TWO PTEN/TRP53 DOUBLE KNOCKOUT (DKO) MOUSE MODELS MONITORED WITH BIOLUMINESCENCE IMAGING (BLI)
Courtney Yong*, Devon Moose, Nadine Bannick, Marion Vanneste, James A. Brown, Iowa City, IA, Michael B. Cohen, Winston-Salem, NC, Michael D. Henry, Iowa City, IA

*Presenting author
MP81-03 THE ROLE OF SPOP & BRCA-1 IN THE REGULATION OF ESTROGENIC ACTIVITY IN PROSTATE STEM CELLS
David Greenwald*, Dan-Ping Hu, Wen-Yang Hu, Gail Prins, Chicago, IL

MP81-04 ALTERATIONS OF TUMOR MICROENVIRONMENT BY NITRIC OXIDE DONOR IMPEDES CASTRATION RESISTANT PROSTATE CANCER GROWTH
HIMANSHU ARORA*, Kush Panara, Manish Kuchakulla, Shathiyah Kuldandavelu, Kerry L Burnstein, Andrew V Schally, Joshua M Hare, Ranjith Ramasamy, Miami, FL

MP81-05 CRISPR SCREENING REVEALS GENES DRIVING RESISTANCE AND SENSITIVITY TO PARP INHIBITOR IN PROSTATE CANCER CELLS
Tomoki Takai*, Xiao Bai, Takuya Tsujino, Adam Kibel, Li Jia, Boston, MA

MP81-06 OVERCOMING CABAZITAXEL RESISTANCE BY G2/M REGULATING GENES IN CASTRATION-RESISTANT PROSTATE CANCER
Hiroshi Hongo*, Takeo Kosaka, Yoshinori Yanai, Yota Yasumizu, Yasumasa Miyazaki, Nobuyuki Tanaka, Kazuhiro Matsumoto, Ryuichi Mizuno, Eiji Kikuchi, Mototsugu Oya, Shinjuku-ku, Japan

MP81-07 IL-8 PROTECTS PROSTATE CANCER CELLS FROM GSK-3β-INDUCED OXIDATIVE STRESS THROUGH ACTIVATING THE MTOR SIGNALING PATHWAY
Yi Sun*, Lu Yang, Qiang Wei, Chengdu, China, People’s Republic of

MP81-08 COMBINATION THERAPY WITH PARP INHIBITOR AND STATIN FOR CASTRATION-RESISTANT AND TAXANE-RESISTANT PROSTATE CANCER
Yoshitaka Sekine*, Daisuke Oka, Hiroshi Nakayama, Yoshiko Miyazawa, Hidekazu Koike, Hiroshi Matsui, Yoshiyuki Miyazawa, Hidehisa Mori, Tomoya Fukawa, Yasuo Yamamoto, Kunihisa Yamaguchi, Masayuki Takahashi, Hiro-omi Kanayama, Tokushima, Japan

MP81-09 NOVEL LNCAMPC STIMULATED LIF/LIFR PATHWAY PROMOTES METASTASIS AND SERVES AS THERAPEUTIC TARGET IN PROSTATE CANCER
Wei Zhang*, Xiaolei Shi, Rui Chen, Shancheng Ren, Yinghao Sun, Shanghai, China, People’s Republic of

MP81-10 LUTEOLIN SUPPRESSES ANDROGEN RECEPTOR SPICE VARIANT 7 EXPRESSION VIA MiRNA RECRUITMENT IN CASTRATION-RESISTANT PROSTATE CANCER
Taku Naiki*, Aya Naiki-Ito, Toshiki Etani, Keitaro Iida, Ryosuke Ando, Takashi Nagai, Noriyasu Kawai, Satoru Takahashi, Takahiro Yasui, Nagoya, Japan

MP81-11 IDENTIFICATION OF NOVEL CELL-SPECIFIC DDS PEPTIDE IN PROSTATE CANCER BY IN VIVO PHAGE DISPLAY
Akinori Wada*, Hitode kojima, Tomoya Terashima, Susumu Kageyama, Akihiro Kawachi, Otsu, Japan

MP81-12 GALECTIN-3 IS INVOLVED IN THE TUMOR PROGRESSION AND DRUG RESISTANCE INDUCED BY TAXANE CHEMOTHERAPY AND POLY(ADENOSINE DIPHOSPHATE [ADP]-RIBOSE) POLYMERASE (PARP) INHIBITOR IN CASTRATION-RESISTANT PROSTATE CANCER
Tomoharu Fukumon*, Kei Daizumoto, Megumi Tsuda, Keisuke Ozaki, Yoshiho Kusuha, Hidehisa Mori, Tomoya Fukawa, Yasuo Yamamoto, Kunihisa Yamaguchi, Masayuki Takahashi, Hiro-omi Kanayama, Tokushima, Japan

MP81-13 UNDERSTANDING THE ROLE OF WNT SIGNALING IN PROSTATE CANCER BONE METASTATIC TROPISM
Udit Singh*, Yugang Wang, Yuanruan Qiao, Therese M. Roth, Ann Arbor, MI, Jae-Seung Chung, Busan, Korea, Republic of, Jacob A. Belardo, Hao Zhang, Russell S. Taichman, Alexander B. Zaslavsky, Ganesh S. Palapattu, Arul M. Chinnaiyan, Todd M. Morgan, Ann Arbor, MI

MP81-14 LNCRNA CCAT1 PROMOTES PROSTATE CANCER CELL PROLIFERATION BY INTERACTING WITH DDX5 AND MIR-28-5P
Zonghao You*, Chunhua Liu, Can Wang, Bin Xu, Nanjing, China, People’s Republic of, Han Guan, Bengbu, China, People’s Republic of, Ming Chen, Nanjing, China, People’s Republic of

MP81-15 LNCRNA MEG3 FUNCTIONS AS A TUMOR-SUPPRESSOR IN PROSTATE CANCER
Bin Xu, Nanjing, China, People’s Republic of, Rufang Liu, Buffalo, NY, Ming Chen, Nanjing, China, People’s Republic of, Dean G. Tang*, Buffalo, NY

MP81-16 METHYLATION OF SRD5A2 PROMOTER PREDICTS A BETTER OUTCOME FOR PATIENTS UNDERGOING ANDROGEN DEPRIVATION THERAPY IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER
Tao Deng, Xueming Lin, Shulin Wu, Zhenwei Zhang, Chin-Lee Wu, Boston, MA, Liying Yan, Hopkinton, MA, Mary-Ellen Taplin, Zongwei Wang, Aria Olumi*, Boston, MA

MP81-17 THE PHENOTYPE OF TUMOR INFILTRATING T CELLS AND THE EXPRESSION OF PD1, PD-L1 AND B7-H4 IN PROSTATE CANCER
ZheWen Wei, Jihong Liu, Tao Wang, Xian Wei*, Wuhan, China, People’s Republic of
mp81-18 Investigating a novel recombinant antibody to attenuate prostate cancer progression by targeting cell surface grp78
Ali Al-Hashimi*, Kevin Won, Hamilton, Canada, Elizabeth Pham, Julie Bailis, South San Francisco, CA, Natalie Mariano, South San Francisco, CA, Bobby Shayegan, Richard Austin, Hamilton, Canada

mp81-19 Mechanisms of anti-androgen resistance in a 3D patient-derived organoid model of bone metastatic prostate cancer
Danielle Burner*, Theresa Mendoza, Michelle Muldong, Sanghee Lee, Catalina Arreola, Olga Makiicheva-Greenburg, William Zhu, Christina Wu, La Jolla, CA, Nicholas Cacalano, Westwood, CA, Catriona Jamieson, Christopher Kane, Anna Kulidjian, Christina Jamieson, La Jolla, CA

mp81-20 Automated image analysis of histologically benign prostate biopsies predicts cancer presence
Tyler Etheridge, Adam Schultz, Johnathon McCormick, Shivashankar Damodaran, Bing Yang*, Glenn O. Allen, Wei Huang, Madison, WI, Peter LaViolette, Milwaukee, WI, David Jarrard, Madison, WI

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
10:30 PD64-07 A NOVEL URINE TEST HIGHLY SPECIFIC FOR PROSTATE CANCER DETECTION
Christian Pavlovich*, Jillian Eskra, Daniel Rabizadeh, Jiayi Zhang, William Isaacs, Jun Luo, Baltimore, MD

10:40 PD64-08 IDENTIFICATION OF CLINICALLY SIGNIFICANT PROSTATE CANCER USING A NOVEL MULTIPLEXED URINE BIOMARKER PANEL
Yashar Niknafs*, Jeffrey Tosolian, Scott Tomlins, Todd Morgan, Arul Chinnaiyan, Ann Arbor, MI

10:50 PD64-09 THE FOUR-KALLIKREIN DISCRIMINATES PROSTATE CANCER AND AGGRESSIVE DISEASE IN A MULTIETHNIC POPULATION
Christopher Haiman, Peggy Wan, Alisha Chou, Los Angeles, CA, Emily Vertosick, New York, NY, Lynne Wilkens, Loic Le Marchand, Honolulu, HI, Andrew Vickers*, Hans Lilja, New York, NY

11:00 PD64-10 IMPACT OF HEALTH LITERACY ON DECISION-MAKING FOR PROSTATE-SPECIFIC ANTIGEN SCREENING IN THE UNITED STATES
David-Dan Nguyen*, Quoc-Dien Trinh, Paul L. Nguyen, Boston, MA, Jesse D. Sammon, Portland, ME

11:10 PD64-11 THE PRACTICAL POLYGENIC RISK SCORE IS ASSOCIATED WITH PROSTATE CANCER MORTALITY INDEPENDENT OF PSA BUT HAS LOW PREDICTIVE VALUE

11:20 PD64-12 GENETIC RISK SCORE PREDICTS EARLY AGE-ONSET OF PROSTATE CANCER
Craig Labbate*, Chicago, IL, Zhuqing Shi, Shanghai, China, People's Republic of, Mary Helen Black, Shuwei Li, Holly Laduca, Aliso Viejo, CA, Chi-Haung Wang, Hongjie Yu, Brian Heffand, Evanston, IL, William Isaacs, Baltimore, MD, Jianfeng Xu, Evanston, IL

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
<table>
<thead>
<tr>
<th>Time</th>
<th>Number</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:40</td>
<td>PD65-08</td>
<td>POOR SLEEP QUALITY IS ASSOCIATED WITH CLINICALLY SIGNIFICANT LOWER URINARY TRACT SYMPTOMS</td>
<td>Jenna Bates*, Houston, TX, Taylor Kohn, Baltimore, MD, Katherine Rodríguez, Houston, TX, John Sigalos, Los Angelos, CA, Asad Hasan, Houston, TX, Alexander Pastuszak, Salt Lake City, UT, Larry Lipshultz, Houston, TX</td>
</tr>
<tr>
<td>10:50</td>
<td>PD65-09</td>
<td>IMPACT OF THE CONTROLLING NUTRITIONAL STATUS (CONUT) SCORE ON SEVERE NOCTURIA IN MALES</td>
<td>Masaya Ito*, Yasukazu Nakanishi, Madoka Katoaka, Kazumasa Sakamoto, Kosuke Takemura, Hiroaki Suzuki, Noriyuki Iida, Kenichi Tobisu, Fumitaka Koga, Tokyo, Japan</td>
</tr>
<tr>
<td>11:00</td>
<td>PD65-10</td>
<td>EARLY NOCTURNAL SURGE IN URINE PRODUCTION IN PATIENTS WITH NOCTURNAL POLYURIA SYNDROME</td>
<td>Thomas Monaghan*, Matthew Epstein, Kyle Michelson, Nicholas Suss, Viktor Flores, Zhan Wu, Brooklyn, NY, Donald Bilwise, Atlanta, GA, François Hervé, Karel Everaert, Ghent, Belgium, Jeffrey Weiss, Brooklyn, NY</td>
</tr>
<tr>
<td>11:10</td>
<td>PD65-11</td>
<td>NOCTURNAL DIURESIS RATE PATTERNS IN NOCTURNAL POLYURIA SYNDROME AND SECONDARY NOCTURNAL POLYURIA</td>
<td>Matthew Epstein*, Thomas Monaghan, Kyle Michaelson, Zhan Wu, Nicholas Suss, Arturo Holmes, Brooklyn, NY, Donald Bilwise, Atlanta, GA, Jason Lazar, Jeffrey Weiss, Brooklyn, NY</td>
</tr>
<tr>
<td>11:20</td>
<td>PD65-12</td>
<td>SALT INTAKE REDUCTION AS A TREATMENT OPTION FOR OVERACTIVE BLADDER</td>
<td>Tomohiro Matsuo*, Yasuyoshi Miyata, Tsutomu Yuno, Kyoei Araki, Yuichiro Nakamura, Yuji Sagara, Kojiro Obha, Hideki Sakai, Nagasaki, Japan</td>
</tr>
</tbody>
</table>

Monday, May 6, 2019
Podium Session 66
9:30 am - 11:30 am

BLADDER CANCER: EPIDEMIOLOGY & EVALUATION II
Room W185a @ McCormick Place
Moderators: Arthur Sagalowsky, John Sfakianos & Brock O’Neil

<table>
<thead>
<tr>
<th>Time</th>
<th>Number</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:30</td>
<td>PD66-01</td>
<td>PROXIMITY TO OIL REFINERIES AND RISK OF BLADDER CANCER: A POPULATION-BASED ANALYSIS</td>
<td>Mohamed Ray-Zack*, Preston Kerr, Yong Shan, Jacques Baillargeon, Yong-Fang Kuo, Hemakumar Mehta, Stephen Williams, Galveston, TX</td>
</tr>
<tr>
<td>09:40</td>
<td>PD66-02</td>
<td>TRAVEL DISTANCE INFLUENCES POST-CYSTECTOMY READMISSION PATTERNS</td>
<td>Nathan Hale*, Charleston, WV, Liam Macleod, Jonathan Yabes, Robert Turner, Pittsburgh, PA, Mina Fam, Brick, NJ, Jeffrey Gingrich, Durham, NC, Lindsay Sabik, Benjamin Davies, Bruce Jacobs, Pittsburgh, PA</td>
</tr>
<tr>
<td>09:50</td>
<td>PD66-03</td>
<td>DOES THE DIAGNOSIS OF BLADDER CANCER LEAD TO HIGHER RATES OF SMOKING CESSATION? FINDINGS FROM THE MEDICARE HEALTH OUTCOMES SURVEY.</td>
<td>Brian Winters*, Sarah Holt, Atreya Dash, John Gore, George Schade, Jonathan Wright, Seattle, WA</td>
</tr>
<tr>
<td>10:00</td>
<td>PD66-04</td>
<td>NATIONAL TRENDS AND PATHOLOGIC OUTCOMES OF NEOADJUVANT CHEMOTHERAPY AMONG PATIENTS WITH MICROPAPILLARY VARIANT UROTHELIAL CARCINOMA OF THE BLADDER</td>
<td>Juan Javier-DesLoges*, New Haven, CT, Alejandro Abello, Jamil Syed, New Haven, CT, Preston Sprentkle, Michael Hurwitz, New Haven, CT, Patrick Kenney, New Haven, CT, Michael Leapman, New Haven, CT</td>
</tr>
<tr>
<td>10:10</td>
<td>PD66-05</td>
<td>DEVELOPMENT AND VALIDATION OF A HEMATURIA CANCER RISK SCORE TO IDENTIFY PATIENTS AT RISK OF HARBOURING CANCER</td>
<td>Wei Shen Tan*, Amar Ahmad, Andrew Feber, London, United Kingdom, Hugh Mostafid, Surrey, United Kingdom, Jo Cresswell, Middlesbrough, United Kingdom, Christian Fankhauser, Sharon Waisbrod, Thomas Hermanns, Zurich, Switzerland, Peter Sasieni, John Kelly, London, United Kingdom</td>
</tr>
</tbody>
</table>
PROSPECTIVE EVALUATION OF CYSTOSCOPY AND BLADDER MAPPING REVEALS NEARLY A 30% MISS RATE FOR ≥PT2 PATHOLOGY

ELECTRONIC RAPID FITNESS ASSESSMENT IDENTIFIES FACTORS ASSOCIATED WITH ADVERSE EARLY POSTOPERATIVE OUTCOMES FOLLOWING RADICAL CYSTECTOMY

RETHINKING THE ONE-SIZE-FITS-MOST APPROACH TO VENOUS THROMBOEMBOLISM PROPHYLAXIS AFTER RADICAL CYSTECTOMY
Lauren E Corona*, Uditi Singhal, Khadeef Hafez, Lindsey Herrel, Samuel Kaffenberger, Jeffrey Montgomery, Todd M Morgan, Alon Z Weizer, Yongmei Qin, Sapan N Ambani, Ann Arbor, MI

ALVIMOPAN IS ASSOCIATED WITH A REDUCTION IN LENGTH OF STAY AND HOSPITAL COSTS FOR PATIENTS UNDERGOING RADICAL CYSTECTOMY
Tzu-Hao Huang*, Matthew Mossanen, Mark Preston, Boston, MA, Benjamin I. Chung, Stanford, CA, William J. Huang, Taipei City, Taiwan, Steven L. Chang, Boston, MA

IMPLEMENTATION OF A REDUCED OPIOID UTILIZATION PROTOCOL FOR RADICAL CYSTECTOMY
Daniel Greenberg*, Jessica Kee, Kerri Stevenson, Eliza Van Zyl, Anisia Dugala, Kris Prado, Harcharan Gill, Eila Skinner, Jay Shah, Stanford, CA

EXPLORING PATIENT AND CAREGIVER PERSPECTIVES REGARDING READMISSION FOLLOWING RADICAL CYSTECTOMY: A QUALITATIVE APPROACH TO IDENTIFYING NOVEL TARGETS FOR READMISSION REDUCTION
Tudor Borza*, Madison, WI, Daniela A Wittmann, Kevin Zhu, Benjamin Li, Ann Arbor, MI, Ken Urish, Pittsburgh, PA, Jonathan E Helm, Bloomington, IN, Mariel Lavieri, Ann Arbor, MI, Bruce L Jacobs, Pittsburgh, PA, Ted A Skolarus, Ann Arbor, MI

ALVIMOPAN IS ASSOCIATED WITH A REDUCTION IN LENGTH OF STAY AND HOSPITAL COSTS FOR PATIENTS UNDERGOING RADICAL CYSTECTOMY
Tzu-Hao Huang*, Matthew Mossanen, Mark Preston, Boston, MA, Benjamin I. Chung, Stanford, CA, William J. Huang, Taipei City, Taiwan, Steven L. Chang, Boston, MA

IMPLEMENTATION OF A REDUCED OPIOID UTILIZATION PROTOCOL FOR RADICAL CYSTECTOMY
Daniel Greenberg*, Jessica Kee, Kerri Stevenson, Eliza Van Zyl, Anisia Dugala, Kris Prado, Harcharan Gill, Eila Skinner, Jay Shah, Stanford, CA

EXPLORING PATIENT AND CAREGIVER PERSPECTIVES REGARDING READMISSION FOLLOWING RADICAL CYSTECTOMY: A QUALITATIVE APPROACH TO IDENTIFYING NOVEL TARGETS FOR READMISSION REDUCTION
Tudor Borza*, Madison, WI, Daniela A Wittmann, Kevin Zhu, Benjamin Li, Ann Arbor, MI, Ken Urish, Pittsburgh, PA, Jonathan E Helm, Bloomington, IN, Mariel Lavieri, Ann Arbor, MI, Bruce L Jacobs, Pittsburgh, PA, Ted A Skolarus, Ann Arbor, MI

ALVIMOPAN IS ASSOCIATED WITH A REDUCTION IN LENGTH OF STAY AND HOSPITAL COSTS FOR PATIENTS UNDERGOING RADICAL CYSTECTOMY
Tzu-Hao Huang*, Matthew Mossanen, Mark Preston, Boston, MA, Benjamin I. Chung, Stanford, CA, William J. Huang, Taipei City, Taiwan, Steven L. Chang, Boston, MA

A NOVEL RISK BASED APPROACH SIMULATING ONCOLOGIC SURVEILLANCE ACCORDING TO SMOKING STATUS AFTER RADICAL NEPHROURETERECTOMY WITH UPPER TRACT UROTHELIAL CARCINOMA
Shigeta Keisuke*, Eiji Kikuchi, Masayuki Hagiwara, Takayuki Abe, Koichiro Ogihara, Ryuichi Mizuno, Mototsugu Oya, Tokyo, Japan

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Monday, May 6, 2019
Podium Session 67
9:30 am - 11:30 am

GENERAL & EPIDEMIOLOGICAL TRENDS & SOCIOECONOMICS: VALUE OF CARE: COST AND OUTCOMES MEASURES II
Room W181c @ McCormick Place
Moderators: Yair Lotan, John Hollingsworth & Celeste Alston

ABSTRACT
TIME NUMBER TITLE
9:30 PD67-01 IMPACT OF MEDICARE EVALUATION AND MANAGEMENT PAYMENT POLICY ON UROLOGY PRACTICES
Parth K. Modi*, Samuel R. Kaufman, Vahakn B. Shahinian, Brent K. Hollenbeck, Ann Arbor, MI

ABSTRACT
TIME NUMBER TITLE
9:50 PD67-03 MEDICARE ACCOUNTABLE CARE ORGANIZATIONS REDUCE SPENDING ON UROLOGICAL SURGERY
Parth K. Modi*, Nicholas M. Moloci, Lindsey A. Herrel, Brent K. Hollenbeck, Andrew M. Ryan, John M. Hollingsworth, Ann Arbor, MI

ABSTRACT
TIME NUMBER TITLE
10:00 PD67-04 ARE ACCOUNTABLE CARE ORGANIZATIONS ASSOCIATED WITH REDUCED EXPENDITURES FOR MEN WITH PROSTATE CANCER?
Alexander Putnam Cole*, Anna Krasnova, Ashwin Ramaswamy, David Fallon Friedlander, Sean Anthony Fletcher, Maxine Sun, Toni K. Choueiri, Joel S. Weissmann, Stuart R. Lipsitz, Adam S. Kibel, Quoc-Dien Trinh, Boston, MA

ABSTRACT
TIME NUMBER TITLE
10:40 PD66-08 RETHINKING THE ONE-SIZE-FITS-MOST APPROACH TO VENOUS THROMBOEMBOLISM PROPHYLAXIS AFTER RADICAL CYSTECTOMY
Lauren E Corona*, Uditi Singhal, Khadeef Hafez, Lindsey Herrel, Samuel Kaffenberger, Jeffrey Montgomery, Todd M Morgan, Alon Z Weizer, Yongmei Qin, Sapan N Ambani, Ann Arbor, MI

ABSTRACT
TIME NUMBER TITLE
11:00 PD66-10 IMPLEMENTATION OF A REDUCED OPIOID UTILIZATION PROTOCOL FOR RADICAL CYSTECTOMY
Daniel Greenberg*, Jessica Kee, Kerri Stevenson, Eliza Van Zyl, Anisia Dugala, Kris Prado, Harcharan Gill, Eila Skinner, Jay Shah, Stanford, CA

ABSTRACT
TIME NUMBER TITLE
11:10 PD66-11 EXPLORING PATIENT AND CAREGIVER PERSPECTIVES REGARDING READMISSION FOLLOWING RADICAL CYSTECTOMY: A QUALITATIVE APPROACH TO IDENTIFYING NOVEL TARGETS FOR READMISSION REDUCTION
Tudor Borza*, Madison, WI, Daniela A Wittmann, Kevin Zhu, Benjamin Li, Ann Arbor, MI, Ken Urish, Pittsburgh, PA, Jonathan E Helm, Bloomington, IN, Mariel Lavieri, Ann Arbor, MI, Bruce L Jacobs, Pittsburgh, PA, Ted A Skolarus, Ann Arbor, MI

ABSTRACT
TIME NUMBER TITLE
11:20 PD66-12 A NOVEL RISK BASED APPROACH SIMULATING ONCOLOGIC SURVEILLANCE ACCORDING TO SMOKING STATUS AFTER RADICAL NEPHROURETERECTOMY WITH UPPER TRACT UROTHELIAL CARCINOMA
Shigeta Keisuke*, Eiji Kikuchi, Masayuki Hagiwara, Takayuki Abe, Koichiro Ogihara, Ryuichi Mizuno, Mototsugu Oya, Tokyo, Japan

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
10:10 PD67-05 CONSOLIDATION OF BILLING LEVELS FOR OUTPATIENT OFFICE VISITS: IMPACT OF PROPOSED MEDICARE CHANGE ON REIMBURSEMENT FOR UROLOGISTS
Catherine Nam*, Frances Kim, David Howard, Christopher Filson, Atlanta, GA

10:20 PD67-06 IS OUTPATIENT CLASSIFICATION JUSTIFIED FOR MINIMALLY-INVASIVE RENAL SURGERY? RESULTS FROM A STATEWIDE QUALITY IMPROVEMENT COLLABORATIVE
Kyle Johnson*, Alon Weizer, Lindsey Herrel, Anna Johnson, Tae Kim, Ji Qi, Ann Arbor, MI, Craig Rogers, Detroit, MI, Richard Sarle, Troy, MI, Brian Lane, Grand Rapids, MI, for the Michigan Urological Surgery Improvement Collaborative, Ann Arbor, MI

10:30 PD67-07 SUCCESS RATE AND SAFETY OF OFFERING SAME-DAY DISCHARGE FOLLOWING ROBOTIC PROSTATECTOMY
Robert Gerhard, Oscar Martinez, Ronney Abaza*, Dublin, OH

10:40 PD67-08 IDENTIFYING FACTORS ASSOCIATED WITH POOR GENITOURINARY CANCER CLINICAL TRIAL ACCRUAL USING A NOVEL DATA EXTRACTION ALGORITHM
Kristian Stensland*, Lael Reinstafler, Lebanon, NH, Alireza Moinzadeh, Burlington, MA, Matt Galsky, New York, NY

10:50 PD67-09 EVALUATION OF ASYMPTOMATIC MICROSCOPIC HEMATURIA: RISK OF MALIGNANCY AND ESTIMATED COST BASED ON HEMATURIA RISK INDEX
Daniel Rabinowitz*, Andrew Wood, NY, NY, Allison Marziliano, Andre Perez-Orozco, Andrew Ng, Michael Diefenbach, Justin Han, Manish Vira, Simon J Hall, Great Neck, NY

11:00 PD67-10 RISKS AND BENEFITS OF FREQUENT SURVEILLANCE CYSTOSCOPY AMONG PATIENTS WITH LOW-RISK NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC)
Florian Schroed*, White River Junction, VT, Kristine Lynch, Salt Lake City, UT, Zhongze Li, Todd MacKenzie, John Seigne, David Han, Lebanon, NH, Douglas Robertson, Brenda Sirovich, Philip Goodney, White River Junction, VT

11:10 PD67-11 CAN GUIDELINES SUPPORT DEIMPLEMENTATION OF CT FOR A COMMON CONDITION? TRENDS IN DIAGNOSTIC EVALUATION FOR HEMATURIA WITHIN & ACROSS HEALTH CARE SYSTEMS
Mark Ehlers*, Chapel Hill, NC, Sheila Weinmann, Portland, OR, Michael Parchman, Seattle, WA, Marilyn Kwan, Oakland, CA, Jenny Staab, Portland, OR, David Aaronson, Oakland, CA, Matthew Wagner, Portland, OR, Matthew Nielsen, Chapel Hill, NC

11:20 PD67-12 BENEFIT OF EARLY TREATMENT WITH BONE-MODIFYING AGENTS FOR PREVENTING SKELETAL-RELATED EVENTS IN PATIENTS WITH GENITOURINARY CANCER WITH BONE METASTASIS: A LARGE SCALE MULTI-INSTITUTIONAL STUDY
Takuya Owari*, Makito Miyake, Yoshitaka Itami, Kenton Onishi, Nobumichi Tanaka, Kyohide Fujimoto, Kashihara-shi, Japan

MONDAY
*Presenting author

MONDAY
APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Video Session 12
FEMALE PELVIC MEDICINE & RECONSTRUCTION

The videos in this session as well as the video libraries from the 2012-2018 Annual Meetings may be viewed in the Surgical Video Library and purchased in the AUA Store during the Annual Meeting. AUA members receive free online access to the Surgical Video Library throughout the year through AUA University. Visit www.AUAnet.org/University to access.

Room W187b @ McCormick Place

Moderators: Maude Carmel, Ariana Smith & Humphrey Atiemo

<table>
<thead>
<tr>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:30</td>
<td>V12-01</td>
<td>AUTOLOGOUS FASCIA LATA SPIRAL SLING ANAL SPHINCTER RECONSTRUCTION FOR IMPROVED FECAL CONTINENCE</td>
</tr>
<tr>
<td>9:40</td>
<td>V12-06</td>
<td>NEURO-UROLOGY IN DAILY PRACTICE PART 2: PHYSICAL EXAM</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:50</td>
<td>V12-07</td>
<td>PELVIC FLOOR CHEMODERNERATION FOR REFRACTORY HIGH TONE PELVIC FLOOR DYSFUNCTION</td>
</tr>
<tr>
<td>10:00</td>
<td>V12-02</td>
<td>RETROGRADE PERCUTANEOUS TECHNIQUE OF LEAD PLACEMENT FOR CHRONIC TIBIAL NERVE STIMULATION, AN OFFICE BASED PROCEDURE</td>
</tr>
</tbody>
</table>

299
10:10 V12-04 PLACEMENT OF AN IMPLANTABLE TIBIAL NERVE STIMULATOR UNDER LOCAL ANESTHESIA: STEP BY STEP INSTRUCTIONS
Laura Giusto*, Patricia Zahner, Howard Goldman, Cleveland, OH

10:20 V12-03 AUTOLOGOUS RECTUS FASCIAL PUBOVAGINAL SLING AFTER VAGINOPLASTY: AN OLD TRICK FOR A NEW PROBLEM
Rajveer Purohit, Jerry G. Blaivas, Senad Kalkan*, New York, NY

10:30 V12-09 ROBOTIC-ASSISTED VAGINAL RECONSTRUCTION WITH THE DAVYDOV TECHNIQUE
Ervin Kocjancic, Omer Acar*, David Greenwald, Ryan Dobbs, Whitney Halgrimson, Simone Crivellaro, Chicago, IL

10:40 V12-05 IMMEDIATE EVALUATION AND ROBOT ASSISTED REPAIR OF A URINARY INJURY FOLLOWING A VAGINAL HYSTERECTOMY
Robin Djang*, Kris Strohbehn, John Seigne, Lebanon, NH

10:50 V12-08 ROBOT-ASSISTED VESICO-VAGINAL FISTULA REPAIR: TECHNIQUE & EXPERIENCE
Shrawan K Singh*, Girdhar Bora, Kalpesh Parmar, Ravimohan. Mavudu, Sudheer Devana, Aditya Sharma, Arup Kumar Mandal, Chandigarh, India

11:00 V12-10 URETHROPLASTY: URETHRAL-CLITORAL ECTOPY
Poone Shoureshi*, Kamran Sajadi, Portland, OR

11:10 V12-11 TRANSVAGINAL BLADDER NECK CLOSURE
Jerry G. Blaivas*, Senad Kalkan, New York, NY, Eric S.W. Li, Brooklyn, NY

11:20 V12-12 ROBOTIC SACROCOLPOPEXY WITH VENTRAL RECTOPEXY FOR MULTICOMPARTMENT PELVIC ORGAN PROLAPSE
Carrie Stewart*, Ariel Moradzadeh, Beth Moore, Jennifer Anger, Karyn Eilber, Beverly Hills, CA

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
Monday, May 6, 2019 1:00 pm - 5:00 pm

UROLOGIC SOCIETY FOR TRANSPLANTATION & RENAL SURGERY (USTRS)
Room W192 @ McCormick Place

1:00 ADDING PERITONEAL DIALYSIS SURGERY TO YOUR UROLOGY PRACTICE
Neal Rowe

1:20 PROSTATE CANCER IN KIDNEY TRANSPLANT Recipients: IS ACTIVE SURVEILLANCE AN OPTION?
Laurence Klotz

1:50 RECYCLING KIDNEYS: RE-TRANSPLANTATION OF PREVIOUSLY TRANSPLANTED KIDNEYS
Jeffrey Veale

2:10 ROBOTIC VS OPEN RENAL TRANSPLANTATION
Debaters: Alberto Breda, David A. Goldfarb

2:30 CROSSFIRE: IS CYTOREDUCTIVE NEPHRECTOMY DEAD?
Debater - Pro: Rodney Breau
Debater - Con: Anil Kapoor

2:50 NOVICK PRESENTATIONS

DAILY USE OF A MUSCLE PUMP ACTIVATOR DEVICE REDUCES HOSPITALIZATION AND IMPROVES GRAFT FUNCTION POST TRANSPLANTATION: A RANDOMIZED CONTROLLED TRIAL
Wen Yan Xie

NOVEL COOLING DEVICE FOR KIDNEY TRANSPLANT SURGERY
Ali Dergham

3:50 RECEPTION, VIEW POSTERS & PRESENTATION OF NOVICK AWARD

4:30 USTRS BUSINESS MEETING

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Monday, May 6, 2019 1:15 pm - 5:00 pm

PAN AFRICAN UROLOGICAL SURGEONS ASSOCIATION/CARIBBEAN UROLOGICAL SURGEONS ASSOCIATION (PAUSA/CURA)
Jackson Park CD @ Hyatt McCormick

1:15 WELCOME REMARKS
CURA President: Christy Daniel
PAUSA President: Mobile Kampanga

1:30 SESSION 1: INVITED LECTURES
Program Chairs: Lester Goetz, Mobile Kampanga

USE OF GENOMIC MARKERS IN THE MANAGEMENT OF LOCALIZED PROSTATE CANCER
Walter Rayford

TEACHING RADICAL PROSTATECTOMY IN SUBSAHARIAN AFRICA
Albert Ruenes

2:00 SESSION 2: ON THE SCIENTIFIC FRONTIER
Program Chairs: Serigne Gueye, Robin Roberts

MINIMALLY INVASIVE MANAGEMENT OF URINARY STONES IN A SINGLE CENTER IN CAMEROON
Cyril Kamadjou

EPIDEMOLOGY, ENDOSCOPY, AND LAPAROSCOPY
Augustin Punga-Maole

UROLOGY AND DIGITAL HEALTH TECHNOLOGY IN AFRICA
Emmauel Abara

*Presenting author
ENHANCING UROLOGICAL EDUCATION, TRAINING AND SERVICES IN SUBSAHARAN AFRICA
Alex Danso

IS KIDNEY TRANSPLANTATION SUSTAINABLE IN THE BLACK NATION?: INITIAL EXPERIENCE IN ANTIGUA AND SOUTH EASTERN NIGERIA
Obi Ekwenna

CITRATE LEVELS IN PATIENTS WITH URINARY CALCULI
Wanda Bellamy

PROSTATE CANCER PRESENTATION AND OUTCOMES IN YOUNGER JAMAICAN MEN (<60 YEARS) TREATED AT THE UNIVERSITY HOSPITAL OF THE WEST INDIES
Belinda Morrison-Blidgen

EPIDEMIOLOGICAL, BIOLOGICAL AND CLINICAL PROFILE OF TESTICULAR CANCER IN CONGOLESE PATIENTS
TBA

SESSION 3: PANEL DISCUSSION - TESTICULAR CANCER IN AFRICA & THE CARIBBEAN
Moderator: E. Oluwabunmi Olapade-Olaopa
Panelists: Bahoueli Guy Roger Gaudji, Lester Goetz, Mobile Kampanga, Alexander Nwofor

SESSION 4: AOB - PAUSA/CURA BUSINESS MEETING
Program Chair: E. Oluwabunmi Olapade-Olaopa

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Monday, May 6, 2019 2:00 pm - 4:00 pm

PHILIPINE UROLOGICAL ASSOCIATION (PUA)
Room W193a @ McCormick Place

2:00 WELCOME REMARKS
Society President: Samuel Yrastorza

2:15 CYTOREDUCTIVE NEPHRECTOMY IN METASTATIC RCCA IN THE TKA ERA
Raymond Leveillee

2:30 UPDATE: IN OFFICE PROCEDURES FOR BPH
Michael Gomez

2:45 MALE SLING FOR URINARY INCONTINENCE
Michael Chua

3:00 NEW INFORMATION ABOUT COMBINED MEDICAL THERAPY FOR BPH: SAFETY AND EFFICACY
Micahel Manyak

3:15 CYTOREDUCTIVE PROSTATECTOMY IN THE SETTING OF ADVANCED PROSTATE CANCER
Maxwell Meng

3:30 RATIONALE FOR HEREDITARY TESTING IN PROSTATE CANCER
Raoul Concepcion

3:45 CLOSING REMARKS
<table>
<thead>
<tr>
<th>Name</th>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Perineologic</td>
<td>1735</td>
</tr>
<tr>
<td>Peruvian Society of Urology</td>
<td>1029</td>
</tr>
<tr>
<td>Pfizer Oncology</td>
<td>4007</td>
</tr>
<tr>
<td>Philips</td>
<td>1607</td>
</tr>
<tr>
<td>Photocure</td>
<td>2214</td>
</tr>
<tr>
<td>PracticeLink.com</td>
<td>4909</td>
</tr>
<tr>
<td>Presbyterian Healthcare Services</td>
<td>2236</td>
</tr>
<tr>
<td>PROCEPT BioRobotics</td>
<td>4027</td>
</tr>
<tr>
<td>ProEndoscopy</td>
<td>1416</td>
</tr>
<tr>
<td>Profound Medical</td>
<td>4831</td>
</tr>
<tr>
<td>Progenics Pharmaceuticals, Inc.</td>
<td>1711</td>
</tr>
<tr>
<td>Prolixe TUTD</td>
<td>5205</td>
</tr>
<tr>
<td>Promaxo</td>
<td>1207</td>
</tr>
<tr>
<td>Prometheus Group, The</td>
<td>2004</td>
</tr>
<tr>
<td>Prostate Conditions Education Council</td>
<td>1515</td>
</tr>
<tr>
<td>Providence St. Joseph Health</td>
<td>1431</td>
</tr>
<tr>
<td>PRS - Physician Reimbursement Systems</td>
<td>4541</td>
</tr>
<tr>
<td>Pure Processing</td>
<td>1214</td>
</tr>
<tr>
<td>Pusen Medical</td>
<td>1834</td>
</tr>
<tr>
<td>Q Urological</td>
<td>2040</td>
</tr>
<tr>
<td>QED Pathology Services</td>
<td>1216</td>
</tr>
<tr>
<td>QED Therapeutics</td>
<td>1449</td>
</tr>
<tr>
<td>Qualgen</td>
<td>3741</td>
</tr>
<tr>
<td>Quanta System SPA</td>
<td>4818</td>
</tr>
<tr>
<td>REFLEXONIC</td>
<td>4414</td>
</tr>
<tr>
<td>Rejuvenation</td>
<td>2341</td>
</tr>
<tr>
<td>Renal &amp; Urology News</td>
<td>2229</td>
</tr>
<tr>
<td>Retropin</td>
<td>4731</td>
</tr>
<tr>
<td>RG Medical</td>
<td>1426</td>
</tr>
<tr>
<td>Richard Wolf Medical Instruments</td>
<td>1507</td>
</tr>
<tr>
<td>Rigicon Inc. - UA</td>
<td>4809</td>
</tr>
<tr>
<td>RIMSCIENCE</td>
<td>1531</td>
</tr>
<tr>
<td>Rocamed</td>
<td>5015</td>
</tr>
<tr>
<td>Rose Micro Solutions</td>
<td>2023, 2612, 4014, 5020</td>
</tr>
<tr>
<td>Russer</td>
<td>1418</td>
</tr>
<tr>
<td>Sagent Urology</td>
<td>5018</td>
</tr>
<tr>
<td>Sanford Health</td>
<td>4540</td>
</tr>
<tr>
<td>SBH</td>
<td>2535</td>
</tr>
<tr>
<td>ScanMed</td>
<td>4043</td>
</tr>
<tr>
<td>Sciton</td>
<td>2337</td>
</tr>
<tr>
<td>Scivita Medical Technology Co., Ltd.</td>
<td>1634</td>
</tr>
<tr>
<td>SCSA Diagnostics</td>
<td>4512</td>
</tr>
<tr>
<td>Second To None Beauty</td>
<td>5126</td>
</tr>
<tr>
<td>Sedation Systems LLC</td>
<td>5208</td>
</tr>
<tr>
<td>SH Medical Corporation</td>
<td>1817</td>
</tr>
<tr>
<td>Shenzhen HuiMed Medical Technical Development CO., Ltd.</td>
<td>3443</td>
</tr>
<tr>
<td>Shenzhen HuiKang Medical Apparatus Co., Ltd.</td>
<td>1432</td>
</tr>
<tr>
<td>Siemens Healthineers</td>
<td>4023</td>
</tr>
<tr>
<td>Skills Workshop 1747, 2147, 2547, 2947, 3247</td>
<td>1032</td>
</tr>
<tr>
<td>Sociedad Argentina de Urologia</td>
<td>1031</td>
</tr>
<tr>
<td>Sociedade Brasileira de Urologia/Levitatur</td>
<td>932</td>
</tr>
<tr>
<td>Societa' Italiana Di Urologia</td>
<td>1130</td>
</tr>
<tr>
<td>Societe Internationale D'Urologie</td>
<td>1614</td>
</tr>
<tr>
<td>Society of Government Service Urologists</td>
<td>2334</td>
</tr>
<tr>
<td>SoFi</td>
<td>3640</td>
</tr>
<tr>
<td>Sonacare Medical</td>
<td>4211</td>
</tr>
<tr>
<td>Sonomatic</td>
<td>1917</td>
</tr>
<tr>
<td>Sortec Instruments</td>
<td>1609</td>
</tr>
<tr>
<td>Sony Electronics</td>
<td>2030</td>
</tr>
<tr>
<td>Soundable Health, Inc.</td>
<td>1026</td>
</tr>
<tr>
<td>Special Surgery Resources &amp; Repair, Inc.</td>
<td>1334</td>
</tr>
<tr>
<td>SpermCheck Vasectomy Home Test</td>
<td>1611</td>
</tr>
<tr>
<td>Springer</td>
<td>4238</td>
</tr>
<tr>
<td>SRS Medical Corp.</td>
<td>3006</td>
</tr>
<tr>
<td>Stille Surgical Inc.</td>
<td>1734</td>
</tr>
<tr>
<td>Sun Pharma</td>
<td>1310</td>
</tr>
<tr>
<td>Supramedical LLC</td>
<td>4332</td>
</tr>
<tr>
<td>Surgical Lasers Inc.</td>
<td>1537</td>
</tr>
<tr>
<td>SurgiTel/General Scientific</td>
<td>3740</td>
</tr>
<tr>
<td>Sutter Health Sacramento Sierra Region</td>
<td>2941</td>
</tr>
<tr>
<td>SYNERGO</td>
<td>4634</td>
</tr>
<tr>
<td>TEAC</td>
<td>2540</td>
</tr>
<tr>
<td>Tecnofarma</td>
<td>3618</td>
</tr>
<tr>
<td>TerSera Therapeutics</td>
<td>1511</td>
</tr>
<tr>
<td>Tesla</td>
<td>1023</td>
</tr>
<tr>
<td>Thermi</td>
<td>4232</td>
</tr>
<tr>
<td>TIMS Medical</td>
<td>4838</td>
</tr>
<tr>
<td>Tissue Regeneration Technologies</td>
<td>2240</td>
</tr>
<tr>
<td>Tolmar Pharmaceuticals</td>
<td>3614</td>
</tr>
<tr>
<td>U.S. Navy Recruiting Command</td>
<td>1231</td>
</tr>
<tr>
<td>Uberlube</td>
<td>4842</td>
</tr>
<tr>
<td>UC-CARE</td>
<td>4324</td>
</tr>
<tr>
<td>UFM Underwear for Men</td>
<td>4240</td>
</tr>
<tr>
<td>Ultra Light Optics Inc.</td>
<td>2841</td>
</tr>
<tr>
<td>United Endoscopy</td>
<td>1423</td>
</tr>
<tr>
<td>United Medical Systems, Inc.</td>
<td>4614</td>
</tr>
<tr>
<td>United Urologic Innovations</td>
<td>4111</td>
</tr>
<tr>
<td>University Compounding Pharmacy</td>
<td>7129</td>
</tr>
<tr>
<td>Urethrotech</td>
<td>4542</td>
</tr>
<tr>
<td>URO-1, Inc.</td>
<td>1828</td>
</tr>
<tr>
<td>UroCare</td>
<td>1240</td>
</tr>
<tr>
<td>UroGen Pharma</td>
<td>3840</td>
</tr>
<tr>
<td>UroGPO</td>
<td>2441</td>
</tr>
<tr>
<td>UroGyn Medical, Inc.</td>
<td>1926</td>
</tr>
<tr>
<td>Urology Times</td>
<td>4524</td>
</tr>
<tr>
<td>Uromedica, Inc.</td>
<td>1138</td>
</tr>
<tr>
<td>Urotomic</td>
<td>4640</td>
</tr>
<tr>
<td>UroVu Corporation</td>
<td>4810</td>
</tr>
<tr>
<td>US Nutraceuticals</td>
<td>4333</td>
</tr>
<tr>
<td>Uliva</td>
<td>4329</td>
</tr>
<tr>
<td>Vascular Technology</td>
<td>2027</td>
</tr>
<tr>
<td>Vasectomyshorts.com</td>
<td>2434</td>
</tr>
<tr>
<td>Vasectomystore.com</td>
<td>4012</td>
</tr>
<tr>
<td>Viveve</td>
<td>4336</td>
</tr>
<tr>
<td>Weatherby Healthcare</td>
<td>2840</td>
</tr>
<tr>
<td>WebMD/Vasectomy.com</td>
<td>4112</td>
</tr>
<tr>
<td>Well Lead Medical Co. Ltd.</td>
<td>1026</td>
</tr>
<tr>
<td>WellSpan Health</td>
<td>4927</td>
</tr>
<tr>
<td>Western Section, AUA</td>
<td>2336</td>
</tr>
<tr>
<td>Wisdom Medical Technologies</td>
<td>3343</td>
</tr>
<tr>
<td>Wolters Kluwer</td>
<td>1409</td>
</tr>
<tr>
<td>YouCare Technology Co., Ltd. (Wuhan)</td>
<td>1407</td>
</tr>
<tr>
<td>Zenflow, Inc.</td>
<td>4840</td>
</tr>
<tr>
<td>Zero Gravity Skin</td>
<td>2025</td>
</tr>
<tr>
<td>Zimmer MedizinSystems</td>
<td>2340</td>
</tr>
</tbody>
</table>
Save the DATE

AUA 2020
Washington, DC
May 15-18, 2020

AUA2020.ORG
Give More Patients the OPDIVO® Opportunity.

OPDIVO® (nivolumab)
INJECTION FOR INTRAVENOUS USE 10 mg/mL

While attending this meeting, please visit us at Booth 5206